"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2019/074842 A1,032-936-070-855-055,2019-04-18,2019,US 2018/0054857 W,2018-10-08,US 201762569989 P,2017-10-09,ONCOLYTIC CANCER IMMUNOTHERAPIES AND METHODS OF USE,"Disclosed herein are methods of treating a brain cancer comprising administering to a subject in need thereof a viral composition comprising a flavivirus or portion of a flavivirus wherein the flavivirus is engineered to comprise a heterologous nucleic acid sequence encoding a suicide gene. In some embodiments, the brain cancer is selected from the group consisting of astrocytoma, oligodendroglioma, ependymoma, meningioma, schwannoma, craniopharyngioma, germinoma, and pineocytoma. In some embodiments.the flavivirus comprises Zika virus, spondweni virus, kedougous virus, or a combination thereof In some embodiments, the flavivirus comprises Zika virus. In some embodiments, the suicide gene encodes a protein that converts a prodrug into a cytotoxic agent. In some embodiments, the viral composition is administered in combination with the immunostimulatory agent.",BLACK KEITH,BLACK KEITH,,https://lens.org/032-936-070-855-055,Patent Application,yes,4,1,2,2,3,A61K39/12;;A61K39/12;;A01K2207/12;;A01K2227/105;;A01K2267/0331;;A61K31/7052;;A61K35/768;;A61K35/768;;A61K45/06;;A61K48/00;;A61K2039/5256;;A61K2039/5256;;A61K2039/585;;A61K2039/585;;A61K2039/80;;A61P35/00;;A61P35/00;;C12N7/00;;C12N2770/24132;;C12N2770/24132;;C12N2770/24134;;Y02A50/30,A61K35/76;;A61K39/00;;A61K48/00;;A61P35/00,,2,2,023-035-783-496-027;;023-897-900-114-585,pmc5626408;;28874392;;10.1084/jem.20171093;;19092857;;10.1038/gt.2008.169,"ZHU ET AL.: ""Zika virus has oncolytic activity against glioblastoma stem cells"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 214, 5 September 2017 (2017-09-05), pages 2843 - 2857, XP055436428, DOI: doi:10.1084/jem.20171093;;HOANG-LE ET AL.: ""A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy"", GENE THERAPY, vol. 16, 10 December 2008 (2008-12-10), pages 190 - 199, XP002528588, DOI: doi:10.1038/GT.2008.169",PENDING
2,EP,A4,EP 1850852 A4,109-596-493-904-06X,2009-11-18,2009,EP 06735574 A,2006-02-22,US 2006/0005980 W;;US 65507505 P,2005-02-22,"USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN BARRIER",,CEDARS SINAI MEDICAL CENTER,BLACK KEITH,,https://lens.org/109-596-493-904-06X,Search Report,no,1,0,5,6,0,A61K31/415;;A61K31/415;;A61K31/22;;A61K31/22;;A61K31/519;;A61K31/519;;A61P7/00;;A61P25/28,A61K31/22;;A61K31/415;;A61K31/44;;A61P25/28,,2,2,034-643-119-078-087;;021-675-444-105-119,9500450;;18674521;;pmc2632551;;10.1016/j.brainres.2008.06.122,"SUGITA MASAO ET AL: ""Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors"", CANCER RESEARCH, vol. 58, no. 5, 1 March 1998 (1998-03-01), pages 914 - 920, XP002548317, ISSN: 0008-5472;;BLACK K L ET AL: ""PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model"", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1230, 16 September 2008 (2008-09-16), pages 290 - 302, XP024521420, ISSN: 0006-8993, [retrieved on 20080714]",DISCONTINUED
3,WO,A3,WO 2006/091542 A3,112-439-793-255-582,2009-04-16,2009,US 2006/0005980 W,2006-02-22,US 65507505 P,2005-02-22,"USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN BARRIER","This invention relates to compositions, methods and kits for enhancing the permeability of the blood-brain barrier. Particularly, compositions comprising 5-phosphodiesterase inhibitors, such as sildenafil, vardenafil, or tadalafil, when administered to a mammal, will selectively enhance the permeability of the blood-brain barrier in abnormal brain tissue. This selective enhancement allows for selective delivery of therapeutic agents to treat the abnormal brain tissue; for example, a brain tumor.",CEDARS SINAI MEDICAL CENTER;;BLACK KEITH,BLACK KEITH,,https://lens.org/112-439-793-255-582,Search Report,yes,1,0,5,6,0,A61K31/415;;A61K31/415;;A61K31/22;;A61K31/22;;A61K31/519;;A61K31/519;;A61P7/00;;A61P25/28,A01N43/42;;A01N43/50;;A61K31/415;;A61K31/44,,2,1,063-285-100-536-089,10.1161/01.cir.102.25.3068;;11120696,"PHILLIPS, B.G. ET AL., CIRCULATION, vol. 102, 2000, pages 3068 - 3073, XP008122152;;See also references of EP 1850852A4",PENDING
4,US,A1,US 2020/0330592 A1,085-502-495-067-745,2020-10-22,2020,US 201816754106 A,2018-10-08,US 201816754106 A;;US 201762569977 P;;US 2018/0054854 W,2017-10-09,COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S AND OTHER AMYLOID RELATED DISEASES,"The present disclosure relates to methods of treating, delaying the onset, alleviating a symptom, and/or deterring the progression of a disease related to beta amyloid deposits, neurological damage, tauopathy, and/or neurodegeneration by administering a myelin sheath protein and an antibody, such as an anti-tau antibody and/or an antibody that binds amyloid beta. The present disclosure relates to methods of using a myelin sheath protein and/or an antibody, such as an anti-tau antibody and/or an antibody that binds amyloid beta, to treat or to slow the progression of a disease characterized in part by beta amyloid (A) expression or activity, or by aberrant deposition of beta amyloid in a subject, such as in Alzheimers disease, and the pathologies associated with such a disease, including for example, behavioral changes or cognitive dysfunction associated with Alzheimers disease.",BLACK KEITH,BLACK KEITH,,https://lens.org/085-502-495-067-745,Patent Application,yes,0,1,2,2,70,A61K39/3955;;A61K38/1709;;A61K38/1709;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61P25/28;;C07K14/4713;;C07K14/70503;;C07K16/18;;C07K2317/31,A61K39/395;;A61K38/17;;A61P25/28,,0,0,,,,DISCONTINUED
5,WO,A1,WO 2019/074840 A1,006-951-289-467-99X,2019-04-18,2019,US 2018/0054854 W,2018-10-08,US 201762569977 P,2017-10-09,COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S AND OTHER AMYLOID RELATED DISEASES,"The present disclosure relates to methods of treating, delaying the onset, alleviating a symptom, and/or deterring the progression of a disease related to beta amyloid deposits, neurological damage, tauopathy, and/or neurodegeneration by administering a myelin sheath protein and an antibody, such as an anti-tau antibody and/or an antibody that binds amyloid beta. The present disclosure relates to methods of using a myelin sheath protein and/or an antibody, such as an anti-tau antibody and/or an antibody that binds amyloid beta, to treat or to slow the progression of a disease characterized in part by beta amyloid (A) expression or activity, or by aberrant deposition of beta amyloid in a subject, such as in Alzheimers disease, and the pathologies associated with such a disease, including for example, behavioral changes or cognitive dysfunction associated with Alzheimers disease.",BLACK KEITH,BLACK KEITH,,https://lens.org/006-951-289-467-99X,Patent Application,yes,8,4,2,2,70,A61K39/3955;;A61K38/1709;;A61K38/1709;;A61K39/3955;;A61K2039/505;;A61K2039/507;;A61P25/28;;C07K14/4713;;C07K14/70503;;C07K16/18;;C07K2317/31,A61K39/00;;A61K39/395;;C07K14/47,,1,1,010-779-529-243-841,pmc5425508;;28197669;;10.1007/s00018-017-2463-7,"ZUROFF ET AL.: ""Clearance of cerebral Abeta in Alzheimer's disease: reassessing the role of microglia and monocytes"", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 74, no. 12, 14 February 2017 (2017-02-14), pages 2167 - 2201, XP036232186, DOI: doi:10.1007/s00018-017-2463-7",PENDING
6,EP,A2,EP 1850852 A2,042-830-723-450-213,2007-11-07,2007,EP 06735574 A,2006-02-22,US 2006/0005980 W;;US 65507505 P,2005-02-22,"USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN BARRIER",,CEDARS SINAI MEDICAL CENTER,BLACK KEITH,,https://lens.org/042-830-723-450-213,Patent Application,yes,0,0,5,6,0,A61K31/415;;A61K31/415;;A61K31/22;;A61K31/22;;A61K31/519;;A61K31/519;;A61P7/00;;A61P25/28,A61K31/22;;A61K31/415;;A61K31/44;;A61P25/28,,0,0,,,,DISCONTINUED
7,US,A1,US 2020/0330581 A1,044-428-527-562-354,2020-10-22,2020,US 201816754108 A,2018-10-08,US 201816754108 A;;US 201762569989 P;;US 2018/0054857 W,2017-10-09,ONCOLYTIC CANCER IMMUNOTHERAPIES AND METHODS OF USE,"Disclosed herein are methods of treating a brain cancer comprising administering to a subject in need thereof a viral composition comprising a flavivirus or portion of a flavivirus wherein the flavivirus is engineered to comprise a heterologous nucleic acid sequence encoding a suicide gene. In some embodiments, the brain cancer is selected from the group consisting of astrocytoma, oligodendroglioma, ependymoma, meningioma, schwannoma, craniopharyngioma, germinoma, and pineocytoma. In some embodiments the flavivirus comprises Zika virus, spondweni virus, kedougous virus, or a combination thereof. In some embodiments, the flavivirus comprises Zika virus. In some embodiments, the suicide gene encodes a protein that converts a prodrug into a cytotoxic agent. In some embodiments, the viral composition is administered in combination with the immunostimulatory agent.",BLACK KEITH,BLACK KEITH,,https://lens.org/044-428-527-562-354,Patent Application,yes,0,4,2,2,3,A61K39/12;;A61K39/12;;A01K2207/12;;A01K2227/105;;A01K2267/0331;;A61K31/7052;;A61K35/768;;A61K35/768;;A61K45/06;;A61K48/00;;A61K2039/5256;;A61K2039/5256;;A61K2039/585;;A61K2039/585;;A61K2039/80;;A61P35/00;;A61P35/00;;C12N7/00;;C12N2770/24132;;C12N2770/24132;;C12N2770/24134;;Y02A50/30,A61K39/12;;A61K31/7052;;A61K35/768;;A61K45/06;;A61P35/00;;C12N7/00,,0,0,,,,DISCONTINUED
8,WO,A2,WO 2006/091542 A2,190-384-896-113-986,2006-08-31,2006,US 2006/0005980 W,2006-02-22,US 65507505 P,2005-02-22,"USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN BARRIER","This invention relates to compositions, methods and kits for enhancing the permeability of the blood-brain barrier. Particularly, compositions comprising 5-phosphodiesterase inhibitors, such as sildenafil, vardenafil, or tadalafil, when administered to a mammal, will selectively enhance the permeability of the blood-brain barrier in abnormal brain tissue. This selective enhancement allows for selective delivery of therapeutic agents to treat the abnormal brain tissue; for example, a brain tumor.",CEDARS SINAI MEDICAL CENTER;;BLACK KEITH,BLACK KEITH,,https://lens.org/190-384-896-113-986,Patent Application,yes,0,15,5,6,0,A61K31/415;;A61K31/415;;A61K31/22;;A61K31/22;;A61K31/519;;A61K31/519;;A61P7/00;;A61P25/28,A61K31/519,,1,0,,,See references of EP 1850852A4,PENDING
9,CA,A1,CA 2162055 A1,041-484-042-788-168,1994-11-24,1994,CA 2162055 A,1994-04-19,US 5962393 A,1993-05-10,METHOD FOR SELECTIVE OPENING OF ABNORMAL BRAIN TISSUE CAPILLARIES,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK KEITH L,BLACK KEITH L,,https://lens.org/041-484-042-788-168,Patent Application,no,0,0,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/17;;A61K38/04;;A61P9/08,,0,0,,,,DISCONTINUED
10,AU,A,AU 1974/074320 A,150-082-453-010-852,1976-04-15,1976,AU 1974/074320 A,1973-10-30,AU 546173 A,1973-10-30,BUILDING CONSTRUCTION,,TULLOCH LTD,BLACK KEITH STUART,,https://lens.org/150-082-453-010-852,Patent Application,no,0,1,1,1,0,E04B1/14,E04B1/14,,0,0,,,,DISCONTINUED
11,AU,B2,AU 679530 B2,104-718-869-161-980,1997-07-03,1997,AU 1994/067701 A,1994-04-19,US 5962393 A;;US 9404269 W,1993-05-10,Method for selective opening of abnormal brain tissue capillaries,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK KEITH L,BLACK KEITH L,,https://lens.org/104-718-869-161-980,Granted Patent,no,1,0,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/17;;A61K38/04;;A61P9/08,,0,0,,,,EXPIRED
12,WO,A1,WO 1994/027133 A1,112-208-112-986-278,1994-11-24,1994,US 9404269 W,1994-04-19,US 5962393 A,1993-05-10,METHOD FOR SELECTIVE OPENING OF ABNORMAL BRAIN TISSUE CAPILLARIES,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK KEITH L,BLACK KEITH L,,https://lens.org/112-208-112-986-278,Patent Application,yes,1,0,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/04;;A61P9/08;;A61K38/17,,0,0,,,,PATENTED
13,CA,A1,CA 2309947 A1,189-248-986-132-222,1999-05-20,1999,CA 2309947 A,1998-11-10,US 96816997 A;;US 9823932 W,1997-11-12,ENHANCED OPENING OF ABNORMAL BRAIN TISSUE CAPILLARIES,Improved compositions and methods for increasing permeability of abnormal brain tissue to pharmaceutical agents. Cyclic GMP specific phosphodiesterase inhibitors are combined with bradykinin or a bradykinin analog to provide enhanced permeability of brain capillaries which is limited to abnormal brain tissue. Neuropharmaceutical and neurodiagnostic agents introduced into the bloodstream are directed selectively to the abnormal brain tissue. The pharmaceutical preparation composed of bradykinin or a bradykinin analog and a cyclic GMP specific phosphodiesterase inhibitor may be administered either intravenously or directly into the carotid artery.,UNIV CALIFORNIA,BLACK KEITH L,,https://lens.org/189-248-986-132-222,Patent Application,no,0,0,7,7,0,A61K38/043;;A61K38/043,A61K38/04,,0,0,,,,DISCONTINUED
14,AT,T1,AT E220329 T1,100-962-638-156-948,2002-07-15,2002,AT 94915822 T,1994-04-19,US 5962393 A;;US 9404269 W,1993-05-10,ZUSAMMENSETZUNG ENTHALTEND BRADYKININ ZUM SELEKTIVEN OFFNEN VON ANORMALEN GEHIRNGEWEBES KAPILLAREN,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK KEITH L,BLACK KEITH L,,https://lens.org/100-962-638-156-948,Granted Patent,no,0,0,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/17;;A61K38/04;;A61P9/08,,0,0,,,,DISCONTINUED
15,US,A,US 6043223 A,142-862-166-093-963,2000-03-28,2000,US 96816997 A,1997-11-12,US 96816997 A,1997-11-12,Enhanced opening of abnormal brain tissue capillaries,Improved compositions and methods for increasing permeability of abnormal brain tissue to pharmaceutical agents. Cyclic GMP specific phosphodiesterase inhibitors are combined with bradykinin or a bradykinin analog to provide enhanced permeability of brain capillaries which is limited to abnormal brain tissue. Neuropharmaceutical and neurodiagnostic agents introduced into the bloodstream are directed selectively to the abnormal brain tissue. The pharmaceutical preparation composed of bradykinin or a bradykinin analog and a cyclic GMP specific phosphodiesterase inhibitor may be administered either intravenously or directly into the carotid artery.,UNIV CALIFORNIA,BLACK KEITH L,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1997-10-25),https://lens.org/142-862-166-093-963,Granted Patent,yes,6,6,7,7,0,A61K38/043;;A61K38/043,A61K38/04,514/15;;514/261;;514/79;;514/48;;514/17;;536/26.11;;435/240.242;;435/240.243;;435/240.241;;435/240.23;;435/240.24,2,1,035-708-560-486-04X,8752174,"Marrian Webster s Collegiate Dictionary, 10th ed; 1996, p. 748.;;Nakano, S., Matsukado, K. and Black K.L., Increased Brain Tumor Microvessel Permeability After Intracarotid Bradykinn Infusion Is Mediated by Nitric Oxide, Cancer Research 56, 4027 4031 (1996).",EXPIRED
16,WO,A1,WO 1999/024053 A1,164-167-724-352-469,1999-05-20,1999,US 9823932 W,1998-11-10,US 96816997 A,1997-11-12,ENHANCED OPENING OF ABNORMAL BRAIN TISSUE CAPILLARIES,Improved compositions and methods for increasing permeability of abnormal brain tissue to pharmaceutical agents. Cyclic GMP specific phosphodiesterase inhibitors are combined with bradykinin or a bradykinin analog to provide enhanced permeability of brain capillaries which is limited to abnormal brain tissue. Neuropharmaceutical and neurodiagnostic agents introduced into the bloodstream are directed selectively to the abnormal brain tissue. The pharmaceutical preparation composed of bradykinin or a bradykinin analog and a cyclic GMP specific phosphodiesterase inhibitor may be administered either intravenously or directly into the carotid artery.,UNIV CALIFORNIA,BLACK KEITH L,,https://lens.org/164-167-724-352-469,Patent Application,yes,4,3,7,7,0,A61K38/043;;A61K38/043,A61K38/04,,1,0,,,See also references of EP 1028740A4,PATENTED
17,US,A,US 5141022 A,181-620-932-348-623,1992-08-25,1992,US 79660591 A,1991-11-21,US 79660591 A;;US 50836490 A,1990-04-12,Pressure regulating valve apparatus,"A fluid pressure regulating valve apparatus for controlling either upstream or downstream fluid pressure includes a lower housing including a lower interior space and an upper housing including an upper interior space which is separated from the lower space by a deformable diaphragm. The diaphragm and lower space together define a substantially smooth, generally void free fluid receiving cavity with which first and second conduits are connected. The first conduit includes a constriction and the second conduit is angled relative to the first conduit. A valve is provided including a valve closure member movable between flow-permitting and flow-preventing positions. An upper stem element is connected to the diaphragm and extends through the upper interior space to an upper and disposed exterior of the upper housing such that pressure regulation and regulator adjustment may both be carried out from outside the lower housing.",CASHCO INC,BLACK W KEITH,,https://lens.org/181-620-932-348-623,Granted Patent,yes,7,32,1,4,0,G05D16/0655;;G05D16/0655;;Y10T137/7782;;Y10T137/7782;;Y10T137/7825;;Y10T137/7825,G05D16/06,137/495;;137/505.41;;251/284,0,0,,,,EXPIRED
18,EP,B1,EP 0698203 B1,061-931-689-061-661,2002-07-10,2002,EP 94915822 A,1994-04-19,US 9404269 W;;US 5962393 A,1993-05-10,COMPOSITION COMPRISING BRADYKININ FOR SELECTIVE OPENING OF ABNORMAL BRAIN TISSUE CAPILLARIES,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK KEITH L,BLACK KEITH L,,https://lens.org/061-931-689-061-661,Granted Patent,yes,1,0,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/17;;A61K38/04;;A61P9/08,,2,0,,,"JOURNAL OF NEUROSURGERY, vol. 72, no. 6, June 1990, SPRINGFIELD, IL, US, pages 912-916, XP000612095 K.L. BLACK ET AL.: ""SELECTIVE OPENING OF THE BLOOD-TUMOR BARRIER BY INTRACAROTID INFUSION OF LEUKOTRIENE C4."";;JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, vol. 14, no. 5, September 1994, NEW YORK, N.Y., US, pages 862-870, XP000612061 T. INAMURA ET AL.: ""BRADYKININ SELECTIVELY OPENS BLOOD-TUMOR BARRIER IN EXPERIMENTAL BRAIN TUMORS.""",EXPIRED
19,ES,T3,ES 2179843 T3,010-177-909-504-400,2003-02-01,2003,ES 94915822 T,1994-04-19,US 5962393 A,1993-05-10,METODO PARA LA ABERTURA SELECTIVA DE CAPILARES DE TEJIDO CEREBRAL ANORMAL.,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK KEITH L,BLACK KEITH L,,https://lens.org/010-177-909-504-400,Granted Patent,no,0,0,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/04;;A61P9/08;;A61K38/17,,0,0,,,,EXPIRED
20,EP,A1,EP 0451326 A1,135-926-713-825-649,1991-10-16,1991,EP 90118645 A,1990-09-28,US 50836490 A,1990-04-12,Pressure regulating valve apparatus.,"A fluid pressure regulating valve apparatus for controlling either upstream or downstream fluid pressure includes a lower housing (20) including a lower interior space (24) and an upper housing (22) including an upper interior space (46) which is separated from the lower interior space by a deformable diaphragm (38). The diaphragm (38) and lower interior space (24) together define a substantially smooth, generally void free fluid receiving cavity with which first and second conduits (26,28) are connected. The first conduit (26)includes a constriction (30) and the second conduit (28) is angled relative to the first conduit (26). A valve is provided including a valve closure member (58) movable between flow-permitting and flow-preventing positions. An upper stem element (72) connected to the diaphragm (38) and extends through the upper interior space (46) to an upper end disposed exterior of the upper housing such that pressure regulation and regulator adjustment may both be carried out from outside the lower housing.",CASHCO INC,BLACK W KEITH,,https://lens.org/135-926-713-825-649,Patent Application,yes,4,3,3,4,0,G05D16/0655;;Y10T137/7782;;Y10T137/7825;;Y10T137/7782;;Y10T137/7825;;G05D16/0655,F16K17/30;;G05D16/06,,0,0,,,,DISCONTINUED
21,EP,A4,EP 1028740 A4,027-827-811-990-673,2003-04-16,2003,EP 98956694 A,1998-11-10,US 9823932 W;;US 96816997 A,1997-11-12,ENHANCED OPENING OF ABNORMAL BRAIN TISSUE CAPILLARIES,,UNIV CALIFORNIA,BLACK KEITH L,,https://lens.org/027-827-811-990-673,Search Report,no,0,0,7,7,0,A61K38/043;;A61K38/043,A61K38/04,,6,4,110-874-009-938-464;;034-643-119-078-087;;001-750-822-248-814;;021-034-071-659-388,10.1006/exnr.1996.0175;;8912895;;9500450;;9713849;;10.1080/01616412.1998.11740564;;10.1023/a:1018938722768;;10496650,"SUGITA M ET AL: ""Cyclic GMP cyclic phosphodiesterase inhibition and intracarotid bradykinin infusion enhances molecular transport into brain tumors."", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, no. 1-2, 1997, 27th Annual Meeting of the Society for Neuroscience;New Orleans, Louisiana, USA; October 25-30, 1997, pages 2269, XP009005737, ISSN: 0190-5295;;BARTUS R T ET AL: ""Controlled Modulation of BBB Permeability Using the Bradykinin Agonist, RMP-7"", EXPERIMENTAL NEUROLOGY, SAN DIEGO, CA, US, vol. 142, 1996, pages 14 - 28, XP002195901;;SUGITA MASAO ET AL: ""Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors."", CANCER RESEARCH, vol. 58, no. 5, 1 March 1998 (1998-03-01), pages 914 - 920, XP001145561, ISSN: 0008-5472;;SUGITA MASAO ET AL: ""Nitric oxide and cyclic GMP attenuate sensitivity of the blood-tumor barrier permeability to bradykinin."", NEUROLOGICAL RESEARCH, vol. 20, no. 6, September 1998 (1998-09-01), pages 559 - 563, XP009005738, ISSN: 0161-6412;;MACKIC JASMINA B ET AL: ""Cereport(R) (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers."", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 16, no. 9, 1999, pages 1360 - 1365, XP009005762, ISSN: 0724-8741;;See also references of WO 9924053A1",DISCONTINUED
22,EP,A1,EP 0698203 A1,070-378-488-996-183,1996-02-28,1996,EP 94915822 A,1994-04-19,US 9404269 W;;US 5962393 A,1993-05-10,METHOD FOR SELECTIVE OPENING OF ABNORMAL BRAIN TISSUE CAPILLARIES,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK KEITH L,BLACK KEITH L,,https://lens.org/070-378-488-996-183,Patent Application,yes,0,0,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/17;;A61K38/04;;A61P9/08,,0,0,,,,EXPIRED
23,US,A,US 5527778 A,019-719-685-968-580,1996-06-18,1996,US 38934795 A,1995-02-16,US 38934795 A;;US 5962393 A,1993-05-10,Method for selective opening of abnormal brain tissue capillaries,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin or bradykinin analog into the carotid artery. The dose of bradykinin or bradykinin analog is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK; KEITH L.,BLACK KEITH L,,https://lens.org/019-719-685-968-580,Granted Patent,yes,1,13,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/04;;A61P9/08;;A61K38/17,514/15;;514/17,19,19,100-464-230-273-428;;032-286-413-299-782;;116-546-679-026-195;;008-722-406-612-978;;054-245-421-663-57X;;034-876-936-157-815;;006-421-807-603-683;;067-307-229-123-664;;089-202-451-359-958;;038-606-625-014-177;;008-951-755-999-583;;082-644-251-549-750;;139-713-373-843-029;;110-488-192-415-358;;088-493-513-386-879;;060-183-363-855-923;;121-812-539-777-325;;034-781-597-280-314;;115-572-647-761-710,7346145;;7420270;;10.1007/bf01059646;;2479862;;10.2176/nmc.29.696;;10.1227/00006123-199207000-00013;;1641114;;10.1097/00006123-199207000-00013;;10.1002/ana.410210111;;3493728;;2303532;;10.1038/jcbfm.1990.30;;2999632;;3142506;;8301343;;10.1007/bf01057033;;10.1097/00001813-199502000-00002;;7756680;;1851050;;10.1002/1097-0142(19910601)67:11<2844::aid-cncr2820671123>3.0.co;2-k;;1460453;;8062241;;6094798;;6588976;;6091177;;10.1159/000408227;;10.1097/00006123-198301000-00006;;10.1227/00006123-198301000-00006;;6219298;;10.2176/nmc.30.113;;1695331;;3080944;;10.1002/ana.410190110,"Blasberg et al. Regional Blood Flow, Capillary permeability and glucose utilization in two brain turion models: preliminary observations and pharmakinetic implications , Cancer Treatment Rep. 1981 2:3 12. Abstract.;;Levin et al, Heonistic Modeling of Drug Delivery to Malignant Brain Tumors , L. Pharmacokinetic. Biophasn 1980 83:257 96. Abstract.;;Shibata et al, (Ultrastructural) study of capillary permeability of lipsome encapsulates cisplatin in are experimental rat Brain Tumor Model , Neurol Med Chir 1989, 29 (8):696 700. Abstract.;;Watts, R. G. and Merchant, R. E. Cerebaovascular Effects and Tumor Kinetics After a single Inbratumoral injection of human recomb, I1 2 . . . in a rat model of Glionia , Neurosurgery 1992, 31 (1) 89 98; discussion 98 99. Abstract.;;Phillips et al. Reduced Cerabral Glucose Metabolism and Increase Brain Capillary Permeability Follows High Dose Metabolism Chemotherapy: a positron emision tomographic study . Ann Neurol. 1987 21 (1) 59 63. Abstract.;;Robinson P. L. et al. Model for Drug Uptabe by Brain Tumors: Effects of Osmotic Treatment and of Diffosion in Brain . J. Cereb. Flow Metab. 1990, 10(2):153 156. Abstract.;;Miyagami et al., ACNU Delivery to maglignant cpeoia tissue by osmotic blood Brain Barrier Modification with Intracarotic Infusion q Hyperosolar Mannitol . No Shinkei Geka 1985 13(9):955 963. Abstract.;;Miyagami et al. The Effect on the Tumor Vessel Permeability by Hyperosmotic Blood Brain Barrier Disruption , No To Shinkei 1988 40(9):875 82 (Abstract).;;Hodozuka et al., Sequential Change of Capillary Permeability in the Rat Brain After Surgical Removal of a Experimental Brain Tumor , L. Neuroohcol. 1993 16(3):191 200. Abstract.;;Koehler, P. J. Uses of Corticosteroids in Neuro oncology. Anticancer Drugs 1995 61:19 33. Abstract.;;Marh Jewicz et al. Intracauotic Therapy with Etoposide and Cisplation for Malignant Brain Tumors , Cancer 1991 67:11 2844 9. Abstract.;;Wiranocoska, M., Blood Brian Barriers and Treatment of Central Nervous System Tumors, J. Fla. Med. Assoc.,1992, 79 10:707 10. Abstract.;;Yuan et al. Vascular Permeability and Microcirulation of Gliomas and Mammary Carcinomas Transplanted in Rat and Mouse Cranial Windows . Cancer Res. 1994. 54(17) 4564 8. Abstract.;;Blasberg et al., Concurrent Measurements of Blood Flow and Transcapillary Transport in Avian Sarcoma oiros induced experimental Brain Tumors: Implications for Chemotherapy . J. Pharmacol Exp. Ther. 1984 231 (3):724 35 Abstract.;;Yamada et al., Local Blood Flow and Capillary Permeability in the Experimental Meningeal Carcinomatosis, No To Shinkei, 1984 36(3):221 26. Abstract.;;Groothius et al., Regional Blood Flow and Blood to Tissue Transport in Five Brain Tumor Models, Implications for Chemotherapy: Prog Exp Tumor Res. 1984 27 132 53. Abstract.;;Neuweh et al., Inability of Dimethyl sulfoxide and 5 fluorouabcil to Open the Blood Brain Barrier . Neurosurgery 1983 12(1):29 34.;;Aizawa et al., Measurement of Cerebral Blood Flow, Cerebrial Blood Volume, and Cerebral Capillary Permeability in Gluonia Bearing Rats . Nerol. Med. Chir 1990 30 (2):113 18. Abstract.;;Hiesiger et al. Opening the Blood Brain and Blood tumor Barriers in Experimental Rat Brain Tumors: the Effect of Intracaroted Hyper Osmolar Mannitol on Capillary Permeability and Blood Flow. Annual. Neurol. 1986 19 (1):50 9. Abstract.",EXPIRED
24,AU,A,AU 1974/070585 A,104-796-571-000-045,1976-01-08,1976,AU 1974/070585 A,1972-10-10,AU PB077172 A,1972-10-10,FLOOR/CEILING CONSTRUCTION,,TULLOCH LTD,BLACK KEITH STUART,,https://lens.org/104-796-571-000-045,Patent Application,no,0,0,1,1,0,E04B1/34315,E04B1/343,,0,0,,,,DISCONTINUED
25,US,A,US 5070901 A,088-506-125-915-820,1991-12-10,1991,US 50836490 A,1990-04-12,US 50836490 A,1990-04-12,PRESSURE REGULATING VALVE APPARATUS,"A fluid pressure regulating valve apparatus for controlling either upstream or downstream fluid pressure includes a lower housing including a lower interior space and an upper housing including an upper interior space which is separated from the lower space by a deformable diaphragm. The diaphragm and lower space together define a substantially smooth, generally void free fluid receiving cavity with which first and second conduits are connected. The first conduit includes a constriction and the second conduit is angled relative to the first conduit. A valve is provided including a valve closure member movable between flow-permitting and flow-preventing positions. An upper stem element is connected to the diaphragm and extends through the upper interior space to an upper end disposed exterior of the upper housing such that pressure regulation and regulator adjustment may both be carried out from outside the lower housing.",CASHCO INC,BLACK W KEITH,CASHCO INC. A CORPORATION OF KS (1992-01-07);;CASHCO INC. P.O. BOX 6 ELLSWORTH A CORP. OF KS (1990-05-16),https://lens.org/088-506-125-915-820,Granted Patent,yes,22,11,3,4,0,G05D16/0655;;Y10T137/7782;;Y10T137/7825;;Y10T137/7782;;Y10T137/7825;;G05D16/0655,F16K17/30;;G05D16/06,137/495;;137/505.41;;251/284,0,0,,,,EXPIRED
26,US,A1,US 2008/0188480 A1,080-265-858-508-928,2008-08-07,2008,US 81349406 A,2006-02-22,US 81349406 A;;US 65507505 P;;US 2006/0005980 W,2005-02-22,"Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier","This invention relates to compositions, methods and kits for enhancing the permeability of the blood-brain barrier. Particularly, compositions comprising 5-phosphodiesterase inhibitors, such as sildenafil, vardenafil, or tadalafil, when administered to a mammal, will selectively enhance the permeability of the blood-brain barrier in abnormal brain tissue. This selective enhancement allows for selective delivery of therapeutic agents to treat the abnormal brain tissue; for example, a brain tumor.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2007-07-05),https://lens.org/080-265-858-508-928,Patent Application,yes,47,10,5,6,0,A61K31/415;;A61K31/415;;A61K31/22;;A61K31/22;;A61K31/519;;A61K31/519;;A61P7/00;;A61P25/28,A61K31/4985;;A61K31/519;;A61P7/00,514/250;;514/262.1,0,0,,,,DISCONTINUED
27,AU,A,AU 1999/013154 A,124-575-676-360-588,1999-05-31,1999,AU 1999/013154 A,1998-11-10,US 96816997 A;;US 9823932 W,1997-11-12,Enhanced opening of abnormal brain tissue capillaries,,UNIV CALIFORNIA,BLACK KEITH L,,https://lens.org/124-575-676-360-588,Patent Application,no,0,0,7,7,0,A61K38/043;;A61K38/043,A61K38/04,,0,0,,,,EXPIRED
28,EP,A4,EP 0698203 A4,140-358-259-091-777,1997-02-26,1997,EP 94915822 A,1994-04-19,US 9404269 W;;US 5962393 A,1993-05-10,METHOD FOR SELECTIVE OPENING OF ABNORMAL BRAIN TISSUE CAPILLARIES,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK KEITH L,BLACK KEITH L,,https://lens.org/140-358-259-091-777,Search Report,no,0,0,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/17;;A61K38/04;;A61P9/08,,2,2,017-600-680-062-666;;026-292-803-341-871,2338576;;10.3171/jns.1990.72.6.0912;;10.1038/jcbfm.1994.108;;8063881,"K.L. BLACK ET AL.: ""SELECTIVE OPENING OF THE BLOOD-TUMOR BARRIER BY INTRACAROTID INFUSION OF LEUKOTRIENE C4."", JOURNAL OF NEUROSURGERY, vol. 72, no. 6, June 1990 (1990-06-01), SPRINGFIELD, IL, US, pages 912 - 916, XP000612095;;T. INAMURA ET AL.: ""BRADYKININ SELECTIVELY OPENS BLOOD-TUMOR BARRIER IN EXPERIMENTAL BRAIN TUMORS."", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, vol. 14, no. 5, September 1994 (1994-09-01), NEW YORK, N.Y., US, pages 862 - 870, XP000612061",EXPIRED
29,AU,B2,AU 745588 B2,135-828-863-040-581,2002-03-21,2002,AU 1999/013154 A,1998-11-10,US 96816997 A;;US 9823932 W,1997-11-12,Enhanced opening of abnormal brain tissue capillaries,,UNIV CALIFORNIA,BLACK KEITH L,,https://lens.org/135-828-863-040-581,Granted Patent,no,3,0,7,7,0,A61K38/043;;A61K38/043,A61K38/04,,0,0,,,,EXPIRED
30,EP,A1,EP 1028740 A1,122-075-550-763-556,2000-08-23,2000,EP 98956694 A,1998-11-10,US 9823932 W;;US 96816997 A,1997-11-12,ENHANCED OPENING OF ABNORMAL BRAIN TISSUE CAPILLARIES,,UNIV CALIFORNIA,BLACK KEITH L,,https://lens.org/122-075-550-763-556,Patent Application,yes,0,0,7,7,0,A61K38/043;;A61K38/043,A61K38/04,,0,0,,,,DISCONTINUED
31,DE,T2,DE 69430951 T2,102-773-093-675-739,2003-03-27,2003,DE 69430951 T,1994-04-19,US 5962393 A;;US 9404269 W,1993-05-10,ZUSAMMENSETZUNG ENTHALTEND BRADYKININ ZUM SELEKTIVEN OFFNEN VON ANORMALEN GEHIRNGEWEBES KAPILLAREN,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK KEITH L,BLACK KEITH L,,https://lens.org/102-773-093-675-739,Granted Patent,no,0,0,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/17;;A61K38/04;;A61P9/08,,0,0,,,,EXPIRED
32,US,A1,US 2009/0048179 A1,175-852-985-151-643,2009-02-19,2009,US 23887208 A,2008-09-26,US 23887208 A;;US 81349407 A;;US 2006/0005980 W;;US 97616107 P;;US 65507505 P,2005-02-22,USE OF 5-PHOSPHODIESTERASE INHIBITORS TO ENHANCE THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER OF ABNORMAL BRAIN TISSUE AND THE BLOOD-TUMOR BARRIER,"This invention relates to methods and kits for enhancing the permeability of the blood-brain barrier of abnormal brain tissue or the blood-tumor barrier. Particularly, methods comprising the administration of 5-phosphodiesterase inhibitors, such as sildenafil and vardenafil, to selectively enhance the permeability of the blood-brain barrier of abnormal brain tissue or the blood-tumor barrier are described. This selective enhancement allows for selective delivery of therapeutic agents or imaging to treat the abnormal brain tissue or a tumor, including brain tumors and non-central nervous system tumors.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2008-09-30),https://lens.org/175-852-985-151-643,Patent Application,yes,4,7,1,6,0,A61K45/06;;A61K45/06;;A61K31/282;;A61K31/282;;A61K31/4985;;A61K31/4985;;A61K31/519;;A61K31/519;;A61K38/043;;A61K38/043;;A61P35/00,A61K38/08;;A61K31/282;;A61K31/4985;;A61K31/519;;A61P35/00,514/15;;514/252.16;;514/250;;514/34;;514/492,0,0,,,,DISCONTINUED
33,US,A,US 5434137 A,006-223-137-429-710,1995-07-18,1995,US 5962393 A,1993-05-10,US 5962393 A,1993-05-10,Method for selective opening of abnormal brain tissue capillaries,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK; KEITH L.,BLACK KEITH L,,https://lens.org/006-223-137-429-710,Granted Patent,yes,2,47,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/04;;A61P9/08;;A61K38/17,514/15;;514/17,9,7,002-160-319-556-349;;031-907-397-850-732;;000-052-341-986-694;;143-231-148-980-396;;017-600-680-062-666;;049-116-936-194-985;;067-140-093-724-978,2843554;;10.1038/jcbfm.1988.109;;10.1017/s0317167100036301;;3742336;;10.1038/jcbfm.1984.82;;6501443;;10.1080/01616412.1992.11740093;;1282688;;2338576;;10.3171/jns.1990.72.6.0912;;1675639;;10.1038/jcbfm.1991.115;;1506887;;10.3171/jns.1992.77.3.0407,"Wahl, et al. (1987) Effects of Bradykinin on Cerebral Haemodynamics and Blood Brain Barrier Function , In Peptidergic Mechanisms in the Cerebral Circulation (Edvinsson, L. and McCulloch, J., Eds.) Chichester, Horwood, pp. 166 190.;;Wahl, et al. (1988) Mediators of Blood Brain Barrier Dysfunction and Formation of Basogenic Brain Edema , J. Cerebral Blood Flow and Metabolism, 8:621 634.;;Raymond, et al. (1986) Pharmacological Modification of Bradykinin Induced Breakdown of the Blood Brain Barrier , Can. J. Neur. Sci., 13:214 220.;;Wahl, et al. (1986) Cerebrovascular Effects of Bradykinin, in Neural Regulation of Brain Circulation (Owman, C. and Hardebo, J. E. Eds), Elsevier Science Publishers B.V., pp. 419 430.;;Unterberg, et al. (1984) Effects of Bradykinin on Permeability and Diameter of Pial Vessels in Vivo, J. Cerebral Blood Flow and Metabolism, 4:574 585.;;Black, et al. (1992) Increased Opening of Blood Tumor Barrier by Leukotriene C 4 is Dependent on Size of Molecules, Neurological Research, 14: 402 404.;;Black, et al. (1990) Selective Opening of the Blood Tumor Barrier by Intracarotid Infusion of Leukotriene C 4 , J. Neurosurg., 72:912 916.;;Baba, T., et al. (1991) Intracarotid Infusion of Leukotriene C 4 Selectively Increases Blood Brain Barrier Permeability After Focal Ischemica in Rats, Journal of Cerebral Blood Flow and Metabolism, 11:638 643.;;Chio, et al. (1992) Selective Blood Tumor Barrier Disruption by Leukotrienes, J. Neurosurg., 77:407 410.",EXPIRED
34,AU,A,AU 1973/058957 A,110-660-757-491-051,1975-02-06,1975,AU 1973/058957 A,1973-08-06,GB 3793072 A,1972-08-15,ILLUMINATED TELEPHONE DIAL,,STANDARD TELEPHONES CABLES LTD,BLACK KEITH MARRIOTT,,https://lens.org/110-660-757-491-051,Patent Application,no,0,0,3,4,0,H04M1/22,H04M1/22,,0,0,,,,DISCONTINUED
35,DE,A1,DE 2340141 A1,199-148-023-411-231,1974-02-28,1974,DE 2340141 A,1973-08-08,GB 3793072 A,1972-08-15,NUMMERNSCHALTER,,INT STANDARD ELECTRIC CORP,BLACK KEITH MARRIOTT,,https://lens.org/199-148-023-411-231,Patent Application,no,0,0,3,4,0,H04M1/22,H04M1/22,,0,0,,,,PENDING
36,AU,A,AU 1994/067701 A,012-631-785-168-66X,1994-12-12,1994,AU 1994/067701 A,1994-04-19,US 5962393 A;;US 9404269 W,1993-05-10,Method for selective opening of abnormal brain tissue capillaries,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK KEITH L,BLACK KEITH L,,https://lens.org/012-631-785-168-66X,Patent Application,no,0,0,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/17;;A61K38/04;;A61P9/08,,0,0,,,,EXPIRED
37,DE,D1,DE 69430951 D1,126-401-375-238-274,2002-08-14,2002,DE 69430951 T,1994-04-19,US 5962393 A;;US 9404269 W,1993-05-10,ZUSAMMENSETZUNG ENTHALTEND BRADYKININ ZUM SELEKTIVEN OFFNEN VON ANORMALEN GEHIRNGEWEBES KAPILLAREN,A method for selectively opening abnormal brain tissue capillaries of a mammal in order to allow selective passage of both low and high molecular weight neuropharmaceutical agents into abnormal brain tissue. The method utilizes direct infusion of bradykinin into the carotid artery. The dose of bradykinin is maintained at levels which provide opening of abnormal brain tissue capillaries without opening normal brain capillaries. The method is useful for introducing a wide variety of neuropharmaceutical agents selectively to brain tumors and other abnormal brain tissue.,BLACK KEITH L,BLACK KEITH L,,https://lens.org/126-401-375-238-274,Granted Patent,no,0,0,14,14,0,A61K38/043;;A61P9/08;;A61K38/043,A61K38/17;;A61K38/04;;A61P9/08,,0,0,,,,EXPIRED
38,WO,A2,WO 2006/091587 A2,177-677-844-249-599,2006-08-31,2006,US 2006/0006088 W,2006-02-22,US 65500905 P,2005-02-22,USE OF MINOXIDIL SULFATE AS AN ANTI-TUMOR DRUG,"The invention relates to compositions, methods and kits for the treatment of cancer. ATP-dependent potassium channel agonists, salts thereof, or chemical analogs thereof, for example, minoxidil sulfate, have been found to possess anti-neoplastic properties. Administering minoxidil sulfate may prolong the life of a cancer patient; for example, a patient with a brain tumor.",CEDARS SINAI MEDICAL CENTER;;BLACK KEITH;;WHEELER CHRISTOPHER,BLACK KEITH;;WHEELER CHRISTOPHER,,https://lens.org/177-677-844-249-599,Patent Application,yes,0,2,6,6,0,A61K31/44;;A61K31/506;;A61K45/06;;A61P35/00;;A61P35/04;;A61K39/4615;;A61K2239/47;;A61K39/4622;;A61K39/46432;;A61K31/44;;A61K45/06;;A61K31/506,A61K39/02;;A61K31/00,,0,0,,,,PENDING
39,EP,A2,EP 1850663 A2,112-634-173-462-429,2007-11-07,2007,EP 06735656 A,2006-02-22,US 2006/0006088 W;;US 65500905 P,2005-02-22,USE OF MINOXIDIL SULFATE AS AN ANTI-TUMOR DRUG,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH;;WHEELER CHRISTOPHER,,https://lens.org/112-634-173-462-429,Patent Application,yes,0,0,6,6,0,A61K31/44;;A61K31/506;;A61K45/06;;A61P35/00;;A61P35/04;;A61K39/4615;;A61K2239/47;;A61K39/4622;;A61K39/46432;;A61K31/44;;A61K45/06;;A61K31/506,A61K31/44;;A61K31/00;;A61K31/506;;A61P35/00,,0,0,,,,DISCONTINUED
40,US,A1,US 2018/0015047 A1,118-287-584-040-815,2018-01-18,2018,US 201715650329 A,2017-07-14,US 201715650329 A;;US 201662363769 P,2016-07-18,MAGNETIC PARTICLE-BASED SUBSTANCE REMOVAL FROM TISSUE,Provided herein are methods and compositions for removal of a substance using magnetic nanoparticles comprising a tagging element capable of targeting the nanoparticle to the substance. Further provided herein are methods and devices for removal of magnetic nanoparticle bound substances using a magnetic field generating device.,FORTEM NEUROSCIENCES INC,BLACK KEITH;;KAVANAUGH JACK,FORTEM NEUROSCIENCES INC (2017-10-24),https://lens.org/118-287-584-040-815,Patent Application,yes,2,1,2,2,0,A61K9/5115;;A61B2017/00345;;A61B34/73;;A61K41/0052;;A61B2090/3954;;A61B18/04;;A61B18/12;;A61F2007/009;;A61B2090/374;;A61B2090/3762;;A61B2218/007;;A61B2017/00876;;A61K9/0009;;A61K9/5094;;A61B34/73;;A61K41/0052;;A61K47/50;;A61B2090/3954;;A61B2017/00345;;A61K9/5115;;A61B2090/374;;A61B18/04;;A61F2007/009;;A61B18/12;;A61B2090/3762;;A61B2218/007;;A61B17/320092;;A61B2017/00876;;A61K9/0009;;A61K9/5094;;A61M25/0127,A61K9/50;;A61B17/00;;A61B17/32;;A61K9/00;;A61M25/01,,0,0,,,,DISCONTINUED
41,WO,A2,WO 2021/026522 A2,175-236-078-151-640,2021-02-11,2021,US 2020/0045570 W,2020-08-10,US 201962884570 P,2019-08-08,METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY,Described herein are compositions and methods for treating cancer and autoimmune diseases.,CEDARS SINAI MEDICAL CENTER,YU JOHN;;BLACK KEITH,,https://lens.org/175-236-078-151-640,Patent Application,yes,0,0,5,5,31,A61K39/0011;;A61K2039/5158;;A61K39/001192;;A61K39/001186;;A61K39/001188;;A61K39/001156;;A61K39/001148;;A61K39/001106;;A61K39/001119;;A61P35/00;;A61K39/39;;A61K39/00119;;A61K2039/80;;A61K39/001106;;A61K39/001188;;A61K39/001192;;A61K39/001119;;A61K39/001178;;A61K39/001122;;A61K39/001186;;A61K31/15;;A61K31/165;;A61K31/341;;A61K2039/5158,A61K39/00,,0,0,,,,PENDING
42,US,A1,US 2010/0271825 A1,066-592-095-638-062,2010-10-28,2010,US 76680710 A,2010-04-23,US 76680710 A;;US 17218609 P,2009-04-23,SYSTEMS AND METHODS FOR SEALING A LIGHTING FIXTURE,"Systems, methods and apparatuses for providing a reliable enclosure and seal for a system or a device, such as a lighting fixture, are disclosed. The solution presented utilizes a silicone gasket combined with an o-ring chord, an acrylic optic and an extrusion to provide a water-tight, air-tight and water-proof enclosure for the lighting fixture. The seal created by the enclosure is maintained regardless of any temperature or environmental changes, as well as any changes in sizes of the components of the enclosure due to the temperature changes. The silicone gasket, in combination with one or more o-rings, end caps and the extrusion adjust for any expansion or contraction of any components of the enclosure due to temperature changes of the lighting fixture or any other enclosed apparatus, system or device.",INTEGRATED ILLUMINATION SYSTEM,BLACK JOHN;;TRACY KEITH,INTEGRATED ILLUMINATION SYSTEMS INC (2010-04-21),https://lens.org/066-592-095-638-062,Patent Application,yes,12,18,3,3,0,F21V31/00;;F21V31/00;;F21V31/005,F21V31/00,362/267,0,0,,,,INACTIVE
43,US,B2,US 8585245 B2,093-337-101-823-581,2013-11-19,2013,US 76680710 A,2010-04-23,US 76680710 A;;US 17218609 P,2009-04-23,Systems and methods for sealing a lighting fixture,"Systems, methods and apparatuses for providing a reliable enclosure and seal for a system or a device, such as a lighting fixture, are disclosed. The solution presented utilizes a silicone gasket combined with an o-ring chord, an acrylic optic and an extrusion to provide a water-tight, air-tight and water-proof enclosure for the lighting fixture. The seal created by the enclosure is maintained regardless of any temperature or environmental changes, as well as any changes in sizes of the components of the enclosure due to the temperature changes. The silicone gasket, in combination with one or more o-rings, end caps and the extrusion adjust for any expansion or contraction of any components of the enclosure due to temperature changes of the lighting fixture or any other enclosed apparatus, system or device.",BLACK JOHN;;TRACY KEITH;;INTEGRATED ILLUMINATION SYSTEMS INC,BLACK JOHN;;TRACY KEITH,INTEGRATED ILLUMINATION SYSTEMS INC (2010-04-21),https://lens.org/093-337-101-823-581,Granted Patent,yes,112,14,3,3,0,F21V31/00;;F21V31/00;;F21V31/005,F21V31/00;;F21V15/04,362/267;;362/223;;362/217.1;;362/362,69,1,007-574-932-040-14X,10.1016/b978-155558310-1/50010-0,"""1-Wire Products Deliver a Powerful Combination . . . "", Mixed-Signal Design Guide, Dallas Semiconductor Maxim, 2005, 7 pages.;;""Conductivity with the BS2/OWL2"", EME Systems, 2002, pp. 1-3.;;""Dimmable Fluorescent Ballast"", ATAVRFBKIT/EVLB001, User Guide, ATMEL, 2007, pp. 1-33.;;""High-side current sensing for driving a string of white LEDs"", EDN, 1 page.;;""Understanding Boost Power Stages in Switchmode Power Supplies"", Application Report, Texas Instruments, Mixed Signal Products, Mar. 1999, pp. 1-28.;;""Understanding Buck Power Stages in Switchmode Power Supplies"", Application Report, Texas Instruments, Mixed Signal Products, Mar. 1999, pp. 1-32.;;Barberis, C. ""Precision current sink costs less than $20"", EDN Design Ideas.;;Bellcomb Technologies Incoporated, ""Edges, Joiners, Attachments"", Web Address: http://www.bellcomb.com/caps/edges.htm, Apr. 22, 2007, pp. 1-3.;;Bookmarks Menu-Controllers/Wireless-Deisgn Ideas, dated Dec. 6, 2012, 1 pg.;;Bowling, S. ""Buck-Boost LED Driver Using the PIC16F785 MCU"", Microchip, AN1047, 2006, pp. 1-12.;;By Staff, Dali Delivers Control and Cost Savings, Headaches Too, Consulting-Specifying Engineer, Jun. 2002, 2 pages.;;Canny, D. ""Controlling slew times tames EMI in offline supplies"", EDN Design Ideas, Nov. 14, 2002.;;Control Freak Addict Data Sheet, Copyright 2008, Creative Lighting, 5 pages.;;Curtis, K. ""High Power IR LED Driver Using the PIC16C781/782"", Microchip, TB062, 2002, pp. 1-8.;;CybroTech, Managing Lights with Dali, TN-012, rev 2, Cybrotech Ltd., 2007, 11 pgs.;;Cypress Perform, Implementing an Integrated DMX512 Receiver, Item ID: 39762, Dec. 16, 2009, 1 pg.;;Cypress Semiconductor Corporation, PowerPSoC (R) Intelligent LED Driver, Document No. 001-46319, Rev. G, 2009.;;Dali-AG website, Dali at work, 1 pg.;;Davidovic, et al., Lead-Acid Battery Charger Becomes a Subfuction in a Microcontroller, The Authority on Emerging Technologies for Design Solutions, Mar. 2007, 2 pages.;;Davmark Ltd., Dali-Protocol, 2007, 6 pages.;;Di Jasio, ""A Technique to Increase the Frequency Resolution of PlCmicro MCU PWM Modules"", Microchip, AN1050, 2006, pp. 1-10.;;Dietz, et al. ""Very Low-Cost Sensing and Communication Using Bidirectional LEDs"", Mitsubishi Electric Research Laboratories, Jul. 2003, 19 pgs.;;Distler, T. ""LED Effects Stream TM v2.0 Protocol (Revision C)"", Jun. 2, 2005, pp. 1-5.;;Dunn, J. ""Matching MOSFET Drivers to MOSEFTs"", Microchip, AN799, 2004, pp. 1-10.;;Fosler, R. ""The RS-232/DALI Bridge Interface"", Microchip, AN811, 2002, pp. 1-8.;;Fosler, R. ""Use a microcontroller to design a boost converter"", EDN design ideas, Mar. 4, 2004, pp. 74-75.;;Fosler, R., et al. ""Digitally Addressable DALI Dimming Ballast"", Microchip, AN809, 2002, pp. 1-18.;;Ghulyani, L. ""Simple MPPT-Based Lead Acid Charger Using bq2031"", Texas Instruments, Dec. 2009, pp. 1-5.;;Google Search Results for dali query group, search completed on Apr. 8, 2010, accessed at google.com, http://www.google.com/search?hl=en&c1ient=firefox-a&rls=org.mozilla:en-, 2 pages.;;Hardwick, M. ""DC power wire also carries clock or data"", EDN Design Ideas.;;Hexcel Composites, ""Sandwich Panel Fabrication Technology"", Web Address: http://www.hexcel.com/NR/rdonlyres/B4574C2C-0644-43AC-96E2-CC15967A4b)5/4547 Sandwich Fabrication.pdf, Jan. 1997, pp. 1-16.;;High-Side Current Monitor, ZETEX, Apr. 2001, ZXCT1009, Issue 3, pp. 1-8.;;Implementing Infrared Object Detection, http://web.archive.org/web/20080528042614rejwww.seattlerobotics.org/guide/infrared.html, original publication date known, retrieved Apr. 7, 2010, seattlerobotics.org, 4 pages.;;Jackson, S. ""Circuit protects bus from 5V swings"", EDN Design Ideas, Nov. 14, 2002.;;Klepin, K. ""Temperature Compensation for High Brightness LEDs using EZ-Color (TM) and PSoC Express"", Cypress Perform, AN14406, Aug. 10, 2007, pp. 1-4.;;Kremin, V. et al. ""Multichannel LED Dimmer with CapSense Control-AN13943"", Cypress Perform, Jul. 20, 2007.;;Kropf, B. ""Firmware-RGB Color Mixing Firmware for EZ-Color (TM)-AN16035"", Cypress Perform, Jun. 13, 2007, pp. 1-7.;;Lager, A. ""Use a 555 timer as a switch-mode power supply"", EDN Design Ideas, Nov. 14, 2002.;;Lee, M. Shunt Battery Charger Provides 1A Continuous Current, EDN Magazine, 1997.;;Locher, R. ""Introduction to Power MOSEFETs and their Applications"", Fairchild Semiconductor (TM), Application Note 558, Rev B, Oct. 1998, 15 pgs.;;Miller, R. ""Digital addressable lighting interface protocol fosters systems interoperability for lower costs and greater design flexibility"", RNM Engineering, Inc., Apr. 2003, pp. 1-20.;;Nell, S. ""VCO uses programmable logic"", EDN Design Ideas, Nov. 14, 2002.;;News & Events DALI Digital addressable lighting interface lamp luminaire control, accessed at http://www.dali-ag.org/ on Apr. 8, 2010, original publication date unknown, updated Apr. 8, 2010, 1 pg.;;O'Loughlin, M. ""350-W, Two-Phase Interleaved PFC Pre-regulator Design Review"", Texas Instruments, Application Report, Revised Mar. 2007, pp. 1-.;;O'Loughlin, M., PFC Pre-Regulator Frequency Dithering Circuit, Texas Instruments, May 2007, pp. 1-8.;;Perrin, R. Inexpensive Relays Form Digital Potentiometer, EDN Design Ideas, 1998, 2 pages.;;Petersen, A. ""Harness solar power with smart power-conversion techniques"", EDN, Green Electronics designfeature, Feb. 4, 1999, pp. 119-124.;;Prendergast, P. ""How to Design a Three-Channel LED Driver"", Cypress Perform, Jan. 2008, pp. 1-9.;;Renesas, R8C/25 Demonstration Example for DALI Lighting Protocol Stack, REU05B0077-0100/Rev.1.00, Jul. 2008, 14 pgs.;;Richardson, C., Matching Driver to LED, National Semiconductor, Jan. 2008, 5 pgs.;;Richardson. C., LM3404 Driving a Seoul Semi Zpower P4 1A LED-RD-I34, National Semiconductor, Apr. 2007, 6 pages.;;Shanmugam, S. ""Design of a linear Fresnel lens system for solar photovoltaic electrical power source"", Center for Robotics Research.;;Shill, M. ""Simple logic probe uses bicolor LED"", EDN Design Ideas.;;Software Design Specification, Z-Wave Protocol Overview, Z wave the wireless language, Zensys A/S, May 9, 2007, pp. 1-16.;;Soundlight, Operating Manual, DALI and DMX Dekoder 7064A-H Mk1, 2008, 8 pgs.;;Takahashi A., Methods and Features of LED Drivers, National Semiconductor, Mar. 2008, 3 pgs.;;Universal Powerline Bus Communication Technology, Overview, PCS Powerline Control Systems UPB (Universal Powerline Bus), Jan. 8, 2002, pp. 1-13.;;UPB Technology Description, PCS-Powerline Control Systems, UPB (Universal Powerline Bus), Version 1.4, Apr. 16, 2007, 68 pages.;;Use Gate Charge to Design the Gate Drive Circuit for Power MOSEFETs and IGBTs, International Rectifier, Application Note AN-944, 5 pgs.;;Van Dorsten, Arian, A Low Cost Step-up Converter by IC 555, posted Jul. 21, 2007, http://www.eleccircuit.comla-low-cost-step-up-converter-by-ic-5551, retrieved Apr. 7, 2010, 2 pages.;;Walma, K., DALI: Forerunner of Today's Breakthrough Lighting Technology, Feb. 2007, 2 pages.;;Wikipedia, Digital Addressable Lighting Interface, original publication date unknown, Retrieved from:Retrieved from ""http://en.wikipedia.org/wikiJDigital-Addressable-Lighting-Interface"" accessed on Apr. 8, 2010, 3 pages.;;Witt, J. ""Switched-capacitor regulator provides gain"", EDN Design Ideas.;;Wojslaw, C. ""DPP adds versatility to VFC"", EDN, design ideas, Nov. 14, 2002, pp. 99-110.;;Young, R. ""Power circuit terminates DDR DRAMs"", EDN Design Ideas, Nov. 14, 2002.;;Zarr, R. Driving High-Power LEDs, Machine Design, Oct. 2007, 3 pages.;;Zensys ASCII Interface, Vizia, 2007.;;Zetex, High-Side Current Monitor, Apr. 2001, Issue 3, 8 pages.;;Z-Wave Vizia Etc thread, retrieved at http://groups.google.com/group/comp.home.automation/browse-thread/thread/449c2c66934dfSfb/fSl12116a8231aa1?Ink=st&q=z-wave&rnum=98#fSl12116a8231aa1, www.ztech.com, 18 pages.",INACTIVE
44,WO,A1,WO 2018/132658 A1,171-133-117-576-215,2018-07-19,2018,US 2018/0013491 W,2018-01-12,US 201762446271 P,2017-01-13,ONCOLYTIC VIRUSES AND METHODS OF USE,Disclosed herein are viruses and compounds for use in the treatment of cancer.,SESTAN NENAD;;BLACK KEITH,SESTAN NENAD;;BLACK KEITH,,https://lens.org/171-133-117-576-215,Patent Application,yes,4,0,1,1,2,A61K35/768;;A61K39/12;;A61K2039/585;;A61K2039/80;;C12N7/00;;C12N2770/24121;;C12N2770/24132;;C12N2770/24134;;C12N2770/24143;;C12N2770/24152;;Y02A50/30,A61K39/00;;A61K39/12;;A61K39/193;;A61K48/00;;C07K14/18;;C12N7/01;;C12N7/04,,1,1,022-341-334-384-336,19367259;;pmc2835221;;10.1038/mt.2009.73,"FRIEDMAN ET AL.: ""Herpes Simplex Virus Oncolytic Therapy for Pediatric Malignancies"", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 17, no. 7, 1 July 2009 (2009-07-01), pages 1125 - 1135, XP055506688",PENDING
45,WO,A1,WO 2018/017417 A1,020-025-314-565-642,2018-01-25,2018,US 2017/0042143 W,2017-07-14,US 201662363769 P,2016-07-18,MAGNETIC PARTICLE-BASED SUBSTANCE REMOVAL FROM TISSUE,Provided herein are methods and compositions for removal of a substance using magnetic nanoparticles comprising a tagging element capable of targeting the nanoparticle to the substance. Further provided herein are methods and devices for removal of magnetic nanoparticle bound substances using a magnetic field generating device.,FORTEM NEUROSCIENCES INC,BLACK KEITH;;KAVANAUGH JACK,,https://lens.org/020-025-314-565-642,Patent Application,yes,3,0,2,2,0,A61K9/5115;;A61B2017/00345;;A61B34/73;;A61K41/0052;;A61B2090/3954;;A61B18/04;;A61B18/12;;A61F2007/009;;A61B2090/374;;A61B2090/3762;;A61B2218/007;;A61B2017/00876;;A61K9/0009;;A61K9/5094;;A61B34/73;;A61K41/0052;;A61K47/50;;A61B2090/3954;;A61B2017/00345;;A61K9/5115;;A61B2090/374;;A61B18/04;;A61F2007/009;;A61B18/12;;A61B2090/3762;;A61B2218/007;;A61B17/320092;;A61B2017/00876;;A61K9/0009;;A61K9/5094;;A61M25/0127,A61B5/00;;A61B5/06;;A61K9/00;;A61K9/51;;A61M1/00;;A61M1/14;;A61M1/34,,0,0,,,,PENDING
46,WO,A3,WO 2006/091587 A3,162-699-104-609-467,2007-06-21,2007,US 2006/0006088 W,2006-02-22,US 65500905 P,2005-02-22,USE OF MINOXIDIL SULFATE AS AN ANTI-TUMOR DRUG,"The invention relates to compositions, methods and kits for the treatment of cancer. ATP-dependent potassium channel agonists, salts thereof, or chemical analogs thereof, for example, minoxidil sulfate, have been found to possess anti-neoplastic properties. Administering minoxidil sulfate may prolong the life of a cancer patient; for example, a patient with a brain tumor.",CEDARS SINAI MEDICAL CENTER;;BLACK KEITH;;WHEELER CHRISTOPHER,BLACK KEITH;;WHEELER CHRISTOPHER,,https://lens.org/162-699-104-609-467,Search Report,yes,1,0,6,6,0,A61K31/44;;A61K31/506;;A61K45/06;;A61P35/00;;A61P35/04;;A61K39/4615;;A61K2239/47;;A61K39/4622;;A61K39/46432;;A61K31/44;;A61K45/06;;A61K31/506,A01N25/00;;A01N65/00;;A61K31/00,,5,5,127-225-074-113-722;;024-005-552-575-851;;039-517-839-798-722;;132-128-494-986-42X;;006-599-510-877-171,8752398;;2469513;;10.1016/0006-8993(89)90191-1;;10.1517/13543776.11.7.1137;;14695207;;6197493;;10.1111/1523-1747.ep12259181,"KAJI ET AL.: ""Potassium Channel dysfunction at the lesion site in multifocal motor neuroatphy as revealed by threshold electronus"", ION CHANNEL MEDIA: GLIA RESEARCH PORTAL, RINSHO SHINKEIGAKU, vol. 35, 1995, pages 1368 - 1369;;BRISMAR ET AL.: ""Potassium and sodium channels in human malignant glioma cells"", BRAIN RESEARCH, vol. 480, no. 1-2, 20 February 1989 (1989-02-20), pages 259 - 267, XP008092305;;TANHEHCO E.: ""Potassium Channel modulators as anti-inflammatory agents"", EXPERT OPIN. THER. PATENTS, vol. 11, no. 7, 2001, pages 1137 - 1145, XP002902310;;NAGENDRA ET AL.: ""Adenosine 5'triphosphate-sensitive Potassium Channel-mediated Blood-Brain Tumor Barrier Permeability Increase in a Rat Brain Tumor Model"", CANCER RESEARCH, vol. 63, 15 December 2003 (2003-12-15), pages 8899 - 8911, XP002350235;;COHEN ET AL.: ""Direct Effects of Minoxidil on Epidermal Cells in Culture"", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 82, 1984, pages 82, AND 90 - 93, XP000985165",PENDING
47,WO,A3,WO 2021/026522 A3,152-531-252-428-180,2021-05-27,2021,US 2020/0045570 W,2020-08-10,US 201962884570 P,2019-08-08,METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY,Described herein are compositions and methods for treating cancer and autoimmune diseases.,CEDARS SINAI MEDICAL CENTER,YU JOHN;;BLACK KEITH,,https://lens.org/152-531-252-428-180,Search Report,yes,6,0,5,5,31,A61K39/0011;;A61K2039/5158;;A61K39/001192;;A61K39/001186;;A61K39/001188;;A61K39/001156;;A61K39/001148;;A61K39/001106;;A61K39/001119;;A61P35/00;;A61K39/39;;A61K39/00119;;A61K2039/80;;A61K39/001106;;A61K39/001188;;A61K39/001192;;A61K39/001119;;A61K39/001178;;A61K39/001122;;A61K39/001186;;A61K31/15;;A61K31/165;;A61K31/341;;A61K2039/5158,A61K38/44,,2,2,019-317-759-142-06X;;038-806-769-951-481,31324216;;pmc6642547;;10.1186/s40425-019-0671-4;;pmc1895303;;15972448;;10.1182/blood-2005-03-1257,"DAVID M. RICHARDS, VIOLA MARSCHALL, KATHARINA BILLIAN-FREY, KARL HEINONEN, CHRISTIAN MERZ, MAURICIO REDONDO MÜLLER, JULIAN P. SEFR: ""HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of Fc-gamma-R-binding functionality"", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, no. 1, 19 July 2019 (2019-07-19), pages 1 - 13, XP055826709;;EMMANUEL ZORN, HAESOOK T. KIM, STEPHANIE J. LEE, BLAIR H. FLOYD, DESPINA LITSA, SANKARI ARUMUGARAJAH, ROBERTO BELLUCCI, EDWIN P. A: ""Reduced frequency of FOXP3+ CD 4+ CD 25+ regulatory T cells in patients with chronic graft-versus-host disease"", BLOOD, vol. 106, no. 8, 15 October 2005 (2005-10-15), pages 2903 - 2911, XP055826711, DOI: 10.1182/blood-2005-03-1257",PENDING
48,US,A1,US 2014/0071685 A1,179-728-233-856-998,2014-03-13,2014,US 201314081576 A,2013-11-15,US 201314081576 A;;US 76680710 A;;US 17218609 P,2009-04-23,SYSTEMS AND METHODS FOR SEALING A LIGHTING FIXTURE,"Systems, methods and apparatuses for providing a reliable enclosure and seal for a system or a device, such as a lighting fixture, are disclosed. The solution presented utilizes a silicone gasket combined with an o-ring chord, an acrylic optic and an extrusion to provide a water-tight, air-tight and water-proof enclosure for the lighting fixture. The seal created by the enclosure is maintained regardless of any temperature or environmental changes, as well as any changes in sizes of the components of the enclosure due to the temperature changes. The silicone gasket, in combination with one or more o-rings, end caps and the extrusion adjust for any expansion or contraction of any components of the enclosure due to temperature changes of the lighting fixture or any other enclosed apparatus, system or device.",INTEGRATED ILLUMINATION SYSTEMS INC,BLACK JOHN;;TRACY KEITH,INTEGRATED ILLUMINATION SYSTEMS INC (2010-04-21),https://lens.org/179-728-233-856-998,Patent Application,yes,1,10,3,3,0,F21V31/00;;F21V31/00;;F21V31/005,F21V31/00,362/267,1,0,,,"Bal Seal Engineering, ""Coefficient of Thermal Expansion for Various Materials at Different Temperatures"", June 25, 2004",DISCONTINUED
49,EP,A4,EP 1850663 A4,128-276-098-261-478,2008-03-19,2008,EP 06735656 A,2006-02-22,US 2006/0006088 W;;US 65500905 P,2005-02-22,USE OF MINOXIDIL SULFATE AS AN ANTI-TUMOR DRUG,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH;;WHEELER CHRISTOPHER,,https://lens.org/128-276-098-261-478,Search Report,no,5,0,6,6,0,A61K31/44;;A61K31/506;;A61K45/06;;A61P35/00;;A61P35/04;;A61K39/4615;;A61K2239/47;;A61K39/4622;;A61K39/46432;;A61K31/44;;A61K45/06;;A61K31/506,A61K31/44;;A61K31/00;;A61K31/506;;A61P35/00,,0,0,,,,DISCONTINUED
50,US,B2,US 7705010 B2,008-135-843-937-934,2010-04-27,2010,US 81346106 A,2006-02-22,US 81346106 A;;US 65500905 P;;US 2006/0006088 W,2005-02-22,Use of minoxidil sulfate as an anti-tumor drug,"The invention relates to compositions, methods and kits for the treatment of cancer. ATP-dependent potassium channel agonists, salts thereof, or chemical analogs thereof, for example, minoxidil sulfate, have been found to possess anti-neoplastic properties. Administering minoxidil sulfate may prolong the life of a cancer patient; for example, a patient with a brain tumor.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;WHEELER CHRISTOPHER,CEDARS-SINAI MEDICAL CENTER (2007-07-05),https://lens.org/008-135-843-937-934,Granted Patent,yes,17,3,6,6,0,A61K31/44;;A61K31/506;;A61K45/06;;A61P35/00;;A61P35/04;;A61K39/4615;;A61K2239/47;;A61K39/4622;;A61K39/46432;;A61K31/44;;A61K45/06;;A61K31/506,A61K31/506;;A61K31/00,514/275,17,15,051-431-019-161-598;;004-324-136-280-950;;021-106-272-678-091;;053-011-544-281-709;;005-090-083-125-929;;010-441-795-897-073;;117-911-401-985-542;;098-300-752-073-932;;055-556-983-046-287;;035-857-332-739-788;;127-225-074-113-722;;024-005-552-575-851;;039-517-839-798-722;;132-128-494-986-42X;;006-599-510-877-171,10.1158/0008-5472.can-05-3627;;16585151;;10.1054/bjoc.2001.1796;;pmc2363645;;11355958;;9493131;;10.1007/s002329900332;;12183081;;10.1016/s0304-3835(02)00348-8;;10.3892/or.9.5.961;;12168055;;12926074;;1780909;;10.1159/000139218;;7972323;;2335212;;10.1016/0014-5793(90)80217-7;;10.1158/1078-0432.ccr-04-0497;;15328167;;8752398;;2469513;;10.1016/0006-8993(89)90191-1;;10.1517/13543776.11.7.1137;;14695207;;6197493;;10.1111/1523-1747.ep12259181,"Sausville et al. Cancer Research, 2006, vol. 66, pp. 3351-3354.;;Johnson et al. British J. of Cancer, 2001, 84(10):1424-1431.;;Wondergem et al. J. Membr. Biol., 1998, vol. 161, No. 3, pp. 257-262 (Abstract attached).;;Abdul et al. Cancer Lett., 2002, vol. 186, No. 1, pp. 99-105 (Abstract attached).;;Abdul et al. Oncol. Rep., 2002, vol. 9, No. 5, pp. 961-964 (Abstract attached).;;Abdul et al. Anticancer Res., 2003, vol. 23, No. 4, pp. 3347-3351 (Abstract attached).;;Takeda et al. Tokai J. Exp. Clin. Med., 1991, vol. 16, No. 1, pp. 73-76 (Abstract attached).;;Lee et al., In Vitro Antitumor Activity of Cromakalim in Human Brain Tumor Cells, Pharmacology, (1994), pp. 69-74, 49.;;Ito et al., Cromakalim, A Vasodilator, Differentially Inhibits Ca2+ Currents in NG108-15 Neuroblastoma X Glioma Hybrid Cells, FEBS, (Mar. 1990), pp. 313-316, 262(2).;;Ito, Y., Effects of Potassium Channel Opener Cromakalim on Calcium and Potassium Channels, Kanazawa Daigaku Juzen Igakkai Zasshi, (1992), pp. 46-56, 101(1).;;Wheeler et al., Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy After Vaccination, Clinical Cancer Research, (Aug. 15, 2004), pp. 5316-5326, 10.;;Kaji et al., Potassium Channel Dysfunction at the Lesion Site in Multifocal Motor Neuropathy As Revealed by Threshold Electronus, Ion Channel Media, Glia Research Portal, (1995), pp. 1368-1369, 35, Abstract Only.;;Brismar et al., Potassium and Sodium Channels in Human Malignant Glioma Cells, Brain Research, (Feb. 20, 1989), pp. 259-267, 480(1-2), Abstract Only.;;Tanhehco, E.T., Potassium Channel Modulators As Anti-Inflammatory Agents, Expert Opinions on Therapeutic Patents, (Jul. 1, 2001), pp. 1137-1145, 11(7).;;Ningaraj et al., Adenosine 5'-Triphosphate-Sensitive Potassium Channel-Mediated Blood-Brain Tumor Barrier Permeability Increase in a Rat Brain Tumor Model, Cancer Research, (Dec. 15, 2003), pp. 8899-8911, 63.;;Cohen et al., Direct Effects of Minoxidil on Epidermal Cells in Culture, Journal of Investigative Dermatology, (1984), pp. 90-93, 82.;;Zhang et al., T Cell Activity in Glioma Chemoresponsiveness and Genetics, Gene Therapy and Molecular Biology, (2005), pp. 401-416, 9.",INACTIVE
51,US,A,US 5420280 A,093-523-658-276-318,1995-05-30,1995,US 93782192 A,1992-10-20,GB 9007724 A;;GB 9100531 W,1990-04-05,Piperidin-4-spiro-oxiranes,"PCT No. PCT/GB91/00531 Sec. 371 Date Oct. 20, 1992 Sec. 102(e) Date Oct. 20, 1992 PCT Filed Apr. 5, 1990 PCT Pub. No. WO91/15492 PCT Pub. Date Oct. 17, 1991. <IMAGE> (I) Novel piperidin-4-spiro-oxiranes of formula (I) are provided which have application in the synthesis of various anilidopiperidine compounds. The novel compounds can be synthesised in a one pot reaction from 4-substituted piperidones and phenylsulphoxide or sulphone starting materials. Use of the novel compounds allows anilidopiperidines to be produced in a significantly reduced number of stages than with previously known methods.",SECR DEFENCE BRIT,BLACK ROBIN M;;BREWSTER KEITH,SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S THE GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (1992-09-28),https://lens.org/093-523-658-276-318,Granted Patent,yes,0,0,10,10,0,C07D211/48;;C07D211/58;;C07D491/10;;C07D491/10;;C07D211/58;;C07D211/48,C07D211/48;;C07D211/58;;C07D491/10;;C07D493/10;;C07D491/107,546/16;;546/216;;546/223;;546/224;;546/233,5,1,049-534-040-388-228,10.1016/0040-4039(88)85228-6,"McOmis Protective Groups in Organic Chemistry Plenum Press, p. 61 (1974).;;Satoh et al Epoxy Sufoxides as Intermediates in Organic Synthesis II Chem. Soc. Japan, 58 2849 54 (1985) (cited on PCT Search Report).;;Satoh et al A Novel Approach to Synthesis of Chiral Epoxides Tetra. Lett. 29 2851 2854 (1988).;;Satoh et al A Novel Method of Annulation of Epoxid Sulfoxide Chem. Lett Japan, 1949 50 (1987).;;Satoh et al A Novel Synthesis of 2 Acrylic Ether . . . Bull. Chem. Soc. Jpn. 61 2109 2115 (1988).",EXPIRED
52,WO,A1,WO 1991/015492 A1,175-794-535-796-222,1991-10-17,1991,GB 9100531 W,1991-04-05,GB 9007724 A,1990-04-05,NOVEL PIPERIDIN-4-SPIRO-OXIRANES,Novel piperidin-4-spiro-oxiranes of formula (I) are provided which have application in the synthesis of various anilidopiperidine compounds. The novel compounds can be synthesised in a one pot reaction from 4-substituted piperidones and phenyl-sulphoxide or sulphone starting materials. Use of the novel compounds allows anilidopiperidines to be produced in a significantly reduced number of stages than with previously known methods.,SECR DEFENCE BRIT,BLACK ROBIN MICHAEL;;BREWSTER KEITH,,https://lens.org/175-794-535-796-222,Patent Application,yes,0,0,10,10,0,C07D211/48;;C07D211/58;;C07D491/10;;C07D491/10;;C07D211/58;;C07D211/48,C07D211/48;;C07D211/58;;C07D491/10;;C07D491/107;;C07D493/10,,2,2,078-980-803-120-150;;036-375-795-497-003,10.1246/bcsj.58.2849;;10.1246/bcsj.59.457,"Bulletin of the Chemical Society of Japan, volume 58, no. 10, October 1985, The Chemical Society of Japan, (Tokyo, JP), T. Satoh et al.: ""alpha, beta-epoxy sulfoxides as useful intermediates in organic synthesis. II. A novel synthesis of alpha-sulfenylated ketones and alphasulfenylated aldehydes from alpha, betepoxy sulfoxides"", pages 2849-2854;;Bulletin of the Chemical Society of Japan, volume 59, no. 2, February 1986, The Chemical Society of Japan, (Tokyo, JP), T. Satoh et al.: ""Alpha, beta-epoxy sulfoxides as useful intermediates in organic synthesis. III. A novel synthesis of alpha-amino ketones and alpha-amino aldehydes by aminolysis of alpha, beta-epoxy sulfoxides"", pages 457-463",PENDING
53,CA,A1,CA 2079791 A1,192-448-426-986-099,1991-10-06,1991,CA 2079791 A,1991-04-05,GB 9007724 A,1990-04-05,PIPERIDIN-4-SPIRO-OXIRANES PIPERIDIN-4-SPIRO-OXIRANES,2079791 9115492 PCTABS00007 Novel piperidin-4-spiro-oxiranes of formula (I) are provided which have application in the synthesis of various anilidopiperidine compounds. The novel compounds can be synthesised in a one pot reaction from 4-substituted piperidones and phenyl-sulphoxide or sulphone starting materials. Use of the novel compounds allows anilidopiperidines to be produced in a significantly reduced number of stages than with previously known methods.,SECR DEFENCE BRIT,BLACK ROBIN M;;BREWSTER KEITH,,https://lens.org/192-448-426-986-099,Patent Application,no,0,0,10,10,0,C07D211/48;;C07D211/58;;C07D491/10;;C07D491/10;;C07D211/58;;C07D211/48,C07D493/10;;C07D211/48;;C07D211/58;;C07D491/10;;C07D491/107,,0,0,,,,DISCONTINUED
54,AU,A,AU 1991/075777 A,083-254-797-072-942,1991-10-30,1991,AU 1991/075777 A,1991-04-05,GB 9007724 A;;GB 9100531 W,1990-04-05,NOVEL PIPERIDIN-4-SPIRO-OXIRANES,,SECR DEFENCE BRIT,BLACK ROBIN MICHAEL;;BREWSTER KEITH,,https://lens.org/083-254-797-072-942,Patent Application,no,0,1,10,10,0,C07D211/48;;C07D211/58;;C07D491/10;;C07D491/10;;C07D211/58;;C07D211/48,C07D493/10;;C07D211/48;;C07D211/58;;C07D491/10;;C07D491/107,,0,0,,,,EXPIRED
55,AU,B2,AU 656892 B2,100-979-489-156-944,1995-02-23,1995,AU 1991/075777 A,1991-04-05,GB 9007724 A;;GB 9100531 W,1990-04-05,Novel piperidin-4-spiro-oxiranes,,SECR DEFENCE BRIT,BLACK ROBIN MICHAEL;;BREWSTER KEITH,,https://lens.org/100-979-489-156-944,Granted Patent,no,0,0,10,10,0,C07D211/48;;C07D211/58;;C07D491/10;;C07D491/10;;C07D211/58;;C07D211/48,C07D493/10;;C07D211/48;;C07D211/58;;C07D491/10;;C07D491/107,,0,0,,,,EXPIRED
56,US,A1,US 2008/0166939 A1,149-040-491-673-701,2008-07-10,2008,US 62141807 A,2007-01-09,US 62141807 A,2007-01-09,Acoustical Substrate,"The present disclosure provides an acoustical substrate including nonwoven material which includes a two component adhesive system which may be treated with a fluid repelling compound. The two component adhesive system may comprise two adhesive components having different melting points to allow for flexible industrial post processing and laminating. The adhesives may be applied by a variety of methods and may exist in the substrate in, e.g., either discrete or continuous web forms.",FREUDENBERG NONWOVENS L P,BLACK KEITH;;REYNOLDS MICHAEL L,FREUDENBERG NONWOVENS L.P (2007-02-07),https://lens.org/149-040-491-673-701,Patent Application,yes,22,2,2,2,0,B32B37/1292;;B32B2037/1269;;B32B2305/20;;B32B2307/102;;B32B2309/02;;B60R13/08;;B60R13/0815;;B60R13/0892;;C08K5/02;;C08K5/54;;C09J2400/263;;G10K11/162;;D06N2209/128;;D06N3/0004;;D06N3/047;;D06N3/128;;D06N2209/025;;C09J7/35;;C09J7/21;;Y10T442/2746;;C09J2301/204;;C09J2301/41;;Y10T442/2746;;B32B37/1292;;B60R13/0892;;B32B2037/1269;;B60R13/08;;G10K11/162;;C08K5/02;;B32B2307/102;;C08K5/54;;B60R13/0815;;B32B2309/02;;B32B2305/20;;C09J2400/263;;D06N3/128;;D06N2209/025;;D06N3/0004;;D06N3/047;;D06N2209/128;;C09J7/35;;C09J7/21;;C09J2301/41;;C09J2301/204,B29C65/02;;B32B5/02;;B32B37/04,442/150;;156/275.7,0,0,,,,DISCONTINUED
57,EP,A1,EP 0523125 A1,168-143-493-213-304,1993-01-20,1993,EP 91907208 A,1991-04-05,GB 9007724 A,1990-04-05,NOVEL PIPERIDIN-4-SPIRO-OXIRANES.,"Nouveaux pipéridine-4-spiro-oxyranes de formule (I) s'utilisant dans la synthèse de différents composés d'anilidopéridine. Les nouveaux composés peuvent se synthétiser à partir d'une seule réaction résultant de pipéridones substituées en position 4 et de matières de départ de phényle, sulfoxyde ou sulfone. L'utilisation de ces nouveaux composés permet la production d'anilidopipéridines en un nombre d'étapes considérablement réduit par rapport aux procédés connus antérieurement.",SECR DEFENCE BRIT,BLACK ROBIN MICHAEL;;BREWSTER KEITH,,https://lens.org/168-143-493-213-304,Patent Application,yes,0,0,10,10,0,C07D211/48;;C07D211/58;;C07D491/10;;C07D491/10;;C07D211/58;;C07D211/48,C07D493/10;;C07D211/48;;C07D211/58;;C07D491/10;;C07D491/107,,0,0,,,,DISCONTINUED
58,AU,B2,AU 674114 B2,016-831-279-654-659,1996-12-05,1996,AU 1995/020185 A,1995-05-22,GB 9007724 A,1990-04-05,Intermediates useful in preparing piperidin-4-spiro-oxiranes,,SECR DEFENCE BRIT,BLACK ROBIN MICHAEL;;BREWSTER KEITH,,https://lens.org/016-831-279-654-659,Granted Patent,no,1,0,10,10,0,C07D211/48;;C07D211/58;;C07D491/10;;C07D491/10;;C07D211/58;;C07D211/48,C07D493/10;;C07D211/48;;C07D211/58;;C07D491/10;;C07D491/107,,0,0,,,,EXPIRED
59,US,A1,US 2008/0207657 A1,081-576-010-283-914,2008-08-28,2008,US 81346106 A,2006-02-22,US 81346106 A;;US 65500905 P;;US 2006/0006088 W,2005-02-22,Use Of Minoxidil Sulfate As An Anti-Tumor Drug,"The invention relates to compositions, methods and kits for the treatment of cancer. ATP-dependent potassium channel agonists, salts thereof, or chemical analogs thereof, for example, minoxidil sulfate, have been found to possess anti-neoplastic properties. Administering minoxidil sulfate may prolong the life of a cancer patient; for example, a patient with a brain tumor.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;WHEELER CHRISTOPHER,CEDARS-SINAI MEDICAL CENTER (2007-07-05),https://lens.org/081-576-010-283-914,Patent Application,yes,12,8,6,6,0,A61K31/44;;A61K31/506;;A61K45/06;;A61P35/00;;A61P35/04;;A61K39/4615;;A61K2239/47;;A61K39/4622;;A61K39/46432;;A61K31/44;;A61K45/06;;A61K31/506,A61K31/506;;A61K31/00;;A61K31/4409;;A61P35/04,514/275;;514/353,0,0,,,,INACTIVE
60,WO,A1,WO 2008/086399 A1,092-142-168-281-004,2008-07-17,2008,US 2008/0050587 W,2008-01-09,US 62141807 A,2007-01-09,ACOUSTICAL SUBSTRATE,"The present disclosure provides an acoustical substrate including nonwoven material which includes a two component adhesive system which may be treated with a fluid repelling compound. The two component adhesive system may comprise two adhesive components having different melting points to allow for flexible industrial post processing and laminating. The adhesives may be applied by a variety of methods and may exist in the substrate in, e.g., either discrete or continuous web forms.",FREUDENBERG NONWOVENS L P;;BLACK KEITH;;REYNOLDS MICHAEL L,BLACK KEITH;;REYNOLDS MICHAEL L,,https://lens.org/092-142-168-281-004,Patent Application,yes,3,1,2,2,0,B32B37/1292;;B32B2037/1269;;B32B2305/20;;B32B2307/102;;B32B2309/02;;B60R13/08;;B60R13/0815;;B60R13/0892;;C08K5/02;;C08K5/54;;C09J2400/263;;G10K11/162;;D06N2209/128;;D06N3/0004;;D06N3/047;;D06N3/128;;D06N2209/025;;C09J7/35;;C09J7/21;;Y10T442/2746;;C09J2301/204;;C09J2301/41;;Y10T442/2746;;B32B37/1292;;B60R13/0892;;B32B2037/1269;;B60R13/08;;G10K11/162;;C08K5/02;;B32B2307/102;;C08K5/54;;B60R13/0815;;B32B2309/02;;B32B2305/20;;C09J2400/263;;D06N3/128;;D06N2209/025;;D06N3/0004;;D06N3/047;;D06N2209/128;;C09J7/35;;C09J7/21;;C09J2301/41;;C09J2301/204,G10K11/00;;E04B1/74,,0,0,,,,PENDING
61,AU,A,AU 1995/020185 A,156-206-599-297-593,1995-08-03,1995,AU 1995/020185 A,1995-05-22,GB 9007724 A,1990-04-05,Intermediates useful in preparing piperidin-4-spiro-oxiranes,,SECR DEFENCE BRIT,BLACK ROBIN MICHAEL;;BREWSTER KEITH,,https://lens.org/156-206-599-297-593,Patent Application,no,0,0,10,10,0,C07D211/48;;C07D211/58;;C07D491/10;;C07D491/10;;C07D211/58;;C07D211/48,C07D493/10;;C07D211/48;;C07D211/58;;C07D491/10;;C07D491/107,,0,0,,,,EXPIRED
62,EP,A2,EP 1663239 A2,003-460-669-430-755,2006-06-07,2006,EP 04783849 A,2004-09-10,US 2004/0029787 W;;US 50215903 P;;US 52844003 P;;US 54863604 P,2003-09-10,POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/003-460-669-430-755,Patent Application,yes,0,0,6,6,0,A61K31/4184;;A61K31/506;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;A61P9/00;;A61K45/06;;A61K31/506;;A61K31/4184,A61K31/4184;;A61K/;;A61K31/445;;A61K31/505;;A61K31/506;;A61K31/513;;A61K45/06;;A61K49/00;;A61P35/00,,0,0,,,,DISCONTINUED
63,WO,A3,WO 2001/054680 A3,075-248-274-186-560,2002-06-27,2002,US 0102742 W,2001-01-26,US 49150000 A;;US 61585400 A,2000-01-26,METHOD FOR USING POTASSIUM CHANNEL ACTIVATION FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN REGION AND/OR A MALIGNANT TUMOR,"Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a calcium- or ATP-dependent potassium channel [KCa or KATP] activator (other than bradykinin or a bradykinin analog), such as a direct potassium channel agonist or an indirect potassium channel activator, such as an activator of soluble guanylyl cyclase (e.g., nitric oxide or a nitric oxide donor) or an activator of cyclic GMP-dependent protein kinase, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel activator together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/075-248-274-186-560,Search Report,yes,2,0,9,13,0,A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/4245;;A61K31/44;;A61K31/475;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,A61K45/00;;A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/401;;A61K31/4025;;A61K31/4245;;A61K31/43;;A61K31/44;;A61K31/4409;;A61K31/475;;A61K31/495;;A61K31/506;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K33/04;;A61K33/26;;A61K38/00;;A61K45/06;;A61K45/08;;A61K49/00;;A61K49/04;;A61K51/12;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,,3,3,014-496-263-323-136;;022-858-388-092-074;;110-874-009-938-464,10.1006/mvre.1999.2152;;10388601;;10.1016/s0006-8993(96)01021-9;;9017232;;10.1006/exnr.1996.0175;;8912895,"OAK Z. CHI ET AL: ""Effects of Cyclic GMP on Microvascular Permeability of the Cerebral Cortex"", MICROVASCULAR RESEARCH, vol. 58, 1999, pages 35 - 40, XP002195899;;W. G. MAYHAN: ""Role of nitric oxide in histamine-induced increases in permeability of the blood-brain barrier"", BRAIN RESEARCH, vol. 743, 1996, pages 70 - 76, XP002195900;;R. T. BARTUS ET AL: ""Controlled Modulation of BBB Permeability Using the Bradykinin Agonist, RMP-7"", EXPERIMENTAL NEUROLOGY, vol. 142, 1996, pages 14 - 28, XP002195901",PENDING
64,US,A1,US 2004/0057935 A1,080-450-287-927-532,2004-03-25,2004,US 25114802 A,2002-09-20,US 25114802 A,2002-09-20,Intratumoral delivery of dendritic cells,"
   Methods included herein describe the treatment of a tumor by administering dendritic cells either directly into the same or into its surrounding tissue. Further methods describe the induction of immune cell infiltration into tumors and the treatment of tumors with unprimed dendritic cells by administering dendritic cells in a similar fashion. The methods of the present invention are particularly advantageous in the treatment of brain tumors and other solid tumors disposed throughout the body of a mammal that are difficult or impossible to treat by conventional surgical means. Dendritic cell-based compositions effective in the treatment of such tumors are also described. 
",CEDARS SINAI MEDICAL CENTER,YU JOHN;;BLACK KEITH;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2002-11-05),https://lens.org/080-450-287-927-532,Patent Application,yes,8,29,1,1,0,A61K39/4644;;A61K39/4615;;A61K39/4611;;A61K39/4622;;A61K2039/5152;;A61K2039/5154;;A61K35/15,A61K39/00,424/93.7,0,0,,,,DISCONTINUED
65,CA,A1,CA 3150273 A1,180-478-254-020-58X,2021-02-11,2021,CA 3150273 A,2020-08-10,US 201962884570 P;;US 2020/0045570 W,2019-08-08,METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY,Described herein are compositions and methods for treating cancer and autoimmune diseases.,CEDARS SINAI MEDICAL CENTER,YU JOHN SUN;;BLACK KEITH L,,https://lens.org/180-478-254-020-58X,Patent Application,no,0,0,5,5,31,A61K39/0011;;A61K2039/5158;;A61K39/001192;;A61K39/001186;;A61K39/001188;;A61K39/001156;;A61K39/001148;;A61K39/001106;;A61K39/001119;;A61P35/00;;A61K39/39;;A61K39/00119;;A61K2039/80;;A61K39/001106;;A61K39/001188;;A61K39/001192;;A61K39/001119;;A61K39/001178;;A61K39/001122;;A61K39/001186;;A61K31/15;;A61K31/165;;A61K31/341;;A61K2039/5158,A61K39/00,,0,0,,,,PENDING
66,WO,A2,WO 2001/054771 A2,089-966-698-507-49X,2001-08-02,2001,US 0102743 W,2001-01-26,US 49150000 A;;US 61585400 A,2000-01-26,METHOD FOR USING POTASSIUM CHANNEL AGONISTS FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN REGION AND/OR A MALIGNANT TUMOR,"Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a calcium- or ATP-dependent potassium channel [KCa or KATP] activator (other than bradykinin or a bradykinin analog), such as a direct potassium channel agonist or an indirect potassium channel activator, such as an activator of soluble guanylyl cyclase (e.g., nitric oxide or a nitric oxide donor) or an activator of cyclic GMP-dependent protein kinase, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel activator together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/089-966-698-507-49X,Patent Application,yes,0,26,9,13,0,A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/4245;;A61K31/44;;A61K31/475;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,A61K45/00;;A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/401;;A61K31/4025;;A61K31/4245;;A61K31/43;;A61K31/44;;A61K31/4409;;A61K31/475;;A61K31/495;;A61K31/506;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K33/04;;A61K33/26;;A61K38/00;;A61K45/06;;A61K45/08;;A61K49/00;;A61K49/04;;A61K51/12;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,,0,0,,,,PENDING
67,WO,A2,WO 2001/054680 A2,131-189-608-203-394,2001-08-02,2001,US 0102742 W,2001-01-26,US 49150000 A;;US 61585400 A,2000-01-26,METHOD FOR USING POTASSIUM CHANNEL ACTIVATION FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN REGION AND/OR A MALIGNANT TUMOR,"Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a calcium- or ATP-dependent potassium channel [KCa or KATP] activator (other than bradykinin or a bradykinin analog), such as a direct potassium channel agonist or an indirect potassium channel activator, such as an activator of soluble guanylyl cyclase (e.g., nitric oxide or a nitric oxide donor) or an activator of cyclic GMP-dependent protein kinase, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel activator together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/131-189-608-203-394,Patent Application,yes,0,13,9,13,0,A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/4245;;A61K31/44;;A61K31/475;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,A61K45/00;;A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/401;;A61K31/4025;;A61K31/4245;;A61K31/43;;A61K31/44;;A61K31/4409;;A61K31/475;;A61K31/495;;A61K31/506;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K33/04;;A61K33/26;;A61K38/00;;A61K45/06;;A61K45/08;;A61K49/00;;A61K49/04;;A61K51/12;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,,0,0,,,,PENDING
68,AU,A,AU 1998/083979 A,175-630-019-230-029,1999-02-10,1999,AU 1998/083979 A,1998-07-15,US 89576397 A;;US 9814450 W,1997-07-17,Method and apparatus for radiation and hyperthermia therapy of tumors,,MEDLENNIUM TECHNOLOGIES INC,BLACK KEITH L;;HALIMI EDWARD M,,https://lens.org/175-630-019-230-029,Patent Application,no,0,0,2,2,0,A61B6/00;;A61N5/02;;A61N5/1081;;A61N5/1084;;A61N2005/1055;;A61N2005/1061;;A61B2018/20351;;A61B2018/208;;A61N5/1084,A61B6/00;;A61B18/20;;A61N5/00;;A61N5/02;;A61N5/10,,0,0,,,,DISCONTINUED
69,EP,A1,EP 1676132 A1,174-990-786-952-252,2006-07-05,2006,EP 04795865 A,2004-10-20,US 2004/0034761 W;;US 51304003 P,2003-10-21,Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma,,CEDARS SINAI MEDICAL CENTER,WHEELER CHRISTOPHER;;DAS ASHA;;BLACK KEITH,,https://lens.org/174-990-786-952-252,Patent Application,yes,0,0,9,9,3,A61K31/203;;A61K31/282;;A61K31/454;;A61K31/4745;;A61K31/704;;A61K31/7048;;A61K45/06;;A61P35/00;;A61P43/00;;A61K33/243;;A61K2239/38;;A61K39/4622;;A61K39/464499;;A61K39/4615;;A61K2239/47;;A61K39/46432;;A61K45/06;;A61K31/454;;A61K31/7048;;A61K39/00;;A61K31/203;;A61K31/282;;A61K39/0011;;A61K2039/5154;;A61K31/704;;A61K31/4745;;A61K33/243,A61K45/06;;A61K31/203;;A61K31/282;;A61K31/454;;A61K31/704;;A61K33/243;;A61K39/00;;C12N5/02;;C12N5/08,,0,0,,,,ACTIVE
70,WO,A3,WO 2004/078920 A3,198-693-632-577-031,2005-03-03,2005,US 0306176 W,2003-02-27,US 0306176 W;;US 97696101 A,2001-10-12,METHOD FOR INDUCING SELECTIVE CELL DEATH OF MALIGNANT CELLS BY ACTIVATION OF CALCIUM-ACTIVATED POTASSIUM CHANNELS (KCA),"Disclosed are a method of inducing apoptosis of a malignant cell, which employs a calcium-activated postassium channel (KCa) activator and is useful for treating a malignant tumor in a human subject. Also disclosed are methods of selectively inhibiting the proliferation of malignant cells compared to non-malignant cells in a mixed population of malignant and non-malignant cells and of inhibiting the growth of a malignant tumor, such as a glial tumor, in a mammalian subject. A kit for inducing apoptosis of malignant cells is also disclosed.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/198-693-632-577-031,Search Report,yes,2,0,4,7,0,A61K31/13;;A61K31/7076;;A61K38/043;;A61K31/13;;A61K38/043;;A61K31/7076,A61K31/13;;A61K31/7076;;A61K38/04,,1,1,037-205-105-214-42X,12023511;;10.1124/jpet.301.3.838,"DATABASE CAPLUS NINGARAJ ET AL.: ""Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels"", XP002984284",PENDING
71,AU,A,AU 2001/034602 A,014-061-893-015-071,2001-08-07,2001,AU 2001/034602 A,2001-01-26,US 49150000 A;;US 61585400 A;;US 0102743 W,2000-01-26,Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/014-061-893-015-071,Patent Application,no,0,0,9,13,0,A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/4245;;A61K31/44;;A61K31/475;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,A61K45/00;;A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/401;;A61K31/4025;;A61K31/4245;;A61K31/43;;A61K31/44;;A61K31/4409;;A61K31/475;;A61K31/495;;A61K31/506;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K33/04;;A61K33/26;;A61K38/00;;A61K45/06;;A61K45/08;;A61K49/00;;A61K49/04;;A61K51/12;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,,0,0,,,,PENDING
72,TW,A,TW 201740101 A,084-759-500-409-525,2017-11-16,2017,TW 106111283 A,2017-03-31,US 201662317449 P;;US 201662317451 P;;US 201662317452 P;;US 201662317455 P;;US 201662317453 P;;US 201662317456 P;;US 201662317443 P;;US 201662317459 P;;US 201662317460 P;;US 201662351615 P,2016-04-01,"Systems, devices, and methods for time-resolved fluorescent spectroscopy","Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.",BLACK LIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;BLACK KEITH;;KAVANAUGH JACK,,https://lens.org/084-759-500-409-525,Patent of Addition,no,0,3,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,G01N21/64,,0,0,,,,PENDING
73,US,A1,US 2017/0284940 A1,108-956-928-080-304,2017-10-05,2017,US 201715475750 A,2017-03-31,US 201715475750 A;;US 201662317443 P;;US 201662317449 P;;US 201662317451 P;;US 201662317452 P;;US 201662317453 P;;US 201662317455 P;;US 201662317456 P;;US 201662317459 P;;US 201662317460 P;;US 201662351615 P,2016-04-01,"SYSTEMS, DEVICES, AND METHODS FOR TIME-RESOLVED FLUORESCENT SPECTROSCOPY","Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.",BLACK LIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;BLACK KEITH;;KAVANAUGH JACK,BLACK LIGHT SURGICAL INC (2017-03-22);;CEDARS-SINAI MEDICAL CENTER (2017-04-05),https://lens.org/108-956-928-080-304,Patent Application,yes,0,20,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,G01J3/02;;G01N21/64;;G01J3/44,,2,2,051-032-387-057-366;;002-067-858-020-547,19572006;;10.1364/ol.34.002081;;pmc4083182;;10.1117/12.2283679,"Sun et al., ""Fluorescence lifetime imaging microscopy: in vivo application to diagnosis of oral carcinoma,"" July 1, 2009, Optics Letters, Vol. 34, No. 13, pp. 2081 - 2083.;;B.C. Wilson, ""An optical fiber-based diffuse reflectance spectrometer for non-invasive investigation of photodynamic sensitizers in vivo,"" January 21, 1990, Proceedings of SPIE, Vol. 10306, doi:10.1117/12.2283679, pp. 219 - 232.",ACTIVE
74,US,B2,US 7487190 B2,139-329-319-070-17X,2009-02-03,2009,US 92767604 A,2004-08-27,US 92767604 A,2004-08-27,Automated identification and marking of new and changed content in a structured document,"A method for indicating changes in a structured document includes identifying a new topic or a modified topic in an updated version of a structured document having one or more topics, generating a table of contents having one or more topic entries associated with the one or more topics, marking a topic entry associated with the new topic or the modified topic with a marker indicating that the associated topic is new or modified. A system includes an unmarked table of contents having an entry associated with a unit of updated topic content, and a marking module marking the entry if the unit of updated topic content has changed or the unit of updated topic content comprises a new topic.",MICROSOFT CORP,BLACK JASON E;;BURNARD KEITH A,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2004-08-26),https://lens.org/139-329-319-070-17X,Granted Patent,yes,6,18,2,2,0,G06F40/197;;G06F40/143;;G06F40/197;;G06F40/143,G06F17/30;;G06F40/143,707/203,0,0,,,,INACTIVE
75,EP,A2,EP 4010009 A2,022-036-112-371-950,2022-06-15,2022,EP 20850517 A,2020-08-10,US 201962884570 P;;US 2020/0045570 W,2019-08-08,METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY,,CEDARS SINAI MEDICAL CENTER,YU JOHN SUN;;BLACK KEITH L,,https://lens.org/022-036-112-371-950,Patent Application,yes,0,0,5,5,31,A61K39/0011;;A61K2039/5158;;A61K39/001192;;A61K39/001186;;A61K39/001188;;A61K39/001156;;A61K39/001148;;A61K39/001106;;A61K39/001119;;A61P35/00;;A61K39/39;;A61K39/00119;;A61K2039/80;;A61K39/001106;;A61K39/001188;;A61K39/001192;;A61K39/001119;;A61K39/001178;;A61K39/001122;;A61K39/001186;;A61K31/15;;A61K31/165;;A61K31/341;;A61K2039/5158,A61K38/44,,0,0,,,,PENDING
76,US,A1,US 2005/0089473 A1,092-405-842-912-579,2005-04-28,2005,US 93867404 A,2004-09-10,US 93867404 A;;US 54863604 P;;US 52844003 P;;US 50215903 P,2003-09-10,Potassium channel mediated delivery of agents through the blood-brain barrier,"This invention includes pharmaceutical compositions, methods and kits for the treatment or diagnosis of a malignant tumors, including brain tumors, and diseases or disorders characterized by abnormal brain tissue.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,CEDARS-SINAI MEDICAL CENTER (1998-10-15),https://lens.org/092-405-842-912-579,Patent Application,yes,4,196,6,6,1,A61K31/4184;;A61K31/506;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;A61P9/00;;A61K45/06;;A61K31/506;;A61K31/4184,A61K/;;A61K31/445;;A61K31/505;;A61K31/513;;A61K49/00,424/9.1;;514/269;;514/317,0,0,,,,DISCONTINUED
77,WO,A1,WO 1999/003397 A1,175-103-445-914-920,1999-01-28,1999,US 9814450 W,1998-07-15,US 89576397 A,1997-07-17,METHOD AND APPARATUS FOR RADIATION AND HYPERTHERMIA THERAPY OF TUMORS,"A system (10) includes a three-dimensional tumor image (12) such as MRI or CAT scan for establishing the tumor location (14) within a patient (16). At least two radiation sources (18, 20) are located exteriorly of the patient with each radiation source being capable of providing a beam of radiation at selected radiation intensities.",MEDLENNIUM TECHNOLOGIES INC;;BLACK KEITH L;;HALIMI EDWARD M,BLACK KEITH L;;HALIMI EDWARD M,,https://lens.org/175-103-445-914-920,Patent Application,yes,1,43,2,2,0,A61B6/00;;A61N5/02;;A61N5/1081;;A61N5/1084;;A61N2005/1055;;A61N2005/1061;;A61B2018/20351;;A61B2018/208;;A61N5/1084,A61B6/00;;A61B18/20;;A61N5/00;;A61N5/02;;A61N5/10,,0,0,,,,PENDING
78,US,A,US 5786104 A,026-611-612-628-891,1998-07-28,1998,US 77565896 A,1996-12-31,US 77565896 A,1996-12-31,Method and apparatus for humidification of incoming fuel cell process gases,A fuel gas and an oxidant gas are humidified using a flow transmitter and a static mixer to achieve saturation of fuel and oxidant process gases prior to feeding to a fuel cell.,DOW CHEMICAL CO,BLACK LANCE L;;PLOWMAN KEITH R,DOW CHEMICAL COMPANY THE (1997-04-15),https://lens.org/026-611-612-628-891,Granted Patent,yes,7,40,1,1,0,H01M8/04119;;H01M2300/0082;;Y02E60/50;;H01M8/04119;;H01M2300/0082,H01M8/04,429/13;;429/25;;429/30;;180/65.3,0,0,,,,EXPIRED
79,AU,A,AU 2001/033052 A,060-946-967-594-499,2001-08-07,2001,AU 2001/033052 A,2001-01-26,US 49150000 A;;US 61585400 A;;US 0102742 W,2000-01-26,Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/060-946-967-594-499,Patent Application,no,0,0,9,13,0,A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/4245;;A61K31/44;;A61K31/475;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,A61K45/00;;A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/401;;A61K31/4025;;A61K31/4245;;A61K31/43;;A61K31/44;;A61K31/4409;;A61K31/475;;A61K31/495;;A61K31/506;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K33/04;;A61K33/26;;A61K38/00;;A61K45/06;;A61K45/08;;A61K49/00;;A61K49/04;;A61K51/12;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,,0,0,,,,PENDING
80,AU,A1,AU 2003/217821 A1,189-870-031-089-700,2004-09-28,2004,AU 2003/217821 A,2003-02-27,US 0306176 W,2003-02-27,METHOD FOR INDUCING SELECTIVE CELL DEATH OF MALIGNANT CELLS BY ACTIVATION OF CALCIUM-ACTIVATED POTASSIUM CHANNELS (KCA),,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/189-870-031-089-700,Patent Application,no,0,0,2,7,0,,A61K31/00;;A61K31/13;;A61K38/17;;A61K38/47,,0,0,,,,DISCONTINUED
81,EP,A4,EP 1663239 A4,035-786-470-590-824,2008-07-23,2008,EP 04783849 A,2004-09-10,US 2004/0029787 W;;US 50215903 P;;US 52844003 P;;US 54863604 P,2003-09-10,POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/035-786-470-590-824,Search Report,no,1,0,6,6,0,A61K31/4184;;A61K31/506;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;A61P9/00;;A61K45/06;;A61K31/506;;A61K31/4184,A61K31/4184;;A61K/;;A61K31/445;;A61K31/505;;A61K31/506;;A61K31/513;;A61K45/06;;A61K49/00;;A61P35/00,,2,1,132-128-494-986-42X,14695207,"NINGARAJ N S ET AL: ""Role of KCa and KATP channels in blood-brain tumor barrier permeability in rats"", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, & 31ST ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; SAN DIEGO, CALIFORNIA, USA; NOVEMBER 10-15, 2001, pages 578, XP009101222, ISSN: 0190-5295;;NINGARAJ N S ET AL: ""Adenosine 5'-triphosphate-sensitive Potassium Channel-mediated Blood-Brain Tumor Barrier Permeability Increase in a Rat Brain Tumor Model"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 63, no. 24, 15 December 2003 (2003-12-15), pages 8899 - 8911, XP002350235, ISSN: 0008-5472",DISCONTINUED
82,EP,A4,EP 1676132 A4,048-007-829-254-429,2007-05-09,2007,EP 04795865 A,2004-10-20,US 2004/0034761 W;;US 51304003 P,2003-10-21,"SYSTEM AND METHOD FOR THE TREATMENT OF CANCER, INCLUDING CANCERS OF THE CENTRAL NERVOUS SYSTEM",,CEDARS SINAI MEDICAL CENTER,WHEELER CHRISTOPHER;;DAS ASHA;;BLACK KEITH,,https://lens.org/048-007-829-254-429,Search Report,no,1,0,9,9,0,A61K31/203;;A61K31/282;;A61K31/454;;A61K31/4745;;A61K31/704;;A61K31/7048;;A61K45/06;;A61P35/00;;A61P43/00;;A61K33/243;;A61K2239/38;;A61K39/4622;;A61K39/464499;;A61K39/4615;;A61K2239/47;;A61K39/46432;;A61K45/06;;A61K31/454;;A61K31/7048;;A61K39/00;;A61K31/203;;A61K31/282;;A61K39/0011;;A61K2039/5154;;A61K31/704;;A61K31/4745;;A61K33/243,A61K39/00;;A01N63/00;;A01N65/00;;A61K33/243;;A61K39/38;;A61K39/395;;A61K45/06;;C12N5/00;;C12N5/02;;C12N5/08;;G01N33/48,,12,10,022-982-723-684-607;;092-859-198-377-451;;021-602-438-381-646;;006-604-900-808-204;;085-702-051-840-908;;108-207-855-841-062;;019-264-483-343-031;;057-105-231-226-816;;080-647-403-540-300;;022-665-264-045-910,10.14670/hh-18.435;;12647794;;12538481;;12209978;;10.1002/ijc.10597;;12759442;;10.4049/jimmunol.170.11.5625;;10.1007/s005950300060;;12707821;;14555310;;12667889;;10.1016/s0163-7258(03)00014-7;;10.1053/pb.2000.6691;;10914414;;11221866;;10.1034/j.1600-0463.2003.11107802.x;;12974772,"SHIN J Y ET AL: ""Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model."", HISTOLOGY AND HISTOPATHOLOGY APR 2003, vol. 18, no. 2, April 2003 (2003-04-01), pages 435 - 447, XP009080916, ISSN: 0213-3911;;YU BIN ET AL: ""Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JAN 2003, vol. 9, no. 1, January 2003 (2003-01-01), pages 285 - 294, XP002425821, ISSN: 1078-0432;;TANAKA FUMIAKI ET AL: ""Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo."", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 20 SEP 2002, vol. 101, no. 3, 20 September 2002 (2002-09-20), pages 265 - 269, XP002425822, ISSN: 0020-7136;;GHOSH MONIDIPA ET AL: ""Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 JUN 2003, vol. 170, no. 11, 1 June 2003 (2003-06-01), pages 5625 - 5629, XP002425823, ISSN: 0022-1767;;INOUE NAOYA ET AL: ""Dendritic cells coinjected with tumor cells treated with an anticancer drug to induce tumor rejection."", SURGERY TODAY 2003, vol. 33, no. 4, April 2003 (2003-04-01), pages 269 - 276, XP002425824, ISSN: 0941-1291;;REICHARDT VOLKER L ET AL: ""Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells."", HAEMATOLOGICA OCT 2003, vol. 88, no. 10, October 2003 (2003-10-01), pages 1139 - 1149, XP002425825, ISSN: 1592-8721;;CHUI-SY ET AL.: ""Dendritic cell vaccination following high dose chemotherapy with autologous stem cell support for breast cancer: Long term followup"", PROC. AM SOC CLIN ONCOL, vol. 22, June 2003 (2003-06-01), Abstract 682, XP002425826;;CASTRO M G ET AL: ""Current and future strategies for the treatment of malignant brain tumors."", PHARMACOLOGY & THERAPEUTICS APR 2003, vol. 98, no. 1, April 2003 (2003-04-01), pages 71 - 108, XP002425828, ISSN: 0163-7258;;POLLACK ET AL: ""Exploitation of immune mechanisms in the treatment of central nervous system cancer"", SEMINARS IN PEDIATRIC NEUROLOGY, SAUNDERS, PHILADELPHIA, PA, US, vol. 7, no. 2, June 2000 (2000-06-01), pages 131 - 143, XP005443125, ISSN: 1071-9091;;YU J S ET AL: ""Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration."", CANCER RESEARCH 1 FEB 2001, vol. 61, no. 3, 1 February 2001 (2001-02-01), pages 842 - 847, XP002425827, ISSN: 0008-5472;;STEINMAN RALPH M: ""Some interfaces of dendritic cell biology."", APMIS : ACTA PATHOLOGICA, MICROBIOLOGICA, ET IMMUNOLOGICA SCANDINAVICA 2003 JUL-AUG, vol. 111, no. 7-8, July 2003 (2003-07-01), pages 675 - 697, XP002425947, ISSN: 0903-4641;;See also references of WO 2005043155A1",ACTIVE
83,AU,A8,AU 2003/217821 A8,041-995-848-429-740,2004-09-28,2004,AU 2003/217821 A,2003-02-27,US 0306176 W,2003-02-27,Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (kca),,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/041-995-848-429-740,Patent Application,no,0,0,2,7,0,,A61K31/00;;A61K31/13;;A61K38/17;;A61K38/47,,0,0,,,,DISCONTINUED
84,EP,B1,EP 1676132 B1,026-352-333-984-638,2014-01-22,2014,EP 04795865 A,2004-10-20,US 2004/0034761 W;;US 51304003 P,2003-10-21,Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma,,CEDARS SINAI MEDICAL CENTER,WHEELER CHRISTOPHER;;DAS ASHA;;BLACK KEITH,,https://lens.org/026-352-333-984-638,Granted Patent,yes,2,0,9,9,0,A61K31/203;;A61K31/282;;A61K31/454;;A61K31/4745;;A61K31/704;;A61K31/7048;;A61K45/06;;A61P35/00;;A61P43/00;;A61K33/243;;A61K2239/38;;A61K39/4622;;A61K39/464499;;A61K39/4615;;A61K2239/47;;A61K39/46432;;A61K45/06;;A61K31/454;;A61K31/7048;;A61K39/00;;A61K31/203;;A61K31/282;;A61K39/0011;;A61K2039/5154;;A61K31/704;;A61K31/4745;;A61K33/243,A61K45/06;;A61K31/203;;A61K31/282;;A61K31/454;;A61K31/704;;A61K33/243;;A61K39/00;;C12N5/02;;C12N5/08,,17,17,071-699-972-336-631;;108-599-572-220-595;;053-672-692-937-579;;077-788-577-496-048;;005-926-044-608-888;;026-304-558-215-155;;160-717-493-067-916;;003-616-087-027-77X;;025-760-264-704-263;;026-304-558-215-155;;120-862-791-424-707;;010-981-337-785-354;;071-699-972-336-631;;053-672-692-937-579;;021-056-467-881-097;;153-662-306-900-396;;035-857-332-739-788,9754652;;10.1002/(sici)1097-0215(19981005)78:2<196::aid-ijc13>3.0.co;2-9;;10350260;;10.3171/jns.1999.90.6.1115;;10.1016/s0165-5728(99)00172-1;;10674985;;12516968;;10.1007/bf03401956;;pmc1949998;;11713365;;10.1093/jjco/hye076;;11574635;;10914698;;10.1097/00002371-200307000-00002;;12843792;;12222879;;10.1093/jjco/hye076;;11574635;;11676393;;10.1007/s002620100205;;pmc3903051;;10.1007/s00262-007-0426-9;;18057935;;9754652;;10.1002/(sici)1097-0215(19981005)78:2<196::aid-ijc13>3.0.co;2-9;;10.1016/s0165-5728(99)00172-1;;10674985;;pmc4030524;;10.1158/1078-0432.ccr-06-1576;;17255279;;10.1007/s00262-002-0297-z;;12202903;;10.1158/1078-0432.ccr-04-0497;;15328167,"OKADA H ET AL: ""Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms."", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 5 OCT 1998 LNKD- PUBMED:9754652, vol. 78, no. 2, 5 October 1998 (1998-10-05), pages 196 - 201, ISSN: 0020-7136;;LIAU L M ET AL: ""Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens"", JOURNAL OF NEUROSURGERY, AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS, US LNKD- DOI:10.3171/JNS.1999.90.6.1115, vol. 90, no. 6, 1 June 1999 (1999-06-01), pages 1115 - 1124, XP002966871, ISSN: 0022-3085;;HEIMBERGER A B ET AL: ""Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma."", JOURNAL OF NEUROIMMUNOLOGY 1 FEB 2000 LNKD- PUBMED:10674985, vol. 103, no. 1, 1 February 2000 (2000-02-01), pages 16 - 25, ISSN: 0165-5728;;LI WEIWEI ET AL: ""Fas-mediated signaling enhances sensitivity of human soft tissue sarcoma cells to anticancer drugs by activation of p38 kinase."", MOLECULAR CANCER THERAPEUTICS DEC 2002 LNKD- PUBMED:12516968, vol. 1, no. 14, December 2002 (2002-12-01), pages 1343 - 1348, ISSN: 1535-7163;;SOLING A ET AL: ""Dendritic cell therapy of primary brain tumors."", MOLECULAR MEDICINE (CAMBRIDGE, MASS.) OCT 2001 LNKD- PUBMED:11713365, vol. 7, no. 10, October 2001 (2001-10-01), pages 659 - 667, ISSN: 1076-1551;;OSADA T ET AL: ""Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report."", JAPANESE JOURNAL OF CLINICAL ONCOLOGY AUG 2001 LNKD- PUBMED:11574635, vol. 31, no. 8, August 2001 (2001-08-01), pages 403 - 406, ISSN: 0368-2811;;FRIEDMAN ET AL: ""Temozolomide and treatment of malignant glioma."", CLINICAL CANCER RESEARCH, vol. 6, no. 7, 1 July 2000 (2000-07-01), pages 2585 - 2597, XP055047738, ISSN: 1078-0432;;LIU GENTAO ET AL: ""Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma."", JOURNAL OF IMMUNOTHERAPY (HAGERSTOWN, MD. : 1997) 2003 JUL-AUG, vol. 26, no. 4, July 2003 (2003-07-01), pages 301 - 312, ISSN: 1524-9557;;KNUTSON KEITH L: ""Technology evaluation: DCVax, Northwest Biotherapeutics."", CURRENT OPINION IN MOLECULAR THERAPEUTICS AUG 2002, vol. 4, no. 4, August 2002 (2002-08-01), pages 403 - 407, ISSN: 1464-8431;;T. OSADA ET AL: ""Dendritic Cells Activate Antitumor Immunity for Malignant Intracranial Germ Cell Tumor: a Case Report"", JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol. 31, no. 8, 1 August 2001 (2001-08-01), pages 403 - 406, XP055047739, ISSN: 0368-2811, DOI: 10.1093/jjco/hye076;;KIKUCHI T ET AL: ""Results of a phase I clinical trial of vaccination of glioma patients with fusion of dendritic and glioma cells"", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE, vol. 50, no. 7, 1 September 2001 (2001-09-01), pages 337 - 344, XP003007938, ISSN: 0340-7004, DOI: 10.1007/S002620100205;;ALISON MERRICK ET AL: ""Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naÃve cytotoxic priming and anti-tumour therapy"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 57, no. 6, 4 December 2007 (2007-12-04), pages 897 - 906, XP019586737, ISSN: 1432-0851;;HIDEHO OKADA ET AL: ""Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms"", INTERNATIONAL JOURNAL OF CANCER, vol. 78, no. 2, 5 October 1998 (1998-10-05), pages 196 - 201, XP055047741, ISSN: 0020-7136, DOI: 10.1002/(SICI)1097-0215(19981005)78:2<196::AID-IJC13>3.0.CO;2-9;;AMY B HEIMBERGER ET AL: ""Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma"", JOURNAL OF NEUROIMMUNOLOGY, vol. 103, no. 1, 1 February 2000 (2000-02-01), pages 16 - 25, XP055047742, ISSN: 0165-5728, DOI: 10.1016/S0165-5728(99)00172-1;;J. G. ZHANG ET AL: ""Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell-Based Therapeutics"", CLINICAL CANCER RESEARCH, vol. 13, no. 2, 15 January 2007 (2007-01-15), pages 566 - 575, XP055047743, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-06-1576;;TETSURO KIKUCHI ET AL: ""Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model"", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 51, no. 8, 1 October 2002 (2002-10-01), pages 424 - 430, XP055055230, ISSN: 0340-7004, DOI: 10.1007/s00262-002-0297-z;;C. J. WHEELER ET AL: ""Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination"", CLINICAL CANCER RESEARCH, vol. 10, no. 16, 15 August 2004 (2004-08-15), pages 5316 - 5326, XP055067695, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-04-0497",ACTIVE
85,US,B1,US 7018979 B1,093-286-072-267-733,2006-03-28,2006,US 49150000 A,2000-01-26,US 49150000 A,2000-01-26,Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor,"Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel agonist (other than bradykinin or a bradykinin analog), such as NS-1619,1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levcromakalim, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel agonist together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,CEDAR-SINAI MEDICAL CENTER (2000-01-13),https://lens.org/093-286-072-267-733,Granted Patent,yes,31,9,1,13,1,A61K38/2013;;A61K38/2013;;A61K31/00;;A61K31/00;;A61K38/1841;;A61K38/1841;;A61K38/191;;A61K38/191;;A61K38/21;;A61K38/21,A01N61/00;;A01N37/18;;A61K31/00;;A61K38/00,514/1;;514/2,100,95,070-365-441-056-693;;010-962-309-119-713;;049-459-884-312-015;;048-667-850-459-609;;118-130-598-429-949;;024-468-761-648-050;;008-543-281-483-880;;071-270-626-859-438;;001-824-195-541-34X;;084-375-283-301-629;;027-843-421-507-391;;001-383-734-663-24X;;012-402-423-442-108;;022-978-069-860-28X;;025-868-569-756-237;;039-525-513-762-535;;001-736-794-972-707;;028-304-051-785-83X;;053-158-792-859-449;;004-676-058-581-30X;;009-725-443-859-515;;121-947-870-534-516;;125-131-551-080-717;;052-294-094-479-828;;067-137-272-559-915;;040-080-255-642-333;;092-052-365-201-668;;016-327-800-994-150;;018-461-168-823-445;;041-027-833-379-383;;071-242-975-379-629;;098-300-752-073-932;;004-110-041-349-851;;091-702-682-605-311;;062-531-095-237-192;;072-023-407-412-378;;003-683-883-184-346;;001-466-422-935-967;;000-339-837-993-749;;087-536-743-298-912;;152-043-081-265-985;;049-047-297-671-127;;003-355-880-612-197;;011-761-465-396-697;;037-556-524-970-267;;068-403-005-839-803;;067-729-246-069-516;;039-360-737-889-460;;091-548-088-448-349;;091-707-185-898-304;;038-190-050-726-029;;057-848-429-087-900;;097-427-809-434-391;;071-126-991-508-699;;029-522-882-125-084;;074-641-544-901-232;;042-381-960-539-114;;014-496-263-323-136;;022-858-388-092-074;;110-874-009-938-464;;037-646-595-525-530;;053-352-441-869-273;;072-227-871-529-398;;034-209-481-283-751;;151-527-204-670-388;;027-027-073-715-331;;071-721-550-521-659;;002-818-173-797-403;;037-054-305-654-491;;060-284-024-576-893;;003-529-260-374-113;;026-069-643-638-868;;052-345-642-722-188;;028-177-280-286-568;;029-306-087-771-718;;035-226-538-694-262;;008-506-398-798-357;;011-819-495-181-565;;139-348-171-684-514;;042-552-913-600-924;;049-863-895-994-482;;023-921-909-935-926;;038-024-452-415-705;;103-176-876-765-571;;101-930-902-274-143;;056-788-592-012-783;;022-858-388-092-074;;003-393-099-236-792;;035-708-560-486-04X;;037-205-105-214-42X;;027-646-677-320-843;;076-299-205-928-31X;;001-947-483-239-137;;074-492-662-492-867;;084-662-539-348-036,8914799;;10497901;;10.1016/s0014-2999(99)00489-6;;10.1016/s0014-2999(99)00277-0;;10422791;;10319023;;pmc3220370;;10.1046/j.1365-2613.1998.00081.x;;10.1111/j.1440-1681.1996.tb02760.x;;8800565;;10.1007/bf02089945;;7553734;;2605498;;10.1016/0006-8993(89)90296-5;;10383148;;7692443;;pmc47488;;10.1073/pnas.90.19.8996;;10.1016/0006-8993(95)00811-4;;8574662;;10.1016/0006-8993(92)90374-i;;1611469;;10.1007/s002329900379;;9592079;;10.1097/00005392-199904010-00547;;10397265;;10226542;;10.1111/j.1432-1033.1988.tb13807.x;;3345741;;10368254;;10.1046/j.1464-410x.1999.00101.x;;9157969;;10.1016/s0065-2571(97)00015-0;;9762359;;10335479;;10.1097/00002371-199905000-00002;;10.1124/mol.56.2.308;;10419549;;10.1021/bi9915972;;10529237;;10.1016/0006-8993(94)90499-5;;7987685;;8977165;;10.1111/j.1440-1681.1996.tb01175.x;;9443939;;10.1124/mol.53.1.123;;10.1111/j.1749-6632.1986.tb27151.x;;3028229;;9766317;;10.1097/00006123-199810000-00097;;8825352;;10.1111/j.1476-5381.1996.tb15163.x;;pmc1909362;;2292138;;10.1007/bf00046364;;10.1007/978-1-4615-2920-0_8;;8392782;;10201690;;10.1097/00000542-199904000-00032;;7660420;;10.1161/01.str.26.9.1713;;10.1159/000139218;;7972323;;10.1113/jphysiol.1994.sp020247;;pmc1155683;;7965846;;10323267;;10.1016/s0014-2999(99)00128-4;;10.1023/a:1012038930172;;9034214;;7900779;;10.1152/ajpcell.1995.268.3.c747;;10.1006/bbrc.1997.6989;;9240467;;10510003;;10.1016/s0003-4975(99)00611-6;;9484789;;10.1016/s0006-2952(97)00240-2;;9694955;;9788617;;8985722;;10.1111/j.1472-8206.1996.tb00610.x;;10.1073/pnas.89.22.10832;;1438285;;pmc50436;;10.1007/978-1-4615-2920-0_12;;8333349;;10.1016/0006-8993(94)90319-0;;7525022;;10.1016/0959-8049(94)00236-x;;7880613;;7982064;;10.1016/0006-8993(94)90403-0;;10.1006/abbi.1998.0887;;9799554;;9368578;;10.1161/01.str.28.11.2290;;10.1002/(sici)1096-9926(199911)60:5<260::aid-tera6>3.0.co;2-p;;10525203;;10.1002/(sici)1096-9926(199911)60:5<260::aid-tera6>3.3.co;2-g;;10.1097/00005344-199906000-00006;;10367589;;10379926;;10.1540/jsmr.35.11;;10.1007/bf00666044;;8534871;;10.1152/ajpheart.1997.273.3.h1342;;9321824;;10436787;;10.1023/a:1008340820288;;10.1093/annonc/10.suppl_4.s60;;10.1161/01.atv.19.9.2041;;10479644;;10.1111/j.1476-5381.1991.tb12315.x;;1878752;;pmc1908107;;10.1006/mvre.1999.2152;;10388601;;10.1016/s0006-8993(96)01021-9;;9017232;;10.1006/exnr.1996.0175;;8912895;;9666071;;10.1016/s0006-8993(98)00462-4;;10.1006/viro.1996.0484;;8806568;;10710123;;10.1097/00005344-200003000-00007;;10.1016/0006-8993(96)00142-4;;8782899;;6822617;;10.1038/jcbfm.1983.5;;11896472;;10.1038/sj.ijir.3900801;;9536024;;7519348;;10.1159/000139202;;10.1007/bf01060218;;8787854;;10.1007/pl00005231;;9721012;;10.1074/jbc.274.16.10927;;10196172;;10.1023/a:1005908805527;;9544424;;9841514;;10.1152/ajpheart.1998.274.6.h1865;;9641478;;10.1097/00005344-199806000-00017;;9038926;;10.1152/ajpheart.1997.272.1.h91;;11245034;;8698845;;10.1002/(sici)1097-4652(199604)167:1<89::aid-jcp10>3.0.co;2-k;;7913997;;10.1080/01616412.1994.11740209;;10.3171/jns.1994.81.5.0752;;7931623;;8062426;;10.1161/01.res.75.3.528;;10.1097/00005344-199811000-00003;;9821841;;10.1007/pl00005232;;9721013;;11547933;;10.1179/016164101101198929;;9721011;;10.1007/pl00005230;;7526626;;10.1007/978-3-7091-9334-1_109;;10.1007/pl00005233;;9721014;;10.1016/s0006-8993(96)01021-9;;9017232;;8623120;;10.1161/01.str.27.5.965;;8752174;;12023511;;10.1124/jpet.301.3.838;;1595245;;pmc1003235;;8338137;;10.1152/ajpcell.1993.265.1.c299;;10.1038/sj.bjp.0702439;;pmc1565911;;10217538;;9691227;;10.1159/000028228;;10.1016/s0306-3623(98)00087-1;;9888258,"Sabate, et al., 1996. Clinical Neuroscience, vol. 3, pp. 317-321.;;Adeagbo, A.S., 1-Ethyl-2-benzimidazolinone stimulates endothelial K(Ca) Channels and nitric oxide formation in rat mesenteric vessels, Eur. J./ Pharmacol, 379(2-3):151-9 (Aug. 27, 1999). Abstract Only.;;Akar, F., et al., Protective effect of cromakalim and diazoxide, and proulcerogenic effect of glibenclamide on indomethacin-induced gastric injury, Eur. J. Pharmacol, 374(3):461-70 (Jun. 25, 1999). Abstract Only.;;Andrade, S.P., et al., Pharmacological reactivity of neoplastic and non-neoplastic associated neovasculature to vasoconstrictors, Int. J. Exp. Pathol, 79(6):425-32 (Dec. 1998). Abstract Only.;;Brian, J.E., Jr., et al., Recent insights into the regulation of cerebral circulation, Clin. Exp. Pharmacol Physiol, 23(6-7):449-57 (Jun.-Jul. 1996). Abstract Only.;;Brismar, T., et al., Mechanism of high K+ and TI+ uptake in cultured human glioma cells, Cell Mol. Neurobiol, 15(3):351-60 (Jun. 1995). Abstract Only.;;Brismar, T., et al., Thallium-201 uptake relates to membrane potential and potassium permeability in human glioma cells, Brain Res., 500(1-2):30-6 (Oct. 23, 1989). Abstract Only.;;Burg, M.A., et al., NG2 proteoglycan-binding peptides target tumor neovasculature, Cancer Res., 59(12):2869-74 (Jun. 15, 1999). Abstract Only.;;Burrows, F. J., et al., Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature, Proc. Natl. Acad. Science U.S.A., 90(19):8996-9000 (Oct. 1, 1993). Abstract Only.;;Butt, A.M., Effect of inflammatory agents on electrical resistance across the blood-brain barrier in pial microvessels of anaesthetized rats, Brain Res., 696(1-2):145-50 (Oct. 23, 1995). Abstract Only.;;Butt, A.M., et al., Effect of histamine and antagonists on electrical resistance across the blood-brain barrier in rat brain-surface microvessels, Brain Res., 569(1):100-5 (Jan. 8, 1992). Abstract Only.;;Cai, S., et al., Single-Channel characterization of the pharmacological properties of the K(Ca2+) channel of intermediate conductance in bovine aortic endothelial cells, J. Membr. Biol., 163(2):147-58 (May 15, 1998). Abstract Only.;;Chang, S.S., et al., Five different anti-prostate-specific membrane antigen(PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature, Cancer Res., 59(13):3192-8 (Jul. 1, 1999). Abstract Only.;;Chaplin, D.J., et al., Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate, Anticancer Res., 19(1A):189-95 (Jan.-Feb. 1999). Abstract Only.;;Chassande, O., et al., The Na+/K+/Cl- cotransport in C6 glioma cells, Properties and role in volume regulation, Eur. J. Biochem., 171(3)425-33 (Feb. 1, 1988). Abstract Only.;;Chess-Williams, R., et al., In vitro investigation of the bladder-vascular selectivity of levcromakalim and YM934 in human tissues, BJU Int., 83(9):1050-4 (Jun. 1999). Abstract Only.;;Dark, G.G., et al., Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature, Cancer Res., 57(10):1829-34 (May 15, 1997). Abstract Only.;;Denekamp, J., et al., Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy? Adv. Enzyme Regul., 38:281-99 (1998). Abstract Only.;;Desai, S.B., et al., Tumor angiogenesis and endothelial cell modulatory factors, J. Immunother, 22(3):186-211 (May 1999). Abstract Only.;;D'hahan, N., et al., A transmembrane domain of the sulfonylurea receptor mediates activation of ATP-sensitive K(+) channels by K(+) channel openers, Mol. Pharmacol, 56(2):308-15 (Aug. 1999). Abstract Only.;;Duda, T., Mutations in the Rod Outer Segment Membrane Guanylate Cyclase in a Cone-Rod Dystrophy Cause Defects in Calcium Signaling, Biochemistry, 38(42):13912-13919 (Oct. 19, 1999). Abstract Only.;;Faraci, F.M., et al., Responses of cerebral arterioles to N-methyl-D-aspartate and activation of ATP-sensitive potassium channels in old rats, Brain Res., 654(2):349-51 (Aug. 22, 1994). Abstract Only.;;Faraci, F.M., et al., Potassium channels and the cerebral circulation, Clin. Exp. Pharmacol Physiol, 23(12):1091-5 (Dec. 1996). Abstract Only.;;Friebe, A., et al., Mechanism of YC-1-induced activation of soluble guanylyl cyclase, Mol. Pharmacol, 53(1):123-7 (Jan. 1998). Abstract Only.;;Goldstein, G. W., et al., In vitro studies of the blood-brain barrier using isolated brain capillaries and cultured endothelial cells, Ann. N.Y. Acad. Science, 481:202-13 (1986). Abstract Only.;;Harland, S. P., et al., Expression of enthothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707, Neurosurgery, 43(4):890-8; discussion 898-9 (Oct. 1998). Abstract Only.;;Holland, M., et al., Effects of the BKCa channel activator, NS1619, on rat cerebral artery smooth muscle, Br. J. Pharmacol, 117(1):119-29 (Jan. 1996). Abstract Only.;;Jain, R. K., Vascular and interstitial barriers to delivery of therapeutic agents in tumors, Cancer Metastasis Rev., 9(3):253-66 (Nov. 1990). Abstract Only.;;Keep, R. F., et al., Potassium transport at the blood-brain and blood-CSF barriers, Adv. Exp. Med. Biol., 331:43-54 (1993). Abstract Only.;;Konoshita, H., et al., Differential effects of lidocaine and mexiletine on relaxations to ATP-sensitive K+ channel openers in rat aortas, Anesthesiology, 90(4):1165-70 (Apr. 1999). Abstract Only.;;Kitazono, T., et al., Role of potassium channels in cerebral blood vessels, Stroke, 26(9):1713-23 (Sep. 1995). Abstract Only.;;Lee, Y.S., et al., In vitro antitumor activity of cromakalim in human brain tumor cells, Pharmacology, 49(2):69-74 (Aug. 1994). Abstract Only.;;Manor, D., et al., Interactions among calcium compartments in C6 rat glioma cells; involvement of potassium channels, J. Physiol.(Lond.), 478(Pt.2):251-63 (Jul. 15, 1994). Abstract Only.;;Miller, T.R., et al., Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 huma medulloblastoma cell line, Eur. J. Pharmacol, 37092):179-85 (Apr. 9, 1999). Abstract Only.;;Molema, G., et al., Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy, Pharm. Res., 14(1):2-10 (Jan. 1997). Abstract Only.;;O'Donnell, M.E. et al., Cerebral microvascular endothelial cell Na-K-CI cotransport: regulation by astrocyte-conditioned medium, Am. J. Physiol., 268(3 Pt. 1):C747-54 (Mar. 1995). Abstract Only.;;Ohizumi, I., et al., Antibody-based therapy targeting tumor vascular endothelial cells suppresses solid tumor growth in rats, Biochem Biophys. Res. Commun., 236(2);493-6 (Jul. 18, 1997). Abstract Only.;;Ohta, Y., et al., Tumor angiogenesis and recurrence in stage I non-small cell lung cancer, Ann. Thorac. Surg., 68(3):1034-8 (Sep. 1999). Abstract Only.;;Panchal, R.G., Novel therapeutic strategies to selectively kill cancer cells, Biochem Pharmacol., 55(3):247-52 (Feb. 1, 1998). Abstract Only.;;Patel, H.J., et al., Inhibition of cholinergic neurotransmission in guinea pig trachea by NS1619, a putative activator of large-conductance, calcium-activated potassium channels, J. Pharmacol. Exp. Ther., 286(2):952-8 (Aug. 1998). Abstract Only.;;Ran, S., et al., Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature, Cancer Res., 58(20):4646-53 (Oct. 15, 1998). Abstract Only.;;Redrobe, J.P., et al., The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice, Fundam. Clin. Pharmacol., 10(6):524-8 (1996). Abstract Only.;;Rettig, W.J., et al., Identificatgion of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer, Proc. Natl. Acad. Sci. U.S.A., 89(22):10832-6 (Nov. 15, 1992). Abstract Only.;;Revest, P.A., et al., The transendothelial DC potential of rat blood-brain barrier vessels in situ, Adv. Exp. Med. Biol., 331:71-4 (1993). Abstract Only.;;Revest, P.A., et al., Transendothelial electrical potential across pial vessels in anaesthetised rats: a study of ion permeability and transport at the blood-brain barrier, Brain Res., 652(1):76-82 (Jul. 25, 1994). Abstract Only.;;Sandstrom, P.E., et al., Identification of potassium flux pathways and their role in the cytotoxicity of estramustine in human malignant glioma, prostatic carcinoma and pulmonary carcinoma cell lines, Eur. J. Cancer, 30A(12):1822-6 (1994). Abstract Only.;;Schilling, L., et al., Opening of the blood-brain barrier during cortical superfusion with histamine, Brain Res., 653(1-2):289-96 (Aug. 8, 1994). Abstract Only.;;Serfass, L., et al., Effect of heme oxygenase inhibitors on soluble guanylyl cyclase activity, Arch. Biochem. Biophys., 359(1):8-16 (1998). Abstract Only.;;Sobey, C.G., et al., Mechanisms of bradykinin-induced cerebral vasodilatation in rats. Evidence that reactive oxygen species activate K+ channels, Stroke, 28(11):2290-4; discussion 2295 (Nov. 1997). Abstract Only.;;Smoak, I.W., Cromakalim: embryonic effects and reduction of tolbutamide-induced dysmorphogenesis in vitro, Teratology, 60(5):260-264 (Nov. 1999). Abstract Only.;;Sugai, K. et al., Levcromakalim decreases cytoplasmic Ca2+ and vascular tone in basilar artery of SAH model dogs, J. Cardiovasc. Pharmacol., 33(6):868-75 (Jun. 1999). Abstract Only.;;Teramoto, N. et al., Comparative studies on the relaxing action of several adenosine 5'-triphosphate-sensitive K+ channel openers in pig urethra, J. Smooth Muscle Res., 35(1):11-22 (Feb. 1999). Abstract Only.;;Thorpe, P. E. et al., Antibody-directed targeting of the vasculatlure of solid tumors, Breast Cancer Res. Treat., 36(2):237-51 (1995). Abstract Only.;;Toyoda, K. et al., Role of ATP-sensitive potassium channels in brain stem circulation during hypotension, Am. J. Physiol., 273(Pt. 2):H1342-6 (Sep. 1997). Abstract Only.;;Van Hinsbergh, V. W. et al., Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors, Ann. Oncol., 10 Supl 4:60-3 (1999). Abstract only.;;Walter, J. J. et al., Angiostatin binds to smooth muscle cells in the coronary artery and inhibits smooth muscle cell proliferation and migration in vitro, Arterioscler. Throm. Vasc. Bio., 19(9):2041-8 (Sep. 1999). Abstract Only.;;Wickenden, A.D. et al., Comparison of the effects of the K(+)-channel openers cromakalim and minoxidil suplhate on vascular smooth muscle, Br. J. Pharmacol., 103(1):1148-52 (May 1991). Abstract Only.;;XP-002195899-Oak, Z. et al., Effects of Cyclic GMP on Microvascular Permeability of the Cerebral Cortex, Microvascular Research, vol. 58, pp. 35-40 (1999).;;XP-002195900-Role of nitric oxide in histamine-induced increases in permeability of the blood-brain barrier, Mayhan, William G., Brain Research, vol. 743, pp. 70-76 (1996).;;XP-002195901-Bartus, R. T. et al., Controlled Modulation of BBB Permeability Using the Bradykinin Agonist, RMP-07, Experimental Neurology, vol. 142, pp. 14-28 (1996).;;International Search Report re PCT/US01/02743, P mailed Apr. 26, 2002.;;Armstead, W.M., Contribution of kca channel activation to hypoxic cerebrovasodilation does not involve NO, Brain Res., 799:44-48 (1998). Abstract Only.;;Barna, M., et al., Activation of type III nitric oxide synthase in astrocytes following a neurotropic viral infection, Virology, 223: 331-343 (1996).;;Becker, E.M., et al., The vasodilator-stimulated phosphoprotein(VASP): target of YC-1 and nitric oxide effects in human and rate platelets. J Cardiovasc Pharmacol. 35(3):390-7 (2000). Abstract Only.;;Boje, K. M., Inhibition of nitric oxide synthase attenuates blood-brain barrier disruption during experimental meningitis, Brain Research, 720:75-83 (1996).;;Brandt, L., et al., Effects of topical application of calcium antagonist (nifedipine) on feline cortical pial microvasculature under normal conditions and in focal ischemia, Journal of Cerebral Blood Flow and Metabilism, 3:44-50 (1983).;;Brioni, J.D., et al., Activators of soluble guanylate cyclase for treatment of male erectile dysfunction, International Journal of Impotence Research, 14:8-14 (2002).;;Bychkov, R., et al. Calicum-activated potassium channels and nitrate-induced vasodilation in human coronary arteries, J. Pharacol Exp Therap, 285:293-8 (1998). Abstract Only.;;Chandran, S., et al., Nitric oxide: concepts, current perspectives and future therapeutic implications, Indian Journal of Pharmacology, 30:351-366 (1998).;;Chi, O.Z., et al. Effect of inhibition of nitric oxide synthase on blood-brain barrier transport in focal cerebral ischemia, Pharmacologylogy, 48:367-373 (1994).;;Cloughesy, T.F., et al., Pharmacological blood-brain barrier modification for selective drug delivery, Journal of Neuro-Oncology, 26:125-132 (1995).;;Feelisch, M., The use of nitric oxide donors in pharmacological studies, Naunyn-Schmiedeberg's Arch Pharmcol, 358:113-122 (1998).;;Fukao, M., et al., Cyclic GMP-dependent protein kindase activates cloned BKCa channels expressed in mammalian cells by direct phophorylation at serine 1072, J Biol Chem, 274(16):10927-35 (1999).;;Fukumura, D., et al., Role of nitric oxide in angiogenesis and microcirculation in tumors, Cancer and Metastasis Reviews, 17:77-89 (1998).;;He, P., et al., cGMP modulates basal and activated microvessel permeability independenty of [Ca2+]i, Am J Physiol, 274:H1865-74 (1998). Abstracts Only.;;Herrera, G.M., et al., Maintained vasodilatory response to cromakalim after inhibition of nitric oxide synthesis, J Cardiovasc Pharmacol, 31:921-9 (1998). Abstract Only.;;Holschermann, H., et al., Dual role of cGMP in modulation of macromolecule permeability of aortic endothelial cells, Am J Physiol, 272:H91-8 (1997). Abstract Only.;;Hongli, X., et al., Opening blood-brain-barrier by intracarotid infusion of papaverine in treatment of malignant cerebral glioma, Chinese Medical Journal, 111(8):751-753 (1998).;;Hurst, R.D., et al., Nitric oxide-induced perturbations in a cell culture model of the blood-brain barrier, Journal of Cellular Physiology, 167:89-94 (1996).;;Inamura, T., et al., Intracarotid histamine infusion increases blood tumour permeability in RG2 glioma, Neurological Research, 16:125-128 (1994).;;Inamura, T., et al., Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors, J Neurosurg, 81:752-758 (1994).;;Janigro, D., et al., Regulation of blood-brain barrier endothelial cells by nitric oxide, Circulation Research, 75:528-528 (1994).;;Kimura, M., et al., Responses of human basilar and other isolated arteries to novel nitric oxide donors, J Cardiovasc Pharmacol, 32: 695-701 (1998). Abstract Only.;;Koesling, D., Modulators of soluble guanylyl cyclase, Naunyn-Schmiedeberg's Arch Pharmacol, 358:123-126 (1998).;;Liu, Y., et al., Repeated, short-term ischemia augments bradykinin-mediated opening of the blood-tumor barrier in rats with RG2 glioma, Neurological Research, 23:631-639 (2001).;;Lohse, M.J., et al., Pharmacology of NO:cGMP signal transduction, Naunyn-Schmiedeberg's Arch Pharmcol, 358:111-112 (1998).;;Matukado, T., et al., Selective Increase in Blood Tumor Permeability by Calcium Antagonists in Transplanted Brain Tumors, Acta Neurochir, 60:403-405 (1994).;;Mayer, B., et al., Nitric oxide synthases: catalytic function and progress toward selective inhibitions, Naunyn-Schmiedeberg's Arch Pharmcol, 358:127-133 (1998).;;Mayham, W.G., Role of nitric oxide in histamine-induced increases in permeability of the blood-brain barrier, Brain Research, 743:70-76 (1996).;;Mayhan, W.G., et al., Glutamate-induced disruption of the blood-brain barrier in rats, Stroke, 27:965-970 (1996).;;Nakano, S., et al., Increased brain microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide, Cancer Research, 56;4027-4031 (1996).;;Ningaraj, N.S., et al., Role of ATP-sensitive K+ channels in blood-brain tumor barrier permeability, Congress of Neurological Surgeons Annual Meeting, 50<SUP>th </SUP>Anniversary Celebration, Sep. 23-28, 2000, Henry B. Gonzalez Convention Center, San Antonio, Texas, ABSTRACT No. 4309, p. 215.;;Ningaraj, N.S., et al., Ca2+ -dependent K+ channels are a key regulatory of blood-brain tumor barrier permeability, Congress of Neurological Surgeons Annual Meeting, 50<SUP>th </SUP>Anniversary Celebration, Sep. 23-28, 2000, Henry B. Gonzalez Convention Center, San Antonio, Texas, ABSTRACT No. 428, p. 219.;;Ningaraj, N.S., et al., Nitric oxide donors increase blood-brain tumor barrier permeability via Kca channels, Society for Neuroscience, 30<SUP>th </SUP>Annual Meeting, New Orleans, LA, Nov. 4-9, 2000, 26 Part 1, p. 338, ABSTRACT No. 126.8.;;Ningaraj, N.S., et al., Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels, The Journal of Pharmacolgy, Jun. 2002, 301:838-851.;;Pardrige, W., et al., Blood -brain barrier and new approaches to drug delivery, West J Med, 156:281-286 (1992).;;Robertson, B.E., et al., cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells, Am J Physiol, 265:C299-C303 (1993).;;Sobey, C.G., et al., Inhibitory effect of 4-aminopyridine on responses of the basilar artery to nitric oxide, Br J Pharmacol, 126:1437-43 (1999). Abstract Only.;;Salom, J.B., et al., Relaxant effects of sodium nitroprusside and NONOates in rabbit basilar artery, Pharmacology, 57:79-97 (1998). Abstract Only.;;Salom, J.B., et al., Comparative relaxant effects of the NO donors sodium nitroprusside, DEA/NO and SPER/NO in rabbit carotid arteries, Gen Pharmacol, 32:75-59 (1999). Abstract Only.",EXPIRED
86,US,A1,US 2005/0095196 A1,128-345-711-888-444,2005-05-05,2005,US 69667603 A,2003-10-29,US 69667603 A,2003-10-29,Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor,"Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor In a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel agonist (other than bradykinin or a bradykinin analog), such as NS-1619,1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levcromakalim, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel agonist together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.",BLACK KEITH L.;;NINGARAJ NAGENDRA S.,BLACK KEITH L;;NINGARAJ NAGENDRA S,CEDARS-SINAI MEDICAL CENTER (2000-01-13),https://lens.org/128-345-711-888-444,Patent Application,yes,5,3,1,1,0,A61K38/1841;;A61K45/06;;A61K38/191;;A61K38/2013;;A61K38/21;;A61K31/4184;;A61K45/06;;A61K38/1841;;A61K38/21;;A61K38/2013;;A61K38/191;;A61K31/4184,A61K38/18;;A61K38/19;;A61K45/06,424/1.11;;514/12;;514/34;;514/44;;514/251;;514/109;;424/85.1;;424/649;;514/492,0,0,,,,DISCONTINUED
87,ES,T3,ES 2717836 T3,187-006-380-772-845,2019-06-25,2019,ES 04813049 T,2004-12-03,US 52733003 P;;US 2004/0040660 W,2003-12-05,Sistema de administración de fármacos multifuncional a base de ácido polimálico,,ARROGENE INC;;CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA;;BLACK KEITH;;HOLLER EGGEHARD,,https://lens.org/187-006-380-772-845,Granted Patent,no,0,0,12,14,0,A61K47/60;;A61K47/593;;A61K47/6883;;A61K47/6849;;A61P35/00;;A61K47/6883;;A61K47/593;;A61K47/60;;A61K47/6849;;A61P35/00,A61K47/59;;A61K47/48;;A61K47/60;;A61K47/68;;A61P35/00,,0,0,,,,ACTIVE
88,WO,A3,WO 2001/054771 A3,147-440-865-631-320,2002-06-20,2002,US 0102743 W,2001-01-26,US 49150000 A;;US 61585400 A,2000-01-26,METHOD FOR USING POTASSIUM CHANNEL AGONISTS FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN REGION AND/OR A MALIGNANT TUMOR,"Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a calcium- or ATP-dependent potassium channel [KCa or KATP] activator (other than bradykinin or a bradykinin analog), such as a direct potassium channel agonist or an indirect potassium channel activator, such as an activator of soluble guanylyl cyclase (e.g., nitric oxide or a nitric oxide donor) or an activator of cyclic GMP-dependent protein kinase, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel activator together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/147-440-865-631-320,Search Report,yes,6,0,9,13,0,A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/4245;;A61K31/44;;A61K31/475;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,A61K45/00;;A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/401;;A61K31/4025;;A61K31/4245;;A61K31/43;;A61K31/44;;A61K31/4409;;A61K31/475;;A61K31/495;;A61K31/506;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K33/04;;A61K33/26;;A61K38/00;;A61K45/06;;A61K45/08;;A61K49/00;;A61K49/04;;A61K51/12;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,,4,3,014-496-263-323-136;;110-874-009-938-464;;022-858-388-092-074,10.1006/mvre.1999.2152;;10388601;;10.1006/exnr.1996.0175;;8912895;;10.1016/s0006-8993(96)01021-9;;9017232,"OAK Z. CHI ET AL: ""Effects of Cyclic GMP on Microvascular Permeability of the Cerebral Cortex"", MICROVASCULAR RESEARCH, vol. 58, 1999, pages 35 - 40, XP002195899;;R. T. BARTUS ET AL: ""Controlled Modulation of BBB Permeability Using the Bradykinin Agonist, RMP-7"", EXPERIMENTAL NEUROLOGY, vol. 142, 1996, pages 14 - 28, XP002195901;;W. G. MAYHAN: ""Role of nitric oxide in histamine-induced increases in permeability of the blood-brain barrier"", BRAIN RESEARCH, vol. 743, 1996, pages 70 - 76, XP002195900;;See also references of EP 1251838A2",PENDING
89,US,A1,US 2022/0370586 A1,082-361-678-961-71X,2022-11-24,2022,US 202017633505 A,2020-08-10,US 202017633505 A;;US 201962884570 P;;US 2020/0045570 W,2019-08-08,METHOD OF GENERATING ACTIVATED T CELLS FOR CANCER THERAPY,Described herein are compositions and methods for treating cancer and autoimmune diseases.,CEDARS SINAI MEDICAL CENTER,YU JOHN SUN;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2022-02-04),https://lens.org/082-361-678-961-71X,Patent Application,yes,0,0,5,5,31,A61K39/0011;;A61K2039/5158;;A61K39/001192;;A61K39/001186;;A61K39/001188;;A61K39/001156;;A61K39/001148;;A61K39/001106;;A61K39/001119;;A61P35/00;;A61K39/39;;A61K39/00119;;A61K2039/80;;A61K39/001106;;A61K39/001188;;A61K39/001192;;A61K39/001119;;A61K39/001178;;A61K39/001122;;A61K39/001186;;A61K31/15;;A61K31/165;;A61K31/341;;A61K2039/5158,A61K39/00;;A61K31/15;;A61K31/165;;A61K31/341,,0,0,,,,PENDING
90,CN,A,CN 102570132 A,129-337-729-996-351,2012-07-11,2012,CN 201110362241 A,2011-09-02,US 87497010 A,2010-09-02,Electrical connector having shaped dielectric insert for controlling impedance,"A electrical connector that includes a connector housing (100) having mating (104) and terminating ends(106). The connector housing has a housing cavity (105) and a leading edge (108) at the mating end that defines an opening (110) to the housing cavity. A central axis(190) extends through the housing cavity between the mating and terminating ends. The electrical connector (112) also includes a dielectric insert within the housing cavity and an electrical contact (125) that is held by the insert along the central axis. The insert has a recess surface (210) that faces the mating end and extends a radial distance(RD4), outward from the electrical contact. The insert includes a dielectric rim(222) that projects from the recess surface toward the mating end. The dielectric rim surrounds: and is radially spaced from at least a portion of the electrical contact. The dielectric rim and the recess surface define an impedance-control space (134) that surrounds at least the portion of the electrical contact.",TYCO ELECTRONICS CO LTD,BLACK FRANCIS J;;FOLTZ KEITH RICHARD,,https://lens.org/129-337-729-996-351,Patent Application,no,4,2,5,5,0,H01R24/44;;H01R24/44,H01R13/46;;H01R13/02,,0,0,,,,ACTIVE
91,US,A,US 5505635 A,183-179-028-819-800,1996-04-09,1996,US 34436894 A,1994-11-23,US 34436894 A,1994-11-23,Zero insertion force battery receptacle,"A zero insertion force receptacle for a battery powered device including a battery storage area having a pair of parallel battery cradles. A pair of stationary contacts are positioned at the first end of the cradles and a pivotable connector is positioned at the second end of the cradles. The pivotable connector includes a pair of actuator arms which are engaged by a shoulder on a removable cover as the cover is closed. The shoulder displaces the actuator arms and causes the pivotable connector to rotate about a pair of pivot pins to bring a pair of contact arms into engagement with the batteries. As the closing of the cover increases, the actuator arms are pivoted further about the pivot pins to increase the force between the contact arms and the batteries. In the preferred embodiment, the actuator arms are linked to the contact arms by spring sections. Because the pivotable connector includes a conductive path between the contact arms, the pivotable connector forms an electrical connection between the batteries.",FLUKE CORP,WILLOWS KEITH S;;BLACK MICHAEL J,FLUKE CORPORATION (1994-11-09),https://lens.org/183-179-028-819-800,Granted Patent,yes,5,22,1,1,0,Y10S439/911;;Y02E60/10;;H01M50/213;;H01M50/50;;Y10S439/911;;H01M50/213;;H01M50/50,H01M50/50,439/500;;429/97,0,0,,,,EXPIRED
92,WO,A1,WO 2005/043155 A1,170-790-504-147-422,2005-05-12,2005,US 2004/0034761 W,2004-10-20,US 51304003 P,2003-10-21,"SYSTEM AND METHOD FOR THE TREATMENT OF CANCER, INCLUDING CANCERS OF THE CENTRAL NERVOUS SYSTEM","The invention relates to the treatment of cancer, and particularly to the treatment of cancers of the central nervous system, such as glioblastoma multiforme. A dual therapeutic approach is provided, including the administration of a dendritic cell-based cancer vaccine and a regimen of chemotherapy. The two therapies may be administered concurrently with one another and/or with an initial vaccination preceding chemotherapy. In various embodiments, the dendritic cell-based cancer vaccine includes either primed or unprimed dendritic cells; for instance, the dendritic cells may be autologous tumor antigen-presented dendritic cells. The dual therapeutic approach of the instant invention beneficially influences the chemosensitivity of a mammal with cancer.",CEDARS SINAI MEDICAL CENTER;;WHEELER CHRISTOPHER;;DAS ASHA;;BLACK KEITH,WHEELER CHRISTOPHER;;DAS ASHA;;BLACK KEITH,,https://lens.org/170-790-504-147-422,Patent Application,yes,2,16,9,9,0,A61K31/203;;A61K31/282;;A61K31/454;;A61K31/4745;;A61K31/704;;A61K31/7048;;A61K45/06;;A61P35/00;;A61P43/00;;A61K33/243;;A61K2239/38;;A61K39/4622;;A61K39/464499;;A61K39/4615;;A61K2239/47;;A61K39/46432;;A61K45/06;;A61K31/454;;A61K31/7048;;A61K39/00;;A61K31/203;;A61K31/282;;A61K39/0011;;A61K2039/5154;;A61K31/704;;A61K31/4745;;A61K33/243,A61K33/243;;A61K39/00;;A61K45/06;;C12N5/02;;C12N5/08,,4,0,,,"SINGLETON ET AL.: ""Dictionary of Microbiology and Molecular Biology"", 1994, J. WILEY & SONS;;MARCH: ""Advanced Organic Chemistry Reactions, Mechanisms and Structure"", 1992, J. WILEY & SONS;;SAMBROOK; RUSSEL: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;See also references of EP 1676132A4",PENDING
93,WO,A3,WO 2005/025511 A3,175-753-739-037-868,2005-11-03,2005,US 2004/0029787 W,2004-09-10,US 50215903 P;;US 52844003 P;;US 54863604 P,2003-09-10,POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER,"This invention includes pharmaceutical compositions, methods and. kits for the treatment or diagnosis of a malignant tumors, including brain tumors, and diseases or disorders characterized by abnormal brain tissue.",CEDARS SINAI MEDICAL CENTER;;BLACK KEITH L;;NINGARAJ NAGENDRA S,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/175-753-739-037-868,Search Report,yes,3,0,6,6,0,A61K31/4184;;A61K31/506;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;A61P9/00;;A61K45/06;;A61K31/506;;A61K31/4184,A61K/;;A61K31/445;;A61K31/505;;A61K31/513;;A61K49/00,,0,0,,,,PENDING
94,US,B2,US 7211561 B2,015-778-385-202-174,2007-05-01,2007,US 97696101 A,2001-10-12,US 97696101 A;;US 0306176 W,2001-10-12,Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa),"Disclosed are a method of inducing apoptosis of a malignant cell, which employs a calcium-activated potassium channel (K Ca ) activator and is useful for treating a malignant tumor in a human subject. Also disclosed are methods of selectively inhibiting the proliferation of malignant cells compared to non-malignant cells in a mixed population of malignant and non-malignant cells and of inhibiting the growth of a malignant tumor, such as a glial tumor, in a mammalian subject. A kit for inducing apoptosis of malignant cells is also disclosed.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,CEDARS-SINAI MEDICAL CENTER (2002-02-04),https://lens.org/015-778-385-202-174,Granted Patent,yes,30,1,4,7,0,A61K31/13;;A61K31/7076;;A61K38/043;;A61K31/13;;A61K38/043;;A61K31/7076,A01N33/02;;A61K31/13;;A61K31/7076;;A61K38/04,514/12;;514/12;;514/663,106,100,023-534-799-983-707;;078-036-937-217-941;;044-115-097-620-237;;016-741-666-114-290;;068-503-996-022-586;;033-454-184-242-69X;;015-540-402-994-020;;010-962-309-119-713;;049-459-884-312-015;;048-667-850-459-609;;037-646-595-525-530;;085-092-739-028-162;;072-227-871-529-398;;017-600-680-062-666;;001-957-571-837-224;;118-130-598-429-949;;024-468-761-648-050;;008-543-281-483-880;;071-270-626-859-438;;001-824-195-541-34X;;027-843-421-507-391;;084-375-283-301-629;;059-995-414-090-093;;071-721-550-521-659;;001-383-734-663-24X;;012-402-423-442-108;;022-978-069-860-28X;;025-868-569-756-237;;039-525-513-762-535;;058-128-660-403-559;;001-736-794-972-707;;028-304-051-785-83X;;053-158-792-859-449;;004-676-058-581-30X;;009-725-443-859-515;;121-947-870-534-516;;125-131-551-080-717;;060-284-024-576-893;;004-324-033-441-248;;052-294-094-479-828;;003-529-260-374-113;;026-069-643-638-868;;013-452-910-395-515;;053-119-019-015-749;;067-137-272-559-915;;096-399-069-824-367;;023-534-799-983-707;;101-369-881-707-235;;040-080-255-642-333;;052-345-642-722-188;;028-177-280-286-568;;092-052-365-201-668;;029-306-087-771-718;;066-265-972-637-419;;001-924-199-616-968;;016-327-800-994-150;;018-461-168-823-445;;047-811-311-580-116;;068-503-996-022-586;;049-863-895-994-482;;041-027-833-379-383;;071-242-975-379-629;;023-921-909-935-926;;056-867-665-310-200;;044-115-097-620-237;;098-300-752-073-932;;125-060-274-549-04X;;061-310-936-779-311;;103-176-876-765-571;;148-291-758-431-884;;004-110-041-349-851;;101-930-902-274-143;;056-788-592-012-783;;091-702-682-605-311;;035-289-658-641-243;;062-531-095-237-192;;056-462-047-838-934;;078-036-937-217-941;;031-827-799-811-242;;072-023-407-412-378;;003-683-883-184-346;;001-466-422-935-967;;000-339-837-993-749;;091-707-185-898-304;;078-843-115-662-908;;002-738-750-441-82X;;038-190-050-726-029;;057-848-429-087-900;;097-427-809-434-391;;071-126-991-508-699;;169-690-400-227-977;;029-522-882-125-084;;035-687-338-046-30X;;074-641-544-901-232;;042-381-960-539-114;;011-839-192-324-985;;021-870-469-819-314;;088-746-564-233-162;;053-999-279-141-15X;;087-536-743-298-912,pmc23879;;9207149;;10.1073/pnas.94.14.7661;;10783394;;10.1074/jbc.m002535200;;10.1046/j.1471-4159.1997.69041570.x;;9326286;;10.1016/s0304-3835(99)00280-3;;10660093;;10657756;;10.1159/000028350;;15217801;;10.1152/ajpheart.00431.2004;;3470138;;10497901;;10.1016/s0014-2999(99)00489-6;;10.1016/s0014-2999(99)00277-0;;10422791;;10319023;;pmc3220370;;10.1046/j.1365-2613.1998.00081.x;;9666071;;10.1016/s0006-8993(98)00462-4;;10690349;;10.1016/s0008-6363(99)00116-9;;10710123;;10.1097/00005344-200003000-00007;;2338576;;10.3171/jns.1990.72.6.0912;;10851046;;10.1038/sj.onc.1203527;;10.1111/j.1440-1681.1996.tb02760.x;;8800565;;10.1007/bf02089945;;7553734;;2605498;;10.1016/0006-8993(89)90296-5;;10383148;;7692443;;pmc47488;;10.1073/pnas.90.19.8996;;10.1016/0006-8993(92)90374-i;;1611469;;10.1016/0006-8993(95)00811-4;;8574662;;8719784;;pmc1909162;;10.1111/j.1476-5381.1995.tb15112.x;;9536024;;10.1007/s002329900379;;9592079;;10.1097/00005392-199904010-00547;;10397265;;10226542;;10.1111/j.1432-1033.1988.tb13807.x;;3345741;;10368254;;10.1046/j.1464-410x.1999.00101.x;;9654359;;10.1016/s0304-3940(98)00316-4;;9157969;;10.1016/s0065-2571(97)00015-0;;9762359;;10335479;;10.1097/00002371-199905000-00002;;10.1124/mol.56.2.308;;10419549;;10.1021/bi9915972;;10529237;;10.1016/0006-8993(94)90499-5;;7987685;;8977165;;10.1111/j.1440-1681.1996.tb01175.x;;10.1007/pl00005231;;9721012;;10.1038/sj.bjp.0702607;;pmc1566069;;10401570;;9443939;;10.1124/mol.53.1.123;;10.1074/jbc.274.16.10927;;10196172;;10.1023/a:1005908805527;;9544424;;10.1016/s0022-5223(96)70335-5;;8614135;;10.1152/ajpcell.1999.277.4.c673;;10516097;;10.1111/j.1749-6632.1986.tb27151.x;;3028229;;10642328;;10.1161/01.hyp.35.1.379;;pmc23879;;9207149;;10.1073/pnas.94.14.7661;;9758642;;10.1161/01.res.83.7.721;;9766317;;10.1097/00006123-199810000-00097;;9841514;;10.1152/ajpheart.1998.274.6.h1865;;9641478;;10.1097/00005344-199806000-00017;;8825352;;10.1111/j.1476-5381.1996.tb15163.x;;pmc1909362;;9038926;;10.1152/ajpheart.1997.272.1.h91;;10.1002/(sici)1521-2254(200005/06)2:3<204::aid-jgm104>3.3.co;2-x;;10.1002/(sici)1521-2254(200005/06)2:3<204::aid-jgm104>3.0.co;2-5;;10894266;;7679257;;10.1152/ajpheart.1993.264.1.h238;;2292138;;10.1007/bf00046364;;10.1007/978-1-4615-2920-0_8;;8392782;;8061011;;10657756;;10.1159/000028350;;10.1097/00005344-199811000-00003;;9821841;;10201690;;10.1097/00000542-199904000-00032;;7660420;;10.1161/01.str.26.9.1713;;10.1007/pl00005232;;9721013;;10.1046/j.1365-201x.2000.00632.x;;10691778;;10.1046/j.1471-4159.1997.69041570.x;;9326286;;10.1159/000139218;;7972323;;pmc1564500;;10.1038/sj.bjp.0700939;;9051315;;9281373;;10.1006/excr.1997.3675;;9721011;;10.1007/pl00005230;;7838129;;10.1113/jphysiol.1994.sp020247;;pmc1155683;;7965846;;7526626;;10.1007/978-3-7091-9334-1_109;;10.1007/pl00005233;;9721014;;10323267;;10.1016/s0014-2999(99)00128-4;;10.3171/jns.1994.81.3.0411;;8057149;;10.1023/a:1012038930172;;9034214;;10938328;;10.1152/jn.2000.84.2.1062;;10783394;;10.1074/jbc.m002535200;;10.1074/jbc.274.43.31000;;10521497;;7900779;;10.1152/ajpcell.1995.268.3.c747;;10.1006/bbrc.1997.6989;;9240467;;10510003;;10.1016/s0003-4975(99)00611-6;;9484789;;10.1016/s0006-2952(97)00240-2;;10.1002/(sici)1096-9926(199911)60:5<260::aid-tera6>3.0.co;2-p;;10525203;;10.1002/(sici)1096-9926(199911)60:5<260::aid-tera6>3.3.co;2-g;;10.1007/pl00005234;;9721015;;10.1016/s1053-0770(00)90048-x;;10698385;;10.1097/00005344-199906000-00006;;10367589;;10379926;;10.1540/jsmr.35.11;;10.1007/bf00666044;;8534871;;10.1152/ajpheart.1997.273.3.h1342;;9321824;;9655848;;10436787;;10.1023/a:1008340820288;;10.1093/annonc/10.suppl_4.s60;;10232601;;10.1161/01.atv.19.9.2041;;10479644;;10.1111/j.1476-5381.1991.tb12315.x;;1878752;;pmc1908107;;10.1073/pnas.97.14.8151;;10884437;;pmc16685;;10.1203/00006450-199507000-00021;;7478789;;9353410;;9353411;;9694955,"Gulbins et al. (Proc. Natl. Acad. Sci. USA 1997, 94: 7661-7666).;;Nietsch et al. (J. Biol. Chem. 2000, 275 (27): 20556-20561).;;Lauritzen et al. (J. Neurochem. 1997, 69: 1570-1579).;;Choi et al. (Cancer Letters 1999, 147: 85-93).;;Kim et al. (Pharmacology 2000, 60 (2): 74-81).;;Wang et al. (Am. J. Physiol. Heart Cir. Physiol. 2004; 287: H2070-H2077.;;Yamada et al. (Cancer Research 1987; 47: 2123-2128.;;Adeagbo, A. S., 1-Ethyl-2-benzimidazolinone stimulates endothelial K (Ca) channels and nitric oxide formation in rat mesenteric vessels, Eur J. Pharmacol, 379(2-3):151-9 (Aug. 27, 1999). Abstract Only.;;Akar, F. et al, Protective effect of cromakalim and diazoxide, and proulcerogenic effect of glibenclamide on indomethacin-induced gastric injury, Eur J. Pharmacol, 374(3):461-70 (Jun. 25, 1999). Abstract Only.;;Andrade, S.P. et al., Pharmacological reactivity of neoplastic and non-neoplastic associated neovasculature to vasoconstrictors, Int J Exp Pathol, 79(6):425-32 (Dec. 1998). Abstract Only.;;Armstead. W.M., Contribution of kca channel activation to hypoxic cerebrovasodilatation does not involve NO, Brain Res. 799(1):44-8 (Jul. 13, 1998). Abstract Only.;;Bang, L. et al., Nitroglycerin-mediated vasorelaxation is modulated by endothelial calcium-activated potassium channels, Cardiovasc Res, 43(3):772-8 (Aug. 15, 1999). Abstract Only.;;Becker, E.M. et al., The vasodilator-stimulated phosphoprotein (VASP):target of YC-1 and nitric oxide effects in human and rat platelets, J. Cardiovasc Pharmacol, 35(3):390-7 (Mar. 2000). Abstract Only.;;Black, K.L. et al., Selective opening of the blood-tumor barrier by intracarotid infusion of leukotriene C<SUB>4</SUB>, J. Neurosurg, 72:912-916 (Jun. 1990).;;Bowman, T. et al., STATs in oncogenesis, Oncogene, 19(21):2474-88 (May 15, 2000). Abstract Only.;;Brian, J.E., Jr. et al., Recent insights into the regulation of cerebral circulation, Clin Exp Pharmacol Physiol, 23(6-7):449-57 (Jun.-Jul. 1996). Abstract Only.;;Brismar, T. et al., Mechanism of high K+ and Ti+ uptake in cultured human glioma cells, Cell Mol Neurobiol. 15(3):351-60 (Jun. 1995). Abstract Only.;;Brismar, T. et al., Thallium-201 uptake relates to membrane potential and potassium permeability in human glioma cells, Brain Res, 500(1-2):30-6 (Oct. 23, 1989). Abstract Only.;;Burg, M.A. et al., NG2 proteoglycan-binding peptides target tumor neovasculature, Cancer Res, 59(12):2869-74 (Jun. 15, 1999). Abstract Only.;;Burrows, F.J. et al., Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature, Proc Natl Acad Sci U S A, 90(19):8996-9000 (Oct. 1, 1993). Abstract Only.;;Butt, A.M., Effect of histamine and antagonists on electrical resistance across the blood-brain barrier in rat brain-surface microvessels, Brain Res, 569(1):100-5 (Jan. 8, 1992). Abstract Only.;;Butt, A.M., Effect of inflammatory agents on electrical resistance across the blood-brain barrier in pial microvessels of anaesthetized rats, Brain Res, 696(1-2):145-50 (Oct. 23, 1995). Abstract Only.;;Butt, E. et al., Inhibition of cyclic GMP-dependent protein kinase-mediated effects by (Rp)-8-bromo-PET-cyclic GMPS, Br J. Pharmacol, 116(8):3110-6 (Dec. 1995). Abstract Only.;;Bychkov, R. et al., Calcium-activated potassium channels and nitrate-induced vasodilation in human coronary arteries, J. Pharmacol Exp Ther, 285(1):293-8 (Apr. 1998). Abstract Only.;;Cai, S. et al., Single-channel characterizationof the pharmacological properties of the K(Ca2+) channel of intermediate conductance in bovine aortic endothelial cells, J Membr Biol, 163(2):147-58 (May 15, 1998). Abstract Only.;;Chang, S.S. et al., Five different anti-prostate-specific membrane antigen (PSMA0 antibodies confirm PSMA expression in tumor-associated neovasculature, Cancer Res, 59(13):3192-8 (Jul. 1, 1999). Abstract Only.;;Chaplin, D.J. et al., Anti-vascular approaches to solid tumour therapy: evaluationof combretastatin A4 phosphate, Anticancer Res. 19(1A):189-95 (Jan.-Feb. 1999). Abstract Only.;;Chassande. O. et al., The Na+/K+/Cl- cotransport in C6 glioma cells. Properties and role in volume regulation, Eur J. Biochem, 171(3):425-33 (Feb. 1, 1988). Abstract Only.;;Chess-Williams, R. et al., In vitro investigationof the bladder-vascular selectivity of levcromakalim and YM934 in human tissues, BJU Int, B3(9):1050-4 (Jun. 1999). Abstract Only.;;Chen, C.H. et al., Ntric oxide activates Ca2+-activated K+ channels in cultured bovine adrenal chromaffin cells, Neurosci Lett, 248(2):127-9 (May 29, 1998). Abstract Only.;;Dark. G.G. et al., Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature, Cancer Res, 57 (10):1829-34 (May 15, 1997). Abstract Only.;;Denekamp, J. et al., Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy? Adv Enzyme Regul, 38:281-99 (1998). Abstract Only.;;Desai, S.B. et al., Tumor angiogenesis and endothelial cell modulatory factors, J. Immunother, 22(3):186-211 (May 1999). Abstract Only.;;D'hahan, N. et al., A transmembrane domain of the sulfonylurea receptor mediates activation of ATP-sensitive K(+) channels by K(+) channel openers, Mol Pharmacol. 56(2):308-15 (Aug. 1999). Abstract Only.;;Duda, T. et al., Mutations in the Rod Outer Segment Membrane Guanylate Cyclase in a Cone-Rod Dystrophy Cause Defects in Calcium Signaling, Biochemistry, 38(42):132912-13919 (Oct. 19, 1999), Abstract Only.;;Faraci, F.M. et al., Responses of cerebral arterioles to N-methyl-D-aspartate and activation of ATP-sensitive potassium channels in old rats, Brain Res, 654(2):349-51 (Aug. 22, 1994). Abstract Only.;;Faraci, F.M. et al., Potassium channels and the cerebral circulation, Clin Exp Pharmacol Physiol, 23(12):1091-5 (Dec. 1996). Abstract Only.;;Feelisch, Martin, The use of nitric oxide donors in pharmacological studies, Naunyn-Schmiedeberg's Arch Pharmacol, 358:113-122 (Springer-Veriag 1998).;;Ferrero, R. et al., Comparative effects of several nitric oxide donors on intracellular cyclic GMP levels in bovine chromaffin cells: correlation with nitric oxide production, Br J. Pharmacol. 127(3):779-87 (Jun. 1999). Abstract Only.;;Friebe, A. et al., Mechanism of YC-1-induced activation of soluble guanylyl cyclase, Mol Pharmacol, 53(1):123-7 (Jan. 1998). Abstract Only.;;Fukao, M. et al., Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylationat serine 1072, J Biol Chem, 274(16): 10927-35 (Apr. 16, 1999). Abstract Only.;;Fukamura, D. et al., Role of nitric oxide in angiogenesis and microcirculation in tumors, Cancer and Metastasis Reviews, 17:77-89 (1998).;;Fullerton, D.A. et al., Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation, J. Thorac Cardiovasc Surg, 111(4):753-62; discussion 762-3 (Apr. 1996). Abstract Only.;;Gbadegesin, M. et al., Hypoxia modulates nitric oxide-induced regulation of NMDA receptor currents and neuronal cell death, Am J Physiol, 277 (4 Pt 1):C673-83 (Oct. 1999). Abstract only.;;Goldstein, G.W. et al., In vitro studies of the blood-brain barrier using isolated brain capillaries and cultured endothelial cells, Ann N Y Acad Sci, 481:202-13 (1986). Abstract Only.;;Goto, K. et al., Sympathetic control of arterial membrane potential by ATP-sensitive K(+)-channels, Hypertension, 35 (1 Pt 2):379-84 (Jan. 2000) Abstract Only.;;Gulbins, E. et al., Ceramide-induced inhibition of T lymphocyte voltage-gated potassium channel is mediated by tyrosine kinases, Proc natl Acad Sci M S A, 94(14):7661-6 (Jul. 8, 1997). Abstract Only.;;Hardy, P. et al., A mojor role for prostacyclin in nitric oxide-iinduced ocular vasorelaxation in the piglet, Circ Res, 83(7):721-9 (Oct. 5, 1998). Abstract Only.;;Harland, S.P. et al., Expressionof endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PC156707, Neurosurgery, 43(4):890-8; discussion 898-9, (Oct. 1998) Abstract Only.;;He, P. et al., cGMP modulates basal and activated microvessel permeability independently of (Ca2+)i, Am J Physiol, 274(6 Pt 2):H1865-74 (Jun. 1998). Abstract Only.;;Herrera, G.M. et al., Maintained vasodilatory response to cromakalim after inhibition of nitric oxide synthesis, J Cardiovasc Pharmacol, 31(6):921-9 (Jun. 1998). Abstract Only.;;Holland, M. et al., Effects of the BKCa channel activator, NS1619, on rat cerebral artery smooth muscle, Br J Pharmacol, 117(1):119-29 (Jan. 1996). Abstract Only.;;Holschermann, H. et al., Dual Role of cGMP in modulation of macromolecule permeability of aortic endothelial cells, Am J Physiol, 272(1 Pl 2):H91-8 (Jan. 1997), Abstract Only.;;Islam, T.C. et al., BTK mediated apoptosis, a possible mechanism for failure to generate high titer retroviral producer clones, J Gene Med, 2(3):204-9 (May-Jun. 2000). Abstract Only.;;Jackson, W.F. et al., Prostacyclin-induced vasodilation in rabbit heart is mediated by ATP-sensitive potassium channels, Am J Physiol, 264(1 Pt 2):H238-43 (Jan. 1993). Abstract Only.;;Jain, R.K., Vascular and interstitial barriers to delivery of therapeutic agents in tumors, Cancer Metastasis Rev, 9(3):253-66 (Nov. 1990). Abstract Only.;;Keep, R.F. et al., Potassium transport at the blood-brain and blood-CSF barriers, Adv Exp Med Biol, 331:43-54 (1993). Abstract Only.;;Kiegler-Jensen, N. et al., Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance, J Heart Lung Transplant, 13(3):366-75 (May-Jun. 1994). Abstract Only.;;Kim, J. A. et al., Ca2+ influx mediates apoptosis induced by 4-aminopyridine, a K+ channel blocker, in HepG2 human hepatoblastoma cells, Pharmacology, 60(2):74-81 (Feb. 2000). Abstract Only.;;Kimura, M. et al., Responses of human basilar and other isolated arteries to novel nitric oxide donors, J Cardiovasc Pharmacol, 32(5):695-701 (Nov. 1998). Abstract Only.;;Kinoshita, H. et al., Differential effects of lidocaine and mexiletine on relaxations to ATP-sensitive K+ channels openers in rat aortas. Anesthesiology, 90(4): 1165-70 (Apr. 1999). Abstract Only.;;Kitazono, T. et al., Role of potassium channels in cerebral blood vessels, Stroke, 26(9):1713-23 (Sep. 1995). Abstract Only.;;Koesling, D., Modulators of soluble guanylyl cyclase, Naunyn-Schmiedeberg's Arch Pharmacol, 358:123-126 (Springer-Veriag1998).;;Kurtz, A. et al., Mode of nitric oxide action on the renal vasculature, Acta Physiol Scand, 168(1):41-45 (Jan. 2000). Abstract Only.;;Lauritzen, I. et al., The potassium channel opener (-)-cromakalim prevents glutamate-induced cell death in hippocampal neurons, J Neurochem, 69(4):1570-9 (Oct. 1997). Abstract Only.;;Lee, Y.S. et al., In vitro antitumor activity of cromakalim in human brain tumor cells, Pharmacology, 49(2):69-74 (Aug. 1994). Abstract Only.;;Liu, Q. et al., Hypoxic dilatation of porcine small coronary arteries: role of endothelium and KATP-channels, Br J Pharmacol, 120(4):728-34 (Feb. 1997). Abstract Only.;;Liu, S.M. et al., Nitric acid and cGMP regulate endothelial permeability and F-actin distributinin hydrogen peroxide-treated endothelial cells. Exp Cell Res, 235(1):238-44 (Aug. 25, 1997). Abstract Only.;;Lohse, M., Pharamcology of NO:cGMP signal transduction, Naunyn-Schmiedeberg's Arch Pharmacol, 538:111-112(Springer-Veriag 1998). Abstract Only.;;Malayev, A.A. et al., Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel, Mol Pharmacol, 47(1):198-205 (Jan. 1995). Abstract Only.;;Manor, D. et al., Interactions among calcium compartments in C6 rat glioma cells:involvement of potassium channels, J Physiol (Lond), 478 (Pt 2):251-63 (Jul. 15, 1994). Abstract Only.;;Matsukado, K. et al., Selective increase in blood-tumor barrier permeability by calcium antagonists in transplanted rat brain tumors, Acta Neurochir Suppl (Wien), 60:403-5 (1994). Abstract Only.;;Mayer, Bernd et al.., Nitric oxide synthases: catalytic function and progress towards selective inhibition, Naunyn-Schmiedeberg's Arch Pharmacol, 358:127-133 (Springer-Veriag 1998).;;Miller, T.R. et al., Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 human medulloblastoma cell line, Eur J Pharmacol, 370(2):179-85 (Apr. 9, 1999). Abstract Only.;;Miyaji, Katsuya et al., Effect of tyrphostin on cell growth and tyrosine kinase activity of epidermal growth factor receptor in human gliomas, J Neurosurg, 81:411-419 (1994).;;Molema, G. et al., Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy, Pharm Res, 14(1):2-10 (Jan. 1997). Abstract Only.;;Nadeau, H. et al., ROMK1 (Kir1.1) causes apoptosis and chronic silencing of hippocampal neurons, J Neurophysiol, 84(2):1062-75 (Aug. 2000). Abstract Only.;;Nietsch, Hubert H. et al., Activation of Potassium and Chloride Channels by Tumor Necrosis Factor a, Journal of Biological Chemistry, 275(27):20556-20561 (Jul. 7, 2000).;;Ningaraj, N: S. et al., Nitric Oxide Donors Increase Blood Brain Tumor Barrier Permeability Via K<SUB>CA </SUB>Channels, Blood Brain Barrier: Models and Mechanisms, Sunday PM, #126.8, Society for Neuroscience, 30<SUP>th </SUP>Annual Meeting, New Orleans, LA, 26 Part 1 (Nov. 4-9, 2000). Abstract Only.;;Ningaraj, Nagendra S. et al., Tumor, Role of ATP-sensitive K+ Channels in Blood-Brain Tumor Barrier Permeability, Congress of Neurological Surgeons Annual Meeting, 50<SUP>th </SUP>Anniversary Celebration, Poster Program Book, Abstract # 430, (Sep. 23-28, 2000).;;Ningaraj, Nagendra S. et al., Tumor, Ca2+-dependent K+ Channels Are a Key Regulator of Blood-Brain Tumor Barrier Permeability, Congress of Neurological Surgeons Annual Meeting, 50<SUP>th </SUP>Anniversary Celebration, Poster Program Book, Abstract # 438, (Sep. 23-28, 2000).;;Nogami, K. et al., Role of Factor VIII C2 Domain in Factor VIII Binding to Factor Xa, J Biol. Chem, 274(43):31000-31007 (Oct. 22, 1999). Abstract Only.;;O'Donnell, M.E. et al., Cerebral microvascular endothelial cell Na-K-Cl cotransport: regulation by astrocyte-conditioned medium, Am J Physiol, 268(3 Pt 1):C747-54 (Mar. 1995). Abstract Only.;;Ohizumi, I. et al., Antibody-based therapy targeting tumor vascular endothelial cells suppresses solid tumor growth in rats, Biochem Biophys Res Commun, 236(2):493-6 (Jul. 18, 1997). Abstract Only.;;Ohta, Y. et al., Tumor angiogenesis and recurrence in stage l non-small cell lung cancer, Ann Thorac Surg, 68(3):1034-8 (Sep. 1999). Abstract Only.;;Panchal, R.G., Novel therapeutic strategies to selectively kill cancer cells, Biochem Pharmacol, 55(3):247-52 (Feb. 1, 1998). Abstract Only.;;Smoak, I.W., Cromakalim: embryonic effects and reduction of tolbutamide-induced dysmorphogenesis in vitro, Teratology, 60(5):260-264 (Nov. 1999). Abstract Only.;;Smolenski, A. et al., Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects, Naunyn-Schmiedenberg's Arch Pharmacol, 358:134-138 (Springer-Veriag 1988).;;Solina, A. et al., A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients, J Cardiothorac Vasc Anesth 14(1):12-7 (Feb. 2000). Abstract Only.;;Sugai, K. et al., Levcromakalim decreases cytoplasmic Ca2+ and vascular tone in basilar artery of SAH model dogs, J Cardiovasc Pharmacol, 33(6):868-75 (Jun. 1999). Abstract Only.;;Teramoto, N. et al., Comparative studies on the relaxing action of several adenosine 5'-triphosphate-sensitive K+ channel openers in pig urethra, J Smooth Muscle Res, 35(1):11-22 (Feb. 1999). Abstract Only.;;Thorpe, P.E. et al., Antibody-directed targeting of the vasculature of solid tumors, Breast Cancer Res Treat, 36(2):237-51 (1995). Abstract Only.;;Toyoda, K. et al., Role of ATP-sensitive potassium channels in brain stem circulation during hypotension, Am J Physiol, 273(3 Pt 2):H1342-6 (Sep. 1997). Abstract Only.;;Uchida, Mikito et al., Cyclic GMP-dependent Blood-Brain Tumor Barrier Permeability is Not Mediated by Cyclic GMP-Dependent Protein Kinase, Congress of Neurological Surgeons Annual Meeting, 50<SUP>th </SUP>Anniversary Celebration, Poster Program Book, #440 (Sep. 23-28, 2000).;;Vaali, K et al., Relaxing effects of NO donors on guinea pig trachea in vitro are mediated by calcium-sensitive potassium channels, J Pharmacol Exp Ther, 286(1):110-4 (Jul. 1998). Abstract Only.;;van Hinsbergh, V. W. et al., Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors, Ann Oncol, 10 Suppl 4:60-3 (1999) Abstract Only.;;Vodovotz, Y et al., Regulation of transforming growth factor beta1 by nitric oxide, Cancer Res, 59(9):2142-9 (May 1, 1999) Abstract Only.;;Walter, J. J. et al, Angiostatin binds to smooth muscle cells in the coronary artery and inhibits smooth muscle cell proliferation and migration in vitro, Arterioscler Thromb Vasc Biol, 19(9):2041-8 (Sep. 1999). Abstract Only.;;Wickenden, A. D. et al., Comparison of the effects of the K(+)-channel openers cromakalim and minoxidil sulphate on vascular smooth muscle, Br J Pharmacol, 103(1):1148-52 (May 1991). Abstract Only.;;Wulff, Heike et al., Design of a potent and selective inhibitor of the intermediate-conductance Ca<SUP>2+</SUP>-activated K<SUP>+ </SUP>channel, IKCa1: A potential immunosuppressant, PNAS, 97(14):8151-8156 (Jul. 5, 2000).;;Yakubu, M. A. et al., Hematoma-induced enhanced cerebral vasoconstrictions to leukotriene C4 and endothelin-1 in piglets: role of prostanoids, Pediatr Res, 38(1):119-23 (Jul. 1995). Abstract Only.;;Web site: Sigma-Aldrich, Search Results, p. 1; http://vsearch.sial.com/search97cgi/s97<SUB>-</SUB>cgi, downloaded May 31, 2000.;;Web site: NO Donors/Precursors, TOCRIS, pp. 1-2; http://www.tocris.com/cat/nodonorstxt.html, downloaded May 31, 2000.;;Patel, A.I. et al., Activation of guanosine 3',5'-cyclic monophosphate (cGMP)-dependent protein kinase in rabbit aorta by nitroglycerin and sodium nitroprusside, J Pharmacol Exp Ther, 283(2):885-93 (Nov. 1997).;;Patel, A.I. et al., Activation of guanosine 3',5'-cyclic monophosphate (cGMP)-dependent protein kinase in rat vas deferens and distal colon is not accompanied by inhibition of contraction, J Pharmacol Exp Ther, 283(2):894-900 (Nov. 1997). Abstract Only.;;Patel, H.J. et al., Inhibition of cholinergic neurotransmission in guinea pig trachea by NS1619, a putative activator of large-conductance, calcium-activated potassium channels, J Pharmacol Exp Ther, 286(2):952-8 (Aug. 1998). Abstract Only.",EXPIRED
95,US,A1,US 2008/0050337 A1,064-488-945-364-502,2008-02-28,2008,US 85665407 A,2007-09-17,US 85665407 A;;US 99886604 A;;US 61585400 A;;US 49150000 A,2000-01-26,METHOD FOR USING CALCIUM-SENSITIVE POTASSIUM CHANNEL AGONIST FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN REGION AND/OR A MALIGNANT TUMOR,"Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel activator (other than bradykinin or a bradykinin analog), such as NS-1619, EBIO, a guanylyl cyclase activating protein, an activator of soluble guanylyl cyclase (e.g., nitric oxide or a nitric oxide donor) or an activator of cyclic GMP-dependent protein kinase, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,CEDARS-SINAI MEDICAL CENTER (2000-06-23),https://lens.org/064-488-945-364-502,Patent Application,yes,3,2,1,13,1,A61K9/0085;;A61K31/4184;;A61K31/506;;A61K31/555;;A61K33/00;;A61K38/1841;;A61K38/191;;A61K38/20;;A61K38/21;;A61K45/06;;A61K31/4162;;A61K31/498;;A61P43/00;;A61K31/4162;;A61K31/506;;A61K31/555;;A61K45/06;;A61K9/0085;;A61K33/00;;A61K38/1841;;A61K38/20;;A61K38/191;;A61K38/21;;A61K31/4184;;A61K31/498,A61K38/20;;A61K31/4164;;A61K31/555;;A61K39/00;;A61P43/00,424/85.2;;424/184.1;;514/185;;514/394,0,0,,,,DISCONTINUED
96,EP,A2,EP 1251840 A2,157-914-432-178-385,2002-10-30,2002,EP 01905141 A,2001-01-26,US 0102742 W;;US 49150000 A;;US 61585400 A,2000-01-26,METHOD FOR USING POTASSIUM CHANNEL ACTIVATION FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN REGION AND/OR A MALIGNANT TUMOR,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/157-914-432-178-385,Patent Application,yes,0,0,9,13,0,A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/4245;;A61K31/44;;A61K31/475;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,A61K45/00;;A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/401;;A61K31/4025;;A61K31/4245;;A61K31/43;;A61K31/44;;A61K31/4409;;A61K31/475;;A61K31/495;;A61K31/506;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K33/04;;A61K33/26;;A61K38/00;;A61K45/06;;A61K45/08;;A61K49/00;;A61K49/04;;A61K51/12;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;C12N15/88,,1,0,,,See references of WO 0154680A3,DISCONTINUED
97,JP,A,JP 2010132684 A,065-620-403-858-163,2010-06-17,2010,JP 2010022614 A,2010-02-03,US 51304003 P,2003-10-21,"SYSTEM AND METHOD FOR TREATMENT OF CANCER, INCLUDING CANCER OF CENTRAL NERVOUS SYSTEM","<P>PROBLEM TO BE SOLVED: To provide a new approach to cancer therapy. <P>SOLUTION: The treatment is for cancer, particularly the treatment for cancers of the central nervous system, such as glioblastoma multiforme. A dual therapeutic approach is provided, which includes the administration of a dendritic cell-based cancer vaccine and a regimen of chemotherapy. These two therapies can be simultaneously administered with each other and/or simultaneously with the initial vaccination before the chemotherapy. In various embodiments, the dendritic cell-based cancer vaccine includes either primed or unprimed dendritic cells; for instance, the dendritic cells may be autologous tumor antigen-presented dendritic cells. The dual therapeutic approach of the instant invention beneficially influences the chemosensitivity of a mammal with cancer. <P>COPYRIGHT: (C)2010,JPO&INPIT",CEDARS SINAI MEDICAL CENTER,WHEELER CHRISTOPHER;;DAS ASHA;;BLACK KEITH,,https://lens.org/065-620-403-858-163,Patent Application,no,3,0,9,9,0,A61K31/203;;A61K31/282;;A61K31/454;;A61K31/4745;;A61K31/704;;A61K31/7048;;A61K45/06;;A61P35/00;;A61P43/00;;A61K33/243;;A61K2239/38;;A61K39/4622;;A61K39/464499;;A61K39/4615;;A61K2239/47;;A61K39/46432;;A61K45/06;;A61K31/454;;A61K31/7048;;A61K39/00;;A61K31/203;;A61K31/282;;A61K39/0011;;A61K2039/5154;;A61K31/704;;A61K31/4745;;A61K33/243,A61K35/12;;A61K33/243;;A61K39/00;;A61K45/00;;A61K45/06;;A61P35/00;;A61P43/00;;C12N5/02;;C12N5/08,,0,0,,,,DISCONTINUED
98,EP,A2,EP 1251838 A2,065-749-321-164-659,2002-10-30,2002,EP 01906729 A,2001-01-26,US 0102743 W;;US 49150500 A;;US 61585400 A,2000-01-26,METHOD FOR USING POTASSIUM CHANNEL AGONISTS FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN REGION AND/OR A MALIGNANT TUMOR,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/065-749-321-164-659,Patent Application,yes,0,0,1,13,0,,A61K31/00,,2,1,063-211-144-314-507,10.1002/med.10060;;14705169,"R.MANNHOLD: ""K-ATP Channel Openeers: Structure -Activity Relationships and Therapeutic Potential"", MEDICINAL RESEARCH REVIEWS, vol. 24, no. 2, 2004, pages 213 - 266;;See also references of WO 0154771A3",DISCONTINUED
99,WO,A2,WO 2005/025511 A2,081-608-006-844-006,2005-03-24,2005,US 2004/0029787 W,2004-09-10,US 50215903 P;;US 52844003 P;;US 54863604 P,2003-09-10,POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER,"This invention includes pharmaceutical compositions, methods and. kits for the treatment or diagnosis of a malignant tumors, including brain tumors, and diseases or disorders characterized by abnormal brain tissue.",CEDARS SINAI MEDICAL CENTER;;BLACK KEITH L;;NINGARAJ NAGENDRA S,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/081-608-006-844-006,Patent Application,yes,0,6,6,6,0,A61K31/4184;;A61K31/506;;A61K45/06;;A61P25/00;;A61P31/00;;A61P35/00;;A61P43/00;;A61P9/00;;A61K45/06;;A61K31/506;;A61K31/4184,A61K/;;A61K31/445;;A61K31/505;;A61K31/513;;A61K49/00,,0,0,,,,PENDING
100,WO,A2,WO 2004/078920 A2,108-163-586-351-601,2004-09-16,2004,US 0306176 W,2003-02-27,US 0306176 W;;US 97696101 A,2001-10-12,METHOD FOR INDUCING SELECTIVE CELL DEATH OF MALIGNANT CELLS BY ACTIVATION OF CALCIUM-ACTIVATED POTASSIUM CHANNELS (KCA),"Disclosed are a method of inducing apoptosis of a malignant cell, which employs a calcium-activated postassium channel (KCa) activator and is useful for treating a malignant tumor in a human subject. Also disclosed are methods of selectively inhibiting the proliferation of malignant cells compared to non-malignant cells in a mixed population of malignant and non-malignant cells and of inhibiting the growth of a malignant tumor, such as a glial tumor, in a mammalian subject. A kit for inducing apoptosis of malignant cells is also disclosed.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/108-163-586-351-601,Patent Application,yes,0,1,4,7,0,A61K31/13;;A61K31/7076;;A61K38/043;;A61K31/13;;A61K38/043;;A61K31/7076,A61K31/13;;A61K31/7076;;A61K38/04,,0,0,,,,PENDING
101,US,A1,US 2006/0280730 A1,194-962-709-251-345,2006-12-14,2006,US 46604906 A,2006-08-21,US 46604906 A;;US 97696101 A,2001-10-12,INDUCTION OF APOPTOSIS OF MALIGNANT CELLS BY ACTIVATION OF CALCIUM-ACTIVATED POTASSIUM CHANNELS,"Disclosed are a method of inducing apoptosis of a malignant cell, which employs a calcium-activated potassium channel (K Ca ) activator and is useful for treating a malignant tumor in a human subject. Also disclosed are methods of selectively inhibiting the proliferation of malignant cells compared to non-malignant cells in a mixed population of malignant and non-malignant cells and of inhibiting the growth of a malignant tumor, such as a glial tumor, in a mammalian subject. A kit for inducing apoptosis of malignant cells is also disclosed.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/194-962-709-251-345,Patent Application,yes,2,1,1,7,0,A61K31/13;;A61K38/043;;A61K38/043;;A61K31/13,A61K31/13;;A61K38/46;;A61K38/22,424/94.6;;514/12;;514/663,0,0,,,,DISCONTINUED
102,US,A1,US 2003/0072748 A1,017-398-686-692-267,2003-04-17,2003,US 97696101 A,2001-10-12,US 97696101 A;;US 0306176 W,2001-10-12,Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (Kca),"
    Disclosed are a method of inducing apoptosis of a malignant cell, which employs a calcium-activated potassium channel (K _{Ca} ) activator and is useful for treating a malignant tumor in a human subject. Also disclosed are methods of selectively inhibiting the proliferation of malignant cells compared to non-malignant cells in a mixed population of malignant and non-malignant cells and of inhibiting the growth of a malignant tumor, such as a glial tumor, in a mammalian subject. A kit for inducing apoptosis of malignant cells is also disclosed. 
",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,CEDARS-SINAI MEDICAL CENTER (2002-02-04),https://lens.org/017-398-686-692-267,Patent Application,yes,23,17,4,7,0,A61K31/13;;A61K31/7076;;A61K38/043;;A61K31/13;;A61K38/043;;A61K31/7076,A61K31/13;;A61K31/7076;;A61K38/04,424/94.61;;514/12;;514/663;;514/45,0,0,,,,EXPIRED
103,WO,A1,WO 2017/173315 A1,153-445-587-040-896,2017-10-05,2017,US 2017/0025451 W,2017-03-31,US 201662317443 P;;US 201662317459 P;;US 201662317456 P;;US 201662351615 P;;US 201662317452 P;;US 201662317449 P;;US 201662317460 P;;US 201662317453 P;;US 201662317455 P;;US 201662317451 P,2016-04-01,"SYSTEMS, DEVICES, AND METHODS FOR TIME-RESOLVED FLUORESCENT SPECTROSCOPY","Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.",BLACK LIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;BLACK KEITH;;KAVANAUGH JACK,,https://lens.org/153-445-587-040-896,Patent Application,no,4,8,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,G01N21/64;;A61B6/00;;G01N21/25;;G01N21/62;;G01N21/63,,0,0,,,,PENDING
104,US,A1,US 2011/0257458 A1,162-204-451-878-023,2011-10-20,2011,US 200913141193 A,2009-12-23,US 200913141193 A;;US 14078708 P;;US 14549209 P;;US 2009/0069437 W,2008-12-24,METHOD OF USING TUMOR CELL DEBRIS TO REDUCE BRAIN TUMOR RECURRENCE OR GROWTH,"The present invention describes compositions comprising tumor cell debris, tumor lysate or tumor antigens and methods of using tumor cell debris, tumor lysate or tumor antigens for stimulating a specific immune response. The compositions may further comprise at least one TLR ligand. The stimulation of the specific immune response may be used to treat tumors, particularly, brain tumors. The treatment method may also reduce the recurrence of a tumor and/or inhibit or slow down the growth of a tumor.",CEDARS SINAI MEDICAL CENTER,MORRIS-IRVIN DWAIN;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2009-12-20),https://lens.org/162-204-451-878-023,Patent Application,yes,3,3,2,2,0,A61K35/30;;A61K39/0011;;A61K2039/55511;;A61K2039/55561;;A61K2039/55572;;A61P35/00;;A61P37/04;;A61K35/30;;A61K2039/55511;;A61K2039/55561;;A61K2039/55572;;A61K39/0011,A61M37/00;;A61B18/18;;A61K35/30;;A61K39/00;;A61K39/39;;A61M5/32;;A61P35/00;;A61P37/04,600/1;;424/277.1;;424/257.1;;424/258.1;;424/278.1;;604/239;;606/33,0,0,,,,DISCONTINUED
105,US,A1,US 2006/0047682 A1,177-262-271-532-519,2006-03-02,2006,US 92767604 A,2004-08-27,US 92767604 A,2004-08-27,Automated identification and marking of new and changed content in a structured document,"A method for indicating changes in a structured document includes identifying a new topic or a modified topic in an updated version of a structured document having one or more topics, generating a table of contents having one or more topic entries associated with the one or more topics, marking a topic entry associated with the new topic or the modified topic with a marker indicating that the associated topic is new or modified. A system includes an unmarked table of contents having an entry associated with a unit of updated topic content, and a marking module marking the entry if the unit of updated topic content has changed or the unit of updated topic content comprises a new topic.",MICROSOFT CORP,BLACK JASON E;;BURNARD KEITH A,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2004-08-26),https://lens.org/177-262-271-532-519,Patent Application,yes,1,55,2,2,0,G06F40/197;;G06F40/143;;G06F40/197;;G06F40/143,G06F7/00;;G06F17/00;;G06F40/143,707/102,0,0,,,,INACTIVE
106,US,A1,US 2005/0153940 A1,033-414-962-195-556,2005-07-14,2005,US 99886604 A,2004-11-29,US 99886604 A;;US 61585400 A;;US 9491500 A,2000-01-26,Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor,"Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel activator (other than bradykinin or a bradykinin analog), such as an activator of soluble guanylyl cyclase (e.g., nitric oxide or a nitric oxide donor) or an activator of cyclic GMP-dependent protein kinase, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel activator together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;NINGARAJ NAGENDRA S,,https://lens.org/033-414-962-195-556,Patent Application,yes,24,1,1,13,1,A61K31/513;;A61K31/513;;A61K31/00;;A61K31/00;;A61K31/04;;A61K31/04;;A61K31/198;;A61K31/198;;A61K31/21;;A61K31/21;;A61K31/282;;A61K31/282;;A61K31/295;;A61K31/295;;A61K31/4245;;A61K31/4245;;A61K31/44;;A61K31/44;;A61K31/475;;A61K31/475;;A61K31/519;;A61K31/519;;A61K31/655;;A61K31/655;;A61K31/675;;A61K31/675;;A61K31/69;;A61K31/69;;A61K33/00;;A61K33/00;;A61K45/06;;A61K45/06,A61K31/00;;A61K31/04;;A61K31/198;;A61K31/21;;A61K31/282;;A61K31/295;;A61K31/4245;;A61K31/44;;A61K31/475;;A61K31/513;;A61K31/519;;A61K31/655;;A61K31/675;;A61K31/69;;A61K33/00;;A61K45/06;;A61K49/00;;A61K49/04;;A61K51/12,514/149;;514/235.5;;514/509,0,0,,,,DISCONTINUED
107,GB,A,GB 2560145 A,004-239-971-782-974,2018-09-05,2018,GB 201620564 A,2016-12-03,GB 201620564 A,2016-12-03,"Solid food composition with time released energy, being suitable for diabetics or persons wishing to aid weight loss, build muscle and improve health","A solid food product comprising oats with a plurality of assorted particles selected from chia seeds, flaxseed, pumpkin seed, almond seed, hemp seed, cinnamon, nutmeg husk and/or mace, with added fortified vitamins and minerals. The food is very low in fat and capable of supressing appetite. The slow releasing carbohydrates also provide an extended energy provision to the consumer. The ingredients in this oat based mix also ensure a high level of protein to aid weight loss and to encourage the building of muscle structure, additionally this combination is very high in fibre which is very advantageous for the digestive system, enhancing the products attributes as a food.",KEITH ANDREW HENRY;;PATRICE ALVIN BLACK,KEITH ANDREW HENRY;;PATRICE ALVIN BLACK,,https://lens.org/004-239-971-782-974,Patent Application,no,4,0,2,2,0,A23L7/00;;A23L7/148;;A23L25/20;;A23L33/105;;A23L33/15;;A23L33/16;;A23L33/22,A23L7/00,,0,0,,,,DISCONTINUED
108,WO,A1,WO 2010/075525 A1,052-811-372-819-072,2010-07-01,2010,US 2009/0069437 W,2009-12-23,US 14078708 P;;US 14549209 P,2008-12-24,METHOD OF USING TUMOR CELL DEBRIS TO REDUCE BRAIN TUMOR RECURRENCE OR GROWTH,"The present invention describes compositions comprising tumor cell debris, tumor lysate or tumor antigens and methods of using tumor cell debris, tumor lysate or tumor antigens for stimulating a specific immune response. The compositions may further comprise at least one TLR ligand. The stimulation of the specific immune response may be used to treat tumors, particularly, brain tumors. The treatment method may also reduce the recurrence of a tumor and/or inhibit or slow down the growth of a tumor.",CEDARS SINAI MEDICAL CENTER;;MORRIS-IRVIN DWAIN;;BLACK KEITH L,MORRIS-IRVIN DWAIN;;BLACK KEITH L,,https://lens.org/052-811-372-819-072,Patent Application,yes,5,2,2,2,0,A61K35/30;;A61K39/0011;;A61K2039/55511;;A61K2039/55561;;A61K2039/55572;;A61P35/00;;A61P37/04;;A61K35/30;;A61K2039/55511;;A61K2039/55561;;A61K2039/55572;;A61K39/0011,A61K39/00;;A61K35/30;;A61K39/395,,0,0,,,,PENDING
109,US,B2,US 6900146 B2,179-020-164-621-752,2005-05-31,2005,US 38541103 A,2003-03-10,US 38541103 A;;US 873601 A;;US 25168300 P,2000-12-06,Method of forming an imaged compound textile fabric,"The present invention contemplates a method of forming a textile laminate or composite fabric from a plurality of woven fabric layers, with the method contemplating use of a three-dimensional image transfer device to facilitate efficient and commercially viable use of the method. Herein is disclosed a method of forming an imaged textile laminate or composite compound fabric, the fabric having a first textile fabric layer comprising a plurality of interwoven warp and weft yarns and at least one other textile fabric layer, the lamination of the fabric layers and imaging of the construct occurring on a three-dimensional image transfer device. The image transfer device has a foraminous, image-forming surface comprising a regular pattern of three-dimensional surface elements.",POLYMER GROUP INC,BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,AVINTIV SPECIALTY MATERIALS INC (2015-06-04),https://lens.org/179-020-164-621-752,Granted Patent,yes,12,2,11,11,0,B32B5/26;;D06C23/00;;D06P5/003;;D06P7/00;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;D03D1/00;;D10B2331/04;;D10B2201/02;;D03D13/004;;D03D15/283;;D03D15/217;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;B32B2437/00;;B32B2262/0276;;B32B2262/0261;;B32B2262/0253;;B32B2262/0246;;B32B5/26;;D06C23/00;;D06P7/00;;D06P5/003;;D03D25/00;;D03D15/217;;D03D15/283,B32B5/26;;D04H1/46;;D04H13/00;;D06C23/00;;D06P5/24;;D06P7/00,442/240;;442/246;;442/247;;442/276;;442/304;;442/318,0,0,,,,EXPIRED
110,CA,A1,CA 2436604 A1,043-111-785-884-848,2002-06-13,2002,CA 2436604 A,2001-12-06,US 25168300 P;;US 0146446 W,2000-12-06,METHOD OF FORMING AN IMAGED COMPOUND TEXTILE FABRIC,"The present invention contemplates a method of forming a textile laminate or composite fabric from a plurality of woven fabric layers, with the method contemplating use of a three-dimensional image transfer device to facilitate efficient and commercially viable use of the method. Herein is disclosed a method of forming an imaged textile laminate or composite compound fabric, t he fabric having a first textile fabric layer (11) comprising a plurality of interwoven warp and weft yarns and at least one other textile fabric layer (10), the lamination of the fabric layers and imaging of the construct occurring on a three-dimensional image transfer device (18). The image transfer device (18) has a foraminous, image-forming surface comprising a regular pattern of three-dimensional surface elements.",POLYMER GROUP INC,CURTIS CHARLES KEITH;;MORAN SHANE JAMES;;BLACK SAMUEL KEITH,,https://lens.org/043-111-785-884-848,Patent Application,no,0,0,11,11,0,B32B5/26;;D06C23/00;;D06P5/003;;D06P7/00;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;D03D1/00;;D10B2331/04;;D10B2201/02;;D03D13/004;;D03D15/283;;D03D15/217;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;B32B2437/00;;B32B2262/0276;;B32B2262/0261;;B32B2262/0253;;B32B2262/0246;;B32B5/26;;D06C23/00;;D06P7/00;;D06P5/003;;D03D25/00;;D03D15/217;;D03D15/283,B32B5/26;;D04H1/46;;D04H13/00;;D06C23/00;;D06P5/24;;D06P7/00,,0,0,,,,DISCONTINUED
111,EP,A2,EP 1348054 A2,186-507-572-874-896,2003-10-01,2003,EP 01995352 A,2001-12-06,US 0146446 W;;US 25168300 P,2000-12-06,METHOD OF FORMING AN IMAGED COMPOUND TEXTILE FABRIC,,POLYMER GROUP INC,BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,,https://lens.org/186-507-572-874-896,Patent Application,yes,0,0,11,11,0,B32B5/26;;D06C23/00;;D06P5/003;;D06P7/00;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;D03D1/00;;D10B2331/04;;D10B2201/02;;D03D13/004;;D03D15/283;;D03D15/217;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;B32B2437/00;;B32B2262/0276;;B32B2262/0261;;B32B2262/0253;;B32B2262/0246;;B32B5/26;;D06C23/00;;D06P7/00;;D06P5/003;;D03D25/00;;D03D15/217;;D03D15/283,B32B5/26;;D04H1/46;;D04H13/00;;D06C23/00;;D06P5/24;;D06P7/00,,0,0,,,,DISCONTINUED
112,WO,A3,WO 2002/046509 A3,120-418-063-104-077,2003-03-13,2003,US 0146446 W,2001-12-06,US 25168300 P,2000-12-06,METHOD OF FORMING AN IMAGED COMPOUND TEXTILE FABRIC,"The present invention contemplates a method of forming a textile laminate or composite fabric from a plurality of woven fabric layers, with the method contemplating use of a three-dimensional image transfer device to facilitate efficient and commercially viable use of the method. Herein is disclosed a method of forming an imaged textile laminate or composite compound fabric, the fabric having a first textile fabric layer (11) comprising a plurality of interwoven warp and weft yarns and at least one other textile fabric layer (10), the lamination of the fabric layers and imaging of the construct occurring on a three-dimensional image transfer device (18). The image transfer device (18) has a foraminous, image-forming surface comprising a regular pattern of three-dimensional surface elements.",POLYMER GROUP INC,BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,,https://lens.org/120-418-063-104-077,Search Report,yes,6,0,11,11,0,B32B5/26;;D06C23/00;;D06P5/003;;D06P7/00;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;D03D1/00;;D10B2331/04;;D10B2201/02;;D03D13/004;;D03D15/283;;D03D15/217;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;B32B2437/00;;B32B2262/0276;;B32B2262/0261;;B32B2262/0253;;B32B2262/0246;;B32B5/26;;D06C23/00;;D06P7/00;;D06P5/003;;D03D25/00;;D03D15/217;;D03D15/283,B32B5/26;;D04H1/46;;D04H13/00;;D06C23/00;;D06P5/24;;D06P7/00,,0,0,,,,PENDING
113,US,A1,US 2003/0009862 A1,165-838-757-861-025,2003-01-16,2003,US 873602 A,2002-05-20,US 873602 A;;US 25168300 P,2000-12-06,Method of forming an imaged compound textile fabric,"
   The present invention contemplates a method of forming a textile laminate or composite fabric from a plurality of woven fabric layers, with the method contemplating use of a three-dimensional image transfer device to facilitate efficient and commercially viable use of the method. 

   Herein is disclosed a method of forming an imaged textile laminate or composite compound fabric, the fabric having a first textile fabric layer comprising a plurality of interwoven warp and weft yarns and at least one other textile fabric layer, the lamination of the fabric layers and imaging of the construct occurring on a three-dimensional image transfer device. The image transfer device has a foraminous, image-forming surface comprising a regular pattern of three-dimensional surface elements. 
",BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,POLYMER GROUP INC (2002-01-29),https://lens.org/165-838-757-861-025,Patent Application,yes,0,11,11,11,0,B32B5/26;;D06C23/00;;D06P5/003;;D06P7/00;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;D03D1/00;;D10B2331/04;;D10B2201/02;;D03D13/004;;D03D15/283;;D03D15/217;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;B32B2437/00;;B32B2262/0276;;B32B2262/0261;;B32B2262/0253;;B32B2262/0246;;B32B5/26;;D06C23/00;;D06P7/00;;D06P5/003;;D03D25/00;;D03D15/217;;D03D15/283,B32B5/26;;D04H1/46;;D04H13/00;;D06C23/00;;D06P5/24;;D06P7/00,28/104;;28/163,0,0,,,,PENDING
114,EP,A4,EP 1348054 A4,015-863-549-700-193,2004-07-21,2004,EP 01995352 A,2001-12-06,US 0146446 W;;US 25168300 P,2000-12-06,METHOD OF FORMING AN IMAGED COMPOUND TEXTILE FABRIC,,POLYMER GROUP INC,BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,,https://lens.org/015-863-549-700-193,Search Report,no,3,0,11,11,0,B32B5/26;;D06C23/00;;D06P5/003;;D06P7/00;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;D03D1/00;;D10B2331/04;;D10B2201/02;;D03D13/004;;D03D15/283;;D03D15/217;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;B32B2437/00;;B32B2262/0276;;B32B2262/0261;;B32B2262/0253;;B32B2262/0246;;B32B5/26;;D06C23/00;;D06P7/00;;D06P5/003;;D03D25/00;;D03D15/217;;D03D15/283,B32B5/26;;D04H1/46;;D04H13/00;;D06C23/00;;D06P5/24;;D06P7/00,,0,0,,,,DISCONTINUED
115,US,A1,US 2003/0153231 A1,021-181-914-408-676,2003-08-14,2003,US 38541103 A,2003-03-10,US 38541103 A;;US 873601 A;;US 25168300 P,2000-12-06,Method of forming an imaged compound textile fabric,"
   The present invention contemplates a method of forming a textile laminate or composite fabric from a plurality of woven fabric layers, with the method contemplating use of a three-dimensional image transfer device to facilitate efficient and commercially viable use of the method. 

   Herein is disclosed a method of forming an imaged textile laminate or composite compound fabric, the fabric having a first textile fabric layer comprising a plurality of interwoven warp and weft yarns and at least one other textile fabric layer, the lamination of the fabric layers and imaging of the construct occurring on a three-dimensional image transfer device. The image transfer device has a foraminous, image-forming surface comprising a regular pattern of three-dimensional surface elements. 
",BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,AVINTIV SPECIALTY MATERIALS INC (2015-06-04),https://lens.org/021-181-914-408-676,Patent Application,yes,14,0,11,11,0,B32B5/26;;D06C23/00;;D06P5/003;;D06P7/00;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;D03D1/00;;D10B2331/04;;D10B2201/02;;D03D13/004;;D03D15/283;;D03D15/217;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;B32B2437/00;;B32B2262/0276;;B32B2262/0261;;B32B2262/0253;;B32B2262/0246;;B32B5/26;;D06C23/00;;D06P7/00;;D06P5/003;;D03D25/00;;D03D15/217;;D03D15/283,B32B5/26;;D04H1/46;;D04H13/00;;D06C23/00;;D06P5/24;;D06P7/00,442/408;;442/327,0,0,,,,EXPIRED
116,AU,A,AU 2002/025909 A,045-252-819-618-84X,2002-06-18,2002,AU 2002/025909 A,2001-12-06,US 25168300 P;;US 0146446 W,2000-12-06,Method of forming an imaged compound textile fabric,,POLYMER GROUP INC,BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,,https://lens.org/045-252-819-618-84X,Patent Application,no,0,0,11,11,0,B32B5/26;;D06C23/00;;D06P5/003;;D06P7/00;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;D03D1/00;;D10B2331/04;;D10B2201/02;;D03D13/004;;D03D15/283;;D03D15/217;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;B32B2437/00;;B32B2262/0276;;B32B2262/0261;;B32B2262/0253;;B32B2262/0246;;B32B5/26;;D06C23/00;;D06P7/00;;D06P5/003;;D03D25/00;;D03D15/217;;D03D15/283,B32B5/26;;D04H1/46;;D04H13/00;;D06C23/00;;D06P5/24;;D06P7/00,,0,0,,,,PENDING
117,WO,A2,WO 2002/046509 A2,042-105-646-634-681,2002-06-13,2002,US 0146446 W,2001-12-06,US 25168300 P,2000-12-06,METHOD OF FORMING AN IMAGED COMPOUND TEXTILE FABRIC,"The present invention contemplates a method of forming a textile laminate or composite fabric from a plurality of woven fabric layers, with the method contemplating use of a three-dimensional image transfer device to facilitate efficient and commercially viable use of the method. Herein is disclosed a method of forming an imaged textile laminate or composite compound fabric, the fabric having a first textile fabric layer (11) comprising a plurality of interwoven warp and weft yarns and at least one other textile fabric layer (10), the lamination of the fabric layers and imaging of the construct occurring on a three-dimensional image transfer device (18). The image transfer device (18) has a foraminous, image-forming surface comprising a regular pattern of three-dimensional surface elements.",POLYMER GROUP INC,BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,,https://lens.org/042-105-646-634-681,Patent Application,yes,0,1,11,11,0,B32B5/26;;D06C23/00;;D06P5/003;;D06P7/00;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;D03D1/00;;D10B2331/04;;D10B2201/02;;D03D13/004;;D03D15/283;;D03D15/217;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;B32B2437/00;;B32B2262/0276;;B32B2262/0261;;B32B2262/0253;;B32B2262/0246;;B32B5/26;;D06C23/00;;D06P7/00;;D06P5/003;;D03D25/00;;D03D15/217;;D03D15/283,B32B5/26;;D04H1/46;;D04H13/00;;D06C23/00;;D06P5/24;;D06P7/00,,0,0,,,,PENDING
118,US,B2,US 6564436 B2,079-397-623-919-270,2003-05-20,2003,US 873601 A,2001-12-06,US 873601 A;;US 25168300 P,2000-12-06,Method of forming an imaged compound textile fabric,"
    The present invention contemplates a method of forming a textile laminate or composite fabric from a plurality of woven fabric layers, with the method contemplating use of a three-dimensional image transfer device to facilitate efficient and commercially viable use of the method. 

    Herein is disclosed a method of forming an imaged textile laminate or composite compound fabric, the fabric having a first textile fabric layer comprising a plurality of interwoven warp and weft yarns and at least one other textile fabric layer, the lamination of the fabric layers and imaging of the construct occurring on a three-dimensional image transfer device. The image transfer device has a foraminous, image-forming surface comprising a regular pattern of three-dimensional surface elements. 
",POLYMER GROUP INC,BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,POLYMER GROUP INC (2002-01-29),https://lens.org/079-397-623-919-270,Granted Patent,yes,12,12,11,11,0,B32B5/26;;D06C23/00;;D06P5/003;;D06P7/00;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;D03D1/00;;D10B2331/04;;D10B2201/02;;D03D13/004;;D03D15/283;;D03D15/217;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;B32B2437/00;;B32B2262/0276;;B32B2262/0261;;B32B2262/0253;;B32B2262/0246;;B32B5/26;;D06C23/00;;D06P7/00;;D06P5/003;;D03D25/00;;D03D15/217;;D03D15/283,B32B5/26;;D04H1/46;;D04H13/00;;D06C23/00;;D06P5/24;;D06P7/00,28/104;;28/163;;28/167,0,0,,,,EXPIRED
119,WO,A9,WO 2002/046509 A9,149-079-375-625-276,2003-07-17,2003,US 0146446 W,2001-12-06,US 25168300 P,2000-12-06,METHOD OF FORMING AN IMAGED COMPOUND TEXTILE FABRIC,"The present invention contemplates a method of forming a textile laminate or composite fabric from a plurality of woven fabric layers, with the method contemplating use of a three-dimensional image transfer device to facilitate efficient and commercially viable use of the method. Herein is disclosed a method of forming an imaged textile laminate or composite compound fabric, the fabric having a first textile fabric layer (11) comprising a plurality of interwoven warp and weft yarns and at least one other textile fabric layer (10), the lamination of the fabric layers and imaging of the construct occurring on a three-dimensional image transfer device (18). The image transfer device (18) has a foraminous, image-forming surface comprising a regular pattern of three-dimensional surface elements.",POLYMER GROUP INC,BLACK SAMUEL KEITH;;CURTIS CHARLES KEITH;;MORAN SHANE JAMES,,https://lens.org/149-079-375-625-276,Patent Application,no,0,0,11,11,0,B32B5/26;;D06C23/00;;D06P5/003;;D06P7/00;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;D03D1/00;;D10B2331/04;;D10B2201/02;;D03D13/004;;D03D15/283;;D03D15/217;;Y10T442/3528;;Y10T442/488;;Y10T442/689;;Y10T442/3772;;Y10T442/40;;Y10T442/348;;Y10T442/60;;Y10T442/3537;;B32B2437/00;;B32B2262/0276;;B32B2262/0261;;B32B2262/0253;;B32B2262/0246;;B32B5/26;;D06C23/00;;D06P7/00;;D06P5/003;;D03D25/00;;D03D15/217;;D03D15/283,B32B5/26;;D04H1/46;;D04H13/00;;D06C23/00;;D06P5/24;;D06P7/00,,0,0,,,,PENDING
120,US,A1,US 2007/0020297 A1,093-832-231-182-258,2007-01-25,2007,US 57543806 A,2006-04-11,US 57543806 A;;US 51304003 P;;US 2004/0034761 W,2003-10-21,"System and method for the treatment of cancer, including cancers of the central nervous system","The invention relates to the treatment of cancer, and particularly to the treatment of cancers of the central nervous system, such as glioblastoma multiforme. A dual therapeutic approach is provided, including the administration of a dendritic cell-based cancer vaccine and a regimen of chemotherapy. The two therapies may be administered concurrently with one another and/or with an initial vaccination preceding chemotherapy. In various embodiments, the dendritic cell-based cancer vaccine includes either primed or unprimed dendritic cells; for instance, the dendritic cells may be autologous tumor antigen-presented dendritic cells. The dual therapeutic approach of the instant invention beneficially influences the chemosensitivity of a mammal with cancer.",CEDARS SINAI MEDCAL CT,WHEELER CHRISTOPHER;;DAS ASHA;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2006-03-30),https://lens.org/093-832-231-182-258,Patent Application,yes,37,33,9,9,0,A61K31/203;;A61K31/282;;A61K31/454;;A61K31/4745;;A61K31/704;;A61K31/7048;;A61K45/06;;A61P35/00;;A61P43/00;;A61K33/243;;A61K2239/38;;A61K39/4622;;A61K39/464499;;A61K39/4615;;A61K2239/47;;A61K39/46432;;A61K45/06;;A61K31/454;;A61K31/7048;;A61K39/00;;A61K31/203;;A61K31/282;;A61K39/0011;;A61K2039/5154;;A61K31/704;;A61K31/4745;;A61K33/243,A61K39/00;;A61K31/203;;A61K31/282;;A61K31/454;;A61K31/4745;;A61K31/704;;A61K31/7048;;A61K33/243;;A61K45/06;;C12N5/02;;C12N5/08,424/277.1;;424/649;;514/27;;514/34;;514/283;;514/323;;514/559;;514/492,0,0,,,,ACTIVE
121,MX,A,MX 2021006655 A,021-097-129-133-564,2021-07-07,2021,MX 2021006655 A,2019-12-06,US 201862776710 P;;US 2019/0065031 W,2018-12-07,AUTO EXTRUDED SPLIT/SPHERICAL TEE AND FULL ENCIRCLEMENT SADDLE.,"The disclosure describes an automated system and method to manufacture extruded split tees, spherical tees, and full encirclement saddle (FES) component parts. The system and method provide for the manufacture of pipe reinforcement components from raw material plates, comprising: an input storage for the raw material plates; one or more ovens for heating the plates; one or more extrusion presses for extruding the heated raw material plates into one or more pipe reinforcement components and an output storage for the pipe reinforcement components. A robotic device is adapted to automatically access and perform operations at the input storage, at the one or more ovens, at the one or more extrusion presses, and at the output storage.",TEAM IND SERVICES INC,GHAFARI RIZK;;KOBAYASHI KEITH;;BLACK-WELL GERALD,,https://lens.org/021-097-129-133-564,Patent Application,no,0,0,5,5,0,F16L47/32;;B25J9/1687;;B25J9/1697;;B25J11/0065;;B25J15/0019;;B29D23/003;;F16L47/32;;F16L57/00;;B23P23/06;;B21C37/29,E21B17/00;;E21B43/12;;E21B43/16,,0,0,,,,PENDING
122,KR,A,KR 20230061388 A,164-961-491-085-926,2023-05-08,2023,KR 20237007501 A,2021-08-02,US 202063060553 P;;US 2021/0044195 W,2020-08-03,알츠하이머병을 치료하기 위한 조성물 및 방법,"본원에는 가족성 알츠하이머병, 조기 발병 알츠하이머병, 및 중기 내지 말기 알츠하이머병을 포함하는 알츠하이머병을 갖거나 가질 위험이 있는 개체에서 인지를 개선하기 위한 조성물 및 방법이 제공된다.",CEDARS SINAI MEDICAL CENTER;;FORTEM NEUROSCIENCES INC,KORONYO MAYA;;BLACK KEITH L;;KAVANAUGH JACK,,https://lens.org/164-961-491-085-926,Patent Application,no,0,0,8,8,6,A61P25/28;;A61K31/548;;C12Y201/01;;A61K31/548;;A61P25/28;;A61P25/28;;A61K31/548,A61K31/548;;A61P25/28,,0,0,,,,PENDING
123,US,B2,US 7939090 B2,083-670-238-388-169,2011-05-10,2011,US 57543806 A,2006-04-11,US 57543806 A;;US 51304003 P;;US 2004/0034761 W,2003-10-21,"System and method for the treatment of cancer, including cancers of the central nervous system","The invention relates to the treatment of cancer, and particularly to the treatment of cancers of the central nervous system, such as glioblastoma multiforme. A dual therapeutic approach is provided, including the administration of a dendritic cell-based cancer vaccine and a regimen of chemotherapy. The two therapies may be administered concurrently with one another and/or with an initial vaccination preceding chemotherapy. In various embodiments, the dendritic cell-based cancer vaccine includes either primed or unprimed dendritic cells; for instance, the dendritic cells may be autologous tumor antigen-presented dendritic cells. The dual therapeutic approach of the instant invention beneficially influences the chemosensitivity of a mammal with cancer.",CEDARS SINAI MEDICAL CENTER,WHEELER CHRISTOPHER;;DAS ASHA;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2006-03-30),https://lens.org/083-670-238-388-169,Granted Patent,yes,55,1,9,9,3,A61K31/203;;A61K31/282;;A61K31/454;;A61K31/4745;;A61K31/704;;A61K31/7048;;A61K45/06;;A61P35/00;;A61P43/00;;A61K33/243;;A61K2239/38;;A61K39/4622;;A61K39/464499;;A61K39/4615;;A61K2239/47;;A61K39/46432;;A61K45/06;;A61K31/454;;A61K31/7048;;A61K39/00;;A61K31/203;;A61K31/282;;A61K39/0011;;A61K2039/5154;;A61K31/704;;A61K31/4745;;A61K33/243,A61K39/00;;A61K33/243;;A61K45/06;;C12N5/02;;C12N5/08,424/277.1,73,70,074-416-675-238-759;;080-647-403-540-300;;160-717-493-067-916;;003-616-087-027-77X;;025-760-264-704-263;;026-304-558-215-155;;120-862-791-424-707;;021-056-467-881-097;;010-981-337-785-354;;071-699-972-336-631;;108-599-572-220-595;;053-672-692-937-579;;022-982-723-684-607;;092-859-198-377-451;;021-602-438-381-646;;006-604-900-808-204;;085-702-051-840-908;;108-207-855-841-062;;019-264-483-343-031;;057-105-231-226-816;;080-647-403-540-300;;022-665-264-045-910;;078-639-700-866-831;;013-855-584-540-778;;057-785-668-031-036;;108-599-572-220-595;;041-406-340-961-551;;006-884-247-056-538;;035-857-332-739-788;;034-409-534-864-530;;153-662-306-900-396;;086-946-791-527-279;;053-906-705-994-097;;035-823-463-717-575;;065-777-065-691-692;;126-067-752-107-202;;049-915-366-620-516;;032-932-040-924-322;;138-771-752-862-480;;168-705-133-516-75X;;016-059-509-686-365;;022-798-233-953-966;;045-700-919-027-517;;011-954-218-606-176;;044-750-837-062-887;;092-707-572-319-639;;018-870-261-171-506;;090-928-883-705-496;;006-148-652-132-981;;068-473-895-492-963;;060-861-375-524-523;;012-105-359-936-435;;044-084-260-816-039;;055-983-972-565-643;;063-225-571-358-608;;003-924-024-298-446;;139-500-660-556-55X;;133-716-008-515-719;;078-723-209-803-023;;075-344-720-447-282;;018-681-549-217-136;;065-777-065-691-692;;010-628-726-217-388;;076-867-150-716-864;;096-919-431-021-193;;052-358-709-302-448;;009-491-278-782-50X;;046-847-065-587-168;;026-958-333-907-92X;;005-926-044-608-888,11606390;;11221866;;10914698;;10.1097/00002371-200307000-00002;;12843792;;12222879;;10.1093/jjco/hye076;;11574635;;11676393;;10.1007/s002620100205;;pmc4030524;;10.1158/1078-0432.ccr-06-1576;;17255279;;pmc3903051;;10.1007/s00262-007-0426-9;;18057935;;9754652;;10.1002/(sici)1097-0215(19981005)78:2<196::aid-ijc13>3.0.co;2-9;;10350260;;10.3171/jns.1999.90.6.1115;;10.1016/s0165-5728(99)00172-1;;10674985;;10.14670/hh-18.435;;12647794;;12538481;;12209978;;10.1002/ijc.10597;;12759442;;10.4049/jimmunol.170.11.5625;;10.1007/s005950300060;;12707821;;14555310;;12667889;;10.1016/s0163-7258(03)00014-7;;10.1053/pb.2000.6691;;10914414;;11221866;;10.1034/j.1600-0463.2003.11107802.x;;12974772;;10.1097/00006123-199903000-00110;;10069601;;10.1227/00006123-199305000-00003;;10.1097/00006123-199305000-00003;;8388081;;10.1093/jnci/85.9.704;;8478956;;10350260;;10.3171/jns.1999.90.6.1115;;10.1023/a:1024969422010;;10.1007/bf02700016;;12952282;;10.4049/jimmunol.171.9.4927;;14568975;;10.1158/1078-0432.ccr-04-0497;;15328167;;18632651;;10.1158/0008-5472.can-07-5973;;10.1007/s00262-002-0297-z;;12202903;;10.1038/sj.onc.1208519;;15897911;;10.1586/14760584.5.2.233;;16608423;;12907622;;10.3349/ymj.2004.45.suppl.48;;15250050;;17380773;;10.1006/cimm.1998.1298;;9637766;;11449066;;11265767;;10.1097/00002371-200103000-00004;;10.1586/14737175.5.4.497;;16026233;;15383564;;10.4049/jimmunol.173.7.4352;;10.2741/1747;;15970545;;11196166;;12941147;;10.1046/j.1365-2567.2003.01726.x;;pmc1783031;;11471194;;12616102;;10.1097/00002371-200303000-00003;;10.1177/107327480401100307;;15153843;;12391241;;10.4049/jimmunol.169.9.5227;;11731436;;10.1007/s002620050465;;9558003;;pmc521140;;10.1073/pnas.0400067101;;15381773;;17939761;;10.1586/14737175.7.10.1235;;10.1177/107327480301000205;;12712008;;15256472;;10.1158/0008-5472.can-03-3504;;15162438;;10.1002/eji.200425081;;10.2174/157488708783330530;;18474011;;7774624;;10.1002/eji.1830250511;;8027569;;10.4049/jimmunol.153.3.996;;12109820;;10.1053/clon.2001.0038;;11440627;;10.1089/104303401750270995;;10.1093/jnci/94.11.805;;12048268;;10024247;;10.1126/science.283.5405.1183;;10.3349/ymj.2004.45.suppl.48;;15250050;;11895781;;10.1182/blood.v99.7.2468;;15312683;;10.1016/j.canlet.2004.04.010;;15571138;;12874257;;10.1084/jem.20030422;;pmc2194081;;10.1084/jem.171.4.1315;;pmc2187833;;2139102;;10.1158/0008-5472.can-03-3505;;15256471;;pmc2192415;;10.1084/jem.183.1.87;;8551248;;10.1007/bf03401956;;pmc1949998;;11713365,"Tong et al (Cancer Research, 2001, 61:7530-7535.;;Yu et al I (Cancer Research, 2001, 61:842-847, IDS).;;Friedman et al (Clinical Cancer Research, 2000, 6:2585-2597).;;Liu et al (J of Immunotherapy, Jul./Aug. 2003, 26:301-312).;;Knutson (Current Opinion in Molecular Therapeutics, Aug. 2002, 4:403-407).;;Osada et al (Jpn J Clinical Oncology, 2001, 31:403-406).;;Kikuchi et al (Cancer Immunol Immunother, 2001, 50:337-344).;;Zhang et al (Clinical Cancer Research, 2007, 13:566-575).;;Merrick et al (Cancer Immunol Immunother, 2008, 57:897-906).;;Okada et al (Int J Cancer, 1998, 78:196-201).;;Liau et al (J Neurosurgery, 1999, 90:1115-1124).;;Heimberger et al (J of Neuroimmunology, 2000, 103:16-25).;;Shin et al, Antitumor Effect of Intratumoral Administration of Dendrite Cell Combination With Vincristine Chemotherapy in a Murine Fabrosarcoma Model, Histology and Histopathology, Apr. 2003, pp. 435-447, 18:2.;;Yu et al., Effective Combination of Chemotherapy and Dendritic Cell Administration for the Treatment of Advanced-Stage Experimental Breast Cancer, Clinical Cancer Research, Jan. 2003, pp. 285-294, 9:1.;;Tanaka et al., Intratumoral Injection of Dendritic Cells After Treatment of Anticancer Drugs Induces Tumor-Specific Antitumor Effect in Vivo, International Journal of Cancer, Sep. 20, 2002, pp. 265-269, 101:3.;;Ghosh et al., Dendrite Cell-Based Immunotherapy Combined With Antimony-Based Chemotherapy Cures Established Murine Visceral Leishmanlasis, The Journal of Immunology, Jun. 1, 2003, pp. 5625-5629, 170:11.;;Inoue et al., Dendrite Cell Coinjected With Tumor Cells Treated With an Anticancer Drug to Induce Tumor Rejection, Surgery Today, Apr. 4, 2003, pp. 269-276, 33:4.;;Reichardt et al., Idiotype Vaccination of Multiple Meyloma Patients Using Monocyte-Derived Dendritic Cells, Haematologica, Oct. 2003, pp. 1139-1149, 88:10.;;Chui et al., Dendrite Cell Vaccination Following High Dose Chemotherapy With Autologous Stem Cell Support for Breast Cancer. Long-Term Follow-Up, Proceedings of the American Society of Clinical Oncology, Jun. 2003, 22 (Abstract Only).;;Castro et al., Current and Future Strategies for the Treatment of Malignant Brain Tumors, Pharmacology & Therapeutics, Apr. 2003, pp. 71-108, 98:1.;;Pollack et al., Exploitation of Immune Machanisms in the Treatment of Central Nervous System Cancer, Seminars in Pediatric Neurology, Jun. 2000, pp. 131-143, 7:2.;;Yu et al., Vaccination of Malignant Morrie Patients With Peptide-Pulsed Dendritic Cells Elicits Systemic Cytotoxicity and Intracranial T-Cell Infiltration, Cancer Research, Feb. 1, 2001, pp. 842-847, 61:3.;;Steinman, R.M., Some Interfaces of Dendritic Cell Biology, Acta Pathologica, Microbiologica, et Immunologica Scandinavica, Jul. 2003, pp. 675-897, 111:7-8.;;Bowles, Jr. et al., ""Long-term Remission of Malignant Brain Tumors after Intracranial Infection: A Report of Four Cases,"" Neurosurgery, vol. 44: 636-642 (1999).;;Chandler et al., ""Long-Term Survival in Patients with Glioblastoma Multiforme,"" Neurosurgery, vol. 32:716-720 (1993).;;Curran et al., ""Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials,"" J Natl Cancer Inst, vol. 85:704-710 (1993).;;Liau et al., ""Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens,"" J Neurosurg, vol. 90:1115-1124 (1999).;;Okada et al., ""Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy,"" Journal of Neuro-Oncology, vol. 64:13-20 (2003).;;Stupp et al., ""Recent Developments in the Management of Malignant Glioma,"" American Society of Clinical Oncology Educational Book, 779-788 (2003).;;Wheeler et al., ""Thymic CD8+ T Cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality,"" The Journal of Immunology, vol. 171:4927-4933 (2003).;;Wheeler et al., ""Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination,"" Clin. Cancer Res., 10:5316-26 (2004).;;Wheeler et al., ""Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients,"" Cancer Res., 68:5955-64 (2008).;;Kikuchi et al., ""Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model,"" Cancer Immunol. Immumother., 51:424-430 (2002).;;Liu et al., ""Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy,"" Oncogene, 24:5226-34 (2005).;;Liu et al., ""Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination,"" Expert Rev. Vaccines, 5:233-247 (2006).;;Nowak et al., ""Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors,"" Cancer Res., 63:4490-96 (2003).;;Song et al., ""Strategies to improve dendritic cell-based immunotherapy against cancer,"" Yonsei Med. J., 45(Suppl):48-52 (2004).;;Yu et al., ""Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination,"" Clin. Neurosurg., 53:345-351 (2006).;;Abdel-Wahab et al., ""Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity,"" Cell. Immunol., 186:63-74 (1998).;;Akasaki et al., ""Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model,"" J. Immunother., 24:106-113 (2001).;;Akasaki et al., ""Dendritic cell-based immunotherapy for malignant gliomas,"" Expert Rev. Neurother., 5:497-508 (2005).;;Akasaki et al., ""Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma,"" J. Immunol., 173:4352-59 (2004).;;Akasaki et al., ""T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches,"" Front. Biosci., 10:2908-21 (2005).;;Candido et al., ""Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents,"" Cancer Res., 61:228-236 (2001).;;Casey et al., ""Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine,"" Immunology, 110:105-111 (2003).;;Dietz, ""Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia,"" Croatian Med. J., 42:428-435 (2001).;;Ehtesham et al., ""Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats,"" J. Immunother., 26:107-116 (2003).;;Ehtesham et al., ""Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials,"" Cancer Control, 11:192-207 (2004).;;Gatza et al., ""Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma,"" J. Immunol., 169:5227-35 (2002).;;Geiger et al., ""Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression,"" Cancer Res., 61:8513-19 (2001).;;Gilboa et al., ""Immunotherapy of cancer with dendritic-cell-based vaccines,"" Cancer Immunol. Immunother., 46:82-87 (1998).;;Hirschmann-Jax et al., ""A distinct 'side population' of cells with high drug efflux capacity in human tumor cells,"" Proc. Natl. Acad. Sci. USA, 39:14228-33 (2004).;;Liu et al., ""Cancer vaccines: a novel strategy to sensitize malignant glioma to chemotherapy,"" Expert Rev. Neurother., 7:1235-37 (2007).;;Liu et al., ""Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma,"" Cancer Control, 10:138-147 (2003).;;Liu et al., ""HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells,"" Cancer Res., 64:4980-86 (2004).;;Liu et al., ""Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Thl response,"" Eur. J. Immunol., 34:1680-87 (2004).;;Luptrawan et al., ""Dendritic cell immunotherapy for malignant gliomas,"" Rev. Recent Clin. Trials, 3:10-21 (2008).;;Mehta-Damani et al., ""Generation of antigen-specific CD4+ T cell lines from naïve precursors,"" Eur. J. Immunol., 5:1206-11 (1995).;;Mehta-Damani et al., ""Generation of antigen-specific CD8+ CTLs from naïve precursors,"" J. Immunol., 153:996-1003 (1994).;;Melcher et al., ""Dendritic cells for the immunotherapy of cancer,"" Clin. Oncol., 14:185-192 (2002).;;Mi et al., ""Induced apoptosis supports spread of adenovirus rectors in tumors,"" Hum. Gene Ther., 12:1343-52 (2001).;;Parmiani et al., ""Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?"" J. Natl. Cancer Inst., 94:805-818 (2002).;;Rissoan et al., ""Reciprocal control of T helper cell and dendritic cell differentiation,"" Science, 283:1183-86 (1999).;;Song et al., ""Strategies to improve dendritic cell-based immunotherapy against cancer,"" Yonsei Med. J., 45(Suppl):48-52 (2004).;;Steinbrink et al., ""CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity,"" Blood, 99:2468-76 (2002).;;Takagi et al., ""Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells,"" Cancer Lett., 213:49-55 (2004).;;Wheeler et al., ""Cellular immunity in the treatment of brain tumors,"" Clin. Neurosurg., 51:132-139 (2004).;;Yamazaki et al., ""Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells,"" J. Exp. Med., 198:235-247 (2003).;;Young et al., ""Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells,"" J. Exp. Med., 171:1315-32 (1990).;;Yu et al., ""Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma,"" Cancer Res., 64:4973-79 (2004).;;Zitvogel et al., ""Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-1 associated cytokines,"" J. Exp. Med., 183:87-97 (1996).;;Soling et al., ""Dendritic cell therapy of primary brain tumors,"" Mol. Med., 7:659-667 (2001).;;European Examiner Oskar Lechner, Communication for Application No. EP 04795865.7, dated Oct. 4, 2010, 7 pages.",ACTIVE
124,WO,A3,WO 2022/031606 A3,075-883-378-476-549,2022-07-21,2022,US 2021/0044195 W,2021-08-02,US 202063060553 P,2020-08-03,COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE,"Provided herein are compositions and methods that improve cognition in individuals having or at risk of having Alzheimers disease, including familial Alzheimers disease, early-onset Alzheimers disease, and middle to late stage Alzheimers disease.",CEDARS SINAI MEDICAL CENTER;;FORTEM NEUROSCIENCES INC,KORONYO MAYA;;BLACK KEITH L;;KAVANAUGH JACK,,https://lens.org/075-883-378-476-549,Search Report,yes,3,0,8,8,3,A61P25/28;;A61K31/548;;C12Y201/01;;A61K31/548;;A61P25/28;;A61P25/28;;A61K31/548,A61K31/202;;A61K31/232;;A61K31/27;;A61P25/28,,1,1,044-521-298-432-949,10.1038/376775a0;;7651536,"ROGAEV ET AL.: ""Familial Alzheimer's disease In kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene"", NATURE, vol. 376, no. 6543, 31 August 1995 (1995-08-31), pages 775 - 778, XP000196835, DOI: 10.1038/376775a0",PENDING
125,US,A1,US 2011/0212048 A1,085-220-626-549-985,2011-09-01,2011,US 201113097364 A,2011-04-29,US 201113097364 A;;US 58099907 A;;US 2004/0040660 W;;US 52733003 P,2003-12-05,POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM,"A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system's circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH;;HOLLER EGGEHARD,ARROGENE NANOTECHNOLOGY INC (2012-07-19);;CEDARS-SINAI MEDICAL CENTER (2006-04-13);;ARROGENE INC (2017-05-24),https://lens.org/085-220-626-549-985,Patent Application,yes,1,0,12,14,2,A61K47/60;;A61K47/593;;A61K47/6883;;A61K47/6849;;A61P35/00;;A61K47/6883;;A61K47/593;;A61K47/60;;A61K47/6849;;A61P35/00,A61K47/48;;A61P35/00;;C08F8/30,424/78.17;;525/54.2;;525/54.1,0,0,,,,ACTIVE
126,US,A1,US 2024/0009203 A1,101-594-470-600-688,2024-01-11,2024,US 202118040310 A,2021-08-02,US 202118040310 A;;US 202063060553 P;;US 2021/0044195 W,2020-08-03,COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE,"Provided herein are compositions and methods that improve cognition in individuals having or at risk of having Alzheimers disease, including familial Alzheimers disease, early-onset Alzheimers disease, and middle to late stage Alzheimers disease.",CEDARS SINAI MEDICAL CENTER;;FORTEM NEUROSCIENCES INC,KORONYO MAYA;;KAVANAUGH JACK;;BLACK KEITH L,FORTEM NEUROSCIENCES INC (2023-02-14);;CEDARS-SINAI MEDICAL CENTER (2023-02-06),https://lens.org/101-594-470-600-688,Patent Application,yes,0,0,8,8,3,A61P25/28;;A61K31/548;;C12Y201/01;;A61K31/548;;A61P25/28;;A61P25/28;;A61K31/548,A61K31/548;;A61P25/28,,0,0,,,,PENDING
127,WO,A1,WO 2005/079581 A1,006-865-743-750-12X,2005-09-01,2005,US 2004/0001612 W,2004-01-20,US 2004/0001612 W,2004-01-20,INTRATUMORAL DELIVERY OF DENDRITIC CELLS,Methods included herein describe the treatment of a tumor by administering dendritic cells either directly into the same or into its surrounding tissue. Further methods describe the induction of immune cell infiltration into tumors and the treatment of tumors with unprimed dendritic cells by administering dendritic cells in a similar fashion. The methods of the present invention are particularly advantageous in the treatment of brain tumors and other solid tumors disposed throughout the body of a mammal that are difficult or impossible to treat by conventional surgical means. Dendritic cell-based compositions effective in the treatment of such tumors are also described.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;BLACK KEITH;;EHTESHAM MONEEB,,https://lens.org/006-865-743-750-12X,Patent Application,yes,0,12,2,2,0,A61K2039/54;;A61K39/4644;;A61K39/4622;;A61K39/4615;;A61K2239/46;;A61K39/4614;;A61K2239/31,A01N63/00;;A61K35/14;;A61K35/16;;A61K39/00;;C12N5/08,,2,2,080-647-403-540-300;;044-750-837-062-887,11221866;;12616102;;10.1097/00002371-200303000-00003,"YU J S ET AL: ""Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration"", vol. 61, 1 February 2001 (2001-02-01), pages 842 - 847, XP002983453;;EHTESHAM M ET AL: ""Intratumoral dendritic cell vaccination elitics potent tumroicidal immunity against malignant glioma in rats"", JOURNAL OF IMMUNOTHERAPY, vol. 26, no. 2, March 2003 (2003-03-01), pages 107 - 116, XP002983473",PENDING
128,US,B2,US 8562964 B2,132-989-791-702-15X,2013-10-22,2013,US 201113097364 A,2011-04-29,US 201113097364 A;;US 58099907 A;;US 2004/0040660 W;;US 52733003 P,2003-12-05,Polymalic acid-based multifunctional drug delivery system,"A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system's circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms.",LJUBIMOVA JULIA Y;;BLACK KEITH;;HOLLER EGGEHARD;;CEDARS SINAI MEDICAL CENTER;;ARROGENE NANOTECHNOLOGY INC,LJUBIMOVA JULIA Y;;BLACK KEITH;;HOLLER EGGEHARD,ARROGENE NANOTECHNOLOGY INC (2012-07-19);;CEDARS-SINAI MEDICAL CENTER (2006-04-13);;ARROGENE INC (2017-05-24),https://lens.org/132-989-791-702-15X,Granted Patent,yes,1,13,12,14,2,A61K47/60;;A61K47/593;;A61K47/6883;;A61K47/6849;;A61P35/00;;A61K47/6883;;A61K47/593;;A61K47/60;;A61K47/6849;;A61P35/00,A61K47/48;;A61P35/00;;C08F8/30,424/78.17;;525/54.1;;525/54.2,0,0,,,,ACTIVE
129,US,A1,US 2019/0117145 A1,094-472-771-817-71X,2019-04-25,2019,US 201716301585 A,2017-06-02,US 201716301585 A;;US 201662344877 P;;US 2017/0035835 W,2016-06-02,VISUAL STIMULI MAZE TEST FOR DETECTING VISUAL ABNORMALITIES IN PRODROMAL ALZHEIMER'S DISEASE AND IN ALZHEIMER'S DISEASE,"Disclosed herein is a rodent and human behavioral test for evaluating visual dysfunctions associated with the retinal changes in Alzheimer disease progression. In one example, the inventors developed a maze that tests rodent's ability to identify (1) specific contrasts, (2) specific colors, (3) certain items in the visual field, and (4) other ‘non-typical’ peripheral and night vision functions associated with AD. For instance, the inventors developed a maze the tests the rodents ability to avoid certain colors or contrasts gradients. The maze may include certain rooms with specific visual markers (e.g., colors, contrasts, objects or other visual features) that also contain shock plates.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;KORONYO YOSEF;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2017-06-07),https://lens.org/094-472-771-817-71X,Patent Application,yes,0,6,3,3,0,A01K1/031;;A01K15/02;;A01K1/031;;A01K15/02;;A01K2267/0312;;A61B3/0091;;A61B3/022;;A61B3/06;;A61B5/4088;;A61B2503/40,A61B5/00;;A01K1/03;;A01K15/02;;A61B3/00;;A61B3/02;;A61B3/06,,0,0,,,,ACTIVE
130,KR,A,KR 20060116850 A,123-880-557-273-865,2006-11-15,2006,KR 20067016411 A,2006-08-16,KR 20067016411 A,2006-08-16,INTRATUMORAL DELIVERY OF DENDRITIC CELLS,Methods included herein describe the treatment of a tumor by administering dendritic cells either directly into the same or into its surrounding tissue. Further methods describe the induction of immune cell infiltration into tumors and the treatment of tumors with unprimed dendritic cells by administering dendritic cells in a similar fashion. The methods of the present invention are particularly advantageous in the treatment of brain tumors and other solid tumors disposed throughout the body of a mammal that are difficult or impossible to treat by conventional surgical means. Dendritic cell-based compositions effective in the treatment of such tumors are also described.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;BLACK KEITH;;EHTESHAM MONEEB,,https://lens.org/123-880-557-273-865,Patent Application,no,0,0,1,1,0,A61K9/0012;;A61K9/0019;;A61K35/15;;A61K35/28;;C12N2501/22;;C12N2501/2304,A61K35/14;;A61K35/16;;A61K35/28,,0,0,,,,DISCONTINUED
131,WO,A1,WO 2017/210645 A1,043-474-737-897-612,2017-12-07,2017,US 2017/0035835 W,2017-06-02,US 201662344877 P,2016-06-02,VISUAL STIMULI MAZE TEST FOR DETECTING VISUAL ABNORMALITIES IN PRODROMAL ALZHEIMER'S DISEASE AND IN ALZHEIMER'S DISEASE,"Disclosed herein is a rodent and human behavioral test for evaluating visual dysfunctions associated with the retinal changes in Alzheimer disease progression. In one example, the inventors developed a maze that tests rodent's ability to identify (1) specific contrasts, (2) specific colors, (3) certain items in the visual field, and (4) other 'non-typical' peripheral and night vision functions associated with AD. For instance, the inventors developed a maze the tests the rodents ability to avoid certain colors or contrasts gradients. The maze may include certain rooms with specific visual markers (e.g., colors, contrasts, objects or other visual features) that also contain shock plates.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;KORONYO YOSEF;;BLACK KEITH L,,https://lens.org/043-474-737-897-612,Patent Application,yes,4,4,3,3,0,A01K1/031;;A01K15/02;;A01K1/031;;A01K15/02;;A01K2267/0312;;A61B3/0091;;A61B3/022;;A61B3/06;;A61B5/4088;;A61B2503/40,A01K1/03;;A01K15/00;;A01K15/02;;A01K29/00;;A61K35/12;;A61K35/30,,0,0,,,,PENDING
132,CN,A,CN 116194097 A,187-035-275-401-105,2023-05-30,2023,CN 202180068069 A,2021-08-02,US 202063060553 P;;US 2021/0044195 W,2020-08-03,Compositions and methods for treating Alzheimer's disease,"Provided herein are compositions and methods for improving cognition in an individual having or at risk of developing Alzheimer's disease, including familial Alzheimer's disease, premature Alzheimer's disease, and mid-advanced Alzheimer's disease.",CEDARS SINAI MEDICAL CENTER;;FORTUM NEUROSCIENCES INC,MAYA COLONYO;;BLACK KEITH L;;KAVLAUF JACK,,https://lens.org/187-035-275-401-105,Patent Application,no,0,0,8,8,0,A61P25/28;;A61K31/548;;C12Y201/01;;A61K31/548;;A61P25/28;;A61P25/28;;A61K31/548,A61K31/232,,0,0,,,,PENDING
133,US,B2,US 11425889 B2,047-643-613-404-150,2022-08-30,2022,US 201716301585 A,2017-06-02,US 201716301585 A;;US 201662344877 P;;US 2017/0035835 W,2016-06-02,Visual stimuli maze test for detecting visual abnormalities in prodromal Alzheimer's disease and in Alzheimer's disease,"Disclosed herein is a rodent and human behavioral test for evaluating visual dysfunctions associated with the retinal changes in Alzheimer disease progression. In one example, the inventors developed a maze that tests rodent's ability to identify (1) specific contrasts, (2) specific colors, (3) certain items in the visual field, and (4) other ‘non-typical’ peripheral and night vision functions associated with AD. For instance, the inventors developed a maze the tests the rodents ability to avoid certain colors or contrasts gradients. The maze may include certain rooms with specific visual markers (e.g., colors, contrasts, objects or other visual features) that also contain shock plates.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;KORONYO YOSEF;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2017-06-07),https://lens.org/047-643-613-404-150,Granted Patent,yes,7,0,3,3,0,A01K1/031;;A01K15/02;;A01K1/031;;A01K15/02;;A01K2267/0312;;A61B3/0091;;A61B3/022;;A61B3/06;;A61B5/4088;;A61B2503/40,A01K15/02;;A01K1/03;;A61B3/00;;A61B3/02;;A61B3/06;;A61B5/00,,0,0,,,,ACTIVE
134,EP,A1,EP 1705992 A1,095-193-499-082-498,2006-10-04,2006,EP 04703716 A,2004-01-20,US 2004/0001612 W,2004-01-20,INTRATUMORAL DELIVERY OF DENDRITIC CELLS,,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;BLACK KEITH;;EHTESHAM MONEEB,,https://lens.org/095-193-499-082-498,Patent Application,yes,0,0,2,2,0,A61K2039/54;;A61K39/4644;;A61K39/4622;;A61K39/4615;;A61K2239/46;;A61K39/4614;;A61K2239/31,A01N63/00;;A61K35/14;;A61K35/16;;A61K39/00;;C12N5/08,,0,0,,,,DISCONTINUED
135,EP,A2,EP 4188360 A2,149-456-552-700-507,2023-06-07,2023,EP 21852216 A,2021-08-02,US 202063060553 P;;US 2021/0044195 W,2020-08-03,COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE,,CEDARS SINAI MEDICAL CENTER;;FORTEM NEUROSCIENCES INC,KORONYO MAYA;;BLACK KEITH L;;KAVANAUGH JACK,,https://lens.org/149-456-552-700-507,Patent Application,yes,0,0,8,8,3,A61P25/28;;A61K31/548;;C12Y201/01;;A61K31/548;;A61P25/28;;A61P25/28;;A61K31/548,A61K31/202;;A61K31/232;;A61K31/27;;A61P25/28,,0,0,,,,PENDING
136,AU,A1,AU 2021/320639 A1,172-251-142-208-733,2023-03-30,2023,AU 2021/320639 A,2021-08-02,US 202063060553 P;;US 2021/0044195 W,2020-08-03,Compositions and methods for treating alzheimer's disease,"Provided herein are compositions and methods that improve cognition in individuals having or at risk of having Alzheimers disease, including familial Alzheimers disease, early-onset Alzheimers disease, and middle to late stage Alzheimers disease.",CEDARS SINAI MEDICAL CENTER;;FORTEM NEUROSCIENCES INC,KORONYO MAYA;;BLACK KEITH L;;KAVANAUGH JACK,,https://lens.org/172-251-142-208-733,Patent Application,no,0,0,8,8,0,A61P25/28;;A61K31/548;;C12Y201/01;;A61K31/548;;A61P25/28;;A61P25/28;;A61K31/548,A61K31/202;;A61K31/232;;A61K31/27;;A61P25/28,,0,0,,,,PENDING
137,US,A1,US 2008/0003907 A1,119-724-831-638-216,2008-01-03,2008,US 42717906 A,2006-06-28,US 42717906 A,2006-06-28,Facing Product for Vehicular Trim,"A composite facing material is disclosed that may be used in combination with, e.g. foam, fibers and/or shoddy in a vehicular application. The composite may provide heat insulation and/or sound attenuation in a vehicular trim panel. The facing material may include a layer of staple fibers with a spunbonded continuous filament web layer. The layers may be intermittently thermally bonded in a desired pattern.",BLACK SAMUEL KEITH;;KAMPF QUENTIN;;MORIN SEAN,BLACK SAMUEL KEITH;;KAMPF QUENTIN;;MORIN SEAN,FREUDENBERG NONWOVENS L.P (2006-08-07),https://lens.org/119-724-831-638-216,Patent Application,yes,57,19,3,3,0,B32B5/26;;D04H1/559;;D04H3/14;;B32B5/00;;B32B5/022;;B32B5/08;;B32B7/12;;B32B2250/40;;B32B2262/02;;B32B2262/04;;B32B2262/06;;B32B2262/14;;B32B2272/00;;B32B2307/102;;B32B2605/00;;B60R13/02;;B32B7/05;;Y10T442/60;;B32B7/027;;Y10T442/60;;D04H3/14;;B32B5/00;;B32B2262/02;;B32B2262/06;;B32B5/26;;B32B2262/04;;B32B2307/102;;B32B2262/14;;D04H1/559;;B32B2605/00;;B32B5/022;;B32B7/12;;B32B2272/00;;B32B5/08;;B32B2250/40;;B60R13/02;;B32B7/05;;B32B7/027,D04H13/00;;B32B7/027,442/327,0,0,,,,DISCONTINUED
138,US,A1,US 2014/0288433 A1,182-551-422-488-415,2014-09-25,2014,US 201414267902 A,2014-05-01,US 201414267902 A;;US 201213666915 A;;US 201161554122 P,2011-11-01,UV IMAGING FOR INTRAOPERATIVE TUMOR DELINEATION,"A medical imaging system and method. A UV/visible camera uses a back illuminated silicon imaging detector to observe a surface of a brain of a subject in vivo during brain surgery for excision of a cancerous tumor. The detector can be a CCD detector or a CMOS detector. Under UV illumination, the camera can record images that can be processed to detect the location and extent of a cancerous tumor because the presence of auto-fluorescent NADH variations can be detected between normal and cancerous cells. The image data is processed in a general purpose programmable computer. In some instances, an image is also taken using visible light, and the identified cancerous region is displayed as an overlay on the visible image.",KATEB BABAK;;BLACK KEITH L;;NIKZAD SHOULEH,KATEB BABAK;;BLACK KEITH L;;NIKZAD SHOULEH,,https://lens.org/182-551-422-488-415,Patent Application,yes,6,1,1,3,0,A61B5/4064;;A61B5/4064;;A61B5/0042;;A61B5/0042;;A61B5/0071;;A61B5/0071;;A61B5/0077;;A61B5/0077;;A61B5/7425;;A61B5/7425,A61B5/00,600/476;;600/407,4,2,029-051-931-129-754;;017-739-751-563-684,10.1109/iscas.2008.4541802;;21054116;;10.1117/1.3486612;;pmc2966493,"Park et al. Back-Illuminated Ultraviolet Image Sensor in Silicon-on-Sapphire. IEEE International Symposium on Circuits and Systems. p. 1854-1857. 18 May 2008.;;Sun et al . Fluorescence lifetime imaging microscopy for brain tumor image-guided surgery. J Biomed Opt. 15(5):056022-1. Sept 2010.;;Nikzad et al. Delta-doped CCDs for enhanced UV performance. Proc SPIE 2278, X-ray and UV detectors, 138. July 1994.;;Hoenk (âDelta doping Technology for UV Photon Counting Detector Arraysâ, presentation given at the KISS Single Photon Counting Detectors Workshop at California Institute of Technology, Jan. 25-29, 2010)",DISCONTINUED
139,WO,A2,WO 2022/031606 A2,068-621-194-958-152,2022-02-10,2022,US 2021/0044195 W,2021-08-02,US 202063060553 P,2020-08-03,COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE,"Provided herein are compositions and methods that improve cognition in individuals having or at risk of having Alzheimers disease, including familial Alzheimers disease, early-onset Alzheimers disease, and middle to late stage Alzheimers disease.",CEDARS SINAI MEDICAL CENTER;;FORTEM NEUROSCIENCES INC,KORONYO MAYA;;BLACK KEITH L;;KAVANAUGH JACK,,https://lens.org/068-621-194-958-152,Patent Application,yes,0,0,8,8,3,A61P25/28;;A61K31/548;;C12Y201/01;;A61K31/548;;A61P25/28;;A61P25/28;;A61K31/548,A61K31/547,,0,0,,,,PENDING
140,US,B2,US 9764014 B2,033-031-796-593-920,2017-09-19,2017,US 201414247028 A,2014-04-07,US 201414247028 A;;US 99543410 A;;US 2009/0047640 W;;US 7320508 P,2008-06-17,Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors,"Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendritic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;MORRIS-IRVIN DWAIN;;ARDITI MOSHE,CEDARS-SINAI MEDICAL CENTER (2009-06-17),https://lens.org/033-031-796-593-920,Granted Patent,yes,17,0,5,5,0,A61K38/164;;A61K45/06;;C12N5/0639;;A61K2039/55561;;A61K2039/55572;;A61P35/00;;A61P37/04;;A61K39/4615;;A61K2239/38;;A61K2239/47;;A61K39/4622;;A61K2239/31;;A61K39/464499;;A61K35/15;;A61K38/164;;A61K45/06;;C12N5/0639;;A61K2039/5154;;A61K2039/55561;;A61K2039/55572;;A61K39/0011,A61K35/15;;A61K38/16;;A61K39/00;;A61K45/06;;C12N5/0784,,39,29,109-565-213-148-182;;017-762-302-959-224;;012-063-847-650-863;;085-543-991-034-265;;093-871-129-922-741;;022-313-882-423-019;;000-243-131-526-368;;026-180-547-792-932;;023-655-000-432-80X;;007-076-847-610-580;;061-919-090-545-764;;106-515-346-786-167;;127-839-209-175-741;;012-818-574-571-598;;012-122-056-161-104;;146-760-363-257-283;;031-329-299-894-094;;007-502-688-416-455;;052-565-618-877-440;;125-239-346-378-244;;095-718-757-221-788;;041-677-195-849-997;;076-637-532-898-559;;046-847-065-587-168;;092-707-572-319-639;;003-030-356-432-987;;012-946-606-269-104;;067-911-159-686-453;;056-649-998-351-849,17383632;;10.1016/j.ejphar.2007.02.018;;10.1038/ni1223;;15995707;;pmc3760217;;10.1002/ijc.20331;;15252850;;10.1073/pnas.0710145104;;pmc2154458;;18077358;;17290189;;10.1227/01.neu.0000249280.61761.2e;;10.1007/bf00200001;;16906541;;10.1002/glia.20401;;16775224;;10.1215/15228517-2006-008;;pmc1871955;;10.1186/1479-5876-4-15;;16573834;;pmc1501057;;17160140;;pmc1646255;;10.2174/138920206778426951;;17568998;;10.1007/s11060-007-9415-2;;15353342;;10.2741/1465;;10.2174/1568011043352911;;15281907;;3739492;;17013976;;10.1002/eji.200635910;;205357;;18224680;;10.1002/ijc.23366;;10.1097/cji.0b013e318155a0f6;;18049330;;17295916;;10.1186/1479-5876-5-10;;pmc1802742;;16799333;;10.1097/01.cji.0000199199.20717.67;;10.1200/jco.2008.26.15_suppl.11021;;pmc2196048;;10.1084/jem.20020732;;12186845;;18167273;;10.1158/0008-5472.can-03-3505;;15256471;;10.1177/107327480401100307;;15153843;;10.1038/nm1039;;15122249;;10364168;;10.1074/jbc.274.25.17406;;pmc165983;;10.1128/iai.71.8.4238-4249.2003;;12874299;;14520441;;pmc2394324;;10.1038/sj.bjc.6601268,"Garay (European Journal of Pharmacology, 2007, vol. 563, pp. 1-17).;;Napolitani et al, Nature Immunology, 2005, vol. 6, pp. 769-776.;;Saito et al, International Journal of Cancer, vol. 2004, vol. 111, pp. 777-782.;;PCT/US2009/047640 International Search Report dated Aug. 7, 2009.;;Salio et al. Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. PNAS (2007). 104(51): 20490-20495.;;PCT/US2009/047640 Written Opinion dated Aug. 7, 2009.;;PCT/US2009/047640 International Preliminary Report on Patentability dated Dec. 18, 2010.;;PCT/US2009/069437 International Search Report dated Feb. 25, 2010.;;PCT/US2009/069437 Written Opinion dated Feb. 25, 2010.;;PCT/US2009/069437 International Preliminary Report on Patentability dated Jun. 29, 2011.;;Chicoine et al. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by toll-like receptor 4. Neurosurgery (2007) 60(2):372-381.;;De et al. Human glioma tumour-associated antigens. Cancer Immunol Immunother (1980) vol. 9(4):207-211. Abstract Only.;;El Andaloussi et al. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. GLIA (2006) 54:526-535.;;Hussain et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology (2006) pp. 261-279.;;Hussain et al. Innate immune functions of microglia isolated from human glioma patients. Journal of Translational Medicine. (2006) 4(15): 9 pages.;;Iizuka et al. Identification of a new antigen recognized by cytotoxic T lymphocytes specific for glioma. Society for Neuroscience Abstract Viewer and Itinerary Planner. (2003) 2003: Abstract Only.;;Lichtor et al. Antigenic differences between normal and malignant cells as a basis for treatment of intracerebral neoplasms using a DNA-based vaccine. Current Genomics (2006) 7(4):253-261.;;Mariani et al. Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas. J. Neurooncol (2007) 85:231-240.;;Prins et al. Cellular immunity and immunotherapy of brain tumors. Frontiers in Bioscience (2004) 9: 3124-3136.;;Prasad et al. Recent advances in experimental molecular therapeutics for malignant gliomas. Curr Med Chem—Anti-Cancer Agents (2004) 4: 347-361.;;Romodanov et al. Efficacy of experimental active specific immunotherapy and immunoprevention of malignant gliomas of the braina. Zh Vopr Neirokhir Im N N Burdenko (1986) Abstract Only.;;Reizenstein et al. Biological Response to Acute Leukemia. I. Tumor-Associated Antigens and Antigen-Independent Tumor Surveillance. Cancer Treatment Symposia (1985). 1:101-105.;;Scheel et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur. J. Immunol. (2006) 36:2807-2816.;;Tracey et al. Growth of transplanted rat tumors following administration of cell-free tumor antigens. Cancer Research (1978). 38:1208-1212.;;Ueda et al. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. Int. J. Cancer (2008). 122(10). Abstract Only.;;Wu et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. Journal of Immunotherapy (2007) 30(8):789-797.;;Zhu et al. Toll Like Receptor-3 Ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. Journal of Translational Medicine (2007) 5(10): 15 pages.;;Pilon-Thomas et al. Immunostimulatory Effects of CpG-ODN Upon Dendritic Cell-Based Immunotherapy in a Murine Melanoma Model. Journal of Immunotherapy (2006). 29(4):381-387.;;Prines et al. Autologous tumor-lysate pulsed dendritic cell vaccination, together with the TLR-7 agonist 5% imiquimod, and serum pro-inflammatory cytokine levels in glioblastoma patients. Journal of Clinical Oncology (2008). Abstract Only.;;Vicari et al. Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti-Interleukin 10 Receptor Antibody. J. Exp. Med. (2002). 196:541-549.;;You et al. Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity. Zhonghua Yi Xue Za Zhi (2007). 87(39):2785-90. Abstract Only.;;Yu et al. Vaccination with Tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic t-cells in patients with malignant glioma. Cancer Research (2004). 64:4973-4979.;;Moneeb et al. Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control (2004). 11(3): 192-207.;;Figdor et al. Dendritic cell immunotherapy: mapping the way. Nature Medicine (2004). 10(5):475-480.;;Shubina et al. Protective effect of dendritic cells in mice infected by Klebsiella pneumonia. Experimental Immunology (2007). 32:189-195.;;Semenov et al. Cellular and molecular events during introduction of polycomponent bacterial vaccine and infection with Salmonella typhimurium. Molekulyarnaya Meditsina (2005). 4:53-58. Abstract Only.;;Schwandner et al. Peptidoglycan-and Lipoteichoic Acid-induced Cell Activation is Mediated by Toll-Like Receptor 2*. Journal of Biological Chemistry (1999). 274:17406-17409.;;Uehori et al. Simultaneous Blocking of Human Toll-Like Receptors 2 and 4 Suppresses Myeloid Dendritic Cell Activation Induced by Mycobacterium bovis Bacillus Calmette-Guerin Peptidoglycan. Infection and Immunity (2003). 71(8): 4238-4249.;;Yamanaka et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. British Journal of Cancer (2003). 89:1172-1179.",ACTIVE
141,US,B2,US 8097256 B2,085-990-574-364-831,2012-01-17,2012,US 86417707 A,2007-09-28,US 86417707 A;;US 82726006 P,2006-09-28,Cancer vaccines and vaccination methods,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",YU JOHN S;;LIU GENTAO;;BLACK KEITH L;;CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (2009-05-07);;CEDARS-SINAI MEDICAL CENTER (2009-05-11),https://lens.org/085-990-574-364-831,Granted Patent,yes,81,36,17,17,71,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/00;;A61K35/12;;C12P21/00,424/184.1;;424/185.1;;435/70.1,105,99,065-771-990-828-281;;049-915-366-620-516;;032-932-040-924-322;;138-771-752-862-480;;168-705-133-516-75X;;016-059-509-686-365;;029-311-860-898-924;;078-639-700-866-831;;027-915-134-983-264;;022-798-233-953-966;;045-700-919-027-517;;013-855-584-540-778;;057-785-668-031-036;;059-717-731-643-077;;011-954-218-606-176;;092-707-572-319-639;;160-717-493-067-916;;044-555-535-916-468;;090-928-883-705-496;;006-148-652-132-981;;046-986-959-047-056;;096-505-815-317-436;;053-672-692-937-579;;085-702-051-840-908;;003-865-790-341-418;;082-930-667-453-661;;060-861-375-524-523;;012-105-359-936-435;;055-983-972-565-643;;063-225-571-358-608;;124-257-229-162-56X;;097-470-977-075-432;;003-924-024-298-446;;139-500-660-556-55X;;133-716-008-515-719;;010-981-337-785-354;;078-723-209-803-023;;035-823-463-717-575;;071-699-972-336-631;;041-406-340-961-551;;026-304-558-215-155;;075-344-720-447-282;;060-667-322-361-290;;018-117-667-758-278;;108-207-855-841-062;;018-681-549-217-136;;030-955-335-211-791;;022-982-723-684-607;;192-609-714-372-280;;010-628-726-217-388;;076-867-150-716-864;;021-602-438-381-646;;074-416-675-238-759;;096-919-431-021-193;;052-358-709-302-448;;021-056-467-881-097;;032-294-227-563-850;;007-174-971-453-251;;019-264-483-343-031;;011-191-194-524-48X;;011-643-567-958-26X;;044-750-837-062-887;;040-713-726-205-55X;;018-870-261-171-506;;008-169-153-417-267;;049-560-808-242-058;;007-894-661-068-687;;120-862-791-424-707;;153-662-306-900-396;;025-760-264-704-263;;057-002-651-793-17X;;108-599-572-220-595;;019-963-559-470-014;;019-377-086-323-88X;;086-946-791-527-279;;044-084-260-816-039;;003-616-087-027-77X;;053-906-705-994-097;;001-000-221-109-111;;022-705-571-480-334;;139-500-660-556-55X;;026-887-607-952-029;;063-547-669-345-057;;032-969-718-122-323;;065-766-887-494-547;;057-105-231-226-816;;046-028-954-444-037;;065-777-065-691-692;;022-665-264-045-910;;109-735-000-316-284;;014-782-564-302-045;;078-538-820-088-074;;113-598-986-994-212;;128-972-796-335-47X;;034-409-534-864-530;;035-857-332-739-788;;006-884-247-056-538;;032-084-932-733-530;;045-609-027-418-523,10.1200/jco.2010.30.7744;;21149657;;pmc3056467;;10.1006/cimm.1998.1298;;9637766;;11449066;;11265767;;10.1097/00002371-200103000-00004;;10.1586/14737175.5.4.497;;16026233;;15383564;;10.4049/jimmunol.173.7.4352;;10.2741/1747;;15970545;;pmc2241749;;10.4049/jimmunol.174.8.4812;;15814707;;10.1097/00006123-199903000-00110;;10069601;;10.4049/jimmunol.170.4.1822;;12574347;;11196166;;12941147;;10.1046/j.1365-2567.2003.01726.x;;pmc1783031;;10.1227/00006123-199305000-00003;;10.1097/00006123-199305000-00003;;8388081;;10.1093/jnci/85.9.704;;8478956;;17293384;;10.1158/0008-5472.can-06-4038;;11471194;;10.1177/107327480401100307;;15153843;;10914698;;10.1158/0008-5472.can-04-1364;;15466194;;11731436;;10.1007/s002620050465;;9558003;;16397045;;10.1158/1078-0432.ccr-05-1178;;16331615;;10.1002/ijc.21616;;10.1016/s0165-5728(99)00172-1;;10674985;;10.1007/s005950300060;;12707821;;19944974;;10.1016/j.nec.2009.08.006;;pmc2786895;;10.1182/blood.v97.6.1776;;11238120;;17939761;;10.1586/14737175.7.10.1235;;10.1177/107327480301000205;;12712008;;15162438;;10.1002/eji.200425081;;10.2174/157488708783330530;;18474011;;10.1038/nm0697-625;;9176488;;18539965;;10.1200/jco.2007.15.1472;;7774624;;10.1002/eji.1830250511;;8027569;;10.4049/jimmunol.153.3.996;;12109820;;10.1053/clon.2001.0038;;pmc3903051;;10.1007/s00262-007-0426-9;;18057935;;11440627;;10.1089/104303401750270995;;12907622;;9754652;;10.1002/(sici)1097-0215(19981005)78:2<196::aid-ijc13>3.0.co;2-9;;10.1023/a:1024969422010;;10.1007/bf02700016;;12952282;;10.1093/jjco/hye076;;11574635;;10.1093/jnci/94.11.805;;12048268;;pmc1137064;;7519851;;10.1042/bj3010847;;10945499;;10.1054/bjoc.2000.1289;;pmc2374651;;14555310;;10024247;;10.1126/science.283.5405.1183;;10.1038/nm0398-321;;9500606;;pmc2064864;;10.14670/hh-18.435;;12647794;;14522905;;11895781;;10.1182/blood.v99.7.2468;;15312683;;10.1016/j.canlet.2004.04.010;;12209978;;10.1002/ijc.10597;;11606390;;15571138;;12874257;;10.1084/jem.20030422;;pmc2194081;;pmc4030524;;10.1158/1078-0432.ccr-06-1576;;17255279;;10.1016/s0022-1759(02)00142-4;;12135802;;9973437;;12667889;;10.1016/s0163-7258(03)00014-7;;10.1073/pnas.91.3.1004;;pmc521442;;8302824;;11454721;;12616102;;10.1097/00002371-200303000-00003;;1709722;;10.1038/351290a0;;12391241;;10.4049/jimmunol.169.9.5227;;10.1097/00002371-200107000-00008;;11565834;;10728667;;pmc2430890;;10.4049/jimmunol.168.2.951;;11777994;;11676393;;10.1007/s002620100205;;10.1007/s00262-002-0297-z;;12202903;;12222879;;10.1038/nbt947;;15004565;;10350260;;10.3171/jns.1999.90.6.1115;;15076139;;10.1097/00002371-200405000-00006;;17140455;;pmc1697823;;10.1186/1476-4598-5-67;;10.1038/sj.onc.1208519;;15897911;;15256472;;10.1158/0008-5472.can-03-3504;;10.1097/00002371-200307000-00002;;12843792;;10.1586/14760584.5.2.233;;16608423;;9743519;;10.1084/jem.188.6.1005;;pmc2212536;;10.4049/jimmunol.176.3.1796;;16424210;;8027569;;10.4049/jimmunol.153.3.996;;12231526;;9809996;;1476743;;10886507;;10.1046/j.1523-1747.2000.00023.x;;10.1053/pb.2000.6691;;10914414;;7585538;;10.3349/ymj.2004.45.suppl.48;;15250050;;10.1034/j.1600-0463.2003.11107802.x;;12974772;;7690811;;10.1016/j.vaccine.2006.02.025;;16530303;;pmc1850619;;10.1084/jem.184.6.2207;;pmc2211562;;8976176;;18298336;;10.1089/cbr.2007.0427;;10.1016/j.exphem.2006.05.011;;16982333;;18632651;;10.1158/0008-5472.can-07-5973;;10.1158/1078-0432.ccr-04-0497;;15328167;;10.4049/jimmunol.171.9.4927;;14568975;;10754316;;10.4049/jimmunol.164.8.4204;;10.3892/or.16.6.1317;;17089056,"Liu et al, Cancer Res, 64:4980-86, 2004, IDS #:69, Nov. 13, 2009.;;Liu et al (J Immunother, 27:220-6, 2004, IDS #:66, Nov. 13, 2009.;;Yu et al (Cancer Res. 64:4973-79, 2004, IDS #:98 Nov. 13, 2009.;;Okano et al Clin Cancer Res 8:2851-5, 2002, IDS # 75, Nov. 13, 2009.;;Yu et al, Cancer Res. 61:842-847, 2001, IDS #: 97, filed Nov. 23, 2009.;;Okada et al J Clin Oncol 29: 330-336, 2011.;;Abdel-Wahab et al., ""Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity,"" Cell. Immunol., 186:63-74 (1998).;;Akasaki et al., ""Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model,"" J. Immunother., 24:106-113 (2001).;;Akasaki et al., ""Dendritic cell-based immunotherapy for malignant gliomas,"" Expert Rev. Neurother., 5:497-508 (2005).;;Akasaki et al., ""Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma,"" J. Immunol., 173:4352-59 (2004).;;Akasaki et al., ""T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches,"" Front. Biosci., 10:2908-21 (2005).;;Borbulevych et al., ""Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design,"" J. Immunol., 174:4812-20 (2005).;;Bowles, Jr. et al., ""Long-term remission of malignant brain tumors after intracranial infection: a report of four cases,"" Neurosurgery, 44:636-642 (1999).;;Bullock et al., ""Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells,"" J. Immunol., 170:1822-29 (2003).;;Candido et al., ""Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents,"" Cancer Res., 61:228-236 (2001).;;Casey et al., ""Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine,"" Immunology, 110:105-111 (2003).;;Chandler et al., ""Long-term survival in patients with glioblastoma multiforme,"" Neurosurgery, 32:716-720 (1993).;;Curran et al., ""Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials,"" J. Natl. Cancer Inst., 85:704-710 (1993).;;Czerniecki et al., ""Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion,"" Cancer Res., 67:1842-52 (2007).;;Dietz, ""Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia,"" Croatian Med. J., 42:428-435 (2001).;;Ehtesham et al., ""Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials,"" Cancer Control, 11:192-207 (2004).;;Friedman et al., ""Temozolomide and treatment of malignant glioma,"" Clin. Cancer Res., 6:2585-97 (2000).;;Galli et al., ""Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma,"" Cancer Res., 64:7011-21 (2004).;;Geiger et al., ""Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression,"" Cancer Res., 61:8513-19 (2001).;;Gilboa et al., ""Immunotherapy of cancer with dendritic-cell-based vaccines,"" Cancer Immunol. Immunother., 46:82-87 (1998).;;Haas et al., ""Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine,"" Clin. Cancer Res., 12:214-222 (2006).;;Hahn et al., ""Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer,"" Int. J. Cancer, 118:2220-31 (2006).;;Heimberger et al., ""Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma,"" J. Neuroimmunol., 103:16-24 (2000).;;Inoue et al., ""Dendritic cells coinjected with tumor cells treated with an anticancer drug to induce tumor rejection,"" Surg. Today, 33:269-276 (2003).;;Ji et al., ""Glioma stem cell research for the development of immunotherapy,"" Neurosurg. Clin. N. Am., 21:159-66 (2010).;;La Rosa et al., ""Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries,"" Blood, 97:1776-86 (2001).;;Liu and Yu, ""Cancer vaccines: a novel strategy to sensitize malignant glioma to chemotherapy,"" Expert Rev. Neurother., 7:1235-37 (2007).;;Liu et al., ""Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma,"" Cancer Control, 10:138-147 (2003).;;Liu et al., ""Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response,"" Eur. J. Immunol., 34:1680-87 (2004).;;Luptrawan et al., ""Dendritic cell immunotherapy for malignant gliomas,"" Rev. Recent Clin. Trials, 3:10-21 (2008).;;Lynch et al., ""Flt3 ligand induces tumor regression and antitumor immune responses in vivo,"" Nat. Med., 3:625-631 (1997).;;Maitland and Collins, ""Prostate cancer stem cells: a new target for therapy,"" J. Clin. Oncol., 26:2862-70 (2008).;;Mehta-Damani et al., ""Generation of antigen-specific CD4+ T cell lines from naïve precursors,"" Eur. J. Immunol., 5:1206-11 (1995).;;Mehta-Damani et al., ""Generation of antigen-specific CD8+ CTLs from naive precursors,"" J. Immunol., 153:996-1003 (1994).;;Melcher et al., ""Dendritic cells for the immunotherapy of cancer,"" Clin. Oncol., 14:185-192 (2002).;;Merrick et al., ""Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy,"" Cancer Immunol. Immunother., 57:897-906 (2008).;;Mi et al., ""Induced apoptosis supports spread of adenovirus vectors in tumors,"" Hum. Gene Ther., 12:1343-52 (2001).;;Nowak et al., ""Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors,"" Cancer Res., 63:4490-96 (2003).;;Okada et al., ""Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms,"" Int. J. Cancer, 78:196-201 (1998).;;Okada et al., ""Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy,"" J. Neurooncol., 64:13-20 (2003).;;Osada et al., ""Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report,"" Jpn. J. Clin. Oncol., 31:403-406 (2001).;;Parmiani et al., ""Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?"" J. Natl. Cancer Inst., 94:805-818 (2002).;;Pinilla et al., ""Investigation of antigen-antibody interactions using a soluble, non-support-bound synthetic decapeptide library composed of four trillion (4×1012) sequences,"" Biochem. J., 301:847-853 (1994).;;Pirtskhalaishvili et al., ""Cytokine-mediated protection of human dendritic cells from prostate cancer induced apoptosis is regulated by the Bc1-2 family of proteins,"" Br. J. Cancer, 83:506-513 (2000).;;Reichardt et al., ""Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells,"" Haematologica, 88:1139-49 (2003).;;Rissoan et al., ""Reciprocal control of T helper cell and dendritic cell differentiation,"" Science, 283:1183-86 (1999).;;Rosenberg et al , ""Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma,"" Nat. Med., 4:321-327 (1998).;;Shin et al., ""Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model,"" Histol. Histopathol., 18:435-447 (2003).;;Singh et al., ""Identification of a cancer stem cell in human brain tumors,"" Cancer Res., 63:5821-28 (2003).;;Steinbrink et al., ""CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity,"" Blood, 99:2468-76 (2002).;;Takagi et al., ""Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells,"" Cancer Lett., 213:49-55 (2004).;;Tanaka et al., ""Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo,"" Int. J. Cancer, 101:265-269 (2002).;;Tong et al., ""Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors,"" Cancer Res., 61:7530-35 (2001).;;Wheeler et al., ""Cellular immunity in the treatment of brain tumors,"" Clin. Neurosurg., 51:132-139 (2004).;;Yamazaki et al., ""Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells,"" J. Exp. Med., 198:235-247 (2003).;;Zhang et al., ""Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics,"" Clin. Cancer Res., 13:566-575 (2007).;;Borràs et al., ""Findings on T cell specificity revealed by synthetic combinatorial libraries,"" J. Immunol. Methods, 267:79-97 (2002).;;Castelli et al., ""Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens,"" J. Immunol., 162:1739-48 (1999).;;Castro et al., ""Current and future strategies for the treatment of malignant brain tumors,"" Pharmacol. Ther., 98:71-108 (2003).;;Chen et al., ""Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies,"" Proc. Natl. Acad. Sci. USA, 91:1004-08 (1994).;;Debinsky, ""Correspondence re: B. H. Joshi et al., Interluekin-13 Receptor alpha Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas. Cancer Res., 60: 1168-1172, 2000,"" Cancer Res., 61:5660 (2001).;;Ehtesham et al., ""Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats,"" J. Immunother., 26:107-116 (2003).;;Falk et al., ""Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,"" Nature, 351:290-296 (1991).;;Gatza et al., ""Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma,"" J. Immunol., 169:5227-35 (2002).;;Harada et al., ""Melanoma-reactive CD8+T cells recognize a novel tumor antigen expressed in a wide variety of tumor types,"" J. Immunother., 24:323-333 (2001).;;Joshi et al., ""Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas,"" Cancer Res., 60:1168-72 (2000).;;Khong et al., ""Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy,"" J. Immunol, 168:951-956 (2002).;;Kikuchi et al., ""Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells,"" Cancer Immunol. Immumother., 50:337-344 (2002).;;Kikuchi et al., ""Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model,"" Cancer Immunol. Immumother., 51:424-430 (2002).;;Knutson et al., ""Technology evaluation: DCVax, Northwest Biotherapeutics,"" Curr. Opin. Mol. Ther., 4:403-407 (2002).;;Lemmel et al., ""Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling,"" Nat. Biotechnol., 22:450-454 (2004).;;Liau et al., ""Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens,"" J. Neurosurg., 90:1115-24 (1999).;;Liu et al., ""AIM-2: a novel tumor antigen is expressed and presented by human glioma cells,"" J. Immunother., 27:220-226 (2004).;;Liu et al., ""Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma,"" Mol. Cancer, 5:67 (2006).;;Liu et al., ""Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy,"" Oncogene, 24:5226-34 (2005).;;Liu et al., ""HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells,"" Cancer Res., 64:4980-86 (2004).;;Liu et al., ""Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma,"" J. Immunother., 26:301-312 (2003).;;Liu et al., ""Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination,"" Expert Rev. Vaccines, 5:233-247 (2006).;;Lupetti et al., ""Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage,"" J. Exp. Med., 188:1005-16 (1998).;;Lustgarten et al., ""Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope,"" J. Immunol., 176:1796-1805 (2006).;;Mehta-Damani et al., ""Generation of antigen-specific CD8+ CTLs from naive precursors,"" J. Immunol., 153:996-1003 (1994).;;Okano et al., ""Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain,"" Clin. Cancer Res., 8:2851-55 (2002).;;Parkhurst et al., ""Identification of a shared HLA-A *0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2),"" Cancer Res., 58:4895-4901 (1998).;;Pinilla et al., ""Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries,"" Biotechniques, 13:901-905 (1992).;;Pisarra et al., ""Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization,"" J. Invest. Dermatol., 115:48-56 (2000).;;Pollack et al., ""Exploitation of immune mechanisms in the treatment of central nervous system cancer,"" Semin. Pediatr. Neurol., 7:131-143 (2000).;;Salgaller et al., ""Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides,"" Cancer Res., 55:4972-79 (1995).;;Song et al., ""Strategies to improve dendritic cell-based immunotherapy against cancer,"" Yonsei Med. J., 45(Suppl):48-52 (2004).;;Steinman, ""Some interfaces of dendritic cell biology,"" APMIS, 111:675-697 (2003).;;Storkus et al., ""Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes,"" J. Immunol., 151:3719-27 (1993).;;Stupp et al., ""Recent Developments in the Management of Malignant Glioma,"" American Society of Clinical Oncology Educational Book, 779-788 (2003).;;Wang et al., ""An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens,"" Vaccine, 24:3477-89 (2006).;;Wang et al., ""Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes,"" J. Exp. Med., 184:2207-16 (1996).;;Wei et al., ""Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell responses,"" Cancer Biother. Radiopharm., 23:121-128 (2008).;;Weigel et al., ""Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses,"" Exp. Hematol., 34:1403-12 (2006).;;Wheeler et al., ""Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients,"" Cancer Res., 68:5955-64 (2008).;;Wheeler et al., ""Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination,"" Clin. Cancer Res., 10:5316-26 (2004).;;Wheeler et al., ""Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality,"" J. Immunol., 171:4927-33 (2003).;;Yang et al., ""Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3,"" J Immunol., 164:4204-11 (2000).;;Yasuda et al., ""Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells,"" Oncol. Rep., 16:1317-24 (2006).",ACTIVE
142,US,A1,US 2017/0088601 A1,093-109-370-208-814,2017-03-30,2017,US 201615162921 A,2016-05-24,US 201615162921 A;;US 201313826737 A;;US 55294509 A;;US 19071808 P,2008-09-02,CD133 EPITOPES,"An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;BLACK KEITH L;;LIU GENTAO,CEDARS-SINAI MEDICAL CENTER (2010-01-05),https://lens.org/093-109-370-208-814,Patent Application,yes,0,0,13,13,19,A61K39/0011;;C07K7/06;;C07K14/70596;;A61P35/00;;A61P37/04;;A61K39/0011;;C07K7/06;;C07K14/70596;;A61K45/06,A61K39/00;;C07K14/705,,0,0,,,,DISCONTINUED
143,US,A1,US 2020/0206304 A1,100-023-189-353-712,2020-07-02,2020,US 202016815760 A,2020-03-11,US 202016815760 A;;US 2018/0053873 W;;US 201762566813 P;;US 201962818890 P,2017-10-02,METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY THROUGH MULTIPLE BIO BARRIERS,"Mini nanodrugs that include a polymalic-based molecular scaffold with one or more peptides capable of crossing the blood-brain barrier, one or more plaque-binding peptides and one or more therapeutic agents attached to the scaffold are provided. Methods of treating brain diseases or abnormal conditions, and imaging of the same in a subject by administering the mini nanodrugs are described. Methods for reducing formation of amyloid plaques in the brain of a subject are disclosed.",CEDARS SINAI MEDICAL CENTER,HOLLER EGGEHARD;;LJUBIMOVA JULIA Y;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2020-03-03),https://lens.org/100-023-189-353-712,Patent Application,yes,0,4,1,6,15,A61K38/08;;A61K38/10;;A61K47/593;;A61K47/60;;A61K47/64;;A61K47/6811;;A61K47/6811;;A61K47/6849;;A61K47/6883;;A61K49/14;;A61P25/28;;A61P25/28;;A61P35/00;;A61P35/00;;B82Y5/00;;C12N15/111;;C12N15/1137;;C12N2310/11;;C12N2320/32,A61K38/10;;A61K47/60;;A61K47/64;;A61K47/68;;A61K49/14;;A61P25/28;;A61P35/00;;C12N15/113,,0,0,,,,DISCONTINUED
144,CA,A1,CA 2324795 A1,181-677-767-810-69X,2002-04-25,2002,CA 2324795 A,2000-10-25,CA 2324795 A,2000-10-25,INSERTED LASER WELDED BLANKS,,POWERLASERS LTD,BLACK GARY KEITH;;MORRIS BRIAN;;STAPLES MICHAEL JAMES,,https://lens.org/181-677-767-810-69X,Patent Application,no,0,1,2,2,0,B23K26/244;;B23K2101/185,B23K26/044;;B23K26/00;;B23K26/24,,0,0,,,,EXPIRED
145,EP,A2,EP 2611288 A2,037-513-201-516-422,2013-07-10,2013,EP 11822431 A,2011-08-29,US 37854610 P;;US 2011/0049544 W,2010-08-31,BED BUG MONITORING DEVICE,,FMC CORP,BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,,https://lens.org/037-513-201-516-422,Patent Application,yes,0,0,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00,,0,0,,,,DISCONTINUED
146,US,A1,US 2013/0219771 A1,034-728-457-572-937,2013-08-29,2013,US 201113819358 A,2011-08-29,US 201113819358 A;;US 37854610 P;;US 2011/0049544 W,2010-08-31,Bed Bug Monitoring Device,The invention is directed to a bed bug monitoring device comprising a bed bug attractant element and a harborage section comprising a support member having a traversable surface and one or more protuberances depending therefrom. The harborage defines at least one entrance through which bed bugs attracted to the device can enter. The device can further include a base section placed over at least a portion of the traversable surface and adapted to by placed flush with the surface against which the device is to be placed.,BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH;;FMC CORP,BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,FMC CORPORATION (2013-03-08),https://lens.org/034-728-457-572-937,Patent Application,yes,7,21,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,A01M1/10;;A01M1/14,43/114;;43/123;;43/132.1,0,0,,,,DISCONTINUED
147,EP,A2,EP 2328923 A2,116-772-941-657-175,2011-06-08,2011,EP 09812172 A,2009-09-02,US 2009/0055759 W;;US 19071808 P,2008-09-02,CD133 EPITOPES,,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,,https://lens.org/116-772-941-657-175,Patent Application,yes,0,3,13,13,19,A61K39/0011;;A61K39/0011;;A61K45/06;;A61P35/00;;A61P37/04;;C07K14/70596;;C07K14/70596;;C07K7/06;;C07K7/06,C07K14/705;;A61K39/00;;A61P35/00;;C07K7/06,,0,0,,,,ACTIVE
148,PL,T3,PL 2328923 T3,165-078-543-478-427,2016-06-30,2016,PL 09812172 T,2009-09-02,US 19071808 P;;EP 09812172 A;;US 2009/0055759 W,2008-09-02,CD133 EPITOPES,,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,,https://lens.org/165-078-543-478-427,Patent Application,no,0,0,13,13,0,A61K39/0011;;A61K39/0011;;A61K45/06;;A61P35/00;;A61P37/04;;C07K14/70596;;C07K14/70596;;C07K7/06;;C07K7/06,C07K14/705;;A61K39/00;;A61P35/00;;C07K7/06,,0,0,,,,PENDING
149,WO,A2,WO 2012/030717 A2,021-832-696-571-497,2012-03-08,2012,US 2011/0049544 W,2011-08-29,US 37854610 P,2010-08-31,BED BUG MONITORING DEVICE,The invention is directed to a bed bug monitoring device comprising a bed bug attractant element and a harborage section comprising a support member having a traversable surface and one or more protuberances depending therefrom. The harborage defines at least one entrance through which bed bugs attracted to the device can enter. The device can further include a base section placed over at least a portion of the traversable surface and adapted to by placed flush with the surface against which the device is to be placed.,FMC CORP;;BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,,https://lens.org/021-832-696-571-497,Patent Application,yes,0,3,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,A01M1/02;;A01M1/00;;A01M1/14;;C09J201/00,,0,0,,,,PENDING
150,US,B2,US 9433667 B2,113-761-232-322-96X,2016-09-06,2016,US 201113327125 A,2011-12-15,US 201113327125 A;;US 86417707 A;;US 82726006 P,2006-09-28,Cancer vaccines and vaccination methods,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",YU JOHN S;;LIU GENTAO;;BLACK KEITH L;;CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (2009-05-07);;CEDARS-SINAI MEDICAL CENTER (2012-04-24),https://lens.org/113-761-232-322-96X,Granted Patent,yes,103,3,17,17,71,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/00;;A61K35/12;;C12N5/0784,,102,84,080-647-403-540-300;;046-847-065-587-168;;019-963-559-470-014;;084-085-138-348-898;;064-388-641-569-789;;097-167-161-561-41X;;006-027-796-241-692;;077-678-786-447-085;;025-457-637-309-732;;101-169-326-244-167;;042-796-720-165-197;;043-164-984-018-36X;;028-167-813-228-119;;004-397-008-209-727;;054-439-756-152-283;;165-292-111-716-265;;068-473-895-492-963;;006-885-984-877-437;;043-357-937-051-619;;017-862-373-044-791;;046-010-966-436-821;;116-248-902-411-147;;047-903-330-676-744;;054-045-955-566-76X;;077-262-310-785-629;;078-642-510-799-292;;100-984-968-676-329;;033-662-847-189-276;;028-211-379-291-005;;096-830-349-650-74X;;096-741-767-207-949;;039-376-070-403-51X;;026-219-340-070-989;;039-936-793-486-518;;000-347-673-674-126;;022-618-370-567-630;;043-498-574-177-034;;035-444-720-129-695;;035-033-143-909-694;;074-128-014-644-585;;009-782-141-099-662;;004-045-625-151-197;;054-484-357-087-819;;030-031-127-445-729;;071-463-964-030-172;;157-642-321-785-08X;;002-637-847-823-805;;099-464-580-091-161;;038-241-086-015-47X;;061-756-489-300-343;;081-222-505-017-37X;;049-537-999-449-717;;035-263-789-910-604;;012-638-135-148-028;;093-530-607-257-147;;003-646-738-432-814;;053-393-265-065-68X;;049-915-366-620-516;;032-932-040-924-322;;138-771-752-862-480;;168-705-133-516-75X;;016-059-509-686-365;;029-311-860-898-924;;032-294-227-563-850;;078-639-700-866-831;;027-915-134-983-264;;022-798-233-953-966;;045-700-919-027-517;;007-174-971-453-251;;019-264-483-343-031;;013-855-584-540-778;;011-191-194-524-48X;;062-108-416-505-04X;;057-785-668-031-036;;059-717-731-643-077;;011-643-567-958-26X;;011-954-218-606-176;;044-750-837-062-887;;092-707-572-319-639;;040-713-726-205-55X;;160-717-493-067-916;;044-555-535-916-468;;018-870-261-171-506;;090-928-883-705-496,11221866;;10.1158/0008-5472.can-03-3505;;15256471;;15076139;;10.1097/00002371-200405000-00006;;10.1073/pnas.0530291100;;pmc153034;;12629218;;18665745;;10.1158/0008-5472.can-06-4180;;17483311;;10.1038/nrc1740;;16327766;;18539956;;10.1200/jco.2008.17.7436;;19903840;;pmc2789196;;10.1158/0008-5472.can-09-2687;;10.1016/j.neuron.2009.08.038;;pmc2789107;;19840551;;10.1073/pnas.142298299;;pmc125045;;12114532;;9841453;;10.1126/science.282.5391.1061;;11239426;;10.1016/s0896-6273(01)00209-4;;17412894;;10.1634/stemcells.2006-0624;;10.1189/jlb.1002483;;12773508;;pmc299944;;14645703;;10.1073/pnas.2036535100;;pmc521140;;10.1073/pnas.0400067101;;15381773;;12832694;;10.1634/stemcells.21-4-405;;pmc1782333;;16836618;;10.1111/j.1365-2567.2006.02412.x;;15908947;;pmc2377345;;10.1038/nn1473;;15277692;;10.1634/stemcells.22-4-448;;10.1002/path.2283;;18067118;;17307142;;10.1016/j.bbrc.2007.01.159;;17122772;;10.1038/nature05372;;10.1007/978-1-59745-280-9_15;;19582431;;17079441;;10.1158/0008-5472.can-06-2048;;10.1038/35102167;;11689955;;1553558;;10.1126/science.1553558;;1432110;;10.1523/jneurosci.12-11-04565.1992;;pmc6575989;;16120861;;10.1056/nejmra043666;;15378086;;10.1038/sj.onc.1207946;;10.1038/nature03128;;15549107;;17024127;;pmc2360579;;10.1038/sj.bjc.6603369;;10.1095/biolreprod57.3.561;;9282991;;10.3171/foc.2006.20.4.17;;16709033;;10.1186/1476-4598-3-25;;15469606;;pmc524518;;18535153;;10.1634/stemcells.2008-0078;;17077937;;10.1007/s11060-006-9265-3;;18787206;;10.1634/stemcells.2008-0459;;10.1089/scd.2007.0063;;18230026;;10.1182/blood.v90.12.5002.5002_5002_5012;;9389720;;10.1182/blood.v90.12.5002;;12042327;;10.1074/jbc.m202349200;;10.1200/jco.2007.15.5465;;18539969;;11533706;;10.1038/nm0901-1028;;10.1002/jcp.21541;;18651561;;10.1158/1078-0432.ccr-09-1322;;20068073;;pmc3682507;;18245488;;10.1158/0008-5472.can-07-0445;;10.4049/jimmunol.164.2.861;;10623833;;9743339;;10.1126/science.1135308;;17185560;;12717023;;10.1110/ps.0239403;;pmc2323871;;12640097;;10.1097/01.mp.0000056981.16578.c3;;10.4049/jimmunol.157.6.2539;;8805655;;3276675;;10.1016/s0021-9258(19)77935-6;;18542072;;10.1038/sj.bjc.6604437;;pmc2453027;;8617954;;17540729;;10.1073/pnas.0608635104;;pmc1885220;;10.1006/cimm.1998.1298;;9637766;;11449066;;11265767;;10.1097/00002371-200103000-00004;;10.1586/14737175.5.4.497;;16026233;;15383564;;10.4049/jimmunol.173.7.4352;;10.2741/1747;;15970545;;pmc2241749;;10.4049/jimmunol.174.8.4812;;15814707;;10.1016/s0022-1759(02)00142-4;;12135802;;10.1097/00006123-199903000-00110;;10069601;;10.4049/jimmunol.170.4.1822;;12574347;;11196166;;12941147;;10.1046/j.1365-2567.2003.01726.x;;pmc1783031;;9973437;;12667889;;10.1016/s0163-7258(03)00014-7;;10.1227/00006123-199305000-00003;;10.1097/00006123-199305000-00003;;8388081;;10.1073/pnas.91.3.1004;;pmc521442;;8302824;;10.3727/096368909x12483162196962;;19523342;;10.1093/jnci/85.9.704;;8478956;;17293384;;10.1158/0008-5472.can-06-4038;;11454721;;11471194;;12616102;;10.1097/00002371-200303000-00003;;10.1177/107327480401100307;;15153843;;1709722;;10.1038/351290a0;;10914698;;10.1158/0008-5472.can-04-1364;;15466194;;12391241;;10.4049/jimmunol.169.9.5227;;11731436,"Yu et al Cancer Res. 61:842-847, 2001, Yu 2001.;;Yu et al , Cancer Res. 64:4973-79, 2004, Yu 2004.;;Liu et al J Immunother 27:220-226, 2004.;;Al-Hajj et al., ""Prospective identification of tumorigenic breast cancer cells,"" Proc. Natl. Acad. Sci. USA, 7:3983-88 (2003).;;Altaner, ""Glioblastoma and stem cells,"" Neoplasma, 55:369-374 (2008).;;Beier et al., ""CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles,"" Cancer Res., 67:4010-15 (2007).;;Bjerkvig et al., ""Opinion: the origin of the cancer stem cell: current controversies and new insights,"" Nat. Rev. Cancer, 11:899-904 (2005).;;Boman et al., ""Cancer stem cells: a step toward the cure,"" J. Clin. Oncol., 26:2795-99 (2008).;;Brown et al., ""Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells,"" Cancer Res., 69:8886-93 (2009).;;Carpentier et al., Neuron, 64: 79-92 (2009).;;Drukker et al., ""Characterization of the expression of MHC proteins in human embryonic stem cells,"" Proc. Natl. Acad. Sci. USA, 99:9864-69 (2002).;;Communication for Application No. EP 07843269.7, dated Feb. 2, 2011, 9 pages.;;Gearhart, Science, 282: 1061-1062 (1998).;;Geschwind et al., ""A genetic analysis of neural progenitor differentiation,"" Neuron, 2:325-39 (2001).;;Ghods et al., ""Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells,"" Stem Cells, 7:1645-53 (2007).;;Harizi et al., ""Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subytpes,"" J. Leukocyte Biol., 73:756-763 (2003).;;Hemmati et al., ""Cancerous stem cells can arise from pediatric brain tumors,"" Proc. Natl. Acad. Sci. USA, 25:15178-83 (2003).;;Hirschmann-Jax et al., ""A distinct 'side population' of cells with high drug efflux capacity in human tumor cells,"" Proc. Natl. Acad. Sci. USA, 39:14228-33 (2004).;;Hori et al., ""Neural progenitor cells lack immunogenecity and resist destruction as allografts,"" Stem Cells, 21:405-416 (2003).;;International Search Report and Written Opinion of the International Searching Authority for PCT/US2007/79600, mailed on Mar. 27, 2008, 10 pages.;;International Search Report and Written Opinion; PCT/US2014/16562; Jun. 3, 2014; 37 pp.;;International Search Report and Written Opinion; PCT/US2014/16610; Jun. 5, 2014; 24 pp.;;Koch et al., ""Immune-privileged embryonic Swiss mouse STO and STO cell-derived progenitor cells: major histocompatibility complex and cell differentiation antigen expression patterns resemble those of human embryonic stem cell lines,"" Immunology, 119:98-115 (2006).;;Lee et al., ""Isolation of neural stem cells from the postnatal cerebellum,"" Nat. Neurosci., 6:723-729 (2005).;;Li et al., ""Human embryonic stem cells possess immune-privileged properties,"" Stem Cells, 22:448-456 (2004).;;Mizrak et al., ""CD133: molecule of the moment,"" J. Pathol., 214:3-9 (2008).;;Neuzil et al., ""Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?"" Biochem. Biophys. Res. Commun., 355:855-859 (2007).;;O'Brien et al., ""A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,"" Nature, 7123:106-110 (2007).;;Pellegatta et al., ""Dendritic cell vaccines for cancer stem cells,"" Methods Mol. Biol., 568:233-247 (2009).;;Pellegatta et al., ""Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas,"" Cancer Res., 66:10247-52 (2006).;;Reya et al., ""Stem cells, cancer, and cancer stem cells,"" Nature, 6859:105-111 (2001).;;Reynolds and Weiss, ""Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system,"" Science, 5052:1707-10 (1992).;;Reynolds et al, ""A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes,"" J. Neurosci., 11:4565-74 (1992).;;Sanai et al., ""Neural stem cells and the origin of gliomas,"" N. Eng. J. Med., 8:811-822 (2005).;;Singh et al., ""Cancer stem cells in nervous tumors,"" Oncogene, 23:7267-73 (2004).;;Singh et al., ""Identification of human brain tumor initiating cells"", Nature, 7015:396-401 (2004).;;Steele et al., ""The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens,"" Br. J. Cancer 95:1202-11 (2006).;;Tian et al., ""Expression of immunoglobulin superfamily cell adhesion molecules on murine embryonic stem cells,"" Biol. Reprod., 57:561-568 (1997).;;Tunici et al., ""Brain tumor stem cells: new targets for clinical treatments?"" Neurosurg. Focus, 4:E27 (2006).;;Tunici et al., ""Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma,"" Mol. Cancer, 3:25 (2004).;;Wu et al., ""Embryonic stem cells and their differentiated derivatives have fragile immune privilege but still represent novel targets of immune attack,"" Stem Cells, 26:1939-50 (2008).;;Wu et al., ""Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy,"" J. Neurooncol., 83:121-131 (2007).;;Xu et al., ""Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas,"" Stem Cells, 26:3018-26 (2008).;;Yamanaka et al.; 2003; British J. Can. vol. 89: 1172-79 (0006002).;;Yin et al., ""Expression and regulation of major histocompatibility complex on neural stem cells and their lineages,"" Stem Cells Dev., 17:53-65 (2008).;;Yin et al., ""AC133, a novel marker for human hematopoietic stem and progenitor cells,"" Blood, 12:5002-12 (1997).;;Yu et al., ""AC133-2, a novel isoform of human AC133 stem cell antigen,"" J. Biol. Chem., 23:20711-16 (2002).;;Zabierowski and Herlyn, ""Melanoma stem cells: the dark seed of melanoma,"" J. Clin. Oncol., 26:2890-94 (2008).;;Zhou et al., ""The ABC transporter Berp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype,"" Nat. Med., 9:1028-34 (2001).;;Zou et al., ""Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver,"" J. Cell. Physiol., 217:598-604 (2008).;;Ahmed et al.; ""HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors""; Clin Cancer Res.; 16(2); 474-85.;;European Patent Office Communication for European Application No. 09812172.6, mailed May 23, 2012, 5 pages.;;Garcia-Hernandez et al., ""Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in the Absence of Autoimmunity"", Cancer Res., vol. 68, No. 3, (2008), pp. 861-869.;;Hemmer et al., ""Contribution of Individual Amino Acids Within MHC Molecule or Antigenic Peptide to TCR Ligand Potency,"" J. Immunol., 164:861-871 (2000).;;International Preliminary Report on Patentability for App. Ser. No. PCT/US2010/034082, mailed Nov. 17, 2011, 5 pages.;;International Preliminary Report on Patentability of International Application No. PCT/US2009/055759, issued Mar. 8, 2011 (mailed Mar. 17, 2011), 7 pages.;;International Search Report and Written Opinion of International Application No. PCT/US2009/055759, mailed Jun. 28, 2010, 12 pages.;;International Search Report and Written Opinion of International Application No. PCT/US2010/034082, mailed Feb. 22, 2011, 9 pages.;;Kalinski et al., ""Prostaglandin E2 induces the final maturation of IL-12 deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation,"" J. Immunol, 161:2804-09 (1998).;;Kimchi-Sarfaty et al., ""A ""Silent"" Polymorphism in the MDR1 Gene Changes Substrate Specificity"", Science, vol. 315, (2007), pp. 525-528 (Erratum, 1 page).;;NCBI GenBank Accession No. NM-006017 (Jul. 13, 2008), 5 pages.;;Nielsen et al., ""Reliable prediction of T-cell epitopes using neural networks with novel sequence representations,"" Protein Sci., 12:1007-1017 (2003).;;Ordonez et al.; ""Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma""; Mod. Pathol., Mar. 2003; vol. 16, No. 3, pp. 192-197.;;Parkhurst et al., ""Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues,"" J. Immunol., 157:2539-2548 (1996).;;Posnett et al., ""A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain,"" J. Biol. Chem., 263:1719-25 (1988).;;Smith et al., ""CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers,"" Br. J. Cancer, 99:100-109 (2008).;;USPTO Final Office Action in U.S. Appl. No. 12/552,945, mailed Aug. 16, 2012, 13 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 12/552,945, mailed Mar. 12, 2012, 20 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 12/776,200, mailed Apr. 18, 2012, 10 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 12/776,200, mailed Aug. 7, 2012, 14 pages.;;USPTO Final Office Action in U.S. Appl. No. 13/365,666, mailed Oct. 6, 2014, 14 pages.;;USPTO Final Office Action in U.S. Appl. No. 12/552,945, mailed Oct. 22, 2014, 27 pages.;;Van Der Burg et al., ""Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability"", J. Immunol., 156:3308-3314 (1996).;;Zhang et al., ""Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization,"" PNAS 24:10193-10198 (2007).;;USPTO Non-Final Office Action in U.S. Appl. No. 13/828,432, mailed Dec. 1, 2014 (12 pages).;;Abdel-Wahab et al., ""Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T cell cultures with similar phonotype and lytic activity,"" Cell. Immunol., 186:63-74 (1998).;;Akasaki et al., ""Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model,"" J. Immunother., 24:106-113 (2001).;;Akasaki et al., ""Dendritic cell-based immunotherapy for malignant gliomas,"" Expert Rev. Neurother., 5:497-508 (2005).;;Akasaki et al., ""Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma,"" J. Immunol., 173:4352-59 (2004).;;Akasaki et al., ""T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches,"" Front. Biosci., 10:2908-21 (2005).;;Borbulevych et al., ""Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design,"" J. Immunol., 174:4812-20 (2005).;;Borras et al., ""Findings on T cell specificity revealed by synthetic combinatorial libraries,"" J. Immunol. Methods, 267:79-97 (2002).;;Bowles, Jr. et al., ""Long-term remission of malignant brain tumors after intracranial infection: a report of four cases,"" Neurosurgery, 44:636-642 (1999).;;Bullock et al., ""Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells,"" J. Immunol., 170:1822-29 (2003).;;Candido et al., ""Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents,"" Cancer Res., 61:228-236 (2001).;;Casey et al., ""Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine,"" Immunology, 110:105-111 (2003).;;Castelli et al., ""Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens,"" J. Immunol., 162:1739-48 (1999).;;Castro et al., ""Current and future strategies for the treatment of malignant brain tumors,"" Pharmacol. Ther., 98:71-108 (2003).;;Chandler et al., ""Long-term survival in patients with glioblastoma multiforme,"" Neurosurgery, 32:716-720 (1993).;;Chen et al., ""Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies,"" Proc. Natl. Acad. Sci. USA, 91:1004-08 (1994).;;Cho et al., ""Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas,"" Cell Transplant., 18:977-983 (2009).;;Curran et al., ""Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials,"" J. Natl. Cancer Inst., 85:704-710 (1993).;;Czerniecki et al., ""Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion,"" Cancer Res., 67:1842-52 (2007).;;Debinsky, ""Correspondence re: B. H. Joshi et al., Interluekin-13 Receptor alpha Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas. Cancer Res., 60: 1168-1172, 2000,"" Cancer Res., 61:5660 (2001).;;Dietz, ""Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia,"" Croatian Med. J., 42:428-435 (2001).;;Ehtesham et al., ""Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats,"" J. Immunother., 26:107-116 (2003).;;Ehtesham et al., ""Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials,"" Cancer Control, 11:192-207 (2004).;;Falk et al., ""Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,"" Nature, 351:290-296 (1991).;;Friedman et al., ""Temozolomide and treatment of malignant glioma,"" Clin. Cancer Res., 6:2585-97 (2000).;;Galli et al., ""Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma,"" Cancer Res., 64:7011-21 (2004).;;Gatza et al., ""Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma,"" J. Immunol., 169:5227-35 (2002).;;Geiger et al., ""Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression,"" Cancer Res., 61:8513-19 (2001).",ACTIVE
151,US,B2,US 8911717 B2,159-886-153-339-251,2014-12-16,2014,US 201314031561 A,2013-09-19,US 201314031561 A;;US 201113097364 A;;US 58099907 A;;US 2004/0040660 W;;US 52733003 P,2003-12-05,Polymalic acid-based multifunctional drug delivery system,"A drug delivery system for delivering a drug payload to a specific tissue or cell type is disclosed. The system includes a polymalic acid molecular scaffold which can be used for attaching a plurality of molecular modules. Molecular modules include targeting antibodies for promoting cellular uptake by a target cell, and pro-drugs for altering cellular metabolism, for example, a pro-drug that alters expression of protein kinase CK2.",CEDARS SINAI MEDICAL CENTER;;ARROGENE NANOTECHNOLOGY INC,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,ARROGENE NANOTECHNOLOGY INC (2014-07-24);;CEDARS-SINAI MEDICAL CENTER (2014-07-24);;ARROGENE INC (2017-05-24),https://lens.org/159-886-153-339-251,Granted Patent,yes,8,2,2,14,5,A61K47/60;;A61K47/60;;A61K47/593;;A61K47/593;;A61K47/6883;;A61K47/6883;;A61P35/00,A61K47/48;;A61P35/00;;C08F8/30,424/78.17;;525/54.1;;525/54.2,80,74,027-767-565-745-071;;010-586-072-524-473;;132-372-225-925-009;;120-057-020-523-828;;074-117-757-519-423;;069-764-206-551-021;;010-084-423-107-920;;002-410-830-739-846;;053-390-613-704-481;;022-962-759-811-219;;027-327-439-480-050;;101-523-476-724-00X;;005-068-515-810-831;;019-068-052-192-616;;081-535-546-606-522;;048-551-084-856-415;;043-263-823-749-982;;033-337-348-972-822;;012-529-188-555-935;;070-217-550-786-105;;084-804-379-761-825;;016-130-071-571-991;;091-843-097-683-406;;007-736-347-486-414;;067-176-202-940-165;;122-563-304-750-445;;121-705-764-271-79X;;085-389-958-075-222;;145-523-027-249-174;;001-280-492-710-987;;021-383-028-538-332;;092-704-236-824-35X;;041-096-604-932-631;;094-717-970-788-379;;021-138-842-966-383;;050-185-841-748-492;;143-247-059-865-683;;100-392-131-292-623;;016-795-130-437-95X;;036-550-119-702-468;;125-704-838-833-312;;065-513-307-731-185;;058-546-248-134-723;;053-130-150-863-097;;031-009-176-924-174;;004-329-899-218-795;;040-861-043-363-027;;016-276-524-241-605;;002-057-097-140-560;;015-845-411-216-05X;;071-446-219-522-092;;122-990-056-888-627;;061-454-537-963-94X;;027-518-915-267-472;;004-569-967-691-895;;044-914-849-410-277;;087-365-800-456-427;;160-788-201-223-007;;056-318-394-213-772;;010-800-681-313-086;;080-676-605-062-549;;089-207-455-463-763;;101-937-544-377-16X;;013-753-717-969-918;;114-357-812-206-334;;030-769-003-988-749;;114-097-940-181-735;;037-478-719-421-857;;159-835-915-641-650;;116-305-745-084-880;;025-444-780-060-105;;065-084-770-968-763;;010-713-998-880-948;;030-564-677-109-748,10.1007/s11010-005-3077-1;;16342410;;10.1016/s0928-0987(97)00069-9;;16256709;;2438036;;10.1200/jco.2001.19.8.2189;;11304771;;10688605;;10807948;;10.1016/s0006-2952(00)00310-5;;10.1021/bm0300608;;14715019;;10.1002/1097-0029(20001101)51:3<280::aid-jemt7>3.0.co;2-o;;11054877;;11751392;;10991985;;10.1016/j.jconrel.2003.06.001;;14636717;;10.1002/(sici)1097-0177(200006)218:2<213::aid-dvdy1>3.0.co;2-r;;10842354;;pmc102580;;10648777;;10.1093/nar/28.4.868;;12489851;;10.1074/jbc.m010155200;;11278628;;12454288;;pmc138567;;10.1073/pnas.252649399;;10.1016/s0006-291x(02)02642-6;;12445830;;10.1002/ijc.10233;;11920587;;10.1016/s0140-6736(00)03207-4;;11095261;;10845554;;10.1023/a:1006760632766;;14578463;;2937447;;10.1021/bi00350a005;;10.1002/(sici)1097-0215(19980316)75:6<864::aid-ijc8>3.0.co;2-t;;9506531;;11223987;;10.1038/sj.gt.3301327;;11156378;;10658911;;10.1038/modpathol.3880010;;10.1073/pnas.97.17.9591;;pmc16909;;10944225;;10554005;;7723285;;11454714;;10.1016/s1359-6349(04)80616-5;;10066093;;10.1023/a:1006150506789;;10.1083/jcb.200302126;;12741393;;pmc2172901;;10.1083/jcb.jcb.200302126;;2072663;;10.1083/jcb.137.3.685;;9151674;;pmc2139892;;10.1016/s0076-6879(01)40429-0;;11494857;;12083850;;10.1016/s1044-579x(02)00023-8;;10.1177/002215540205000813;;12133914;;10506168;;10.1074/jbc.274.41.29130;;10.1002/(sici)1098-2388(199801/02)14:1<3::aid-ssu2>3.0.co;2-f;;9407626;;11106372;;10.1073/pnas.250332397;;pmc18983;;10.1083/jcb.153.5.933;;pmc2174323;;11381080;;9212909;;10.1089/oli.1.1997.7.187;;9325016;;10.1006/cyto.1997.0212;;pmc134646;;11809810;;10.1128/mcb.22.4.1194-1202.2002;;10.1023/a:1014573204062;;11964076;;6501412;;pmc2113570;;10.1083/jcb.99.6.2034;;11813879;;10.14670/hh-17.301;;10652480;;10.1016/s1357-4310(99)01638-x;;8622906;;pmc39574;;10.1073/pnas.93.8.3161;;pmc3487708;;17109197;;10.1007/s10456-006-9046-9;;10.1017/cbo9780511546402.025;;10.1038/sj.gt.3302507;;15759014;;10.1017/cbo9780511546402.030;;10.1016/s0169-409x(00)00139-3;;11259843;;10.1021/js9800836;;9811482;;10.1006/exnr.1996.0178;;8912898;;10416675;;10.1016/s0141-8130(99)00042-2;;2765532;;10.1021/bi00438a045;;9855188;;10.1016/s0142-9612(98)00095-7;;10840193;;10.1016/s0939-6411(00)00075-8;;10.1139/m95-187;;10.1021/bc980123x;;10346884;;10.1007/s002530051445;;11733118;;10.1016/s0169-409x(01)00221-6;;12564977;;10.1016/s0169-409x(02)00179-5;;10.1021/bc990039x;;10502354;;pmc16586;;10840060;;10.1073/pnas.130187497;;7508268;;10.1021/bc00024a015;;10.1124/pr.54.4.561;;12429868;;12095305;;10.1006/mthe.2002.0633;;16146715;;10.2741/1781;;pmc3506377;;10.1002/(sici)1097-0215(19980330)76:1<63::aid-ijc11>3.0.co;2-h;;9533763;;pmc2913688;;10.1007/s11010-008-9831-4;;18612802,"Lee et al., Delivery of antisense oligonucleotides and transferrin receptor antibody in vitro and in vivo using a new multifunctional drug delivery system based on polymalic acid, Proceedings of The American Association for Cancer Research Annual Meeting, vol. 45, Mar. 2004, pp. 149-150.;;Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K. Downregulation of CK2 induces apoptosis in cancer cells-a potential approach to cancer therapy. Molecular and cellular biochemistry, 274:77-84, 2005.;;Abdellaoui et al. Metabolite-derived Artificial Polymers Designed for Drug Targeting, Cell Penetration and Bioresorption, European Journal of Pharmaceutical Sciences, vol. 6, No. 1 (1998), pp. 61-73.;;Albini et al. A rapid in Vitro Assay for Quantitating the Invasive Potentia of Tumor Cells, Cancer Research, (Jun. 15, 1997), pp. 3239-3245, 47(12).;;Andrews et al. Resultes of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-like Growth Factor Type I Receptor in Malignant Astrocytomas, Journal of Clinical Oncology, (Apr. 15, 2001), pp. 2189-2200, 19(8).;;Arora et al. c-Myc Antisense Limits Rat Liver Regeneration and Indicates Role for c-Myc in Regulating Cytochrome P-450 3A Activity, Kournal of Pharmacology and Experimental Therapeutics, (Mar. 2009), pp. 921-928, 292(3).;;Astriab-Fisher et al. Antisense Inhibition of P-Glycoprotein Expression Using Peptide-Oligonucleotide Conjugates, Biochemical Pharmacology (Jul. 1, 200), pp. 83-90, 60(1), (2000).;;Barbosa et al. Investigation of the Degradation Mechanism of Poly(malic acid) Esters in Vitro and their Related Cytotoxicities on J774 Macrophages, Biomacromolecules 2004, vol. 5, No. 1, pp. 137-143.;;Belkin et al. Integrins as Receptors for Laminins, Microscopy Research and Technique, (Nov. 1, 2000), pp. 280-301, 51(3).;;Beello et al. Simultaneous Inhibition of Glioma Angiogenesis, Cell Proliferation, and Invasion by a Naturally Occurring Fragment of Human Metalloproteinase-2, Cancer Research, (Dec. 15, 2001), pp. 8730-8736, 61(24).;;Boardo et al. Antisense-Mediated Down-Regulation of the Human Huntingtin Gene, Journal of Pharmacology and Experimental Therapy, (Oct. 200), pp. 239-243, 295(1), (2000).;;Bulmus et al., A new pH-Responsive and Glutathione-reactive Endosomal Membrane-disruptive Polymeric Carrier for Intracellular Delivery of Biomolecular Drugs, Journal of Controlled Release, (2003), 93: 105-120.;;Colognato et al., Form and Function: The Laminin Family of Heterotrimers, Developmental Dynamics, (Jun. 2000), pp. 213-234, 218(2).;;De Diesbach et al.,Identification, Purification and Partial Charaterozation of an Oligonucleotide Receptor in Membranes of HepG3 Cells, Nucleic Acids Research, (Feb. 15, 2000), pp. 868-874, 28(4).;;Dias et al., Antisense Oligonucleotides: Basic Concepts and Mechanisms, Molecular Cancer Therapy, (Mar. 2002), pp. 3470355, 1(15).;;Fujiwara et al., Purification and Characterization of Human Laminin-8 Stimulates Cell Adhesion and Migration Through a3beta1 and a6p Integrins, Journal of Biological Chemistry, (May 18, 2001), pp. 17550-17558, 276(20).;;Gonzales et al., Complex Interactions Between the Laminin a4 Subunit and Integrins Regulate Endothelial Cell Behaviour In Vitro and Angiogenesis In Vivo, Proceedings of the National Academy of Sciences USA, (Dec. 10, 2002), pp. 16075-16080, 99(25).;;Hayashi et al., Identification and Recombination Production of Human Laminin a4 Subunit Splice Variants, Biochemical and Biophysical Research Communications, (Dec. 6, 2002), pp. 498-504, 299(3).;;Herold-Mende et al. Clinical Impact and Functional Aspects of Tenascin-C Expression During Glioma Progression, International Journal of Cancer, (Mar. 20, 2002), pp. 362-369, 98(3).;;Jansen et al., Chemosensitisation of Malignant Melanoma by BCL2 Antisense Therapy, Lancet, (Nov. 18, 2000), pp. 1728-1733, 356(9243).;;Kachra et a;. Expression of Matrix Metalloproteinases and Their Inhibitors in Human Brain Tumrors, Clinical and Experimental Metastasis, (1999), pp. 555-566, 17(7).;;Khazenzon et al., Antisense Inhibition of Laminin-8 Expression Reduces Invasion of Human Gliomas In Vitro, Molecular Cancer Therapeutics, (2003), pp. 985-994,2.;;Khazenzon et al., Novel Angiogenic Targets for Human Glioma Prevention and Regulation of Their Expression, International Journal of Molecular Medicine, 2002, 10:Supplementa 1, p. S41, XP008091390.;;Kleinman et al., Basement Membrane Complexes with Biological Activity, Biochemistry, (Jan. 28, 2986), pp. 312-318, 25(2), (1986).;;Knott et al., Stimulation of Extracellular Matrix Components in the Normal Brain by Invading Glioma Cells, International of Cancer, (Mar. 16, 1998), pp. 864-872, 75(6).;;Komata et al., Combination Therapy of Malignant Glioma Cells With 2-5A-Antisense Telomerase RNA and Recombinant Adenovirus p53, Gene Therapy, (Dec. 2000), pp. 20171-2079, 7(24).;;Kondragantiet al., Selective Supression of Matrix Metalloproteinase-9 in Human Glioblastoma Cells by Antisense GeneTransfer Impairs Glioblastoma Cell Invasion, Cancer Research, (Dec. 15, 2000), pp. 6851-6855, 60(24).;;Kulla et al., Tenascin Expression Patterns and Cells of Monocyte Lineage: Relationship in Human Gliomas, Moder Pathology, (Jan. 2000), pp. 58-67, 13(1).;;Lacera et al., Restoration of Hemaglobin A Synthesis in Erythroid Cells From Peripheral Blood of Thalassemic Patients, Proceedings of the National Academy of Sciences USA, (Aug. 15, 2000), pp. 9591-9596, 97(17).;;Lal et al., A Public Database for Gene Expression in Human Cancers, Cancer Research, (Nov. 1, 1999), pp. 5403-5407, 59(21).;;Ljubimov et al. Human Corneal Basement Membrane Heterogeneity, Topographical Differences in the Expression of Type IV Collagen and Laminin Isoforms, Lab Invetsigation, (Apr. 1995), pp. 461-473, 72(4).;;Ljubimova et al., Gene Array Analysis of Differentially Expressed Genes in Human Glial Tumors, International Journal of Oncology, (2001), pp. 287-295, 18.;;Ljubimova et al., Overexpression of a4 Chain-Containing Laminins in Human Glial Tumors Identified by Gene Microarray Analysis, Cancer Research (Jul. 15, 2001), pp. 5601-5610, 61(14).;;Ljubimova et al. A new Multifunctional Drug Delivery System Based on Polymalic Acid to Inhibit Angiogenesis and Invasion of Human Gliomas In Vitro and In Vivo, European Journal of Cancer, Supplement, 2004, 2:8, p. 184. XP004640052.;;Ljubimova et al. Development of an In Vitro System to Block the Angiogenic Target, Laminin-8, in Human Gliomas, Proceedings of the American Association for Cancer Annual Meeting, Mar. 2002, vol. 43, p. 177, XP001536931.;;MacDonald et al., Urokinase Induces Receptor Mediated Brain Tumor Cell Migration and Invasion, Journal of Neuro Oncology, (Dec. 1998), pp. 215-226, 40(3).;;McKean et al., FAK Induces Expression of Prx1 to Promote Tenascin-C-Dependent Fibroblast Migration, Journal of Cell Biology, (Apr. 28, 2003), pp. 393-402, 161(2).;;Minakawa et al., In Vitro Interaction of Astrocytes and Pericytes With Capillary-Like Structures of Brain Microvessel Endothelium, Lab Investigation, (Jul. 1991), pp. 32-40, 65(1).;;Miner et al. The Laminin Alpha Chains: Expression, Developmental Transitions, and Chromosomal Locations of A1-5, Identificationof Heterotrimeric Laminins 8-11, and Cloning of a Novel a3 Isoform, Journal of Cell Biology, (May 5, 1997), pp. 685-701, 137(3).;;Nielsen et al., Peptide Nucleic Acid Targeting of Double-Stranded DNA. Methods in Enzymology, 2001, pp. 329-340, 340.;;Patarroyo et al., Laminin Isoforms in Tumor Invasion, Angiogenesis, and Metastasis Seminars, Seminars in Cancer Biology, (Jun. 2002), pp. 197-207, 12(3).;;Petajaniemi et al., Localization of Laminin a4-Chain in developing and Adult Human Tissues, The Journal of Histochemistry and Cytochemistry, (Aug. 2002), pp. 1113-1130, 50(8).;;Qin et al., The Transcription Factors Sp1, Sp3, and AP-2 are required for Constitutive Matrix Metalloproteinase-2 Gene Expression in Astroglioma Cells, Journal of Biological Chemistry, (Oct. 8, 1999), pp. 29130-29137.;;Sehgal, A., molecular Changes During the Genesis of Human Gliomas, Seminars in Surgical Oncology, (Jan.-Feb. 1998), pp. 3-12, 14(1).;;Shi et al., Antisense Imaging of Gene Expression in the Brain, Proceedings of the National Academy of Sciences USA, (Dec. 19, 2000), pp. 14709-14714, 97(26).;;Sixt et al., Endothelial Cell Laminin Isoforms, Laminins 8 and 10, Play Decisive Roles in T Cell Recruitement Across the Blood-Brain Barrier in Experimental Autoimmune Encephalomyelitis, Journal of Cell Biology, (May 28, 2001), pp. 933-947, 153(5).;;Summerton et al., Morpholino Antisense Oligomers: Design, Preparation and Properties, Antisense and Nucleic Acid Drug Development, (Jun. 1997), pp. 187-195, 7(3).;;Taylor et al., Comparison of Efficacy of Antisense Oligomers Directed Toward TNF-a in Helper T and Macrophage Cell Lines, Cytokine, ((Sep. 1997), pp. 672-681, 9(9).;;Thyboll et al., Deletion of the Laminin a4 Chain Leads to Impaired Microvessel Maturation, Molecular and Cellular Biology, (Feb. 2002), pp. 1194-1202, 22(4).;;Tsuji et al., Regulation of Melanoma Cell Migration and Invasion by Laminin-5 and a3beta1 Integrin (VLA-3), Clinical and Experimental Metastasis, (2002), pp. 127-134, 19(2).;;Voyta et al., Identification and Isolation of Endothelial Cells Based on Their Increased Uptake of acetylated-Low Density Lipoprotein, Journal of Cell Biology, (Dec. 1984), pp. 2034-2040, 99(6).;;Zagazag et al., Angiogenesis in the Central Nervous System: A role for Vascular Endothelial Growth Factor/Vascular Permeability Factor and Tenascin-C. Common Molecular Effectors in Cerebral Neoplastic and Non-Neoplastic ""Angiogenic Diseases,"" Histol Histopathol, 17: 301-321, 2002.;;Agrawal et al., Anntisense Therapeutics: Is It as Simple as Complimentary Base Recognition?, Molecular Medicine Today, (Feb. 2000), pp. 72-81, 6.;;Gewirtz et al., Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on Its Promise, Proceedings of the National Academy of Sciences of USA, (Apr. 1996), pp. 3161-3163, 93.;;Fujita et al., Inhibition of Laminin-8 In Vivo Using a Novel Poly(Malic Acid)-Based Carrier Reduces Glioma Angiogenesis, Angiogenesis, (2006), pp. 183-191. 9.;;Lu et al., Delivering siRNA In Vivo for Functional Genomics and Novel Therapeutics, RNA Interference Technology, (2205), pp. 303-317, (2005).;;Nielsen P.E., The Last Hurdle?, Gene Therapy, (2005), pp. 956-957, 12.;;Samarsky et al., RNAi in Drug Development: Practical considerations, RNA Interference Technology, (2005), pp. 384-395.;;Bickel et al., Delivery of Peptides and Proteins Through the Blood-Brain Barrier, Advanced Drug Delivery Reviews, (2001), pp. 247-279, 46.;;Boado et al., Drug delivery of Antisense Molecules to the Brain for Treatemnet of Alzheimer's Disease and Cerebral AIDS, Journal of Pharmacological Science, (1998), pp. 1308-1315, 87.;;Broadwell et al., Transcytosis of Protein Through the Mammalian Cerebral Epithelium and Endothelium III Receptor-Mediated Transcytosis Through the Blood-Brain of Blood-Borne Transferrin and Antibpdy Against the Transferrin Receptor, Experimental Neurology, (1996), pp. 47-65, 142.;;Cammas et al., Polymers of Malic Acid and 3-Akylmalic Acid as Synthetic PHAs in the Design of Biocompatible Hydrolyzable Devices, International Journal of Biological Macromolecules, (1999), pp. 273-282, 25.;;Fischer et al., An Unusual Polyanion From Physarum Polycephalum That Inhibits Homologoes DNA Polymerase A In Vitro, Biochemistry, (1989), pp. 5219-5226, 28.;;Iwata et al., A Novel Surgical Glue Composed of Gelatin and N-Hydroxysuccinimide Activate Poly(L-Glutamic Acid): Part 1 Synthesis of Activated Poly(L-Glutamic Acid) and Its Gelation With Gelatin, Biomaterials, (1998), pp. 1859-1876, 19.;;Kopecek et al., HPMA Copolymer-Anticancer Drug Conjugates: Design, Activity, and Mechanism of Action, european Journal of Biopharmacology, (2000), pp. 61-81, 50.;;Korherr et al., Poly ((beta-1 Malate) Hydrolase From Plasmodia of Physarum Polycephalum, Canadian Journal of Microbioligy, (1995), pp. 192-199, 41 (Suppl. 1).;;Kurihara et al., Epidermal Growth Factor Radiopharmaceuticals:111m Cheladon, Conjugation to a Blood-Brain Barrier Delivery Vector Via a Biotin-Polyethylene Linker, Pharmacokinetics, and In Vivo Imaging of Experimental Brain Tumors, Bioconjugate Chemistry, (1999), 505-511, 10.;;Lee et al., Effects of Culture Conditions on beta-Poly(I-Malate) Production by Physarum Polycephalum, Applied Microbiology and Biotechnology, (1999), pp. 647-652, 51.;;Pichon et al., Histidine-Rich Peptides and Polymers for Nucleic Acid Delivery, Advanced Drug Delivery Reviews, (2001), pp. 75-94, 53.;;Saito et al., drug Delivery Strategy Utilizing Conjugation via Reversible Disulide Linkages: Role and Site of Cellular Reducing Activities, Advanced Drug Delivery Reviews, (2003), pp. 192-215, 55.;;Schnaible et al., identification of Fluorescein-5'-Isothiocynate-Modification Sites in Proteins by Electrospray-Ionization Mass Spectrosopy, Bioconjugates Chemistry, (1999), pp. 861-866, 10.;;Shi et al., Noninvasive Gene Targeting to the Brain, Proceedings of the National Academy of Sciences, (2000), pp. 7567-7572, 97.;;Willner et al., (6-Maleimidocaproyl) Hydrazone of Doxorubicin-ANew Derivative for the Preparation of Immunoconjugates of Doxorubicin, Boconjugate Chemistry, (193), pp. 521-527, 1993.;;Qian et al., Targeted Drug Delivery via the Transferrin Receptor-mediated Endocytosis Pathway, Pharmacology Reviews. vol. 54, No. 4, (Dec. 2002), pp. 561-587.;;Zhang et al., Antisense Gene Therapy of Brain Cancer with Artificial Virus Gene Delivery System, Molecular Therpay, vol. 6, No. 1 (Jul. 2002), pp. 67-72.;;Ljubimova et al., Changes in Laminin Isoforms Associated with Brain Tumor Invasion and Angiogenesis, Frontiers in Bioscience, (Jan. 1, 2006), vol. 11, pp. 81-88.;;Ljubimova et al., Development of Anti-Angiogenic and Anti-Invasive Inhibitors of Human Gliomas Using a New Multifunctional Drug delivery System Based on Polymakic Acid, Preclinica (Sep./Oct. 2004), 2(5), p. 366.;;Nagato et al., Downregulations of Laminin a-4 Chain Expression Inhibits Glioma Invasion In Vitro and In Vivo, Int. Journal of Cancer (onlune Jun. 16, 2004), pp. 604-612.;;Fukushima et al. Integrin a3beta1-mediated Interaction with Laminin-5 Stimulates Adhesion, Migration and Invasion of Malignant Glioma Cells, Int. Journal of Cancer (Mar. 30, 1998), 76(1), pp. 63-72.;;Kramerov et al., Inhibition of Protein Kinase CK2 Suppresses Angiogenesis and Hematopoietic Stem Cell Recruitment to Retinal Neovascularization Sites. Molecular and Cellular Biochemistry 316:177-186, 2008.",ACTIVE
152,WO,A3,WO 2005/055980 A3,186-193-969-423-728,2006-01-05,2006,US 2004/0040660 W,2004-12-03,US 52733003 P,2003-12-05,POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM,"A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system&apos;s circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms.",ARROGENE INC;;LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,,https://lens.org/186-193-969-423-728,Search Report,yes,2,0,12,14,0,A61K47/60;;A61K47/593;;A61K47/6883;;A61K47/6849;;A61P35/00;;A61K47/6883;;A61K47/593;;A61K47/60;;A61K47/6849;;A61P35/00,A61K47/48,,8,8,027-327-439-480-050;;010-586-072-524-473;;025-444-780-060-105;;010-084-423-107-920;;116-305-745-084-880;;084-804-379-761-825;;050-127-840-017-705;;021-383-028-538-332,10.1016/j.jconrel.2003.06.001;;14636717;;10.1016/s0928-0987(97)00069-9;;16256709;;12095305;;10.1006/mthe.2002.0633;;10.1021/bm0300608;;14715019;;10.1124/pr.54.4.561;;12429868;;14578463;;10.1016/s0142-9612(99)00210-0;;10735463;;10.1016/s1359-6349(04)80616-5,"BULMUS V ET AL: ""A new pH-responsive and glutathione-reactive, endosomal membrane-disruptive polymeric carrier for intracellular delivery of biomolecular drugs"", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 93, no. 2, December 2003 (2003-12-01), pages 105 - 120, XP004473631, ISSN: 0168-3659;;ABDELLAOUI K ET AL: ""METABOLITE-DERIVED ARTIFICIAL POLYMERS DESIGNED FOR DRUG TARGETING, CELL PENETRATION AND BIORESORPTION"", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 1, 1998, pages 61 - 73, XP008047861, ISSN: 0928-0987;;ZHANG Y. ET AL: ""Antisense gene therapy of brain cancer with an artificial virus gene delivery system"", MOLECULAR THERAPY, vol. 6, no. 1, July 2002 (2002-07-01), pages 67 - 72, XP008054256;;MARTINEZ BARBOSA M. E. ET AL: ""Investigation of the degradation mechanisms of poly(malic acid) esters in vitro and their related cytotoxicities in J774 macrophages"", BIOMACROMOLECULES, vol. 5, December 2003 (2003-12-01), pages 137 - 143, XP008054218;;MING QIAN Z. ET AL: ""Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway"", PHARMACOLOGICAL REVIEWS, vol. 54, 2002, pages 561 - 587, XP008054257;;KHAZENZON N M ET AL: ""Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro"", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 2, no. 10, October 2003 (2003-10-01), pages 985 - 994, XP002986547, ISSN: 1535-7163;;OSANAI S ET AL: ""Effects of complexation between liposome and poly(malic acid) on aggregation and leakage behaviour"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 9, May 2000 (2000-05-01), pages 867 - 876, XP004202452, ISSN: 0142-9612;;LJUBIMOVA J Y ET AL: ""608 A new multifunctional drug delivery system based on polymalic acid to inhibit angiogenesis and invasion of human gliomas in vitro and in vivo"", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 2, no. 8, September 2004 (2004-09-01), pages 184, XP004640052, ISSN: 1359-6349",PENDING
153,CA,C,CA 2324795 C,030-313-681-199-006,2009-02-10,2009,CA 2324795 A,2000-10-25,CA 2324795 A,2000-10-25,INSERTED LASER WELDED BLANKS,"A method of creating a tailored blank assembly, the assembly comprising a first blank having an aperture and a second blank having an embossment. The first and second blank s being positioned in a face to face relation and the configuration of the embossmen t being complementary to and nested within the aperture. The first and second blanks are welded together about the embossment to join the first and second blanks.",POWERLASERS LTD,MORRIS BRIAN;;STAPLES MICHAEL JAMES;;BLACK GARY KEITH,,https://lens.org/030-313-681-199-006,Granted Patent,no,0,0,2,2,0,B23K26/244;;B23K2101/185,B23K26/044;;B23K26/00;;B23K26/24,,0,0,,,,EXPIRED
154,US,A1,US 2011/0104210 A1,041-275-052-019-644,2011-05-05,2011,US 99543409 A,2009-06-17,US 99543409 A;;US 7320508 P;;US 2009/0047640 W,2008-06-17,USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS,"Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;MORRIS-IRVIN DWAIN;;ARDITI MOSHE,CEDARS-SINAI MEDICAL CENTER (2009-06-17),https://lens.org/041-275-052-019-644,Patent Application,yes,10,10,5,5,0,A61K38/164;;A61K45/06;;C12N5/0639;;A61K2039/55561;;A61K2039/55572;;A61P35/00;;A61P37/04;;A61K39/4615;;A61K2239/38;;A61K2239/47;;A61K39/4622;;A61K2239/31;;A61K39/464499;;A61K35/15;;A61K38/164;;A61K45/06;;C12N5/0639;;A61K2039/5154;;A61K2039/55561;;A61K2039/55572;;A61K39/0011,A61K39/00;;A61K35/12;;A61K35/15;;A61K38/16;;A61P35/00;;A61P37/04,424/277.1;;424/93.71,12,9,125-239-346-378-244;;041-677-195-849-997;;076-637-532-898-559;;046-847-065-587-168;;092-707-572-319-639;;003-030-356-432-987;;012-946-606-269-104;;067-911-159-686-453;;056-649-998-351-849,16799333;;10.1097/01.cji.0000199199.20717.67;;pmc2196048;;10.1084/jem.20020732;;12186845;;18167273;;10.1158/0008-5472.can-03-3505;;15256471;;10.1177/107327480401100307;;15153843;;10.1038/nm1039;;15122249;;10364168;;10.1074/jbc.274.25.17406;;pmc165983;;10.1128/iai.71.8.4238-4249.2003;;12874299;;14520441;;pmc2394324;;10.1038/sj.bjc.6601268,"Pilon-Thomas (Journal of Immunotherapy, 2006, Vol. 29, pp. 381-387).;;abstract of Prins et al (Journal of Clinical Oncology, May 20, 2008, supplement, Abstract No. 11021);;Vicari et al (Journal of Experimental Medicine, 2002, Vol. 196, pp. 541-549);;abstract of You et al (Zhonghua Yi Xue Za Zhi, 2007 Oct 23, Vol. 87, pp. 2785-2790);;Yu et al (Cancer Research, 2004, Vol. 64, pp. 4973-4979);;Moneeb et al (Cancer Control, 2004, Vol. 11, pp. 192-207);;Figdor et al (Nature Medicine, 2004, Vol. 10, pp. 475-480);;Shubina et al (Experimental Immunology, 2007, Vol. 32, pp. 189-195);;the abstract of Semenov et al (Molekulyarnaya Meditsina, 2005, Vol. 4, pp. 53-58);;Schwandner et al (Journal of Biological Chemistry, 1999, Vol. 274, pp. 17406-17409);;Uehori et al (Infection and Immunity, 2003, Vol. 71, pp. 4238-4249).;;Yamanaka et al (British Journal of Cancer, 2003, Vol. 89, pp. 1172-1179).",ACTIVE
155,US,B2,US 9382308 B2,115-597-505-310-659,2016-07-05,2016,US 201313826737 A,2013-03-14,US 201313826737 A;;US 55294509 A;;US 19071808 P,2008-09-02,CD133 epitopes,"An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO: 1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO: 1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO: 13). The immunogens can be used in compositions and in the treatment of disorders.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;BLACK KEITH L;;LIU GENTAO,CEDARS-SINAI MEDICAL CENTER (2010-01-05),https://lens.org/115-597-505-310-659,Granted Patent,yes,103,3,13,13,19,A61K39/0011;;A61K39/0011;;A61K45/06;;A61P35/00;;A61P37/04;;C07K14/70596;;C07K14/70596;;C07K7/06;;C07K7/06,A61K39/00;;A61K35/15;;A61K45/06;;C07K7/06;;C07K14/705,,105,95,003-646-738-432-814;;124-282-566-991-152;;053-393-265-065-68X;;101-486-822-726-957;;081-457-468-429-178;;032-932-040-924-322;;138-771-752-862-480;;168-705-133-516-75X;;016-059-509-686-365;;084-085-138-348-898;;064-388-641-569-789;;097-167-161-561-41X;;006-027-796-241-692;;077-678-786-447-085;;029-311-860-898-924;;032-294-227-563-850;;078-639-700-866-831;;025-457-637-309-732;;022-798-233-953-966;;045-700-919-027-517;;013-855-584-540-778;;062-108-416-505-04X;;057-785-668-031-036;;011-954-218-606-176;;044-750-837-062-887;;092-707-572-319-639;;040-713-726-205-55X;;160-717-493-067-916;;044-555-535-916-468;;002-637-847-823-805;;018-870-261-171-506;;090-928-883-705-496;;028-167-813-228-119;;004-397-008-209-727;;006-148-652-132-981;;008-169-153-417-267;;054-439-756-152-283;;021-901-512-648-514;;053-672-692-937-579;;165-292-111-716-265;;099-464-580-091-161;;068-473-895-492-963;;006-885-984-877-437;;085-702-051-840-908;;067-905-202-866-732;;003-865-790-341-418;;038-241-086-015-47X;;153-662-306-900-396;;120-862-791-424-707;;061-756-489-300-343;;025-760-264-704-263;;082-930-667-453-661;;017-862-373-044-791;;004-602-946-239-391;;057-002-651-793-17X;;108-599-572-220-595;;019-963-559-470-014;;019-377-086-323-88X;;060-861-375-524-523;;012-105-359-936-435;;086-946-791-527-279;;044-084-260-816-039;;003-616-087-027-77X;;053-906-705-994-097;;055-983-972-565-643;;063-225-571-358-608;;022-705-571-480-334;;097-470-977-075-432;;070-884-634-385-754;;003-924-024-298-446;;139-500-660-556-55X;;133-716-008-515-719;;010-981-337-785-354;;078-723-209-803-023;;116-248-902-411-147;;047-903-330-676-744;;103-932-348-507-545;;081-222-505-017-37X;;035-823-463-717-575;;054-045-955-566-76X;;041-406-340-961-551;;071-699-972-336-631;;026-887-607-952-029;;026-304-558-215-155;;063-547-669-345-057;;035-263-789-910-604;;075-344-720-447-282;;033-947-267-268-874;;077-262-310-785-629;;078-642-510-799-292;;009-792-025-501-449;;060-667-322-361-290;;032-969-718-122-323;;018-117-667-758-278;;057-105-231-226-816,8617954;;8557366;;pmc173770;;10.1128/iai.64.1.363-365.1996;;17540729;;10.1073/pnas.0608635104;;pmc1885220;;15226377;;10.1242/jcs.01222;;24375541;;pmc3952931;;10.5966/sctm.2013-0135;;11449066;;11265767;;10.1097/00002371-200103000-00004;;10.1586/14737175.5.4.497;;16026233;;15383564;;10.4049/jimmunol.173.7.4352;;10.2741/1747;;15970545;;10.1073/pnas.0530291100;;pmc153034;;12629218;;18665745;;10.1158/0008-5472.can-06-4180;;17483311;;10.1038/nrc1740;;16327766;;18539956;;10.1200/jco.2008.17.7436;;pmc2241749;;10.4049/jimmunol.174.8.4812;;15814707;;10.1016/s0022-1759(02)00142-4;;12135802;;10.1097/00006123-199903000-00110;;10069601;;19903840;;pmc2789196;;10.1158/0008-5472.can-09-2687;;11196166;;12941147;;10.1046/j.1365-2567.2003.01726.x;;pmc1783031;;10.1227/00006123-199305000-00003;;10.1097/00006123-199305000-00003;;8388081;;10.3727/096368909x12483162196962;;19523342;;10.1093/jnci/85.9.704;;8478956;;11471194;;12616102;;10.1097/00002371-200303000-00003;;10.1177/107327480401100307;;15153843;;1709722;;10.1038/351290a0;;10914698;;10.1158/0008-5472.can-04-1364;;15466194;;18245488;;10.1158/0008-5472.can-07-0445;;12391241;;10.4049/jimmunol.169.9.5227;;11731436;;11239426;;10.1016/s0896-6273(01)00209-4;;17412894;;10.1634/stemcells.2006-0624;;10.1007/s002620050465;;9558003;;10.1097/00002371-200107000-00008;;11565834;;10.1189/jlb.1002483;;12773508;;10.1046/j.1432-1327.1999.00154.x;;10091592;;10.1016/s0165-5728(99)00172-1;;10674985;;pmc299944;;14645703;;10.1073/pnas.2036535100;;10.4049/jimmunol.164.2.861;;10623833;;pmc521140;;10.1073/pnas.0400067101;;15381773;;12832694;;10.1634/stemcells.21-4-405;;10.1007/s005950300060;;12707821;;pmc2881867;;10.1371/journal.pone.0010974;;20539758;;19944974;;10.1016/j.nec.2009.08.006;;pmc2786895;;9743339;;10.1007/s00262-002-0297-z;;12202903;;11676393;;10.1007/s002620100205;;10.1126/science.1135308;;17185560;;12222879;;10.1182/blood.v97.6.1776;;11238120;;15908947;;pmc2377345;;10.1038/nn1473;;19194651;;10.1007/s00701-009-0185-9;;10.1038/nbt947;;15004565;;10350260;;10.3171/jns.1999.90.6.1115;;15076139;;10.1097/00002371-200405000-00006;;17140455;;pmc1697823;;10.1186/1476-4598-5-67;;17939761;;10.1586/14737175.7.10.1235;;10.1177/107327480301000205;;12712008;;10.1038/sj.onc.1208519;;15897911;;15256472;;10.1158/0008-5472.can-03-3504;;10.1097/00002371-200307000-00002;;12843792;;10.1586/14760584.5.2.233;;16608423;;15162438;;10.1002/eji.200425081;;10.2174/157488708783330530;;18474011;;10.4049/jimmunol.176.3.1796;;16424210;;18539965;;10.1200/jco.2007.15.1472;;10.1634/stemcells.22-6-1101;;15536199;;7774624;;10.1002/eji.1830250511;;8027569;;10.4049/jimmunol.153.3.996;;12109820;;10.1053/clon.2001.0038;;pmc3903051;;10.1007/s00262-007-0426-9;;18057935;;11440627;;10.1089/104303401750270995;;10.1002/path.2283;;18067118;;17307142;;10.1016/j.bbrc.2007.01.159;;10.1007/978-1-4684-6831-1_14;;12717023;;10.1110/ps.0239403;;pmc2323871;;12907622;;17122772;;10.1038/nature05372;;10.1023/a:1024969422010;;10.1007/bf02700016;;12952282;;9754652;;10.1002/(sici)1097-0215(19981005)78:2<196::aid-ijc13>3.0.co;2-9;;12231526;;10.1093/jjco/hye076;;11574635;;9809996;;10.4049/jimmunol.157.6.2539;;8805655;;10.1093/jnci/94.11.805;;12048268;;10764250;;10.1227/00006123-200004000-00002;;10.1097/00006123-200004000-00002;;10.1007/978-1-59745-280-9_15;;19582431;;17079441;;10.1158/0008-5472.can-06-2048;;10.1200/jco.2010.28.15_suppl.2097;;pmc1137064;;7519851;;10.1042/bj3010847;;1476743;;10945499;;10.1054/bjoc.2000.1289;;pmc2374651;;10.1053/pb.2000.6691;;10914414,"Burg et al., Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stabilityl The Journal of Immuno/ogy, 1996, 156; 3308-3314.;;Feng et al P55, an Immunogenic but Nonprotective 55-Kilodalton Borrelia burgdorferi Protein in Murine Lyme Disease Infection and Immunity, Jan. 1996, p. 363-365.;;Zhang et al Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization PNAS | Jun. 12, 2007 | vol. t04 | No. 24 1019).-10198.;;Richardson et al ., CD133, a novel marker for human prostatic epithelial stem cells Journal of Cell Science 117, 3539-3545 Published by the Company of Biologists 2004.;;Ji et al Identification of Novel Human Leukocyte Antigen-A*0201-Restricted, CytotoxicT Lymphocyte Epitopes on CD133 for Cancer Stem Cell Immunotherapy Stem Cells Trans Med 2014, 3:356-364.;;Ludewig et al., Adoptive Immunotherapy: Methods and Protocols Non-self MHC-restricted CTL 2005 Human Press Inc. p. 216-217.;;Akasaki et al., ""Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model,"" J. Immunother., 24:106-113 (2001).;;Akasaki et al., ""Dendritic cell-based immunotherapy for malignant gliomas,"" Expert Rev. Neurother., 5:497-508 (2005).;;Akasaki et al., ""Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma,"" J. Immunol., 173:4352-59 (2004).;;Akasaki et al., ""T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches,"" Front. Biosci., 10:2908-21 (2005).;;Al-Hajj et al., ""Prospective identification of tumorigenic breast cancer cells,"" Proc. Natl. Acad. Sci. USA, 7:3983-88 (2003).;;Altaner, ""Glioblastoma and stem cells,"" Neoplasma, 55:369-374 (2008).;;Beier et al., ""CD133+ and CD133-31 glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles,"" Cancer Res., 67:4010-15 (2007).;;Bjerkvig et al., ""Opinion: the origin of the cancer stem cell: current controversies and new insights,"" Nat. Rev. Cancer, 11:899-904 (2005).;;Boman et al., ""Cancer stem cells: a step toward the cure,"" J. Clin. Oncol., 26:2795-99 (2008).;;Borbulevych et al., ""Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design,"" J. Immunol , 174:4812-20 (2005).;;Borras et al., ""Findings on T cell specificity revealed by synthetic combinatorial libraries,"" J. Immunol Methods, 267:79-97 (2002).;;Bowles, Jr. et al., ""Long-term remission of malignant brain tumors after intracranial infection: a report of four cases,"" Neurosurgery, 44:636-642 (1999).;;Brown et al., ""Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells,"" Cancer Res., 69:8886-93 (2009).;;Candido et al., ""Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents,"" Cancer Res., 61:228-236 (2001).;;Casey et al., ""Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine,"" Immunology, 110:105-111 (2003).;;Chandler et al., ""Long-term survival in patients with glioblastoma multiforme,"" Neurosurgery, 32:716-720 (1993).;;Cho et al., ""Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas,"" Cell Transplant., 18:977-983 (2009).;;Curran et al., ""Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials,"" J. Natl. Cancer Inst., 85:704-710 (1993).;;Dietz, ""Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia,"" Croatian Med. J., 42:428-435 (2001).;;Ehtesham et al., ""Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats,"" J. Immunother., 26:107-116 (2003).;;Ehtesham et al., ""Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials,"" Cancer Control, 11:192-207 (2004).;;European Patent Office Communication for European Application No. 09812172.6, mailed May 23, 2012, 5 pages.;;Falk et al., ""Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,"" Nature, 351:290-296 (1991).;;Friedman et al., ""Temozolomide and treatment of malignant glioma,"" Clin. Cancer Res., 6:2585-97 (2000).;;Galli et al., ""Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma,"" Cancer Res., 64:7011-21 (2004).;;Garcia-Hernandez et al., ""Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in the Absence of Autoimmunity"", Cancer Res., vol. 68, No. 3, (2008), pp. 861-869.;;Gatza et al., ""Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma,"" J. Immunol , 169:5227-35 (2002).;;Geiger et al., ""Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression,"" Cancer Res., 61:8513-19 (2001).;;Geschwind et al., ""A genetic analysis of neural progenitor differentiation,"" Neuron, 2:325-39 (2001).;;Ghods et al., ""Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells,"" Stem Cells, 7:1645-53 (2007).;;Gilboa et al., ""Immunotherapy of cancer with dendritic-cell-based vaccines,"" Cancer Immunol. Immunother., 46:82-87 (1998).;;Harada et al., ""Melanoma-reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types,"" J. Immunother., 24:323-333 (2001).;;Harizi et al., ""Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subytpes,"" J. Leukocyte Biol., 73:756-763 (2003).;;Haynes et al., ""Molecular characterization of the B"" regulatory subunit gene family of Arabidopsis protein phosphatase 2A, Euro J. Biochem., vol. 260, (1999), pp. 127-136.;;Heimberger et al., ""Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma,"" J. Neuroimmunol., 103:16-25 (2000).;;Hemmati et al., ""Cancerous stem cells can arise from pediatric brain tumors,"" Proc. Natl. Acad. Sci. USA, 25:15178-83 (2003).;;Hemmer et al., ""Contribution of Individual Amino Acids Within MHC Molecule or Antigenic Peptide to TCR Ligand Potency,"" J. Immunol , 164:861-871 (2000).;;Hirschmann-Jax et al., ""A distinct 'side population' of cells with high drug efflux capacity in human tumor cells,"" Proc. Natl. Acad. Sci. USA, 39:14228-33 (2004).;;Hori et al., ""Neural progenitor cells lack immunogenecity and resist destruction as allografts,"" Stem Cells, 21:405-416 (2003).;;Inoue et al., ""Dendritic cells coinjected with tumor cells treated with an anticancer drug to induce tumor rejection,"" Surg. Today, 33:269-276 (2003).;;International Preliminary Report on Patentability for App. Serial No. PCT/US2010/034082, mailed Nov. 17, 2011, 5 pages.;;International Preliminary Report on Patentability of International Application No. PCT/US2009/055759, mailed Mar. 8, 2011.;;International Search Report and Written Opinion of International Application No. PCT/US2009/055759, mailed Jun. 28, 2010.;;International Search Report and Written Opinion of International Application No. PCT/US2010/034082, mailed Feb. 22, 2011, 9 pages.;;Irvin et al., ""T cells enhance stem-like properties and conditional malignancy in gliomas,"" PLoS One, 5(6):e10974 (2010).;;Ji et al., ""Glioma stem cell research for the development of immunotherapy,"" Neurosurg. Clin. N. Am., 21:159-66 (2010).;;Kalinski et al., ""Prostaglandin E2 induces the final maturation of IL-12 deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation,"" J. Immunol, 161:2804-09 (1998).;;Kikuchi et al., ""Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model,"" Cancer Immunol Immumother., 51:424-430 (2002).;;Kikuchi et al., ""Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells,"" Cancer Immunol Immumother., 50:337-344 (2001).;;Kimchi-Sarfaty et al., ""A ""Silent"" Polymorphism in the MDR1 Gene Changes Substrate Specificity"", Science, vol. 315, (2007), pp. 525-528 (Erratum, 1 page).;;Knutson et al., ""Technology evaluation: DCVax, Northwest Biotherapeutics,"" Curr. Opin. Mol. Ther., 4:403-407 (2002).;;Kuby et al., Immunology, W. H. Freeman and Co., pp. 523-524 (1992).;;La Rosa et al., ""Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries,"" Blood, 97:1776-86 (2001).;;Lee et al., ""Isolation of neural stem cells from the postnatal cerebellum,"" Nat. Neurosci., 6:723-729 (2005).;;Lefranc, ""Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomas,"" Acta Neurochir. (Wien), 151:109-112 (2009).;;Lemmel et al., ""Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling,"" Nat. Biotechnol., 22:450-454 (2004).;;Liau et al., ""Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens,"" J. Neurosurg., 90:1115-24 (1999).;;Liu et al., ""AIM-2: a novel tumor antigen is expressed and presented by human glioma cells,"" J. Immunother., 27:220-226 (2004).;;Liu et al., ""Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma,"" Mol. Cancer, 5:67 (2006).;;Liu et al., ""Cancer vaccines: a novel strategy to sensitize malignant glioma to chemotherapy,"" Expert Rev. Neurother., 7:1235-37 (2007).;;Liu et al., ""Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma,"" Cancer Control, 10:138-147 (2003).;;Liu et al., ""Chemoresistance of stem-like cells isolated from glioblastoma,"" Proc. Amer. Assoc. Cancer Res., 47:75, abstract #320 (2006).;;Liu et al., ""Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy,"" Oncogene, 24:5226-34 (2005).;;Liu et al., ""HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells,"" Cancer Res., 64:4980-86 (2004).;;Liu et al., ""Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma,"" J. Immunother., 26:301-312 (2003).;;Liu et al., ""Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination,"" Expert Rev. Vaccines, 5:233-247 (2006).;;Liu et al., ""Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response,"" Eur. J. Immunol , 34:1680-87 (2004).;;Luptrawan et al., ""Dendritic cell immunotherapy for malignant gliomas,"" Rev. Recent Clin. Trials, 3:10-21 (2008).;;Lustgarten et al., ""Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope,"" J. Immunol , 176:1796-1805 (2006).;;Maitland et al., ""Prostate cancer stem cells: a new target for therapy,"" J. Clin. Oncol., 26:2862-70 (2008).;;Mammolenti et al., ""Absence of major histocompatibility complex class I on neural stem cells does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro,"" Stem Cells, 22:1101-10 (2004).;;Mehta-Damani et al., ""Generation of antigen-specific CD4+ T cell lines from naive precursors,"" Eur. J. Immunol , 5:1206-11 (1995).;;Mehta-Damani et al., ""Generation of antigen-specific CD8+ CTLs from naive precursors,"" J. Immunol., 153:996-1003 (1994).;;Melcher et al., ""Dendritic cells for the immunotherapy of cancer,"" Clin. Oncol., 14:185-192 (2002).;;Merrick et al., ""Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naive cytotoxic priming and anti-tumour therapy,"" Cancer Immunol Immunother., 57:897-906 (2008).;;Mi et al., ""Induced apoptosis supports spread of adenovirus vectors in tumors,"" Hum. Gene Ther., 12:1343-52 (2001).;;Mizrak et al., ""CD133: molecule of the moment,"" J. Pathol., 214:3-9 (2008).;;NCBI GenBank Accession No. NM-006017 (Jul. 13, 2008).;;Neuzil et al., ""Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?"" Biochem. Biophys. Res. Commun., 355:855-859 (2007).;;Ngo et al., ""Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,"" The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (eds.), Birkhauser Boston: Boston, MA, pp. 433 and 492-495 (1994).;;Nielsen et al., ""Reliable prediction of T-cell epitopes using neural networks with novel sequence representations,"" Protein Sci., 12:1007-1017 (2003).;;Nowak et al., ""Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors,"" Cancer Res., 63:4490-96 (2003).;;O'Brien et al., ""A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,"" Nature, 7123:106-110 (2007).;;Okada et al., ""Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy,"" J. Neurooncol., 64:13-20 (2003).;;Okada et al., ""Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms,"" Int. J. Cancer, 78:196-201 (1998).;;Okano et al., ""Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor I2 chain,"" Clin. Cancer Res., 8:2851-55 (2002).;;Osada et al., ""Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report,"" Jpn. J. Clin. Oncol., 31:403-406 (2001).;;Parkhurst et al., ""Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2),"" Cancer Res., 58:4895-4901 (1998).;;Parkhurst et al., ""Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues,"" J. Immunol., 157:25392548 (1996).;;Parmiani et al., ""Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?"" J. Natl. Cancer Inst., 94:805-818 (2002).;;Parney et al., ""Glioma immunology and immunotherapy,"" Neurosurgery, 46:778-792 (2000).;;Pellegatta et al., ""Dendritic cell vaccines for cancer stem cells,"" Methods Mol. Biol., 568:233-247 (2009).;;Pellegatta et al., ""Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas,"" Cancer Res., 66:10247-52 (2006).;;Phuphanich et al., ""Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107),"" J. Clin. Oncol., 28(15 suppl.):2097 (abstract) (2010).;;Phuphanich et al., ""Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107),"" poster presented at 2010 ASCO Annual Meeting, Jun. 4-8, 2010.;;Pinilla et al., ""Investigation of antigen-antibody interactions using a soluble, non-support-bound synthetic decapeptide library composed of four trillion (4×1012) sequences,"" Biochem. J., 301:847-853 (1994).;;Pinilla et al., ""Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries,"" Biotechniques, 13:901-905 (1992).;;Pirtskhalaishvili et al., ""Cytokine-mediated protection of human dendritic cells from prostate cancer induced apoptosis is regulated by the Bc1-2 family of proteins,"" Br. J. Cancer, 83:506-513 (2000).;;Pollack et al., ""Exploitation of immune mechanisms in the treatment of central nervous system cancer,"" Semin. Pediatr. Neurol., 7:131-143 (2000).",ACTIVE
156,US,A1,US 2017/0112897 A1,132-122-764-364-886,2017-04-27,2017,US 201615332880 A,2016-10-24,US 201615332880 A;;US 201562245895 P,2015-10-23,METHODS FOR TREATING BRAIN INSULIN RESISTANCE,The invention provides methods for treating brain insulin resistance and/or diseases associated therewith in a subject in need thereof. The methods include providing a composition comprising a dual GLP-1 receptor/GIP receptor (GLP-1R/GIPR) agonist and administering an effective amount of the composition to the subject to treat brain insulin resistance and diseases associated therewith.,CEDARS SINAI MEDICAL CENTER;;UNIV CITY NEW YORK RES FOUND,TALBOT KONRAD;;WANG HOAU-YAN;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2016-11-07);;RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (2017-05-23),https://lens.org/132-122-764-364-886,Patent Application,yes,0,11,1,1,2,A61K38/16;;A61K45/06;;A61K31/13;;A61K38/16;;A61K45/06;;A61K31/13,A61K38/16;;A61K31/13;;A61K45/06,,0,0,,,,DISCONTINUED
157,EP,A1,EP 1037986 A1,137-513-624-277-262,2000-09-27,2000,EP 98963127 A,1998-12-11,US 9826461 W;;US 98975097 A,1997-12-12,GENE ASSOCIATED WITH NEOPLASTIC DISEASE OR MALIGNANCY ASSOCIATED GENE,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH;;LJUBIMOVA JULIA Y;;DEMETRIOU ACHILLES A,,https://lens.org/137-513-624-277-262,Patent Application,yes,0,0,4,4,0,A61K38/00;;C07K14/47,G01N33/53;;A61K38/00;;C07K14/47;;C07K16/18;;C12N15/09;;C12N15/12;;C12Q1/68;;G01N33/566;;G01N33/574,,1,0,,,See references of WO 9929859A1,DISCONTINUED
158,US,A,US 6012042 A,146-615-406-782-31X,2000-01-04,2000,US 69881696 A,1996-08-16,US 69881696 A;;US 243495 P,1995-08-16,Security analysis system,An improved securities analysis system includes a data conversion device for converting both technical and fundamental data about a security into a unified format for analysis by an analysis process engine. The analysis process engine processes the disparate data in accordance with a set of rules and the results are forwarded to a display for viewing or used in further analysis.,WINDOW ON WALLSTREET INC,BLACK KEITH T;;JENNINGS JOHN R;;LASKA ANDREW,WINDOW ON WALLSTREET INC (1999-04-16),https://lens.org/146-615-406-782-31X,Granted Patent,yes,5,246,1,1,0,G06Q40/04;;G06Q40/04;;G06Q40/00;;G06Q40/00;;G06Q40/06;;G06Q40/06,G06F12/00;;G06F15/00;;G06G7/52;;G06Q40/00,705/36;;705/35;;395/726;;707/533,0,0,,,,EXPIRED
159,WO,A8,WO 2001/015046 A8,005-453-477-875-386,2001-12-20,2001,US 0023152 W,2000-08-23,US 37955899 A,1999-08-23,SECURITY AND MARKET MAKER ANALYSIS SYSTEM,"La présente invention concerne un système amélioré d'analyse des titres et valeurs comportant un dispositif de saisie et de mémorisation des données. Ce dispositif sert à la saisie et à la mémorisation en suites cohérentes des données, qui sont détenues par des teneurs de marchés de niveau II, et qui se rapportent à un titre. A cet effet, un convertisseur de données relie entre elles plusieurs données d'écart minimum se rapportant aux activités de niveau I et de niveau II de teneurs de marchés, et produit une suite cohérente. Pour traiter des données disparates, le moteur d'analyse utilise des outils d'analyse technique. Il ne reste plus qu'à envoyer les résultats en vue de leur affichage ou de compléments d'analyse.",WINDOW ON WALLSTREET INC,BLACK T KEITH;;JENNINGS JOHN R;;DHINGRA RAMESH,,https://lens.org/005-453-477-875-386,Patent Application,no,0,0,3,3,0,G06Q40/04,G06Q40/00,,0,0,,,,PENDING
160,AU,A,AU 2000/070669 A,020-838-809-461-851,2001-03-19,2001,AU 2000/070669 A,2000-08-23,US 37955899 A;;US 0023152 W,1999-08-23,Security and market maker analysis system,,WINDOW ON WALLSTREET INC,BLACK T KEITH;;JENNINGS JOHN R;;DHINGRA RAMESH,,https://lens.org/020-838-809-461-851,Patent Application,no,0,0,3,3,0,G06Q40/04,G06Q40/00,,0,0,,,,DISCONTINUED
161,EP,A4,EP 3691670 A4,194-015-884-870-148,2021-08-04,2021,EP 18864985 A,2018-10-02,US 201762566813 P;;US 2018/0053873 W,2017-10-02,METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY THROUGH MULTIPLE BIO BARRIERS,,CEDARS SINAI MEDICAL CENTER,HOLLER EGGEHARD;;LJUBIMOVA JULIA Y;;BLACK KEITH L,,https://lens.org/194-015-884-870-148,Search Report,no,0,0,5,6,0,A61P35/00;;A61K31/713;;A61K38/00;;A61K38/08;;A61K47/593;;A61K47/64;;A61P25/00;;C07K5/0808;;C07K5/0812;;C07K7/06;;C07K14/43572;;C07K14/4711;;C07K14/8117;;C07K14/8121;;C07K17/08;;C07K19/00;;C07K2319/01;;C07K2319/03;;C07K2319/06,A61K38/00;;A61K31/713;;A61K38/08;;A61K47/59;;A61K47/64;;A61P25/00;;A61P35/00;;C07K5/083;;C07K5/087;;C07K7/00;;C07K7/06;;C07K7/08;;C07K14/435;;C07K14/47;;C07K14/81;;C07K17/08;;C07K19/00,,3,2,082-341-260-346-21X;;083-600-046-001-528,30633492;;pmc7641102;;10.1021/acsnano.8b06437;;10.1073/pnas.1015385107,"ISRAEL LIRON L. ET AL: ""A Combination of Tri-Leucine and Angiopep-2 Drives a Polyanionic Polymalic Acid Nanodrug Platform Across the Blood-Brain Barrier"", ACS NANO, 26 February 2019 (2019-02-26), US, XP055811026, ISSN: 1936-0851, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641102/pdf/nihms-1054603.pdf> DOI: 10.1021/acsnano.8b06437;;""Correction for Ding et al., Inhibition of brain tumor growth by intravenous poly(L-malic) acid nanobioconjugate with pH-dependent drug release"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 45, 27 October 2010 (2010-10-27), pages 19603 - 19603, XP055098887, ISSN: 0027-8424, DOI: 10.1073/pnas.1015385107;;See also references of WO 2019070645A1",DISCONTINUED
162,CN,A,CN 111182913 A,044-116-854-282-648,2020-05-19,2020,CN 201880065055 A,2018-10-02,US 201762566813 P;;US 2018/0053873 W,2017-10-02,METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY THROUGH MULTIPLE BIO BARRIERS,"Mini nanodrugs that include a polymalic-based molecular scaffold with one or more peptides capable of crossing the blood-brain barrier, one or more plaque-binding peptides and one or more therapeuticagents attached to the scaffold are provided. Methods of treating brain diseases or abnormal conditions, and imaging of the same in a subject by administering the mini nanodrugs are described. Methodsfor reducing formation of amyloid plaques in the brain of a subject are disclosed.",CEDARS SINAI MEDICAL CENTER,HOLLER EGGEHARD;;LJUBIMOVA JULIA Y;;BLACK KEITH L,,https://lens.org/044-116-854-282-648,Patent Application,no,11,1,5,6,0,A61K38/00;;A61P25/00;;A61P35/00;;C07K19/00;;C07K17/08;;C07K2319/03;;A61K47/593;;A61K47/64;;C07K14/8117;;C07K5/0812;;C07K7/06;;C07K14/43572;;C07K14/4711;;C07K2319/01;;C07K2319/06;;C07K5/0808;;C07K14/8121;;A61K38/08;;A61K31/713,A61K38/00;;A61K47/59;;A61K47/64;;C07K7/00;;C07K7/06;;C07K7/08;;C07K14/435,,1,0,,,"SUSANNE AILEEN FUNKE等: ""Development of a small D-enantiomeric Alzheimer\'s amyloid-β binding peptide ligand for future in vivo imaging applications""",DISCONTINUED
163,US,A1,US 2010/0135975 A1,191-564-945-747-171,2010-06-03,2010,US 55294509 A,2009-09-02,US 55294509 A;;US 19071808 P,2008-09-02,CD133 Epitopes,"An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.",YU JOHN S;;BLACK KEITH L;;LIU GENTAO,YU JOHN S;;BLACK KEITH L;;LIU GENTAO,CEDARS-SINAI MEDICAL (2009-07-31);;CEDARS-SINAI MEDICAL CENTER (2009-08-17),https://lens.org/191-564-945-747-171,Patent Application,yes,95,21,13,13,19,A61K39/0011;;A61K39/0011;;A61K45/06;;A61P35/00;;A61P37/04;;C07K14/70596;;C07K14/70596;;C07K7/06;;C07K7/06,A61K45/00;;A61K31/7088;;A61K39/00;;A61P35/00;;A61P37/04;;C07H21/00;;C07K7/06;;C12N5/0783;;C12N15/74,424/93.71;;530/328;;424/185.1;;536/23.1;;435/320.1;;X514 44  R;;435/377,10,7,063-710-398-275-735;;103-932-348-507-545;;157-642-321-785-08X;;003-646-738-432-814;;124-282-566-991-152;;053-393-265-065-68X;;081-457-468-429-178,10.1007/978-1-349-02718-7_1;;10.1007/978-1-4684-6831-1_14;;10.1158/1078-0432.ccr-09-1322;;20068073;;pmc3682507;;8617954;;8557366;;pmc173770;;10.1128/iai.64.1.363-365.1996;;17540729;;10.1073/pnas.0608635104;;pmc1885220;;24375541;;pmc3952931;;10.5966/sctm.2013-0135,"Yu et al., Journal of immunotherapy NOV-DEC 2008, pp. 928. CD133 as a Potential Target of Anti-cancer Stem Cell Immunotherapy: Identification of an HLA-A*02 Restricted CD133 Epitope. Abstract.;;Rudinger, J., ""Characteristics of the amino acids as components of a peptide hormone sequence"",in ""PEPTIDE HORMONES, University Park Press: Baltimore, MD, pp. 1-7, 1976;;Ngo, J. et al., ""Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox"", 1994, The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (eds.), Birkhauser Boston: Boston, MA, pp. 433 and 492-495.;;Voet, Biochemistry John Wiley and Sons, 1990, pp. 126-128.;;Ahmed et al ., HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental TumorsClin Cancer Res; 16(2); 474-85.;;Burg et al., Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stabilityl The Journal of lmmuno/ogy, 1996, 156; 3308-3314.;;Feng et al P55, an Immunogenic but Nonprotective 55-Kilodalton Borrelia burgdorferi Protein in Murine Lyme Disease INFECTION AND IMMUNITY, Jan. 1996, p. 363-365;;Zhang et al Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization PNAS I June 12. 2007 I vol. t04 I no. 24 I 1019).-10198;;Ji et al., Identification of Novel Human Leukocyte Antigen-A*0201-Restricted, Cytotoxic T Lymphocyte Epitopes on CD133 for Cancer Stem Cell Immunotherapy MEDICINE 2014;3:356-364;;Ludewig et al., Adoptive Immunotherapy: Methods and Protocols Non-self MHC-restricted CTL 2005 Human Press Inc. page 216-217",ACTIVE
164,US,A1,US 2014/0302097 A1,052-453-732-748-195,2014-10-09,2014,US 201414247028 A,2014-04-07,US 201414247028 A;;US 99543410 A;;US 2009/0047640 W;;US 7320508 P,2008-06-17,USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS,"Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendritic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;MORRIS-IRVIN DWAIN;;ARDITI MOSHE,CEDARS-SINAI MEDICAL CENTER (2009-06-17),https://lens.org/052-453-732-748-195,Patent Application,yes,1,1,5,5,0,A61K38/164;;A61K45/06;;C12N5/0639;;A61K2039/55561;;A61K2039/55572;;A61P35/00;;A61P37/04;;A61K39/4615;;A61K2239/38;;A61K2239/47;;A61K39/4622;;A61K2239/31;;A61K39/464499;;A61K35/15;;A61K38/164;;A61K45/06;;C12N5/0639;;A61K2039/5154;;A61K2039/55561;;A61K2039/55572;;A61K39/0011,A61K39/00;;A61K35/14;;A61K35/15;;A61K38/16,424/277.1;;424/93.71;;435/375,3,3,109-565-213-148-182;;017-762-302-959-224;;012-063-847-650-863,17383632;;10.1016/j.ejphar.2007.02.018;;10.1038/ni1223;;15995707;;pmc3760217;;10.1002/ijc.20331;;15252850,"Garay (European Journal of Pharmacology, 2007, Vol. 563, pp. 1-17);;Napolitani et al, Nature Immunology, 2005, Vol. 6, pp. 769-776;;Saito et al, International Journal of Cancer, Vol. 2004, Vol. 111, pp. 777-782",ACTIVE
165,EP,A2,EP 1689443 A2,094-013-042-451-241,2006-08-16,2006,EP 04813049 A,2004-12-03,US 2004/0040660 W;;US 52733003 P,2003-12-05,POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM,,ARROGENE INC,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,"CEDARS-SINAI MEDICAL CENTER (2006-11-02);;ARROGENE, INC. (2006-11-02)",https://lens.org/094-013-042-451-241,Patent Application,yes,0,0,12,14,0,A61K47/60;;A61K47/593;;A61K47/6883;;A61K47/6849;;A61P35/00;;A61K47/6883;;A61K47/593;;A61K47/60;;A61K47/6849;;A61P35/00,A61K47/48;;A61K47/59;;A61K47/60;;A61K47/68;;A61P35/00,,0,0,,,,ACTIVE
166,CR,A,CR 20130091 A,113-317-857-829-727,2013-07-09,2013,CR 20130091 A,2013-02-28,US 37854610 P;;US 2011/0049544 W,2010-08-31,DISPOSITIVO PARA MONITOREO DE CHINCHES DE CAMA,La invención se refiere a un dispositivo para el monitoreo de chinches de cama que comprende un elemento atrayente para las chinches de cama y una sección de anclaje que comprende un miembro de soporte que tiene una superficie que se puede atravesar y una o más protuberancias que penden desde ella.,FMC CORP,BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,,https://lens.org/113-317-857-829-727,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,A01M1/02;;A01M1/00;;A01M1/14;;C09J201/00,,0,0,,,,PENDING
167,ES,T3,ES 2565779 T3,044-526-075-846-485,2016-04-06,2016,ES 09812172 T,2009-09-02,US 19071808 P;;US 2009/0055759 W,2008-09-02,Epítopos CD133,"Un inmunógeno aislado que consiste en un péptido aislado de 30 restos de aminoácido o menos que comprende la secuencia amino ILSAFSVYV (SEC ID N.º 1) con dos o menos sustituciones de aminoácido, en el que el inmunógeno es capaz de unirse a antígeno de leucocitos humanos (HLA), en el que el inmunógeno está unido opcionalmente a uno cualquiera de: un vehículo inmunogénico, un agonista del receptor tipo Toll, un péptido inmunogénico que se sabe que estimula una respuesta inmunitaria del tipo de células T auxiliares, una citoquina, un anticuerpo, un ligando de receptor, un lípido, un péptido antigénico múltiple, polietilenglicol, una secuencia líder, una secuencia de secreción, o una secuencia empleada para la purificación del péptido.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,,https://lens.org/044-526-075-846-485,Granted Patent,no,0,0,13,13,0,A61K39/0011;;C07K7/06;;C07K14/70596;;A61P35/00;;A61P37/04;;A61K39/0011;;C07K7/06;;C07K14/70596;;A61K45/06,A61K39/00;;C07K14/705;;A61P35/00;;C07K7/06,,0,0,,,,ACTIVE
168,US,B2,US 9068020 B2,060-295-022-270-675,2015-06-30,2015,US 55294509 A,2009-09-02,US 55294509 A;;US 19071808 P,2008-09-02,CD133 epitopes,"An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.",YU JOHN S;;BLACK KEITH L;;LIU GENTAO;;CEDARS SINAI MEDICAL CENTER,YU JOHN S;;BLACK KEITH L;;LIU GENTAO,CEDARS-SINAI MEDICAL (2009-07-31);;CEDARS-SINAI MEDICAL CENTER (2009-08-17),https://lens.org/060-295-022-270-675,Granted Patent,yes,104,3,13,13,19,A61K39/0011;;A61K39/0011;;A61K45/06;;A61P35/00;;A61P37/04;;C07K14/70596;;C07K14/70596;;C07K7/06;;C07K7/06,A61K39/00;;A61K45/06;;C07K7/06;;C07K14/705,,109,102,063-710-398-275-735;;103-932-348-507-545;;157-642-321-785-08X;;003-646-738-432-814;;124-282-566-991-152;;053-393-265-065-68X;;081-457-468-429-178;;032-932-040-924-322;;138-771-752-862-480;;084-085-138-348-898;;064-388-641-569-789;;097-167-161-561-41X;;006-027-796-241-692;;077-678-786-447-085;;029-311-860-898-924;;032-294-227-563-850;;078-639-700-866-831;;025-457-637-309-732;;022-798-233-953-966;;045-700-919-027-517;;019-264-483-343-031;;013-855-584-540-778;;062-108-416-505-04X;;057-785-668-031-036;;011-954-218-606-176;;044-750-837-062-887;;092-707-572-319-639;;040-713-726-205-55X;;160-717-493-067-916;;044-555-535-916-468;;018-870-261-171-506;;090-928-883-705-496;;028-167-813-228-119;;004-397-008-209-727;;006-148-652-132-981;;008-169-153-417-267;;054-439-756-152-283;;053-672-692-937-579;;165-292-111-716-265;;099-464-580-091-161;;068-473-895-492-963;;006-885-984-877-437;;085-702-051-840-908;;067-905-202-866-732;;003-865-790-341-418;;038-241-086-015-47X;;153-662-306-900-396;;120-862-791-424-707;;025-760-264-704-263;;082-930-667-453-661;;017-862-373-044-791;;004-602-946-239-391;;108-599-572-220-595;;060-861-375-524-523;;019-377-086-323-88X;;012-105-359-936-435;;055-983-972-565-643;;019-963-559-470-014;;086-946-791-527-279;;044-084-260-816-039;;003-616-087-027-77X;;053-906-705-994-097;;063-225-571-358-608;;022-705-571-480-334;;097-470-977-075-432;;070-884-634-385-754;;003-924-024-298-446;;139-500-660-556-55X;;133-716-008-515-719;;010-981-337-785-354;;078-723-209-803-023;;116-248-902-411-147;;047-903-330-676-744;;081-222-505-017-37X;;035-823-463-717-575;;054-045-955-566-76X;;071-699-972-336-631;;041-406-340-961-551;;026-887-607-952-029;;026-304-558-215-155;;063-547-669-345-057;;035-263-789-910-604;;075-344-720-447-282;;033-947-267-268-874;;077-262-310-785-629;;078-642-510-799-292;;009-792-025-501-449;;060-667-322-361-290;;032-969-718-122-323;;018-117-667-758-278;;057-105-231-226-816;;012-638-135-148-028;;108-207-855-841-062;;100-984-968-676-329;;033-662-847-189-276;;028-211-379-291-005;;018-681-549-217-136;;030-955-335-211-791;;096-830-349-650-74X;;022-982-723-684-607;;096-741-767-207-949;;192-609-714-372-280,10.1007/978-1-349-02718-7_1;;10.1007/978-1-4684-6831-1_14;;10.1158/1078-0432.ccr-09-1322;;20068073;;pmc3682507;;8617954;;8557366;;pmc173770;;10.1128/iai.64.1.363-365.1996;;17540729;;10.1073/pnas.0608635104;;pmc1885220;;24375541;;pmc3952931;;10.5966/sctm.2013-0135;;11449066;;11265767;;10.1097/00002371-200103000-00004;;10.1586/14737175.5.4.497;;16026233;;10.1073/pnas.0530291100;;pmc153034;;12629218;;18665745;;10.1158/0008-5472.can-06-4180;;17483311;;10.1038/nrc1740;;16327766;;18539956;;10.1200/jco.2008.17.7436;;pmc2241749;;10.4049/jimmunol.174.8.4812;;15814707;;10.1016/s0022-1759(02)00142-4;;12135802;;10.1097/00006123-199903000-00110;;10069601;;19903840;;pmc2789196;;10.1158/0008-5472.can-09-2687;;11196166;;12941147;;10.1046/j.1365-2567.2003.01726.x;;pmc1783031;;12667889;;10.1016/s0163-7258(03)00014-7;;10.1227/00006123-199305000-00003;;10.1097/00006123-199305000-00003;;8388081;;10.3727/096368909x12483162196962;;19523342;;10.1093/jnci/85.9.704;;8478956;;11471194;;12616102;;10.1097/00002371-200303000-00003;;10.1177/107327480401100307;;15153843;;1709722;;10.1038/351290a0;;10914698;;10.1158/0008-5472.can-04-1364;;15466194;;12391241;;10.4049/jimmunol.169.9.5227;;11731436;;11239426;;10.1016/s0896-6273(01)00209-4;;17412894;;10.1634/stemcells.2006-0624;;10.1007/s002620050465;;9558003;;10.1097/00002371-200107000-00008;;11565834;;10.1189/jlb.1002483;;12773508;;10.1016/s0165-5728(99)00172-1;;10674985;;pmc299944;;14645703;;10.1073/pnas.2036535100;;10.4049/jimmunol.164.2.861;;10623833;;pmc521140;;10.1073/pnas.0400067101;;15381773;;12832694;;10.1634/stemcells.21-4-405;;10.1007/s005950300060;;12707821;;pmc2881867;;10.1371/journal.pone.0010974;;20539758;;19944974;;10.1016/j.nec.2009.08.006;;pmc2786895;;9743339;;10.1007/s00262-002-0297-z;;12202903;;11676393;;10.1007/s002620100205;;12222879;;10.1182/blood.v97.6.1776;;11238120;;15908947;;pmc2377345;;10.1038/nn1473;;19194651;;10.1007/s00701-009-0185-9;;10350260;;10.3171/jns.1999.90.6.1115;;17939761;;10.1586/14737175.7.10.1235;;17140455;;pmc1697823;;10.1186/1476-4598-5-67;;10.1177/107327480301000205;;12712008;;15162438;;10.1002/eji.200425081;;15076139;;10.1097/00002371-200405000-00006;;10.1038/sj.onc.1208519;;15897911;;15256472;;10.1158/0008-5472.can-03-3504;;10.1097/00002371-200307000-00002;;12843792;;10.1586/14760584.5.2.233;;16608423;;10.2174/157488708783330530;;18474011;;10.4049/jimmunol.176.3.1796;;16424210;;18539965;;10.1200/jco.2007.15.1472;;10.1634/stemcells.22-6-1101;;15536199;;7774624;;10.1002/eji.1830250511;;8027569;;10.4049/jimmunol.153.3.996;;12109820;;10.1053/clon.2001.0038;;pmc3903051;;10.1007/s00262-007-0426-9;;18057935;;11440627;;10.1089/104303401750270995;;10.1002/path.2283;;18067118;;17307142;;10.1016/j.bbrc.2007.01.159;;12717023;;10.1110/ps.0239403;;pmc2323871;;12907622;;17122772;;10.1038/nature05372;;9754652;;10.1002/(sici)1097-0215(19981005)78:2<196::aid-ijc13>3.0.co;2-9;;10.1023/a:1024969422010;;10.1007/bf02700016;;12952282;;12231526;;10.1093/jjco/hye076;;11574635;;9809996;;10.4049/jimmunol.157.6.2539;;8805655;;10.1093/jnci/94.11.805;;12048268;;10764250;;10.1227/00006123-200004000-00002;;10.1097/00006123-200004000-00002;;10.1007/978-1-59745-280-9_15;;19582431;;17079441;;10.1158/0008-5472.can-06-2048;;10.1200/jco.2010.28.15_suppl.2097;;pmc1137064;;7519851;;10.1042/bj3010847;;1476743;;10945499;;10.1054/bjoc.2000.1289;;pmc2374651;;10.1053/pb.2000.6691;;10914414;;3276675;;10.1016/s0021-9258(19)77935-6;;14555310;;10.1038/35102167;;11689955;;1553558;;10.1126/science.1553558;;1432110;;10.1523/jneurosci.12-11-04565.1992;;pmc6575989;;10024247;;10.1126/science.283.5405.1183;;10.1038/nm0398-321;;9500606;;pmc2064864;;16120861;;10.1056/nejmra043666;;10.14670/hh-18.435;;12647794;;15378086;;10.1038/sj.onc.1207946;;14522905,"Yu et al., Journal of immunotherapy Nov.-Dec. 2008, pp. 928. CD133 as a Potential Target of Anti-cancer Stem Cell Immunotherapy: Identification of an HLA-A*02 Restricted CD133 Epitope. Abstract.;;Rudinger, J., ""Characteristics of the amino acids as components of a peptide hormone sequence"",in Peptide Hormones, University Park Press: Baltimore, MD, pp. 1-7, 1976.;;Ngo, J. et al., ""Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox"", 1994, The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (eds.), Birkhauser Boston: Boston, MA, pp. 433 and 492-495.;;Voet, Biochemistry John Wiley and Sons, 1990, pp. 126-128.;;Ahmed et al ., HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental TumorsClin Cancer Res; 16(2); 474-85.;;Burg et al., Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability the Journal of Immunology, 1996, 156; 3308-3314.;;Feng et al P55, an Immunogenic but Nonprotective 55-Kilodalton Borrelia burgdorferi Protein in Murine Lyme Disease Infection and Immunity, Jan. 1996, p. 363-365.;;Zhang et al Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization PNAS | Jun. 12, 2007 | vol. t04 | No. 24 | 1019).-10198.;;Ji et al., Identification of Novel Human Leukocyte Antigen-A*0201-Restricted, Cytotoxic T Lymphocyte Epitopes on CD133 for Cancer Stem Cell Immunotherapy Medicine 2014;3:356-364.;;Ludewig et al., Adoptive Immunotherapy: Methods and Protocols Non-self MHC-restricted CTL 2005 Human Press Inc. pp 216-217.;;Akasaki et al., ""Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model,"" J. Immunother., 24:106-113 (2001).;;Akasaki et al., ""Dendritic cell-based immunotherapy for malignant gliomas,"" Expert Rev. Neurother., 5:497-508 (2005).;;Al-Hajj et al., ""Prospective identification of tumorigenic breast cancer cells,"" Proc. Natl. Acad. Sci. USA, 7:3983-88 (2003).;;Altaner, ""Glioblastoma and stem cells,"" Neoplasma, 55:369-374 (2008).;;Beier et al., ""CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles,"" Cancer Res., 67:4010-15 (2007).;;Bjerkvig et al., ""Opinion: the origin of the cancer stem cell: current controversies and new insights,"" Nat. Rev. Cancer, 11:899-904 (2005).;;Boman et al., ""Cancer stem cells: a step toward the cure,"" J. Clin. Oncol., 26:2795-99 (2008).;;Borbulevych et al., ""Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design,"" J. Immunol., 174:4812-20 (2005).;;Borras et al., ""Findings on T cell specificity revealed by synthetic combinatorial libraries,"" J. Immunol. Methods, 267:79-97 (2002).;;Bowles, Jr. et al., ""Long-term remission of malignant brain tumors after intracranial infection: a report of four cases,"" Neurosurgery, 44:636-642 (1999).;;Brown et al., ""Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells,"" Cancer Res., 69:8886-93 (2009).;;Candido et al., ""Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents,"" Cancer Res., 61:228-236 (2001).;;Casey et al., ""Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine,"" Immunology, 110:105-111 (2003).;;Castro et al., ""Current and future strategies for the treatment of malignant brain tumors,"" Pharmacol. Ther., 98:71-108 (2003).;;Chandler et al., ""Long-term survival in patients with glioblastoma multiforme,"" Neurosurgery, 32:716-720 (1993).;;Cho et al., ""Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas,"" Cell Transplant., 18:977-983 (2009).;;Curran et al., ""Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials,"" J. Natl. Cancer Inst., 85:704-710 (1993).;;Dietz, ""Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia,"" Croatian Med. J., 42:428-435 (2001).;;Ehtesham et al., ""Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats,"" J. Immunother., 26:107-116 (2003).;;Ehtesham et al., ""Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials,"" Cancer Control, 11:192-207 (2004).;;Falk et al., ""Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,"" Nature, 351:290-296 (1991).;;Friedman et al., ""Temozolomide and treatment of malignant glioma,"" Clin. Cancer Res., 6:2585-97 (2000).;;Galli et al., ""Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma,"" Cancer Res., 64:7011-21 (2004).;;Gatza et al., ""Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma,"" J. Immunol , 169:5227-35 (2002).;;Geiger et al., ""Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression,"" Cancer Res., 61:8513-19 (2001).;;Geschwind et al., ""A genetic analysis of neural progenitor differentiation,"" Neuron, 2:325-39 (2001).;;Ghods et al., ""Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells,"" Stem Cells, 7:1645-53 (2007).;;Gilboa et al., ""Immunotherapy of cancer with dendritic-cell-based vaccines,"" Cancer Immunol. Immunother., 46:82-87 (1998).;;Harada et al., ""Melanoma-reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types,"" J. Immunother., 24:323-333 (2001).;;Harizi et al., ""Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subytpes,"" J. Leukocyte Biol., 73:756-763 (2003).;;Heimberger et al., ""Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma,"" J. Neuroimmunol., 103:16-25 (2000).;;Hemmati et al., ""Cancerous stem cells can arise from pediatric brain tumors,"" Proc. Natl. Acad. Sci. USA, 25:15178-83 (2003).;;Hemmer et al., ""Contribution of Individual Amino Acids Within MHC Molecule or Antigenic Peptide to TCR Ligand Potency,"" J. Immunol., 164:861-871 (2000).;;Hirschmann-Jax et al., ""A distinct 'side population' of cells with high drug efflux capacity in human tumor cells,"" Proc. Natl. Acad. Sci. USA, 39:14228-33 (2004).;;Hori et al., ""Neural progenitor cells lack immunogenecity and resist destruction as allografts,"" Stem Cells, 21:405-416 (2003).;;Inoue et al., ""Dendritic cells coinjected with tumor cells treated with an anticancer drug to induce tumor rejection,"" Surg. Today, 33:269-276 (2003).;;Irvin et al., ""T cells enhance stem-like properties and conditional malignancy in gliomas,"" PLoS One, 5(6):e10974 (2010).;;Ji et al., ""Glioma stem cell research for the development of immunotherapy,"" Neurosurg. Clin. N. Am., 21:159-66 (2010).;;Kalinski et al., ""Prostaglandin E2 induces the final maturation of IL-12 deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation,"" J. Immunol, 161:2804-09 (1998).;;Kikuchi et al., ""Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model,"" Cancer Immunol Immumother., 51:424-430 (2002).;;Kikuchi et al., ""Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells,"" Cancer Immunol. Immumother., 50:337-344 (2001).;;Knutson et al., ""Technology evaluation: DCVax, Northwest Biotherapeutics,"" Curr. Opin. Mol. Ther., 4:403-407 (2002).;;Kuby et al., Immunology, W. H. Freeman and Co., pp. 523-524 (1992).;;La Rosa et al., ""Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries,"" Blood, 97:1776-86 (2001).;;Lee et al., ""Isolation of neural stem cells from the postnatal cerebellum,"" Nat. Neurosci., 6:723-729 (2005).;;Lefranc, ""Editorial: On the road to multi-modal and pluri-disciplinary treatment of glioblastomas,"" Acta Neurochir. (Wien), 151:109-112 (2009).;;Liau et al., ""Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens,"" J. Neurosurg., 90:1115-24 (1999).;;Liu et al., ""Cancer vaccines: a novel strategy to sensitize malignant glioma to chemotherapy,"" Expert Rev. Neurother., 7:1235-37 (2007).;;Liu et al., ""Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma,"" Mol. Cancer, 5:67 (2006).;;Liu et al., ""Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma,"" Cancer Control, 10:138-147 (2003).;;Liu et al., ""Chemoresistance of stem-like cells isolated from glioblastoma,"" Proc. Amer. Assoc. Cancer Res., 47:75, abstract #320 (2006).;;Liu et al., ""Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response,"" Eur. J. Immunol., 34:1680-87 (2004).;;Liu et al., ""AIM-2: a novel tumor antigen is expressed and presented by human glioma cells,"" J. Immunother., 27:220-226 (2004).;;Liu et al., ""Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy,"" Oncogene, 24:5226-34 (2005).;;Liu et al., ""HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells,"" Cancer Res., 64:4980-86 (2004).;;Liu et al., ""Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma,"" J. Immunother., 26:301-312 (2003).;;Liu et al., ""Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination,"" Expert Rev. Vaccines, 5:233-247 (2006).;;Luptrawan et al., ""Dendritic cell immunotherapy for malignant gliomas,"" Rev. Recent Clin. Trials, 3:10-21 (2008).;;Lustgarten et al., ""Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope,"" J. Immunol., 176:1796-1805 (2006).;;Maitland et al., ""Prostate cancer stem cells: a new target for therapy,"" J. Clin. Oncol., 26:2862-70 (2008).;;Mammolenti et al., ""Absence of major histocompatibility complex class I on neural stem cells does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro,"" Stem Cells, 22:1101-10 (2004).;;Mehta-Damani et al., ""Generation of antigen-specific CD4+ T cell lines from naive precursors,"" Eur. J. Immunol., 5:1206-11 (1995).;;Mehta-Damani et al., ""Generation of antigen-specific CD8+ CTLs from naive precursors,"" J. Immunol., 153:996-1003 (1994).;;Melcher et al., ""Dendritic cells for the immunotherapy of cancer,"" Clin. Oncol., 14:185-192 (2002).;;Merrick et al., ""Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naive cytotoxic priming and anti-tumour therapy,"" Cancer Immunol. Immunother., 57:897-906 (2008).;;Mi et al., ""Induced apoptosis supports spread of adenovirus vectors in tumors,"" Hum. Gene Ther., 12:1343-52 (2001).;;Mizrak et al., ""CD133: molecule of the moment,"" J. Pathol., 214:3-9 (2008).;;NCBI GenBank Accession No. NM-006017 (Jul. 13, 2008).;;Neuzil et al., ""Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?"" Biochem. Biophys. Res. Commun., 355:855-859 (2007).;;Nielsen et al., ""Reliable prediction of T-cell epitopes using neural networks with novel sequence representations,"" Protein Sci., 12:1007-1017 (2003).;;Nowak et al., ""Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors,"" Cancer Res., 63:4490-96 (2003).;;O'Brien et al., ""A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,"" Nature, 7123:106-110 (2007).;;Okada et al., ""Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms,"" Int. J. Cancer, 78:196-201 (1998).;;Okada et al., ""Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy,"" J. Neurooncol., 64:13-20 (2003).;;Okano et al., ""Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor 12 chain,"" Clin. Cancer Res., 8:2851-55 (2002).;;Osada et al., ""Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report,"" Jpn. J. Clin. Oncol., 31:403-406 (2001).;;Parkhurst et al., ""Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2),"" Cancer Res., 58:4895-4901 (1998).;;Parkhurst et al., ""Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues,"" J. Immunol., 157:2539-2548 (1996).;;Parmiani et al., ""Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?"" J. Natl. Cancer Inst., 94:805-818 (2002).;;Parney et al., ""Glioma immunology and immunotherapy,"" Neurosurgery, 46:778-792 (2000).;;Pellegatta et al., ""Dendritic cell vaccines for cancer stem cells,"" Methods Mol. Biol., 568:233-247 (2009).;;Pellegatta et al., ""Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas,"" Cancer Res., 66:10247-52 (2006).;;Phuphanich et al., ""Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107),"" J. Clin. Oncol., 28(15 suppl.):2097 (abstract) (2010).;;Phuphanich et al., ""Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107),"" poster presented at 2010 ASCO Annual Meeting, Jun. 4-8, 2010.;;Pinilla et al., ""Investigation of antigen-antibody interactions using a soluble, non-support-bound synthetic decapeptide library composed of four trillion (4×1012) sequences,"" Biochem. J., 301:847-853 (1994).;;Pinilla et al., ""Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries,"" Biotechniques, 13:901-905 (1992).;;Pirtskhalaishvili et al., ""Cytokine-mediated protection of human dendritic cells from prostate cancer induced apoptosis is regulated by the Bcl-2 family of proteins,"" Br. J. Cancer, 83:506-513 (2000).;;Pollack et al., ""Exploitation of immune mechanisms in the treatment of central nervous system cancer,"" Semin. Pediatr. Neurol., 7:131-143 (2000).;;Posnett et al., ""A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain,"" J. Biol. Chem., 263:1719-25 (1988).;;Reichardt et al., ""Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells,"" Haematologica, 88:1139-49 (2003).;;Reya et al., ""Stem cells, cancer, and cancer stem cells,"" Nature, 6859:105-111 (2001).;;Reynolds et al., ""Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system,"" Science, 5052:1707-10 (1992).;;Reynolds et al, ""A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes,"" J. Neurosci., 11:4565-74 (1992).;;Rissoan et al., ""Reciprocal control of T helper cell and dendritic cell differentiation,"" Science, 283:1183-86 (1999).;;Rosenberg et al., ""Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma,"" Nat. Med., 4:321-327 (1998).;;Sanai et al., ""Neural stem cells and the origin of gliomas,"" N. Eng. J. Med., 8:811-822 (2005).;;Shin et al., ""Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model,"" Histol. Histopathol., 18:435-447 (2003).;;Singh et al., ""Cancer stem cells in nervous tumors,"" Oncogene, 23:7267-73 (2004).;;Singh et al., ""Identification of a cancer stem cell in human brain tumors,"" Cancer Res., 63:5821-28 (2003).",ACTIVE
169,WO,A2,WO 2005/055980 A2,167-200-707-169-41X,2005-06-23,2005,US 2004/0040660 W,2004-12-03,US 52733003 P,2003-12-05,POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM,"A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system&apos;s circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms.",ARROGENE INC;;LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,,https://lens.org/167-200-707-169-41X,Patent Application,yes,0,9,12,14,0,A61K47/60;;A61K47/593;;A61K47/6883;;A61K47/6849;;A61P35/00;;A61K47/6883;;A61K47/593;;A61K47/60;;A61K47/6849;;A61P35/00,A61K47/48,,0,0,,,,PENDING
170,WO,A2,WO 2010/028066 A2,190-032-073-418-501,2010-03-11,2010,US 2009/0055759 W,2009-09-02,US 19071808 P,2008-09-02,CD133 EPITOPES,"An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.",CEDARS SINAI MEDICAL CENTER;;YU JOHN S;;LIU GENTAO;;BLACK KEITH L,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,,https://lens.org/190-032-073-418-501,Patent Application,yes,0,9,13,13,0,A61K39/0011;;A61K39/0011;;A61K45/06;;A61P35/00;;A61P37/04;;C07K14/70596;;C07K14/70596;;C07K7/06;;C07K7/06,C07K14/705;;A61K39/00;;A61P35/00;;C07K7/06,,1,0,,,See references of EP 2328923A4,PENDING
171,US,A1,US 2017/0173130 A1,001-117-077-769-244,2017-06-22,2017,US 201615227552 A,2016-08-03,US 201615227552 A;;US 201113327125 A;;US 86417707 A;;US 82726006 P,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2012-04-24),https://lens.org/001-117-077-769-244,Patent Application,yes,0,3,17,17,71,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/00;;A61K35/12;;C12N5/0784,,0,0,,,,ACTIVE
172,US,B2,US 8871211 B2,017-666-492-875-020,2014-10-28,2014,US 86399007 A,2007-09-28,US 86399007 A;;US 82726006 P,2006-09-28,Cancer vaccines and vaccination methods,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",YU JOHN S;;LIU GENTAO;;BLACK KEITH L;;CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2009-05-12),https://lens.org/017-666-492-875-020,Granted Patent,yes,102,7,17,17,62,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K35/12;;A61K39/00;;C12N5/0784,424/184.1;;424/277.1,102,96,032-294-227-563-850;;007-174-971-453-251;;019-264-483-343-031;;011-191-194-524-48X;;011-643-567-958-26X;;040-713-726-205-55X;;018-870-261-171-506;;008-169-153-417-267;;049-560-808-242-058;;007-894-661-068-687;;120-862-791-424-707;;153-662-306-900-396;;025-760-264-704-263;;057-002-651-793-17X;;108-599-572-220-595;;019-963-559-470-014;;086-946-791-527-279;;044-084-260-816-039;;003-616-087-027-77X;;053-906-705-994-097;;001-000-221-109-111;;022-705-571-480-334;;139-500-660-556-55X;;026-887-607-952-029;;063-547-669-345-057;;032-969-718-122-323;;065-766-887-494-547;;057-105-231-226-816;;046-028-954-444-037;;065-777-065-691-692;;022-665-264-045-910;;109-735-000-316-284;;014-782-564-302-045;;078-538-820-088-074;;113-598-986-994-212;;128-972-796-335-47X;;034-409-534-864-530;;035-857-332-739-788;;006-884-247-056-538;;032-084-932-733-530;;045-609-027-418-523;;009-491-278-782-50X;;092-859-198-377-451;;126-067-752-107-202;;080-647-403-540-300;;046-847-065-587-168;;030-768-232-817-332;;026-958-333-907-92X;;049-915-366-620-516;;032-932-040-924-322;;138-771-752-862-480;;168-705-133-516-75X;;016-059-509-686-365;;029-311-860-898-924;;078-639-700-866-831;;027-915-134-983-264;;022-798-233-953-966;;045-700-919-027-517;;013-855-584-540-778;;057-785-668-031-036;;059-717-731-643-077;;011-954-218-606-176;;092-707-572-319-639;;160-717-493-067-916;;044-555-535-916-468;;090-928-883-705-496;;006-148-652-132-981;;046-986-959-047-056;;096-505-815-317-436;;053-672-692-937-579;;085-702-051-840-908;;003-865-790-341-418;;082-930-667-453-661;;060-861-375-524-523;;012-105-359-936-435;;055-983-972-565-643;;063-225-571-358-608;;124-257-229-162-56X;;097-470-977-075-432;;003-924-024-298-446;;133-716-008-515-719;;010-981-337-785-354;;078-723-209-803-023;;035-823-463-717-575;;071-699-972-336-631;;041-406-340-961-551;;026-304-558-215-155;;075-344-720-447-282;;060-667-322-361-290;;018-117-667-758-278;;108-207-855-841-062;;018-681-549-217-136;;030-955-335-211-791;;022-982-723-684-607;;192-609-714-372-280;;010-628-726-217-388,10.1016/s0022-1759(02)00142-4;;12135802;;9973437;;12667889;;10.1016/s0163-7258(03)00014-7;;10.1073/pnas.91.3.1004;;pmc521442;;8302824;;11454721;;1709722;;10.1038/351290a0;;12391241;;10.4049/jimmunol.169.9.5227;;10.1097/00002371-200107000-00008;;11565834;;10728667;;pmc2430890;;10.4049/jimmunol.168.2.951;;11777994;;11676393;;10.1007/s002620100205;;10.1007/s00262-002-0297-z;;12202903;;12222879;;10.1038/nbt947;;15004565;;10350260;;10.3171/jns.1999.90.6.1115;;15076139;;10.1097/00002371-200405000-00006;;10.1038/sj.onc.1208519;;15897911;;15256472;;10.1158/0008-5472.can-03-3504;;10.1097/00002371-200307000-00002;;12843792;;10.1586/14760584.5.2.233;;16608423;;9743519;;10.1084/jem.188.6.1005;;pmc2212536;;10.4049/jimmunol.176.3.1796;;16424210;;8027569;;10.4049/jimmunol.153.3.996;;12231526;;9809996;;1476743;;10886507;;10.1046/j.1523-1747.2000.00023.x;;10.1053/pb.2000.6691;;10914414;;7585538;;10.3349/ymj.2004.45.suppl.48;;15250050;;10.1034/j.1600-0463.2003.11107802.x;;12974772;;7690811;;10.1016/j.vaccine.2006.02.025;;16530303;;pmc1850619;;10.1084/jem.184.6.2207;;pmc2211562;;8976176;;18298336;;10.1089/cbr.2007.0427;;10.1016/j.exphem.2006.05.011;;16982333;;18632651;;10.1158/0008-5472.can-07-5973;;10.1158/1078-0432.ccr-04-0497;;15328167;;10.4049/jimmunol.171.9.4927;;14568975;;10754316;;10.4049/jimmunol.164.8.4204;;10.3892/or.16.6.1317;;17089056;;10.1084/jem.171.4.1315;;pmc2187833;;2139102;;12538481;;17380773;;11221866;;10.1158/0008-5472.can-03-3505;;15256471;;16081793;;10.4049/jimmunol.175.4.2252;;pmc2192415;;10.1084/jem.183.1.87;;8551248;;10.1006/cimm.1998.1298;;9637766;;11449066;;11265767;;10.1097/00002371-200103000-00004;;10.1586/14737175.5.4.497;;16026233;;15383564;;10.4049/jimmunol.173.7.4352;;10.2741/1747;;15970545;;pmc2241749;;10.4049/jimmunol.174.8.4812;;15814707;;10.1097/00006123-199903000-00110;;10069601;;10.4049/jimmunol.170.4.1822;;12574347;;11196166;;12941147;;10.1046/j.1365-2567.2003.01726.x;;pmc1783031;;10.1227/00006123-199305000-00003;;10.1097/00006123-199305000-00003;;8388081;;10.1093/jnci/85.9.704;;8478956;;17293384;;10.1158/0008-5472.can-06-4038;;11471194;;10.1177/107327480401100307;;15153843;;10914698;;10.1158/0008-5472.can-04-1364;;15466194;;11731436;;10.1007/s002620050465;;9558003;;16397045;;10.1158/1078-0432.ccr-05-1178;;16331615;;10.1002/ijc.21616;;10.1016/s0165-5728(99)00172-1;;10674985;;10.1007/s005950300060;;12707821;;19944974;;10.1016/j.nec.2009.08.006;;pmc2786895;;10.1182/blood.v97.6.1776;;11238120;;17939761;;10.1586/14737175.7.10.1235;;10.1177/107327480301000205;;12712008;;15162438;;10.1002/eji.200425081;;10.2174/157488708783330530;;18474011;;10.1038/nm0697-625;;9176488;;18539965;;10.1200/jco.2007.15.1472;;7774624;;10.1002/eji.1830250511;;12109820;;10.1053/clon.2001.0038;;pmc3903051;;10.1007/s00262-007-0426-9;;18057935;;11440627;;10.1089/104303401750270995;;12907622;;9754652;;10.1002/(sici)1097-0215(19981005)78:2<196::aid-ijc13>3.0.co;2-9;;10.1023/a:1024969422010;;10.1007/bf02700016;;12952282;;10.1093/jjco/hye076;;11574635;;10.1093/jnci/94.11.805;;12048268;;pmc1137064;;7519851;;10.1042/bj3010847;;10945499;;10.1054/bjoc.2000.1289;;pmc2374651;;14555310;;10024247;;10.1126/science.283.5405.1183;;10.1038/nm0398-321;;9500606;;pmc2064864;;10.14670/hh-18.435;;12647794;;14522905;;11895781;;10.1182/blood.v99.7.2468,"Yu et al (Cancer Res. 64:4973-79, 2004, IDS # 98, filed on Nov. 13, 2009).;;Liu et al (J Immunother 27:220-226, 2004, IDS, #66, filed on Nov. 13, 2009).;;Yu et al, Cancer Res. 61:842-847, 2001, IDS #: 97, filed Nov. 23, 2009.;;Borràs et al., ""Findings on T cell specificity revealed by synthetic combinatorial libraries,"" J. Immunol. Methods, 267:79-97 (2002).;;Castelli et al., ""Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens,"" J. Immunol., 162:1739-48 (1999).;;Castro et al., ""Current and future strategies for the treatment of malignant brain tumors,"" Pharmacol. Ther., 98:71-108 (2003).;;Chen et al., ""Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies,"" Proc. Natl. Acad. Sci. USA, 91:1004-08 (1994).;;Debinsky, ""Correspondence re: B. H. Joshi et al., Interluekin-13 Receptor alpha Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas. Cancer Res., 60: 1168-1172, 2000,"" Cancer Res., 61:5660 (2001).;;Falk et al., ""Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,"" Nature, 351:290-296 (1991).;;Gatza et al., ""Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma,"" J. Immunol., 169:5227-35 (2002).;;Harada et al., ""Melanoma-reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types,"" J. Immunother., 24:323-333 (2001).;;Joshi et al., ""Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas,"" Cancer Res., 60:1168-72 (2000).;;Khong et al., ""Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy,"" J. Immunol, 168:951-956 (2002).;;Kikuchi et al., ""Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells,"" Cancer Immunol. Immumother., 50:337-344 (2002).;;Kikuchi et al., ""Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model,"" Cancer Immunol. Immumother., 51:424-430 (2002).;;Knutson et al., ""Technology evaluation: DCVax, Northwest Biotherapeutics,"" Curr. Opin. Mol. Ther., 4:403-407 (2002).;;Lemmel et al., ""Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling,"" Nat. Biotechnol., 22:450-454 (2004).;;Liau et al., ""Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens,"" J. Neurosurg., 90:1115-24 (1999).;;Liu et al., ""AIM-2: a novel tumor antigen is expressed and presented by human glioma cells,"" J. Immunother., 27:220-226 (2004).;;Liu et al., ""Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy,"" Oncogene, 24:5226-34 (2005).;;Liu et al., ""HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells,"" Cancer Res., 64:4980-86 (2004).;;Liu et al., ""Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma,"" J. Immunother., 26:301-312 (2003).;;Liu et al., ""Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination,"" Expert Rev. Vaccines, 5:233-247 (2006).;;Lupetti et al., ""Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage,"" J. Exp. Med., 188:1005-16 (1998).;;Lustgarten et al., ""Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope,"" J. Immunol., 176:1796-1805 (2006).;;Mehta-Damani et al., ""Generation of antigen-specific CD8+ CTLs from naive precursors,"" J. Immunol., 153:996-1003 (1994).;;Okano et al., ""Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain,"" Clin. Cancer Res., 8:2851-55 (2002).;;Parkhurst et al., ""Identification of a shared HLA-A *0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2),"" Cancer Res., 58:4895-4901 (1998).;;Pinilla et al., ""Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries,"" Biotechniques, 13:901-905 (1992).;;Pisarra et al., ""Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization,"" J. Invest. Dermatol., 115:48-56 (2000).;;Pollack et al., ""Exploitation of immune mechanisms in the treatment of central nervous system cancer,"" Semin. Pediatr. Neurol., 7:131-143 (2000).;;Salgaller et al., ""Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides,"" Cancer Res., 55:4972-79 (1995).;;Song et al., ""Strategies to improve dendritic cell-based immunotherapy against cancer,"" Yonsei Med. J., 45(Suppl):48-52 (2004).;;Steinman, ""Some interfaces of dendritic cell biology,"" APMIS, 111:675-697 (2003).;;Storkus et al., ""Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes,"" J. Immunol., 151:3719-27 (1993).;;Stupp et al., ""Recent Developments in the Management of Malignant Glioma,"" American Society of Clinical Oncology Educational Book, 779-788 (2003).;;Wang et al., ""An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens,"" Vaccine, 24:3477-89 (2006).;;Wang et al., ""Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes,"" J. Exp. Med., 184:2207-16 (1996).;;Wei et al., ""Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell responses,"" Cancer Biother. Radiopharm., 23:121-128 (2008).;;Weigel et al., ""Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses,"" Exp. Hematol., 34:1403-12 (2006).;;Wheeler et al., ""Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients,"" Cancer Res., 68:5955-64 (2008).;;Wheeler et al., ""Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination,"" Clin. Cancer Res., 10:5316-26 (2004).;;Wheeler et al., ""Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality,"" J. Immunol., 171:4927-33 (2003).;;Yang et al., ""Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3,"" J Immunol., 164:4204-11 (2000).;;Yasuda et al., ""Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells,"" Oncol. Rep., 16:1317-24 (2006).;;Young et al., ""Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells,"" J. Exp. Med., 171:1315-32 (1990).;;Yu et al., ""Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer,"" Clin. Cancer Res., 9:285-294 (2003).;;Yu et al., ""Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination,"" Clin. Neurosurg., 53:345-351 (2006).;;Yu et al., ""Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration,"" Cancer Res., 61:842-847 (2001).;;Yu et al., ""Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma,"" Cancer Res., 64:4973-79 (2004).;;Zhu et al., ""Insertion of the dibasic motif in the flanking region of a cryptic self-determinant leads to activation of the epitope-specific T cells,"" J. Immunol., 175:2252-60 (2005).;;Zitvogel et al., ""Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-1 associated cytokines,"" J. Exp. Med., 183:87-97 (1996).;;International Search Report of International Application No. PCT/US07/79846, mailed Jul. 14, 2008.;;International Search Report of International Application No. PCT/US07/79857, mailed Apr. 8, 2008.;;Abdel-Wahab et al., ""Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity,"" Cell. Immunol., 186:63-74 (1998).;;Akasaki et al., ""Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model,"" J. Immunother., 24:106-113 (2001).;;Akasaki et al., ""Dendritic cell-based immunotherapy for malignant gliomas,"" Expert Rev. Neurother., 5:497-508 (2005).;;Akasaki et al., ""Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma,"" J. Immunol., 173:4352-59 (2004).;;Akasaki et al., ""T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches,"" Front. Biosci., 10:2908-21 (2005).;;Borbulevych et al., ""Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design,"" J. Immunol., 174:4812-20 (2005).;;Bowles, Jr. et al., ""Long-term remission of malignant brain tumors after intracranial infection: a report of four cases,"" Neurosurgery, 44:636-642 (1999).;;Bullock et al., ""Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells,"" J. Immunol., 170:1822-29 (2003).;;Candido et al., ""Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents,"" Cancer Res., 61:228-236 (2001).;;Casey et al., ""Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine,"" Immunology, 110:105-111 (2003).;;Chandler et al., ""Long-term survival in patients with glioblastoma multiforme,"" Neurosurgery, 32:716-720 (1993).;;Curran et al., ""Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials,"" J. Natl. Cancer Inst., 85:704-710 (1993).;;Czerniecki et al., ""Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion,"" Cancer Res., 67:1842-52 (2007).;;Dietz, ""Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia,"" Croatian Med. J., 42:428-435 (2001).;;Ehtesham et al., ""Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials,"" Cancer Control, 11:192-207 (2004).;;Friedman et al., ""Temozolomide and treatment of malignant glioma,"" Clin. Cancer Res., 6:2585-97 (2000).;;Galli et al., ""Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma,"" Cancer Res., 64:7011-21 (2004).;;Geiger et al., ""Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression,"" Cancer Res., 61:8513-19 (2001).;;Gilboa et al., ""Immunotherapy of cancer with dendritic-cell-based vaccines,"" Cancer Immunol. Immunother., 46:82-87 (1998).;;Haas et al., ""Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine,"" Clin. Cancer Res., 12:214-222 (2006).;;Hahn et al., ""Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer,"" Int. J. Cancer, 118:2220-31 (2006).;;Heimberger et al., ""Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma,"" J. Neuroimmunol., 103:16-24 (2000).;;Inoue et al., ""Dendritic cells coinjected with tumor cells treated with an anticancer drug to induce tumor rejection,"" Surg. Today, 33:269-276 (2003).;;Ji et al., ""Glioma stem cell research for the development of immunotherapy,"" Neurosurg. Clin. N. Am., 21:159-66 (2010).;;La Rosa et al., ""Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries,"" Blood, 97:1776-86 (2001).;;Liu and Yu, ""Cancer vaccines: a novel strategy to sensitize malignant glioma to chemotherapy,"" Expert Rev. Neurother., 7:1235-37 (2007).;;Liu et al., ""Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma,"" Cancer Control, 10:138-147 (2003).;;Liu et al., ""Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response,"" Eur. J. Immunol., 34:1680-87 (2004).;;Luptrawan et al., ""Dendritic cell immunotherapy for malignant gliomas,"" Rev. Recent Clin. Trials, 3:10-21 (2008).;;Lynch et al., ""F1t3 ligand induces tumor regression and antitumor immune responses in vivo,"" Nat. Med., 3:625-631 (1997).;;Maitland and Collins, ""Prostate cancer stem cells: a new target for therapy,"" J. Clin. Oncol., 26:2862-70 (2008).;;Mehta-Damani et al., ""Generation of antigen-specific CD4+ T cell lines from naïve precursors,"" Eur. J. Immunol., 5:1206-11 (1995).;;Melcher et al., ""Dendritic cells for the immunotherapy of cancer,"" Clin. Oncol., 14:185-192 (2002).;;Merrick et al., ""Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy,"" Cancer Immunol. Immunother., 57:897-906 (2008).;;Mi et al., ""Induced apoptosis supports spread of adenovirus vectors in tumors,"" Hum. Gene Ther., 12:1343-52 (2001).;;Nowak et al., ""Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors,"" Cancer Res., 63:4490-96 (2003).;;Okada et al., ""Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms,"" Int. J. Cancer, 78:196-201 (1998).;;Okada et al., ""Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy,"" J. Neurooncol., 64:13-20 (2003).;;Osada et al., ""Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report,"" Jpn. J. Clin. Oncol., 31:403-406 (2001).;;Parmiani et al., ""Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?"" J. Natl. Cancer Inst., 94:805-818 (2002).;;Pinilla et al., ""Investigation of antigen-antibody interactions using a soluble, non-support-bound synthetic decapeptide library composed of four trillion (4×1012) sequences,"" Biochem. J., 301:847-853 (1994).;;Pirtskhalaishvili et al., ""Cytokine-mediated protection of human dendritic cells from prostate cancer induced apoptosis is regulated by the Bc1-2 family of proteins,"" Br. J. Cancer, 83:506-513 (2000).;;Reichardt et al., ""Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells,"" Haematologica, 88:1139-49 (2003).;;Rissoan et al., ""Reciprocal control of T helper cell and dendritic cell differentiation,"" Science, 283:1183-86 (1999).;;Rosenberg et al , ""Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma,"" Nat. Med., 4:321-327 (1998).;;Shin et al., ""Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model,"" Histol. Histopathol., 18:435-447 (2003).;;Singh et al., ""Identification of a cancer stem cell in human brain tumors,"" Cancer Res., 63:5821-28 (2003).;;Steinbrink et al., ""CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity,"" Blood, 99:2468-76 (2002).",ACTIVE
173,US,A1,US 2019/0290687 A1,078-160-564-928-166,2019-09-26,2019,US 201716303053 A,2017-05-22,US 201716303053 A;;US 201662339681 P;;US 2017/0033875 W,2016-05-20,METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE AND ASSOCIATED CONDITIONS,"The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;RENTSENDORJ ALTANCHIMEG;;KORONYO YOSEF;;BLACK KEITH,CEDARS-SINAI MEDICAL CENTER (2017-05-23),https://lens.org/078-160-564-928-166,Patent Application,yes,0,0,13,13,0,A61K38/02;;A61K38/19;;A61P25/28;;A61K45/06;;A61K39/4614;;A61K2239/31;;A61K39/4622;;A61K39/46433;;A61K2239/38;;A61K39/4621;;A61P25/28;;A61K38/07;;A61K2239/31;;A61K39/4622;;A61K2239/38;;A61K39/4621;;A61K39/4614;;A61K39/46433;;A61P25/28;;A61K31/7088;;A61K35/15;;A61K38/02;;A61K38/18;;A61K38/19,A61K35/15;;A61K31/7088;;A61K38/02;;A61K38/18;;A61K38/19;;A61P25/28,,0,0,,,,ACTIVE
174,SG,A1,SG 188209 A1,141-865-962-990-531,2013-04-30,2013,SG 2013010731 A,2011-08-29,US 37854610 P;;US 2011/0049544 W,2010-08-31,BED BUG MONITORING DEVICE,The invention is directed to a bed bug monitoring device comprising a bed bug attractant element and a harborage section comprising a support member having a traversable surface and one or more protuberances depending therefrom. The harborage defines at least one entrance through which bed bugs attracted to the device can enter. The device can further include a base section placed over at least a portion of the traversable surface and adapted to by placed flush with the surface against which the device is to be placed.,FMC CORP,BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,,https://lens.org/141-865-962-990-531,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,,,0,0,,,,PENDING
175,JP,A,JP 2010163468 A,130-731-347-565-901,2010-07-29,2010,JP 2010107780 A,2010-05-07,US 52733003 P,2003-12-05,POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM,"<P>PROBLEM TO BE SOLVED: To provide a structured drug system that is useful for delivering a drug payload to a specific tissue or cell type. <P>SOLUTION: The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can be used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. <P>COPYRIGHT: (C)2010,JPO&INPIT",ARROGENE INC;;CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,,https://lens.org/130-731-347-565-901,Patent Application,no,0,0,12,14,0,A61K47/60;;A61K47/593;;A61K47/6883;;A61K47/6849;;A61P35/00;;A61K47/6883;;A61K47/593;;A61K47/60;;A61K47/6849;;A61P35/00,A61K47/42;;A61K31/711;;A61K47/34;;A61K47/48;;A61P35/00;;A61P43/00,,0,0,,,,DISCONTINUED
176,US,A1,US 2007/0259008 A1,178-604-571-309-670,2007-11-08,2007,US 58099904 A,2004-12-03,US 58099904 A;;US 52733003 P;;US 2004/0040660 W,2003-12-05,Polymalic Acid-Based Multi-Functional Drug Delivery System,"A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system's circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms.",LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,ARROGENE NANOTECHNOLOGY INC (2012-07-19);;CEDARS-SINAI MEDICAL CENTER (2006-04-13);;ARROGENE INC (2017-05-24),https://lens.org/178-604-571-309-670,Patent Application,yes,3,17,12,14,0,A61K47/60;;A61K47/593;;A61K47/6883;;A61K47/6849;;A61P35/00;;A61K47/6883;;A61K47/593;;A61K47/60;;A61K47/6849;;A61P35/00,A61K9/00;;A61K47/48;;A61K31/7088,424/400;;514/44;;514/772.3,0,0,,,,ACTIVE
177,EP,B1,EP 2328923 B1,178-851-937-759-026,2016-01-13,2016,EP 09812172 A,2009-09-02,US 2009/0055759 W;;US 19071808 P,2008-09-02,CD133 EPITOPES,,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,,https://lens.org/178-851-937-759-026,Granted Patent,yes,5,2,13,13,0,A61K39/0011;;A61K39/0011;;A61K45/06;;A61P35/00;;A61P37/04;;C07K14/70596;;C07K14/70596;;C07K7/06;;C07K7/06,C07K14/705;;A61K39/00;;A61P35/00;;C07K7/06,,9,0,,,"HAYNES J GEORGIA ET AL: ""Molecular characterization of the B' regulatory subunit gene family of Arabidopsis protein phosphatase 2A"", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 260, no. 1, February 1999 (1999-02), pages 127-136, XP002674390, ISSN: 0014-2956;;WEIGMANN ANJA ET AL: ""Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 94, 11 November 1997 (1997-11-11), pages 12425-12430, XP002143047, ISSN: 0027-8424, DOI: 10.1073/PNAS.94.23.12425;;YU JOHN S ET AL: ""CD133 as a Potential Target of Anti-cancer Stem Cell Immunotherapy: Identification of an HLA-A*02 Restricted CD133 Epitope"", JOURNAL OF IMMUNOTHERAPY, vol. 31, no. 9, 31 October 2008 (2008-10-31), - 2 November 2008 (2008-11-02), page 928, XP002674391, & 23RD ANNUAL MEETING OF THE INTERNATIONAL-SOCIETY-FOR-BIOLOGICAL-THERA PY-OF-CANCER; SAN DIEGO, CA, USA; 20081030, ISSN: 1524-9557;;DATABASE GENBANK 13 July 2008 'amino acid sequence and gene sequence', XP008144875 Database accession no. NM_006017;;SMITH, L. M. ET AL.: 'CD133/prominin-I is a potential therapeutic target for a ntibody-drug conjugates in hepatocellular and gastric cancers.' BRITISH JOURNAL OF CANCER. vol. 99, no. 1, 10 June 2008, pages 100 - 109, XP002619785;;WU, A. ET AL.: 'Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immuotherapy.' JOURNAL OF NEUROONCOLOGY. vol. 83, no. 2, 01 November 2006, pages 121 - 131, XP019506783;;BROWN, C. E. ET AL.: 'Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.' CANCER RESEARCH. vol. 69, no. 23, 10 November 2009, pages 8886 - 8893, XP008144870;;JI J. ET AL.: 'Glioma stem cell research for the development of immunotherapy' NEUROSURGERY CLINICS OF NORTH AMERICA vol. 21, no. 1, January 2010, pages 159 - 166, XP008144888;;YANG, I. ET AL.: 'Modulation of major histocompatibility complex class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme.' JOURNAL OF NEUROSURGERY. vol. 100, no. 2, February 2004, pages 310 - 319, XP008144886",ACTIVE
178,AU,A,AU 1999/018215 A,032-936-566-959-544,1999-06-28,1999,AU 1999/018215 A,1998-12-11,US 98975097 A;;US 9826461 W,1997-12-12,Gene associated with neoplastic disease or malignancy associated gene,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH;;LJUBIMOVA JULIA Y;;DEMETRIOU ACHILLES A,,https://lens.org/032-936-566-959-544,Patent Application,no,0,0,4,4,0,A61K38/00;;C07K14/47,G01N33/53;;A61K38/00;;C07K14/47;;C07K16/18;;C12N15/09;;C12N15/12;;C12Q1/68;;G01N33/566;;G01N33/574,,0,0,,,,DISCONTINUED
179,US,A1,US 2014/0039125 A1,085-057-982-304-338,2014-02-06,2014,US 201314031561 A,2013-09-19,US 201314031561 A;;US 201113097364 A;;US 58099907 A;;US 2004/0040660 W;;US 52733003 P,2003-12-05,POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM,"A drug delivery system for delivering a drug payload to a specific tissue or cell type is disclosed. The system includes a polymalic acid molecular scaffold which can be used for attaching a plurality of molecular modules. Molecular modules include targeting antibodies for promoting cellular uptake by a target cell, and pro-drugs for altering cellular metabolism, for example, a pro-drug that alters expression of protein kinase CK2.",ARROGENE NANOTECHNOLOGY INC;;CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,ARROGENE NANOTECHNOLOGY INC (2014-07-24);;CEDARS-SINAI MEDICAL CENTER (2014-07-24);;ARROGENE INC (2017-05-24),https://lens.org/085-057-982-304-338,Patent Application,yes,0,2,2,14,5,A61K47/60;;A61K47/60;;A61K47/593;;A61K47/593;;A61K47/6883;;A61K47/6883;;A61P35/00,A61K47/48,525/54.1,0,0,,,,ACTIVE
180,EP,B1,EP 1689443 B1,127-619-499-386-947,2019-03-13,2019,EP 04813049 A,2004-12-03,US 2004/0040660 W;;US 52733003 P,2003-12-05,POLYMALIC ACID-BASED MULTIFUNCTIONAL DRUG DELIVERY SYSTEM,,ARROGENE INC;;CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,"CEDARS-SINAI MEDICAL CENTER (2006-11-02);;ARROGENE, INC. (2006-11-02)",https://lens.org/127-619-499-386-947,Granted Patent,yes,0,0,12,14,0,A61K47/60;;A61K47/593;;A61K47/6883;;A61K47/6849;;A61P35/00;;A61K47/6883;;A61K47/593;;A61K47/60;;A61K47/6849;;A61P35/00,A61K47/59;;A61K47/48;;A61K47/60;;A61K47/68;;A61P35/00,,1,0,,,"LEE BONG-SEOP ET AL: ""Delivery of antisense oligonucleotides and transferrin receptor antibody in vitro and in vivo using a new multifunctional drug delivery system based on polymalic acid."", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 45, March 2004 (2004-03-01), & 95TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ORLANDO, FL, USA; MARCH 27 -31, 2004, pages 149 - 150, XP008120390, ISSN: 0197-016X",ACTIVE
181,CN,A,CN 103079402 A,115-640-697-175-762,2013-05-01,2013,CN 201180042077 A,2011-08-29,US 2011/0049544 W;;US 37854610 P,2010-08-31,Bed bug monitoring device,The invention is directed to a bed bug monitoring device comprising a bed bug attractant element and a harborage section comprising a support member having a traversable surface and one or more protuberances depending therefrom. The harborage defines at least one entrance through which bed bugs attracted to the device can enter. The device can further include a base section placed over at least a portion of the traversable surface and adapted to by placed flush with the surface against which the device is to be placed.,FMC CORP,BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,,https://lens.org/115-640-697-175-762,Patent Application,no,11,0,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,A01M1/02;;A01M1/00;;A01M1/14;;C09J201/00,,0,0,,,,DISCONTINUED
182,US,B2,US 9095538 B2,013-534-142-098-022,2015-08-04,2015,US 201313828432 A,2013-03-14,US 201313828432 A;;US 86399007 A;;US 82726006 P,2006-09-28,Cancer vaccines and vaccination methods,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2009-05-12),https://lens.org/013-534-142-098-022,Granted Patent,yes,102,14,17,17,62,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,C12N15/00;;A61K35/12;;A61K39/00;;C12N5/0784,,102,77,157-642-321-785-08X;;084-085-138-348-898;;064-388-641-569-789;;097-167-161-561-41X;;006-027-796-241-692;;077-678-786-447-085;;025-457-637-309-732;;101-169-326-244-167;;042-796-720-165-197;;002-637-847-823-805;;043-164-984-018-36X;;028-167-813-228-119;;004-397-008-209-727;;054-439-756-152-283;;165-292-111-716-265;;099-464-580-091-161;;068-473-895-492-963;;006-885-984-877-437;;038-241-086-015-47X;;061-756-489-300-343;;043-357-937-051-619;;017-862-373-044-791;;046-010-966-436-821;;116-248-902-411-147;;047-903-330-676-744;;081-222-505-017-37X;;054-045-955-566-76X;;049-537-999-449-717;;035-263-789-910-604;;077-262-310-785-629;;078-642-510-799-292;;012-638-135-148-028;;100-984-968-676-329;;033-662-847-189-276;;028-211-379-291-005;;096-830-349-650-74X;;096-741-767-207-949;;039-376-070-403-51X;;093-530-607-257-147;;026-219-340-070-989;;039-936-793-486-518;;000-347-673-674-126;;022-618-370-567-630;;043-498-574-177-034;;035-444-720-129-695;;035-033-143-909-694;;068-431-834-637-887;;056-649-998-351-849;;074-128-014-644-585;;009-782-141-099-662;;004-045-625-151-197;;054-484-357-087-819;;030-031-127-445-729;;071-463-964-030-172;;049-915-366-620-516;;032-932-040-924-322;;138-771-752-862-480;;168-705-133-516-75X;;016-059-509-686-365;;029-311-860-898-924;;032-294-227-563-850;;078-639-700-866-831;;027-915-134-983-264;;022-798-233-953-966;;045-700-919-027-517;;007-174-971-453-251;;019-264-483-343-031;;013-855-584-540-778;;011-191-194-524-48X;;062-108-416-505-04X;;057-785-668-031-036;;059-717-731-643-077;;011-643-567-958-26X;;011-954-218-606-176;;044-750-837-062-887;;092-707-572-319-639;;040-713-726-205-55X,10.1158/1078-0432.ccr-09-1322;;20068073;;pmc3682507;;10.1073/pnas.0530291100;;pmc153034;;12629218;;18665745;;10.1158/0008-5472.can-06-4180;;17483311;;10.1038/nrc1740;;16327766;;18539956;;10.1200/jco.2008.17.7436;;19903840;;pmc2789196;;10.1158/0008-5472.can-09-2687;;10.1016/j.neuron.2009.08.038;;pmc2789107;;19840551;;10.1073/pnas.142298299;;pmc125045;;12114532;;18245488;;10.1158/0008-5472.can-07-0445;;9841453;;10.1126/science.282.5391.1061;;11239426;;10.1016/s0896-6273(01)00209-4;;17412894;;10.1634/stemcells.2006-0624;;10.1189/jlb.1002483;;12773508;;pmc299944;;14645703;;10.1073/pnas.2036535100;;10.4049/jimmunol.164.2.861;;10623833;;pmc521140;;10.1073/pnas.0400067101;;15381773;;12832694;;10.1634/stemcells.21-4-405;;9743339;;10.1126/science.1135308;;17185560;;pmc1782333;;16836618;;10.1111/j.1365-2567.2006.02412.x;;15908947;;pmc2377345;;10.1038/nn1473;;15277692;;10.1634/stemcells.22-4-448;;10.1002/path.2283;;18067118;;17307142;;10.1016/j.bbrc.2007.01.159;;12717023;;10.1110/ps.0239403;;pmc2323871;;17122772;;10.1038/nature05372;;12640097;;10.1097/01.mp.0000056981.16578.c3;;10.4049/jimmunol.157.6.2539;;8805655;;10.1007/978-1-59745-280-9_15;;19582431;;17079441;;10.1158/0008-5472.can-06-2048;;3276675;;10.1016/s0021-9258(19)77935-6;;10.1038/35102167;;11689955;;1553558;;10.1126/science.1553558;;1432110;;10.1523/jneurosci.12-11-04565.1992;;pmc6575989;;16120861;;10.1056/nejmra043666;;15378086;;10.1038/sj.onc.1207946;;10.1038/nature03128;;15549107;;18542072;;10.1038/sj.bjc.6604437;;pmc2453027;;17024127;;pmc2360579;;10.1038/sj.bjc.6603369;;10.1095/biolreprod57.3.561;;9282991;;10.3171/foc.2006.20.4.17;;16709033;;10.1186/1476-4598-3-25;;15469606;;pmc524518;;18535153;;10.1634/stemcells.2008-0078;;17077937;;10.1007/s11060-006-9265-3;;18787206;;10.1634/stemcells.2008-0459;;10.1038/sj.bjc.6605142;;19568241;;pmc2720199;;14520441;;pmc2394324;;10.1038/sj.bjc.6601268;;10.1089/scd.2007.0063;;18230026;;10.1182/blood.v90.12.5002.5002_5002_5012;;9389720;;10.1182/blood.v90.12.5002;;12042327;;10.1074/jbc.m202349200;;10.1200/jco.2007.15.5465;;18539969;;11533706;;10.1038/nm0901-1028;;10.1002/jcp.21541;;18651561;;10.1006/cimm.1998.1298;;9637766;;11449066;;11265767;;10.1097/00002371-200103000-00004;;10.1586/14737175.5.4.497;;16026233;;15383564;;10.4049/jimmunol.173.7.4352;;10.2741/1747;;15970545;;pmc2241749;;10.4049/jimmunol.174.8.4812;;15814707;;10.1016/s0022-1759(02)00142-4;;12135802;;10.1097/00006123-199903000-00110;;10069601;;10.4049/jimmunol.170.4.1822;;12574347;;11196166;;12941147;;10.1046/j.1365-2567.2003.01726.x;;pmc1783031;;9973437;;12667889;;10.1016/s0163-7258(03)00014-7;;10.1227/00006123-199305000-00003;;10.1097/00006123-199305000-00003;;8388081;;10.1073/pnas.91.3.1004;;pmc521442;;8302824;;10.3727/096368909x12483162196962;;19523342;;10.1093/jnci/85.9.704;;8478956;;17293384;;10.1158/0008-5472.can-06-4038;;11454721;;11471194;;12616102;;10.1097/00002371-200303000-00003;;10.1177/107327480401100307;;15153843;;1709722;;10.1038/351290a0,"Yu et al , Cancer Res. 61:842-847, 2001, IDS #219 filed on Mar. 14, 2013.;;Yu et al , Cancer Res. 64:4973-79, 2004, IDS #220, filed on Mar. 14, 2013.;;Liu et al, J lmmunother 27:220-226, 2004, IDS #144 filed on Mar. 14, 2013.;;Ahmed et al.; ""HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors""; Clin Cancer Res.; 16(2); 474-85.;;Al-Hajj et al., ""Prospective identification of tumorigenic breast cancer cells,"" Proc. Natl. Acad. Sci. USA, 7:3983-88 (2003).;;Altaner, ""Glioblastoma and stem cells,"" Neoplasma, 55:369-374 (2008).;;Beier et al., ""CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles,"" Cancer Res., 67:4010-15 (2007).;;Bjerkvig et al., ""Opinion: the origin of the cancer stem cell: current controversies and new insights,"" Nat. Rev. Cancer, 11:899-904 (2005).;;Boman et al., ""Cancer stem cells: a step toward the cure,"" J. Clin. Oncol., 26:2795-99 (2008).;;Brown et al., ""Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells,"" Cancer Res., 69:8886-93 (2009).;;Carpentier et al., 2009, Neuron, 64: 79-92.;;Drukker et al., ""Characterization of the expression of MHC proteins in human embryonic stem cells,"" Proc. Natl. Acad. Sci. USA, 99:9864-69 (2002).;;Communication for Application No. EP 07843269.7, dated Feb. 2, 2011, 9 pages.;;European Patent Office Communication for European Application No. 09812172.6, mailed May 23, 2012, 5 pages.;;Garcia-Hernandez et al., ""Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in the Absence of Autoimmunity"", Cancer Res., vol. 68, No. 3, (2008), pp. 861-869.;;Gearhart, 1998, Science, 282: 1061-1062.;;Geschwind et al., ""A genetic analysis of neural progenitor differentiation,"" Neuron, 2:325-39 (2001).;;Ghods et al., ""Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells,"" Stem Cells, 7:1645-53 (2007).;;Harizi et al., ""Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subytpes,"" J. Leukocyte Biol., 73:756-763 (2003).;;Hemmati et al., ""Cancerous stem cells can arise from pediatric brain tumors,"" Proc. Natl. Acad. Sci. USA, 25:15178-83 (2003).;;Hemmer et al., ""Contribution of Individual Amino Acids Within MHC Molecule or Antigenic Peptide to TCR Ligand Potency,"" J. Immunol., 164:861-871 (2000).;;Hirschmannn-Jax et al., ""A distinct 'side population' of cells with high drug efflux capacity in human tumor cells,"" Proc. Natl. Acad. Sci. USA, 39:14228-33 (2004).;;Hori et al., ""Neural progenitor cells lack immunogenecity and resist destruction as allografts,"" Stem Cells, 21:405-416 (2003).;;International Preliminary Report on Patentability for App. Ser. No. PCT/US07/079846, mailed Apr. 9, 2009, 5 pages.;;International Preliminary Report on Patentability for App. Ser. No. PCT/US07/079857, mailed Apr. 9, 2009, 5 pages.;;International Preliminary Report on Patentability for App. Ser. No. PCT/US2010/034082, mailed Nov. 17, 2011, 5 pages.;;International Preliminary Report on Patentability of International Application No. PCT/US2009/055759, issued Mar. 8, 2011 (mailed Mar. 17, 2011).;;International Search Report and Written Opinion of International Application No. PCT/US2009/055759, mailed Jun. 28, 2010.;;International Search Report and Written Opinion of International Application No. PCT/US2010/034082, mailed Feb. 22, 2011, 9 pages.;;International Search Report and Written Opinion of the International Searching Authority for PCT/US2007/79600, mailed on Mar. 27, 2008, 10 pages.;;International Search Report and Written Opinion; PCT/US2014/16562; Jun. 3, 2014; 37 pp.;;International Search Report and Written Opinion; PCT/US2014/16610; Jun. 5, 2014; 24 pp.;;Kalinski et al., ""Prostaglandin E2 induces the final maturation of IL-12 deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation,"" J. Immunol, 161:2804-09 (1998).;;Kimchi-Sarfaty et al., ""A ""Silent"" Polymorphism in the MDR1 Gene Changes Substrate Specificity"", Science, vol. 315, (2007), pp. 525-528 (Erratum, 1 page).;;Koch et al , ""Immune-privileged embryonic Swiss mouse STO and STO cell-derived progenitor cells: major histocompatibility complex and cell differentiation antigen expression patterns resemble those of human embryonic stem cell lines,"" Immunology, 119:98-115 (2006).;;Lee et al., ""Isolation of neural stem cells from the postnatal cerebellum,"" Nat. Neurosci., 6:723-729 (2005).;;Li et al., ""Human embryonic stem cells possess immune-privileged properties,"" Stem Cells, 22:448-456 (2004).;;Mizrak e al., ""CD133: molecule of the moment,"" J. Pathol., 214:3-9 (2008).;;NCBI GenBank Accession No. NM-006017 (Jul. 13, 2008).;;Neuzil et al., ""Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?"" Biochem. Biophys. Res. Commun., 355:855-859 (2007).;;Nielsen et al., ""Reliable prediction of T-cell epitopes using neural networks with novel sequence representations,"" Protein Sci., 12:1007-1017 (2003).;;O'Brien et al., ""A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,"" Nature, 7123:106-110 (2007).;;Ordonez et al.; ""Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma""; Mod. Pathol., Mar. 2003; vol. 16, No. 3, pp. 192-197.;;Parkhurst et al., ""Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues,"" J. Immunol., 157:2539-2548 (1996).;;Pellegatta et al., ""Dendritic cell vaccines for cancer stem cells,"" Methods Mol. Biol., 568:233-247 (2009).;;Pellegatta et al., ""Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas,"" Cancer Res., 66:10247-52 (2006).;;Posnett et al., ""A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain,"" J. Biol. Chem., 263:1719-25 (1988).;;Reya et al., ""Stem cells, cancer, and cancer stem cells,"" Nature, 6859:105-111 (2001).;;Reynolds and Weiss, ""Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system,"" Science, 5052:1707-10 (1992).;;Reynolds et al, ""A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes,"" J. Neurosci., 11:4565-74 (1992).;;Sanai et al., ""Neural stem cells and the origin of gliomas,"" N. Eng. J. Med., 8:811-822 (2005).;;Singh et al., ""Cancer stem cells in nervous tumors,"" Oncogene, 23:7267-73 (2004).;;Singh et al., ""Identification of human brain tumor initiating cells"", Nature, 7015:396-401 (2004).;;Smith et al., ""CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers,"" Br. J. Cancer, 99:100-109 (2008).;;Steele et al., ""The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens,"" Br. J. Cancer 95:1202-11 (2006).;;Supplementary European Search Report for European Application No. 09812172.6, mailed May 4, 2012, 6 pages.;;Tian et al., ""Expression of immunoglobulin superfamily cell adhesion molecules on murine embryonic stem cells,"" Biol. Reprod., 57:561-568 (1997).;;Tunici et al., ""Brain tumor stem cells: new targets for clinical treatments?"" Neurosurg. Focus, 4:E27 (2006).;;Tunici et al., ""Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma,"" Mol. Cancer, 3:25 (2004).;;USPTO Final Office Action in U.S. Appl. No. 11/863,990, mailed May 12, 2011, 18 pages.;;USPTO Final Office Action in U.S. Appl. No. 11/864,177, mailed May 13, 2011, 18 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 11/863,990, mailed Aug. 26, 2010, 15 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 11/864,177, mailed Aug. 26, 2010, 16 pages.;;USPTO Final Office Action in U.S. Appl. No. 12/552,945, mailed Aug. 16, 2012, 13 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 12/552,945, mailed Mar. 12, 2012, 20 pages.;;USPTO Non-Final Office Action in U.S. App. U.S. Appl. No. 12/776,200, mailed Apr. 18, 2012, 10 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 12/776,200, mailed Aug. 7, 2012, 14 pages.;;USPTO Final Office Action in U.S. Appl. No. 13/365,666, mailed Oct. 6, 2014, 14 pages.;;Wu et al., ""Embryonic stem cells and their differentiated derivatives have fragile immune privilege but still represent novel targets of immune attack,"" Stem Cells, 26:1939-50 (2008).;;Wu et al., ""Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy,"" J. Neurooncol., 83:121-131 (2007).;;Xu et al., ""Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas,"" Stem Cells, 26:3018-26 (2008).;;Xu et al.; ""Isolation of tumour stem-like cells from benign tumours""; British Journal of Cancer; (2009) 101, pp. 303-311.;;Yamanaka et al; Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune response: results of a clinical phase I/II trial; British Journal of Cancer (2003) 89, 1172-1179.;;Yin et al., ""Expression and regulation of major histocompatibility complex on neural stem cells and their lineages,"" Stem Cells Dev., 17:53-65 (2008).;;Yin et al., ""AC133, a novel marker for human hematopoietic stem and progenitor cells,"" Blood, 12:5002-12 (1997).;;Yu et al., ""AC133-2, a novel isoform of human AC133 stem cell antigen,"" J. Biol. Chem., 23:20711-16 (2002).;;Zabierowski and Herlyn, ""Melanoma stem cells: the dark seed of melanoma,"" J. Clin. Oncol., 26:2890-94 (2008).;;Zhou et al., ""The ABC transporter Berp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype,"" Nat. Med., 9:1028-34 (2001).;;Zou et al., ""Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver,"" J. Cell. Physiol., 217:598-604 (2008).;;Abdel-Wahab et al., ""Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity,"" Cell. Immunol., 186:63-74 (1998).;;Akasaki et al., ""Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model,"" J. Immunother., 24:106-113 (2001).;;Akasaki et al., ""Dendritic cell-based immunotherapy for malignant gliomas,"" Expert Rev. Neurother., 5:497-508 (2005).;;Akasaki et al., ""Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma,"" J. Immunol , 173:4352-59 (2004).;;Akasaki et al., ""T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches,"" Front. Biosci., 10:2908-21 (2005).;;Borbulevych et al., ""Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design,"" J. Immunol , 174:4812-20 (2005).;;Borràs et al., ""Findings on T cell specificity revealed by synthetic combinatorial libraries,"" J. Immunol Methods, 267:79-97 (2002).;;Bowles, Jr. et al., ""Long-term remission of malignant brain tumors after intracranial infection: a report of four cases,"" Neurosurgery, 44:636-642 (1999).;;Bullock et al., ""Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells,"" J. Immunol , 170:1822-29 (2003).;;Candido et al., ""Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents,"" Cancer Res., 61:228-236 (2001).;;Casey et al., ""Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine,"" Immunology, 110:105-111 (2003).;;Castelli et al., ""Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens,"" J. Immunol , 162:1739-48 (1999).;;Castro et al., ""Current and future strategies for the treatment of malignant brain tumors,"" Pharmacol. Ther., 98:71-108 (2003).;;Chandler et al., ""Long-term survival in patients with glioblastoma multiforme,"" Neurosurgery, 32:716-720 (1993).;;Chen et al., ""Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies,"" Proc. Natl. Acad. Sci. USA, 91:1004-08 (1994).;;Cho et al., ""Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas,"" Cell Transplant., 18:977-983 (2009).;;Curran et al., ""Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials,"" J. Natl. Cancer Inst., 85:704-710 (1993).;;Czerniecki et al., ""Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion,"" Cancer Res., 67:1842-52 (2007).;;Debinsky, ""Correspondence re: B. H. Joshi et al., Interluekin-13 Receptor alpha Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas. Cancer Res., 60: 1168-1172, 2000,"" Cancer Res., 61:5660 (2001).;;Dietz, ""Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia,"" Croatian Med. J., 42:428-435 (2001).;;Ehtesham et al., ""Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats,"" J. Immunother., 26:107-116 (2003).;;Ehtesham et al., ""Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials,"" Cancer Control, 11:192-207 (2004).;;Falk et al., ""Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,"" Nature, 351:290-296 (1991).",ACTIVE
183,US,A1,US 2013/0183378 A1,097-405-002-585-01X,2013-07-18,2013,US 201313826737 A,2013-03-14,US 201313826737 A;;US 55294509 A;;US 19071808 P,2008-09-02,CD133 Epitopes,"An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.",CEDARS SINAI MEDICAL CENTER;;CEDARS SINAI MEDICAL CENTER,YU JOHN S;;BLACK KEITH L;;LIU GENTAO,CEDARS-SINAI MEDICAL CENTER (2010-01-05),https://lens.org/097-405-002-585-01X,Patent Application,yes,4,9,13,13,19,A61K39/0011;;A61K39/0011;;A61K45/06;;A61P35/00;;A61P37/04;;C07K14/70596;;C07K14/70596;;C07K7/06;;C07K7/06,C07K14/705;;A61K39/00;;A61K45/06,424/450;;530/300;;530/328;;530/391.7;;530/409;;530/324;;424/185.1;;424/85.2;;424/85.1;;530/363;;530/395;;530/405,6,5,003-646-738-432-814;;124-282-566-991-152;;053-393-265-065-68X;;101-486-822-726-957;;081-457-468-429-178,8617954;;8557366;;pmc173770;;10.1128/iai.64.1.363-365.1996;;17540729;;10.1073/pnas.0608635104;;pmc1885220;;15226377;;10.1242/jcs.01222;;24375541;;pmc3952931;;10.5966/sctm.2013-0135,"Burg et al., Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stabilityl The Journal of lmmuno/ogy, 1996, 156; 3308-3314.;;Feng et al P55, an Immunogenic but Nonprotective 55-Kilodalton Borrelia burgdorferi Protein in Murine Lyme Disease INFECTION AND IMMUNITY, Jan. 1996, p. 363-365;;Zhang et al Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization PNAS I June 12. 2007 I vol. t04 I no. 24 I 1019).-10198;;Richardson et al ., CD133, a novel marker for human prostatic epithelial stem cells Journal of Cell Science 117, 3539-3545 Published by The Company of Biologists 2004;;Ji et al Identification of Novel Human Leukocyte Antigen-A*0201-Restricted, CytotoxicT Lymphocyte Epitopes on CD133 for Cancer Stem Cell Immunotherapy Stem Cells Trans Med 2014, 3:356-364.;;Ludewig et al., Adoptive Immunotherapy: Methods and Protocols Non-self MHC-restricted CTL 2005 Human Press Inc. page 216-217",ACTIVE
184,US,B2,US 10226519 B2,099-549-873-959-967,2019-03-12,2019,US 201615227552 A,2016-08-03,US 201615227552 A;;US 201113327125 A;;US 86417707 A;;US 82726006 P,2006-09-28,Cancer vaccines and vaccination methods,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2012-04-24),https://lens.org/099-549-873-959-967,Granted Patent,yes,153,0,17,17,71,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/00;;A61K35/12;;C12N5/0784,,302,227,049-915-366-620-516;;157-642-321-785-08X;;032-932-040-924-322;;138-771-752-862-480;;168-705-133-516-75X;;016-059-509-686-365;;084-085-138-348-898;;064-388-641-569-789;;097-167-161-561-41X;;006-027-796-241-692;;077-678-786-447-085;;029-311-860-898-924;;032-294-227-563-850;;078-639-700-866-831;;025-457-637-309-732;;027-915-134-983-264;;022-798-233-953-966;;101-169-326-244-167;;045-700-919-027-517;;007-174-971-453-251;;019-264-483-343-031;;013-855-584-540-778;;011-191-194-524-48X;;062-108-416-505-04X;;057-785-668-031-036;;059-717-731-643-077;;011-954-218-606-176;;042-796-720-165-197;;044-750-837-062-887;;092-707-572-319-639;;040-713-726-205-55X;;124-282-566-991-152;;160-717-493-067-916;;044-555-535-916-468;;002-637-847-823-805;;018-870-261-171-506;;043-164-984-018-36X;;090-928-883-705-496;;028-167-813-228-119;;004-397-008-209-727;;006-148-652-132-981;;046-986-959-047-056;;096-505-815-317-436;;008-169-153-417-267;;054-439-756-152-283;;021-901-512-648-514;;053-672-692-937-579;;165-292-111-716-265;;099-464-580-091-161;;068-473-895-492-963;;006-885-984-877-437;;085-702-051-840-908;;067-905-202-866-732;;003-865-790-341-418;;038-241-086-015-47X;;007-894-661-068-687;;120-862-791-424-707;;153-662-306-900-396;;061-756-489-300-343;;025-760-264-704-263;;043-357-937-051-619;;082-930-667-453-661;;017-862-373-044-791;;004-602-946-239-391;;057-002-651-793-17X;;046-010-966-436-821;;108-599-572-220-595;;060-861-375-524-523;;019-377-086-323-88X;;019-963-559-470-014;;012-105-359-936-435;;086-946-791-527-279;;044-084-260-816-039;;003-616-087-027-77X;;053-906-705-994-097;;055-983-972-565-643;;001-000-221-109-111;;063-225-571-358-608;;022-705-571-480-334;;124-257-229-162-56X;;097-470-977-075-432;;070-884-634-385-754;;139-500-660-556-55X;;003-924-024-298-446;;133-716-008-515-719;;010-981-337-785-354;;078-723-209-803-023;;116-248-902-411-147;;047-903-330-676-744;;103-932-348-507-545;;081-222-505-017-37X;;035-823-463-717-575;;054-045-955-566-76X;;071-699-972-336-631;;041-406-340-961-551;;049-537-999-449-717;;026-304-558-215-155;;063-547-669-345-057;;035-263-789-910-604;;075-344-720-447-282;;033-947-267-268-874;;077-262-310-785-629;;078-642-510-799-292;;009-792-025-501-449;;032-969-718-122-323;;060-667-322-361-290;;018-117-667-758-278;;065-766-887-494-547;;057-105-231-226-816;;012-638-135-148-028;;108-207-855-841-062;;100-984-968-676-329;;033-662-847-189-276;;028-211-379-291-005;;018-681-549-217-136;;030-955-335-211-791;;063-710-398-275-735;;046-028-954-444-037;;096-830-349-650-74X;;034-123-379-564-453;;022-982-723-684-607;;192-609-714-372-280;;039-376-070-403-51X;;096-741-767-207-949;;093-530-607-257-147;;005-926-044-608-888;;065-777-065-691-692;;026-219-340-070-989;;010-628-726-217-388;;022-665-264-045-910;;109-735-000-316-284;;076-867-150-716-864;;021-602-438-381-646;;037-026-666-022-301;;039-936-793-486-518;;074-416-675-238-759;;046-503-066-966-531;;000-347-673-674-126;;022-618-370-567-630;;003-646-738-432-814;;014-782-564-302-045;;078-538-820-088-074;;113-598-986-994-212;;128-972-796-335-47X;;012-912-288-809-826;;078-960-740-243-971;;034-409-534-864-530;;096-919-431-021-193;;035-857-332-739-788;;006-884-247-056-538;;043-498-574-177-034;;035-444-720-129-695;;036-291-566-706-918;;035-033-143-909-694;;068-431-834-637-887;;056-649-998-351-849;;052-358-709-302-448;;069-597-740-399-36X;;032-084-932-733-530;;045-609-027-418-523;;074-128-014-644-585;;009-782-141-099-662;;009-491-278-782-50X;;004-045-625-151-197;;092-859-198-377-451;;126-067-752-107-202;;080-647-403-540-300;;046-847-065-587-168;;115-116-379-661-764;;054-484-357-087-819;;036-870-001-420-126;;000-885-838-243-710;;021-056-467-881-097;;053-393-265-065-68X;;030-031-127-445-729;;030-768-232-817-332;;026-958-333-907-92X;;071-463-964-030-172;;082-685-856-025-336;;079-530-924-604-491;;100-536-485-767-198;;102-689-032-778-02X;;098-816-864-321-352;;014-632-348-567-029;;016-682-361-755-014;;006-358-679-274-408;;048-188-266-680-461;;001-270-738-830-729;;035-880-661-684-138;;074-840-764-720-259;;054-618-496-698-952;;031-512-193-740-666;;039-626-415-012-821;;107-609-264-245-344;;052-059-538-341-011;;021-094-457-214-036;;014-276-712-023-004;;065-909-930-757-329;;072-363-514-726-015;;036-646-968-481-643;;061-975-634-725-939;;076-040-603-290-195;;128-811-364-518-486;;009-344-540-448-663;;003-646-738-432-814;;036-383-918-222-326;;014-460-897-815-306;;125-982-573-617-138;;045-015-312-466-69X;;001-805-436-690-108;;038-826-880-774-012;;036-646-381-404-729;;124-282-566-991-152;;074-014-859-687-59X;;081-457-468-429-178;;016-967-008-227-922;;009-194-434-259-809;;004-930-865-912-874;;046-239-449-467-879;;016-550-735-334-675;;063-673-627-574-692;;101-371-986-812-560;;101-486-822-726-957;;059-982-390-038-406;;072-652-623-064-891;;028-508-783-862-76X;;085-231-328-937-57X,10.1006/cimm.1998.1298;;9637766;;10.1158/1078-0432.ccr-09-1322;;20068073;;pmc3682507;;11449066;;11265767;;10.1097/00002371-200103000-00004;;10.1586/14737175.5.4.497;;16026233;;15383564;;10.4049/jimmunol.173.7.4352;;10.2741/1747;;15970545;;10.1073/pnas.0530291100;;pmc153034;;12629218;;18665745;;10.1158/0008-5472.can-06-4180;;17483311;;10.1038/nrc1740;;16327766;;18539956;;10.1200/jco.2008.17.7436;;pmc2241749;;10.4049/jimmunol.174.8.4812;;15814707;;10.1016/s0022-1759(02)00142-4;;12135802;;10.1097/00006123-199903000-00110;;10069601;;19903840;;pmc2789196;;10.1158/0008-5472.can-09-2687;;10.4049/jimmunol.170.4.1822;;12574347;;11196166;;10.1016/j.neuron.2009.08.038;;pmc2789107;;19840551;;12941147;;10.1046/j.1365-2567.2003.01726.x;;pmc1783031;;9973437;;12667889;;10.1016/s0163-7258(03)00014-7;;10.1227/00006123-199305000-00003;;10.1097/00006123-199305000-00003;;8388081;;10.1073/pnas.91.3.1004;;pmc521442;;8302824;;10.3727/096368909x12483162196962;;19523342;;10.1093/jnci/85.9.704;;8478956;;17293384;;10.1158/0008-5472.can-06-4038;;11471194;;10.1073/pnas.142298299;;pmc125045;;12114532;;12616102;;10.1097/00002371-200303000-00003;;10.1177/107327480401100307;;15153843;;1709722;;10.1038/351290a0;;8557366;;pmc173770;;10.1128/iai.64.1.363-365.1996;;10914698;;10.1158/0008-5472.can-04-1364;;15466194;;18245488;;10.1158/0008-5472.can-07-0445;;12391241;;10.4049/jimmunol.169.9.5227;;9841453;;10.1126/science.282.5391.1061;;11731436;;11239426;;10.1016/s0896-6273(01)00209-4;;17412894;;10.1634/stemcells.2006-0624;;10.1007/s002620050465;;9558003;;16397045;;10.1158/1078-0432.ccr-05-1178;;16331615;;10.1002/ijc.21616;;10.1097/00002371-200107000-00008;;11565834;;10.1189/jlb.1002483;;12773508;;10.1046/j.1432-1327.1999.00154.x;;10091592;;10.1016/s0165-5728(99)00172-1;;10674985;;pmc299944;;14645703;;10.1073/pnas.2036535100;;10.4049/jimmunol.164.2.861;;10623833;;pmc521140;;10.1073/pnas.0400067101;;15381773;;12832694;;10.1634/stemcells.21-4-405;;10.1007/s005950300060;;12707821;;pmc2881867;;10.1371/journal.pone.0010974;;20539758;;19944974;;10.1016/j.nec.2009.08.006;;pmc2786895;;9743339;;pmc2430890;;10.4049/jimmunol.168.2.951;;11777994;;11676393;;10.1007/s002620100205;;10.1007/s00262-002-0297-z;;12202903;;10.1126/science.1135308;;17185560;;12222879;;pmc1782333;;16836618;;10.1111/j.1365-2567.2006.02412.x;;10.1182/blood.v97.6.1776;;11238120;;15908947;;pmc2377345;;10.1038/nn1473;;19194651;;10.1007/s00701-009-0185-9;;10.1038/nbt947;;15004565;;15277692;;10.1634/stemcells.22-4-448;;10350260;;10.3171/jns.1999.90.6.1115;;17939761;;10.1586/14737175.7.10.1235;;17140455;;pmc1697823;;10.1186/1476-4598-5-67;;15076139;;10.1097/00002371-200405000-00006;;10.1177/107327480301000205;;12712008;;10.1038/sj.onc.1208519;;15897911;;15256472;;10.1158/0008-5472.can-03-3504;;10.1097/00002371-200307000-00002;;12843792;;10.1586/14760584.5.2.233;;16608423;;15162438;;10.1002/eji.200425081;;9743519;;10.1084/jem.188.6.1005;;pmc2212536;;10.2174/157488708783330530;;18474011;;10.4049/jimmunol.176.3.1796;;16424210;;10.1038/nm0697-625;;9176488;;18539965;;10.1200/jco.2007.15.1472;;10.1634/stemcells.22-6-1101;;15536199;;8027569;;10.4049/jimmunol.153.3.996;;7774624;;10.1002/eji.1830250511;;12109820;;10.1053/clon.2001.0038;;pmc3903051;;10.1007/s00262-007-0426-9;;18057935;;11440627;;10.1089/104303401750270995;;10.1002/path.2283;;18067118;;17307142;;10.1016/j.bbrc.2007.01.159;;10.1007/978-1-4684-6831-1_14;;12717023;;10.1110/ps.0239403;;pmc2323871;;12907622;;17122772;;10.1038/nature05372;;9754652;;10.1002/(sici)1097-0215(19981005)78:2<196::aid-ijc13>3.0.co;2-9;;10.1023/a:1024969422010;;10.1007/bf02700016;;12952282;;12640097;;10.1097/01.mp.0000056981.16578.c3;;10.1093/jjco/hye076;;11574635;;9809996;;10.4049/jimmunol.157.6.2539;;8805655;;10.1093/jnci/94.11.805;;12048268;;10764250;;10.1227/00006123-200004000-00002;;10.1097/00006123-200004000-00002;;10.1007/978-1-59745-280-9_15;;19582431;;17079441;;10.1158/0008-5472.can-06-2048;;10.1200/jco.2010.28.15_suppl.2097;;1476743;;pmc1137064;;7519851;;10.1042/bj3010847;;10945499;;10.1054/bjoc.2000.1289;;pmc2374651;;10886507;;10.1046/j.1523-1747.2000.00023.x;;10.1053/pb.2000.6691;;10914414;;3276675;;10.1016/s0021-9258(19)77935-6;;14555310;;10.1038/35102167;;11689955;;1553558;;10.1126/science.1553558;;1432110;;10.1523/jneurosci.12-11-04565.1992;;pmc6575989;;10024247;;10.1126/science.283.5405.1183;;10.1038/nm0398-321;;9500606;;pmc2064864;;10.1007/978-1-349-02718-7_1;;7585538;;16120861;;10.1056/nejmra043666;;12900280;;10.1016/s0952-7915(03)00083-9;;10.14670/hh-18.435;;12647794;;14522905;;10.1038/nature03128;;15549107;;15378086;;10.1038/sj.onc.1207946;;18542072;;10.1038/sj.bjc.6604437;;pmc2453027;;10.1007/bf03401956;;pmc1949998;;11713365;;10.3349/ymj.2004.45.suppl.48;;15250050;;17024127;;pmc2360579;;10.1038/sj.bjc.6603369;;11895781;;10.1182/blood.v99.7.2468;;10.1034/j.1600-0463.2003.11107802.x;;12974772;;7690811;;15312683;;10.1016/j.canlet.2004.04.010;;12209978;;10.1002/ijc.10597;;15825167;;10.1002/ijc.21061;;10.1095/biolreprod57.3.561;;9282991;;11606390;;11093159;;10.1002/1521-4141(2000012)30:12<3411::aid-immu3411>3.0.co;2-r;;10.3171/foc.2006.20.4.17;;16709033;;10.1186/1476-4598-3-25;;15469606;;pmc524518;;8617954;;10.1016/j.vaccine.2006.02.025;;16530303;;pmc1850619;;10.1084/jem.184.6.2207;;pmc2211562;;8976176;;18298336;;10.1089/cbr.2007.0427;;10.1016/j.exphem.2006.05.011;;16982333;;pmc24979;;9356465;;10.1073/pnas.94.23.12425;;19322543;;10.1007/978-3-540-31206-2_9;;18632651;;10.1158/0008-5472.can-07-5973;;15571138;;10.1158/1078-0432.ccr-04-0497;;15328167;;10.4049/jimmunol.171.9.4927;;14568975;;18535153;;10.1634/stemcells.2008-0078;;17077937;;10.1007/s11060-006-9265-3;;10.1002/stem.102;;pmc5854496;;19536809;;18787206;;10.1634/stemcells.2008-0459;;10.1038/sj.bjc.6605142;;19568241;;pmc2720199;;14520441;;pmc2394324;;10.1038/sj.bjc.6601268;;12874257;;10.1084/jem.20030422;;pmc2194081;;15086239;;10.3171/jns.2004.100.2.0310;;10754316;;10.4049/jimmunol.164.8.4204;;10.3892/or.16.6.1317;;17089056;;10.1089/scd.2007.0063;;18230026;;10.1182/blood.v90.12.5002.5002_5002_5012;;9389720;;10.1182/blood.v90.12.5002;;10.1084/jem.171.4.1315;;pmc2187833;;2139102;;12042327;;10.1074/jbc.m202349200;;12538481;;17380773;;11221866;;10.1158/0008-5472.can-03-3505;;15256471;;10.1038/sj.onc.1208311;;15558011;;10.1200/jco.2007.15.5465;;18539969;;10.1038/labinvest.3700233;;15716863;;10744623;;10.1096/fasebj.14.5.661;;pmc4030524;;10.1158/1078-0432.ccr-06-1576;;17255279;;17540729;;10.1073/pnas.0608635104;;pmc1885220;;11533706;;10.1038/nm0901-1028;;16081793;;10.4049/jimmunol.175.4.2252;;pmc2192415;;10.1084/jem.183.1.87;;8551248;;10.1002/jcp.21541;;18651561;;pmc1501889;;10.1593/neo.05277;;16207473;;9432985;;10.1084/jem.187.2.265;;pmc2212106;;pmc3297681;;10.1158/1535-7163.mct-11-0454;;22351743;;10.1016/j.immuni.2007.11.003;;18031690;;11358828;;9869522;;10.1007/bf02303486;;10902608;;10.1034/j.1399-0039.2000.550603.x;;24482751;;10.4161/onci.26840;;pmc3894244;;2315699;;10.1126/science.2315699;;21913724;;pmc3270889;;10.1021/pr200503g;;21841125;;10.4049/jimmunol.1101080;;pmc3175636;;16286653;;pmc1287962;;10.1073/pnas.0500721102;;24504800;;10.1002/art.38249;;19176997;;10.4161/cc.8.3.7608;;10.1126/science.1108003;;15761154;;10.1016/0161-5890(94)90155-4;;7823965;;pmc5788015;;10.1007/978-3-642-03858-7_9;;19960314;;2115981;;10.1038/346574a0;;10.1016/j.jprot.2014.07.009;;25050860;;8906823;;10.4049/jimmunol.174.9.5636;;15843563;;10.1038/nri3084;;22076556;;11687234;;10.1016/s0022-1759(01)00459-8;;21598389;;10.1002/pmic.201000531;;pmc43194;;8108441;;10.1073/pnas.91.4.1534;;9469433;;8617954;;10.1002/(sici)1521-4141(200004)30:4<1172::aid-immu1172>3.0.co;2-j;;10760807;;9190931;;10.4049/jimmunol.158.12.5797;;14647477;;10.1038/nri1250;;10.1073/pnas.93.1.136;;pmc40193;;8552591;;10.1097/cji.0b013e31816dad10;;18391753;;10.3109/08830185.2011.572210;;21557641;;22082029;;pmc3283529;;10.1186/1479-5876-9-198;;8557366;;pmc173770;;10.1128/iai.64.1.363-365.1996;;11289108;;24375541;;pmc3952931;;10.5966/sctm.2013-0135;;22790179;;10.1038/nri3254;;10652572;;16137749;;10.1016/j.ygyno.2005.07.019;;10.1517/14728222.9.6.1179;;16300469;;10.1158/1538-7445.am10-5165;;22847020;;10.1007/s00262-012-1319-0;;pmc3541928;;10.1093/intimm/dxg074;;12750359;;15226377;;10.1242/jcs.01222;;10358773;;10.1146/annurev.immunol.17.1.739;;14695148;;20423514;;10.1186/1471-2407-10-163;;pmc2868811;;23174760;;10.3892/ijmm.2012.1195,"Abdel-Wahab et al., “Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity,” Cell. Immunol., 186:63-74 (1998).;;Ahmed et al.; “HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors”; Clin Cancer Res.; 16(2); 474-85.;;Akasaki et al., “Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model,” J. Immunother., 24:106-113 (2001).;;Akasaki et al., “Dendritic cell-based immunotherapy for malignant gliomas,” Expert Rev. Neurother., 5:497-508 (2005).;;Akasaki et al., “Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma,” J. Immunol., 173:4352-59 (2004).;;Akasaki et al., “T cell immunity in patients with malignant glioma: recent progress in dendritic cell-based immunotherapeutic approaches,” Front. Biosci., 10:2908-21 (2005).;;Al-Hajj et al., “Prospective identification of tumorigenic breast cancer cells,” Proc. Natl. Acad. Sci. USA, 7:3983-88 (2003).;;Altaner, “Glioblastoma and stem cells,” Neoplasma, 55:369-374 (2008).;;Beier et al., “CD133+ and CD133-glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles,” Cancer Res., 67:4010-15 (2007).;;Bjerkvig et al., “Opinion: the origin of the cancer stem cell: current controversies and new insights,” Nat. Rev. Cancer, 11:899-904 (2005).;;Boman et al., “Cancer stem cells: a step toward the cure,” J. Clin. Oncol., 26:2795-99 (2008).;;Borbulevych et al., “Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design,” J. Immunol., 174:4812-20 (2005).;;Borràs et al., “Findings on T cell specificity revealed by synthetic combinatorial libraries,” J. Immunol. Methods, 267:79-97 (2002).;;Bowles, Jr. et al., “Long-term remission of malignant brain tumors after intracranial infection: a report of four cases,” Neurosurgery, 44:636-642 (1999).;;Brown et al., “Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells,” Cancer Res., 69:8886-93 (2009).;;Bullock et al., “Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells,” J. Immunol., 170:1822-29 (2003).;;Candido et al., “Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents,” Cancer Res., 61:228-236 (2001).;;Carpentier et al., 2009, Neuron, 64: 79-92.;;Casey et al., “Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine,” Immunology, 110:105-111 (2003).;;Castelli et al., “Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens,” J. Immunol., 162:1739-48 (1999).;;Castro et al., “Current and future strategies for the treatment of malignant brain tumors,” Pharmacol. Ther., 98:71-108 (2003).;;Chandler et al., “Long-term survival in patients with glioblastoma multiforme,” Neurosurgery, 32:716-720 (1993).;;Chen et al., “Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies,” Proc. Natl. Acad. Sci. USA, 91:1004-08 (1994).;;Cho et al., “Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas,” Cell Transplant., 18:977-983 (2009).;;Curran et al., “Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials,” J. Natl. Cancer Inst, 85:704-710 (1993);;Czerniecki et al., “Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion,” Cancer Res., 67:1842-52 (2007).;;Debinsky, “Correspondence re: B. H. Joshi et al., Interluekin-13 Receptor α Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas. Cancer Res., 60: 1168-1172, 2000,” Cancer Res., 61:5660 (2001);;Dietz, “Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia,” Croatian Med. J., 42:428-435 (2001).;;Drukker et al., “Charaeterization of the expression of MHC proteins in human embryonic stem cells,” Proc. Natl. Acad. Sci. USA, 99:9864-69 (2002).;;Ehtesham et al., “Intratumoral dendritic cell Vaccination elicits potent tumoricidal immunity against malignant glioma in rats,” J. Immunothen, 26:107-116 (2003);;Ehtesham et al., “Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials,” Cancer Control, 11:192-207 (2004).;;Falk et al., “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,” Nature, 351:290-296 (1991).;;Feng et al., “P55, an Immunogenic but Nonprotective 55-Kilodalton Borrelia burgdorferi Protein in Murine Lyme Disease”, Infection and Immunity, 336-365 (1996).;;Friedman et al., “Temozolomide and treatment of malignant glioma,” Clin. Cancer Res., 6:2585-97 (2000).;;Galli et al., “Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma,” Cancer Res., 64:7011-21 (2004).;;Garcia-Hernandez et al., “Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in The Absence of Autoimmunity”, Cancer Res, Vol. 68, No. 3, (2008), pp. 861-869;;Gatza et al., “Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma,” J. Immunol., 169:5227-35 (2002).;;Gearhart, 1998, Science, 282: 1061-1062.;;Geiger et al., “Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression,” Cancer Res., 61:8513-19 (2001).;;Geschwind et al., “A genetic analysis of neural progenitor differentiation,” Neuron, 2:325-39 (2001).;;Ghods et al., “Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells,” Stem Cells, 7:1645-53 (2007).;;Gilboa et al., “Immunotherapy of cancer with dendritic-cell-based vaccines,” Cancer Immunol. Immunother., 46:82-87 (1998).;;Haas et al., “Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine,” Clin. Cancer Res., 12:214-222 (2006).;;Hahn et al., “Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer,” Int. J. Cancer, 118:2220-31 (2006).;;Harada et al., “Melanoma-reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types,” J. Immunother., 24:323-333 (2001).;;Harizi et al., “Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes,” J. Leukocyte Biol., 73:756-763 (2003).;;Haynes et al., “Molecular characterization of the B” regulatory subunit gene family of Arabidopsis protein phosphatase 2A, Euro J. Biochem., vol. 260, (1999), pp. 127-136.;;Heimberger et al., “Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma,” J. Neuroimmunol., 103:16-24 (2000).;;Hemmati et al., “Cancerous stem cells can arise from pediatric brain tumors,” Proc. Natl. Acad. Sci. USA, 25:15178-83 (2003).;;Hemmer et al., “Contribution of Individual Amino Acids Within MHC Molecule or Antigenic Peptide to TCR Ligand Potency,” J. Immunol., 164:861-871 (2000).;;Hirschmann-Jax et al., “A distinct ‘side population’ of cells with high drug efflux capacity in human tumor cells,” Proc. Natl. Acad. Sci. USA, 39:14228-33 (2004).;;Hori et al., “Neural progenitor cells lack immunogenecity and resist destruction as allografts,” Stem Cells, 21:405-416 (2003).;;Inoue et al., “Dendritic cells coinjected with tumor cells treated with an anticancer drug to induce tumor rejection,” Surg. Today, 33:269-276 (2003).;;Irvin et al., “T cells enhance stem-like properties and conditional malignancy in gliomas,” PLoS One, 5:e10974 (2010).;;Ji et al., “Glioma stem cell research for the development of immunotherapy,” Neurosurg. Clin. N. Am., 21:159-66 (2010).;;Joshi et al., “Interleukin-13 receptor α chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas,” Cancer Res., 60:1168-72 (2000).;;Kalinski et al., “Prostaglandin E2 induces the final maturation of IL-12 deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation,” J. Immunol, 161:2804-09 (1998).;;Khong et al., “Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy,” J. Immunol, 168:951-956 (2002).;;Kikuchi et al., “Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells,” Cancer Immunol. Immumother., 50:337-344 (2002).;;Kikuchi et al., “Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model,” Cancer Immunol. Immumother., 51:424-430 (2002).;;Kimchi-Sarfaty et al., “A “Silent” Polymorphism in the MDR1 Gene Changes Substrate Specificity”, Science, vol. 315, (2007), pp. 525-528 (Erratum, 1 page).;;Knutson et al., “Technology evaluation: DCVax, Northwest Biotherapeutics,” Curr. Opin. Mol. Ther., 4:403-407 (2002).;;Koch et al., “Immune-privileged embryonic Swiss mouse STO and STO cell-derived progenitor cells: major histocompatibility complex and cell differentiation antigen expression patterns resemble those of human embryonic stem cell lines,” Immunology, 119:98-115 (2006).;;Kuby et al., Immunology, W. H. Freeman and Co., pp. 523-524 (1992).;;La Rosa et al., “Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries,” Blood, 97:1776-86 (2001).;;Lee et al., “Isolation of neural stem cells from the postnatal cerebellum,” Nat. Neurosci., 6:723-729 (2005).;;Lefranc, “Editorial: On the road to multi-modal and pluri-disciplinary treatment of glioblastomas,” Acta Neurochir. (Wien), 151:109-112 (2009).;;Lemmel et al., “Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling,” Nat. Biotechnol., 22:450-454 (2004).;;Li et al., “Human embryonic stem cells possess immune-privileged properties,” Stem Cells, 22:448-456 (2004).;;Liau et al., “Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens,” J. Neurosurg., 90:1115-24 (1999).;;Liu and Yu, “Cancer vaccines: a novel strategy to sensitize malignant glioma to chemotherapy,” Expert Rev. Neurother., 7:1235-37 (2007).;;Liu et al., “Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma,” Mol. Cancer, 5:67 (2006).;;Liu et al., “Chemoresistance of stem-like cells isolated from glioblastoma,” Proc. Amer. Assoc. Cancer Res., 47:75, abstract #320 (2006).;;Liu et al., “AIM-2: a novel tumor antigen is expressed and presented by human glioma cells,” J. Immunother., 27:220-226 (2004);;Liu et al., “Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma,” Cancer Control, 10:138-147 (2003).;;Liu et al., “Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy,” Oncogene, 24:5226-34 (2005);;Liu et 31., “HER-2, gp100, and MAGE-l are expressed in human glioblastoma and recognized by cytotoxic T cells,” Cancer Res, 64:4980-86 (2004);;Liu et al., “Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma,” J. Immunother., 26:301-312 (2003).;;Liu et al., “Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination,” Expert Rev. Vaccines, 5:233-247 (2006).;;Liu et al., “Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response,” Eur. J. Immunol., 34:1680-87 (2004);;Lupetti et al., “Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage,” J. Exp. Med, 188: 1005-16 (1998).;;Luptrawan et al., “Dendritic cell immunotherapy for malignant gliomas,” Rev. Recent Clin. Trials, 3:10-21 (2008).;;Lustgarten et al., “Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope,” J. Immunol., 176:1796-1805 (2006).;;Lynch et al., “Flt3 ligand induces tumor regression and antitumor immune responses in vivo,” Nat. Med., 3:625-631 (1997).;;Maitland and Collins, “Prostate cancer stem cells: a new target for therapy,” J. Clin. Oncol., 26:2862-70 (2008).;;Mammolenti et al., “Absence of major histocompatibility complex class I on neural stem cells does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro,” Stem Cells, 22:1101-10 (2004).;;Mehta-Damani et al., “Generation of antigen-specific CD8+ CTLs from naive precursors,” J. Immunol., 153:996-1003 (1994).;;Mehta-Damani et al., “Generation of antigen-specific CD4+ T cell lines from naïve precursors,” Eur. J. Immunol., 5:1206-11 (1995).;;Melcher et al., “Dendritic cells for the immunotherapy of cancer,” Clin. Oncol., 14:185-192 (2002).;;Merrick et al., “Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy,” Cancer Immunol. Immunother., 57:897-906 (2008).;;Mi et al., “Induced apoptosis supports spread of adenovirus vectors in tumors,” Hum. Gene Ther., 12:1343-52 (2001).;;Mizrak et al., “CD133: molecule of the moment,” J. Pathol., 214:3-9 (2008).;;NCBI GenBank Accession No. NM_006017 (Jul. 13, 2008), 5 pages.;;Neuzil et al., “Tumour-initiating cells vs. cancer ‘stem’ cells and CD133: what's in the name?” Biochem. Biophys. Res. Commun., 355:855-859 (2007).;;Ngo, J. et al., “Computational Complexity, Protein Structure Prediction and the Levinthal Paradox”, (1994), The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (eds.), Birkhauser Boston: Boston, MA, pp. 433 and 492-495.;;Nielsen et al., “Reliable prediction of T-cell epitopes using neural networks with novel sequence representations,” Protein Sci., 12:1007-1017 (2003).;;Nowak et al., “Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors,” Cancer Res., 63:4490-96 (2003).;;O'Brien et al., “A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,” Nature, 7123:106-110 (2007).;;Okada et al., “Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms,” Int. J. Cancer, 78:196-201 (1998).;;Okada et al., “Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy,” J. Neurooncol., 64:13-20 (2003).;;Okada et al., “Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients with Recurrent Malignant Glioma”, J. Clin. Oncology, 29:330-336, (2011).;;Okano et al., “Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor α2 chain,” Clin. Cancer Res., 8:2851-55 (2002).;;Ordonez et al.; “Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma”; Mod. Pathol., Mar. 2003; vol. 16, No. 3, pp. 192-197.;;Osada et al., “Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report,” Jpn. J. Clin. Oncol, 31:403-406 (2001);;Parkhurst et al., “Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2),” Cancer Res., 58:4895-4901 (1998).;;Parkhurst et al., “Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A 0201-Binding Residues,” J. Immunol., 157:2539- 2548 (1996).;;Parmiani et al., “Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?” J. Natl. Cancer Inst., 94:805-818 (2002).;;Parney et al., “Glioma immunology and immunotherapy,” Neurosurgery, 46:778-791 (2000).;;Pellegatta et al., “Dendritic cell vaccines for cancer stem cells,” Methods Mol. Biol., 568:233-247 (2009).;;Pellegatta et al., “Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas,” Cancer Res., 66:10247-52 (2006).;;Phuphanich et al., “Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107),” J. Clin. Oncol., 28(15 suppl.):2097 (abstract) (2010).;;Phuphanich et al., “Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107),” poster presented at 2010 ASCO Annual Meeting, Jun. 4-8, 2010.;;Pinilla et al., “Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries,” Biotechniques, 13:901-905 (1992).;;Pinilla et al., “Investigation of antigen-antibody interactions using a soluble, non-support-bound synthetic decapeptide library composed of four trillion (4 x 1012) sequences,” Biochem. J ., 301:847-853 (1994);;Pirtskhalaishvili et al., “Cytokine-mediated protection of human dendritic cells from prostate cancer induced apoptosis is regulated by the Bc1-2 family of proteins,” Br. J. Cancer, 83:506-513 (2000).;;Pisarra et al., “Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization,” J. Invest. Dermatol., 115:48-56 (2000).;;Pollack et al., “Exploitation of immune mechanisms in the treatment of central nervous system cancer,” Semin. Pediatr. Neurol., 7:131-143 (2000);;Posnett et al., “A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain,” J. Biol. Chem., 263:1719-25 (1988).;;Reichardt et al., “Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells,” Haematologica, 88:1139-49 (2003).;;Reya et al., “Stem cells, cancer, and cancer stem cells,” Nature, 6859:105-111 (2001).;;Reynolds and Weiss, “Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system,” Science, 5052:1707-10 (1992).;;Reynolds et al, “A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes,” J. Neurosci., 11:4565-74 (1992).;;Rissoan et al., “Reciprocal control of T helper cell and dendritic cell differentiation,” Science, 283:1183-86 (1999).;;Rosenberg et al., “Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma,” Nat. Med., 4:321-327 (1998).;;Rudinger, J. “Characteristics of the amino acids as components of a peptide hormone sequence”, Peptide Hormones, University Park Press: Baltimore, MD, pp. 107, 1976.;;Salgaller et al., “Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides,” Cancer Res., 55:4972-79 (1995).;;Sanai et al., “Neural stem cells and the origin of gliomas,” N. Eng. J. Med., 8:811-822 (2005).;;Sette et al., “Epitope-based vaccines: an update on epitope identification, vaccine design and delivery”, Current Opinion in Immunology, vol. 15, (2003), pp. 461-470.;;Shin et al., “Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model,” Histol. Histopathol., 18:435-447 (2003).;;Singh et al., “Identification of a cancer stem cell in human brain tumors,” Cancer Res., 63:5821-28 (2003).;;Singh, “ImmunoCellular Therapeutics, Ltd.” presentation at 13th Annual BIO CEO & Investor Conference, Feb. 14, 2011, 23 pages.;;Singh et al., “Identification of human brain tumor initiating cells,” Nature, 7015:396-401 (2004).;;Singh et al., “Cancer stem cells in nervous tumors,” Oncogene, 23:7267-73 (2004).;;Smith et al., “CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers,” Br. J. Cancer, 99:100-109 (2008).;;Soling et al., “Dendritic cell therapy of primary brain tumors,” Mol. Med., 7:659-667 (2001).;;Song et al., “Strategies to improve dendritic cell-based immunotherapy against cancer,” Yonsei Med. J., 45(Suppl):48-52 (2004).;;Steele et al., “The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens,” Br. J. Cancer 95:1202-11 (2006).;;Steinbrink et al., “CD4+ and CD8+ anergic T cells induced by interleukin-10—treated human dendritic cells display antigen-specific suppressor activity,” Blood, 99:2468-76 (2002).;;Steinman, “Some interfaces of dendritic cell biology,” APMIS, 111:675-697 (2003).;;Storkus et al., “Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes,” J. Immunol., 151:3719-27 (1993).;;Stupp et al., “Recent Developments in the Management of Malignant Glioma,” American Society of Clinical Oncology Educational Book, 779-788 (2003).;;Takagi et al., “Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells,” Cancer Lett., 213:49-55 (2004).;;Tanaka et al., “Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo,” Int. J. Cancer, 101:265-269 (2002).;;Tanaka et al., “Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles,” Int. J. Cancer, 116:624-633 (2005).;;Tian et al., “Expression of immunoglobulin superfamily cell adhesion molecules on murine embryonic stem cells,” Biol. Reprod., 57:561-568 (1997).;;Tong et al., “Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors,” Cancer Res., 61:7530-35 (2001).;;Tourdot et al., “A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes”, Eur. J. Immunol., vol. 30, (2000), pp. 3411-3421.;;Tunici et al., “Brain tumor stem cells: new targets for clinical treatments?” Neurosurg. Focus, 4:E27 (2006).;;Tunici et al., “Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma,” Mol. Cancer, 3:25 (2004).;;Van Der Burg et al., “Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability”, J. Immunol., 156:3308-3314 (1996).;;Voet, D. and Voet, J., “Biochemistry”, Section 6-3. Chemical Evolution, John Wiley and Sons, (1990), pp. 126-128.;;Wang et al., “An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens,” Vaccine, 24:3477-89 (2006).;;Wang et al., “Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes,” J. Exp. Med., 184:2207-16 (1996).;;Wei et al., “Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell responses,” Cancer Biother. Radiopharm., 23:121-128 (2008).;;Weigel et al., “Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses,” Exp. Hematol., 34:1403-12 (2006).;;Weigmann et al., “Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells”, Cell Biology, Proc. Natl. Acad. Sci. USA, vol. 94, (1997), pp. 12425-12430.;;Westphal et al., “Other experimental therapies for glioma,” Recent Results Cancer Res., 171:155-164 (2009).;;Wheeler et al., “Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients,” Cancer Res., 68:5955-64 (2008).;;Wheeler et al., “Cellular immunity in the treatment of brain tumors,” Clin. Neurosurg., 51:132-139 (2004).;;Wheeler et al., “Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination,” Clin. Cancer Res., 10:5316-26 (2004).;;Wheeler et al., “Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality,” J. Immunol., 171:4927-33 (2003).;;Wu et al., “Embryonic stem cells and their differentiated derivatives have fragile immune privilege but still represent novel targets of immune attack,” Stem Cells, 26:1939-50 (2008).;;Wu et al., “Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy,” J. Neurooncol., 83:121-131 (2007).;;Xu et al., “Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens,” Stem Cells, 27:1734-40 (2009).;;Xu et al., “Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas,” Stem Cells, 26:3018-26 (2008).;;Xu et al.; “Isolation of tumour stem-like cells from benign tumours”; British Journal of Cancer; (2009) 101, pp. 303-311.;;Yamanaka et al; Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune response: results of a clinical phase I/II trial; British Journal of Cancer, 89:1172-1179 (2003).;;Yamazaki et al., “Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells,” J. Exp. Med., 198:235-247 (2003).;;Yang et al., “Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme,” J. Neurosurg., 100:310-319 (2004).;;Yang et al., “Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3,” J Immunol., 164:4204-11 (2000).;;Yasuda et al., “Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells,” Oncol. Rep., 16:1317-24 (2006).;;Yin et al., “Expression and regulation of major histocompatibility complex on neural stem cells and their lineages,” Stem Cells Dev., 17:53-65 (2008).;;Yin et al., “AC133, a novel marker for human hematopoietic stem and progenitor cells,” Blood, 12:5002-12 (1997).;;Young et al., “Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells,” J. Exp. Med., 171:1315-32 (1990).;;Yu et al. “CD133 as a Potential Target of Anti-Cancer Stem Cell Immunotherapy: Identification of an HLA-A *02 Restricted CD133 Epitope. Abstract”, Journal of Immunotherapy, Nov.-Dec. 2008, p. 928.;;Yu et al., “AC133-2, a novel isoform of human AC133 stem cell antigen,” J. Biol. Chem., 23:20711-16 (2002).;;Yu et al., “Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer,” Clin. Cancer Res., 9:285-294 (2003).;;Yu et al., “Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination,” Clin. Neurosurg., 53:345-351 (2006).;;Yu et al., “Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration,” Cancer Res., 61:842-847 (2001).;;Yu et al., “Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma,” Cancer Res., 64:4973-79 (2004).;;Yuan et al., “Isolation of cancer stem cells from adult glioblastoma multiforme,” Oncogene, 58:9392-9400 (2004).;;Zabierowski and Herlyn, “Melanoma stem cells: the dark seed of melanoma,” J. Clin. Oncol., 26:2890-94 (2008).;;Zagzag et al., “Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain,” Lab. Invest., 85:328-341 (2005).;;Zeidler et al., “Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1,” FASEB J., 14:661-668 (2000).;;Zhang et al., “Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics,” Clin. Cancer Res., 13:566-575 (2007).;;Zhang et al., “Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization,” PNAS 24:10193-10198 (2007).;;Zhou et al., “The ABC transporter Berp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype,” Nat. Med., 9:1028-34 (2001).;;Zhu et al., “Insertion of the dibasic motif in the flanking region of a cryptic self-determinant leads to activation of the epitope-specific T cells,” J. Immunol., 175:2252-60 (2005).;;Zitvogel et al., “Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-1 associated cytokines,” J. Exp. Med., 183:87-97 (1996).;;Zou et al., “Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver,” J. Cell. Physiol., 217:598-604 (2008).;;International Preliminary Report on Patentability for App. Ser. No. PCT/US07/79846, dated Apr. 9, 2009, 5 pages.;;International Preliminary Report on Patentability for App. Ser. No. PCT/US07/079857, dated Apr. 9, 2009, 5 pages.;;International Preliminary Report on Patentability for App. Ser. No. PCT/US2010/034082, dated Nov. 17, 2011, 5 pages.;;International Preliminary Report on Patentability of International Application No. PCT/US2009/055759, dated Mar. 8, 2011 (dated Mar. 17, 2011), 7 pages.;;International Search Report and Written Opinion of International Application No. PCT/US2009/055759, dated Jun. 28, 2010, 12 pages.;;International Search Report and Written Opinion of International Application No. PCT/US2010/034082, dated Feb. 22, 2011, 9 pages.;;International Search Report and Written Opinion of the International Searching Authority for PCT/US2007/79600, dated Mar. 27, 2008, 10 pages.;;International Search Report and Written Opinion; PCT/US2014/16562; dated Jun. 3, 2014; 37 pp.;;International Preliminary Report on Patenability; PCT/US2014/016562; dated Aug. 27, 2015; 10 pp.;;International Search Report and Written Opinion; PCT/US2014/16610; dated Jun. 5, 2014; 24 pp.;;International Preliminary Report on Patentability, PCT/US2014/16610; dated Aug. 27, 2015; 11 pp.;;International Search Report of International Application No. PCT/US07/79846, dated Jul. 14, 2008.;;International Search Report of International Application No. PCT/US07/79857, dated Apr. 8, 2008.;;USPTO Final Office Action in U.S. Appl. No. 13/365,666, dated Oct. 6, 2014, 14 pages.;;USPTO Non-Final Office Action in U.S. Appl. No. 11/863,990, dated Aug. 26, 2010, 15 pages.;;USPTO Final Office Action in U.S. Appl. No. 11/863,990, dated May 12, 2011, 18 pages. et al.",ACTIVE
185,WO,A1,WO 2009/155332 A1,117-933-309-594-095,2009-12-23,2009,US 2009/0047640 W,2009-06-17,US 7320508 P,2008-06-17,USE OF TOLL-LIKE RECEPTOR LIGANDS AS ADJUVANTS TO VACCINATION THERAPY FOR BRAIN TUMORS,"Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.",CEDARS SINAI MEDICAL CENTER;;BLACK KEITH L;;MORRIS-IRVIN DWAIN;;ARDITI MOSHE,BLACK KEITH L;;MORRIS-IRVIN DWAIN;;ARDITI MOSHE,,https://lens.org/117-933-309-594-095,Patent Application,yes,3,18,5,5,0,A61K38/164;;A61K45/06;;C12N5/0639;;A61K2039/55561;;A61K2039/55572;;A61P35/00;;A61P37/04;;A61K39/4615;;A61K2239/38;;A61K2239/47;;A61K39/4622;;A61K2239/31;;A61K39/464499;;A61K35/15;;A61K38/164;;A61K45/06;;C12N5/0639;;A61K2039/5154;;A61K2039/55561;;A61K2039/55572;;A61K39/0011,A61K35/12;;A61K35/15;;A61K38/16;;A61K39/00,,1,1,085-543-991-034-265,10.1073/pnas.0710145104;;pmc2154458;;18077358,"SALIO ET AL.: ""Modulation of human natural killer T cell ligands on TLR-mediated antigen- presenting cell activation."", PROC NATL ACAD SCI USA., vol. 104, no. 51, 2007, pages 20490 - 20495",PENDING
186,WO,A3,WO 2008/003055 A3,195-627-961-518-118,2008-03-06,2008,US 2007/0072389 W,2007-06-28,US 42717906 A,2006-06-28,FACING PRODUCT FOR VEHICULAR TRIM,"A composite facing material is disclosed that may be used in combination with, e.g. foam, fibers and/or shoddy in a vehicular application. The composite may provide heat insulation and/or sound attenuation in a vehicular trim panel. The facing material may include a layer of staple fibers with a spunbonded continuous filament web layer. The layers may be intermittently thermally bonded in a desired pattern.",FREUDENBERG NONWOVENS L P;;BLACK SAMUEL KEITH;;KAMPF QUENTIN L;;MORIN SEAN,BLACK SAMUEL KEITH;;KAMPF QUENTIN L;;MORIN SEAN,,https://lens.org/195-627-961-518-118,Search Report,yes,2,0,3,3,0,B32B5/26;;D04H1/559;;D04H3/14;;B32B5/00;;B32B5/022;;B32B5/08;;B32B7/12;;B32B2250/40;;B32B2262/02;;B32B2262/04;;B32B2262/06;;B32B2262/14;;B32B2272/00;;B32B2307/102;;B32B2605/00;;B60R13/02;;B32B7/05;;Y10T442/60;;B32B7/027;;Y10T442/60;;D04H3/14;;B32B5/00;;B32B2262/02;;B32B2262/06;;B32B5/26;;B32B2262/04;;B32B2307/102;;B32B2262/14;;D04H1/559;;B32B2605/00;;B32B5/022;;B32B7/12;;B32B2272/00;;B32B5/08;;B32B2250/40;;B60R13/02;;B32B7/05;;B32B7/027,B23B7/04;;B32B7/027,,0,0,,,,PENDING
187,WO,A1,WO 2019/070645 A1,197-114-174-895-204,2019-04-11,2019,US 2018/0053873 W,2018-10-02,US 201762566813 P,2017-10-02,METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY THROUGH MULTIPLE BIO BARRIERS,"Mini nanodrugs that include a polymalic-based molecular scaffold with one or more peptides capable of crossing the blood-brain barrier, one or more plaque-binding peptides and one or more therapeutic agents attached to the scaffold are provided. Methods of treating brain diseases or abnormal conditions, and imaging of the same in a subject by administering the mini nanodrugs are described. Methods for reducing formation of amyloid plaques in the brain of a subject are disclosed.",CEDARS SINAI MEDICAL CENTER,HOLLER EGGEHARD;;LJUBIMOVA JULIA Y;;BLACK KEITH L,,https://lens.org/197-114-174-895-204,Patent Application,yes,10,2,5,6,11,A61P35/00;;A61K31/713;;A61K38/00;;A61K38/08;;A61K47/593;;A61K47/64;;A61P25/00;;C07K5/0808;;C07K5/0812;;C07K7/06;;C07K14/43572;;C07K14/4711;;C07K14/8117;;C07K14/8121;;C07K17/08;;C07K19/00;;C07K2319/01;;C07K2319/03;;C07K2319/06,A61K38/00;;C07K7/00;;C07K7/06;;C07K7/08;;C07K14/435,,2,1,078-199-999-915-581,22848501;;10.1371/journal.pone.0041457;;pmc3404088,"FUNKE ET AL.: ""Development of a small D-enantiomeric Alzheimer's amyloid-P binding peptide ligand for future in vivo imaging applications"", PLOS ONE, vol. 7, 24 July 2012 (2012-07-24), pages 1 - 10, XP055056284, DOI: 10.1371/journal.pone.0041457;;See also references of EP 3691670A4",PENDING
188,US,A1,US 2013/0183328 A1,097-355-327-220-964,2013-07-18,2013,US 201313828432 A,2013-03-14,US 201313828432 A;;US 86399007 A;;US 82726006 P,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",CEDARS SINAI MEDICAL CENTER;;CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2009-05-12),https://lens.org/097-355-327-220-964,Patent Application,yes,3,11,17,17,62,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/00;;A61K35/12,424/185.1;;435/325,3,0,,,"Yu et al , Cancer Res. 61:842-847, 2001, IDS #219 filed on 3/14/2013;;Yu et al , Cancer Res. 64:4973-79, 2004, IDS #220, filed on 3/14/2013;;Liu et al, J Immunother 27:220-226, 2004, IDS #144 filed on 3/14/2013",ACTIVE
189,AU,A1,AU 2011/296215 A1,135-212-704-142-171,2013-03-14,2013,AU 2011/296215 A,2011-08-29,US 37854610 P;;US 2011/0049544 W,2010-08-31,Bed bug monitoring device,The invention is directed to a bed bug monitoring device comprising a bed bug attractant element and a harborage section comprising a support member having a traversable surface and one or more protuberances depending therefrom. The harborage defines at least one entrance through which bed bugs attracted to the device can enter. The device can further include a base section placed over at least a portion of the traversable surface and adapted to by placed flush with the surface against which the device is to be placed.,FMC CORP,BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,,https://lens.org/135-212-704-142-171,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00,,0,0,,,,DISCONTINUED
190,WO,A3,WO 2012/030717 A3,132-025-656-487-796,2012-05-31,2012,US 2011/0049544 W,2011-08-29,US 37854610 P,2010-08-31,BED BUG MONITORING DEVICE,The invention is directed to a bed bug monitoring device comprising a bed bug attractant element and a harborage section comprising a support member having a traversable surface and one or more protuberances depending therefrom. The harborage defines at least one entrance through which bed bugs attracted to the device can enter. The device can further include a base section placed over at least a portion of the traversable surface and adapted to by placed flush with the surface against which the device is to be placed.,FMC CORP;;BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,,https://lens.org/132-025-656-487-796,Search Report,yes,4,0,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,A01M1/02;;A01M1/00;;A01M1/14;;C09J201/00,,0,0,,,,PENDING
191,US,B2,US 8728465 B2,064-365-601-282-407,2014-05-20,2014,US 99543409 A,2009-06-17,US 99543409 A;;US 7320508 P;;US 2009/0047640 W,2008-06-17,Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors,"Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.",BLACK KEITH L;;MORRIS-IRVIN DWAIN;;ARDITI MOSHE;;CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;MORRIS-IRVIN DWAIN;;ARDITI MOSHE,CEDARS-SINAI MEDICAL CENTER (2009-06-17),https://lens.org/064-365-601-282-407,Granted Patent,yes,12,10,5,5,0,A61K38/164;;A61K45/06;;C12N5/0639;;A61K2039/55561;;A61K2039/55572;;A61P35/00;;A61P37/04;;A61K39/4615;;A61K2239/38;;A61K2239/47;;A61K39/4622;;A61K2239/31;;A61K39/464499;;A61K35/15;;A61K38/164;;A61K45/06;;C12N5/0639;;A61K2039/5154;;A61K2039/55561;;A61K2039/55572;;A61K39/0011,A01N63/02;;A61K35/12;;A61K35/15;;A61K35/74;;A61K38/07;;A61K38/08;;A61K38/16;;A61K39/00;;C07H21/04,424/93.71;;424/277.1;;424/282.1;;424/283.1;;424/573;;424/780;;435/325;;435/374;;435/375;;530/327;;530/330;;536/25.6;;514/21.6;;514/21.9;;514/53;;514/54,34,24,125-239-346-378-244;;041-677-195-849-997;;076-637-532-898-559;;046-847-065-587-168;;092-707-572-319-639;;003-030-356-432-987;;012-946-606-269-104;;067-911-159-686-453;;056-649-998-351-849;;093-871-129-922-741;;022-313-882-423-019;;000-243-131-526-368;;026-180-547-792-932;;023-655-000-432-80X;;007-076-847-610-580;;061-919-090-545-764;;106-515-346-786-167;;127-839-209-175-741;;012-818-574-571-598;;012-122-056-161-104;;146-760-363-257-283;;031-329-299-894-094;;007-502-688-416-455;;052-565-618-877-440,16799333;;10.1097/01.cji.0000199199.20717.67;;pmc2196048;;10.1084/jem.20020732;;12186845;;18167273;;10.1158/0008-5472.can-03-3505;;15256471;;10.1177/107327480401100307;;15153843;;10.1038/nm1039;;15122249;;10364168;;10.1074/jbc.274.25.17406;;pmc165983;;10.1128/iai.71.8.4238-4249.2003;;12874299;;14520441;;pmc2394324;;10.1038/sj.bjc.6601268;;17290189;;10.1227/01.neu.0000249280.61761.2e;;10.1007/bf00200001;;16906541;;10.1002/glia.20401;;16775224;;10.1215/15228517-2006-008;;pmc1871955;;10.1186/1479-5876-4-15;;16573834;;pmc1501057;;17160140;;pmc1646255;;10.2174/138920206778426951;;17568998;;10.1007/s11060-007-9415-2;;15353342;;10.2741/1465;;10.2174/1568011043352911;;15281907;;3739492;;17013976;;10.1002/eji.200635910;;205357;;18224680;;10.1002/ijc.23366;;10.1097/cji.0b013e318155a0f6;;18049330;;17295916;;10.1186/1479-5876-5-10;;pmc1802742,"Pilon-Thomas (Journal of Immunotherapy, 2006, vol. 29, pp. 381-387).;;Abstract of Prins et al (Journal of Clinical Oncology, May 20, 2008, supplement, Abstract No. 11021).;;Vicari et al (Journal of Experimental Medicine, 2002, vol. 196, pp. 541-549).;;Abstract of You et al (Zhonghua Yi Xue Za Zhi, Oct. 23, 2007, vol. 87, pp. 2785-2790).;;Yu et al (Cancer Research, 2004, vol. 64, pp. 4973-4979).;;Moneeb et al (Cancer Control, 2004, vol. 11, pp. 192-207).;;Figdor et al (Nature Medicine, 2004, vol. 10, pp. 475-480).;;Shubina et al (Experimental Immunology, 2007, vol. 32, pp. 189-195).;;The abstract of Semenov et al (Molekulyarnaya Meditsina, 2005, vol. 4, pp. 53-58).;;Schwandner et al (Journal of Biological Chemistry, 1999, vol. 274, pp. 17406-17409).;;Uehori et al (Infection and Immunity, 2003, vol. 71, pp. 4238-4249).;;Yamanaka et al (British Journal of Cancer, 2003, vol. 89, pp. 1172-1179).;;PCT/US2009/047640 Written Opinion dated Aug. 7, 2009.;;PCT/US2009/047640 International Preliminary Report on Patentability dated Dec. 18, 2010.;;PCT/US2009/069437 International Search Report dated Feb. 25, 2010.;;PCT/US2009/069437 Written Opinion dated Feb. 25, 2010.;;PCT/US2009/069437 International Preliminary Report on Patentability dated Jun. 29, 2011.;;Chicoine et al. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by toll-like receptor 4. Neurosurgery (2007) 60(2):372-381.;;De et al. Human glioma tumour-associated antigens. Cancer Immunol Immunother (1980) vol. 9(4):207-211. Abstract Only.;;El Andaloussi et al. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. GLIA (2006) 54:526-535.;;Hussain et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology (2006) pp. 261-279.;;Hussain et al. Innate immune functions of microglia isolated from human glioma patients. Journal of Translational Medicine. (2006) 4(15): 9 pages.;;Iizuka et al. Identification of a new antigen recognized by cytotoxic T lymphocytes specific for glioma. Society for Neuroscience Abstract Viewer and Itinerary Planner. (2003): Abstract Only.;;Lichtor et al. Antigenic differences between normal and malignant cells as a basis for treatment of intracerebral neoplasms using a DNA-based vaccine. Current Genomics (2006) 7(4):253-261.;;Mariani et al. Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas. J. Neurooncol (2007) 85:231-240.;;Prins et al. Cellular immunity and immunotherapy of brain tumors. Frontiers in Bioscience (2004) 9: 3124-3136.;;Prasad et al. Recent advances in experimental molecular therapeutics for malignant gliomas. Curr Med Chem-Anti-Cancer Agents (2004) 4: 347-361.;;Romodanov et al. Efficacy of experimental active specific immunotherapy and immunoprevention of malignant gliomas of the braina. Zh Vopr Neirokhir Im N N Burdenko (1986) Abstract Only;;Reizenstein et al. Biological Response to Acute Leukemia. I. Tumor-Associated Antigens and Antigen-Independent Tumor Surveillance. Cancer Treatment Symposia (1985). 1:101-105.;;Scheel et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur. J. Immunol. (2006) 36:2807-2816.;;Tracey et al. Growth of transplanted rat tumors following administration of cell-free tumor antigens. Cancer Research (1978). 38:1208-1212.;;Ueda et al. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. Int. J. Cancer (2008). 122(10). Abstract Only.;;Wu et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother. (2007) 30(8):789-797.;;Zhu et al. Toll Like Receptor-3 Ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. Journal of Translational Medicine (2007) 5(10): 15 pages.",ACTIVE
192,EP,A4,EP 2328923 A4,158-010-769-011-067,2012-05-30,2012,EP 09812172 A,2009-09-02,US 2009/0055759 W;;US 19071808 P,2008-09-02,CD133 EPITOPES,,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,,https://lens.org/158-010-769-011-067,Search Report,no,5,0,13,13,0,A61K39/0011;;A61K39/0011;;A61K45/06;;A61P35/00;;A61P37/04;;C07K14/70596;;C07K14/70596;;C07K7/06;;C07K7/06,C07K14/705;;A61K39/00;;A61P35/00;;C07K7/06,,3,2,021-901-512-648-514;;012-912-288-809-826,10.1046/j.1432-1327.1999.00154.x;;10091592;;pmc24979;;9356465;;10.1073/pnas.94.23.12425,"HAYNES J GEORGIA ET AL: ""Molecular characterization of the B' regulatory subunit gene family of Arabidopsis protein phosphatase 2A"", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 260, no. 1, February 1999 (1999-02-01), pages 127 - 136, XP002674390, ISSN: 0014-2956;;WEIGMANN ANJA ET AL: ""Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 94, 11 November 1997 (1997-11-11), pages 12425 - 12430, XP002143047, ISSN: 0027-8424, DOI: 10.1073/PNAS.94.23.12425;;YU JOHN S ET AL: ""CD133 as a Potential Target of Anti-cancer Stem Cell Immunotherapy: Identification of an HLA-A*02 Restricted CD133 Epitope"", JOURNAL OF IMMUNOTHERAPY, vol. 31, no. 9, 31 October 2008 (2008-10-31) - 2 November 2008 (2008-11-02), & 23RD ANNUAL MEETING OF THE INTERNATIONAL-SOCIETY-FOR-BIOLOGICAL-THERA PY-OF-CANCER; SAN DIEGO, CA, USA; 20081030,, pages 928, XP002674391, ISSN: 1524-9557",ACTIVE
193,WO,A1,WO 1999/029859 A1,164-057-838-464-728,1999-06-17,1999,US 9826461 W,1998-12-11,US 98975097 A,1997-12-12,GENE ASSOCIATED WITH NEOPLASTIC DISEASE OR MALIGNANCY ASSOCIATED GENE,"A nucleic acid encodes a polypeptide associated with liver neoplastic diseases, such as liver cirrhosis and hepatocellular carcinoma, among others. Significantly, the polypeptide is not expressed in normal, non-neoplastic liver. An antibody(ies) binds to the polypeptide of the invention. The polynucleotide, polypeptide and antibody are also provided in kits, and applied to the diagnosis of, and screening of populations for, neoplastic diseases such as liver disease.",CEDARS SINAI MEDICAL CENTER;;BLACK KEITH;;LJUBIMOVA JULIA Y;;DEMETRIOU ACHILLES A,BLACK KEITH;;LJUBIMOVA JULIA Y;;DEMETRIOU ACHILLES A,,https://lens.org/164-057-838-464-728,Patent Application,yes,1,1,4,4,23,A61K38/00;;C07K14/47,G01N33/53;;A61K38/00;;C07K14/47;;C07K16/18;;C12N15/09;;C12N15/12;;C12Q1/68;;G01N33/566;;G01N33/574,,2,1,147-844-917-525-898,9766681,"LJUBIMOVA, J. Y. (1) ET AL: ""Detection of a novel malignancy - associated gene (MAG) in liver cirrhosis and HCC."", JOURNAL OF HEPATOLOGY, (1997) VOL. 26, NO. SUPPL. 1, PP. 138. MEETING INFO.: 32ND ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF LIVER LONDON, ENGLAND, UK APRIL 9-12, 1997 ISSN: 0168-8278., XP002102041;;LJUBIMOVA J Y ET AL: ""Novel human malignancy - associated gene (MAG expressed in various tumors and in some tumor preexisting conditions."", CANCER RESEARCH, (1998 OCT 1) 58 (19) 4475-9. JOURNAL CODE: CNF. ISSN: 0008-5472., United States, XP002102042",PENDING
194,BR,A2,BR 112013004738 A2,168-349-218-786-451,2017-04-04,2017,BR 112013004738 A,2011-08-29,US 2011/0049544 W;;US 37854610 P,2010-08-31,"""dispositivo de monitoramento de percevejo de cama"".","dispositivo de monitoramento de percevejo de cama. trata-se de um dispositivo de monitoramento de percevejo de cama que compreende um elemento atrativo de percevejo de cama e uma seção de refúgio que compreende um membro de suporte que tem uma superfície transponível e uma ou mais protuberâncias que pendem da mesma. o refúgio define pelo menos uma entrada através da qual percevejos de cama atraídos para o dispositivo podem entrar. o dispositivo pode incluir, ainda, uma seção de base colocada sobre pelo menos uma porção da superfície transponível e adaptada para ser colocada de modo nivelado à superfície contra a qual o dispositivo deve ser colocado.",FMC CORP,BRUCE BLACK;;KEITH WOODRUFF;;LINDA VARANYAK;;SHREYA SHETH,,https://lens.org/168-349-218-786-451,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,A01M1/14;;A01M1/00;;A01M1/02;;C09J201/00,,0,0,,,,DISCONTINUED
195,US,A1,US 2008/0311141 A1,025-350-305-095-969,2008-12-18,2008,US 86399007 A,2007-09-28,US 86399007 A;;US 82726006 P,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",YU JOHN S;;LIU GENTAO;;BLACK KEITH L,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2009-05-12),https://lens.org/025-350-305-095-969,Patent Application,yes,67,37,17,17,62,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/00;;A61K35/12;;A61P31/00,424/185.1;;424/277.1,0,0,,,,ACTIVE
196,EP,A1,EP 3691670 A1,037-331-506-129-899,2020-08-12,2020,EP 18864985 A,2018-10-02,US 201762566813 P;;US 2018/0053873 W,2017-10-02,METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY THROUGH MULTIPLE BIO BARRIERS,,CEDARS SINAI MEDICAL CENTER,HOLLER EGGEHARD;;LJUBIMOVA JULIA Y;;BLACK KEITH L,,https://lens.org/037-331-506-129-899,Patent Application,yes,0,0,5,6,11,A61P35/00;;A61K31/713;;A61K38/00;;A61K38/08;;A61K47/593;;A61K47/64;;A61P25/00;;C07K5/0808;;C07K5/0812;;C07K7/06;;C07K14/43572;;C07K14/4711;;C07K14/8117;;C07K14/8121;;C07K17/08;;C07K19/00;;C07K2319/01;;C07K2319/03;;C07K2319/06,A61K38/00;;C07K7/00;;C07K7/06;;C07K7/08;;C07K14/435,,0,0,,,,DISCONTINUED
197,MX,A,MX 2013002433 A,083-717-464-224-432,2013-08-01,2013,MX 2013002433 A,2011-08-29,US 37854610 P;;US 2011/0049544 W,2010-08-31,BED BUG MONITORING DEVICE.,The invention is directed to a bed bug monitoring device comprising a bed bug attractant element and a harborage section comprising a support member having a traversable surface and one or more protuberances depending therefrom. The harborage defines at least one entrance through which bed bugs attracted to the device can enter. The device can further include a base section placed over at least a portion of the traversable surface and adapted to by placed flush with the surface against which the device is to be placed.,FMC CORP,SHETH SHREYA;;VARANYAK LINDA;;BLACK BRUCE;;WOODRUFF KEITH,,https://lens.org/083-717-464-224-432,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,A01M1/02;;A01M1/00;;A01M1/14;;C09J201/00,,0,0,,,,PENDING
198,US,B2,US 11058720 B2,105-180-395-511-903,2021-07-13,2021,US 201716303053 A,2017-05-22,US 201716303053 A;;US 201662339681 P;;US 2017/0033875 W,2016-05-20,Methods of treating or preventing alzheimer's disease and associated conditions,"The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;RENTSENDORJ ALTANCHIMEG;;KORONYO YOSEF;;BLACK KEITH,CEDARS-SINAI MEDICAL CENTER (2017-05-23),https://lens.org/105-180-395-511-903,Granted Patent,yes,12,0,13,13,0,A61K38/02;;A61K38/19;;A61P25/28;;A61K45/06;;A61K39/4614;;A61K2239/31;;A61K39/4622;;A61K39/46433;;A61K2239/38;;A61K39/4621;;A61P25/28;;A61K38/07;;A61K2239/31;;A61K39/4622;;A61K2239/38;;A61K39/4621;;A61K39/4614;;A61K39/46433;;A61P25/28;;A61K31/7088;;A61K35/15;;A61K38/02;;A61K38/18;;A61K38/19,A61K35/15;;A61K31/7088;;A61K38/02;;A61K38/18;;A61K38/19;;A61P25/28,,34,25,090-580-721-037-400;;024-063-822-747-605;;009-261-837-573-736;;098-956-497-141-046;;035-438-499-631-238;;004-668-378-850-361;;070-006-688-796-584;;066-841-655-291-162;;020-235-958-756-618;;010-932-791-325-445;;022-532-689-654-325;;077-532-829-551-519;;002-264-966-090-625;;070-959-113-690-925;;034-356-721-676-31X;;064-187-018-698-676;;009-434-522-525-062;;030-030-967-774-985;;117-800-300-773-071;;099-168-892-040-738;;042-204-626-457-327;;019-817-021-691-872;;001-400-252-595-282;;074-817-300-512-106;;133-677-711-787-450,23141166;;10.1016/j.jneuroim.2012.10.003;;23565338;;pmc3616337;;10.2478/s13380-012-0028-7;;25151457;;pmc4262258;;10.1016/j.expneurol.2014.08.015;;10.1002/glia.22885;;26148976;;10.1038/sj.jcbfm.9600022;;15678124;;10.1002/ddr.10069;;10.1161/strokeaha.110.608315;;21700938;;10.1126/science.1494-b;;10.1126/science.242.4885.1494-b;;10.1073/pnas.0604681103;;16864778;;pmc1544247;;20308780;;10.3233/jad-2010-1309;;7127308;;10.1038/nbt1142;;16151406;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1016/s1389-0344(01)00067-3;;11337275;;14645205;;10.1093/hmg/ddh019;;825377;;10.1002/eji.1830060713;;10.1093/brain/awv150;;pmc4840949;;26049087;;12804068;;10.1089/107999003321829971;;10.1016/j.jalz.2016.06.669;;10.1093/ajhp/46.8.1576;;2672806;;3127726;;10.1038/332323a0;;10.1146/annurev.bb.09.060180.002343;;6994593;;11036658;;10.1016/s0076-6879(00)26070-9;;10.1038/341544a0;;2677748;;12377945;;10.1189/jlb.72.4.752,"Begum-Haque et al. J Neuroimmunol. Jan. 15, 2013;254(1-2):117-24 (Year: 2013).;;Brown, Amanda: Osteopontin: A Key Link Between Immunity, Inflammation and the Central Nervous System. Translational Neuroscience. 3(3):288-293 (2012).;;Chan et al.: Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury. Experimental Neurology. 261:757-771 (2014).;;European Patent Application No. 17800340.6 Extended European Search Report dated Dec. 16, 2019.;;Gliem et al.: Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. GLIA. 63(12):2198- 2207 (2015).;;Meller et al.: Neuroprotection by osteopontin in stroke. Journal of Cerebral Blood Flow & Metabolism. Nature Publising Group. 25(2):217-225 (2005).;;Schwartz et al.: Prospects for Therapeutic Vaccination with Glatiramer Acetate for Neurodegenerative Diseases such as Alzheimer's Disease. Drug Development Research. 56(2):143-149 (2002).;;Van Velthoven et al.: Osteopontin enhances endogenous repair after neonatal hypoxic-ischemic brain injury. Stroke. 42(8):2294-2301 (2011).;;Bird et al.: Single-chain antigen-binding proteins; Science, 242:423-42, 1988.;;Butovsky et al.: Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.; 103(31):11784-11789 (2006).;;Cafiso, Biochem Biophys Acta 649:129 (1981).;;Comi et al.:Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive Decline; Journal of Alzheimer's disease: JAD 19:1143-1148 (2010) .;;Gabizon et al.: Liposomes as in Vivo Carriers of Adriamycin: Reduced Cardiac Uptake and Preserved Antitumor Activity in Mice_ Cancer Research 42, 4734-4739 (1982).;;Greenfield, Antibodies A Laboratory Manual 2nd ed., Cold Spring Harbor Press (Cold Spring Harbor N.Y., 2013); .;;Holliger and Hudson. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23(9):1126-36, 2005 .;;Huston et al. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988 .;;Jankowsky et al.: Co-expression of multiple transgenes in mouse CNS: a comparison of strategies; Biomol Eng; 17(16):157-65 (2001).;;Jankowsky et al.: Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase; Hum Mol Genet; 13(2);159-70 (2004).;;Juliano: Interactions of Proteins and Drugs with Liposomes, in Liposomes, Ibid.;;Kohler and Milstein, Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 6: 511-519, 1976 .;;Koronyo et al., Therapeutic effects of glatiramer acetate and grafted CD115+monocytes in a mouse model of Alzheimer's disease. Brain. 138(Pt 8):2399-2422 (2015).;;Li et al., IFN-gamma induction of osteopontin expression in human monocytoid cells. Journal of Interferon Cytokine Research. 23(5):259-265 (2003).;;Maya et al., Immunomodulatory factor induced by GA mediates macrophage clearance of pathogenic Ab forms and enhances synaptic preservation. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 12(7):P361 (2016).;;Ostro et al.: Use of liposomes as injectable-drug delivery systems; Am J. Hosp. Pharm. 46(8):1576-1587 (1989).;;PCT/US2017/033875 International Search Report and Written Opinion dated Aug. 14, 2017.;;Rentsendorj et al.: A novel role for osteopontin in macrophage-mediated amyloid-β clearance in Alzheimer's models. Brain, Behavior, and Immunity 67:1630-180 (2018) .;;Riechmann et al. Reshaping human antibodies for therapy. Nature, 332.6162 (1988): 323-7.;;Sambrook, et al. Molecular Cloning: A Laboratory Manual. 4th Edition, 2012.;;Singleton, Dictionary of Microbiology and Molecular Biology 3.sup.rd ed., revised ed., J. Wiley & Sons (New York, N.Y. 2006); .;;Smith, March's Advanced Organic Chemistry Reactions, Mechanisms and Structure 7.sup.th ed., J. Wiley & Sons (New York, N.Y. 2013); .;;Szoka: Comparative properties and methods of preparation of lipid vesicles (liposomes); Ann Rev Biophys Eng 9:467 (1980).;;Tomlinson I. and Holliger P. Methods for generating multivalent and bispecific antibody fragments. Methods Enzymol 326:461-479, 2000 .;;Ward et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 334:544-54, 1989 .;;Weber et al., Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. Journal of Leukocyte Biology. 72:752-761 (2002).",ACTIVE
199,KR,A,KR 20130100145 A,167-091-624-310-553,2013-09-09,2013,KR 20137007865 A,2011-08-29,US 37854610 P;;US 2011/0049544 W,2010-08-31,BED BUG MONITORING DEVICE,,FMC CORP,BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,,https://lens.org/167-091-624-310-553,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00,,0,0,,,,DISCONTINUED
200,WO,A3,WO 2010/028066 A3,174-843-672-203-35X,2010-09-02,2010,US 2009/0055759 W,2009-09-02,US 19071808 P,2008-09-02,CD133 EPITOPES,"An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.",CEDARS SINAI MEDICAL CENTER;;YU JOHN S;;LIU GENTAO;;BLACK KEITH L,YU JOHN S;;LIU GENTAO;;BLACK KEITH L,,https://lens.org/174-843-672-203-35X,Search Report,yes,0,0,13,13,0,A61K39/0011;;A61K39/0011;;A61K45/06;;A61P35/00;;A61P37/04;;C07K14/70596;;C07K14/70596;;C07K7/06;;C07K7/06,C07K14/705;;A61K39/00;;A61P35/00;;C07K7/06,,7,5,093-530-607-257-147;;035-444-720-129-695;;025-457-637-309-732;;003-865-790-341-418;;069-597-740-399-36X,18542072;;10.1038/sj.bjc.6604437;;pmc2453027;;17077937;;10.1007/s11060-006-9265-3;;19903840;;pmc2789196;;10.1158/0008-5472.can-09-2687;;19944974;;10.1016/j.nec.2009.08.006;;pmc2786895;;15086239;;10.3171/jns.2004.100.2.0310,"DATABASE GENBANK 13 July 2008 (2008-07-13), ""amino acid sequence and gene sequence"", XP008144875, Database accession no. NM_006017;;SMITH, L. M. ET AL.: ""CD133/prominin-I is a potential therapeutic target for a ntibody-drug conjugates in hepatocellular and gastric cancers."", BRITISH JOURNAL OF CANCER., vol. 99, no. 1, 10 June 2008 (2008-06-10), pages 100 - 109, XP002619785;;WU, A. ET AL.: ""Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immuotherapy."", JOURNAL OF NEUROONCOLOGY., vol. 83, no. 2, 1 November 2006 (2006-11-01), pages 121 - 131, XP019506783;;BROWN, C. E. ET AL.: ""Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells."", CANCER RESEARCH., vol. 69, no. 23, 10 November 2009 (2009-11-10), pages 8886 - 8893, XP008144870;;JI J. ET AL.: ""Glioma stem cell research for the development of immunotherapy"", NEUROSURGERY CLINICS OF NORTH AMERICA, vol. 21, no. 1, January 2010 (2010-01-01), pages 159 - 166, XP008144888;;YANG, I. ET AL.: ""Modulation of major histocompatibility complex class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme."", JOURNAL OF NEUROSURGERY., vol. 100, no. 2, February 2004 (2004-02-01), pages 310 - 319, XP008144886;;See also references of EP 2328923A4",PENDING
201,CA,A1,CA 2809126 A1,164-157-248-100-391,2012-03-08,2012,CA 2809126 A,2011-08-29,US 37854610 P;;US 2011/0049544 W,2010-08-31,BED BUG MONITORING DEVICE,The invention is directed to a bed bug monitoring device comprising a bed bug attractant element and a harborage section comprising a support member having a traversable surface and one or more protuberances depending therefrom. The harborage defines at least one entrance through which bed bugs attracted to the device can enter. The device can further include a base section placed over at least a portion of the traversable surface and adapted to by placed flush with the surface against which the device is to be placed.,FMC CORP,BLACK BRUCE;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH,,https://lens.org/164-157-248-100-391,Patent Application,no,0,1,13,13,0,A01M1/02;;A01M1/026;;A01M1/14;;A01M1/103;;Y02A50/30;;A01M1/00;;A01M1/02;;A01M1/14;;C09J201/00;;A01M1/14;;A01M1/02;;A01M1/026;;Y02A50/30;;A01M1/103,A01M1/02;;A01M1/00;;A01M1/14;;C09J201/00,,0,0,,,,DISCONTINUED
202,DK,T3,DK 2328923 T3,183-265-112-863-426,2016-03-21,2016,DK 09812172 T,2009-09-02,US 19071808 P;;US 2009/0055759 W,2008-09-02,CD133-EPITOPER,,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;BLACK KEITH L;;LIU GENTAO,,https://lens.org/183-265-112-863-426,Granted Patent,no,0,0,13,13,0,A61K39/0011;;A61K39/0011;;A61K45/06;;A61P35/00;;A61P37/04;;C07K14/70596;;C07K14/70596;;C07K7/06;;C07K7/06,C07K14/705;;A61K39/00;;A61P35/00;;C07K7/06,,0,0,,,,ACTIVE
203,WO,A2,WO 2008/003055 A2,022-012-204-476-77X,2008-01-03,2008,US 2007/0072389 W,2007-06-28,US 42717906 A,2006-06-28,FACING PRODUCT FOR VEHICULAR TRIM,"A composite facing material is disclosed that may be used in combination with, e.g. foam, fibers and/or shoddy in a vehicular application. The composite may provide heat insulation and/or sound attenuation in a vehicular trim panel. The facing material may include a layer of staple fibers with a spunbonded continuous filament web layer. The layers may be intermittently thermally bonded in a desired pattern.",FREUDENBERG NONWOVENS L P;;BLACK SAMUEL KEITH;;KAMPF QUENTIN L;;MORIN SEAN,BLACK SAMUEL KEITH;;KAMPF QUENTIN L;;MORIN SEAN,,https://lens.org/022-012-204-476-77X,Patent Application,yes,0,1,3,3,0,B32B5/26;;D04H1/559;;D04H3/14;;B32B5/00;;B32B5/022;;B32B5/08;;B32B7/12;;B32B2250/40;;B32B2262/02;;B32B2262/04;;B32B2262/06;;B32B2262/14;;B32B2272/00;;B32B2307/102;;B32B2605/00;;B60R13/02;;B32B7/05;;Y10T442/60;;B32B7/027;;Y10T442/60;;D04H3/14;;B32B5/00;;B32B2262/02;;B32B2262/06;;B32B5/26;;B32B2262/04;;B32B2307/102;;B32B2262/14;;D04H1/559;;B32B2605/00;;B32B5/022;;B32B7/12;;B32B2272/00;;B32B5/08;;B32B2250/40;;B60R13/02;;B32B7/05;;B32B7/027,D04H13/00;;B32B7/027,,0,0,,,,PENDING
204,WO,A2,WO 2001/015046 A2,018-027-904-497-034,2001-03-01,2001,US 0023152 W,2000-08-23,US 37955899 A,1999-08-23,SECURITY AND MARKET MAKER ANALYSIS SYSTEM,"La présente invention concerne un système amélioré d'analyse des titres et valeurs comportant un dispositif de saisie et de mémorisation des données. Ce dispositif sert à la saisie et à la mémorisation en suites cohérentes des données, qui sont détenues par des teneurs de marchés de niveau II, et qui se rapportent à un titre. A cet effet, un convertisseur de données relie entre elles plusieurs données d'écart minimum se rapportant aux activités de niveau I et de niveau II de teneurs de marchés, et produit une suite cohérente. Pour traiter des données disparates, le moteur d'analyse utilise des outils d'analyse technique. Il ne reste plus qu'à envoyer les résultats en vue de leur affichage ou de compléments d'analyse.",WINDOW ON WALLSTREET INC,BLACK T KEITH;;JENNINGS JOHN R;;DHINGRA RAMESH,,https://lens.org/018-027-904-497-034,Patent Application,yes,0,0,3,3,0,G06Q40/04,G06Q40/00,,0,0,,,,PENDING
205,US,B2,US 7935677 B2,036-928-103-343-01X,2011-05-03,2011,US 58099904 A,2004-12-03,US 58099904 A;;US 52733003 P;;US 2004/0040660 W,2003-12-05,Polymalic acid-based multi-functional drug delivery system,"A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions. Polyethylene glycol groups are attached to extend the drug system's circulation half-life. In addition, fluorescent reported groups can be readily included to aid in visualizing and confirming drug system targeting. The drug system can deliver treatments for a wide range of diseases and is specially advantageous for treatment of neoplasms.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD,ARROGENE NANOTECHNOLOGY INC (2012-07-19);;CEDARS-SINAI MEDICAL CENTER (2006-04-13);;ARROGENE INC (2017-05-24),https://lens.org/036-928-103-343-01X,Granted Patent,yes,7,14,12,14,0,A61K47/60;;A61K47/593;;A61K47/6883;;A61K47/6849;;A61P35/00;;A61K47/6883;;A61K47/593;;A61K47/60;;A61K47/6849;;A61P35/00,C12N15/11;;A61K9/00;;A61K47/30;;A61K47/48,514/44;;424/400;;514/772.3,82,76,017-403-655-208-27X;;027-327-439-480-050;;021-383-028-538-332;;132-372-225-925-009;;120-057-020-523-828;;074-117-757-519-423;;069-764-206-551-021;;002-410-830-739-846;;053-390-613-704-481;;022-962-759-811-219;;101-523-476-724-00X;;005-068-515-810-831;;019-068-052-192-616;;081-535-546-606-522;;048-551-084-856-415;;043-263-823-749-982;;033-337-348-972-822;;012-529-188-555-935;;070-217-550-786-105;;016-130-071-571-991;;091-843-097-683-406;;007-736-347-486-414;;067-176-202-940-165;;122-563-304-750-445;;121-705-764-271-79X;;085-389-958-075-222;;145-523-027-249-174;;001-280-492-710-987;;092-704-236-824-35X;;041-096-604-932-631;;094-717-970-788-379;;021-138-842-966-383;;050-185-841-748-492;;143-247-059-865-683;;100-392-131-292-623;;016-795-130-437-95X;;036-550-119-702-468;;125-704-838-833-312;;065-513-307-731-185;;058-546-248-134-723;;053-130-150-863-097;;031-009-176-924-174;;004-329-899-218-795;;040-861-043-363-027;;016-276-524-241-605;;002-057-097-140-560;;015-845-411-216-05X;;071-446-219-522-092;;084-804-379-761-825;;122-990-056-888-627;;061-454-537-963-94X;;027-518-915-267-472;;004-569-967-691-895;;044-914-849-410-277;;087-365-800-456-427;;027-327-439-480-050;;160-788-201-223-007;;056-318-394-213-772;;010-800-681-313-086;;080-676-605-062-549;;089-207-455-463-763;;101-937-544-377-16X;;013-753-717-969-918;;114-357-812-206-334;;030-769-003-988-749;;114-097-940-181-735;;037-478-719-421-857;;159-835-915-641-650;;010-586-072-524-473;;010-084-423-107-920;;116-305-745-084-880;;025-444-780-060-105;;065-084-770-968-763;;027-533-193-912-497;;044-682-371-514-631;;010-713-998-880-948,19296227;;pmc2664895;;10.1208/s12248-009-9096-1;;10.1016/j.jconrel.2003.06.001;;14636717;;10.1016/s1359-6349(04)80616-5;;2438036;;10.1200/jco.2001.19.8.2189;;11304771;;10688605;;10807948;;10.1016/s0006-2952(00)00310-5;;10.1002/1097-0029(20001101)51:3<280::aid-jemt7>3.0.co;2-o;;11054877;;11751392;;10991985;;10.1002/(sici)1097-0177(200006)218:2<213::aid-dvdy1>3.0.co;2-r;;10842354;;pmc102580;;10648777;;10.1093/nar/28.4.868;;12489851;;10.1074/jbc.m010155200;;11278628;;12454288;;pmc138567;;10.1073/pnas.252649399;;10.1016/s0006-291x(02)02642-6;;12445830;;10.1002/ijc.10233;;11920587;;10.1016/s0140-6736(00)03207-4;;11095261;;10845554;;10.1023/a:1006760632766;;2937447;;10.1021/bi00350a005;;10.1002/(sici)1097-0215(19980316)75:6<864::aid-ijc8>3.0.co;2-t;;9506531;;11223987;;10.1038/sj.gt.3301327;;11156378;;10658911;;10.1038/modpathol.3880010;;10.1073/pnas.97.17.9591;;pmc16909;;10944225;;10554005;;7723285;;11454714;;10066093;;10.1023/a:1006150506789;;10.1083/jcb.200302126;;12741393;;pmc2172901;;10.1083/jcb.jcb.200302126;;2072663;;10.1083/jcb.137.3.685;;9151674;;pmc2139892;;10.1016/s0076-6879(01)40429-0;;11494857;;12083850;;10.1016/s1044-579x(02)00023-8;;10.1177/002215540205000813;;12133914;;10506168;;10.1074/jbc.274.41.29130;;10.1002/(sici)1098-2388(199801/02)14:1<3::aid-ssu2>3.0.co;2-f;;9407626;;11106372;;10.1073/pnas.250332397;;pmc18983;;10.1083/jcb.153.5.933;;pmc2174323;;11381080;;9212909;;10.1089/oli.1.1997.7.187;;9325016;;10.1006/cyto.1997.0212;;pmc134646;;11809810;;10.1128/mcb.22.4.1194-1202.2002;;10.1023/a:1014573204062;;11964076;;6501412;;pmc2113570;;10.1083/jcb.99.6.2034;;11813879;;10.14670/hh-17.301;;10652480;;10.1016/s1357-4310(99)01638-x;;8622906;;pmc39574;;10.1073/pnas.93.8.3161;;pmc3487708;;17109197;;10.1007/s10456-006-9046-9;;14578463;;10.1017/cbo9780511546402.025;;10.1038/sj.gt.3302507;;15759014;;10.1017/cbo9780511546402.030;;10.1016/s0169-409x(00)00139-3;;11259843;;10.1021/js9800836;;9811482;;10.1006/exnr.1996.0178;;8912898;;10.1016/j.jconrel.2003.06.001;;14636717;;10416675;;10.1016/s0141-8130(99)00042-2;;2765532;;10.1021/bi00438a045;;9855188;;10.1016/s0142-9612(98)00095-7;;10840193;;10.1016/s0939-6411(00)00075-8;;10.1139/m95-187;;10.1021/bc980123x;;10346884;;10.1007/s002530051445;;11733118;;10.1016/s0169-409x(01)00221-6;;12564977;;10.1016/s0169-409x(02)00179-5;;10.1021/bc990039x;;10502354;;pmc16586;;10840060;;10.1073/pnas.130187497;;7508268;;10.1021/bc00024a015;;10.1016/s0928-0987(97)00069-9;;16256709;;10.1021/bm0300608;;14715019;;10.1124/pr.54.4.561;;12429868;;12095305;;10.1006/mthe.2002.0633;;16146715;;10.2741/1781;;pmc3506377;;15274074;;10.1002/cncr.20397;;10.1002/ijc.21102;;15915502;;10.1002/(sici)1097-0215(19980330)76:1<63::aid-ijc11>3.0.co;2-h;;9533763,"Odian, G. (1991) Principles of Polymerization, Third Edition. John Wiley and Sons, Inc.;;Yu, et al. (2009) Targeted Delivery Systems for Oligonucleotide Therapeutics. The AAPS Journal, v.11(1):195-203.;;Bulmus et al. (Journal of Controlled Release 93 (Nov. 18, 2003) 105-120.;;Khazenzon, A.J. et al., Novel angiogenic targets for human glioma prevention and regulation of their expression, International Journal of Molecular Medicine, 2002, 10: Supplement 1, p. S41, XP008091390.;;Ljubimova, J.Y. et al., A new multifunctional drug delivery system based on polymalic acid to inhibit angiogenesis and invasion of human gliomas in vitro and in vivo, European Journal of Cancer, Supplement, 2004, 2:8, p. 184, XP004640052.;;Ljubimova, J.Y. et al., Development of an in vitro system to block the angiogenic target, laminin-8, in human gliomas, Proceedings of the American Association for Cancer Research Annual Meeting, Mar. 2002, vol. 43, p. 177, XP001536931.;;Albini et al., A Rapid In Vitro Assay for Quantitating the Invasive Potential of Tumor Cells, Cancer Research, (Jun. 15, 1987), pp. 3239-3245, 47(12).;;Andrews et al., Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrocytomas, Journal of Clinical Oncology, (Apr. 15, 2001), pp. 2189-2200, 19(8).;;Arora et al., c- Myc Antisense Limits Rat Liver Regeneration and Indicates Role for c-myc in Regulating Cytochrome P-450 3A Activity, Journal of Pharmacology and Experimental Therapeutics, (Mar. 2000), pp. 921-928, 292(3).;;Astriab-Fisher et al., Antisense Inhibition of P-Glycoprotein Expression Using Peptide-Oligonucleotide Conjugates, Biochemical Pharmacology (Jul. 1, 2000), pp. 83-90, 60(1).;;Belkin et al., Integrins As Receptors for Laminins, Microscopy Research and Technique, (Nov. 1, 2000), pp. 280-301, 51(3).;;Bello et al., Simultaneous Inhibition of Glioma Angiogenesis, Cell Proliferation, and Invasion by a Naturally Occurring Fragment of Human Metalloproteinase-2, Cancer Research, (Dec. 15, 2001), pp. 8730-8736, 61(24).;;Boado et al., Antisense-Mediated Down-Regulation of the Human Huntingtin Gene, Journal of Pharmacology and Experimental Therapy, (Oct. 2000), pp. 239-243, 295(1).;;Colognato et al., Form and Function: The Laminin Family of Heterotrimers, Developmental Dynamics, (Jun. 2000), pp. 213-234, 218(2).;;De Diesbach et al., Identification, Purification and Partial Characterisation of an Oligonucleotide Receptor in Membranes of HepG2 Cells, Nucleic Acids Research, (Feb. 15, 2000), pp. 868-874, 28(4).;;Dias et al., Antisense Oligonucleotides : Basic Concepts and Mechanisms, Molecular Cancer Therapy, (Mar. 2002), pp. 347-355, 1(5).;;Fujiwara et al., Purification and Characterization of Human Laminin-8. Laminin-8 Stimulates Cell Adhesion and Migration Through a3beta1 and a6p, Integrins, Journal of Biological Chemistry, (May 18, 2001), pp. 17550-17558, 276(20).;;Gonzalez et al., Complex Interactions Between the Laminin a4 Subunit and Integrins Regulate Endothelial Cell Behavior In Vitro and Angiogenesis In Vivo, Proceedings of the National Academy of Sciences USA, (Dec. 10, 2002), pp. 16075-16080, 99(25).;;Hayashi et al., Identification and Recombinant Production of Human Laminin a4 Subunit Splice Variants, Biochemical and Biophysical Research Communications, (Dec. 6, 2002), pp. 498-504, 299(3).;;Herold-Mende et al., Clinical Impact and Functional Aspects of Tenascin-C Expression During Glioma Progression, International Journal of Cancer, (Mar. 20, 2002), pp. 362-369, 98(3).;;Jansen et al., Chemosensitisation of Malignant Melanoma by BCL2 Antisense Therapy, Lancet, (Nov. 18, 2000), pp. 1728-1733, 356(9243).;;Kachra et al., Expression of Matrix Metalloproteinases and Their Inhibitors in Human Brain Tumors, Clinical and Experimental Metastasis, (1999), pp. 555-566, 17(7).;;Kleinman et al., Basement Membrane Complexes With Biological Activity, Biochemistry, (Jan. 28, 1986), pp. 312-318, 25(2).;;Knott et al., Stimulation of Extracellular Matrix Components in the Normal Brain by Invading Glioma Cells, International Journal of Cancer, (Mar. 16, 1998), pp. 864-872, 75(6).;;Komata et al., Combination Therapy of Malignant Glioma Cells With 2-5A-Antisense Telomerase RNA and Recombinant Adenovirus p53, Gene Therapy, (Dec. 2000), pp. 2071-2079, 7(24).;;Kondraganti et al., Selective Suppression of Matrix Metalloproteinase-9 in Human Glioblastoma Cells by Antisense Gene Transfer Impairs Glioblastoma Cell Invasion, Cancer Research, (Dec. 15, 2000), pp. 6851-6855, 60(24).;;Kulla et al., Tenascin Expression Patterns and Cells of Monocyte Lineage: Relationship in Human Gliomas, Modern Pathology, (Jan. 2000), pp. 56-87, 13(1).;;Lacerra et al., Restoration of Hemoglobin A Synthesis in Erythroid Cells From Peripheral Blood of Thalassemic Patients, Proceedings of the National Academy of Sciences USA, (Aug. 15, 2000), pp. 9591-9596, 97(17).;;Lal et al., A Public Database for Gene Expression in Human Cancers. Cancer Research, (Nov. 1, 1999), pp. 5403-5407, 59(21).;;Ljubimov et al., Human Corneal Basement Membrane Heterogeneity: Topographical Differences in the Expression of Type IV Collagen and Laminin Isoforms, Lab Investigation, (Apr. 1995), pp. 461-473, 72(4).;;Ljubimova et al., Gene Array Analysis of Differentially Expressed Genes in Human Glial Tumors. International Journal of Oncology, (2001), pp. 287-295, 18.;;Ljubimova et al., Overexpression of a4 Chain-Containing Laminins in Human Glial Tumors Identified by Gene Microarray Analysis, Cancer Research (Jul. 15, 2001), pp. 5601-5610, 61(14).;;MacDonald et al., Urokinase Induces Receptor Mediated Brain Tumor Cell Migration and Invasion, Journal of Neuro-Oncology, (Dec. 1998), pp. 215-226, 40(3).;;McKean et al., FAK Induces Expression of Prx1 to Promote Tenascin-C-Dependent Fibroblast Migration, Journal of Cell Biology, (Apr. 28, 2003), pp. 393-402, 161(2).;;Minakawa et al., In Vitro Interaction of Astrocytes and Pericytes With Capillary-Like Structures of Brain Microvessel Endothelium, Lab Investigation, (Jul. 1991), pp. 32-40, 65(1).;;Miner et al., The Laminin Alpha Chains: Expression, Developmental Transitions, and Chromosomal Locations of A1-5, Identification of Heterotrimeric Laminins 8-11, and Cloning of a Novel a3 Isoform, Journal of Cell Biology, (May 5, 1997), pp. 685-701, 137(3).;;Nielsen et al., Peptide Nucleic Acid Targeting of Double-Stranded DNA. Methods in Enzymology, 2001, pp. 329-340, 340.;;Patarroyo et al., Laminin Isoforms in Tumor Invasion, Angiogenesis and Metastasis, Seminars . Seminars in Cancer Biology, (Jun. 2002), pp. 197-207, 12(3).;;Petajaniemi et al., Localization of Laminin a4-Chain in Developing and Adult Human Tissues, The Journal of Histochemistry and Cytochemistry, (Aug. 2002), pp. 1113-1130, 50(8).;;Qin et al., The Transcription Factors Sp1, Sp3, and AP-2 are Required for Constitutive Matrix Metalloproteinase-2 Gene Expression in Astroglioma Cells, Journal of Biological Chemistry, (Oct. 8, 1999), pp. 29130-29137, 274(41).;;Sehgal, A., Molecular Changes During the Genesis of Human Gliomas, Seminars in Surgical Oncology, (Jan.-Feb. 1998), pp. 3-12, 14(1).;;Shi et al., Antisense Imaging of Gene Expression in the Brain In Vivo, Proceeding of National Academy of Sciences USA, (Dec. 19, 2000), pp. 14709-14714, 97(26).;;Sixt et al., Endothelial Cell Laminin Isoforms, Laminins 8 and 10, Play Decisive Roles in T Cell Recruitment Across the Blood-Brain Barrier in Experimental Autoimmune Encephalomyelitis, Journal of Cell Biology, (May 28, 2001), pp. 933-946, 153(5).;;Summerton et al., Morpholino Antisense Oligomers: Design, Preparation and Properties, Antisense and Nucleic Acid Drug Development, (Jun. 1997) pp. 187-195, 7(3).;;Taylor et al., Comparison of Efficacy of Antisense Oligomers Directed Toward TNF-a in Helper T and Macrophage Cell Lines, Cytokine, (Sep. 1997), pp. 672-681, 9(9).;;Thyboll et al., Deletion of the Laminin a4 Chain Leads to Impaired Microvessel Maturation, Molecular and Cellular Biology, (Feb. 2002), pp. 1194-1202, 22(4).;;Tsuji et al., Regulation of Melanoma Cell Migration and Invasion by Laminin-5 and a3beta1 lntegrin (VLA-3), Clinical and Experimental Metastasis, (2002), pp. 127-134, 19(2).;;Voyta et al., Identification and Isolation of Endothelial Cells Based on Their Increased Uptake of Acetylated-Low Density Lipoprotein, Journal of Cell Biology, (Dec. 1984), pp. 2034-2040, 99(6).;;Zagzag et al., Angiogenesis in the Central Nervous System: A Role for Vascular Endothelial Growth Factor/Vascular Permeability Factor and Tenascin-C. Common Molecular Effectors in Cerebral Neoplastic and Non-Neoplastic ""Angiogenic Diseases"", Histol Histopathol, 17: 301-321, 2002.;;Agrawal et al., Antisense Therapeutics: Is It As Simple As Complementary Base Recognition?, Molecular Medicine Today, (Feb. 2000), pp. 72-81, 6.;;Gewirtz et al., Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on Its Promise, Proceedings of the National Academy of Sciences of USA, (Apr. 1996), pp. 3161-3163, 93.;;Fujita et al., Inhibition of Laminin-8 In Vivo Using a Novel Poly(Malic Acid)-Based Carrier Reduces Glioma Angiogenesis, Angiogenisis, (2006), pp. 183-191, 9.;;Khazenzon et al., Antisense Inhibition of Laminin-8 Expression Reduces Invasion of Human Gliomas In Vitro, Molecular Cancer Therapeutics, (2003), pp. 985-994, 2.;;Lu et al., Delivering siRNA In Vivo for Functional Genomics and Novel Therapeutics, RNA Interference Technology, (2005), pp. 303-317.;;Nielsen, P.E., The Last Hurdle?, Gene Therapy, (2005), pp. 956-957, 12.;;Samarsky et al., RNAi in Drug Development: Practical Considerations, RNA Interference Technology, (2005), pp. 384-395.;;Bickel et al., Delivery of Peptides and Proteins Through the Blood-Brain Barrier, Advanced Drug Delivery Reviews, (2001), pp. 247-279, 46.;;Boado et al., Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS, Journal of Pharmalogical Science, (1998), pp. 1308-1315, 87.;;Broadwell et al., Transcytosis of Protein Through the Mammalian Cerebral Epithelium and Endothelium III Receptor-Mediated Transcytosis Through the Blood-Brain-Barrier of Blood-Bome Transferrin and Antibody Against the Transferrin Receptor, Experimental Neurology, (1996), pp. 47-85, 142.;;Bulmus et al., A New pH-Responsive and Gluthathione-Reactive, Endosomal Membrane-Siruptive Polymeric Carrier for Intracellular Delivery of Biomolecular Drugs, Journal of Controlled Release, (2003), pp. 105-120, 93.;;Cammas et al., Polymers of Malic Acid and 3-Alkylmalic Acid As Synthetic PHAs in the Design of Biocompatible Hydrolyzable Devices, International Journal of Biological Macromolecules, (1999), pp. 273-282, 25.;;Fischer et al., An Unsual Polyanion From Physarum Polycephalum That Inhibits Homologous DNA Polymerase A In Vitro, Biochemistry, (1989), pp. 5219-5226, 28.;;Iwata et al., A Novel Surgical Glue Composed of Gelatin and N-Hydroxysuccinimide Activate Poly(L-Glutamic Acid): Part 1 Synthesis of Activated Poly(L-Glutamic Acid) and Its Gelation With Gelatin, Biomaterials, (1998), pp. 1869-1876, .19.;;Kopecek et al., HPMA Copolymer-Anticancer Drug Conjugates: Design, Activity, and Mechanism of Action, European Journal of Biopharmacology, (2000). pp. 61-81, 50.;;Korherr et al., Poly (beta-1-Malate) Hydrolase From Plasmodia of Physarum Polycephalum, Canadian Journal of Microbiology, (1995), pp. 192-199, 41(Suppl. 1).;;Kurihara et al., Epidermal Growth Factor Radiopharmaceuticals: 111m Cheladon, Conjugation to a Blood-Brain Barrier Delivery Vector Via A Biotin-Polyethylene Linker, Pharmacokinetics, and In Vivo Imaging of Experimental Brain Tumors, Bioconjugate Chemistry, (1999), pp. 505-511, 10.;;Lee et al., Effects of Culture Conditions on beta-Poly (I-Malate) Production by Physarum Polycephalum, Applied Microbiology and Biotechnology, (1999). pp. 647-652, 51.;;Pichon et al., Histidine-Rich Peptides and Polymers for Nucleic Acid Delivery, Advanced Drug Delivery Reviews, (2001), pp. 75-94, 53.;;Saito et al., Drug Delivery Strategy Utilizing Conjugation Via Reversible Disulfide Linkages: Role and Site of Cellular Reducing Activities, Advanced Drug Delivery Reviews, (2003), pp. 199-215, 55.;;Schnaible et al., Identification of Fluorescein-5'-Isothiocyanate-Modification Sites in Proteins by Electronspray-Ionization Mass Spectroscopy, Bioconjugate Chemistry, (1999), pp. 881-866, 10.;;Shi et al., Noninvasive Gene Targeting to the Brain, Proceedings of the National Academy of Sciences, (2000), pp. 7567-7572, 97.;;Willner et al., (6-Maleimidocaproyl) Hydrazone of Doxorubicin-A New Derivative for the Preparation of Immunoconjugates of Doxotubicin, Bioconjugate Chemistry, (1993), pp. 521-527, 1993.;;Abdellaoui et al., Metabolite-derived Artificial Polymers Designed for Drug Targeting, Cell Penetration and Bioresorption, European Journal of Pharmaceutical Sciences, vol. 6, No. 1 (1998), pp. 61-73.;;Barbosa, et al., Investigation of the Degradation Mechanisms of Poly(malic acid) Esters in Vitro and their Related Cytotoxicities on J774 Macrophages, Biomacromolecules 2004, vol. 5, No. 1, pp. 137-143.;;Qian et al., Targeted Drug Delivery via the Transferrin Receptor-mediated Endocytosis Pathway, Pharmacology Reviews, vol. 54, No. 4, (Dec. 2002), pp. 561-587.;;Zhang et al., Antisense Gene Therapy of Brain Cancer with an Artificial Virus Gene Delivery System, Molecular Therapy, vol. 6, No. 1 (Jul. 2002), pp. 67-72.;;Ljubimova, J. et al., Changes in Laminin Isoforms Associated with Brain Tumor Invasion and Angiogenesis, Frontiers in Bioscience (Jan. 1, 2006), vol. 11, pp. 81-88.;;Ljubimova, J., Black, K., Holler, E., Development of Anti-Angiogenic and Anti-Invasive Inhibitors of Human Gliomas Using a New Multifunctional Drug Delivery System Based on Polymalic Acid, Preclinica (Sep./Oct. 2004), 2(5), p. 366.;;Ljubimova, J. et al., Association between Laminin-8 and Glial Tumor Grade, Recurrence, and Patient Survival, Cancer (online Jun. 16, 2004), 101(3), pp. 604-612.;;Nagato, et al., Downregulations of Laminin alpha-4 Chain Expression Inhibits Glioma Invasion in vitro and in vivo, Int. Journal of Cancer (Oct. 20, 2005), 117(1), pp. 41-50.;;Fukushima et al., Integrin alpha3beta1-mediated Interaction with Laminin-5 Stimulates Adhesion, Migration and Invasion of Malignant Glioma Cells, Int. of Journal Cancer (Mar. 30, 1998), 76(1), pp. 63-72.;;Lee et al., Delivery of antisense oligonucleotides and transferrin receptor antibody in vitro and in vivo using a new multifunctional drug delivery system based on polymalic acid, Proceedings of The American Association for Cancer Research Annual Meeting, vol. 45, Mar. 2004, XP8120390, pp. 149-150.",ACTIVE
206,US,A1,US 2002/0155440 A1,022-773-663-475-115,2002-10-24,2002,US 74155000 A,2000-12-19,US 74155000 A,2000-12-19,Using overexpression of laminin alpha 4 subunit as a diagnostic and prognostic indicator of malignant tumors,"
   Disclosed is a method of diagnosing the presence of a malignant tumor, including a glioma, in a human subject, which involves detecting overexpression of laminin 4 subunit protein or laminin 4-specific MRNA, compared to the expression level in a normal tissue control. Also disclosed are a method of predicting the recurrence of a malignant tumor in a human subject from whom a malignant tumor has been resected and a method of classifying the grade of a malignant tumor, such as a glial tumor, based on a molecular classification. 
",LJUBIMOVA JULIA Y.;;LJUBIMOV ALEXANDER V.;;BLACK KEITH L.,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,LJUBIMOVA JULIA Y (2002-12-19);;BLACK KEITH L (2002-12-19);;CEDARS-SINAI MEDICAL CENTER (2001-03-14);;LJUBIMOV ALEXANDER V (2002-12-19);;ARROGENE INC (2002-12-20),https://lens.org/022-773-663-475-115,Patent Application,yes,0,36,9,9,4,C12Q1/6886;;C12Q2600/158;;G01N33/574;;G01N33/57488;;G01N2333/47;;G01N2800/52;;G01N33/574;;G01N2333/47;;G01N2800/52;;C12Q2600/158;;C12Q1/6886;;G01N33/57488,C12Q1/68;;G01N33/574,435/6;;435/7.23,0,0,,,,DISCONTINUED
207,US,S,US D0629857 S,062-207-623-092-069,2010-12-28,2010,US 35076009 F,2009-11-23,US 35076009 F,2009-11-23,Golf grip,,EATON CORPOTRATION,GILL DAVID KEITH;;WOOD BILLY DEE;;BLACK RICHARD ANDREW,EATON INTELLIGENT POWER LIMITED (2017-12-31);;EATON CORPORATION (2009-12-14),https://lens.org/062-207-623-092-069,Design Right,no,0,8,3,3,0,,,2102;;D21/756,0,0,,,,ACTIVE
208,EP,A4,EP 3265785 A4,077-199-204-923-953,2018-04-04,2018,EP 16860766 A,2016-10-27,US 201562248934 P;;US 2016/0059054 W,2015-10-30,METHODS AND SYSTEMS FOR PERFORMING TISSUE CLASSIFICATION USING MULTI-CHANNEL TR-LIFS AND MULTIVARIATE ANALYSIS,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;BAKER MICHAEL;;JONES HOWLAND;;BUTTE PRAMOD,,https://lens.org/077-199-204-923-953,Search Report,no,2,0,4,4,0,A61B5/00;;A61B5/0075;;G01N2201/129;;A61B10/02;;G01N21/6402;;G01N21/6408;;A61B5/00;;G01N2201/129;;A61B5/0075;;G06F18/24;;A61B5/0071;;A61B5/0091;;A61B5/08;;A61B5/4064;;A61B5/4255;;A61B5/441;;A61B5/7267;;A61B10/02;;A61B2576/026;;G01N21/6402;;G01N21/6408;;G01N2201/06113;;G06T7/0012;;G06T2207/10064;;G06T2207/30016;;G06T2207/30028;;G06T2207/30061;;G06T2207/30068;;G06T2207/30088,G01N21/64;;A61B5/00;;A61B5/08;;A61B10/02;;A61B17/00;;G01J3/02;;G01J3/28;;G01J3/44;;G06K9/62;;G06T7/00,,5,4,075-060-776-388-192;;002-821-937-985-621;;093-376-350-966-243;;018-044-454-204-648,10.2741/1878;;pmc2991156;;16368511;;pmc3335732;;10.1016/j.neuroimage.2010.11.001;;21055475;;10.1117/1.2141624;;16409091;;pmc2981341;;10.1364/ol.33.000630;;pmc10522294;;18347733,"YONG ET AL: ""Distinction of brain tissue, low grade and high grade glioma with time-resolved fluorescence spectroscopy"", FRONTIERS IN BIOSCIENCE, vol. 11, no. 1, 2 January 2006 (2006-01-02), US, pages 1255, XP055453240, ISSN: 1093-9946, DOI: 10.2741/1878;;PRAMOD V BUTTE ET AL: ""Fluorescence lifetime spectroscopy for guided therapy of brain tumors"", NEUROIMAGE, ELSEVIER, AMSTERDAM, NL, vol. 54, 2 November 2010 (2010-11-02), pages S125 - S135, XP028230291, ISSN: 1053-8119, [retrieved on 20101103], DOI: 10.1016/J.NEUROIMAGE.2010.11.001;;PRAMOD V. BUTTE ET AL: ""Diagnosis of meningioma by time-resolved fluorescence spectroscopy"", INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING, vol. 10, no. 6, 2 January 2005 (2005-01-02), PO Box 10 Bellingham WA 98227-0010 USA, pages 064026, XP055453773, ISSN: 1083-3668, DOI: 10.1117/1.2141624;;YINGHUA SUN ET AL: ""Simultaneous time- and wavelength-resolved fluorescence spectroscopy for near real-time tissue diagnosis"", OPTICS LETTERS, OPTICAL SOCIETY OF AMERICA, vol. 33, no. 6, 15 March 2008 (2008-03-15), pages 630 - 632, XP001511963, ISSN: 0146-9592, DOI: 10.1364/OL.33.000630;;See also references of WO 2017075176A1",DISCONTINUED
209,JP,A,JP 2009242428 A,096-197-889-481-237,2009-10-22,2009,JP 2009167047 A,2009-07-15,US 50272903 P,2003-09-12,ANTISENSE INHIBITION OF LAMININ-8 EXPRESSION TO INHIBIT HUMAN GLIOMAS,"<P>PROBLEM TO BE SOLVED: To provide antisense oligonucleotides which bind a specific RNA arrangement and also inactivate this. <P>SOLUTION: Using gene array technology, it is observed that an increase in α4 chain-containing Laminin-8 associated with poor prognosis for patients with brain gliomas. It is established that inhibition of Laminin-8 expression by new generation of highly specific and stable antisense oligonucleotides (Morpholino<SP>TM</SP>) against chains of Laminin-8 can slow or stop the spread of glioma. This has been demonstrated in an in vitro model using human glioblastoma multiforme cell lines M059K and U-87MG co-cultured with normal human brain microvascular endothelial cells (HBMVEC). Using Western blot analysis and immunohistochemistry, it has been confirmed that antisense treatment effectively blocks Laminin-8 protein synthesis. <P>COPYRIGHT: (C)2010,JPO&INPIT",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,,https://lens.org/096-197-889-481-237,Patent Application,no,0,0,10,10,4,A61K31/00;;A61K31/07;;A61K31/7088;;C12N15/113;;C12N2310/11;;C12N2310/3233;;A61P35/00;;A61P43/00;;A61K31/07;;A61K31/00;;C12N15/113;;A61K31/7088;;C12N2310/3233;;C12N2310/11,A61K31/7105;;A01N43/04;;A61K31/00;;A61K31/07;;A61K31/7088;;A61K31/7125;;A61K39/395;;A61P35/00;;A61P43/00;;C07H21/04;;C12N/;;C12N15/09;;C12N15/113;;C12Q1/68,,0,0,,,,DISCONTINUED
210,US,S,US D0618296 S,024-985-213-996-092,2010-06-22,2010,US 31498909 F,2009-05-15,US 31498909 F,2009-05-15,Golf grip,,EATON CORP,GILL DAVID KEITH;;WOOD BILLY DEE;;BLACK RICHARD ANDREW,EATON INTELLIGENT POWER LIMITED (2017-12-31);;EATON CORPORATION (2009-05-13),https://lens.org/024-985-213-996-092,Design Right,no,0,6,3,3,0,,,2102;;D21/756,0,0,,,,ACTIVE
211,WO,A2,WO 2002/059610 A2,055-082-598-346-935,2002-08-01,2002,US 0150292 W,2001-12-19,US 74155000 A,2000-12-19,USING OVEREXPRESSION OF LAMININ ALPHA 4 SUBUNIT AS A DIAGNOSTIC AND PROGNOSTIC INDICATOR OF MALIGNANT TUMORS,"Disclosed is a method of diagnosing the presence of a malignant tumor, including a glioma, in a human subject, which involves detecting overexpression of laminin *4 subunit protein or laminin *4-specific mRNA, compared to the expression level in a normal tissue control. Also disclosed are a method of predicting the recurrence of a malignant tumor in a human subject from whom a malignant tumor has been resected and a method of classifying the grade of a malignant tumor, such as a glial tumor, based on a molecular classification.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,,https://lens.org/055-082-598-346-935,Patent Application,yes,0,0,9,9,4,C12Q1/6886;;C12Q2600/158;;G01N33/574;;G01N33/57488;;G01N2333/47;;G01N2800/52;;G01N33/574;;G01N2333/47;;G01N2800/52;;C12Q2600/158;;C12Q1/6886;;G01N33/57488,C12Q1/68;;G01N33/574,,0,0,,,,PENDING
212,KR,A,KR 20190009374 A,186-650-333-713-587,2019-01-28,2019,KR 20187037154 A,2017-05-22,US 201662339681 P;;US 2017/0033875 W,2016-05-20,알츠하이머병 및 관련 병태의 치료 또는 예방 방법,"본 발명은 OPN 발현을 증가시킴으로써 알츠하이머병 및 관련 병태의 가능성을 치료, 예방, 감소시키거나, 또는 그의 증상을 완화시키는 방법을 기술한다. 본 발명은 인지 기능의 개선을 필요로 하는 대상에서 인지 기능을 개선하는 방법을 추가로 제공한다.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;RENTSENDORJ ALTANCHIMEG;;KORONYO YOSEF;;BLACK KEITH L,,https://lens.org/186-650-333-713-587,Patent Application,no,0,2,13,13,0,A61K38/02;;A61K38/19;;A61P25/28;;A61K45/06;;A61K39/4614;;A61K2239/31;;A61K39/4622;;A61K39/46433;;A61K2239/38;;A61K39/4621;;A61P25/28;;A61K38/07;;A61K2239/31;;A61K39/4622;;A61K2239/38;;A61K39/4621;;A61K39/4614;;A61K39/46433;;A61P25/28;;A61K31/7088;;A61K35/15;;A61K38/02;;A61K38/18;;A61K38/19,A61K38/07;;A61P25/28,,2,0,,,"KORONYO, YOSEF 등, BRAIN, 2015, Vol. 138, pp.2399-2422*;;LUND, SUSAN AMANDA 등, J. Cell Commun. Signal., 2009, Vol. 3, pp. 311-322*",ACTIVE
213,US,A1,US 2002/0007540 A1,011-981-769-790-604,2002-01-24,2002,US 78025101 A,2001-02-09,US 78025101 A;;US 18185700 P,2000-02-11,Imaged nonwoven fabrics,"
   A method of forming durable nonwoven fabrics by hydroentanglement includes providing a precursor web comprising a fibrous matrix of staple length fibers and/or substantially continuous filaments. The precursor web is subjected to hydroentanglement on a three-dimensional image transfer device to create a patterned and imaged fabric. Enhanced imaging is achieved by advancing the precursor web onto the movable imaging surface of the image transfer device at a rate substantially equal to the rate at which the image surface moves relative to one or more associated hydroentangling manifolds. Treatment with a polymeric binder composition enhances the integrity of the fabric, permitting it to exhibit desired physical characteristics, including strength, durability, softness, and drapeability. Mechanical compaction of the imaged and patterned fabric, such as by sanforizing, enhances the desired physical properties. 
",BLACK SAMUEL K.;;CURTIS CHARLES KEITH;;CARLSON CHERYL L.,BLACK SAMUEL K;;CURTIS CHARLES KEITH;;CARLSON CHERYL L,AVINTIV SPECIALTY MATERIALS INC (2001-03-29),https://lens.org/011-981-769-790-604,Patent Application,yes,0,15,6,6,0,D04H1/74;;D04H3/04;;D06C23/00;;D04H18/04;;D04H1/49;;D04H1/495;;D04H3/11;;D04H18/04;;D04H3/04;;D06C23/00;;D04H1/74;;D04H3/11;;D04H1/49;;D04H1/495,D04H1/46;;D04H1/74;;D04H3/04;;D04H3/10;;D06C23/00,28/105;;28/106,0,0,,,,EXPIRED
214,WO,A1,WO 2017/075176 A1,031-650-671-639-841,2017-05-04,2017,US 2016/0059054 W,2016-10-27,US 201562248934 P,2015-10-30,METHODS AND SYSTEMS FOR PERFORMING TISSUE CLASSIFICATION USING MULTI-CHANNEL TR-LIFS AND MULTIVARIATE ANALYSIS,"Described herein are methods and systems for analyzing a sample by applying time resolved laser induced fluorescence spectroscopy to the sample to measure lifetime time decay profile data relating to the sample, and applying multivariate analysis to process the data so as to classify a sample as, for example, normal or abnormal. The sample may be cells, fluid or tissue from any organ. The sample may be in vitro or in vivo . The data may be obtained in situ or in vitro .",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;BAKER MICHAEL;;JONES HOWLAND;;BUTTE PRAMOD,,https://lens.org/031-650-671-639-841,Patent Application,yes,3,3,4,4,0,A61B5/00;;A61B5/0075;;G01N2201/129;;A61B10/02;;G01N21/6402;;G01N21/6408;;A61B5/00;;G01N2201/129;;A61B5/0075;;G06F18/24;;A61B5/0071;;A61B5/0091;;A61B5/08;;A61B5/4064;;A61B5/4255;;A61B5/441;;A61B5/7267;;A61B10/02;;A61B2576/026;;G01N21/6402;;G01N21/6408;;G01N2201/06113;;G06T7/0012;;G06T2207/10064;;G06T2207/30016;;G06T2207/30028;;G06T2207/30061;;G06T2207/30068;;G06T2207/30088,G01N21/64;;A61B5/00;;G01J3/02;;G01J3/28;;G01J3/44,,2,1,029-175-089-918-86X,10.1007/978-94-007-2019-0_19,"BUTTE, P. ET AL.: ""Time-Resolved Laser Induced Fluorescence Spectroscopy (TRLIFS): A Tool for Intra-operative Diagnosis of Brain Tumors and Maximizing Extent of Surgical Resection."", TUMORS OF THE CENTRAL NERVOUS SYSTEM, vol. 5, 2012, pages 161 - 172, XP009501399, Retrieved from the Internet <URL:http://dlib.bpums.ac.ir/multiMediaFile/20773834-4-1.pdf#page=188>;;See also references of EP 3265785A4",PENDING
215,NO,L,NO 20032781 L,073-400-669-117-333,2003-08-18,2003,NO 20032781 A,2003-06-18,US 74155000 A;;US 0150292 W,2000-12-19,Anvendelse av overekspresjon av laminin-alfa-4-subenhet som en diagnostiskog prognostisk indikator for maligne tumorer,"Det beskrives en fremgangsmåte for diagnostisering av nærværet av maligne tumorer inkludert et gliom hos et menneskelig individ, der fremgangsmåten involverer å påvise overekspresjon av laminin-a4-subenhetprotein eller laminin-a4-spesifikk mRNA, sammenliknet med ekspresjonsnivået i en normal vevskontroll. Det beskrives videre en fremgangsmåte for forutsigelse av gjenopptredenen av en malign tumor hos et menneskelig individ, hvorfra en malign tumor er fjernet, og en fremgangsmåte for klassifisering av nivået av en malign tumor som en glial tumor, basert på en molekylær klassifisering.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,,https://lens.org/073-400-669-117-333,Abstract,no,0,0,9,9,0,C12Q1/6886;;C12Q2600/158;;G01N33/574;;G01N33/57488;;G01N2333/47;;G01N2800/52;;G01N33/574;;G01N2333/47;;G01N2800/52;;C12Q2600/158;;C12Q1/6886;;G01N33/57488,C12Q1/68;;G01N33/574,,0,0,,,,DISCONTINUED
216,EP,A4,EP 3458036 A4,121-905-170-443-116,2020-01-15,2020,EP 17800340 A,2017-05-22,US 201662339681 P;;US 2017/0033875 W,2016-05-20,METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE AND ASSOCIATED CONDITIONS,,CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;RENTSENDORJ ALTANCHIMEG;;KORONYO YOSEF;;BLACK KEITH L,,https://lens.org/121-905-170-443-116,Search Report,no,3,0,13,13,0,A61K38/02;;A61K38/19;;A61P25/28;;A61K45/06;;A61K39/4614;;A61K2239/31;;A61K39/4622;;A61K39/46433;;A61K2239/38;;A61K39/4621;;A61P25/28;;A61K38/07;;A61K2239/31;;A61K39/4622;;A61K2239/38;;A61K39/4621;;A61K39/4614;;A61K39/46433;;A61P25/28;;A61K31/7088;;A61K35/15;;A61K38/02;;A61K38/18;;A61K38/19,A61K31/00;;A61K31/7052;;A61K35/12;;A61K35/15;;A61K38/00;;A61K38/02;;A61K38/17;;A61K38/18;;A61K38/19;;A61P25/28,,8,7,024-063-822-747-605;;009-261-837-573-736;;098-956-497-141-046;;035-438-499-631-238;;070-006-688-796-584;;004-668-378-850-361;;027-700-384-551-749,23565338;;pmc3616337;;10.2478/s13380-012-0028-7;;25151457;;pmc4262258;;10.1016/j.expneurol.2014.08.015;;10.1002/glia.22885;;26148976;;10.1038/sj.jcbfm.9600022;;15678124;;10.1161/strokeaha.110.608315;;21700938;;10.1002/ddr.10069;;28860067;;pmc5865478;;10.1016/j.bbi.2017.08.019,"BROWN AMANDA: ""OSTEOPONTIN: A KEY LINK BETWEEN IMMUNITY, INFLAMMATION AND THE CENTRAL NERVOUS SYSTEM."", TRANSLATIONAL NEUROSCIENCE 01 FEB 2012, vol. 3, no. 3, 1 February 2012 (2012-02-01), pages 288 - 293, XP002796005, ISSN: 2081-3856;;CHAN JULIE L ET AL: ""Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury."", EXPERIMENTAL NEUROLOGY NOV 2014, vol. 261, November 2014 (2014-11-01), pages 757 - 771, XP002796006, ISSN: 1090-2430;;GLIEM MICHAEL ET AL: ""Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke."", GLIA DEC 2015, vol. 63, no. 12, December 2015 (2015-12-01), pages 2198 - 2207, XP002796007, ISSN: 1098-1136;;MELLER R ET AL: ""Neuroprotection by osteopontin in stroke"", JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM, NATURE PUBLISHING GROUP, US, vol. 25, no. 2, 1 February 2005 (2005-02-01), pages 217 - 225, XP009103017, ISSN: 0271-678X, DOI: 10.1038/SJ.JCBFM.9600022;;VAN VELTHOVEN CINDY T J ET AL: ""Osteopontin enhances endogenous repair after neonatal hypoxic-ischemic brain injury."", STROKE AUG 2011, vol. 42, no. 8, August 2011 (2011-08-01), pages 2294 - 2301, XP002796008, ISSN: 1524-4628;;SCHWARTZ M ET AL: ""PROSPECTS FOR THERAPEUTIC VACCINATION WITH GLATIRAMER ACETATE FOR NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE"", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 56, no. 2, 1 June 2002 (2002-06-01), pages 143 - 149, XP001205930, ISSN: 0272-4391, DOI: 10.1002/DDR.10069;;RENTSENDORJ ALTAN ET AL: ""A novel role for osteopontin in macrophage-mediated amyloid-[beta] clearance in Alzheimer's models"", BRAIN, BEHAVIOR AND IMMUNITY, vol. 67, 30 August 2017 (2017-08-30), pages 163 - 180, XP085266858, ISSN: 0889-1591, DOI: 10.1016/J.BBI.2017.08.019;;See also references of WO 2017201539A1",ACTIVE
217,ZA,B,ZA 200305097 B,191-186-165-963-003,2004-08-12,2004,ZA 200305097 A,2003-06-30,US 74155000 A,2000-12-19,Lamin alpha 4 subunit as a diagnostic indicator of malignant tumors.,,ARROGENE INC,LJUBIMOVA JULIA Y;;BLACK KEITH L;;LJUBIMOV ALEXANDER V,,https://lens.org/191-186-165-963-003,Granted Patent,no,0,0,9,9,0,C12Q1/6886;;C12Q2600/158;;G01N33/574;;G01N33/57488;;G01N2333/47;;G01N2800/52;;G01N33/574;;G01N2333/47;;G01N2800/52;;C12Q2600/158;;C12Q1/6886;;G01N33/57488,C12Q1/68;;G01N33/574,,0,0,,,,EXPIRED
218,NO,D0,NO 20032781 D0,060-339-366-395-06X,2003-06-18,2003,NO 20032781 A,2003-06-18,US 74155000 A;;US 0150292 W,2000-12-19,Anvendelse av overekspresjon av laminin-alfa-4-subenhet som et diagnostiskmiddel og prognotisk indikator for maligne tumorer,,CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,,https://lens.org/060-339-366-395-06X,Patent Application,no,0,0,9,9,0,C12Q1/6886;;C12Q2600/158;;G01N33/574;;G01N33/57488;;G01N2333/47;;G01N2800/52;;G01N33/574;;G01N2333/47;;G01N2800/52;;C12Q2600/158;;C12Q1/6886;;G01N33/57488,C12Q1/68;;G01N33/574,,0,0,,,,DISCONTINUED
219,EP,A1,EP 1268906 A1,066-255-519-712-207,2003-01-02,2003,EP 01908991 A,2001-02-09,US 0104118 W;;US 18185700 P;;US 78025101 A,2000-02-11,IMAGED NONWOVEN FABRICS,,POLYMER GROUP INC,BLACK SAMUEL K;;CURTIS CHARLES KEITH;;CARLSON CHERYL L,,https://lens.org/066-255-519-712-207,Patent Application,yes,0,0,6,6,0,D04H1/74;;D04H3/04;;D06C23/00;;D04H18/04;;D04H1/49;;D04H1/495;;D04H3/11;;D04H18/04;;D04H3/04;;D06C23/00;;D04H1/74;;D04H3/11;;D04H1/49;;D04H1/495,D04H1/46;;D04H1/74;;D04H3/04;;D04H3/10;;D06C23/00,,0,0,,,,DISCONTINUED
220,US,A1,US 2009/0263379 A1,087-199-512-199-840,2009-10-22,2009,US 47399209 A,2009-05-28,US 47399209 A;;US 57074707 A;;US 2004/0029956 W;;US 50272903 P,2003-09-12,MONOCLONAL ANTIBODIES FOR INHIBITION OF LAMININ-8 EXPRESSION TO INHIBIT HUMAN GLIOMAS,"Using gene array technology, we observed that an increase of the alpha-4 chain-containing Laminin-8 correlated with poor prognosis for patients with brain gliomas. We established that inhibition of Laminin-8 expression by a new generation of highly specific and stable antisense oligonucleotides (Morpholino™) against chains of Laminin-8 could slow or stop the spread of glioma. This was demonstrated in an in vitro model using human glioblastoma multiforme cell lines M059K and U-87MG co-cultured with normal human brain microvascular endothelial cells (HBMVEC). Using Western blot analysis and immunohistochemistry, we confirmed that antisense treatment effectively blocked laminin-8 protein synthesis. Antisense oligonucleotides against both alpha-4 and β1 chains of laminin-8 blocked significantly the invasion of co-cultures through Matrigel. The results show that Laminin-8 may not only contribute to glioma progression and recurrence as part of the neovascularization process but also by directly increasing the invasive potential of tumor cells.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2005-05-05),https://lens.org/087-199-512-199-840,Patent Application,yes,4,1,10,10,4,A61K31/00;;A61K31/07;;A61K31/7088;;C12N15/113;;C12N2310/11;;C12N2310/3233;;A61P35/00;;A61P43/00;;A61K31/07;;A61K31/00;;C12N15/113;;A61K31/7088;;C12N2310/3233;;C12N2310/11,A61K39/395;;A01N43/04;;A61K31/00;;A61K31/07;;A61K31/7088;;C07H21/04;;C12N/;;C12N15/113;;C12Q1/68,424/130.1,0,0,,,,DISCONTINUED
221,EP,A2,EP 1660685 A2,135-528-757-868-882,2006-05-31,2006,EP 04783972 A,2004-09-13,US 2004/0029956 W;;US 50272903 P,2003-09-12,ANTISENSE INHIBITION OF LAMININ-8 EXPRESSION TO INHIBIT HUMAN GLIOMAS,,ARROGENE INC,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2007-04-11),https://lens.org/135-528-757-868-882,Patent Application,yes,0,0,10,10,4,A61K31/00;;A61K31/07;;A61K31/7088;;C12N15/113;;C12N2310/11;;C12N2310/3233;;A61P35/00;;A61P43/00;;A61K31/07;;A61K31/00;;C12N15/113;;A61K31/7088;;C12N2310/3233;;C12N2310/11,A01N43/04;;A61K31/00;;A61K31/07;;A61K31/7088;;C07H21/04;;C12N/;;C12N15/113;;C12Q1/68,,0,0,,,,DISCONTINUED
222,US,B2,US 10383958 B2,167-660-451-180-558,2019-08-20,2019,US 201213441599 A,2012-04-06,US 201213441599 A;;US 201161472362 P,2011-04-06,Polymalic acid based nanoconjugates for imaging,Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.,BLACK KEITH L;;LJUBIMOVA JULIA;;LJUBIMOV ALEXANDER;;HOLLER EGGEHARD;;CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;LJUBIMOVA JULIA;;LJUBIMOV ALEXANDER;;HOLLER EGGEHARD,CEDARS-SINAI MEDICAL CENTER (2012-06-26),https://lens.org/167-660-451-180-558,Granted Patent,yes,30,0,11,12,0,A61K49/128;;A61K49/16;;A61K47/593;;A61P35/00;;A61K49/16;;A61K47/593;;A61K49/128,A61K49/16;;A61K47/59;;A61K49/12,,27,23,029-009-067-740-470;;030-624-392-134-781;;013-415-019-143-842;;021-249-806-935-282;;113-988-814-358-790;;136-882-793-298-133;;028-271-401-020-995;;086-401-060-482-361;;018-366-252-673-210;;035-379-788-709-284;;007-036-578-032-711;;016-204-634-827-524;;067-841-415-918-209;;014-769-543-567-144;;037-068-522-821-636;;063-978-713-434-191;;028-544-752-632-02X;;004-078-600-894-219;;139-983-002-167-711;;015-358-752-508-431;;106-640-130-151-317;;026-135-913-145-143;;011-450-253-768-016,10.1158/1535-7163.mct-05-0325;;16432162;;10.1002/mrm.21029;;17029229;;pmc2734385;;18373429;;10.2217/17435889.3.2.247;;16644743;;10.1002/ana.20009;;14991808;;10.1002/3527600035.bpol3a03;;7640051;;10.1016/0959-8049(94)00514-6;;11277922;;10.1046/j.1432-1327.2001.02073.x;;10.1080/10611860290007496;;11996083;;12121131;;10.1021/bc015578s;;10.1016/s0014-5793(97)00905-8;;9287139;;17376417;;pmc2329596;;10.1016/j.cbi.2007.01.015;;10.1016/j.radi.2010.09.007;;10.1016/j.biomaterials.2009.06.004;;19560199;;22079810;;10.1016/j.jconrel.2011.10.032;;pmc3229931;;10.1021/nn202073m;;21888350;;18975017;;10.1007/s00775-008-0445-9;;pmc3245996;;22013169;;10.1093/neuonc/nor183;;10542390;;10.1016/s1461-5347(99)00211-4;;10.1371/journal.pone.0002175;;18478109;;pmc2364662;;pmc3487710;;10.1021/bc0502457;;16536461;;20921419;;10.1073/pnas.1003919107;;pmc2964197;;10.1158/0008-5472.can-10-3093;;10.31234/osf.io/nyh6f;;21303974;;pmc3428373,"WO2009157561 trans, “Translation of WO2009157561”, printed Sep. 30, 2013.;;Wu, G., et al., “Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates”, 2006, Mol. Cancer. Therap., pp. 52-59.;;Heyn, C., et al., “In Vivo MRI of Cancer Cell Fate at the Single-Cell Level in a Mouse Model of Breast Cancer Metastasis to the Brain”, Mag. Res. Med., 2006, pp. 1001-1010.;;Ljubimova, J. Y., et al., “Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery”, Nanomedicine, 2008, pp. 247-265.;;Andrew B. Newberg, et al., “Safety, Biodistribution, and Dosimetry of 123I-IMPY: A Novel Amyloid Plaque-Imaging Agent for the Diagnosis of Alzheimer's Disease”, Journal of Nuclear Medicine, 2006, 47(5):748-754.;;William E. Klunk, et al., “Imaging Brain Amyloid in Alzheimer's Disease with Pittsburgh Compound-B”, Annals of Neurology, 2004, 55(3):306-319.;;Bong-Seop Lee, et al., “Water-soluble Aliphatic Polyesters: Poly(malic acid)s”, Biopolymers, 2002, 3a(Polyesters):76-103.;;L.W. Seymour, et al., “Influence of Molecular Weight on Passive Tumour Accumulation of a Soluble Macromolecular Drug Carrier”, European Journal of Cancer, 1995, 31A(5):766-770.;;Jae H. Lee, et al., “Receptor mediated uptake of peptides that bind the human transferrin receptor”, European Journal of Biochemistry, 2001, 268(7):2004-2012.;;M. Kovar, et al., “In Vitro and In Vivo Effect of HPMA Copolymer-bound Doxorubicin Targeted to Transferrin Receptor of B-cell Lymphoma 38C13”, Journal of Drug Targeting, 2002, 10(1):23-30.;;Silvia Arpicco, et al., “Novel Poly(ethylene glycol) Derivatives for Preparation of Ribosome-Inactivating Protein Conjugates”, Bioconjugate Chemistry, 2002, 13(4):757-765.;;Kazuo Maruyama, et al., “Immunoliposomes bearing polyethyleneglycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo”, Federation of European Biochemical Societies Letters, 1997, 413(1):177-180.;;Julia Y. Ljubimova, et al., “Nanoconjugate based on polymalic acid for tumor targeting”, Chemico-Biological Interactions, 2008, 171(2):195-203.;;Gill Marshall, et al., “Adverse events caused by MRI contrast agents: Implications for radiographers who inject”, Radiography, 2012, 18(2):132-136.;;Jia-Jyun Lin, et al., “Folic acid-Pluronic F127 magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications”, Biomaterials, 2009, 30(28):5114-5124.;;Ewelina Kluza, et al., “Dual-targeting of alpha v beta 3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo”, Journal of Controlled Release, 2012, 15(2):207-214.;;Tao Chen, et al., “Smart Multifunctional Nanostructure for Targeted Cancer Chemotherapy and Magnetic Resonance Imaging”, ACS Nano, 2011, 5(10):7866-7873.;;Ting-Jung Chen, et al., “Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI”, Journal of Biological Inorganic Chemistry, 2009, 14(2):253-260.;;Boguslaw Tomanek, et al., “Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging”, Neuro-Oncology, 2012, 14(1):53-63.;;Ruth Duncan, “Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway?”, Pharmaceutical Science & Technology Today, 1999, 2(11):441-449.;;Scott Raymond, et al., “Ultrasound Enhanced Delivery of Molecular Imaging and Therapeutic Agents in Alzheimer's Disease Mouse Models”, 2008, PLoS ONE 3(5):1-7.;;Lee, et al., “Polycefin, a New Prototype of a Multifunctional Nanoconjugate Based on Poly(B-L-malic acid for Drug Delivery,” Bioconjugate Chemistry, 2006, 17(2):317-326.;;Ding, Hui et al. “Inhibition of brain tumor growth by intravenous poly (-L-malic) acid nanobioconjugate with pH-dependent drug release”; Proceedings of the National Academy of Sciences, vol. 107, No. 42, pp. 18143-18148 (Oct. 19, 2010) with Correction in vol. 107, No. 45, p. 19603 (Nov. 9, 2010).;;Inoue, Satoshi et al. “Newly designed nanobioconjugate for direct targeting and systemic treatment of HER2-positive breast cancer”; Cancer Research; Proceedings: AACR 101st Annual Meeting 2010; Walter E. Washington Convention Center, Washington, D.C.; Abstract No. 3854; vol. 70, No. 8, suppl., one page (Apr. 1, 2010).;;Inoue, Satoshi et al. “Polymalic Acid-Based Nanobiopolymer Provides Efficient Systemic Breast Cancer Treatment by Inhibiting both HER2/neu Receptor Synthesis and Activity”; Cancer Research, vol. 71, No. 4; pp. 1454-1464 (Feb. 8, 2011).;;Ljubimova, Julia Y. et al. “Molecular Oncology”; Internet citation, XP008143608 (Jul. 1, 2009). Retrieved from the Internet:URL:http://www.cedars-sinai.edu/10141.html (retrieved on Sep. 29, 2011).;;Supplementary European Search Report, European Patent Application No. 12768248.2; dated May 9, 2014 (11 pages).",ACTIVE
223,DE,T2,DE 60117855 T2,161-116-899-404-487,2006-11-30,2006,DE 60117855 T,2001-12-13,US 25584200 P;;US 0148902 W,2000-12-15,"FLAMMENHEMMENDER, BEBILDERTER VLIESSTOFF",,POLYMER GROUP INC,HARTGROVE PARKS;;DE LEON DIAZ;;BLACK KEITH;;HIJENGA JOOST,,https://lens.org/161-116-899-404-487,Granted Patent,no,0,0,12,12,0,D06M15/248;;D06M15/263;;D06M15/564;;D06M2200/30;;Y10S428/92;;Y10S428/921;;D04H1/4266;;D04H1/43;;D04H1/4342;;D04H1/435;;D04H1/49;;D04H1/495;;D04H18/04;;D04H1/587;;D04H1/64;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D04H1/43835;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D06M15/248;;D06M15/564;;D06M2200/30;;D06M15/263;;Y10S428/921;;Y10S428/92;;D04H1/435;;D04H1/4266;;D04H18/04;;D04H1/64;;D04H1/495;;D04H1/4342;;D04H1/43;;D04H1/49;;D04H1/587;;D04H1/43835,B32B27/04;;B27N9/00;;B32B27/12;;D04H1/42;;D04H1/46;;D04H1/64;;D04H13/00;;D06M15/248;;D06M15/263;;D06M15/564,,0,0,,,,EXPIRED
224,US,A1,US 2022/0260591 A1,063-474-309-111-252,2022-08-18,2022,US 202217592433 A,2022-02-03,US 202217592433 A;;US 202163146878 P,2021-02-08,METHOD OF DETECTING COGNITIVE IMPAIRMENT,"The present invention describes a method for the detection, diagnosis and monitoring of cognitive impairment and Alzheimer's disease. The method involves the detection of pericyte loss and deficiency in PDGFRβ, alone or in combination with retinal vascular Aβ deposits. The method also involves detecting an alteration in blood-retinal barrier (BRB) cell tight junction.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;SHI HAOSHEN;;KORONYO YOSEF;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2022-02-14),https://lens.org/063-474-309-111-252,Patent Application,yes,0,1,1,1,0,A61B3/102;;A61B3/12;;G01N33/6896;;A61B5/4088;;A61B3/0025;;G01N2800/2814;;G01N2440/14;;G01N2333/705;;G01N2333/4703;;A61B5/1455;;A61B5/0066;;A61B5/0071;;A61B5/0075;;A61B2576/02;;G06T7/0016;;G06T7/0014;;G06T2207/10101;;G06T2207/30041;;G06T2207/10064;;G01N33/6896;;A61B3/0025;;G01N2800/2821;;A61B3/12;;A61B3/102,G01N33/68;;A61B3/00;;A61B3/10;;A61B3/12,,0,0,,,,PENDING
225,US,A1,US 2019/0321494 A1,094-226-950-005-692,2019-10-24,2019,US 201916434545 A,2019-06-07,US 201916434545 A;;US 201213441599 A;;US 201161472362 P,2011-04-06,POLYMALIC ACID BASED NANOCONJUGATES FOR IMAGING,Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;LJUBIMOVA JULIA;;LJUBIMOV ALEXANDER;;HOLLER EGGEHARD,CEDARS-SINAI MEDICAL CENTER (2012-06-26),https://lens.org/094-226-950-005-692,Patent Application,yes,0,0,1,12,0,A61K49/16;;A61K49/16;;A61K49/085;;A61K49/085;;A61K49/108;;C07K16/22;;C07K16/2863;;C07K16/2881;;C07K16/32;;C07K2317/24;;C07K2317/24,A61K49/16;;A61K49/08;;A61K49/10;;C07K16/22;;C07K16/32,,0,0,,,,DISCONTINUED
226,WO,A1,WO 2001/059194 A1,154-197-792-435-260,2001-08-16,2001,US 0104118 W,2001-02-09,US 18185700 P;;US 78025101 A,2000-02-11,IMAGED NONWOVEN FABRICS,"A method of forming durable nonwoven fabrics by hydroentanglement includes providing a precursor web (P) comprising a fibrous matrix of staple length fibers and/or substantially continuous filaments. The precursor web is subjected to hydroentanglement on a three-dimensional image transfer device (24) to create a patterned and imaged fabric. Enhanced imaging is achieved by advancing the precursor web onto the movable imaging surface of the image transfer device at a rate substantially equal to the rate at which the image surface moves relative to one or more associated hydroentangling manifolds (26). Treatment with a polymeric binder composition (30) enhances the integrity of the fabric, permitting it to exhibit desired physical characteristics, including strength, durability, softness, and drapeability. Mechanical compaction of the imaged and patterned fabric, such as by sanforizing, enhances the desired physical properties.",POLYMER GROUP INC,BLACK SAMUEL K;;CURTIS CHARLES KEITH;;CARLSON CHERYL L,,https://lens.org/154-197-792-435-260,Patent Application,yes,1,11,6,6,0,D04H1/74;;D04H3/04;;D06C23/00;;D04H18/04;;D04H1/49;;D04H1/495;;D04H3/11;;D04H18/04;;D04H3/04;;D06C23/00;;D04H1/74;;D04H3/11;;D04H1/49;;D04H1/495,D04H1/46;;D04H1/74;;D04H3/04;;D04H3/10;;D06C23/00,,0,0,,,,PENDING
227,EP,A1,EP 3458036 A1,169-003-852-119-267,2019-03-27,2019,EP 17800340 A,2017-05-22,US 201662339681 P;;US 2017/0033875 W,2016-05-20,METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE AND ASSOCIATED CONDITIONS,,CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;RENTSENDORJ ALTANCHIMEG;;KORONYO YOSEF;;BLACK KEITH L,,https://lens.org/169-003-852-119-267,Patent Application,yes,0,0,13,13,0,A61K38/02;;A61K38/19;;A61P25/28;;A61K45/06;;A61K39/4614;;A61K2239/31;;A61K39/4622;;A61K39/46433;;A61K2239/38;;A61K39/4621;;A61P25/28;;A61K38/07;;A61K2239/31;;A61K39/4622;;A61K2239/38;;A61K39/4621;;A61K39/4614;;A61K39/46433;;A61P25/28;;A61K31/7088;;A61K35/15;;A61K38/02;;A61K38/18;;A61K38/19,A61K31/00;;A61K31/7052;;A61K35/12;;A61K38/00;;A61K38/17;;A61K38/18,,0,0,,,,ACTIVE
228,EP,B1,EP 3458036 B1,026-018-058-554-778,2023-08-23,2023,EP 17800340 A,2017-05-22,US 201662339681 P;;US 2017/0033875 W,2016-05-20,TREATING OR PREVENTING ALZHEIMER'S DISEASE AND ASSOCIATED CONDITIONS,,CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;RENTSENDORJ ALTANCHIMEG;;KORONYO YOSEF;;BLACK KEITH L,,https://lens.org/026-018-058-554-778,Granted Patent,yes,1,0,13,13,0,A61K38/02;;A61K38/19;;A61P25/28;;A61K45/06;;A61K39/4614;;A61K2239/31;;A61K39/4622;;A61K39/46433;;A61K2239/38;;A61K39/4621;;A61P25/28;;A61K38/07;;A61K2239/31;;A61K39/4622;;A61K2239/38;;A61K39/4621;;A61K39/4614;;A61K39/46433;;A61P25/28;;A61K31/7088;;A61K35/15;;A61K38/02;;A61K38/18;;A61K38/19,A61K31/00;;A61K31/7052;;A61K35/12;;A61K35/15;;A61K38/00;;A61K38/02;;A61K38/17;;A61K38/18;;A61K38/19;;A61K45/06;;A61P25/28,,0,0,,,,ACTIVE
229,US,A1,US 2012/0258049 A1,045-639-483-544-07X,2012-10-11,2012,US 201213441599 A,2012-04-06,US 201213441599 A;;US 201161472362 P,2011-04-06,POLYMALIC ACID BASED NANOCONJUGATES FOR IMAGING,Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.,BLACK KEITH L;;LJUBIMOVA JULIA;;LJUBIMOV ALEXANDER;;HOLLER EGGEHARD;;CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;LJUBIMOVA JULIA;;LJUBIMOV ALEXANDER;;HOLLER EGGEHARD,CEDARS-SINAI MEDICAL CENTER (2012-06-26),https://lens.org/045-639-483-544-07X,Patent Application,yes,10,4,11,12,0,A61K49/128;;A61K49/16;;A61K47/593;;A61P35/00;;A61K49/16;;A61K47/593;;A61K49/128,A61B5/055;;C08G63/91,424/9.34;;525/54.1,4,3,029-009-067-740-470;;030-624-392-134-781;;013-415-019-143-842,10.1158/1535-7163.mct-05-0325;;16432162;;10.1002/mrm.21029;;17029229;;pmc2734385;;18373429;;10.2217/17435889.3.2.247,"WO2009157561 trans, ""Translation of WO2009157561"", printed 9/30/2013;;Wu, G., et al., ""Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates"", 2006, Mol. Cancer. Therap., pp. 52-59;;Heyn, C., et al., ""In Vivo MRI of Cancer Cell Fate at the Single-Cell Level in a Mouse Model of Breast Cancer Metastasis to the Brain"", Mag. Res. Med., 2006, pp. 1001-1010;;Ljubimova, J. Y., et al., ""Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery"", Nanomedicine, 2008, pp. 247-265",ACTIVE
230,US,A1,US 2007/0105797 A1,126-410-016-356-863,2007-05-10,2007,US 57074704 A,2004-09-13,US 57074704 A;;US 50272903 P;;US 2004/0029956 W,2003-09-12,Antisense inhibition of laminin-8 expression to inhibit human gliomas,"Using gene array technology, we observed that an increase of the α4 chain-containing Laminin-8 correlated with poor prognosis for patients with brain gliomas. We established that inhibition of Laminin-8 expression by a new generation of highly specific and stable antisense oligonucleotides (Morpholino™) against chains of Laminin-8 could slow or stop the spread of glioma. This was demonstrated in an in vitro model using human glioblastoma multiforme cell lines M059K and U-87MG co-cultured with normal human brain microvascular endothelial cells (HBMVEC). Using Western blot analysis and immunohistochemistry, we con-firmed that antisense treatment effectively blocked laminin-8 protein synthesis. Antisense oligonucleotides against both α4 and β1 chains of laminin-8 blocked significantly the invasion of co-cultures through Matrigel. The results show that Linin-8 may not only contribute to glioma progression and recurrence as part of the neovascularization process but also by directly increasing the invasive potential of tumor cells.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2005-05-05),https://lens.org/126-410-016-356-863,Patent Application,yes,0,0,10,10,4,A61K31/00;;A61K31/07;;A61K31/7088;;C12N15/113;;C12N2310/11;;C12N2310/3233;;A61P35/00;;A61P43/00;;A61K31/07;;A61K31/00;;C12N15/113;;A61K31/7088;;C12N2310/3233;;C12N2310/11,A61K48/00;;A01N43/04;;A61K31/00;;A61K31/07;;A61K31/7088;;C07H21/04;;C12N/;;C12N15/113;;C12Q1/68,514/44,0,0,,,,INACTIVE
231,PL,A1,PL 366317 A1,133-745-449-973-515,2005-01-24,2005,PL 36631701 A,2001-12-19,US 74155000 A,2000-12-19,USING OVEREXPRESSION OF LAMININ ALPHA 4 SUBUNIT AS A DIAGNOSTIC AND PROGNOSTIC INDICATOR OF MALIGNANT TUMORS,,CEDARS SINAI MEDICAL CENTER,LJUBIMOWA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,,https://lens.org/133-745-449-973-515,Patent Application,no,0,0,9,9,0,C12Q1/6886;;C12Q2600/158;;G01N33/574;;G01N33/57488;;G01N2333/47;;G01N2800/52;;G01N33/574;;G01N2333/47;;G01N2800/52;;C12Q2600/158;;C12Q1/6886;;G01N33/57488,C12Q1/68;;G01N33/574,,0,0,,,,EXPIRED
232,WO,A2,WO 2005/028617 A2,152-803-564-820-41X,2005-03-31,2005,US 2004/0029956 W,2004-09-13,US 50272903 P,2003-09-12,ANTISENSE INHIBITION OF LAMININ-8 EXPRESSION TO INHIBIT HUMAN GLIOMAS,"Using gene array technology, we observed that an increase of the &agr;4 chain- containing Laminin-8 correlated with poor prognosis for patients with brain gliomas. We established that inhibition of Laminin-8 expression by a new generation of highly specific and stable antisense oligonucleotides (MorpholinoTM) against chains of Laminin-8 could slow or stop the spread of glioma. This was demonstrated in an in vitro model using human glioblastoma multiforme cell lines M059K and U-87MG co-cultured with normal human brain microvascular endothelial cells (HBMVEC). Using Western blot analysis and immunohistochemistry, we confirmed that antisense treatment effectively blocked laminin-8 protein synthesis. Antisense oligonucleotides against both &agr;4 and &szlig;1 chains of laminin-8 blocked significantly the invasion of co-cultures through Matrigel. The results show that Laminin-8 may not only contribute to glioma progression and recurrence as part of the neovascularization process but also by directly increasing the invasive potential of tumor cells.",ARROGENE INC;;LJUBIMOVA JULIA Y;;LJUBIMOVA ALEXANDER V;;BLACK KEITH L,LJUBIMOVA JULIA Y;;LJUBIMOVA ALEXANDER V;;BLACK KEITH L,,https://lens.org/152-803-564-820-41X,Patent Application,yes,0,8,10,10,0,A61K31/00;;A61K31/07;;A61K31/7088;;C12N15/113;;C12N2310/11;;C12N2310/3233;;A61P35/00;;A61P43/00;;A61K31/07;;A61K31/00;;C12N15/113;;A61K31/7088;;C12N2310/3233;;C12N2310/11,A01N43/04;;A61K31/00;;A61K31/07;;A61K31/7088;;C07H21/04;;C12N/;;C12N15/113;;C12Q1/68,,0,0,,,,PENDING
233,EP,A4,EP 1268906 A4,155-435-375-414-765,2008-05-28,2008,EP 01908991 A,2001-02-09,US 0104118 W;;US 18185700 P;;US 78025101 A,2000-02-11,IMAGED NONWOVEN FABRICS,,POLYMER GROUP INC,BLACK SAMUEL K;;CURTIS CHARLES KEITH;;CARLSON CHERYL L,,https://lens.org/155-435-375-414-765,Search Report,no,5,0,6,6,0,D04H1/74;;D04H3/04;;D06C23/00;;D04H18/04;;D04H1/49;;D04H1/495;;D04H3/11;;D04H18/04;;D04H3/04;;D06C23/00;;D04H1/74;;D04H3/11;;D04H1/49;;D04H1/495,D04H1/46;;D04H1/74;;D04H3/04;;D04H3/10;;D06C23/00,,1,0,,,See also references of WO 0159194A1,DISCONTINUED
234,DE,D1,DE 60117855 D1,199-600-665-136-372,2006-05-04,2006,DE 60117855 T,2001-12-13,US 25584200 P;;US 0148902 W,2000-12-15,"FLAMMENHEMMENDER, BEBILDERTER VLIESSTOFF",,POLYMER GROUP INC,HARTGROVE PARKS;;DE LEON DIAZ;;BLACK KEITH;;HIJENGA JOOST,,https://lens.org/199-600-665-136-372,Granted Patent,no,0,0,12,12,0,D06M15/248;;D06M15/263;;D06M15/564;;D06M2200/30;;Y10S428/92;;Y10S428/921;;D04H1/4266;;D04H1/43;;D04H1/4342;;D04H1/435;;D04H1/49;;D04H1/495;;D04H18/04;;D04H1/587;;D04H1/64;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D04H1/43835;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D06M15/248;;D06M15/564;;D06M2200/30;;D06M15/263;;Y10S428/921;;Y10S428/92;;D04H1/435;;D04H1/4266;;D04H18/04;;D04H1/64;;D04H1/495;;D04H1/4342;;D04H1/43;;D04H1/49;;D04H1/587;;D04H1/43835,B32B27/04;;B27N9/00;;B32B27/12;;D04H1/42;;D04H1/46;;D04H1/64;;D04H13/00;;D06M15/248;;D06M15/263;;D06M15/564,,0,0,,,,EXPIRED
235,CN,A,CN 109600992 A,192-752-332-612-172,2019-04-09,2019,CN 201780047500 A,2017-05-22,US 201662339681 P;;US 2017/0033875 W,2016-05-20,METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE AND ASSOCIATED CONDITIONS,"The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. Theinvention further provides for a method of improving cognitive function in a subject in need thereof.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;RENTSENDORJ ALTANCHIMEG;;KORONYO YOSEF;;BLACK KEITH L,,https://lens.org/192-752-332-612-172,Patent Application,no,6,1,13,13,0,A61K38/02;;A61K38/19;;A61P25/28;;A61K45/06;;A61K39/4614;;A61K2239/31;;A61K39/4622;;A61K39/46433;;A61K2239/38;;A61K39/4621;;A61P25/28;;A61K38/07;;A61K2239/31;;A61K39/4622;;A61K2239/38;;A61K39/4621;;A61K39/4614;;A61K39/46433;;A61P25/28;;A61K31/7088;;A61K35/15;;A61K38/02;;A61K38/18;;A61K38/19,A61K45/00;;A61K31/7052;;A61K35/12;;A61K38/00;;A61K38/17;;A61K38/18;;A61P25/28,,4,0,,,"YOSEF KORONYO，等: ""Therapeutic effects of glatiramer acetate and grafted CD115(+) monocytes in a mouse model of Alzheimer""s disease"", 《BRAIN》;;XINFANG LI，等: ""IFN-γ induction of osteopontin expression in human monocytoid cells"", 《JOURNAL OF INTERFERON AND CYTOKINE RESEARCH》;;JULIE L.CHAN，等: ""Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury"", 《EXPERIMENTAL NEUROLOGY》;;MAYA K. H.，等: ""Immunomodulatory Factor Induced By GA Mediates Macrophage Clearance of Pathogenic AΒ Forms and Enhances Synaptic Preservation"", 《ALZHEIMER’S & DEMENTIA》",DISCONTINUED
236,US,B2,US 6502288 B2,022-396-971-212-455,2003-01-07,2003,US 78025101 A,2001-02-09,US 78025101 A;;US 18185700 P,2000-02-11,Imaged nonwoven fabrics,"
    A method of forming durable nonwoven fabrics by hydroentanglement includes providing a precursor web comprising a fibrous matrix of staple length fibers and/or substantially continuous filaments. The precursor web is subjected to hydroentanglement on a three-dimensional image transfer device to create a patterned and imaged fabric. Enhanced imaging is achieved by advancing the precursor web onto the movable imaging surface of the image transfer device at a rate substantially equal to the rate at which the image surface moves relative to one or more associated hydroentangling manifolds. Treatment with a polymeric binder composition enhances the integrity of the fabric, permitting it to exhibit desired physical characteristics, including strength, durability, softness, and drapeability. Mechanical compaction of the imaged and patterned fabric, such as by sanforizing, enhances the desired physical properties. 
",POLYMER GROUP INC,BLACK SAMUEL K;;CURTIS CHARLES KEITH;;CARLSON CHERYL L,AVINTIV SPECIALTY MATERIALS INC (2001-03-29),https://lens.org/022-396-971-212-455,Granted Patent,yes,19,55,6,6,0,D04H1/74;;D04H3/04;;D06C23/00;;D04H18/04;;D04H1/49;;D04H1/495;;D04H3/11;;D04H18/04;;D04H3/04;;D06C23/00;;D04H1/74;;D04H3/11;;D04H1/49;;D04H1/495,D04H1/46;;D04H1/74;;D04H3/04;;D04H3/10;;D06C23/00,28/104;;28/163;;28/167,0,0,,,,EXPIRED
237,AU,A,AU 2001/036789 A,051-465-386-171-312,2001-08-20,2001,AU 2001/036789 A,2001-02-09,US 18185700 P;;US 78025101 A;;US 0104118 W,2000-02-11,Imaged nonwoven fabrics,,POLYMER GROUP INC,BLACK SAMUEL K;;CURTIS CHARLES KEITH;;CARLSON CHERYL L,,https://lens.org/051-465-386-171-312,Patent Application,no,0,0,6,6,0,D04H1/74;;D04H3/04;;D06C23/00;;D04H18/04;;D04H1/49;;D04H1/495;;D04H3/11;;D04H18/04;;D04H3/04;;D06C23/00;;D04H1/74;;D04H3/11;;D04H1/49;;D04H1/495,D04H1/46;;D04H1/74;;D04H3/04;;D04H3/10;;D06C23/00,,0,0,,,,PENDING
238,WO,A3,WO 2002/059610 A3,140-587-853-928-540,2003-08-14,2003,US 0150292 W,2001-12-19,US 74155000 A,2000-12-19,LAMIN ALPHA 4 SUBUNIT AS A DIAGNOSTIC INDICATOR OF MALIGNANT TUMORS,"Disclosed is a method of diagnosing the presence of a malignant tumor, including a glioma, in a human subject, which involves detecting overexpression of laminin *4 subunit protein or laminin *4-specific mRNA, compared to the expression level in a normal tissue control. Also disclosed are a method of predicting the recurrence of a malignant tumor in a human subject from whom a malignant tumor has been resected and a method of classifying the grade of a malignant tumor, such as a glial tumor, based on a molecular classification.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,,https://lens.org/140-587-853-928-540,Search Report,yes,2,0,9,9,4,C12Q1/6886;;C12Q2600/158;;G01N33/574;;G01N33/57488;;G01N2333/47;;G01N2800/52;;G01N33/574;;G01N2333/47;;G01N2800/52;;C12Q2600/158;;C12Q1/6886;;G01N33/57488,C12Q1/68;;G01N33/574,,1,1,001-280-492-710-987,11454714,"LJUBIMOVA JULIA Y ET AL: ""Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis."", CANCER RESEARCH, vol. 61, no. 14, 15 July 2001 (2001-07-15), pages 5601 - 5610, XP002231538, ISSN: 0008-5472",PENDING
239,EP,A1,EP 3265785 A1,087-688-981-219-813,2018-01-10,2018,EP 16860766 A,2016-10-27,US 201562248934 P;;US 2016/0059054 W,2015-10-30,METHODS AND SYSTEMS FOR PERFORMING TISSUE CLASSIFICATION USING MULTI-CHANNEL TR-LIFS AND MULTIVARIATE ANALYSIS,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;BAKER MICHAEL;;JONES HOWLAND;;BUTTE PRAMOD,,https://lens.org/087-688-981-219-813,Patent Application,yes,0,0,4,4,0,A61B5/00;;A61B5/0075;;G01N2201/129;;A61B10/02;;G01N21/6402;;G01N21/6408;;A61B5/00;;G01N2201/129;;A61B5/0075;;G06F18/24;;A61B5/0071;;A61B5/0091;;A61B5/08;;A61B5/4064;;A61B5/4255;;A61B5/441;;A61B5/7267;;A61B10/02;;A61B2576/026;;G01N21/6402;;G01N21/6408;;G01N2201/06113;;G06T7/0012;;G06T2207/10064;;G06T2207/30016;;G06T2207/30028;;G06T2207/30061;;G06T2207/30068;;G06T2207/30088,G01N21/64;;A61B5/00;;G01J3/02;;G01J3/28;;G01J3/44,,0,0,,,,DISCONTINUED
240,CA,A,CA 841313 A,090-126-722-119-82X,1970-05-12,1970,CA 841313D A,,CA 841313T A,,TRANSMISSION CONTROL SYSTEM,,GEN MOTORS CORP,BAILEY KEITH A;;BLACK ROBERT L;;FISHER MARK E,,https://lens.org/090-126-722-119-82X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
241,WO,A1,WO 2023/004436 A1,141-115-962-051-611,2023-01-26,2023,US 2022/0074083 W,2022-07-22,US 202163225279 P,2021-07-23,METHODS AND SYSTEMS FOR EARLY DETECTION OF OCULAR AND/OR NEUROLOGICAL CONDITIONS,"The present invention describes systems and method for the detection, diagnosis and monitoring of neurological and/or ocular disease, such as cognitive impairment and Alzheimer's disease. In one example, a method includes differentiating between vein vessels and artery vessels in one or more retinal images of a superior-temporal region of the retina, identifying distal vein branches downstream from a primary vein branch, and quantifying an amount of venular-adjacent amyloid-beta deposits in a venular-adjacent region corresponding to the distal vein branches, wherein the distal vein branches include one or more of secondary veins, secondary vein branches, and tertiary veins. The method further comprises diagnosing the neurological and/or ocular disease based on the amount of venular-adjacent amyloid-beta deposits.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;DOUSTAR JONAH;;KORONYO YOSEF;;BLACK KEITH L,,https://lens.org/141-115-962-051-611,Patent Application,yes,2,0,1,1,0,G06V10/82;;A61B5/4088;;A61B5/7267;;A61B5/7275;;A61B5/489;;A61B5/02007;;G16H50/20;;A61B5/4842;;A61B5/0071;;A61B5/0022;;G06T7/0012;;G16H30/40;;G06V40/193;;G06T2207/30101;;G06T2207/30041;;G06T2207/20081;;G06T2207/20084;;G06N3/0464;;G06N3/09,A61B3/14;;A61B5/00;;G06N20/00;;G06V10/82,,5,4,042-685-215-348-660;;128-433-827-369-558;;037-390-462-952-428;;017-720-190-504-851,10.1172/jci.insight.93621;;pmc5621887;;28814675;;10.1038/s41598-018-37271-6;;pmc6329813;;30635610;;pmc6602142;;31316862;;10.1167/tvst.8.3.60;;pmc4575389;;26363791;;10.1007/s00401-015-1477-1,"KORONYO YOSEF, BIGGS DAVID, BARRON ERNESTO, BOYER DAVID S., PEARLMAN JOEL A., AU WILLIAM J., KILE SHAWN J., BLANCO AUSTIN, FUCHS D: ""Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease"", JCI INSIGHT, vol. 2, no. 16, 17 August 2017 (2017-08-17), pages e93621, XP055842490, DOI: 10.1172/jci.insight.93621;;QUERQUES GIUSEPPE, BORRELLI ENRICO, SACCONI RICCARDO, DE VITIS LUIGI, LEOCANI LETIZIA, SANTANGELO ROBERTO, MAGNANI GIUSEPPE, COMI : ""Functional and morphological changes of the retinal vessels in Alzheimer’s disease and mild cognitive impairment"", SCIENTIFIC REPORTS, vol. 9, no. 1, XP093028038, DOI: 10.1038/s41598-018-37271-6;;ISHIBAZAWA AKIHIRO, MEHTA NIHAAL, SOROUR OSAMA, BRAUN PHILLIP, MARTIN SARAH, ALIBHAI A. YASIN, SAIFUDDIN ADNAN, ARYA MALVIKA, BAUM: ""Accuracy and Reliability in Differentiating Retinal Arteries and Veins Using Widefield En Face OCT Angiography"", TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 8, no. 3, 1 May 2019 (2019-05-01), US , pages 60, XP093028037, ISSN: 2164-2591, DOI: 10.1167/tvst.8.3.60;;HATAMI NIMA, GOLDBAUM MICHAEL: ""Automatic Identification of Retinal Arteries and Veins in Fundus Images using Local Binary Patterns"", ELSEVIER, 30 May 2016 (2016-05-30), XP093028033, Retrieved from the Internet <URL:https://arxiv.org/ftp/arxiv/papers/1605/1605.00763.pdf> [retrieved on 20230301], DOI: 10.48550/arxiv.1605.00763;;XIANG YANG; BU XIAN-LE; LIU YU-HUI; ZHU CHI; SHEN LIN-LIN; JIAO SHU-SHENG; ZHU XIAO-YAN; GIUNTA BRIAN; TAN JUN; SONG WEI-HONG; ZHO: ""Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease"", ACTA NEUROPATHOLOGICA, SPRINGER VERLAG, BERLIN, DE, vol. 130, no. 4, 12 September 2015 (2015-09-12), BERLIN, DE , pages 487 - 499, XP035536701, ISSN: 0001-6322, DOI: 10.1007/s00401-015-1477-1",PENDING
242,US,A1,US 2023/0414658 A1,149-343-422-970-225,2023-12-28,2023,US 202318458428 A,2023-08-30,US 202318458428 A;;US 202117338305 A;;US 201816303053 A;;US 2017/0033875 W;;US 201662339681 P,2016-05-20,METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE AND ASSOCIATED CONDITIONS,"The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;RENTSENDORJ ALTANCHIMEG;;KORONYO YOSEF;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2017-05-23),https://lens.org/149-343-422-970-225,Patent Application,yes,0,0,13,13,0,A61K38/02;;A61K38/19;;A61P25/28;;A61K45/06;;A61K39/4614;;A61K2239/31;;A61K39/4622;;A61K39/46433;;A61K2239/38;;A61K39/4621;;A61P25/28;;A61K38/07;;A61K2239/31;;A61K39/4622;;A61K2239/38;;A61K39/4621;;A61K39/4614;;A61K39/46433;;A61P25/28;;A61K31/7088;;A61K35/15;;A61K38/02;;A61K38/18;;A61K38/19,A61K35/15;;A61K31/7088;;A61K38/02;;A61K38/18;;A61K38/19;;A61P25/28,,0,0,,,,PENDING
243,US,S,US D0731632 S,180-799-020-856-189,2015-06-09,2015,US 201229438879 F,2012-12-04,US 201229438879 F,2012-12-04,Compact dehumidifier,,DRI EAZ PRODUCTS INC,KULP RYAN;;HOFFMAN KEITH;;BRUDERS WILLIAM;;BLACK RICHARD A,DRI-EAZ PRODUCTS INC (2012-12-07);;LEGEND BRANDS INC (2019-12-20),https://lens.org/180-799-020-856-189,Design Right,no,0,15,1,1,0,,,2899;;D23/359,0,0,,,,ACTIVE
244,WO,A1,WO 2017/201539 A1,058-276-787-869-182,2017-11-23,2017,US 2017/0033875 W,2017-05-22,US 201662339681 P,2016-05-20,METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE AND ASSOCIATED CONDITIONS,"The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;RENTSENDORJ ALTANCHIMEG;;KORONYO YOSEF;;BLACK KEITH L,,https://lens.org/058-276-787-869-182,Patent Application,yes,7,4,13,13,0,A61K38/02;;A61K38/19;;A61P25/28;;A61K45/06;;A61K39/4614;;A61K2239/31;;A61K39/4622;;A61K39/46433;;A61K2239/38;;A61K39/4621;;A61P25/28;;A61K38/07;;A61K2239/31;;A61K39/4622;;A61K2239/38;;A61K39/4621;;A61K39/4614;;A61K39/46433;;A61P25/28;;A61K31/7088;;A61K35/15;;A61K38/02;;A61K38/18;;A61K38/19,A61K31/00;;A61K31/7052;;A61K35/12;;A61K38/00;;A61K38/17;;A61K38/18,,34,22,030-030-967-774-985;;009-434-522-525-062;;117-800-300-773-071;;133-677-711-787-450;;009-434-522-525-062;;010-932-791-325-445;;020-235-958-756-618;;028-430-449-875-429;;064-187-018-698-676;;042-204-626-457-327;;017-150-654-990-340;;002-264-966-090-625;;001-400-252-595-282;;077-532-829-551-519;;032-868-001-243-82X;;072-366-322-919-406;;010-519-409-512-153;;022-532-689-654-325;;019-817-021-691-872;;070-959-113-690-925;;034-356-721-676-31X;;009-434-522-525-062,12804068;;10.1089/107999003321829971;;10.1093/brain/awv150;;pmc4840949;;26049087;;10.1016/j.jalz.2016.06.669;;12377945;;10.1189/jlb.72.4.752;;10.1093/brain/awv150;;pmc4840949;;26049087;;20308780;;10.3233/jad-2010-1309;;10.1073/pnas.0604681103;;16864778;;pmc1544247;;24101477;;pmc3808615;;10.1073/pnas.1308887110;;825377;;10.1002/eji.1830060713;;3127726;;10.1038/332323a0;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;11036658;;10.1016/s0076-6879(00)26070-9;;10.1038/nbt1142;;16151406;;10.1201/9781420027693;;4705382;;10.1016/0042-6822(73)90341-3;;6263759;;10.1016/0378-1119(81)90008-1;;7127308;;10.1146/annurev.bb.09.060180.002343;;6994593;;10.1016/s1389-0344(01)00067-3;;11337275;;14645205;;10.1093/hmg/ddh019;;10.1093/brain/awv150;;pmc4840949;;26049087,"LI ET AL.: ""IFN-y Induction of Osteopontin Expression in Human Monocytoid Cells"", JOURNAL OF INTERFERON & CYTOKINE RESEARCH, vol. 23, no. Iss. 5, 1 May 2003 (2003-05-01), pages 259 - 265, XP055448368, Retrieved from the Internet <URL:DOI: 10.1089/107999003321829971>;;KORONYO ET AL.: ""Therapeutic effects of glatiramer acetate and grafted CD 115+ monocytes in a .mouse model of Alzheimer's disease"", BRAIN, vol. 138, no. 8, 6 June 2015 (2015-06-06), pages 2399 - 2422, XP055448373, Retrieved from the Internet <URL:doi:10.1093/brain/awv150>;;MAYA ET AL.: ""Immunomodulatory Factor Induced by GA Mediates Macrophage Clearance of Pathogenic Abeta Forms and Enhances Synaptic Preservation"", ALZHEIMER'S & DEMENTIA, vol. 12, no. Iss. 7, 27 July 2016 (2016-07-27), pages p361, XP055448385;;WEBER ET AL.: ""Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation"", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 72, no. 4, 1 October 2002 (2002-10-01), pages 752 - 761, XP055583270, ISSN: 0741-5400, DOI: 10.1189/jlb.72.4.752;;KORONYO ET AL.: ""Therapeutic effects of glatiramer acetate and grafted CD 115+ monocytes in a .mouse model of Alzheimer's disease"", BRAIN, vol. 138, no. 8, 6 June 2015 (2015-06-06), pages 2399 - 2422;;COMI ET AL., JOURNAL OF ALZHEIMER'S DISEASE: 2010 JAD, vol. 19, pages 1143 - 1148;;BUTOVSKY ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 103, 2006, pages 11784 - 11789;;MCWHORTER ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 110, 2013, pages 17253 - 17258;;SAMBROOKRUSSEL: ""Molecular Cloning: A Laboratory Manual"", 2012, COLD SPRING HARBOR LABORATORY PRESS;;KOHLERMILSTEIN: ""Eur. J. Immunol."", vol. 6, 1976, pages: 511;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323;;BIRD, SCIENCE, vol. 242, 1988, pages 423 - 42;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;WARD ET AL., NATURE, vol. 334, 1989, pages 544 - 54;;TOMLINSON I.HOLLIGER P., METHODS ENZYMOL, vol. 326, 2000, pages 461 - 479;;HOLLIGER P., NAT. BIOTECHNOL., vol. 23, no. 9, September 2005 (2005-09-01), pages 1126 - 36;;BODANSZKY, M.: ""Principles of Peptide Synthesis"", 1984, SPRINGER-VERLAG;;""Fmoc Solid Phase Peptide Synthesis: A Practical Approach"", 2000, OXFORD UNIVERSITY PRESS;;N.L. BENOITON: ""Chemistry of Peptide Synthesis"", 2005, CRC PRESS;;J. JONES: ""Amino Acid and Peptide Synthesis"", 2002, OXFORD UNIVERSITY PRESS;;P. LLOYD-WILLIAMSF. ALBERICIOE. GIRALT: ""Chemical Approaches to the synthesis of peptides and proteins"", 1997, CRC PRESS;;GRAHAM ET AL., VIROLOGY, vol. 52, 1973, pages 456;;OSTROCULLIS, AM. J. HOSP. PHARM., vol. 456, 1989, pages 1567 - 1587;;DAVIS ET AL.: ""Basic Methods in Molecular Biology"", 1986, ELSEVIER;;CHU ET AL., GENE, vol. 13, 1981, pages 197;;GABIZON ET AL., CANCER RESEARCH, vol. 42, 1982, pages 4734;;CAFISO, BIOCHEM BIOPHYS ACTA, vol. 649, 1981, pages 129;;SZOKA, ANN REV BIOPHYS ENG, vol. 9, 1980, pages 467;;DEAMERUSER: ""Liposomes"", 1983, MARCEL DEKKEV, INC., article ""Liposome Preparation: Methods and Mechanisms"";;JULIANO: ""Interactions of Proteins and Drugs with Liposomes"", LIPOSOMES;;JANKOWSKY ET AL., BIOMOL ENG, vol. 17, 2001, pages 157 - 65;;JANKOWSKY ET AL., HUM MOL GENET, vol. 13, 2004, pages 159 - 70;;KORONYO ET AL., BRAIN: A JOURNAL OF NEUROLOGY, vol. 138, 2015, pages 2399 - 2422;;See also references of EP 3458036A4",PENDING
245,US,A1,US 2017/0367583 A1,092-777-496-912-37X,2017-12-28,2017,US 201715683277 A,2017-08-22,US 201715683277 A;;US 2016/0059054 W;;US 201562248934 P,2015-10-30,METHODS AND SYSTEMS FOR PERFORMING TISSUE CLASSIFICATION USING MULTI-CHANNEL TR-LIFS AND MULTIVARIATE ANALYSIS,"Described herein are methods and systems for analyzing a sample by applying time resolved laser induced fluorescence spectroscopy to the sample to measure lifetime time decay profile data relating to the sample, and applying multivariate analysis to process the data so as to classify a sample as, for example, normal or abnormal. The sample may be cells, fluid or tissue from any organ. The sample may be in vitro or in vivo. The data may be obtained in situ or in vitro.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;BAKER MICHAEL;;JONES HOWLAND;;BUTTE PRAMOD,,https://lens.org/092-777-496-912-37X,Patent Application,yes,0,151,4,4,0,A61B5/00;;A61B5/0075;;G01N2201/129;;A61B10/02;;G01N21/6402;;G01N21/6408;;A61B5/00;;G01N2201/129;;A61B5/0075;;G06F18/24;;A61B5/0071;;A61B5/0091;;A61B5/08;;A61B5/4064;;A61B5/4255;;A61B5/441;;A61B5/7267;;A61B10/02;;A61B2576/026;;G01N21/6402;;G01N21/6408;;G01N2201/06113;;G06T7/0012;;G06T2207/10064;;G06T2207/30016;;G06T2207/30028;;G06T2207/30061;;G06T2207/30068;;G06T2207/30088,A61B5/00;;A61B5/08;;A61B10/02;;G01N21/64;;G06K9/62;;G06T7/00,,0,0,,,,DISCONTINUED
246,US,A1,US 2009/0297809 A1,184-230-998-856-490,2009-12-03,2009,US 12941508 A,2008-05-29,US 12941508 A,2008-05-29,DRYER SHEETS INCLUDING BICOMPONENT FIBERS,"A dryer sheet substrate is provided having improved loft and reduced fuzz wherein the substrate comprises relatively low denier bicomponent fibers. The bicomponent fibers may comprise two or more polymers having different melting temperatures, with the relatively lower melting temperature polymer making up at least a portion of the outer surface of the fiber. Upon heating to a sufficient temperature, the lower melting temperature fibers may soften and melt, providing bonding at crossover points of the fibers in the laid web. The web indicates advantageous characteristics with respect to thickness (loft), fuzz factor and ability to absorb a fabric treating composition.",FREUDENBERG NONWOVENS L P,BLACK SAMUEL KEITH;;ZAPLETALOVA TEREZIE;;MCNABB JOHN;;STINE JEFFREY,FREUDENBERG SPUNWEB COMPANY (2008-08-19),https://lens.org/184-230-998-856-490,Patent Application,yes,16,2,3,3,0,C11D17/047;;C11D17/047;;D01F8/14;;D01F8/14;;D04H1/54;;D04H1/54;;D06F58/203;;D06F58/203;;Y10T442/20;;Y10T442/20;;Y10T442/2861;;Y10T442/2861;;Y10T442/637;;Y10T442/637;;Y10T442/638;;Y10T442/638;;Y10T442/64;;Y10T442/64;;Y10T442/641;;Y10T442/641,B32B27/02;;B29C67/24,428/220;;264/123,0,0,,,,INACTIVE
247,US,B2,US 7547511 B2,137-956-095-156-301,2009-06-16,2009,US 57074704 A,2004-09-13,US 57074704 A;;US 50272903 P;;US 2004/0029956 W,2003-09-12,Antisense inhibition of laminin-8 expression to inhibit human gliomas,"Using gene array technology, we observed that an increase of the α4 chain-containing Laminin-8 correlated with poor prognosis for patients with brain gliomas. We established that inhibition of Laminin-8 expression by a new generation of highly specific and stable antisense oligonucleotides (Morpholino™) against chains of Laminin-8 could slow or stop the spread of glioma. This was demonstrated in an in vitro model using human glioblastoma multiforme cell lines M059K and U-87MG co-cultured with normal human brain microvascular endothelial cells (HBMVEC). Using Western blot analysis and immunohistochemistry, we con-firmed that antisense treatment effectively blocked laminin-8 protein synthesis. Antisense oligonucleotides against both α4 and β1 chains of laminin-8 blocked significantly the invasion of co-cultures through Matrigel. The results show that Laminin-8 may not only contribute to glioma progression and recurrence as part of the neovascularization process but also by directly increasing the invasive potential of tumor cells.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2005-05-05),https://lens.org/137-956-095-156-301,Granted Patent,yes,1,2,10,10,4,A61K31/00;;A61K31/07;;A61K31/7088;;C12N15/113;;C12N2310/11;;C12N2310/3233;;A61P35/00;;A61P43/00;;A61K31/07;;A61K31/00;;C12N15/113;;A61K31/7088;;C12N2310/3233;;C12N2310/11,C12Q1/68;;A01N43/04;;A61K31/00;;A61K31/07;;A61K31/7088;;C07H21/02;;C07H21/04;;C12N/;;C12N15/113;;C12P19/34,435/6;;435/91.1;;435/325;;435/375;;536/23.1;;536/24.3;;536/24.33;;536/24.5,53,50,084-804-379-761-825;;071-446-219-522-092;;122-990-056-888-627;;027-518-915-267-472;;061-454-537-963-94X;;002-057-097-140-560;;015-845-411-216-05X;;001-280-492-710-987;;036-550-119-702-468;;085-389-958-075-222;;021-138-842-966-383;;101-523-476-724-00X;;143-247-059-865-683;;002-410-830-739-846;;122-563-304-750-445;;065-513-307-731-185;;031-009-176-924-174;;081-535-546-606-522;;048-551-084-856-415;;069-764-206-551-021;;041-096-604-932-631;;100-392-131-292-623;;145-523-027-249-174;;132-372-225-925-009;;016-130-071-571-991;;094-717-970-788-379;;040-861-043-363-027;;033-337-348-972-822;;016-276-524-241-605;;016-795-130-437-95X;;070-217-550-786-105;;092-704-236-824-35X;;004-329-899-218-795;;067-176-202-940-165;;050-185-841-748-492;;019-068-052-192-616;;058-546-248-134-723;;121-705-764-271-79X;;053-130-150-863-097;;074-117-757-519-423;;053-390-613-704-481;;007-736-347-486-414;;120-057-020-523-828;;012-529-188-555-935;;125-704-838-833-312;;022-962-759-811-219;;091-843-097-683-406;;005-068-515-810-831;;043-263-823-749-982;;021-383-028-538-332,14578463;;pmc3487708;;17109197;;10.1007/s10456-006-9046-9;;10.1017/cbo9780511546402.025;;10.1017/cbo9780511546402.030;;10.1038/sj.gt.3302507;;15759014;;10652480;;10.1016/s1357-4310(99)01638-x;;8622906;;pmc39574;;10.1073/pnas.93.8.3161;;11454714;;10.1002/(sici)1098-2388(199801/02)14:1<3::aid-ssu2>3.0.co;2-f;;9407626;;10554005;;10.1083/jcb.137.3.685;;9151674;;pmc2139892;;10.1002/(sici)1097-0177(200006)218:2<213::aid-dvdy1>3.0.co;2-r;;10842354;;12083850;;10.1016/s1044-579x(02)00023-8;;10.1002/1097-0029(20001101)51:3<280::aid-jemt7>3.0.co;2-o;;11054877;;10658911;;10.1038/modpathol.3880010;;10.1083/jcb.153.5.933;;pmc2174323;;11381080;;pmc134646;;11809810;;10.1128/mcb.22.4.1194-1202.2002;;10.1074/jbc.m010155200;;11278628;;12454288;;pmc138567;;10.1073/pnas.252649399;;10807948;;10.1016/s0006-2952(00)00310-5;;10.1083/jcb.200302126;;12741393;;pmc2172901;;10.1083/jcb.jcb.200302126;;10.1177/002215540205000813;;12133914;;7723285;;2438036;;2937447;;10.1021/bi00350a005;;2072663;;6501412;;pmc2113570;;10.1083/jcb.99.6.2034;;10.1002/ijc.10233;;11920587;;11813879;;10.14670/hh-17.301;;10506168;;10.1074/jbc.274.41.29130;;10845554;;10.1023/a:1006760632766;;10066093;;10.1023/a:1006150506789;;10.1023/a:1014573204062;;11964076;;11156378;;10.1016/s0076-6879(01)40429-0;;11494857;;12489851;;9212909;;10.1089/oli.1.1997.7.187;;10.1073/pnas.97.17.9591;;pmc16909;;10944225;;9325016;;10.1006/cyto.1997.0212;;10688605;;11751392;;11223987;;10.1038/sj.gt.3301327;;10.1200/jco.2001.19.8.2189;;11304771;;10.1016/s0140-6736(00)03207-4;;11095261;;11106372;;10.1073/pnas.250332397;;pmc18983;;10991985;;10.1002/(sici)1097-0215(19980316)75:6<864::aid-ijc8>3.0.co;2-t;;9506531;;pmc102580;;10648777;;10.1093/nar/28.4.868;;10.1016/s0006-291x(02)02642-6;;12445830;;10.1016/s1359-6349(04)80616-5,"Khazenzon et al. Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro. Molecular Cancer Therapeutics, 2003 vol. 2:985-994.;;Fujita et al. Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis. Angiogenesis, 2006 vol. 9:183-191.;;Lu et al. (2005). Deliverying siRNA in vivo for functional genomics and novel therapeutics. From RNA Interference Technology (Cambridge, Appasani, ed., pp. 303-317).;;Samarsky et al. (2005). RNAi in drug development: Practical considerations. From RNA Interference Technology (Cambridge, Appasani, ed., pp. 384-395).;;Nielsen, PE. Systemic delivery. The last hurdle? Gene Therapy, 2005 vol. 12:956-957.;;Agrawal et al. Antisense therapeutics: is it as simple as complementary base recognition? Molecule Medicine Today, Feb. 2000 vol. 6:72-81.;;Gewirtz et al. Facilitating oligonucleotide delivery: helping antisense delivery on its promise. Proc. Natl. Acad. Sci., 1996 vol. 93:3161-3163.;;Ljubimova et al., Gene Array Analysis Of Differentially Expressed Genes In Human Glial Tumors. International Journal of Oncology, (2001), pp. 287-295, 18.;;Ljubimova et al., Overexpression Of a4 Chain-Containing Laminins In Human Glial Tumors Identified By Gene Microarray Analysis, Cancer Research (Jul. 15, 2001), pp. 5601-5610, 61(14).;;Sehgal, A., Molecular Changes During The Genesis Of Human Gliomas, Seminars In Surgical Oncology, (Jan.-Feb. 1998), pp. 3-12, 14(1).;;Lal et al., A Public Database For Gene Expression In Human Cancers. Cancer Research, (Nov. 1, 1999), pp. 5403-5407, 59(21).;;Miner et al., The Laminin Alpha Chains: Expression, Developmental Transitions, and Chromosomal Locations Of A1-5, Identification Of Heterotrimeric Laminins 8-11, and Cloning Of A Novel a3 Isoform, Journal of Cell Biology, (May 5, 1997), pp. 685-701, 137(3).;;Colognato et al., Form And Function: The Laminin Family Of Heterotrimers, Developmental Dynamics, (Jun. 2000), pp. 213-234, 218(2).;;Patarroyo et al., Laminin Isoforms In Tumor Invasion, Angiogenesis And Metastasis, Seminars . Seminars In Cancer Biology, (Jun. 2002), pp. 197-207, 12(3).;;Belkin et al., Integrins As Receptors For Laminins, Microscopy Research and Technique, (Nov. 1, 2000), pp. 280-301, 51(3).;;Kulla et al., Tenascin Expression Patterns and Cells Of Monocyte Lineage: Relationship In Human Gliomas, Modern Pathology, (Jan. 2000), pp. 56-67, 13(1).;;Sixt et al., Endothelial Cell Laminin Isoforms, Laminins 8 And 10, Play Decisive Roles In T Cell Recruitment Across The Blood-Brain Barrier In Experimental Autoimmune Encephalomyelitis Journal of Cell Biology, (May 28, 2001), pp. 933-946, 153(5).;;Thyboll et al., Deletion Of The Laminin a4 Chain Leads To Impaired Microvessel Maturation, Molecular and Cellular Biology, (Feb. 2002), pp. 1194-1202, 22(4).;;Fujiwara et al., Purification And Characterization Of Human Laminin-8. Laminin-8 Stimulates Cell Adhesion And Migration Through a3beta1 and a6p, Integrins, Journal of Biological Chemistry, (May 18, 2001), pp. 17550-17558, 276(20).;;Gonzalez et al., Complex Interactions Between The Laminin a4 Subunit And Integrins Regulate Endothelial Cell Behavior In Vitro And Angiogenesis In Vivo, Proceedings of the National Academy of Sciences USA, (Dec. 10, 2002), pp. 16075-16080, 99(25).;;Astriab-Fisher et al., Antisense Inhibition Of P- Glycoprotein Expression Using Peptide-Oligonucleotide Conjugates, Biochemical Pharmacology (Jul. 1, 2000), pp. 83-90, 60(1).;;McKean et al., FAK induces Expression Of Prx1 To Promote Tenascin-C-Dependent Fibroblast Migration, Journal Of Cell Biology, (Apr. 28, 2003), pp. 393-402, 161(2).;;Petajaniemi et al., Localization Of Laminin a4-Chain In Developing And Adult Human Tissues, The Journal Of Histochemistry and Cytochemistry, (Aug. 2002), pp. 1113-1130, 50(8).;;Ljubimov et al., Human Corneal Basement Membrane Heterogeneity: Topographical Differences In The Expression Of Type IV Collagen And Laminin Isoforms, Lab Investigation, (Apr. 1995), pp. 461-473, 72(4).;;Albini et al., A Rapid In Vitro Assay For Quantitating The Invasive Potential Of Tumor Cells, Cancer Research, (Jun. 15, 1987), pp. 3239-3245, 47(12).;;Kleinman et al., Basement Membrane Complexes With Biological Activity, Biochemistry, (Jan. 28, 1986), pp. 312-318, 25(2).;;Minakawa et al., In Vitro Interaction Of Astrocytes And Pericytes With Capillary-Like Structures Of Brain Microvessel Endothelium, Lab Investigation, (Jul. 1991), pp. 32-40, 65(1).;;Voyta et al., Identification And Isolation Of Endothelial Cells Based On Their Increased Uptake Of Acetylated-Low Density Lipoprotein, Journal Of Cell Biology, (Dec. 1984), pp. 2034-2040, 99(6).;;Herold-Mende et al., Clinical Impact And Functional Aspects Of Tenascin-C Expression During Glioma Progression, International Journal Of Cancer, (Mar. 20, 2002), pp. 362-369, 98(3).;;Zagzag et al., Angiogenesis In The Central Nervous System: A Role For Vascular Endothelial Growth Factor/Vascular Permeability Factor and Tenascin-C. Common Molecular Effectors In Cerebral Neoplastic And Non-Neoplastic ""Angiogenic Diseases"", Histol Histopathol, 17: 301-321, 2002.;;Qin et al., The Transcription Factors Sp1, Sp3, and AP-2 Are Required For Constitutive Matrix Metalloproteinase-2 Gene Expression In Astroglioma Cells, Journal Of Biological Chemistry, (Oct. 8, 1999), pp. 29130-29137, 274(41).;;Kachra et al., Expression Of Matrix Metalloproteinases And Their Inhibitors In Human Brain Tumors, Clinical and Experimental Metastasis, (1999), pp. 555-566, 17(7).;;MacDonald et al., Urokinase Induces Receptor Mediated Brain Tumor Cell Migration And Invasion, Journal Of Neuro-Oncology, (Dec. 1998), pp. 215-226, 40(3).;;Tsuj et al., Regulation Of Melanoma Cell Migration And Invasion By Laminin-5 And a3beta1 Integrin (VLA-3), Clinical and Experimental Metastasis, (2002), pp. 127-134, 19(2).;;Kondraganti et al., Selective Suppression Of Matrix Metalloproteinase-9 In Human Glioblastoma Cells By Antisense Gene Transfer Impairs Glioblastoma Cell Invasion, Cancer Research, (Dec. 15, 2000), pp. 6851-6855, 60(24).;;Nielsen et al., Peptide Nucleic Acid Targeting Of Double-Stranded DNA. Methods In Enzymology, 2001, pp. 329-340, 340.;;Dias et al., Antisense Oligonucleotides : Basic Concepts and Mechanisms, Molecular Cancer Therapy, (Mar. 2002), pp. 347-355, 1(5).;;Summerton et al., Morpholino Antisense Oligomers: Design, Preparation And Properties, Antisense And Nucleic Acid Drug Development, (Jun. 1997) pp. 187-195, 7(3).;;Lacerra et al., Restoration Of Hemoglobin A Synthesis In Erythroid Cells From Peripheral Blood Of Thalassemic Patients, Proceedings of the National Academy Of Sciences USA, (Aug. 15, 2000), pp. 9591-9596, 97(17).;;Taylor et al., Comparison Of Efficacy Of Antisense Oligomers Directed Toward TNF-a In Helper T And Macrophage Cell Lines, Cytokine, (Sep. 1997), pp. 672-681, 9(9).;;Arora et al., c- Myc Antisense Limits Rat Liver Regeneration And Indicates Role For c-myc In Regulating Cytochrome P-450 3A Activity, Journal of Pharmacology And Experimental Therapeutics, (Mar. 2000), pp. 921-928, 292(3).;;Bello et al., Simultaneous Inhibition Of Glioma Angiogenesis, Cell Proliferation, And Invasion By A Naturally Occurring Fragment Of Human Metalloproteinase-2, Cancer Research, (Dec. 15, 2001), pp. 8730-8736, 61(24).;;Komata et al., Combination Therapy Of Malignant Glioma Cells With 2-5A-Antisense Telomerase RNA and Recombinant Adenovirus p53, Gene Therapy, (Dec. 2000), pp. 2071-2079, 7(24).;;Andrews et al., Results Of A Pilot Study Involving The Use Of An Antisense Oligodeoxynucleotide Directed Against The Insulin-Like Growth Factor Type I Receptor In Malignant Astrocytomas, Journal of Clinical Oncology, (Apr. 15, 2001), pp. 2189-2200, 19(8).;;Jansen et al., Chemosensitisation Of Malignant Melanoma By BCL2 Antisense Therapy, Lancet, (Nov. 18, 2000), pp. 1728-1733, 356(9243).;;Shi et al., Antisense Imaging Of Gene Expression In The Brain In Vivo, Proceeding of National Academy of Sciences USA, (Dec. 19, 2000), pp. 14709-14714, 97(26).;;Boado et al., Antisense-Mediated Down-Regulation Of The Human Huntingtin Gene, Journal of Pharmacology and Experimental Therapy, (Oct. 2000), pp. 239-243, 295(1).;;Knott et al., Stimulation Of Extracellular Matrix Components In The Normal Brain By Invading Glioma Cells, International Journal Of Cancer, (Mar. 16, 1998), pp. 864-872, 75(6).;;De Diesbach et al., Identification, Purification and Partial Characterisation Of An Oligonucleotide Receptor In Membranes Of HepG2 Cells, Nucleic Acids Research, (Feb. 15, 2000), pp. 868-874, 28(4).;;Hayashi et al., Identification And Recombinant Production Of Human Laminin a4 Subunit Splice Variants, Biochemical and Biophysical Research Communications, (Dec. 6, 2002), pp. 498-504, 299(3).;;Khazenzon, A.J. et al., Novel angiogenic targets for human glioma prevention and regulation of their expression, International Journal of Molecular Medicine, 2002, 10:Supplement 1, p. S41, XP008091390.;;Ljubimova, J.Y. et al., A new multifunctional drug delivery system based on polymalic acid to inhibit angiogenesis and invasion of human gliomas in vitro and in vivo, European Journal of Cancer, Supplement, 2004, 2:8, p. 184, XP004640052.;;Ljubimova, J.Y. et al., Development of an vitro system to block the angiogenic target, laminin-8, in human gliomas, Proceedings of the American Association for Cancer Research Annual Meeting, Mar. 2002, vol. 43, p. 177, XP001536931.",INACTIVE
248,EP,A2,EP 1356294 A2,170-524-013-263-929,2003-10-29,2003,EP 01994441 A,2001-12-19,US 0150292 W;;US 74155000 A,2000-12-19,LAMININ ALPHA 4 SUBUNIT AS A DIAGNOSTIC INDICATOR OF MALIGNANT TUMORS,,CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,"ARROGENE, INC. (2003-12-10)",https://lens.org/170-524-013-263-929,Patent Application,yes,0,0,9,9,0,C12Q1/6886;;C12Q2600/158;;G01N33/574;;G01N33/57488;;G01N2333/47;;G01N2800/52;;G01N33/574;;G01N2333/47;;G01N2800/52;;C12Q2600/158;;C12Q1/6886;;G01N33/57488,C12Q1/68;;G01N33/574,,0,0,,,,DISCONTINUED
249,US,S,US D0593172 S,028-599-578-738-782,2009-05-26,2009,US 30745808 F,2008-04-22,US 30745808 F,2008-04-22,Golf grip,,EATON CORP,GILL DAVID KEITH;;BLACK RICHARD ANDREW;;WOOD BILLY DEE,EATON INTELLIGENT POWER LIMITED (2017-12-31);;EATON CORPORATION (2008-04-14),https://lens.org/028-599-578-738-782,Design Right,no,0,5,3,3,0,,,2102;;D21/756,0,0,,,,EXPIRED
250,WO,A1,WO 2023/104374 A1,045-723-782-138-719,2023-06-15,2023,EP 2022078461 W,2022-10-13,EP 21212717 A,2021-12-07,METHOD FOR MAKING A NONWOVEN MATERIAL WITH REDUCED QUATERNARY AMMONIUM AFFINITY,"The invention relates to a method to apply chemistry to nonwovens comprising cellulosic fibers to prevent quaternary ammonium disinfectant binding to the fibers. The invention further relates to nonwovens treated via such method and the improved quaternary ammonium release of the nonwoven, and its use in disinfectant wipes.",FIBERTEX NONWOVENS AS,BLACK SAMUEL KEITH;;TEIXEIRA LUIS;;LAYER JONATHAN;;NICHOLSON JIMMY,,https://lens.org/045-723-782-138-719,Patent Application,yes,5,0,1,1,0,D04H1/425;;D04H1/4258;;D04H1/492;;D04H1/74;;A47L13/17;;A01P1/00;;A01N33/12,D04H1/425;;A01N25/34;;A47L13/17;;A61K8/02;;D04H1/4258;;D04H1/492;;D04H1/74,,0,0,,,,PENDING
251,US,A1,US 2021/0290670 A1,066-241-301-084-124,2021-09-23,2021,US 202117338305 A,2021-06-03,US 202117338305 A;;US 201816303053 A;;US 2017/0033875 W;;US 201662339681 P,2016-05-20,METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE AND ASSOCIATED CONDITIONS,"The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;RENTSENDORJ ALTANCHIMEG;;KORONYO YOSEF;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2017-05-23),https://lens.org/066-241-301-084-124,Patent Application,yes,0,0,13,13,0,A61K38/02;;A61K38/19;;A61P25/28;;A61K45/06;;A61K39/4614;;A61K2239/31;;A61K39/4622;;A61K39/46433;;A61K2239/38;;A61K39/4621;;A61P25/28;;A61K38/07;;A61K2239/31;;A61K39/4622;;A61K2239/38;;A61K39/4621;;A61K39/4614;;A61K39/46433;;A61P25/28;;A61K31/7088;;A61K35/15;;A61K38/02;;A61K38/18;;A61K38/19,A61K35/15;;A61K31/7088;;A61K38/02;;A61K38/18;;A61K38/19;;A61P25/28,,2,2,010-932-791-325-445;;009-434-522-525-062,20308780;;10.3233/jad-2010-1309;;10.1093/brain/awv150;;pmc4840949;;26049087,"Comi et al., Journal of Alzheimer’s Disease 19 (2010) 1143–1148. (Year: 2010);;Koronyo et al., Brain (2015) 138; 2399–2422. (Year: 2015)",ACTIVE
252,CA,A1,CA 2664077 A1,139-278-772-563-768,2009-11-29,2009,CA 2664077 A,2009-04-24,US 12941508 A,2008-05-29,DRYER SHEETS INCLUDING BICOMPONENT FIBERS,"A dryer sheet substrate is provided having improved loft and reduced fuzz wherein the substrate comprises relatively low denier bicomponent fibers. Th e bicomponent fibers may comprise two or more polymers having different meltin g temperatures, with the relatively lower melting temperature polymer making u p at least a portion of the outer surface of the fiber. Upon heating to a sufficient temperature, the lower melting temperature fibers may soften and melt, providing bonding at crossover points of the fibers in the laid web. The web indicates advantageous characteristics with respect to thickness (loft), fuzz factor a nd ability to absorb a fabric treating composition.",FREUDENBERG SPUNWEB CO,STINE JEFFREY;;MCNABB JOHN;;ZAPLETALOVA TEREZIE;;BLACK SAMUEL KEITH,,https://lens.org/139-278-772-563-768,Patent Application,no,0,0,3,3,0,C11D17/047;;C11D17/047;;D01F8/14;;D01F8/14;;D04H1/54;;D04H1/54;;D06F58/203;;D06F58/203;;Y10T442/20;;Y10T442/20;;Y10T442/2861;;Y10T442/2861;;Y10T442/637;;Y10T442/637;;Y10T442/638;;Y10T442/638;;Y10T442/64;;Y10T442/64;;Y10T442/641;;Y10T442/641,D04H1/42;;D06M13/00,,0,0,,,,DISCONTINUED
253,US,A,US 3313183 A,142-006-309-052-826,1967-04-11,1967,US 36446564 A,1964-05-04,US 36446564 A,1964-05-04,Transmission,,GEN MOTORS CORP,BAILEY KEITH A;;BLACK ROBERT L;;FISHER MARK E,,https://lens.org/142-006-309-052-826,Granted Patent,no,11,12,2,2,0,F16H47/08;;F16H61/16;;F16H61/686;;F16H61/705;;F16H2061/0425;;F16H2306/20;;F16H2306/44;;F16H2306/52;;Y10S74/01;;F16H61/705;;F16H61/686;;F16H2306/52;;F16H61/16;;F16H2061/0425;;F16H2306/20;;F16H47/08;;F16H2306/44;;Y10S74/01,F16H47/08;;F16H61/16;;F16H61/70,,0,0,,,,EXPIRED
254,US,B2,US 7838449 B2,144-093-345-437-986,2010-11-23,2010,US 12941508 A,2008-05-29,US 12941508 A,2008-05-29,Dryer sheets including bicomponent fibers,"A dryer sheet substrate is provided having improved loft and reduced fuzz wherein the substrate comprises relatively low denier bicomponent fibers. The bicomponent fibers may comprise two or more polymers having different melting temperatures, with the relatively lower melting temperature polymer making up at least a portion of the outer surface of the fiber. Upon heating to a sufficient temperature, the lower melting temperature fibers may soften and melt, providing bonding at crossover points of the fibers in the laid web. The web indicates advantageous characteristics with respect to thickness (loft), fuzz factor and ability to absorb a fabric treating composition.",FREUDENBERG SPUNWEB CO,BLACK SAMUEL KEITH;;ZAPLETALOVA TEREZIE;;MCNABB JOHN;;STINE JEFFREY,FREUDENBERG SPUNWEB COMPANY (2008-08-19),https://lens.org/144-093-345-437-986,Granted Patent,yes,16,2,3,3,0,C11D17/047;;C11D17/047;;D01F8/14;;D01F8/14;;D04H1/54;;D04H1/54;;D06F58/203;;D06F58/203;;Y10T442/20;;Y10T442/20;;Y10T442/2861;;Y10T442/2861;;Y10T442/637;;Y10T442/637;;Y10T442/638;;Y10T442/638;;Y10T442/64;;Y10T442/64;;Y10T442/641;;Y10T442/641,D04H1/00;;D04H3/00;;D04H13/00,442/361;;442/362;;442/363;;442/364;;442/59;;442/164;;264/123,0,0,,,,INACTIVE
255,US,S,US D0602104 S,024-450-700-089-077,2009-10-13,2009,US 31273008 F,2008-11-11,US 31273008 F,2008-11-11,Golf grip,,EATON CORP,BLACK RICHARD ANDREW;;WOOD BILLY DEE;;GILL DAVID KEITH,EATON INTELLIGENT POWER LIMITED (2017-12-31);;EATON CORPORATION (2008-11-04),https://lens.org/024-450-700-089-077,Design Right,no,0,3,3,3,0,,,2102;;D21/756,0,0,,,,EXPIRED
256,EP,A4,EP 1660685 A4,090-853-670-848-115,2008-07-02,2008,EP 04783972 A,2004-09-13,US 2004/0029956 W;;US 50272903 P,2003-09-12,ANTISENSE INHIBITION OF LAMININ-8 EXPRESSION TO INHIBIT HUMAN GLIOMAS,,CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2007-04-11),https://lens.org/090-853-670-848-115,Search Report,no,1,0,10,10,0,A61K31/00;;A61K31/07;;A61K31/7088;;C12N15/113;;C12N2310/11;;C12N2310/3233;;A61P35/00;;A61P43/00;;A61K31/07;;A61K31/00;;C12N15/113;;A61K31/7088;;C12N2310/3233;;C12N2310/11,C12Q1/68;;A01N43/04;;A61K31/00;;A61K31/07;;A61K31/7088;;C07H21/04;;C12N/;;C12N15/113,,5,3,001-280-492-710-987;;058-546-248-134-723;;021-383-028-538-332,11454714;;9212909;;10.1089/oli.1.1997.7.187;;10.1016/s1359-6349(04)80616-5,"LJUBIMOVA J Y ET AL: ""Development of an in vitro system to block the angiogenic target, laminin-8, in human gliomas"", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), pages 177, XP001536931, ISSN: 0197-016X;;KHAZENZON ET AL: ""Novel angiogenic targets for human glioma prevention and regulation of their expression"", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 10, no. Supplement 1, 2002, pages S41, XP008091390, ISSN: 1107-3756;;LJUBIMOVA JULIA Y ET AL: ""Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis"", CANCER RESEARCH, vol. 61, no. 14, 15 July 2001 (2001-07-15), pages 5601 - 5610, XP002231538, ISSN: 0008-5472;;SUMMERTON ET AL: ""Morpholino antisense oligomers: design, preparation, and properties"", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, vol. 7, 1997, pages 187 - 195, XP002136176, ISSN: 1087-2906;;LJUBIMOVA J Y ET AL: ""A new multifunctional drug delivery system based on polymalic acid to inhibit angiogenesis and invasion of human gliomas in vitro and in vivo"", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, vol. 2, no. 8, 1 September 2004 (2004-09-01), pages 184, XP004640052, ISSN: 1359-6349",DISCONTINUED
257,US,S,US D0603921 S,199-711-678-127-805,2009-11-10,2009,US 31324308 F,2008-12-18,US 31324308 F,2008-12-18,Golf grip,,EATON CORP,GILL DAVID KEITH;;BLACK RICHARD ANDREW;;WOOD BILLY DEE,EATON INTELLIGENT POWER LIMITED (2017-12-31);;EATON CORPORATION (2008-12-17),https://lens.org/199-711-678-127-805,Design Right,no,0,4,3,3,0,,,2102;;D21/756,0,0,,,,EXPIRED
258,US,B2,US 11779600 B2,031-544-749-159-882,2023-10-10,2023,US 202117338305 A,2021-06-03,US 202117338305 A;;US 201816303053 A;;US 2017/0033875 W;;US 201662339681 P,2016-05-20,Methods of treating or preventing alzheimer's disease and associated conditions,"The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.",CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;RENTSENDORJ ALTANCHIMEG;;KORONYO YOSEF;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2017-05-23),https://lens.org/031-544-749-159-882,Granted Patent,yes,12,0,13,13,0,A61K38/02;;A61K38/19;;A61P25/28;;A61K45/06;;A61K39/4614;;A61K2239/31;;A61K39/4622;;A61K39/46433;;A61K2239/38;;A61K39/4621;;A61P25/28;;A61K38/07;;A61K2239/31;;A61K39/4622;;A61K2239/38;;A61K39/4621;;A61K39/4614;;A61K39/46433;;A61P25/28;;A61K31/7088;;A61K35/15;;A61K38/02;;A61K38/18;;A61K38/19,A61K35/15;;A61K31/7088;;A61K38/02;;A61K38/18;;A61K38/19;;A61P25/28,,39,28,010-932-791-325-445;;009-434-522-525-062;;090-580-721-037-400;;066-841-655-291-162;;024-063-822-747-605;;020-235-958-756-618;;009-261-837-573-736;;010-932-791-325-445;;022-532-689-654-325;;098-956-497-141-046;;077-532-829-551-519;;002-264-966-090-625;;070-959-113-690-925;;034-356-721-676-31X;;064-187-018-698-676;;009-434-522-525-062;;030-030-967-774-985;;117-800-300-773-071;;035-438-499-631-238;;099-168-892-040-738;;042-204-626-457-327;;004-668-378-850-361;;019-817-021-691-872;;001-400-252-595-282;;070-006-688-796-584;;074-817-300-512-106;;133-677-711-787-450;;031-942-232-153-449,20308780;;10.3233/jad-2010-1309;;10.1093/brain/awv150;;pmc4840949;;26049087;;23141166;;10.1016/j.jneuroim.2012.10.003;;10.1126/science.1494-b;;10.1126/science.242.4885.1494-b;;23565338;;pmc3616337;;10.2478/s13380-012-0028-7;;10.1073/pnas.0604681103;;16864778;;pmc1544247;;25151457;;pmc4262258;;10.1016/j.expneurol.2014.08.015;;20308780;;10.3233/jad-2010-1309;;7127308;;10.1002/glia.22885;;26148976;;10.1038/nbt1142;;16151406;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;10.1016/s1389-0344(01)00067-3;;11337275;;14645205;;10.1093/hmg/ddh019;;825377;;10.1002/eji.1830060713;;10.1093/brain/awv150;;pmc4840949;;26049087;;12804068;;10.1089/107999003321829971;;10.1016/j.jalz.2016.06.669;;10.1038/sj.jcbfm.9600022;;15678124;;10.1093/ajhp/46.8.1576;;2672806;;3127726;;10.1038/332323a0;;10.1002/ddr.10069;;10.1146/annurev.bb.09.060180.002343;;6994593;;11036658;;10.1016/s0076-6879(00)26070-9;;10.1161/strokeaha.110.608315;;21700938;;10.1038/341544a0;;2677748;;12377945;;10.1189/jlb.72.4.752;;pmc2778587;;19798593;;10.1007/s12079-009-0068-0,"Comi et al., Journal of Alzheimer's Disease 19 (2010) 1143-1148. (Year: 2010).;;Koronyo et al., Brain (2015) 138; 2399-2422. (Year: 2015).;;Begum-Haque et al.: Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORyt responses and by increasing IL-10 production in experimental allergic encephalomyelitis. Journal of Neurommunology. 254:117-124 (2013).;;Bird et al.: Single-chain antigen-binding proteins; Science, 242:423-42, 1988.;;Brown, Amanda: Osteopontin: a Key Link Between Immunity, Inflammation and the Central Nervous System. Translational Neuroscience. 3(3):288-293 (2012).;;Butovsky et al.: Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.;103(31):11784-11789 (2006).;;Cafiso, Biochem Biophys Acta 649:129 (1981).;;Chan et al.: Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury. Experimental Neurology. 261:757-771 (2014).;;Comi et al.: Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive Decline; Journal of Alzheimer's disease: JAD 19:1143-1148 (2010).;;European Patent Application No. 17800340.6 Extended European Search Report dated Dec. 16, 2019.;;Gabizon et al.: Liposomes as in Vivo Carriers of Adriamycin: Reduced Cardiac Uptake and Preserved Antitumor Activity in Mice_ Cancer Research 42, 4734-4739 (1982).;;Gliem et al.: Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. GLIA. 63(12):2198-2207 (2015).;;Greenfield, Antibodies a Laboratory Manual 2nd ed., Cold Spring Harbor Press (Cold Spring Harbor N.Y., 2013).;;Holliger et al.: Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23(9):1126-36 (2005).;;Huston et al. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988.;;Jankowsky et al.: Co-expression of multiple transgenes in mouse CNS: a comparison of strategies; Biomol Eng; 17(16):157-65 (2001).;;Jankowsky et al.: Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase; Hum Mol Genet; 13(2);159-70 (2004).;;Juliano: Interactions of Proteins and Drugs with Liposomes, in Liposomes, Ibid.;;Kohler et al.: Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 6: 511-519 (1976).;;Koronyo et al., Therapeutic effects of glatiramer acetate and grafted CD115+ monocytes in a mouse model of Alzheimer's disease. Brain. 138(Pt 8):2399-2422 (2015).;;Li et al., IFN-gamma induction of osteopontin expression in human monocytoid cells. Journal of Interferon Cytokine Research. 23(5):259-265 (2003).;;Maya et al., Immunomodulatory factor induced by GA mediates macrophage clearance of pathogenic Ab forms and enhances synaptic preservation. Alzheimer's & Dementia: the Journal of the Alzheimer's Association 12(7):P361 (2016).;;Meller et al.: Neuroprotection by osteopontin in stroke. Journal of Cerebral Blood Flow & Metabolism. Nature Publising Group. 25(2):217-225 (2005).;;Ostro et al.: Use of liposomes as injectable-drug delivery systems; Am J. Hosp. Pharm. 46(8):1576-1587 (1989).;;PCT/US2017/033875 International Search Report and Written Opinion dated Aug. 14, 2017.;;Rentsendorj et al.: A novel role for osteopontin in macrophage-mediated amyloid-β clearance in Alzheimer's models. Brain, Behavior, and Immunity 67:163-180 (2017).;;Riechmann et al. Reshaping human antibodies for therapy. Nature, 332.6162:323-7 (1988).;;Sambrook, et al. Molecular Cloning: a Laboratory Manual. 4th Edition, 2012.;;Schwartz et al.: Prospects for Therapeutic Vaccination with Glatiramer Acetate for Neurodegenerative Diseases such as Alzheimer's Disease. Drug Development Research. 56(2):143-149(2002).;;Singleton, Dictionary of Microbiology and Molecular Biology S.sup.rd ed., revised ed., J. Wiley & Sons (New York, N.Y. 2006).;;Smith, March's Advanced Organic Chemistry Reactions, Mechanisms and Structure 7.sup.th ed., J. Wiley & Sons (New York, N.Y. 2013).;;Szoka, Comparative properties and methods of preparation of lipid vesicles (liposomes); Ann Rev Biophys Eng 9:467 (1980).;;Tomlinson et al.: Methods for generating multivalent and bispecific antibody fragments. Methods Enzymol 326:461-479 (2000).;;U.S. Appl. No. 16/303,053 Notice of Allowance dated Mar. 12, 2021.;;U.S. Appl. No. 16/303,053 Office Action dated Sep. 3, 2020.;;Van Velthoven et al.: Osteopontin enhances endogenous repair after neonatal hypoxic-ischemic brain injury. Stroke. 42(8):2294-2301 (2011).;;Ward et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 334:544-54, 1989.;;Weber et al., Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. Journal of Leukocyte Biology. 72:752-761 (2002).;;Lund et al.: The role of osteopontin in inflammatory processes. J. Cell Commun. Signal. 3:311-322 (2009).",ACTIVE
259,WO,A3,WO 2005/028617 A3,067-968-651-557-562,2005-06-30,2005,US 2004/0029956 W,2004-09-13,US 50272903 P,2003-09-12,ANTISENSE INHIBITION OF LAMININ-8 EXPRESSION TO INHIBIT HUMAN GLIOMAS,"Using gene array technology, we observed that an increase of the &agr;4 chain- containing Laminin-8 correlated with poor prognosis for patients with brain gliomas. We established that inhibition of Laminin-8 expression by a new generation of highly specific and stable antisense oligonucleotides (MorpholinoTM) against chains of Laminin-8 could slow or stop the spread of glioma. This was demonstrated in an in vitro model using human glioblastoma multiforme cell lines M059K and U-87MG co-cultured with normal human brain microvascular endothelial cells (HBMVEC). Using Western blot analysis and immunohistochemistry, we confirmed that antisense treatment effectively blocked laminin-8 protein synthesis. Antisense oligonucleotides against both &agr;4 and &szlig;1 chains of laminin-8 blocked significantly the invasion of co-cultures through Matrigel. The results show that Laminin-8 may not only contribute to glioma progression and recurrence as part of the neovascularization process but also by directly increasing the invasive potential of tumor cells.",ARROGENE INC;;LJUBIMOVA JULIA Y;;LJUBIMOVA ALEXANDER V;;BLACK KEITH L,LJUBIMOVA JULIA Y;;LJUBIMOVA ALEXANDER V;;BLACK KEITH L,,https://lens.org/067-968-651-557-562,Search Report,yes,0,0,10,10,0,A61K31/00;;A61K31/07;;A61K31/7088;;C12N15/113;;C12N2310/11;;C12N2310/3233;;A61P35/00;;A61P43/00;;A61K31/07;;A61K31/00;;C12N15/113;;A61K31/7088;;C12N2310/3233;;C12N2310/11,A01N43/04;;A61K31/00;;A61K31/07;;A61K31/7088;;C07H21/04;;C12N/;;C12N15/113;;C12Q1/68,,7,7,031-009-176-924-174;;100-392-131-292-623;;061-340-418-555-884;;120-000-992-286-241;;040-020-176-260-711;;002-057-097-140-560;;084-804-379-761-825,pmc134646;;11809810;;10.1128/mcb.22.4.1194-1202.2002;;10.1177/002215540205000813;;12133914;;9094997;;pmc1858190;;10.1634/stemcells.18-5-307;;11007915;;9538686;;10.1016/s0968-0004(97)01155-9;;10652480;;10.1016/s1357-4310(99)01638-x;;14578463,"THYBOLL ET AL: ""Deletion of the laminin alpha 4 chain leads to improved microvessel maturation"", MOLECULAR AND CELLULAR BIOLOGY, vol. 22, 2002, pages 1194 - 1202, XP002986545;;PETAEJAENIEMI ET AL: ""Localizaation of laminin alpha 4 chin in developing and adult human tissues"", JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 50, 2002, pages 1113 - 1130, XP002986546;;VIRTANEN ET AL: ""Distinct changes in the laminin composition of basement membranes in human seminiferous tubules during development and degeneration"", AM J PATHOL, vol. 150, 1997, pages 1421 - 1431, XP008046636;;JEN ET AL: ""Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies"", STEM CELLS, vol. 18, 2000, pages 307 - 319, XP002948605;;FRANCH A.D. ET AL: ""A good antisense molecule is hard to find"", TIBS, vol. 23, 1998, pages 45 - 50, XP002910466;;AGRAWAL: ""Antisense therapeutics: is it as simple as complementary base recognition?"", MOLECULAR MEDICINE, vol. 61, 2000, pages 72 - 81, XP002952062;;KHAZENZON N.M. ET AL: ""Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro"", MOLECULAR CANCER THERAPEUTICS, vol. 2, no. 10, 2003, pages 985 - 994, XP002986547",PENDING
260,US,B2,US 10921859 B2,078-313-942-207-53X,2021-02-16,2021,US 201815950124 A,2018-04-10,US 201815950124 A;;US 201762483880 P,2017-04-10,Composite electronics cases and methods of making and using the same,"A method of making an electronics enclosure that is light-weight, structurally sound and EMI resistant is provided. Preferably the electronics enclosure is made by covering the walls of a mold for the chassis and the lid with a metallic mesh. At least two plies of carbon prepreg are applied over the metallic mesh. The carbon prepreg and metallic mesh are then cured together at high temperature, typically in an autoclave. The wire mesh becomes integrated into the composite material during the curing process when the carbon material shrinks to the mold and the epoxy bonds with the wire mesh. The molds may then be removed leaving an electronics enclosure with superior properties.",SECURAPLANE TECH INC,MAHONEY BRANDON ROSS;;ALI SARAJIN;;MOXLEY DENNIS KEITH;;DICKERSON ANDREW KEITH;;BLACK THOMAS DAVID,SECURAPLANE TECHNOLOGIES INC (2017-04-11),https://lens.org/078-313-942-207-53X,Granted Patent,yes,37,0,2,2,0,H05K9/0047;;G06F1/182;;G06F1/1656;;H05K5/0204;;H05K9/009;;H05K9/0047;;G06F1/182,G06F1/18;;G06F1/16;;H05K5/02;;H05K9/00,,0,0,,,,ACTIVE
261,US,A1,US 2018/0299928 A1,121-136-876-299-984,2018-10-18,2018,US 201815950124 A,2018-04-10,US 201815950124 A;;US 201762483880 P,2017-04-10,COMPOSITE ELECTRONICS CASES AND METHODS OF MAKING AND USING THE SAME,"A method of making an electronics enclosure that is light-weight, structurally sound and EMI resistant is provided. Preferably the electronics enclosure is made by covering the walls of a mold for the chassis and the lid with a metallic mesh. At least two plies of carbon prepreg are applied over the metallic mesh. The carbon prepreg and metallic mesh are then cured together at high temperature, typically in an autoclave. The wire mesh becomes integrated into the composite material during the curing process when the carbon material shrinks to the mold and the epoxy bonds with the wire mesh. The molds may then be removed leaving an electronics enclosure with superior properties.",SECURAPLANE TECH INC,MAHONEY BRANDON ROSS;;ALI SARAJIN;;MOXLEY DENNIS KEITH;;DICKERSON ANDREW KEITH;;BLACK THOMAS DAVID,SECURAPLANE TECHNOLOGIES INC (2017-04-11),https://lens.org/121-136-876-299-984,Patent Application,yes,37,3,2,2,0,H05K9/0047;;G06F1/182;;G06F1/1656;;H05K5/0204;;H05K9/009;;H05K9/0047;;G06F1/182,H05K5/02;;G06F1/16;;H05K9/00,,0,0,,,,ACTIVE
262,US,B2,US 11630061 B2,169-089-673-044-52X,2023-04-18,2023,US 202016849102 A,2020-04-15,US 202016849102 A;;US 201715475750 A;;US 201662351615 P;;US 201662317443 P;;US 201662317449 P;;US 201662317451 P;;US 201662317452 P;;US 201662317453 P;;US 201662317455 P;;US 201662317456 P;;US 201662317459 P;;US 201662317460 P,2016-04-01,"Systems, devices, and methods for time-resolved fluorescent spectroscopy","Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.",BLACK LIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;BLACK KEITH;;KAVANAUGH JACK;;BORTNIK BARTOSZ;;NIE ZHAOJUN,BLACK LIGHT SURGICAL INC (2017-04-08);;CEDARS-SINAI MEDICAL CENTER (2017-04-05),https://lens.org/169-089-673-044-52X,Granted Patent,yes,119,1,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,G01N21/64;;G01J3/02;;G01J3/10;;G01J3/12;;G01J3/28;;G01J3/32;;G01J3/44,,88,34,066-245-873-080-944;;005-826-360-259-909;;046-432-653-211-12X;;093-376-350-966-243;;002-821-937-985-621;;010-683-647-444-461;;029-175-089-918-86X;;046-674-285-678-042;;068-746-006-048-207;;143-241-023-456-995;;133-681-363-351-539;;022-197-225-411-194;;001-474-920-319-622;;042-668-575-106-425;;003-123-485-999-018;;029-771-925-044-012;;064-187-018-698-676;;092-597-622-022-266;;061-997-807-287-859;;002-290-456-036-804;;016-785-501-476-300;;010-663-060-292-43X;;033-307-632-418-805;;042-204-626-457-327;;046-506-476-636-838;;007-110-015-828-727;;187-714-218-797-689;;018-044-454-204-648;;051-032-387-057-366;;004-851-556-711-934;;108-728-744-630-602;;002-067-858-020-547;;097-446-628-940-029;;075-060-776-388-192,20210432;;10.1117/1.3327279;;pmc2847934;;9172260;;10.1088/0031-9155/42/5/005;;18315362;;10.1117/1.2830658;;10.1117/1.2141624;;16409091;;pmc2981341;;pmc3335732;;10.1016/j.neuroimage.2010.11.001;;21055475;;10.1117/1.3374049;;pmc4171753;;20459282;;10.1007/978-94-007-2019-0_19;;10.1016/j.chemolab.2004.04.003;;19281642;;10.1366/000370209787598843;;10.1016/s0924-2031(01)00199-0;;10.1366/0003702001951228;;10.1201/9781420047806;;14654941;;10.3892/ijo.24.1.59;;25673764;;10.1126/scitranslmed.aaa2384;;10.1117/1.1752919;;15250761;;pmc8527862;;10.1117/12.527787;;825377;;10.1002/eji.1830060713;;pmc4482228;;10.1126/scitranslmed.3010611;;26084803;;pmc4361450;;10.1364/boe.6.000987;;25798320;;10.1562/0031-8655(2000)0710178trfsoa2.0.co2;;10687392;;10.1562/0031-8655(2000)071<0178:trfsoa>2.0.co;2;;15339216;;10.1562/2003-12-09-ra-023.1;;10.1016/s0016-5107(03)02687-7;;14745391;;11783938;;10.1562/0031-8655(2001)074<0817:ivnfma>2.0.co;2;;10.1562/0031-8655(2001)0740817ivnfma2.0.co2;;3127726;;10.1038/332323a0;;10.1117/12.57704;;10.1364/ao.42.002995;;12790450;;10.1002/9781118447567;;10.1364/ol.33.000630;;pmc10522294;;18347733;;19572006;;10.1364/ol.34.002081;;pmc4083182;;10.1021/ac00209a024;;10.1021/ac00087a722;;10.1117/12.2283679;;10.1063/1.4869037;;pmc3971822;;24689603;;10.2741/1878;;pmc2991156;;16368511,"L Marcu, “Fluorescence lifetime in cardiovascular diagnostics,” Feb. 2010, Journal of Biomedical Optics, vol. 15, No. 1, pp. 011106-1 to 011106-10 (Year: 2010).;;J. E. Phipps, “Time-resolved fluorescence techniques for atherosclerotic cardiovascular disease characterization,” 2005, a Ph.D. Dissertation, University of California, Davis. 119 pages. (Year: 2005).;;Allen et al., Remington: The Science and Practice of Pharmacy 22nd ed., Pharmaceutical Press (Sep. 15, 2012).;;Bigio et al. Ultraviolet and visible spectroscopies for tissue diagnostics: fluorescence spectroscopy and elastic-scattering spectroscopy. Physics in Medicine and Biology (1997). 42(5):803-814.;;Blackwell et al. In vivo time-resolved autofluorescence measurements to test for glycation of human skin. Journal of Biomedical Optics (2008). 13(1): 014004.;;Butte, et al. 2005. Diagnosis of meningioma by time-resolved fluorescence spectroscopy. Journal of Biomedical Optics, 10(6), 064026. doi:10.1117/1.2141624.;;Butte, et al. 2010. Fluorescence lifetime spectroscopy for guided therapy of brain tumors. NeuroImage, 54, S125-S135. doi:10.1016/j.neuroimage.2010.11.001.;;Butte, et al. 2010. Intraoperative delineation of primary brain tumors using time-resolved fluorescence spectroscopy. Journal of Biomedical Optics, 15(2), 027008. dol:10.1117/1.3374049.;;Butte, P. et al. Time-Resolved Laser Induced Fluorescence Spectroscopy (TRLIFS): A Tool for Intra-operative Diagnosis of Brain Tumors and Maximizing Extent of Surgical Resection. Tumors of the Central Nervous System, vol. 5 (2012), pp. 161-172.;;Co-pending U.S. Appl. No. 16/100,638, inventors Blackkeith; L. et al., filed Aug. 10, 2018.;;EP16860766.1 European Search Report dated Mar. 6, 2018.;;EP17186617.1 European Search Report dated Feb. 7, 2018.;;EP17776805.8 Extended European Search Report dated Nov. 8, 2019.;;European search report with written opinion dated Dec. 12, 2016 for EP14763125.;;Examination Report dated Aug. 3, 2010 European patent application No. 04781453.8 (filed Aug. 19, 2004), 4 pages.;;Examination Report dated Dec. 15, 2008 for European patent application No. 04781453.8 (filed Aug. 19, 2004), 4 pages.;;Examination Report dated Sep. 11, 2009 European patent application No. 04781453.8 (filed Aug. 19, 2004), 2 pages.;;Examination Report dated Feb. 25, 2009 for Japanese patent application No. 2006-523995 (filed Aug. 19, 2004), 7 pages.;;Examination Report dated Feb. 8, 2010 for Japanese patent application No. 2006-523995 (filed Aug. 19, 2004), 4 pages.;;Fang et al., “Time-Domain laser-Induced Fluorescence Spectroscopy Apparatus for Clinical Diagnostics,” Rev. Sci. Instrum., vol. 75, No. 1, pp. 151-162 (2004).;;Gallagher NB, et al., Curve resolution for multivariate images with applications to TOF-SIMS and Raman. Chemometrics and Intelligent Laboratory Systems 2004, 73(1): 105-117.;;Greenfield, Antibodies A Laboratory Manual 2nd ed., Cold Spring Harbor Press (Cold Spring Harbor N.Y., 2013).;;Haaland, DM., et al., Hyperspectral Confocal Fluorescence Imaging: Exploring Alternative Multivariate Curve Resolution Approaches. Appl Spectrosc 2009, 63(3):271-279.;;Haaland, et al., “New augmented classical least squares methods for improved quantitative spectral analyses.” Vibrational Spectroscopy 29.1 (2002): 171-175.;;Haaland, et al., “New prediction-augmented classical least- squares (PACLS) methods: application to unmodeled interferents.” Applied Spectroscopy 54.9 (2000): 1303-1312.;;Hornyak et al., Introduction to Nanoscience and Nanotechnology, CRC Press (2008).;;Huang et al. Laser-induced autofluorescence microscopy of normal and tumor human colonic tissue. Int J Oncol (2004). 24(1):59-63.;;International Preliminary Reporton Patentability dated Sep. 24, 2015 for International Application No. PCT/US2014/029781 (7 pages).;;International Preliminary Reporton Patentability dated Sep. 24, 2015 for International Application No. PCT/US2014/030610 (7 pages).;;International Preliminary Report on Patentability dated Feb. 21, 2006 for PCT patent application No. PCT/US04/26759 (filed Aug. 19, 2004), 6 pages.;;International Search Report and Written Opinion dated Aug. 10, 2017 for International PCT Patent Application No. PCT/US2017/026697.;;International Search Report dated Jul. 25, 2014 for International Application No. PCT/US2014/029781 (3 pages).;;International Search Report dated Jul. 30, 2014 for International Application No. PCT/US2014/030610 (3 pages).;;International search report with written opinion dated Feb. 27, 2017 for PCT/US2016/059054.;;International search report with written opinion dated Jun. 16, 2017 for PCT/US2017/025451.;;International search report with written opinion dated Nov. 14, 2005 for PCT/US2004/026759.;;Jermyn et al., Intraoperative brain cancer detection with Raman spectroscopy in humans, Science Translational Medicine, Feb. 11, 2015, 7(274) 274ra19 (9 pages).;;Jo et al., “Fast Model-Free De-convolution of Fluorescence Decay for Analysis of Biological Systems,” J. Biomed. Opt., vol. 9, No. 4., pp. 743-752 (2004).;;Jo et al., “Laguerre Nonparametric De-convolution Technique of Time-Resolved Fluorescence Data; Application to the Prediction of Concentrations in a Mixture of Biochemical Components” Conference; Jul. 21, 2004; Proc. SPIE, vol. 5326, Jul. 21, 2004.;;Jo et al., “Nonparametric Analysis of Time-Resolved Fluorescence Data Based on the Laguerre Expansion Technique” Proceedings of the 25th Annual International Conference of the IEEE Engineering in Medicine and biology Society, Sep. 17, 2003; pp. 1015-1018; vol. 2.;;Kohler et al. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. European Journal of Immunology, 6.7 (1976): 511-519.;;Kut et al., Detection of Human Brain Cancer Infiltration ex vivo and in vivo Using Quantitative Optical Coherence Tomography*, Sci Transl Med., Jun. 1, 20157; 7(292): 292ra100.;;Lakowicz, J. R. (2006). Principles of fluorescence spectroscopy (3rd ed., p. xxvi, 954 p.). New York: Springer. Retrieved from http://www.loc.gov/catdir/enhancements/fy0824/2006920796-b.html.;;Ma et al., Technique for real-time tissue characterization based on scanning multispectral fluorescence lifetime spectroscopy (ms-TRFS), 2015, Optics Express vol. 6, No. 3, pp. 987-1002.;;Maarek et al., Time-resolved Fluorescence Spectra of Arterial Fluorescent Compounds: Reconstruction with the Laguerre Expansion Technique, 2000, Photochemistry and Photobiology, 71(2), 178-187.;;Marcu, et al. (2004). Fluorescence lifetime spectroscopy of glioblastoma multiforme. Photochemistry and Photobiology, 80, 98-103. doi: 10.1562/2003-12-09-RA-023.1.;;Mayinger et al. Evaluation of in vivo endoscopic autofluorescence spectroscopy in gastric cancer. Gastrointest Endosc (2004). 59(2): 191-198.;;Notice of allowance dated Apr. 4, 2016 for U.S. Appl. No. 14/776.086.;;Notice of Allowance dated Nov. 15, 2010 for U.S. Appl. No. 10/567,248.;;Notice of Allowance dated Dec. 23, 2020 for U.S. Appl. No. 16/382,791.;;Office action dated Feb. 3, 2017 for U.S. Appl. No. 15/196,354.;;Office action dated May 9, 2017 for U.S. Appl. No. 15/475,750.;;Office action dated Aug. 24, 2010 for U.S. Appl. No. 10/567,248.;;Office Action dated Aug. 28, 2017 for U.S. Appl. No. 15/475,750.;;Office Action dated Sep. 5, 2017 for U.S. Appl. No. 15/196,354.;;Office action dated Sep. 11, 2009 for U.S. Appl. No. 10/567,248.;;Office Action dated Sep. 14, 2017 for U.S. Appl. No. 15/482,442.;;Office Action mailed Dec. 10, 2015 for U.S. Appl. No. 14/776,086.;;Pogue, et al. (2001). In vivo NADH fluorescence monitoring as an assay for cellular damage in photodynamic therapy. Photochemistry and Photobiology, 74(6), 817-24. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11783938.;;Riechmann et al. Reshaping human antibodies for therapy. Nature, 332.6162:323-7 (1988).;;Rolinsky et al. (2001) A New Approach to Fluorescence Lifetime Sending Based on Molecular Distributions. Proceedings of SPIE, vol. 4252, pp. 1-11.;;Sambrook, et al. Molecular Cloning: A Laboratory Manual. 4th Edition, 2012.;;Schneckenburger, H. (1992). Fluorescence decay kinetics and imaging of NAD(P)H and flavins as metabolic indicators. Optical Engineering, 31(7), 1447. doi:10.1117/12.57704.;;Search Report dated Sep. 25, 2008 for European patent application No. 04781453.8 (filed Aug. 19, 2004), 5 pages.;;Siegel et al, “Studying Biological Tissue with Fluorescence Lifetime Imaging; Microscopy, Endoscopy, and Decay Profiles,” Applied Optics, vol. 42 pp. 2995-3004 (2003).;;Singleton, Dictionary of DNA and Genome Technology 3rd ed., Wiley-Blackwell (Nov. 28, 2012).;;Singleton, Dictionary of Microbiology and Molecular Biology 3.sup.rd ed., revised ed., J. Wiley & Sons (New York, N.Y. 2006).;;Smith, March's Advanced Organic Chemistry Reactions, Mechanisms and Structure 7.sup.th ed., J. Wiley & Sons (New York, N.Y. 2013).;;Sun et al. Simultaneous time-and wavelength-resolved fluorescence spectroscopy for near real-time tissue diagnosis. Optics Letters (2008). 33(6):630-632.;;Sun, Y., et al. (2009). Fluorescence lifetime imaging microscopy: in vivo application to diagnosis of oral carcinoma. Opt Lett, 34(13), 2081-2083. doi: 183277.;;Thomas, et al., Comparison of multivariate calibration methods for quantitative spectral analysis. Analytical Chemistry 1990 62 (10), 1091-1099.;;Thomas, E.V., A primer on multivariate calibration. Analytical Chemistry 1994 66 (15), 795A-804A.;;U.S. Appl. No. 15/196,354 Notice of Allowance dated Jan. 11, 2019.;;U.S. Appl. No. 15/196,354 Office Action dated Jun. 6, 2018.;;U.S. Appl. No. 15/475,750 Notice of Allowance dated Mar. 5, 2020.;;U.S. Appl. No. 15/475,750 Office Action dated Apr. 8, 2019.;;U.S. Appl. No. 15/475,750 Office Action dated Mar. 5, 2018.;;U.S. Appl. No. 15/475,750 Office Action dated Oct. 11, 2018.;;U.S. Appl. No. 15/475,750 Office Action dated Oct. 24, 2019.;;U.S. Appl. No. 15/482,442 Office Action dated Apr. 16, 2018.;;U.S. Appl. No. 16/382,791 Office Action dated May 5, 2020.;;U.S. Appl. No. 17/198,816 Office Action dated Nov. 8, 2021.;;Wilson, et al. An optical fiber-based diffuse reflectance spectrometer for non-invasive investigation of photodynamic sensitizers in vivo. Proc. SPIE 6, 219-232, Jan. 21, 1990.;;Written Opinion dated Jul. 25, 2014 International Application No. PCT/US2014/029781 (5 pages).;;Written Opinion dated Jul. 30, 2014 for International Application No. PCT/US2014/030610 (5 pages).;;Written Opinion dated Nov. 14, 2005 for PCT patent application No. PCT/US04/26759 (filed Aug. 19, 2004), 5 pages.;;Yankelevich et al. Design and evaluation of a device for fast multispectral time-resolved fluorescence spectroscopy and imaging. Rev Sci Instrum. Mar. 2014;85(3):034303.;;Yong, et al. Distinction of brain tissue, low grade and high grade glioma with time-resolved fluorescence spectroscopy. Front Biosci. May 1, 2006;11:1255-1263. doi: 10.2741/1878.",ACTIVE
263,EP,A4,EP 3436805 A4,181-032-032-295-801,2019-12-11,2019,EP 17776805 A,2017-03-31,US 201662317443 P;;US 201662317459 P;;US 201662317456 P;;US 201662317452 P;;US 201662317449 P;;US 201662317460 P;;US 201662317453 P;;US 201662317455 P;;US 201662317451 P;;US 201662351615 P;;US 2017/0025451 W,2016-04-01,"SYSTEMS, DEVICES, AND METHODS FOR TIME-RESOLVED FLUORESCENT SPECTROSCOPY",,BLACK LIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;BLACK KEITH;;KAVANAUGH JACK;;BORTNIK BARTOSZ;;NIE ZHAOJUN,,https://lens.org/181-032-032-295-801,Search Report,no,5,0,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,G01N21/64;;A61B6/00;;G01J3/02;;G01J3/10;;G01J3/32;;G01J3/44;;G01N21/25;;G01N21/62;;G01N21/63,,0,0,,,,PENDING
264,US,B2,US 8795648 B2,012-325-107-375-365,2014-08-05,2014,US 201213646947 A,2012-10-08,US 201213646947 A;;US 93511010 A;;US 2009/0040252 W;;US 4419108 P,2008-04-11,Poly(beta malic acid) with pendant Leu-Leu-Leu tripeptide for effective cytoplasmic drug delivery,"The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.",CEDARS SINAI MEDICAL CENTER,DING HUI;;LJUBIMOVA JULIA Y;;HOLLER EGGEHARD;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2012-10-18),https://lens.org/012-325-107-375-365,Granted Patent,yes,5,3,9,9,2,A61K9/0019;;A61K9/0024;;A61K9/0095;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711;;A61P35/00;;A61K9/0019;;A61K9/0095;;A61K9/0024;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711,C07H21/04;;A61K47/14;;C12N15/11,424/78.17;;X514 44 A;;514/772;;536/24.5;;977/704;;977/906,10,4,082-428-855-525-972;;094-544-976-445-251;;106-640-130-151-317;;009-843-764-520-632,9472555;;10.1038/sj.gt.3300536;;17630012;;pmc2394675;;10.1016/j.jconrel.2007.05.032;;pmc3487710;;10.1021/bc0502457;;16536461;;10.1016/j.abb.2007.04.013;;pmc2025638;;17562324,"Machine translation of CN 1615855 A, 2005.;;West record of CN 1615855 A, 2005.;;Coonrod, A., et al., ""On the mechanism of DNA transfection: efficient gene transfer without viruses,"" Gene Therapy, 1997, 4:1313-1321.;;Fujita, et al., ""Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid),"" Jour Controlled Release, Oct. 8, 2007, 122(3):356-363.;;GenBank AAB52902.1 (1997).;;Lee, Bong-Seop, et al., ""Delivery of antisense oligonucleotides and transferrin receptor antibody in vitro and in vivo using a new multifunctional drug delivery system based on polymalic acid,"" Proc. Amer. Assoc. Cancer Res., 2004, vol. 45, Abstract #647.;;Lee, Bong-Seop, et al., ""Polycefin, a New Prototype of a Multifunctional Nanoconjugate Based on Poly(beta-L-malic acid) for Drug Delivery,"" Bioconjugate Chem., 2006, 17:317-326.;;Lutsenko, Svetlana, et al., ""Biochemical Basis of Regulation of Human Copper-Transporting ATPases,"" Arch Biochem Biophys., Jul. 15, 2007, 463(2):134-148.;;MDNSI, Molecular Oncology, Jul. 1, 2009, Available on the internet at URL:http://www.cedars-sinai.edu/10141.html.;;PCT International Preliminary Report on Patentability (Chapter I of the Patent Cooperation Treaty) dated Oct. 21, 2010, for International Patent Application No. PCT/US2009/040252, filed Apr. 10, 2009.",ACTIVE
265,WO,A1,WO 2010/033861 A1,144-897-016-065-927,2010-03-25,2010,US 2009/0057569 W,2009-09-18,US 9820608 P,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE,"The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.",CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV;;KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L,KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L,,https://lens.org/144-897-016-065-927,Patent Application,yes,5,17,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,57,50,037-730-606-033-884;;079-004-710-947-368;;137-736-534-542-673;;113-988-814-358-790;;040-117-604-896-515;;048-595-056-540-207;;120-925-953-960-234;;001-919-189-380-465;;000-475-545-005-08X;;178-122-805-959-835;;040-706-070-058-394;;069-088-876-130-831;;011-915-965-410-60X;;117-147-921-146-928;;049-313-319-234-710;;041-582-872-839-824;;109-607-902-701-230;;155-116-058-123-026;;011-124-388-694-014;;024-348-075-858-545;;104-702-548-190-856;;017-033-452-418-343;;006-352-234-052-186;;020-235-958-756-618;;004-900-595-274-528;;017-573-748-497-068;;034-556-396-748-055;;082-246-685-747-38X;;130-962-057-320-330;;090-186-236-924-537;;064-931-509-522-264;;059-179-390-847-956;;003-289-868-506-823;;047-248-975-491-255;;084-166-190-387-012;;118-487-604-409-015;;030-890-177-126-959;;056-400-313-542-404;;099-542-559-876-635;;061-930-813-401-762;;013-462-799-672-471;;118-609-578-680-09X;;150-376-147-307-934;;015-360-798-213-869;;122-914-173-863-23X;;016-032-069-110-02X;;097-112-806-768-373;;127-132-413-417-85X;;001-450-008-710-264;;015-360-798-213-869,7896005;;10.1096/fasebj.9.5.7896005;;12130773;;10.1126/science.1072994;;10.1080/13550280290100969;;12476347;;10.1002/ana.20009;;14991808;;17401090;;10.2967/jnumed.106.037762;;15314250;;10.1385/jmn:24:1:055;;10.1007/s00259-007-0700-2;;18188557;;10.1038/nbt1085;;15834405;;18298677;;10.1111/j.1552-6569.2007.00179.x;;15791432;;10.1007/s00259-005-1780-5;;pmc6725842;;16291932;;10.1523/jneurosci.2990-05.2005;;10.1093/brain/awm191;;17698496;;10.1038/nature06616;;pmc3264491;;18256671;;10.1111/j.1471-4159.1993.tb02147.x;;7687653;;15102905;;pmc6729409;;10.1523/jneurosci.0283-04.2004;;10.1167/iovs.08-1849;;18566467;;pmc3947384;;14507981;;pmc6740409;;10.1523/jneurosci.23-25-08808.2003;;10.1074/jbc.m404751200;;15590663;;17472706;;10.1111/j.1471-4159.2007.04613.x;;10330448;;10.1177/002215549904700601;;11724904;;10.1177/002215540104901210;;10.1016/j.nbd.2006.08.017;;17029828;;pmc1184038;;10.1172/jci23241;;16100572;;10.1073/pnas.0604681103;;16864778;;pmc1544247;;17623022;;10.1111/j.1460-9568.2007.05652.x;;10.1002/eji.200324502;;14768043;;pmc1559772;;10.1073/pnas.0603747103;;16938843;;pmc1181021;;10.1016/s0006-3495(97)78154-2;;9284289;;10.1016/s0140-6736(03)12981-9;;12699953;;18499214;;10.1016/j.visres.2008.04.006;;pmc2582057;;18689704;;10.1167/iovs.07-1211;;10.1167/iovs.07-1447;;18441315;;pmc5557086;;18628464;;10.1158/1078-0432.ccr-08-0024;;17999464;;10.1021/mp700113r;;10.1016/0002-9394(87)90001-8;;3618708;;2678551;;10.1016/0039-6257(89)90127-6;;10.1056/nejm198608213150804;;3736630;;8725899;;10.1016/0197-4580(96)00010-3;;10.1002/ana.410260208;;2774510;;2774509;;10.1002/ana.410260207;;10.1016/s1388-2457(01)00620-4;;11595144;;17460292;;10.1167/iovs.06-1029;;14729357;;10.1016/j.exer.2003.10.011;;12764254;;17888483;;10.1016/j.visres.2007.07.025;;pmc2323206;;15212842;;10.1016/j.neurobiolaging.2003.09.008;;11923249;;10.1007/s10384-004-0156-x;;15838725;;17684098;;10.1073/pnas.0703707104;;pmc1940230;;12764254,"SINGLETON ET AL.: ""Dictionary of Microbiology and Molecular Biology"", 2001, J. WILEY & SONS;;MARCH: ""Advanced Organic Chemistry Reactions, Mechanisms and Structure"", 2001, J. WILEY & SONS;;SAMBROOK; RUSSEL: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;SISODIA, S.S.; PRICE, D.L.: ""Role of the beta-amyloid protein in Alzheimer's disease"", FASEB J, vol. 9, 1995, pages 366 - 370, XP002950391;;HARDY, J.; SELKOE, D.J.: ""The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics"", SCIENCE, vol. 297, 2002, pages 353 - 356;;MCGEER, P.L.; MCGEER, E.G.: ""Local neuroinflammation and the progression of Alzheimer's disease"", JNEUROVIROI, vol. 8, 2002, pages 529 - 538;;KLUNK, W.E. ET AL.: ""Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B"", ANN NEUROL, vol. 55, 2004, pages 306 - 319, XP008031485, DOI: doi:10.1002/ana.20009;;NG, S. ET AL.: ""Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease"", J NUCL MED, vol. 48, 2007, pages 547 - 552;;WANG, Y. ET AL.: ""Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease"", J MOL NEUROSCI, vol. 24, 2004, pages 55 - 62, XP008108084;;NORDBERG, A.: ""Amyloid plaque imaging in vivo: current achievement and future prospects"", EUR J NUCL MED MOL IMAGING, vol. 35, no. 1, 2008, pages 46 - 50, XP019586640;;HINTERSTEINER, M. ET AL.: ""In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe"", NAT BIOTECHNOL, vol. 23, 2005, pages 577 - 583, XP002695064, DOI: doi:10.1038/nbt1085;;NAKADA, T.; MATSUZAWA, H.; IGARASHI, H.; FUJII, Y.; KWEE, I.L.: ""In vivo visualization of senile-plaque-like pathology in Alzheimer's disease patients by MR microscopy on a 7T system"", JNEUROIMAGING, vol. 18, 2008, pages 125 - 129;;TOYAMA, H. ET AL.: ""PET imaging of brain with the beta-amyloid probe, [11C]6-OHBTA- 1, in a transgenic mouse model of Alzheimer's disease"", EUR J NUCL MED MOL IMAGING, vol. 32, 2005, pages 593 - 600, XP019332873, DOI: doi:10.1007/s00259-005-1780-5;;KLUNK, W.E. ET AL.: ""Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain"", J NEUROSCI, vol. 25, 2005, pages 10598 - 10606;;LOCKHART, A. ET AL.: ""PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis"", BRAIN, vol. 130, 2007, pages 2607 - 2615;;MEYER-LUEHMANN, M. ET AL.: ""Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease"", NATURE, vol. 451, 2008, pages 720 - 724;;MORIN, P.J. ET AL.: ""Amyloid precursor protein is synthesized by retinal ganglion cells, rapidly transported to the optic nerve plasma membrane and nerve terminals, and metabolized"", JNEUROCHEM, vol. 61, 1993, pages 464 - 473;;GREEVE, I. ET AL.: ""Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila"", JNEUROSCI, vol. 24, 2004, pages 3899 - 3906, XP002395100, DOI: doi:10.1523/JNEUROSCI.0283-04.2004;;NING, A.; CUI, J.Z.; TO, E.; HSIAO ASHE, K.; MATSUBARA, J.A.: ""Amyloid Beta Deposits Lead to Retinal Degeneration in a Mouse Model of Alzheimer Disease"", INVEST OPHTHALMOL VIS SCI, 2008;;KORONYO-HAMAOUI, M. ET AL.: ""Dendritic-cell based vaccination with a weak agonist of myelin-derived peptide attenuates Alzheimer's-like pathology in APP/PS1 transgenic mice"", SFN ABSTRACT 740.L/QL, 2008;;HAUBEN, E. ET AL.: ""Vaccination with dendritic cells pulsed with peptides of myelin basic protein promotes functional recovery from spinal cord injury"", JNEUROSCI, vol. 23, 2003, pages 8808 - 8819;;YANG, F. ET AL.: ""Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo"", JBIOL CHEM, vol. 280, 2005, pages 5892 - 5901, XP002481312, DOI: doi:10.1074/jbc.M404751200;;GARCIA-ALLOZA, M.; BORRELLI, L.A.; ROZKALNE, A.; HYMAN, B.T.; BACSKAI, B.J.: ""Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially 18 restores distorted neurites in an Alzheimer mouse model"", JNEUROCHEM, vol. 102, 2007, pages 1095 - 1104, XP055054058, DOI: doi:10.1111/j.1471-4159.2007.04613.x;;SCHNELL, S.A.; STAINES, W.A.; WESSENDORF, M.W.: ""Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue"", JHISTOCHEM CYTOCHEM, vol. 47, 1999, pages 719 - 730;;BASCHONG, W.; SUETTERLIN, R.; LAENG, R.H.: ""Control of autofluorescence of archival formaldehyde-fixed, paraffin-embedded tissue in confocal laser scanning microscopy (CLSM"", JHISTOCHEM CYTOCHEM, vol. 49, 2001, pages 1565 - 1572;;GARCIA-ALLOZA, M. ET AL.: ""Characterization of amyloid deposition in the APPswe/PSldE9 mouse model of Alzheimer disease"", NEUROBIOL DIS, vol. 24, 2006, pages 516 - 524, XP024901474, DOI: doi:10.1016/j.nbd.2006.08.017;;FRENKEL, D.; MARON, R.; BURT, D.S.; WEINER, H.L.: ""Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease"", J CLIN INVEST, vol. 115, 2005, pages 2423 - 2433, XP002353832, DOI: doi:10.1172/JCI23241;;BUTOVSKY, O. ET AL.: ""Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1"", PROC NATL ACAD SCI USA, vol. 103, 2006, pages 11784 - 11789, XP002677454, DOI: doi:10.1073/pnas.0604681103;;BUTOVSKY, O.; KUNIS, G.; KORONYO-HAMAOUI, M.; SCHWARTZ, M.: ""Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model"", EUR JNEUROSCI, vol. 26, 2007, pages 413 - 416, XP055211364, DOI: doi:10.1111/j.1460-9568.2007.05652.x;;FORD, M.L.; EVAVOLD, B.D.: ""An MHC anchor-substituted analog of myelin oligodendrocyte glycoprotein 35-55 induces IFN-gamma and autoantibodies in the absence of experimental autoimmune encephalomyelitis and optic neuritis"", EUR J IMMUNOL, vol. 34, 2004, pages 388 - 397;;ZIV, Y.; AVIDAN, H.; PLUCHINO, S.; MARTINO, G.; SCHWARTZ, M.: ""Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury"", PROC NATL ACAD SCI USA, vol. 103, 2006, pages 13174 - 13179;;WACHMAN, E.S.; NIU, W.; FARKAS, D.L.: ""AOTF microscope for imaging with increased speed and spectral versatility"", BIOPHYS, vol. J73, 1997, pages 1215 - 1222;;BURTON, K.; JEONG, J.; WACHSMANN-HOGIU, S.; FARKAS, D. L.: ""Spectral optical imaging in biology and medicine in Biomedical Optical Imaging, Edn"", 2008, OXFORD UNIVERSITY PRESS;;GOLDSTEIN, L.E. ET AL.: ""Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease"", LANCET, vol. 361, 2003, pages 1258 - 1265, XP002531997, DOI: doi:10.1016/S0140-6736(03)12981-9;;CARROLL, J.; CHOI, S.S.; WILLIAMS, D.R.: ""In vivo imaging of the photoreceptor mosaic of a rod monochromat"", VISION RES, vol. 48, 2008, pages 2564 - 2568, XP025626913, DOI: doi:10.1016/j.visres.2008.04.006;;MURATA, H. ET AL.: ""Imaging mouse retinal ganglion cells and their loss in vivo by a fundus camera in the normal and ischemia-reperfusion model"", INVEST OPHTHALMOL VIS SCI, vol. 49, 2008, pages 5546 - 5552;;LEUNG, C.K. ET AL.: ""Longitudinal profile of retinal ganglion cell damage after optic nerve crush with blue-light confocal scanning laser ophthalmoscopy"", INVEST OPHTHALMOL VIS SCI, vol. 49, 2008, pages 4898 - 4902;;DHILLON, N. ET AL.: ""Phase II trial of curcumin in patients with advanced pancreatic cancer"", CLIN CANCER RES, vol. 14, 2008, pages 4491 - 4499;;ANAND, P.; KUNNUMAKKARA, A.B.; NEWMAN, R.A.; AGGARWAL, B.B.: ""Bioavailability of curcumin: problems and promises"", MOL PHARM, vol. 4, 2007, pages 807 - 818, XP008114486, DOI: doi:10.1021/mp700113r;;SADUN, A.A.; BORCHERT, M.; DEVITA, E.; HINTON, D.R.; BASSI, C.J.: ""Assessment of visual impairment in patients with Alzheimer's disease"", AM J OPHTHALMOL, vol. 104, 1987, pages 113 - 120;;KATZ, B.; RIMMER, S.: ""Ophthalmologic manifestations of Alzheimer's disease"", SURV OPHTHALMOL, vol. 34, 1989, pages 31 - 43, XP023266734, DOI: doi:10.1016/0039-6257(89)90127-6;;HINTON, D.R.; SADUN, A.A.; BLANKS, J.C.; MILLER, C.A.: ""Optic-nerve degeneration in Alzheimer's disease"", NENGL J MED, vol. 315, 1986, pages 485 - 487;;BLANKS, J.C.; TORIGOE, Y.; HINTON, D.R.; BLANKS, R.H.: ""Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina"", NEUROBIOL AGING, vol. 17, 1996, pages 377 - 384;;TRICK, G.L.; BARRIS, M.C.; BICKLER-BLUTH, M.: ""Abnormal pattern electroretinograms in patients with senile dementia of the Alzheimer type"", ANN NEUROL, vol. 26, 1989, pages 226 - 231;;KATZ, B.; RIMMER, S.; IRAGUI, V.; KATZMAN, R.: ""Abnormal pattern electroretinogram in Alzheimer's disease: evidence for retinal ganglion cell degeneration?"", ANN NEUROL, vol. 26, 1989, pages 221 - 225;;PARISI, V. ET AL.: ""Morphological and functional retinal impairment in Alzheimer's disease patients"", CLIN NEUROPHYSIOL, vol. 112, 2001, pages 1860 - 1867;;BERISHA, F.; FEKE, G.T.; TREMPE, C.L.; MCMEEL, J.W.; SCHEPENS, C.L.: ""Retinal abnormalities in early Alzheimer's disease"", INVEST OPHTHALMOL VIS SCI, vol. 48, 2007, pages 2285 - 2289;;ANDERSON, D.H. ET AL.: ""Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration"", EXP EYE RES, vol. 78, 2004, pages 243 - 256;;DENTCHEV, T.; MILAM, A.H.; LEE, V.M.; TROJANOWSKI, J.Q.; DUNAIEF, J.L.: ""Amyloidbeta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas"", MOL VIS, vol. 9, 2003, pages 184 - 190, XP003001744;;DING, J.D. ET AL.: ""Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an agerelated macular degeneration mouse model"", VISION RES, vol. 48, 2008, pages 339 - 345, XP022452227, DOI: doi:10.1016/j.visres.2007.07.025;;KORONYO, Y.; KORONYO-HAMAOUI, M.; BLACK, K.L.; SCHWARTZ, M.; FARKAS, D.L., OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE;;JANKOWSKY, J.L. ET AL.: ""APP processing and amyloid deposition in mice haploinsufficient for presenilin 1"", NEUROBIOL AGING, vol. 25, 2004, pages 885 - 892;;MCKINNON SJ; LEHMAN DM; KERRIGAN-BAUMRIND LA; MERGES CA; PEASE ME; KERRIGAN DF; RANSOM NL; TAHZIB NG; REITSAMER HA; LEVKOVITCH-VER, INVEST OPHTHALMOL VIS SCI, vol. 43, 2002, pages 1077 - 1087;;YONEDA S; HARA H; HIRATA A; FUKUSHIMA M; INOMATA Y; TANIHARA H, JPN J OPHTHALMOL, vol. 49, 2005, pages 106 - 108;;GUO L; SALT TE; LUONG V; WOOD N; CHEUNG W; MAASS A; FERRARI G; RUSSO-MARIE F; SILLITO AM; CHEETHAM ME ET AL., PROC NATL ACAD SCI USA, vol. 104, 2007, pages 13444 - 13449;;DENTCHEV T; MILAM AH; LEE VM; TROJANOWSKI JQ; DUNAIEF JL, MOL VIS, vol. 9, 2003, pages 184 - 190;;See also references of EP 2323696A4",PENDING
266,US,B2,US 9629919 B2,020-356-040-926-688,2017-04-25,2017,US 201615054266 A,2016-02-26,US 201615054266 A;;US 201414179195 A;;US 201213513145 A;;US 2010/0059919 W;;US 28549509 P,2009-12-10,Drug delivery of temozolomide for systemic based treatment of cancer,"The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.",CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2012-11-12),https://lens.org/020-356-040-926-688,Granted Patent,yes,6,2,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61K31/4188;;A61K31/425;;C07K16/28;;C07K16/30,,39,34,076-069-720-623-007;;089-773-133-078-99X;;012-251-206-172-978;;064-884-073-662-848;;170-853-882-083-556;;092-864-235-322-940;;024-853-541-370-254;;000-409-501-606-70X;;088-076-682-849-849;;027-177-154-094-913;;003-631-120-479-205;;056-106-508-661-801;;012-497-328-331-068;;078-749-765-604-979;;107-990-469-227-380;;019-524-632-030-548;;135-545-938-771-996;;094-544-976-445-251;;106-640-130-151-317;;086-499-835-921-55X;;149-009-853-252-790;;068-659-879-554-517;;068-082-778-319-717;;013-415-019-143-842;;056-754-795-949-28X;;088-509-278-000-721;;160-717-493-067-916;;068-365-614-968-438;;039-079-455-504-396;;087-520-893-698-325;;044-248-524-774-951;;030-136-053-475-941;;012-011-330-340-059;;131-982-616-033-720,10.1007/s00401-007-0243-4;;17618441;;pmc1929165;;17964023;;10.1016/j.ncl.2007.07.006;;16648043;;10.1016/s1470-2045(06)70665-9;;11780887;;10.3171/jns.2001.95.2.0190;;10.1039/b005652i;;10.1056/nejmoa043330;;15758009;;16985051;;10.1158/1535-7163.mct-05-0428;;18952979;;pmc2718972;;10.1215/15228517-2008-090;;10.1038/nm1002;;14981512;;10.1038/nrd1088;;12750738;;10.1080/10611860400011927;;15621677;;10.1016/j.jconrel.2004.07.009;;15588910;;18654426;;10.1038/nnano.2007.387;;10.1038/nrc1566;;15738981;;10.1016/j.addr.2004.10.006;;15722167;;10.1677/erc.1.01045;;16113096;;12639809;;10.1016/s1567-5769(02)00271-0;;17630012;;pmc2394675;;10.1016/j.jconrel.2007.05.032;;pmc3487710;;10.1021/bc0502457;;16536461;;19699248;;10.1016/j.addr.2009.06.005;;10.1007/s00280-006-0407-2;;17256133;;10.1007/s11060-009-9857-9;;19337695;;pmc1185838;;708370;;10.1042/bj1730723;;pmc2734385;;18373429;;10.2217/17435889.3.2.247;;10609647;;10.1023/a:1020614525534;;6606682;;10.1016/0022-1759(83)90303-4;;10914698;;10.1124/mol.108.045112;;18477668;;pmc3909956;;19525947;;10.1038/nmat2442;;16430958;;10.1016/j.biomaterials.2005.12.022;;16303268;;10.1016/j.ijpharm.2005.10.010;;pmc2761188;;19920915;;10.2147/dddt.s3572;;10.7150/ijms.5.273;;pmc2536715;;18797509;;20387095;;pmc2952070;;10.1007/s11095-010-0091-0,"D.N. Louis, H. Ohgaki, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97-109 (2007).;;2009 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the united States in 2004-2005. http://www.cbtrus.org/reports/2009-NPCR-04-05/CBTRUS-NPCR2004-2005-Report-.pdf (accessed Nov. 17, 2009).;;A.R. Asthagiri, et al. Advances in brain tumor surgery. Neurol Clin. 25:975-1003 (2007).;;W. Stummer, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 7:392-401 (2006).;;M. Lacroix, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurogurg. 95:190198 (2001).;;Arrowsmith, et al. Part 39 synthesis of bis(imidazotetrazine)s with saturated spacer groups. J Chem Soc Perkin Trans 1. 24:4432-4438 (2000).;;R. Stupp, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastma. N Engl J Med. 352:987-996 (2005).;;N. Auger, et al. Genetic alterations associated with acquired with temozolide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther. 5:2182-2192 (2006).;;C.C. Chen, et al. Of Escherichia coli and man: understanding glioma resistance to temozolmide therapy. In E. G. Meir (eds.), CNS Cancer, Humana Press, Atlanta, 2009, pp. 679-711.;;G.J. Kitange, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma kenografts. Neuro Oncol. 11:281-291 (2009).;;R. Stachi-Fainaro, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med. 10:255-261 (2004).;;R. Duncan. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2:347-360 (2003).;;S.V. Vinogradov, et al. Mixed polymer micelles of amphiphilic and cationic copolymers for delivery of antisense oligonucleotides. J Drug Target 12:517-526 (2004).;;A.V. Kabanov, et al. Polymer genomics: shifting the gene and drug delivery paradigms. J Control Release. 101:259-271 (2005).;;D. Peer, et . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2:751-760 (2007).;;M. Ferrari. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 5:161-171 (2005).;;A. Nori, et al. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev. 57:609-636 (2005).;;R. Duncan, et al. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer. 12:S189-S199 (2005).;;H. Maeda, et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its Implications. Int Immunopharmacol. 3:319-328 (2003).;;M. Fujita, et al. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly (b-L-malic acid). J Control Release. 122:356-363 (2007).;;B.S. Lee, et al. Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(b-L-malic acid) for drug delivery. Bioconjug Chem. 17:3170326 (2006).;;E. Segal, and R. Satchi-Fainaro. Design and development of polymer conjugates as anti-angiogenic agents. Adv Drug Deliv Rev. 61:1159-1176 (2009).;;S. Brem, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol. 60:643-650 (2007).;;U. Akbar, et al. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of Intracranial glioma with resection. J. Neurooncol. 94:203-212 (2009).;;L.X. Zhao, et al. Synthesis and antitumour activities of 3-substituted 4-oxo-3 H-imidazo [5,1-d][1,2,3,5] tetrazine-8-carboxylic acids and their derivatives. Chin J Med Chem. 11:263-269 (2001).;;E. Holler, Poly(malic acid) from natural sources. In N.P. Cheremisinoff (eds.), Handbook of Engineering Polymeric Materials, Marcel Dekker, New York, 1997, pp. 93-103.;;J. Carlsson, et al. Protein Thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio) priopionate, a new heterobifunctional reagent. Biochem J. 173:723-737 (1978).;;J.Y. Ljubimova, et al. Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery delivery. Nanomedicine. 3:247-265 (2008).;;F.N. Fu, al. et al Calcein permeability of liposomes mediated by type A botulinum neurotoxin and its light and heavy chains. J. Protein Chem. 18:701-707 (1999).;;T.J. Mosmann. Rapid colorimetric assays for cellular growth and survival: application to proliferation and cytotoxicity assays. Immunol Methods. 65:55-63 (1983).;;H.S. Friedman, et al. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 6:2585-2597 (2000).;;R.N. Trivedi, et al. Human methyl purine DNA glycosylase and DNA polymerase b expression collectively predict sensitivity to temozolomide. Mol Pharmacol. 74:505-516 (2008).;;A.E. Nel, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 8:543-557 (2009).;;M.R. Lorenz, et al. Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials. 27:2820-2828 (2006).;;D.E. Owens, et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 307:93-102 (2006).;;Extended European Search Report dated Oct. 19, 2013 in counterpart European Patent Application No. 10836765.7.;;Braun, et al. Treatment glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry. Drug Design, Development and Therapy, Dove Medical Press Ltd, UK, vol. 2008, No. 2, 289-301 (2009).;;Waldeck, et al. TMZ-BioShuttle—A reformulated temozolomide. International Journal of Medical Sciences, Ivyspring International Publisher, Lake Haven, AU, vol. 5, No. 5,273-284 (2008).;;Rameshwar, et al. Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Ply (l-L-malic acid). Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, vol. 27, No. 11, 2317-2329 (2010).",ACTIVE
267,EP,A4,EP 2509421 A4,022-979-344-139-249,2013-11-06,2013,EP 10836765 A,2010-12-10,US 28549509 P;;US 2010/0059919 W,2009-12-10,DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER,,CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,,https://lens.org/022-979-344-139-249,Search Report,no,2,0,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61K31/425;;A61K47/48,,4,3,030-136-053-475-941;;012-011-330-340-059;;131-982-616-033-720,pmc2761188;;19920915;;10.2147/dddt.s3572;;10.7150/ijms.5.273;;pmc2536715;;18797509;;20387095;;pmc2952070;;10.1007/s11095-010-0091-0,"BRAUN K ET AL: ""Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry"", DRUG DESIGN, DEVELOPMENT AND THERAPY, DOVE MEDICAL PRESS LTD, UNITED KINGDOM, vol. 2008, no. 2, 1 January 2009 (2009-01-01), pages 289 - 301, XP008134745, ISSN: 1177-8881, [retrieved on 20090104], DOI: 10.2147/DDDT.S3572;;WALDECK W ET AL: ""TMZ-BioShuttle - A reformulated temozolomide"", INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, IVYSPRING INTERNATIONAL PUBLISHER, LAKE HAVEN, AU, vol. 5, no. 5, 15 September 2008 (2008-09-15), pages 273 - 284, XP002577646, ISSN: 1449-1907;;RAMESHWAR PATIL ET AL: ""Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(Î-L-malic acid)"", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 27, no. 11, 13 April 2010 (2010-04-13), pages 2317 - 2329, XP019828093, ISSN: 1573-904X;;See also references of WO 2011072240A1",ACTIVE
268,EP,B1,EP 2509421 B1,183-813-011-049-593,2020-02-05,2020,EP 10836765 A,2010-12-10,US 28549509 P;;US 2010/0059919 W,2009-12-10,DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER,,CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,,https://lens.org/183-813-011-049-593,Granted Patent,yes,0,0,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61P35/00;;A61K31/495;;A61K47/65,,2,1,170-853-882-083-556,10.1039/b005652i,"ARROWSMITH J ET AL: ""ANTITUMOUR IMIDAZOTETRAZINES.PART 39.1 SYNTHESIS OF BIS(IMIDAZOTETRAZINE)S WITH SATURATED SPACER GROUPS"", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, ROYAL SOCIETY OF CHEMISTRY, GB, vol. 24, 1 January 2000 (2000-01-01), pages 4432 - 4438, XP001069597, ISSN: 0300-922X, DOI: 10.1039/B005652I;;ZHAO LIN-XIANG ET AL: ""Synthesis and Antitumour Activities of 3-Substituted 4-Oxo-3H-imidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxylic Acids and Their Derivatives"", ZHONGGUO YAOWU HUAXUE ZAZHI - CHINESE JOURNAL OF MEDICINAL CHEMIS, GAI-KAI BIANJIBU, SHENYANG, CN, vol. 11, no. 5, 1 January 2001 (2001-01-01), pages 263 - 269, XP009114359, ISSN: 1005-0108",ACTIVE
269,EP,A4,EP 2658574 A4,019-687-664-480-152,2014-03-12,2014,EP 10861515 A,2010-12-30,US 2010/0062515 W,2010-12-30,POLYMALIC ACID-BASED NANOBIOPOLYMER COMPOSITIONS AND METHODS FOR TREATING CANCER,,CEDARS SINAI MEDICAL CENTER,INOUE SATOSHI;;DING HUI;;HOLLER EGGEHARD;;BLACK KEITH;;LJUBIMOVA JULIA,,https://lens.org/019-687-664-480-152,Search Report,no,2,0,4,9,0,A61K39/39558;;A61K47/593;;A61K47/60;;A61K47/6855;;A61K47/6883;;A61K2039/505;;A61P35/00;;A61P35/04;;A61P43/00;;C07K16/32;;C12N15/113;;C12N15/1138;;C12N2310/11;;C12N2310/14;;C12N2310/3233;;C12N2320/31;;C12N2320/32,A61K47/48;;A61K38/16;;A61K39/395;;A61K47/30;;A61P35/00,,3,2,113-433-411-873-182;;026-135-913-145-143,10.1158/1538-7445.am10-3854;;20921419;;10.1073/pnas.1003919107;;pmc2964197,"INOUE SATOSHI ET AL: ""Newly designed nanobioconjugate for direct targeting and systemic treatment of HER2-positive breast cancer"", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 51, April 2010 (2010-04-01), & 101ST ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; WASHINGTON, DC, USA; APRIL 17 -21, 2010, pages 937, XP002719407, ISSN: 0197-016X;;HUI DING ET AL: ""Inhibition of brain tumor growth by intravenous poly(beta-L-malic acid) nanobioconjugate with pH-dependent drug release"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 45, 27 October 2010 (2010-10-27), pages 19603 - 19603, XP055098887, ISSN: 0027-8424, DOI: 10.1073/pnas.1015385107;;See also references of WO 2012091718A1",DISCONTINUED
270,US,A1,US 2013/0084261 A1,082-443-183-586-996,2013-04-04,2013,US 201213646947 A,2012-10-08,US 201213646947 A;;US 93511010 A;;US 2009/0040252 W;;US 4419108 P,2008-04-11,POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY,"The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.",CEDARS SINAI MEDICAL CENTER;;CEDARS SINAI MEDICAL CENTER,DING HUI;;LJUBIMOVA JULIA Y;;HOLLER EGGEHARD;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2012-10-18),https://lens.org/082-443-183-586-996,Patent Application,yes,3,2,9,9,2,A61K9/0019;;A61K9/0024;;A61K9/0095;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711;;A61P35/00;;A61K9/0019;;A61K9/0095;;A61K9/0024;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711,A61K31/711;;A61K47/48,424/78.17,2,0,,,"Machine translation of CN 1615855 A, 2005;;WEST record of CN 1615855 A, 2005",ACTIVE
271,EP,A1,EP 2509421 A1,060-375-917-356-787,2012-10-17,2012,EP 10836765 A,2010-12-10,US 28549509 P;;US 2010/0059919 W,2009-12-10,DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER,,CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,,https://lens.org/060-375-917-356-787,Patent Application,yes,0,0,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61K31/425;;A61K47/48,,0,0,,,,ACTIVE
272,EP,A1,EP 2271368 A1,055-969-526-879-377,2011-01-12,2011,EP 09730249 A,2009-04-10,US 2009/0040252 W;;US 4419108 P,2008-04-11,POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY,,CEDARS SINAI MEDICAL CENTER,DING HUI;;LJUBIMOVA JULIA Y;;HOLLER EGGEHARD;;BLACK KEITH L,,https://lens.org/055-969-526-879-377,Patent Application,yes,0,0,9,9,2,A61K9/0019;;A61K9/0024;;A61K9/0095;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711;;A61P35/00;;A61K9/0019;;A61K9/0095;;A61K9/0024;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711,A61K38/00;;A61K9/00;;A61K9/48;;A61K31/711;;A61K39/00;;A61K47/59;;A61K47/60;;A61K49/00,,0,0,,,,ACTIVE
273,CN,A,CN 108885173 A,096-540-414-900-907,2018-11-23,2018,CN 201780022021 A,2017-03-31,US 201662317443 P;;US 201662317459 P;;US 201662317456 P;;US 201662317452 P;;US 201662317449 P;;US 201662317460 P;;US 201662317453 P;;US 201662317455 P;;US 201662317451 P;;US 201662351615 P;;US 2017/0025451 W,2016-04-01,"Systems, devices, and methods for time-resolved fluorescent spectroscopy","Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bandsso as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decayof the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.",BLACK LIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;BLACK KEITH;;KAVANAUGH JACK;;BORTNIK BARTOSZ;;NIE ZHAOJUN,,https://lens.org/096-540-414-900-907,Patent Application,no,6,4,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,G01N21/64;;A61B6/00;;G01N21/25;;G01N21/62;;G01N21/63,,0,0,,,,DISCONTINUED
274,US,A1,US 2022/0276167 A1,079-057-306-636-647,2022-09-01,2022,US 202217578932 A,2022-01-19,US 202217578932 A;;US 202016849102 A;;US 201715475750 A;;US 201662351615 P;;US 201662317443 P;;US 201662317449 P;;US 201662317451 P;;US 201662317452 P;;US 201662317453 P;;US 201662317455 P;;US 201662317456 P;;US 201662317459 P;;US 201662317460 P,2016-04-01,"SYSTEMS, DEVICES, AND METHODS FOR TIME-RESOLVED FLUORESCENT SPECTROSCOPY","Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.",BLACK LIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;BLACK KEITH;;KAVANAUGH JACK;;BORTNIK BARTOSZ;;NIE ZHAOJUN,BLACK LIGHT SURGICAL INC (2017-04-03);;CEDARS-SINAI MEDICAL CENTER (2017-04-05),https://lens.org/079-057-306-636-647,Patent Application,yes,5,0,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,G01N21/64;;G01J3/02;;G01J3/10;;G01J3/28;;G01J3/32;;G01J3/44,,1,1,006-856-262-369-104,10.1126/science.272.5259.255,"Macklin et al., ""Imaging and Time-Revolved Spectroscopy of Single Molecules at an Interfance"", Science, Vol. 272, pp. 255 - 258. (Year: 1996)",PENDING
275,WO,A1,WO 2011/072240 A1,107-568-291-161-041,2011-06-16,2011,US 2010/0059919 W,2010-12-10,US 28549509 P,2009-12-10,DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER,"The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.",CEDARS SINAI MEDICAL CENTER;;PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,,https://lens.org/107-568-291-161-041,Patent Application,yes,2,6,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61K31/425;;A01N43/52,,40,30,012-011-330-340-059;;064-884-073-662-848;;170-853-882-083-556;;076-069-720-623-007;;089-773-133-078-99X;;012-251-206-172-978;;092-864-235-322-940;;024-853-541-370-254;;000-409-501-606-70X;;088-076-682-849-849;;027-177-154-094-913;;003-631-120-479-205;;056-106-508-661-801;;078-749-765-604-979;;107-990-469-227-380;;019-524-632-030-548;;135-545-938-771-996;;094-544-976-445-251;;106-640-130-151-317;;086-499-835-921-55X;;149-009-853-252-790;;068-659-879-554-517;;068-082-778-319-717;;013-415-019-143-842;;056-754-795-949-28X;;088-509-278-000-721;;160-717-493-067-916;;068-365-614-968-438;;087-520-893-698-325;;044-248-524-774-951,10.7150/ijms.5.273;;pmc2536715;;18797509;;11780887;;10.3171/jns.2001.95.2.0190;;10.1039/b005652i;;10.1007/s00401-007-0243-4;;17618441;;pmc1929165;;17964023;;10.1016/j.ncl.2007.07.006;;16648043;;10.1016/s1470-2045(06)70665-9;;10.1056/nejmoa043330;;15758009;;16985051;;10.1158/1535-7163.mct-05-0428;;18952979;;pmc2718972;;10.1215/15228517-2008-090;;10.1038/nm1002;;14981512;;10.1038/nrd1088;;12750738;;10.1080/10611860400011927;;15621677;;10.1016/j.jconrel.2004.07.009;;15588910;;10.1038/nrc1566;;15738981;;10.1016/j.addr.2004.10.006;;15722167;;10.1677/erc.1.01045;;16113096;;12639809;;10.1016/s1567-5769(02)00271-0;;17630012;;pmc2394675;;10.1016/j.jconrel.2007.05.032;;pmc3487710;;10.1021/bc0502457;;16536461;;19699248;;10.1016/j.addr.2009.06.005;;10.1007/s00280-006-0407-2;;17256133;;10.1007/s11060-009-9857-9;;19337695;;pmc1185838;;708370;;10.1042/bj1730723;;pmc2734385;;18373429;;10.2217/17435889.3.2.247;;10609647;;10.1023/a:1020614525534;;6606682;;10.1016/0022-1759(83)90303-4;;10914698;;10.1124/mol.108.045112;;18477668;;pmc3909956;;16430958;;10.1016/j.biomaterials.2005.12.022;;16303268;;10.1016/j.ijpharm.2005.10.010,"BRAUN ET AL., DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. 2008, no. 2, January 2009 (2009-01-01), pages 289;;WALDECK ET AL., INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, vol. 5, 2008, pages 273;;M. LACROIXD. ABI-SAIDD. R. FOURNEYZ. L. GOKASLANW. SHIF. DEMONTEF. F. LANGI. E. MCCUTCHEONS. J. HASSENBUSCHE. HOLLAND: ""A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival"", J. NEUROSURG, vol. 95, 2001, pages 190 - 198;;J. ARROWSMITHS. A. JENNINGSD. A. LANGNELR. T. WHEELHOUSEM. F. STEVENS: ""Antitumour imidazotetrazines. Part 39 synthesis of bis(imidazotetrazine)s with saturated spacer groups"", J CHEM SOC PERKIN TRANS 1, vol. 24, 2000, pages 4432 - 4438, XP001069597, DOI: 10.1039/b005652i;;D. N. LOUISH. OHGAKIO. D. WIESTLERW. K. CAVENEEP. C. BURGERA. JOUVETB. W. SCHEITHAUERP. KLEIHUES: ""The 2007 WHO classification of tumours of the central nervous system"", ACTA NEUROPATHOL., vol. 114, 2007, pages 97 - 109;;2009 CBTRUS STATISTICAL REPORT: PRIMARY BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS DIAGNOSED, 2004, Retrieved from the Internet <URL:http://www.cbtrus.org/reports/2009-NPCR-04-05/CBTRUS-NPCR2004-2005-Report--.pdf>;;A. R. ASTHAGIRIN. POURATIANJ. SHERMANG. AHMEDM. E. SHAFFREY: ""Advances in brain tumor surgery"", NEUROL CLIN., vol. 25, 2007, pages 975 - 1003;;W. STUMMERU. PICHLMEIERT. MEINELO. D. WIESTLERF. ZANELLAH. J. REULEN: ""Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial"", LANCET ONCOL., vol. 7, 2006, pages 392 - 401;;R. STUPPW. P. MASONM. J. VAN DEN BENTM. WELLERB. FISHERM. J. TAPHOORNK. BELANGERA. A. BRANDESC. MAROSIU. BOGDAHN: ""Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma"", N ENGL J. MED., vol. 352, 2005, pages 987 - 996;;N. AUGERJ. THILLETK. WANHERDRICKA. IDBAIHM. E. LEGRIERB. DUTRILLAUXM. SANSONM. F. POUPON: ""Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line"", MOL CANCER THER., vol. 5, 2006, pages 2182 - 2192;;C. C. CHENK. T. KAHLEK. NGM. NITTAA. D. ANDREA: ""CNS Cancer"", 2009, HUMANA PRESS, article ""Of escherichia coli and man: understanding glioma resistance to temozolomide therapy"", pages: 679 - 711;;G. J. KITANGEB. L. CARLSONM. A. SCHROEDERP. T. GROGANJ. D. LAMONTP. A. DECKERW. WUC. D. JAMESJ. N. SARKARIA: ""Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts"", NEURO ONCOL., vol. 11, 2009, pages 281 - 291;;R. SATCHI-FAINAROM. PUDERJ. W. DAVIESH. T. TRAND. A. SAMPSONA. K. GREENEG. CORFASJ. FOLKMAN: ""Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470"", NAT. MED., vol. 10, 2004, pages 255 - 261, XP002542562, DOI: 10.1038/nm1002;;R. DUNCAN: ""The dawning era of polymer therapeutics"", NAT REV DRUG DISCOV., vol. 2, 2003, pages 347 - 360, XP008034297, DOI: 10.1038/nrd1088;;S. V. VINOGRADOVE. V. BATRAKOVAS. LIA. V. KABANOV: ""Mixed polymer micelles of amphiphilic and cationic copolymers for delivery of antisense oligonucleotides"", J DRUG TARGET, vol. 12, 2004, pages 517 - 526, XP009164815, DOI: 10.1080/10611860400011927;;A. V. KABANOVE. V. BATRAKOVAS. SRIADIBHATLAZ. YANGD. L. KELLYV. Y. ALAKOV: ""Polymer genomics: shifting the gene and drug delivery paradigms"", J CONTROL RELEASE, vol. 101, 2005, pages 259 - 271;;D. PEERJ. M. KARPS. HONGO. C. FAROKHZADR. MARGALITR. LANGER: ""Nanocarriers as an emerging platform for cancer therapy"", NAT. NANOTECHNOL., vol. 2, 2007, pages 751 - 760, XP002531251, DOI: 10.1038/nnano.2007.387;;M. FERRARI: ""Cancer nanotechnology: opportunities and challenges"", NAT REV CANCER, vol. 5, 2005, pages 161 - 171, XP009046171, DOI: 10.1038/nrc1566;;A. NORIJ. KOPECEK: ""Intracellular targeting of polymer-bound drugs for cancer chemotherapy"", ADV DRUG DELIV REV., vol. 57, 2005, pages 609 - 636;;R. DUNCANM. J. VICENTF. GRECOR. I. NICHOLSON: ""Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer"", ENDOCR RELAT CANCER, vol. 12, 2005, pages S189 - S199, XP002768439, DOI: 10.1677/erc.1.01045;;H. MAEDAJ. FANGT. INUTSUKAY. KITAMOTO: ""Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications"", INT IMMUNOPHARMACOL., vol. 3, 2003, pages 319 - 328;;M. FUJITAB. S. LEEN. M. KHAZENZONM. L. PENICHETK. A. WAWROWSKYR. PATILH. DINGE. HOLLERK. L. BLACKJ. Y. LJUBIMOVA: ""Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(b-L-malic acid"", J CONTROL RELEASE, vol. 122, 2007, pages 356 - 363;;B. S. LEEM. FUJITAN. M. KHAZENZONK. A. WAWROWSKYS. WACHSMANN-HOGIUD. L. FARKASK. L. BLACKJ. Y. LJUBIMOVAE. HOLLER: ""Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(b-L-malic acid) for drug delivery"", BIOCONJUG CHEM., vol. 17, 2006, pages 317 - 326;;E. SEGALR. SATCHI-FAINARO: ""Design and development of polymer conjugates as anti-angiogenic agents"", ADV DRUG DELIV REV., vol. 61, 2009, pages 1159 - 1176, XP026698380, DOI: 10.1016/j.addr.2009.06.005;;S. BREMB. TYLERK. LIG. PRADILLAF. LEGNANIJ. CAPLANH. BREM: ""Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model"", CANCER CHEMOTHER PHARMACOL., vol. 60, 2007, pages 643 - 650, XP019539675, DOI: 10.1007/s00280-006-0407-2;;U. AKBART. JONESJ. WINESTONEM. MICHAELA. SHUKLAY. SUNC. DUNTSCH: ""Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection"", J NEUROONCOL., vol. 94, 2009, pages 203 - 212, XP019732575, DOI: 10.1007/s11060-009-9857-9;;L. X. ZHAOJ. L. WANGX. P. DAIY. F. WANGZ. Z. JI: ""Synthesis and antitumour activities of 3-substituted 4-oxo-3H-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acids and their derivatives"", CHIN J MED. CHEM., vol. 11, 2001, pages 263 - 269, XP009114359;;E. HOLLER: ""Handbook of Engineering Polymeric Materials"", 1997, MARCEL DEKKER, article ""Poly(malic acid) from natural sources"", pages: 93 - 103;;J. CARLSSONH. DREVINR. AXEN: ""Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent"", BIOCHEM J., vol. 173, 1978, pages 723 - 737, XP001146511;;J. Y. LJUBIMOVAM. FUJITAA. V. LJUBIMOVV. P. TORCHILINK. L. BLACKE. HOLLER: ""Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery"", NANOMEDICINE, vol. 3, 2008, pages 247 - 265, XP008149326, DOI: 10.2217/17435889.3.2.247;;I. O. F. S. (ISO). METHODS FOR DETERMINATION OF PARTICLE SIZE DISTRIBUTION PART 8: PHOTON CORRELATION SPECTROSCOPY, INTERNATIONAL STANDARD ISO 13321, 1996;;P. C. HIEMENZ: ""Polymer Chemistry: The Basic Concepts"", 1984, MARCEL DECKER, article ""Light scattering by polymer solutions"", pages: 659 - 661;;F. N. FUB. R. SINGH: ""Calcein permeability of liposomes mediated by type A botulinum neurotoxin and its light and heavy chains"", J PROTEIN CHEM., vol. 18, 1999, pages 701 - 707;;T. J. MOSMANN: ""Rapid colorimetric assays for cellular growth and survival: application to proliferation and cytotoxicity assays"", IMMUNOL METHODS, vol. 65, 1983, pages 55 - 63, XP023973702, DOI: 10.1016/0022-1759(83)90303-4;;H. S. FRIEDMANT. KERBYH. CALVERT: ""Temozolomide and treatment of malignant glioma"", CLIN CANCER RES., vol. 6, 2000, pages 2585 - 2597;;R. N. TRIVEDIX. H. WANGE. JELEZCOVAE. M. GOELLNERJ. B. TANGR. W. SOBOL: ""Human methyl purine DNA glycosylase and DNA polymerase b expression collectively predict sensitivity to temozolomide"", MOL. PHARMACOL., vol. 74, 2008, pages 505 - 516;;A. E. NELL. MADLERD. VELEGOLT. XIAE. M. HOEKP. SOMASUNDARANF. KLAESSIGV. CASTRANOVAM. THOMPSON: ""Understanding biophysicochemical interactions at the nano-bio interface"", NAT. MATER., vol. 8, 2009, pages 543 - 557;;M. R. LORENZV. HOLZAPFELA. MUSYANOVYCHK. NOTHELFERP. WALTHERH. FRANKK. LANDFESTERH. SCHREZENMEIERV. MAILANDER: ""Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells"", BIOMATERIALS, vol. 27, 2006, pages 2820 - 2828;;D. E. OWENSN. A. PEPPAS: ""Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles"", INT J. PHARM., vol. 307, 2006, pages 93 - 102;;See also references of EP 2509421A4",PENDING
276,US,B2,US 9827325 B2,013-222-922-123-783,2017-11-28,2017,US 201715450519 A,2017-03-06,US 201715450519 A;;US 201615054266 A;;US 201414179195 A;;US 201213513145 A;;US 2010/0059919 W;;US 28549509 P,2009-12-10,Drug delivery of temozolomide for systemic based treatment of cancer,"The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.",CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2012-11-12),https://lens.org/013-222-922-123-783,Granted Patent,yes,27,1,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61K31/4188;;A61K31/425;;C07K16/28;;C07K16/30,,175,120,010-586-072-524-473;;002-057-097-140-560;;068-659-879-554-517;;132-372-225-925-009;;120-057-020-523-828;;074-117-757-519-423;;170-853-882-083-556;;089-773-133-078-99X;;069-764-206-551-021;;024-853-541-370-254;;010-084-423-107-920;;115-650-595-072-446;;002-410-830-739-846;;053-390-613-704-481;;004-569-967-691-895;;022-962-759-811-219;;044-914-849-410-277;;030-136-053-475-941;;149-009-853-252-790;;087-365-800-456-427;;027-327-439-480-050;;160-788-201-223-007;;068-082-778-319-717;;101-523-476-724-00X;;082-428-855-525-972;;005-068-515-810-831;;019-068-052-192-616;;007-174-756-618-033;;019-524-632-030-548;;027-177-154-094-913;;078-749-765-604-979;;056-318-394-213-772;;160-717-493-067-916;;056-754-795-949-28X;;094-544-976-445-251;;071-446-219-522-092;;057-449-500-429-70X;;081-535-546-606-522;;010-713-998-880-948;;015-845-411-216-05X;;048-551-084-856-415;;043-263-823-749-982;;033-337-348-972-822;;026-135-913-145-143;;026-135-913-145-143;;011-450-253-768-016;;113-433-411-873-182;;039-738-668-274-842;;010-800-681-313-086;;012-529-188-555-935;;056-106-508-661-801;;070-217-550-786-105;;084-804-379-761-825;;000-409-501-606-70X;;016-130-071-571-991;;091-843-097-683-406;;007-736-347-486-414;;067-176-202-940-165;;080-676-605-062-549;;089-207-455-463-763;;030-564-677-109-748;;122-563-304-750-445;;101-937-544-377-16X;;121-705-764-271-79X;;064-884-073-662-848;;085-389-958-075-222;;013-753-717-969-918;;106-640-130-151-317;;145-523-027-249-174;;021-383-028-538-332;;065-084-770-968-763;;016-204-634-827-524;;001-280-492-710-987;;027-533-193-912-497;;013-415-019-143-842;;087-520-893-698-325;;076-069-720-623-007;;122-990-056-888-627;;009-843-764-520-632;;092-704-236-824-35X;;135-545-938-771-996;;041-096-604-932-631;;094-717-970-788-379;;021-138-842-966-383;;088-509-278-000-721;;039-079-455-504-396;;050-185-841-748-492;;061-454-537-963-94X;;107-990-469-227-380;;044-248-524-774-951;;143-247-059-865-683;;012-497-328-331-068;;100-392-131-292-623;;114-357-812-206-334;;116-305-745-084-880;;016-795-130-437-95X;;131-982-616-033-720;;030-769-003-988-749;;027-518-915-267-472;;088-076-682-849-849;;114-097-940-181-735;;086-499-835-921-55X;;036-550-119-702-468;;037-478-719-421-857;;065-513-307-731-185;;012-251-206-172-978;;098-337-997-673-45X;;058-546-248-134-723;;053-130-150-863-097;;031-009-176-924-174;;068-365-614-968-438;;004-329-899-218-795;;003-631-120-479-205;;040-861-043-363-027;;012-011-330-340-059;;159-835-915-641-650;;120-680-307-644-234;;017-403-655-208-27X;;016-276-524-241-605;;025-444-780-060-105,10.1016/s0928-0987(97)00069-9;;16256709;;10652480;;10.1016/s1357-4310(99)01638-x;;10.1007/s11060-009-9857-9;;19337695;;2438036;;10.1200/jco.2001.19.8.2189;;11304771;;10688605;;10.1039/b005652i;;17964023;;10.1016/j.ncl.2007.07.006;;10807948;;10.1016/s0006-2952(00)00310-5;;16985051;;10.1158/1535-7163.mct-05-0428;;10.1021/bm0300608;;14715019;;10.1093/nar/29.23.4873;;pmc96684;;11726697;;10.1002/1097-0029(20001101)51:3<280::aid-jemt7>3.0.co;2-o;;11054877;;11751392;;10.1016/s0169-409x(00)00139-3;;11259843;;10991985;;10.1021/js9800836;;9811482;;pmc2761188;;19920915;;10.2147/dddt.s3572;;10.1007/s00280-006-0407-2;;17256133;;10.1006/exnr.1996.0178;;8912898;;10.1016/j.jconrel.2003.06.001;;14636717;;10416675;;10.1016/s0141-8130(99)00042-2;;pmc1185838;;708370;;10.1042/bj1730723;;10.1002/(sici)1097-0177(200006)218:2<213::aid-dvdy1>3.0.co;2-r;;10842354;;9472555;;10.1038/sj.gt.3300536;;pmc102580;;10648777;;10.1093/nar/28.4.868;;12489851;;10.1016/j.nano.2016.07.013;;pmc5812454;;27520726;;10.1677/erc.1.01045;;16113096;;10.1038/nrd1088;;12750738;;10.1038/nrc1566;;15738981;;2765532;;10.1021/bi00438a045;;10914698;;10609647;;10.1023/a:1020614525534;;17630012;;pmc2394675;;10.1016/j.jconrel.2007.05.032;;pmc3487708;;17109197;;10.1007/s10456-006-9046-9;;10.1186/bcr1011;;15987446;;pmc1175051;;10.1074/jbc.m010155200;;11278628;;10.1002/(sici)1097-0215(19980330)76:1<63::aid-ijc11>3.0.co;2-h;;9533763;;8622906;;pmc39574;;10.1073/pnas.93.8.3161;;12454288;;pmc138567;;10.1073/pnas.252649399;;10.1016/s0006-291x(02)02642-6;;12445830;;10.1002/ijc.10233;;11920587;;20921419;;10.1073/pnas.1003919107;;pmc2964197;;20921419;;10.1073/pnas.1003919107;;pmc2964197;;10.1158/0008-5472.can-10-3093;;10.31234/osf.io/nyh6f;;21303974;;pmc3428373;;10.1158/1538-7445.am10-3854;;12855625;;9855188;;10.1016/s0142-9612(98)00095-7;;10.1016/s0140-6736(00)03207-4;;11095261;;10.1016/j.jconrel.2004.07.009;;15588910;;10845554;;10.1023/a:1006760632766;;14578463;;18952979;;pmc2718972;;10.1215/15228517-2008-090;;2937447;;10.1021/bi00350a005;;10.1002/(sici)1097-0215(19980316)75:6<864::aid-ijc8>3.0.co;2-t;;9506531;;11223987;;10.1038/sj.gt.3301327;;11156378;;10840193;;10.1016/s0939-6411(00)00075-8;;10.1139/m95-187;;pmc2913688;;10.1007/s11010-008-9831-4;;18612802;;10658911;;10.1038/modpathol.3880010;;10.1021/bc980123x;;10346884;;10.1073/pnas.97.17.9591;;pmc16909;;10944225;;11780887;;10.3171/jns.2001.95.2.0190;;10554005;;10.1007/s002530051445;;pmc3487710;;10.1021/bc0502457;;16536461;;7723285;;10.1016/s1359-6349(04)80616-5;;16146715;;10.2741/1781;;pmc3506377;;17376417;;pmc2329596;;10.1016/j.cbi.2007.01.015;;11454714;;15274074;;10.1002/cncr.20397;;pmc2734385;;18373429;;10.2217/17435889.3.2.247;;16430958;;10.1016/j.biomaterials.2005.12.022;;10.1007/s00401-007-0243-4;;17618441;;pmc1929165;;10.1017/cbo9780511546402.025;;10.1016/j.abb.2007.04.013;;pmc2025638;;17562324;;10066093;;10.1023/a:1006150506789;;12639809;;10.1016/s1567-5769(02)00271-0;;10.1083/jcb.200302126;;12741393;;pmc2172901;;10.1083/jcb.jcb.200302126;;2072663;;10.1083/jcb.137.3.685;;9151674;;pmc2139892;;6606682;;10.1016/0022-1759(83)90303-4;;19525947;;10.1038/nmat2442;;10.1016/s0076-6879(01)40429-0;;11494857;;10.1038/sj.gt.3302507;;15759014;;10.1016/j.addr.2004.10.006;;15722167;;16303268;;10.1016/j.ijpharm.2005.10.010;;12083850;;10.1016/s1044-579x(02)00023-8;;18654426;;10.1038/nnano.2007.387;;10.1177/002215540205000813;;12133914;;11733118;;10.1016/s0169-409x(01)00221-6;;10.1124/pr.54.4.561;;12429868;;10506168;;10.1074/jbc.274.41.29130;;20387095;;pmc2952070;;10.1007/s11095-010-0091-0;;12564977;;10.1016/s0169-409x(02)00179-5;;10.1017/cbo9780511546402.030;;10.1038/nm1002;;14981512;;10.1021/bc990039x;;10502354;;19699248;;10.1016/j.addr.2009.06.005;;10.1002/(sici)1098-2388(199801/02)14:1<3::aid-ssu2>3.0.co;2-f;;9407626;;pmc16586;;10840060;;10.1073/pnas.130187497;;10.1083/jcb.153.5.933;;pmc2174323;;11381080;;16648043;;10.1016/s1470-2045(06)70665-9;;10.1016/j.canrad.2005.05.001;;9212909;;10.1089/oli.1.1997.7.187;;9325016;;10.1006/cyto.1997.0212;;pmc134646;;11809810;;10.1128/mcb.22.4.1194-1202.2002;;10.1124/mol.108.045112;;18477668;;pmc3909956;;10.1023/a:1014573204062;;11964076;;10.1080/10611860400011927;;15621677;;6501412;;pmc2113570;;10.1083/jcb.99.6.2034;;10.7150/ijms.5.273;;pmc2536715;;18797509;;7508268;;10.1021/bc00024a015;;15770691;;10.1002/cncr.20970;;19296227;;pmc2664895;;10.1208/s12248-009-9096-1;;11813879;;10.14670/hh-17.301;;12095305;;10.1006/mthe.2002.0633,"Abdellaoui et al. Metabolite-derived Artificial Polymers Designed for Drug Targeting, Cell Penetration and Bioresorption, European Journal of Pharmaceutical Sciences, vol. 6, No. 1 (1998), pp. 61-73.;;Agrawal et al., Anntisense Therapeutics: Is It As Simple As Complimentary Base Recognition?, Molecular Medicine Today, (Feb. 2000), pp. 72-81, 6.;;Akbar, et al. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. Journal of Neuro-Oncology 94 (2009): 203-212.;;Albini et al. A rapid in Vitro Assay for Quantitating the Invasive Potentia of Tumor Cells, Cancer Research, (Jun. 15, 1997), pp. 3239-3245, 47(12).;;Andrews et al. Resultes of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-like Growth Factor Type I Receptor in Malignant Astrocytomas, Journal of Clinical Oncology, (Apr. 15, 2001), pp. 2189-2200, 19(8).;;Arora et al. c-Myc Antisense Limits Rat Liver Regeneration and Indicates Role for c-Myc in Regulating Cytochrome P-450 3A Activity, Kournal of Pharmacology and Experimental Therapeutics, (Mar. 2009), pp. 921-928, 292(3).;;Arrowsmith, et al. Part 39 synthesis of bis(imidazotetrazine)s with saturated spacer groups.Journal of the Chemical Society 1. 24 (2000): 4432-4438.;;Asthagiri, et al. Advances in brain tumor surgery. Neurologic Clinics 25 (2007): 975-1003.;;Astriab-Fisher et al. Antisense Inhibition of P-Glycoprotein Expression Using Peptide- Oligonucleotide Conjugates, Biochemical Pharmacology (Jul. 1, 200), pp. 83-90, 60(1).;;Auger, et al. Genetic alterations associated with acquired with temozolide resistance in Snb- 19, a human glioma cell line. Molecular Cancer Therapeutics 5 (2006): 2182-2192.;;Barbosa et al. Investigation of the Degradation Mechanism of Poly(malic acid) Esters in Vitro and their Related Cytotoxicities on J774 Macrophages, Biomacromolecules 2004, vol. 5, No. 1, pp. 137-143.;;Basye, et al. Triplex formation by morpholino oligodeoxyribonucleotides in the HER-2/neu promoter requires the pyrimidine motif. Nucleic Acids Research, 29 (2001): 4873-4880.;;Belkin et al. Integrins as Receptors for Laminins, Microscopy Research and Technique, (Nov. 1, 2000), pp. 280-301, 51(3).;;Bello et al., Simultaneous Inhibition of Glioma Angiogenesis, Cell Proliferation, and Invasion by a Naturally Occurring Fragment of Human Metalloproteinase-2, Cancer Research, (Dec. 15, 2001), pp. 8730-8736, 61(24).;;Bickel et al., Delivery of Peptides and Proteins Through the Blood-Brain Barrier, Advanced Drug Delivery Reviews, (2001), pp. 247-279, 46.;;Boado et al. Antisense-Mediated Down-Regulation of the Human Huntingtin Gene, Journal of Pharmacology and Experimental Therapy, (Oct. 200), pp. 239-243, 295(1).;;Boado et al., Drug delivery of Antisense Molecules to the Brain for Treatemnet of Alzheimer's Disease and Cerebral Aids, Journal of Pharmacological Science, (1998), pp. 1308-1315, 87.;;Braun, et al. Treatment glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Aider ligation chemistry. Drug Design, Development and Therapy, Dove Medical Press Ltd, UK, 2008.2 (2009): 289-301.;;Brem, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol. 60 (2007): 643-650.;;Broadwell et al., Transcytosis of Protein Through the Mammalian Cerebral Epithelium and Endothelium III Receptor-Mediated Transcytosis Through the Blood-Brain of Blood-Bome Transferrin and Antibpdy Against the Transferrin Receptor, Experimental Neurology, (1996), pp. 47-65, 142.;;Bulmus et al., A new pH-Responsive and Glutathione-reactive Endosomal Membrane-disruptive Polymeric Carrier for Intracellular Delivery of Biomolecular Drugs, Journal of Controlled Release, (2003), 93: 105-120.;;Cammas et al., Polymers of Malic Acid and 3-Akylmalic Acid as Synthetic PHAs in the Design of Biocompatible Hydrolyzable Devices, International Journal of Biological Macromolecules, (1999), pp. 273-282, 25.;;Carlsson, et al. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J. Sep. 1, 1978;173(3):723-737.;;CBTRUS Statistical Report 2009 : Primary Brain and Central Nervous System Tumors Diagnosed in the united States in 2004-2005. http://www.cbtrus.org/reports/2009-NPCR-04-05/CBTRUS-NPCR2004-2005-Report-.pdf (accessed (Nov. 17, 2009).;;Chen, et al. Of escherichia coli and man: understanding glioma resistance to temozolmide therapy. In E. G. Meir (eds.), CN8 Cancer, Humana Press, Atlanta, (2009): 679-711.;;Colognato et al., Form and Function: The Laminin Family of Heterotrimers, Developmental Dynamics, (Jun. 2000), pp. 213-234, 218(2).;;Coonrad, et al. On the mechanism of DNA transfection: efficient gene transfer without viruses, Gene Therapy, 4 (1997): 1313-1321.;;Co-pending U.S. Appl. No. 15/447,439, filed Mar. 2, 2017.;;De Diesbach et al.,Identification, Purification and Partial Charaterozation of An Oligonucleotide Receptor in Membranes of HepG3 Cells, Nucleic Acids Research, (Feb. 15, 2000), pp. 868-874, 28(4).;;Dias et al., Antisense Oligonucleotides: Basic Concepts and Mechanisms, Molecular Cancer Therapy, (Mar. 2002), pp. 3470355, 1(15).;;Ding et al., HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug, Nanomedicine: Nanotechnology, Biology, and Medicine, 13: 631-639 (2017).;;Duncan, et al. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocrine-Related Cancer, 12 (2005): S189-S199.;;Duncan. The dawning era of polymer therapeutics. Nat. Rev. Drug Discovery 2:347-360 (2003).;;EP10836765.7 Extended European Search Report dated Oct. 9, 2013.;;European search report dated Feb. 7, 2014 for EP10861515.;;European search report with written opinion dated Jan. 4, 2013 for EP09730249.;;Ferrari. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161-171 (2005).;;Final Office action dated Sep. 8, 2013 for U.S. Appl. No. 13/513,145.;;Final Office action dated Oct. 29, 2015 for U.S. Appl. No. 13/930,533.;;Fischer et al., An Unusual Polyanion From Physarum Polycephalum That Inhibits Homologoes DNA Polymerase A In Vitro, Biochemistry, (1989), pp. 5219-5226, 28.;;Friedman, et al. Temozolomide and treatment of malignant glioma. Clin Cancer Res. Jul. 2000;6(7):2585-97.;;Fu, et al. Calcein permeability of liposomes mediated by type A botulinum neurotoxin and its light and heavy chains. Journal of protein chemistry 18 (1999): 701-707.;;Fujita, et al. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta- L-malic acid), Journal of Controlled Release, 122.3 (2007): 356-363.;;Fujita et al., Inhibition of Laminin-8 In Vivo Using a Novel Poly(Malic Acid)-Based Carrier Reduces Glioma Angiogenesis, Angiogenesis, (2006), pp. 183-191.;;Fujita, et al. Overexpression of beta1-chain-containing lam in ins in capillary basement membranes of human breast cancer and its metastases, Breast Cancer Research, vol. 7, No. 4, p. R411-R421 (Apr. 6, 2005) Retrieved from the Internet<URL:http://breast-cancer-research.com/contenU7/4/R411>.;;Fujiwara et al., Purification and Characterization of Human Laminin-8 Stimulates Cell Adhesion and Migration Through a3p1 and a6p Integrins, Journal of Biological Chemistry, (May 18, 2001), pp. 17550-17558, 276(20),.;;Fukushima et al. Integrin a3(31-mediated Interaction with Laminin-5 Stimulates Adhesion, Migration and Invasion of Malignant Glioma Cells, Int. Journal of Cancer (Mar. 30, 1998), 76(1), pp. 63-72.;;Gewirtz et al., Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on Its Promise, Proceedings of the National Academy of Sciences of USA, (Apr. 1996), pp. 3161-3163, 93.;;Gonzales et al., Complex Interactions Between the Laminin a4 Subunit and Integrins Regulate Endothelial Cell Behaviour In Vitro and Angiogenesis In Vivo, Proceedings of the National Academy of Sciences USA, (Dec. 10, 2002), pp. 16075-16080, 99(25).;;Hayashi et al., Identification and Recombination Production of Human Laminin a4 Subunit Splice Variants, Biochemical and Biophysical Research Communications, (Dec. 6, 2002), pp. 498-504, 299(3).;;Herold-Mende et al. Clinical Impact and Functional Aspects of Tenascin-C Expression During Glioma Progression, International Journal of Cancer, (Mar. 20, 2002), pp. 362-369, 98(3).;;Holler, Poly(malic acid) from natural sources. In N. P. Cheremisinoff (eds.), Handbook of Engineering Polymeric Materials, Marcel Dekker, New York, 1997, 93-103.;;Hui, et al. Inhibition of brain tumor growth by intravenous poly (-L-malic) acid nanobioconjugate with pH- dependent drug release; Proceedings of the National Academy of Sciences, Correction in vol. 107, No. 45, p. 19603 (Nov. 9, 2010).;;Hui, et al. Inhibition of brain tumor growth by intravenous poly (-L-malic) acid nanobioconjugate with pH- dependent drug release; Proceedings of the National Academy of Sciences, vol. 107, No. 42, pp. 18143-18148 (Oct. 19, 2010).;;Inoue et a., Polymalic Acid—Based Nanobiopolymer Provides Efficient Systemic Breast Cancer Treatment by Inhibiting both HER2/neu Receptor Synthesis and Activity, Cancer Res; 71(4):1454-1464 (2011).;;Inoue, et al. Newly designed nanobioconjugate for direct targeting and systemic treatment of HER2- positive breast cancer, Proceedings of the American Association for Cancer Research Annual Meeting, 101st Annual Meeting of the American Association for Cancer Research, Washington, D.C. vol. 51, p. 937 (Apr. 17-21, 2010).;;International search report with written opinion dated Feb. 11, 2011 for PCT/US2010/059919.;;International search report with written opinion dated Jul. 14, 2009 for PCT/US2009/040252.;;International search report with written opinion dated Oct. 25, 2011 for PCT/US2010/062515.;;Iversen, et al. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clinical Cancer Research, 9 (2003): 2510-2519.;;Iwata et al., A Novel Surgical Glue Composed of Gelatin and N-Hydroxysuccinimide Activate Poly(L-Glutamic Acid): Part 1 Synthesis of Activated Poly(L-Glutamic Acid) and Its Gelation With Gelatin, Biomaterials, (1998), pp. 1859-1876, 19.;;Jansen et al., Chemosensitisation of Malignant Melanoma by BCL2 Antisense Therapy, Lancet, (Nov. 18, 2000), pp. 1728-1733, 356(9243).;;Kabanov, et al. Polymer genomics: shifting the gene and drug delivery paradigms. Journal of Controlled Release 101 (2005): 259-271.;;Kachra et al. Expression of Matrix Metalloproteinases and Their Inhibitors in Human Brain Tumrors, Clinical and Experimental Metastasis, (1999), pp. 555-566, 17(7).;;Khazenzon et al., Antisense Inhibition of Laminin-8 Expression Reduces Invasion of Human Gliomas In Vitro, Molecular Cancer Therapeutics, (2003), pp. 985-994,2.;;KHAZENZON LAKHTER A J, ET AL: ""Novel angiogenic targets for human glioma prevention and regulation of their expression"", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS PUBLICATIONS, GR, vol. 10, no. Supplement 1, 12 October 2002 (2002-10-12), GR, pages S41, XP008091390, ISSN: 1107-3756;;Kitange, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Journal of Neuro-Oncology. 11: (2009) 281-291.;;Kleinman et al., Basement Membrane Complexes with Biological Activity, Biochemistry, (Jan. 28, 2986), pp. 312-318, 25(2).;;Knott et al., Stimulation of Extracellular Matrix Components in the Normal Brain by Invading Glioma Cells, International of Cancer, (Mar. 16, 1998), pp. 864-872, 75(6).;;Komata et al., Combination Therapy of Malignant Glioma Cells With 2-5A-Antisense Telomerase RNA and Recombinant Adenovirus p53, Gene Therapy, (Dec. 2000), pp. 20171-2079, 7(24).;;Kondraganti et al., Selective Supression of Matrix Metalloproteinase-9 in Human Glioblastoma Cells by Antisense GeneTransfer Impairs Glioblastoma Cell Invasion, Cancer Research, (Dec. 15, 2000), pp. 6851-6855, 60(24).;;Kopecek et al., HPMA Copolymer -Anticancer Drug Conjugates: Design, Activity, and Mechanism of Action, european Journal of Biopharmacology, (2000), pp. 61-81, 50.;;Korherr et al., Poly ((3-1 Malate) Hydrolase From Plasmodia of Physarum Polycephalum, Canadian Journal of Microbioligy, (1995), pp. 192-199, 41 (Suppl. 1).;;Kramerov et al., Inhibition of Protein Kinase CK2 Suppresses Angiogenesis and Hematopoietic Stem Cell Recruitment to Retinal Neovascularization Sites. Molecular and Cellular Biochemistry 316:177-186, 2008.;;Kulla et al., Tenascin Expression Patterns and Cells of Monocyte Lineage: Relationship in Human Gliomas, Moder Pathology, (Jan. 2000), pp. 58-67, 13(1).;;Kurihara et al., Epidermal Growth Factor Radiopharmaceuticals:111m Cheladon, Conjugation to a Blood-Brain Barrier Delivery Vector Via a Biotin-Polyethylene Linker, Pharmacokinetics, and In Vivo Imaging of Experimental Brain Tumors, Bioconjugate Chemistry, (1999), 505-511, 10.;;Lacera et al., Restoration of Hemaglobin a Synthesis in Erythroid Cells From Peripheral Blood of Thalassemic Patients, Proceedings of the National Academy of Sciences USA, (Aug. 15, 2000), pp. 9591-9596, 97(17).;;Lacroix, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. Journal of Neurosurgery 95 (2001): 190-198.;;Lal et al., A Public Database for Gene Expression in Human Cancers, Cancer Research, (Nov. 1, 1999), pp. 5403-5407, 59(21).;;Lee, et al. Delivery of antisense oligonucleotides and transferrin receptor antibody in vitro and in vivo using a new multifunctional drug delivery system based on polymalic acid, Proceedings of the American Association for Cancer Research, 45 (2004), Abstract #647.;;Lee et al., Effects of Culture Conditions on p-Poly(I-Malate) Production by Physarum Polycephalum, Applied Microbiology and Biotechnology, (1999), pp. 647-652, 51.;;Lee, et al. Polycefin, a New Prototype of a Multifunctional Nanoconjugate Based on Poly(B-L-malic acid for Drug Delivery, Bioconjugate Chemistry, 17.2 (2006): 317-326.;;Ljubimov et al. Human Corneal Basement Membrane Heterogeneity, Topographical Differences in the Expression of Type IV Collagen and Laminin Isoforms, Lab Invetsigation, (Apr. 1995), pp. 461-473, 72(4).;;LJUBIMOVA, J.Y. HOLLER, E. FUJITA, M. KHAZENZON, N.M. LEE, B. BLACK, K.L.: ""608 A new multifunctional drug delivery system based on polymalic acid to inhibit angiogenesis and invasion of human gliomas in vitro and in vivo"", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 2, no. 8, 1 September 2004 (2004-09-01), GB, pages 184, XP004640052, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(04)80616-5;;Ljubimova et al., Changes in Laminin Isoforms Associated with Brain Tumor Invasion and Angiogenesis, Frontiers in Bioscience, (Jan. 1, 2006), vol. 11, pp. 81-88.;;LJUBIMOVA J Y; KHAZENZON N M; LAKHTER A J; GALPERIN S N; NINGARAJ N S; VIRTANEN I; SOROKIN L M; LJUBIMOV A V; BLACK K L: ""Development of an in vitro system to block the angiogenic target, laminin-8, in human gliomas"", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 43, 10 April 2002 (2002-04-10), US, pages 177, XP001536931, ISSN: 0197-016X;;Ljubimova et al., Development of Anti-Angiogenic and Anti-Invasive Inhibitors of Human Gliomas Using a New Multifunctional Drug delivery System Based on Polymakic Acid, Preclinica (Sep./Oct./2004), 2(5), p. 366.;;Ljubimova et al., Gene Array Analysis of Differentially Expressed Genes in Human Glial Tumors, International Journal of Oncology, (2001), pp. 287-295, 18.;;Ljubimova, et al. Nanoconjugate based on polymalic acid for tumor targeting, Chemico-Biological Interactions, 171.2 (2008): 195-203.;;Ljubimova et al., Overexpression of a4 Chain-Containing Laminins in Human Glial Tumors Identified by Gene Microarray Analysis, Cancer Research (Jul. 15, 2001), pp. 5601-5610, 61(14).;;Ljubimova, J. et al., Association between Laminin-8 and Glial Tumor Grade, Recurrence, and Patient Survival, Cancer (online Jun. 16, 2004), 101(3), pp. 604-612.;;JULIA Y. LJUBIMOVA: ""Molecular Oncology"", 1 July 2009 (2009-07-01), XP008143608, Retrieved from the Internet <URL:http://www.cedars-sinai.edu/10141.html> [retrieved on 20110929];;Ljubimova, Julia Y. et al. Poly( malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery, Nanomedicine, 3.2 (2008): 247-265.;;Lorenz, et al. Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials. 27 (2006): 2820-2828.;;Louis, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114 (2007): 97-109.;;Lu et al., Delivering siRNA In Vivo for Functional Genomics and Novel Therapeutics, RNA Interference Technology, (2205), pp. 303-317.;;Lutsenko, et al. Biochemical Basis of Regulation of Human Copper-Transporting ATPases, Archives of Biochemistry and Biophysics, 463.2 (2007): 134-148.;;MacDonald et al., Urokinase Induces Receptor Mediated Brain Tumor Cell Migration and Invasion, Journal of Neuro Oncology, (Dec. 1998), pp. 215-226, 40(3).;;Machine translation of CN1615855A, 2005, 4 pages.;;Maeda et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. International Immunopharmacology 3:319-328 (2003).;;McKean et al., FAK Induces Expression of Prx1 to Promote Tenascin-C-Dependent Fibroblast Migration, Journal of Cell Biology, (Apr. 28, 2003), pp. 393-402, 161(2).;;Minakawa et al., In Vitro Interaction of Astrocytes and Pericytes With Capillary-Like Structures of Brain Microvessel Endothelium, Lab Investigation, (Jul. 1991), pp. 32-40, 65(1).;;Miner et al. The Laminin Alpha Chains: Expression, Developmental Transitions, and Chromosomal Locations of A1-5, Identification of Heterotrimeric Laminins 8-11, and Cloning of a Novel a3 Isoform, Journal of Cell Biology, (May 5, 1997), pp. 685-701, 137(3).;;Mosmann. Rapid colorimetric assays for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods. 65 (1983): 55-63.;;Nagato et al., Downregulations of Laminin a-4 Chain Expression Inhibits Glioma Invasion In Vitro and In Vivo, Int. Journal of Cancer (onlune Jun. 16, 2004), pp. 604-612.;;NCBI GenBank Accession No. NM—002291 (Nov. 21, 2010)—See the whole document.;;NCBI GenBank Accession No. NM—005228 (Dec. 26, 2010)—See the whole document.;;NCBI GenBank Accession No. X03363 (Mar. 30, 1995)—See the whole document.;;NCBI GenBank Accession No. X91171 (Oct. 7, 2008)—See the whole document.;;NCBI GenBank ATP7B [Homo sapiens] AAB52902.1 (1997): 3 pages.;;Nel, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nature Materials. 8 (2009): 543-557.;;Nielsen et al., Peptide Nucleic Acid Targeting of Double-Stranded DNA. Methods in Enzymology, 2001, pp. 329-340, 340.;;Nielsen P.E. The Last Hurdle?, Gene Therapy, (2005), pp. 956-957, 12.;;Non-Final Office action dated Apr. 4, 2016 for U.S. Appl. No. 15/054,266.;;Non-Final Office action dated Aug. 27, 2015 for U.S. Appl. No. 14/179,195.;;Non-Final Office action dated Nov. 4, 2012 for U.S. Appl. No. 12/935,110.;;Non-Final Office action dated Mar. 14, 2013 for U.S. Appl. No. 13/513,145.;;Non-Final Office action dated Oct. 15, 2014 for U.S. Appl. No. 13/930,533.;;Non-Final Office action dated Jun. 18, 2015 for U.S. Appl. No. 13/930,533.;;Non-Final Office action dated Dec. 19, 2013 for U.S. Appl. No. 13/646,947.;;Nori, et al. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Advanced Drug Delivery Reviews 57 (2005): 609-636.;;Notice of allowance dated Mar. 4, 2011 for U.S. Appl. No. 10/580,999.;;Notice of allowance dated Mar. 8, 2012 for U.S. Appl. No. 12/935,110.;;Notice of allowance dated Apr. 12, 2015 for U.S. Appl. No. 14/179,195.;;Notice of allowance dated Jun. 19, 2013 for U.S. Appl. No. 13/097,364.;;Notice of allowance dated Sep. 3, 2014 for U.S. Appl. No. 14/031,561.;;Notice of allowance dated Apr. 14, 2014 for U.S. Appl. No. 13/513,145.;;Notice of allowance dated Apr. 14, 2014 for U.S. Appl. No. 13/646,947.;;Notice of allowance dated Sep. 14, 2012 for U.S. Appl. No. 12/935,110.;;Notice of allowance dated Dec. 21, 2016 for U.S. Appl. No. 15/054,266.;;Odian, G. (1991) Principles of Polymerization, Third Edition. John Wiley and Sons, Inc.;;Office action dated Jan. 14, 2009 for U.S. Appl. No. 10/580,999.;;Office action dated Feb. 5, 2014 for U.S. Appl. No. 14/031,561.;;Office action dated Mar. 5, 2010 for U.S. Appl. No. 10/580,999.;;Office action dated Apr. 24, 2012 for U.S. Appl. No. 13/097,364.;;Office action dated Aug. 4, 2009 for U.S. Appl. No. 10/580,999.;;Office action dated Sep. 20, 2012 for U.S. Appl. No. 13/097,364.;;Office action dated Dec. 7, 2010 for U.S. Appl. No. 10/580,999.;;Office Action from corresponding European Patent Application No. 10861515.4 dated Feb. 26, 2014, 6 pages.;;Office Action from corresponding Japanese Patent Application No. 2013-547442 dated Oct. 29, 2014, with a Brief Report in English, 6 pages.;;Owens, et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics 307 (2006): 93-102.;;Patarroyo et al., Laminin Isoforms in Tumor Invasion, Angiogenesis, and Metastasis Seminars, Seminars in Cancer Biology, (Jume 2002), pp. 197-207, 12(3).;;PCT/US2009/040252 International Preliminary Report on Patentability dated Oct. 21, 2010.;;Peer, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. Dec. 2007;2(12):751-60.;;Petajaniemi et al., Localization of Laminin a4-Chain in developing and Adult Human Tissues, The Journal of Hrstochemistry and Cytochemistry, (Aug. 2002), pp. 1113-1130, 50(8).;;Pichon et al., Histidine-Rich Peptides and Polymers for Nucleic Acid Delivery, Advanced Drug Delivery Reviews, (2001), pp. 75-94, 53.;;Qian et al., Targeted Drug Delivery via the Transferrin Receptor-mediated Endocytosis Pathway, Pharmacology Reviews. vol. 54, No. 4, (Dec. 2002), pp. 561-587.;;Qin et al., The Transcription Factors Sp1, Sp3, and AP-2 are required for Constitutive Matrix Metalloproteinase-2 Gene Expression in Astroglioma Cells, Journal of Biological Chemistry, (Oct. 8, 1999), pp. 29130-29137.;;Rameshwar, et al. Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Ply (1-L-malic acid). Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, 27.11 (2010): 2317-2329.;;Saito et al., drug Delivery Strategy Utilizing Conjugation via Reversible Disulide Linkages: Role and Site of Cellular Reducing Activities, Advanced Drug Delivery Reviews, (2003), pp. 192-215, 55.;;Samarsky et al., RNAi in Drug Development: Practical considerations, RNA Interference Technology, (2005), pp. 384-395.;;Satchi, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Medicine 10 (2004): 255-261.;;Schnaible et al., identification of Fluorescein-5'-Isothiocynate-Modification Sites in Proteins by Electrospray—Ionization Mass Spectrosopy, Bioconjugates Chemistry, (1999), pp. 861-866, 10.;;Segal, et al. Design and development of polymer conjugates as anti-angiogenic agents. Advanced Drug Delivery Reviews, 61 (2009): 1159-1176.;;Sehgal, A., molecular Changes During the Genesis of Human Gliomas, Seminars in Surgical Oncology, (Jan.-Feb. 1998), pp. 3-12, 14(1).;;Shi et al., Noninvasive Gene Targeting to the Brain, Proceedings of the National Academy of Sciences, (2000), pp. 7567-7572, 97.;;Sixt et al., Endothelial Cell Laminin Isoforms, Laminins 8 and 10, Play Decisive Roles in T Cell Recruitement Across the Blood-Brain Barrier in Experimental Autoimmune Encephalomyelitis, Journal of Cell Biology, (May 28, 2001), pp. 933-947, 153(5).;;Stummer, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology, 7 (2006): 392-401.;;Stupp et al., “Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma,” N. Engl. J. Med. 352:987-996 (2005).;;Summerton et al., Morpholino Antisense Oligomers: Design, Preparation and Properties, Antisense and Nucleic Acid Drug Development, (Jun. 1997), pp. 187-195, 7(3).;;Taylor et al., Comparison of Efficacy of Antisense Oligomers Directed Toward TNF-a in Helper T and Macrophage Cell Lines, Cytokine, ((Sep. 1997), pp. 672-681, 9(9).;;Thyboll et al., Deletion of the Laminin a4 Chain Leads to Impaired Microvessel Maturation, Molecular and Cellular Biology, (Feb. 2002), pp. 1194-1202, 22(4).;;Trivedi, et al. Human methyl purine DNA glycosylase and DNA polymerase b expression collectively predict sensitivity to temozolomide. Mol Pharmacal. 74 (2008): 505-516.;;Tsuji et al., Regulation of Melanoma Cell Migration and Invasion by Laminin-5 and a3(31 Integrin (VLA-3), Clinical and Experimental Metastasis, (2002), pp. 127-134, 19(2).;;Vinogradov, et al. Mixed polymer micelles of amphiphilic and cationic copolymers for delivery of antisense oligonucleotides. Journal of Drug Targeting. 12 (2004): 517-526.;;Voyta et al., Identification and Isolation of Endothelial Cells Based on Their Increased Uptake of Acetylated-Low Density Lipoprotein, Journal Of Cell Biology, (Dec. 1984), pp. 2034-2040, 99(6).;;Waldeck, et al. TMZ-BioShuttle—A reformulated temozolomide. International Journal of Medical Sciences, Ivyspring International Publisher, Lake Haven, AU, 5.5 (2008): 273-284.;;West record of CN1615855A, 2005, 2 pages.;;Willner et al., (6-Maleimidocaproyl) Hydrazone of Doxorubicin—A New Derivative for the Preparation of Immunoconjugates of Doxorubicin, Boconjugate Chemistry, (193), pp. 521-527, 1993.;;Wiseman, et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer, 103.9 (2005): 1770-1777.;;Written opinion dated Jun. 5, 2006 for PCT/US2004/040660.;;Yu, et al. (2009) Targeted Delivery Systems for Oligonucleotide Therapeutics. The AAPS Journal, v.11(1):195-203.;;Zagzag et al., Angiogenesis in the Central Nervous System: A role for Vascular Endothelial Growth FactorNascular Permeability Factor and Tenascin -C. Common Molecular Effectors in Cerebral Neoplastic and Non-Neoplastic “Angiogenic Diseases,” Histol Histopathol, 17: 301-321, 2002.;;Zhang et al., Antisense Gene Therapy of Brain Cancer with Artificial Virus Gene Delivery System, Molecular Therpay, vol. 6, No. 1 (Jul. 2002), pp. 67-72.;;Zhao, et al. Synthesis and antitumour activities of 3-substituted 4-oxo-3 H-imidazo [5, 1-d][1,2,3,5] tetrazine-8- parboxylic acids and their derivatives. Chinese Journal of Medicinal Chemistry 11 (2001): 263-269.",ACTIVE
277,US,A1,US 2016/0175450 A1,030-612-469-131-151,2016-06-23,2016,US 201615054266 A,2016-02-26,US 201615054266 A;;US 201414179195 A;;US 201213513145 A;;US 2010/0059919 W;;US 28549509 P,2009-12-10,DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER,"The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.",CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2012-11-12),https://lens.org/030-612-469-131-151,Patent Application,yes,0,2,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61K47/48;;A61K31/4188;;C07K16/28;;C07K16/30,,0,0,,,,ACTIVE
278,CN,A,CN 115561211 A,169-284-824-373-843,2023-01-03,2023,CN 202211000987 A,2017-03-31,US 201662317443 P;;US 201662317459 P;;US 201662317456 P;;US 201662317452 P;;US 201662317449 P;;US 201662317460 P;;US 201662317453 P;;US 201662317455 P;;US 201662317451 P;;US 201662351615 P;;CN 201780022021 A;;US 2017/0025451 W,2016-04-01,"Systems, devices, and methods for time-resolved fluorescence spectrometry","Provided herein are devices, systems, and methods for real-time characterization of a biological sample in vivo or ex vivo using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, thereby inducing a responsive fluorescent signal. A demultiplexer decomposes the signal into spectral bands and applies a time delay to the spectral bands in order to capture data from multiple spectral bands from a single excitation pulse with a detector. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or attenuation of the spectral band. The sample may comprise one or more exogenous or endogenous fluorophores. The device may be a two-piece probe having a removable disposable distal end. The system can combine fluorescence spectrometry with other optical spectrometry or imaging modes. The light pulses may be focused at a single focal point or scanned or patterned across the entire area.",BLACKLIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTT PRAMOD;;BLACK KEITH;;KAFLAUF JACK;;POTNIK BARTOSZ;;NIE ZHAOJUN,,https://lens.org/169-284-824-373-843,Patent Application,no,0,0,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,G01N21/64;;A61B5/15;;A61B10/00;;G01N21/01;;G01N21/25;;G01N21/33;;G01N21/35;;G01N21/3563;;G01N21/3577;;G01N21/65,,0,0,,,,PENDING
279,US,A1,US 2014/0161762 A1,197-783-139-336-309,2014-06-12,2014,US 201414179195 A,2014-02-12,US 201414179195 A;;US 201213513145 A;;US 2010/0059919 W;;US 28549509 P,2009-12-10,DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER,"The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.",PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y;;CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2012-11-12),https://lens.org/197-783-139-336-309,Patent Application,yes,0,7,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61K47/48,424/78.17;;525/419;;525/54.1,0,0,,,,ACTIVE
280,US,A1,US 2017/0274085 A1,080-493-520-567-271,2017-09-28,2017,US 201715450519 A,2017-03-06,US 201715450519 A;;US 201615054266 A;;US 201414179195 A;;US 201213513145 A;;US 2010/0059919 W;;US 28549509 P,2009-12-10,DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER,"The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.",CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2012-11-12),https://lens.org/080-493-520-567-271,Patent Application,yes,0,0,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61K31/4188;;A61K31/425;;C07K16/28;;C07K16/30,,0,0,,,,ACTIVE
281,EP,A4,EP 2271368 A4,091-215-001-030-121,2013-01-23,2013,EP 09730249 A,2009-04-10,US 2009/0040252 W;;US 4419108 P,2008-04-11,POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY,,CEDARS SINAI MEDICAL CENTER,DING HUI;;LJUBIMOVA JULIA Y;;HOLLER EGGEHARD;;BLACK KEITH L,,https://lens.org/091-215-001-030-121,Search Report,no,2,0,9,9,0,A61K9/0019;;A61K9/0024;;A61K9/0095;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711;;A61P35/00;;A61K9/0019;;A61K9/0095;;A61K9/0024;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711,A61K47/48;;A61K9/00,,1,0,,,See also references of WO 2009126913A1,ACTIVE
282,ES,T3,ES 2694278 T3,105-197-093-759-453,2018-12-19,2018,ES 09815306 T,2009-09-18,US 9820608 P;;US 2009/0057569 W,2008-09-18,Método óptico para la detección de la enfermedad de Alzheimer,"La curcumina para su uso en un método para diagnosticar o pronosticar la enfermedad de Alzheimer en un mamífero, dicho método que comprende: administrar sistémicamente curcumina al mamífero; formar imágenes de la retina del mamífero con un sistema óptico de imágenes; examinar las imágenes para los péptidos Aß teñidos; y ya sea (i) diagnosticar que el mamífero tiene la enfermedad de Alzheimer si están presentes los péptidos Aß teñidos; o (ii) cuantificar el aumento/disminución de péptidos de Aß teñidos en la retina del sujeto, en comparación con un diagnóstico previo; y generar un pronóstico basado en el nivel de péptidos de Aß teñidos en la retina del sujeto.",CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,KORONYO MAYA;;BLACK KEITH;;SCHWARTZ MICHAL;;FARKAS DANIEL;;KORONYO YOSEF,,https://lens.org/105-197-093-759-453,Granted Patent,no,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,0,0,,,,ACTIVE
283,US,A1,US 2012/0328555 A1,131-633-252-889-679,2012-12-27,2012,US 201013513145 A,2010-12-10,US 201013513145 A;;US 28549509 P;;US 2010/0059919 W,2009-12-10,DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER,"The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.",PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y;;CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2012-11-12),https://lens.org/131-633-252-889-679,Patent Application,yes,2,8,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61K47/48;;A61P31/00;;C08G63/91,424/78.17;;525/54.1;;525/419,1,1,149-009-853-252-790,10.1007/s00280-006-0407-2;;17256133,"Brem et al ""Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model"" Cancer Chemother Pharmacol 60:643-650. Published online 26 January 2007.",ACTIVE
284,US,B2,US 9320807 B2,163-981-867-222-274,2016-04-26,2016,US 201414179195 A,2014-02-12,US 201414179195 A;;US 201213513145 A;;US 2010/0059919 W;;US 28549509 P,2009-12-10,Drug delivery of temozolomide for systemic based treatment of cancer,"The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.",CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2012-11-12),https://lens.org/163-981-867-222-274,Granted Patent,yes,6,2,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61K38/00;;A61K31/425;;A61K31/74;;A61K47/48;;C08F283/00;;C08G63/48;;C08G63/91;;C08G69/48;;C08L67/00;;C08L77/00;;C08L89/00,,39,34,076-069-720-623-007;;089-773-133-078-99X;;012-251-206-172-978;;064-884-073-662-848;;170-853-882-083-556;;092-864-235-322-940;;024-853-541-370-254;;000-409-501-606-70X;;088-076-682-849-849;;027-177-154-094-913;;003-631-120-479-205;;056-106-508-661-801;;012-497-328-331-068;;078-749-765-604-979;;107-990-469-227-380;;019-524-632-030-548;;135-545-938-771-996;;094-544-976-445-251;;106-640-130-151-317;;086-499-835-921-55X;;149-009-853-252-790;;068-659-879-554-517;;068-082-778-319-717;;013-415-019-143-842;;056-754-795-949-28X;;088-509-278-000-721;;160-717-493-067-916;;068-365-614-968-438;;039-079-455-504-396;;087-520-893-698-325;;044-248-524-774-951;;030-136-053-475-941;;012-011-330-340-059;;131-982-616-033-720,10.1007/s00401-007-0243-4;;17618441;;pmc1929165;;17964023;;10.1016/j.ncl.2007.07.006;;16648043;;10.1016/s1470-2045(06)70665-9;;11780887;;10.3171/jns.2001.95.2.0190;;10.1039/b005652i;;10.1056/nejmoa043330;;15758009;;16985051;;10.1158/1535-7163.mct-05-0428;;18952979;;pmc2718972;;10.1215/15228517-2008-090;;10.1038/nm1002;;14981512;;10.1038/nrd1088;;12750738;;10.1080/10611860400011927;;15621677;;10.1016/j.jconrel.2004.07.009;;15588910;;18654426;;10.1038/nnano.2007.387;;10.1038/nrc1566;;15738981;;10.1016/j.addr.2004.10.006;;15722167;;10.1677/erc.1.01045;;16113096;;12639809;;10.1016/s1567-5769(02)00271-0;;17630012;;pmc2394675;;10.1016/j.jconrel.2007.05.032;;pmc3487710;;10.1021/bc0502457;;16536461;;19699248;;10.1016/j.addr.2009.06.005;;10.1007/s00280-006-0407-2;;17256133;;10.1007/s11060-009-9857-9;;19337695;;pmc1185838;;708370;;10.1042/bj1730723;;pmc2734385;;18373429;;10.2217/17435889.3.2.247;;10609647;;10.1023/a:1020614525534;;6606682;;10.1016/0022-1759(83)90303-4;;10914698;;10.1124/mol.108.045112;;18477668;;pmc3909956;;19525947;;10.1038/nmat2442;;16430958;;10.1016/j.biomaterials.2005.12.022;;16303268;;10.1016/j.ijpharm.2005.10.010;;pmc2761188;;19920915;;10.2147/dddt.s3572;;10.7150/ijms.5.273;;pmc2536715;;18797509;;20387095;;pmc2952070;;10.1007/s11095-010-0091-0,"D.N. Louis, H. Ohgaki, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97-109 (2007).;;2009 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the united States in 2004-2005. http://www.cbtrus.org/reports/2009-NPCR-04-05/CBTRUS-NPCR2004-2005-Report-.pdf (accessed (Nov. 17, 2009).;;A.R. Asthagiri, et al. Advances in brain tumor surgery. Neurol Clin. 25:975-1003 (2007).;;W. Stummer, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 7:392-401 (2006).;;M. Lacroix, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurogurg. 95:190198 (2001).;;J. Arrowsmith, et al. Part 39 synthesis of bis(imidazotetrazine)s with saturated spacer groups. J Chem Soc Perkin Trans 1. 24:4432-4438 (2000).;;R. Stupp, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastma. N Engl J Med. 352:987-996 (2005).;;N. Auger, et al. Genetic alterations associated with acquired with temozolide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther. 5:2182-2192 (2006).;;C.C. Chen, et al. Of Escherichia coli and man: understanding glioma resistance to temozolmide therapy. In E. G. Meir (eds.), CNS Cancer, Humana Press, Atlanta, 2009, pp. 679-711.;;G.J. Kitange, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 11:281-291 (2009).;;R. Stachi-Fainaro, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med. 10:255-261 (2004).;;R. Duncan. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2:347-360 (2003).;;S.V. Vinogradov, et al. Mixed polymer micelles of amphiphilic and cationic copolymers for delivery of antisense oligonucleotides. J Drug Target. 12:517-526 (2004).;;A.V. Kabanov, et al. Polymer genomics: shifting the gene and drug delivery paradigms. J Control Release. 101:259-271 (2005).;;D. Peer, et . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2:751-760 (2007).;;M. Ferrari. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 5:161-171 (2005).;;A. Nori, et al. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev. 57:609-636 (2005).;;R. Duncan, et al. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer. 12:S189-S199 (2005).;;H. Maeda, et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol. 3:319-328 (2003).;;M. Fujita, et al. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly (b-L-malic acid). J Control Release. 122:356-363 (2007).;;B.S. Lee, et al. Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(b-L-malic acid) for drug delivery. Bioconjug Chem. 17:3170326 (2006).;;E. Segal, and R. Satchi-Fainaro. Design and development of polymer conjugates as anti-angiogenic agents. Adv Drug Deily Rev. 61:1159-1176 (2009).;;S. Brem, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol. 60:643-650 (2007).;;U. Akbar, et al. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. J. Neurooncol. 94:203-212 (2009).;;L.X. Zhao, et al. Synthesis and antitumour activities of 3-substituted 4-oxo-3 H-imidazo [5,1-d][1,2,3,5] tetrazine-8-carboxylic acids and their derivatives. Chin J Med Chem. 11:263-269 (2001).;;E. Holler, Poly(malic acid) from natural sources. In N.P. Cheremisinoff (eds.), Handbook of Engineering Polymeric Materials, Marcel Dekker, New York, 1997, pp. 93-103.;;J. Carlsson, et al. Protein Thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio) priopionate, a new heterobifunctional reagent. Biochem J. 173:723-737 (1978).;;J.Y. Ljubimova, et al. Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery delivery. Nanomedicine. 3:247-265 (2008).;;F.N. Fu, et al. Calcein permeability of liposomes mediated by type A botulinum neurotoxin and its light and heavy chains. J. Protein Chem. 18:701-707 (1999).;;T.J. Mosmann. Rapid colorimetric assays for cellular growth and survival: application to proliferation and cytotoxicity assays. Immunol Methods. 65:55-63 (1983).;;H.S. Friedman, et al. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 6:2585-2597 (2000).;;R.N. Trivedi, et al. Human methyl purine DNA glycosylase and DNA polymerase b expression collectively predict sensitivity to temozolomide. Mol Pharmacol. 74:505-516 (2008).;;A.E. Nel, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 8:543-557 (2009).;;M.R. Lorenz, et al. Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials. 27:2820-2828 (2006).;;D.E. Owens, et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 307:93-102 (2006).;;Extended European Search Report dated Oct. 19, 2013 in counterpart European Patent Application No. 10836765.7.;;Braun, et al. Treatment glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry. Drug Design, Development and Therapy, Dove Medical Press Ltd, UK, vol. 2008, No. 2, 289-301 (2009).;;Waldeck, et al. TMZ-BioShuttle-A reformulated temozolomide. International Journal of Medical Sciences, Ivyspring International Publisher, Lake Haven, AU, vol. 5, No. 5,273-284 (2008).;;Rameshwar, et al. Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Ply (I-L-malic acid). Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, vol. 27, No. 11, 2317-2329 (2010).",ACTIVE
285,CA,A1,CA 3019590 A1,177-520-232-674-767,2017-10-05,2017,CA 3019590 A,2017-03-31,US 201662317443 P;;US 201662317459 P;;US 201662317456 P;;US 201662317452 P;;US 201662317449 P;;US 201662317460 P;;US 201662317453 P;;US 201662317455 P;;US 201662317451 P;;US 201662351615 P;;US 2017/0025451 W,2016-04-01,"SYSTEMS, DEVICES, AND METHODS FOR TIME-RESOLVED FLUORESCENT SPECTROSCOPY","Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.",BLACK LIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;BLACK KEITH;;KAVANAUGH JACK;;BORTNIK BARTOSZ;;NIE ZHAOJUN,,https://lens.org/177-520-232-674-767,Patent Application,no,0,0,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,G01N21/64;;A61B6/00;;G01N21/25;;G01N21/62;;G01N21/63,,0,0,,,,DISCONTINUED
286,US,A1,US 2020/0319108 A1,038-123-271-185-107,2020-10-08,2020,US 202016849102 A,2020-04-15,US 202016849102 A;;US 201715475750 A;;US 201662351615 P;;US 201662317443 P;;US 201662317449 P;;US 201662317451 P;;US 201662317452 P;;US 201662317453 P;;US 201662317455 P;;US 201662317456 P;;US 201662317459 P;;US 201662317460 P,2016-04-01,"SYSTEMS, DEVICES, AND METHODS FOR TIME-RESOLVED FLUORESCENT SPECTROSCOPY","Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.",BLACK LIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;BLACK KEITH;;KAVANAUGH JACK;;BORTNIK BARTOSZ;;NIE ZHAOJUN,BLACK LIGHT SURGICAL INC (2017-04-08);;CEDARS-SINAI MEDICAL CENTER (2017-04-05),https://lens.org/038-123-271-185-107,Patent Application,yes,1,4,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,G01N21/64;;G01J3/02;;G01J3/10;;G01J3/28;;G01J3/32;;G01J3/44,,0,0,,,,ACTIVE
287,ES,T3,ES 2710463 T3,052-441-669-064-736,2019-04-25,2019,ES 09730249 T,2009-04-10,US 4419108 P;;US 2009/0040252 W,2008-04-11,Acido poli(beta málico) con tripéptido colgante Leu-Leu-Leu para la administración eficaz del fármaco citoplasmático,"Una molécula de administración de fármacos que comprende un andamio molecular de ácido polimálico unido covalentemente a uno o más módulos moleculares biológicamente activos, en donde uno de los uno o más módulos moleculares biológicamente activos comprende una unidad de escape de endosoma, Lleucilleucilleucina (LLL).",CEDARS SINAI MEDICAL CENTER,DING HUI;;LJUBIMOVA JULIA Y;;HOLLER EGGEHARD;;BLACK KEITH L,,https://lens.org/052-441-669-064-736,Granted Patent,no,0,0,9,9,0,A61K9/0019;;A61K9/0024;;A61K9/0095;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711;;A61P35/00;;A61K9/0019;;A61K9/0095;;A61K9/0024;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711,A61K38/00;;A61K9/00;;A61K9/48;;A61K31/711;;A61K39/00;;A61K47/59;;A61K47/60;;A61K49/00,,0,0,,,,ACTIVE
288,WO,A1,WO 2020/055455 A1,116-283-506-617-139,2020-03-19,2020,US 2019/0028196 W,2019-04-18,US 201862731671 P,2018-09-14,"TARGETED NANOPARTICLES FOR DIAGNOSING, DETECTING, AND TREATING CANCER","The present invention provides a nanoparticle, comprising: a core, wherein the core comprises at least one iron oxide; a shell surrounding the core, wherein the shell comprises at least one polymer; and at least one targeting moiety attached to the shell, wherein the nanoparticle does not comprise boron, for use in methods for detecting and treating cancer in a subject.",CEDARS SINAI MEDICAL CENTER,PEREZ J MANUEL;;CHUNG LELAND;;ZHANG YI;;BLACK KEITH L,,https://lens.org/116-283-506-617-139,Patent Application,yes,5,3,2,2,5,A61B5/055;;A61B5/0035;;A61B5/0071;;A61B5/0042;;A61B2503/40;;A61B5/4064;;A61K31/337;;A61K38/05;;A61K31/365;;A61P35/00;;A61K31/337;;A61K31/365;;A61K31/47;;A61K31/69;;A61K45/06;;A61K49/0002;;A61K49/0032;;A61K49/0093;;A61K49/126;;A61K49/1818;;A61B5/055,A61B5/00;;A61B6/00;;A61K31/131;;A61K31/335;;A61K31/382;;A61K31/542,,0,0,,,,PENDING
289,EP,A1,EP 3436805 A1,175-250-229-964-595,2019-02-06,2019,EP 17776805 A,2017-03-31,US 201662317443 P;;US 201662317459 P;;US 201662317456 P;;US 201662317452 P;;US 201662317449 P;;US 201662317460 P;;US 201662317453 P;;US 201662317455 P;;US 201662317451 P;;US 201662351615 P;;US 2017/0025451 W,2016-04-01,"SYSTEMS, DEVICES, AND METHODS FOR TIME-RESOLVED FLUORESCENT SPECTROSCOPY",,BLACK LIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;BLACK KEITH;;KAVANAUGH JACK;;BORTNIK BARTOSZ;;NIE ZHAOJUN,,https://lens.org/175-250-229-964-595,Patent Application,yes,0,0,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,A61B6/00;;G01N21/64;;G01N21/25;;G01N21/62;;G01N21/63,,0,0,,,,PENDING
290,WO,A1,WO 2012/091718 A1,087-143-447-656-677,2012-07-05,2012,US 2010/0062515 W,2010-12-30,US 2010/0062515 W,2010-12-30,POLYMALIC ACID-BASED NANOBIOPOLYMER COMPOSITIONS AND METHODS FOR TREATING CANCER,"Nanobiopolymeric conjugates based on biodegradable, non-toxic and non- immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are efficient for treatment a cancer in a subject.",CEDARS SINAI MEDICAL CENTER;;INOUE SATOSHI;;DING HUI;;HOLLER EGGEHARD;;BLACK KEITH;;LJUBIMOVA JULIA,INOUE SATOSHI;;DING HUI;;HOLLER EGGEHARD;;BLACK KEITH;;LJUBIMOVA JULIA,,https://lens.org/087-143-447-656-677,Patent Application,yes,4,6,4,9,9,A61K39/39558;;A61K47/593;;A61K47/60;;A61K47/6855;;A61K47/6883;;A61K2039/505;;A61P35/00;;A61P35/04;;A61P43/00;;C07K16/32;;C12N15/113;;C12N15/1138;;C12N2310/11;;C12N2310/14;;C12N2310/3233;;C12N2320/31;;C12N2320/32,A61K39/395;;A61K38/16;;A61K47/30;;A61P35/00,,5,0,,,"DATABASE NCBI 26 December 2010 (2010-12-26), Database accession no. NM 005228;;DATABASE NCBI 30 March 1995 (1995-03-30), Database accession no. X03363;;DATABASE NCBI 7 October 2008 (2008-10-07), Database accession no. X91171;;DATABASE NCBI 21 November 2010 (2010-11-21), Database accession no. NM 002291;;See also references of EP 2658574A4",PENDING
291,EP,B1,EP 2271368 B1,109-402-835-743-203,2018-12-05,2018,EP 09730249 A,2009-04-10,US 2009/0040252 W;;US 4419108 P,2008-04-11,POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY,,CEDARS SINAI MEDICAL CENTER,DING HUI;;LJUBIMOVA JULIA Y;;HOLLER EGGEHARD;;BLACK KEITH L,,https://lens.org/109-402-835-743-203,Granted Patent,yes,3,0,9,9,0,A61K9/0019;;A61K9/0024;;A61K9/0095;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711;;A61P35/00;;A61K9/0019;;A61K9/0095;;A61K9/0024;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711,A61K38/00;;A61K9/00;;A61K9/48;;A61K31/711;;A61K39/00;;A61K47/59;;A61K47/60;;A61K49/00,,3,0,,,"LUTSENKO ET AL.: 'Biochemical basis of regulation of human copper-transporting ATPases.' ARCH BIOCHEM BIOPHYS. vol. 463, no. 2, 15 July 2007, pages 134 - 148, XP022145503;;FUJITA ET AL.: 'Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid.' JOUR CONTROLLED RELEASE. vol. 122, no. 3, 08 October 2007, pages 356 - 363, XP022336569;;'Molecular Oncology.' MDNSI., [Online] 01 July 2009, XP008143608 Retrieved from the Internet: <URL:http://www.cedars-sinai.edu/10141.html >",ACTIVE
292,WO,A1,WO 2009/126913 A1,124-459-112-040-214,2009-10-15,2009,US 2009/0040252 W,2009-04-10,US 4419108 P,2008-04-11,POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY,"The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.",CEDARS SINAI MEDICAL CENTER;;DING HUI;;LJUBIMOVA JULIA Y;;HOLLER EGGEHARD;;BLACK KEITH L,DING HUI;;LJUBIMOVA JULIA Y;;HOLLER EGGEHARD;;BLACK KEITH L,,https://lens.org/124-459-112-040-214,Patent Application,yes,2,16,9,9,2,A61K9/0019;;A61K9/0024;;A61K9/0095;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711;;A61P35/00;;A61K9/0019;;A61K9/0095;;A61K9/0024;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711,A61K47/48;;A61K9/00,,3,2,009-843-764-520-632;;094-544-976-445-251,10.1016/j.abb.2007.04.013;;pmc2025638;;17562324;;17630012;;pmc2394675;;10.1016/j.jconrel.2007.05.032,"LUTSENKO ET AL.: ""Biochemical basis of regulation of human copper-transporting ATPases."", ARCH BIOCHEM BIOPHYS., vol. 463, no. 2, 15 July 2007 (2007-07-15), pages 134 - 148, XP022145503;;FUJITA ET AL.: ""Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid."", JOUR CONTROLLED RELEASE., vol. 122, no. 3, 8 October 2007 (2007-10-08), pages 356 - 363, XP022336569;;""Molecular Oncology."", MDNSI., 1 July 2009 (2009-07-01), XP008143608, Retrieved from the Internet <URL:http://www.cedars-sinai.edu/10141.html>",PENDING
293,US,B2,US 8785371 B2,145-066-161-925-734,2014-07-22,2014,US 201013513145 A,2010-12-10,US 201013513145 A;;US 28549509 P;;US 2010/0059919 W,2009-12-10,Drug delivery of temozolomide for systemic based treatment of cancer,"The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.",PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y;;CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2012-11-12),https://lens.org/145-066-161-925-734,Granted Patent,yes,6,3,12,12,0,A61K47/65;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K47/60;;A61K47/64;;A61K47/6849;;A61K47/6855;;A61K47/6865;;A61K47/6877;;A61K47/65;;A61K47/6883;;A61K31/495;;A61P35/00;;A61K31/425;;A61K31/4188;;C07K16/2881;;C07K16/3015;;C07K16/3053;;C07K2317/24;;C07K2317/77;;A61K47/593;;A61K47/6889;;A61K47/6851;;A61K47/545;;A61K47/6898;;A61K47/6803,A61K38/00;;A61K31/74;;A61K47/48;;C08F283/00;;C08G63/48;;C08G63/91;;C08G69/48;;C08L67/00;;C08L77/00;;C08L89/00,514/1.1;;514/19.3;;424/78.17;;525/54.1;;525/419,40,35,149-009-853-252-790;;076-069-720-623-007;;089-773-133-078-99X;;012-251-206-172-978;;064-884-073-662-848;;170-853-882-083-556;;092-864-235-322-940;;024-853-541-370-254;;000-409-501-606-70X;;088-076-682-849-849;;027-177-154-094-913;;003-631-120-479-205;;056-106-508-661-801;;012-497-328-331-068;;078-749-765-604-979;;107-990-469-227-380;;019-524-632-030-548;;135-545-938-771-996;;094-544-976-445-251;;106-640-130-151-317;;086-499-835-921-55X;;149-009-853-252-790;;068-659-879-554-517;;068-082-778-319-717;;013-415-019-143-842;;056-754-795-949-28X;;088-509-278-000-721;;160-717-493-067-916;;068-365-614-968-438;;039-079-455-504-396;;087-520-893-698-325;;044-248-524-774-951;;030-136-053-475-941;;012-011-330-340-059;;131-982-616-033-720,10.1007/s00280-006-0407-2;;17256133;;10.1007/s00401-007-0243-4;;17618441;;pmc1929165;;17964023;;10.1016/j.ncl.2007.07.006;;16648043;;10.1016/s1470-2045(06)70665-9;;11780887;;10.3171/jns.2001.95.2.0190;;10.1039/b005652i;;10.1056/nejmoa043330;;15758009;;16985051;;10.1158/1535-7163.mct-05-0428;;18952979;;pmc2718972;;10.1215/15228517-2008-090;;10.1038/nm1002;;14981512;;10.1038/nrd1088;;12750738;;10.1080/10611860400011927;;15621677;;10.1016/j.jconrel.2004.07.009;;15588910;;18654426;;10.1038/nnano.2007.387;;10.1038/nrc1566;;15738981;;10.1016/j.addr.2004.10.006;;15722167;;10.1677/erc.1.01045;;16113096;;12639809;;10.1016/s1567-5769(02)00271-0;;17630012;;pmc2394675;;10.1016/j.jconrel.2007.05.032;;pmc3487710;;10.1021/bc0502457;;16536461;;19699248;;10.1016/j.addr.2009.06.005;;10.1007/s00280-006-0407-2;;17256133;;10.1007/s11060-009-9857-9;;19337695;;pmc1185838;;708370;;10.1042/bj1730723;;pmc2734385;;18373429;;10.2217/17435889.3.2.247;;10609647;;10.1023/a:1020614525534;;6606682;;10.1016/0022-1759(83)90303-4;;10914698;;10.1124/mol.108.045112;;18477668;;pmc3909956;;19525947;;10.1038/nmat2442;;16430958;;10.1016/j.biomaterials.2005.12.022;;16303268;;10.1016/j.ijpharm.2005.10.010;;pmc2761188;;19920915;;10.2147/dddt.s3572;;10.7150/ijms.5.273;;pmc2536715;;18797509;;20387095;;pmc2952070;;10.1007/s11095-010-0091-0,"Brem et al ""Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model"" Cancer Chemother Pharmacol 60:643-650. Published online Jan. 26, 2007.;;D.N. Louis, H. Ohgaki, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97-109 (2007).;;2009 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the united States in 2004-2005. http://www.cbtrus.org/reports/2009-NPCR-04-05/CBTRUS-NPCR2004-2005-Report-.pdf (accessed (Nov. 17, 2009).;;A.R. Asthagiri, et al. Advances in brain tumor surgery. Neurol Clin. 25:975-1003 (2007).;;W. Stummer, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 7:392-401 (2006).;;M. Lacroix, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurogurg. 95:190198 (2001).;;J. Arrowsmith, et al. Part 39 synthesis of bis(imidazotetrazine)s with saturated spacer groups. J Chem Soc Perkin Trans 1. 24:4432-4438 (2000).;;R. Stupp, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastma. N Engl J Med. 352:987-996 (2005).;;N. Auger, et al. Genetic alterations associated with acquired with temozolide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther. 5:2182-2192 (2006).;;C.C. Chen, et al. Of escherichia coli and man: understanding glioma resistance to temozolmide therapy. In E. G. Meir (eds.), CNS Cancer, Humana Press, Atlanta, 2009, pp. 679-711.;;G.J. Kitange, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 11:281-291 (2009).;;R. Stachi-Fainaro, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med. 10:255-261 (2004).;;R. Duncan. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2:347-360 (2003).;;Si V. Vinogradov, et al. Mixed polymer micelles of amphiphilic and cationic copolymers for delivery of antisense oligonucleotides. J Drug Target. 12:517-526 (2004).;;A.V. Kabanov, et al. Polymer genomics: shifting the gene and drug delivery paradigms. J Control Release. 101:259-271 (2005).;;D. Peer, et . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2:751-760 (2007).;;M. Ferrari. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 5:161-171 (2005).;;A. Nori, et al. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev. 57:609-636 (2005).;;R. Duncan, et al. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer. 12:S189-S199 (2005).;;H. Maeda, et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. mplications. Int Immunopharmacol. 3:319-328 (2003).;;M. Fujita, et al. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly (b-L-malic acid). J Control Release. 122:356-363 (2007).;;B. S. Lee, et al. Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(b-L-malic acid) for drug delivery. Bioconjug Chem. 17:3170326 (2006).;;E. Segal, and R. Satchi-Fainaro. Design and development of polymer conjugates as anti-angiogenic agents. Adv Drug Deily Rev. 61:1159-1176 (2009).;;S. Brem, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol. 60:643-650 (2007).;;U. Akbar, et al. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. J. Neurooncol. 94:203-212 (2009).;;L.X. Zhao, et al. Synthesis and antitumour activities of 3-substituted 4-oxo-3 H-imidazo [5,1-d][1,2,3,5] tetrazine-8-carboxylic acids and their derivatives. Chin J Med Chem. 11:263-269 (2001).;;E. Holler, Poly(malic acid) from natural sources. In N. P. Cheremisinoff (eds.), Handbook of Engineering Polymeric Materials, Marcel Dekker, New York, 1997, pp. 93-103.;;J. Carlsson, et al. Protein Thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio) priopionate, a new heterobifunctional reagent. Biochem J. 173:723-737 (1978).;;J.Y. Ljubimova, et al. Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery delivery. Nanomedicine. 3:247-265 (2008).;;F.N. Fu, et al. Calcein permeability of liposomes mediated by type A botulinum neurotoxin and its light and heavy chains. J. Protein Chem. 18:701-707 (1999).;;T.J. Mosmann. Rapid colorimetric assays for cellular growth and survival: application to proliferation and cytotoxicity assays. Immunol Methods. 65:55-63 (1983).;;H.S. Friedman, et al. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 6:2585-2597 (2000).;;R.N. Trivedi, et al. Human methyl purine DNA glycosylase and DNA polymerase b expression collectively predict sensitivity to temozolomide. Mol Pharmacol. 74:505-516 (2008).;;A.E. Nel, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 8:543-557 (2009).;;M.R. Lorenz, et al. Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials. 27:2820-2828 (2006).;;D.E. Owens, et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 307:93-102 (2006).;;Extended European Search Report dated Oct. 19, 2013 in counterpart European Patent Application No. 10836765.7.;;Braun, et al. Treatment glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry. Drug Design, Development and Therapy, Dove Medical Press Ltd, UK, vol. 2008, No. 2, 289-301 (2009).;;Waldeck, et al. TMZ-BioShuttle-A reformulated temozolomide. International Journal of Medical Sciences, Ivyspring International Publisher, Lake Haven, AU, vol. 5, No. 5, 273-284 (2008).;;Rameshwar, et al. Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Ply (I-L-malic acid). Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, vol. 27, No. 11, 2317-2329 (2010).",ACTIVE
294,US,A1,US 2011/0020371 A1,079-489-536-862-358,2011-01-27,2011,US 93511009 A,2009-04-10,US 93511009 A;;US 4419108 P;;US 2009/0040252 W,2008-04-11,POLY(BETA MALIC ACID) WITH PENDANT LEU-LEU-LEU TRIPEPTIDE FOR EFFECTIVE CYTOPLASMIC DRUG DELIVERY,"The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.",CEDARS SINAI MEDICAL CENTER,DING HUI;;LJUBIMOVA JULIA Y;;HOLLER EGGEHARD;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2010-09-23),https://lens.org/079-489-536-862-358,Patent Application,yes,2,5,9,9,2,A61K9/0019;;A61K9/0024;;A61K9/0095;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711;;A61P35/00;;A61K9/0019;;A61K9/0095;;A61K9/0024;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711,A61K39/395;;A61P35/00;;C08G63/91;;C12N5/07,424/178.1;;525/418;;525/54.1;;525/54.2;;435/375,5,3,106-640-130-151-317;;009-843-764-520-632;;082-428-855-525-972,pmc3487710;;10.1021/bc0502457;;16536461;;10.1016/j.abb.2007.04.013;;pmc2025638;;17562324;;9472555;;10.1038/sj.gt.3300536,"Lee et al. (Proc. Amer. Assoc. Cancer Res. 45: Abstract 647, 2004);;Lee et al (Bioconj. Chem. 17(2): 317-326, 2006);;Lutsenko et al (Arch Biochem Biophys. 2007 July 15; 463(2): 134-148);;GenBank AAB52902 (1997);;Coonrod et al (Gene Therapy (1997) 4, 1313-1321)",ACTIVE
295,US,B2,US 10656089 B2,066-522-139-798-41X,2020-05-19,2020,US 201715475750 A,2017-03-31,US 201715475750 A;;US 201662317443 P;;US 201662317449 P;;US 201662317451 P;;US 201662317452 P;;US 201662317453 P;;US 201662317455 P;;US 201662317456 P;;US 201662317459 P;;US 201662317460 P;;US 201662351615 P,2016-04-01,"Systems, devices, and methods for time-resolved fluorescent spectroscopy","Provided herein are devices, systems, and methods for characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy. A light source generates a light pulse or continuous light wave and excites the biological sample, inducing a responsive fluorescent signal. A demultiplexer splits the signal into spectral bands and a time delay is applied to the spectral bands so as to capture data with a detector from multiple spectral bands from a single excitation pulse. The biological sample is characterized by analyzing the fluorescence intensity magnitude and/or decay of the spectral bands. The sample may comprise one or more exogenous or endogenous fluorophore. The device may be a two-piece probe with a detachable, disposable distal end. The systems may combine fluorescence spectroscopy with other optical spectroscopy or imaging modalities. The light pulse may be focused at a single focal point or scanned or patterned across an area.",BLACK LIGHT SURGICAL INC;;CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;BLACK KEITH;;KAVANAUGH JACK;;BORTNIK BARTOSZ;;NIE ZHAOJUN,BLACK LIGHT SURGICAL INC (2017-03-22);;CEDARS-SINAI MEDICAL CENTER (2017-04-05),https://lens.org/066-522-139-798-41X,Granted Patent,yes,89,4,15,15,0,G01N21/6402;;G01N21/6408;;G01N21/6428;;G01N21/6486;;G01N21/25;;G01N21/33;;G01N21/65;;G01N21/3563;;G01N21/3577;;G01N21/35;;G01N21/01;;A61B10/0045;;A61B5/15;;G01N2021/6484;;G01N2021/0112;;G01J3/10;;G01J3/2889;;G01J3/32;;G01J2003/1213;;G01J2003/1265;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01N21/6408;;G01N21/6402;;G01J3/4406;;G01J3/0218;;G01N2021/6484;;G01J2003/1213;;G01J3/32;;G01J3/2889;;G01J3/10;;G01J2003/1265,G01N21/64;;G01J3/02;;G01J3/10;;G01J3/12;;G01J3/28;;G01J3/32;;G01J3/44,,76,34,051-032-387-057-366;;002-067-858-020-547;;061-997-807-287-859;;005-826-360-259-909;;046-432-653-211-12X;;002-821-937-985-621;;010-683-647-444-461;;029-175-089-918-86X;;022-197-225-411-194;;001-474-920-319-622;;042-668-575-106-425;;003-123-485-999-018;;029-771-925-044-012;;064-187-018-698-676;;092-597-622-022-266;;002-290-456-036-804;;010-663-060-292-43X;;033-307-632-418-805;;042-204-626-457-327;;007-110-015-828-727;;187-714-218-797-689;;018-044-454-204-648;;075-060-776-388-192;;093-376-350-966-243;;016-785-501-476-300;;046-506-476-636-838;;051-032-387-057-366;;097-446-628-940-029;;046-674-285-678-042;;068-746-006-048-207;;143-241-023-456-995;;133-681-363-351-539;;004-851-556-711-934;;108-728-744-630-602,19572006;;10.1364/ol.34.002081;;pmc4083182;;10.1117/12.2283679;;pmc4361450;;10.1364/boe.6.000987;;25798320;;9172260;;10.1088/0031-9155/42/5/005;;18315362;;10.1117/1.2830658;;pmc3335732;;10.1016/j.neuroimage.2010.11.001;;21055475;;10.1117/1.3374049;;pmc4171753;;20459282;;10.1007/978-94-007-2019-0_19;;10.1201/9781420047806;;14654941;;10.3892/ijo.24.1.59;;25673764;;10.1126/scitranslmed.aaa2384;;10.1117/1.1752919;;15250761;;pmc8527862;;10.1117/12.527787;;825377;;10.1002/eji.1830060713;;pmc4482228;;10.1126/scitranslmed.3010611;;26084803;;10.1562/0031-8655(2000)0710178trfsoa2.0.co2;;10687392;;10.1562/0031-8655(2000)071<0178:trfsoa>2.0.co;2;;10.1016/s0016-5107(03)02687-7;;14745391;;11783938;;10.1562/0031-8655(2001)074<0817:ivnfma>2.0.co;2;;10.1562/0031-8655(2001)0740817ivnfma2.0.co2;;3127726;;10.1038/332323a0;;10.1364/ao.42.002995;;12790450;;10.1002/9781118447567;;10.1364/ol.33.000630;;pmc10522294;;18347733;;10.2741/1878;;pmc2991156;;16368511;;10.1117/1.2141624;;16409091;;pmc2981341;;15339216;;10.1562/2003-12-09-ra-023.1;;10.1117/12.57704;;19572006;;10.1364/ol.34.002081;;pmc4083182;;10.1063/1.4869037;;pmc3971822;;24689603;;10.1016/j.chemolab.2004.04.003;;19281642;;10.1366/000370209787598843;;10.1016/s0924-2031(01)00199-0;;10.1366/0003702001951228;;10.1021/ac00209a024;;10.1021/ac00087a722,"Sun et al., “Fluorescence lifetime imaging microscopy: in vivo application to diagnosis of oral carcinoma,” Jul. 1, 2009, Optics Letters, vol. 34, No. 13, pp. 2081-2083.;;B.C. Wilson, “An optical fiber-based diffuse reflectance spectrometer for non-invasive investigation of photodynamic sensitizers in vivo,” Jan. 21, 1990, Proceedings of SPIE, vol. 10306, doi:10.1117/12.2283679, pp. 219-232.;;Ma et al., “Technique for real-time tissue characterization based on scanning multispectral fluorescence lifetime spectroscopy (ms-TRFS),”, 2015, Optics Express vol. 6, No. 3, pp. 987-1002. (Year: 2015).;;Allen et al., Remington: The Science and Practice of Pharmacy 22nd ed., Pharmaceutical Press (Sep. 15, 2012).;;Bigio et al. Ultraviolet and visible spectroscopies for tissue diagnostics: fluorescence spectroscopy and elastic-scattering spectroscopy. Physics in Medicine and Biology (1997). 42(5):803-814.;;Blackwell et al. In vivo time-resolved autofluorescence measurements to test for glycation of human skin. Journal of Biomedical Optics (2008). 13(1): 014004.;;Butte, et al. 2010. Fluorescence lifetime spectroscopy for guided therapy of brain tumors. NeuroImage, 54, S125-S135. doi:10.1016/j.neuroimage.2010.11.001.;;“Butte, et al. 2010. Intraoperative delineation of primary brain tumors using time-resolved fluorescence spectroscopy. Journal of Biomedical Optics, 15(2), 027008. doi:10.1117/1.3374049”.;;Butte, P. et al. Time-Resolved Laser Induced Fluorescence Spectroscopy (TRLIFS): A Tool for Intra-operative Diagnosis of Brain Tumors and Maximizing Extent of Surgical Resection. Tumors of the Central Nervous System, vol. 5 (2012), pp. 161-172.;;Co-pending U.S. Appl. No. 15/482,442, filed Apr. 7, 2017.;;European search report with written opinion dated Dec. 12, 2016 for EP14763125.;;Examination Report dated Aug. 3, 2010 European patent application No. 04781453.8 (filed Aug. 19, 2004), 4 pages.;;Examination Report dated Dec. 15, 2008 for European patent application No. 04781453.8 (filed Aug. 19, 2004), 4 pages.;;Examination Report dated Sep. 11, 2009 European patent application No. 04781453.8 (filed Aug. 19, 2004), 2 pages.;;Examination Report dated Feb. 25, 2009 for Japanese patent application No. 2006-523995 (filed Aug. 19, 2004), 7 pages.;;Examination Report dated Feb. 8, 2010 for Japanese patent application No. 2006-523995 (filed Aug. 19, 2004), 4 pages.;;Fang et al., “Time-Domain laser-Induced Fluorescence Spectroscopy Apparatus for Clinical Diagnostics,” Rev. Sci. Instrum., vol. 75, No. 1, pp. 151-162 (2004).;;Greenfield, Antibodies A Laboratory Manual 2nd ed., Cold Spring Harbor Press (Cold Spring Harbor N.Y., 2013).;;Hornyak et al., Introduction to Nanoscience and Nanotechnology, CRC Press (2008).;;Huang et al. Laser-induced autofluorescence microscopy of normal and tumor human colonic tissue. Int J Oncol (2004). 24(1):59-63.;;International Preliminary Report on Patentability dated Sep. 24, 2015 for International Application No. PCT/US2014/030610 (7 pages).;;International Preliminary Report on Patentability dated Sep. 25, 2015 for International Application No. PCT/US2014/029781 (7 pages).;;International Preliminary Report on Patentability dated Feb. 21, 2006 for PCT patent application No. PCT/US04/26759 (filed Aug. 19, 2004), 6 pages.;;International Search Report dated Jul. 25, 2014 for International Application No. PCT/US2014/029781 (3 pages).;;International Search Report dated Jul. 30, 2014 for International Application No. PCT/US2014/030610 (3 pages).;;International search report with written opinion dated Feb. 27, 2017 for PCT/US2016/059054.;;International search report with written opinion dated Jun. 16, 2017 for PCT/US2017/025451.;;Jermyn et al., Intraoperative brain cancer detection with Raman spectroscopy in humans, Science Translational Medicine, Feb. 11, 2015, 7(274) 274ra19 (9 pages).;;Jo et al., “Fast Model-Free De-convolution of Fluorescence Decay for Analysis of Biological Systems,” J. Biomed. Opt., vol. 9, No. 4., pp. 743-752 (2004).;;Jo et al., “Laguerre Nonparametric De-convolution Technique of Time-Resolved Fluorescence Data; Application to the Prediction of Concentrations in a Mixture of Biochemical Components” Conference; Jul. 21, 2004; Proc. SPIE, vol. 5326, Jul. 21, 2004.;;Jo et al., “Nonparametric Analysis of Time-Resolved Fluorescence Data Based on the Laguerre Expansion Technique” Proceedings of the 25th Annual International Conference of the IEEE Engineering in Medicine and biology Society, Sep. 17, 2003; pp. 1015-1018; vol. 2.;;Kohler, Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion, Eur. J. Immunol. Jul. 6, 1976(7):511-9.;;Kut et al., Detection of Human Brain Cancer Infiltration ex vivo and in vivo Using Quantitative Optical Coherence Tomography*, Sci Transl Med., Jun. 17, 2015; 7(292): 292ra100.;;Lakowicz, J. R. (2006). Principles of fluorescence spectroscopy (3rd ed., p. xxvi, 954 p.). New York: Springer. Retrieved from http://www.loc.gov/catdir/enhancements/fy0824/2006920796-b.html.;;Maarek et al., Time-resolved Fluorescence Spectra of Arterial Fluorescent Compounds: Reconstruction with the Laguerre Expansion Technique, 2000, Photochemistry and Photobiology, 71(2), 178-187.;;Mayinger et al. Evaluation of in vivo endoscopic autofluorescence spectroscopy in gastric cancer. Gastrointest Endosc (2004). 59(2):191-198.;;Notice of allowance dated Apr. 4, 2016 for U.S. Appl. No. 14/776,086.;;Notice of allowance dated Nov. 15, 2010 for U.S. Appl. No. 10/567,248.;;Office action dated Feb. 3, 2017 for U.S. Appl. No. 15/196,354.;;“Office action dated Aug. 24, 2010 for U.S. Appl. No. 10/567,248.”;;“Office action dated Sep. 11, 2009 for U.S. Appl. No. 10/567,248.”;;Office Action dated Dec. 10, 2015 for U.S. Appl. No. 14/776,086.;;Pogue, et al. (2001). In vivo NADH fluorescence monitoring as an assay for cellular damage in photodynamic therapy. Photochemistry and Photobiology, 74(6), 817-24. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11783938.;;Riechmann et al., Reshaping human antibodies for therapy, Nature Mar. 24, 1988 332(6162):323-7.;;Sambrook, Molecular Cloning: A Laboratory Manual 4th ed., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, N.Y. 2012).;;Search Report dated Sep. 25, 2008 for European patent application No. 04781453.8 (filed Aug. 19, 2004), 5 pages.;;Siegel et al, “Studying Biological Tissue with Fluorescence Lifetime Imaging; Microscopy, Endoscopy, and Decay Profiles,” Applied Optics, vol. 42 pp. 2995-3004 (2003).;;Singleton, Dictionary of DNA and Genome Technology 3rd ed., Wiley-Blackwell (Nov. 28, 2012).;;Singleton, Dictionary of Microbiology and Molecular Biology 3.sup.rd ed., revised ed., J. Wiley & Sons (New York, N.Y. 2006).;;Smith, March's Advanced Organic Chemistry Reactions, Mechanisms and Structure 7.sup.th ed., J. Wiley & Sons (New York, N.Y. 2013).;;Sun et al. Simultaneous time-and wavelength-resolved fluorescence spectroscopy for near real-time tissue diagnosis. Optics Letters (2008). 33(6):630-632.;;Written Opinion dated Jul. 25, 2014 International Application No. PCT/US2014/029781 (5 pages).;;Written Opinion dated Jul. 30, 2014 for International Application No. PCT/US2014/030610 (5 pages).;;Written Opinion dated Nov. 14, 2005 for PCT patent application No. PCT/US04/26759 (filed Aug. 19, 2004), 5 pages.;;Yong, et al. (2006). Distinction of brain tissue, low grade and high grade glioma with time-resolved fluorescence spectroscopy. Frontiers in Bioscience: A Journal and Virtual Library, 11(4), 1255-63. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16368511.;;Butte, et al. 2005. Diagnosis of meningioma by time-resolved fluorescence spectroscopy. Journal of Biomedical Optics, 10(6), 064026. doi:10.1117/1.2141624.;;International Search Report and Written Opinion dated Aug. 10, 2017 for International PCT Patent Application No. PCT/US2017/026697.;;Marcu, et al. (2004). Fluorescence lifetime spectroscopy of glioblastoma multiforme. Photochemistry and Photobiology, 80, 98-103. doi:10.1562/2003-12-09-RA-023.1.;;Office Action dated Sep. 5, 2017 for U.S. Appl. No. 15/196,354.;;Office Action dated Sep. 14, 2017 for U.S. Appl. No. 15/482,442.;;Rolinsky et al. (2001) A New Approach to Fluorescence Lifetime Sending Based on Molecular Distributions. Proceedings of SPIE, vol. 4252, pp. 1-11.;;Schneckenburger, H. (1992). Fluorescence decay kinetics and imaging of NAD(P)H and flavins as metabolic indicators. Optical Engineering, 31(7), 1447. doi:10.1117/12.57704.;;Sun, Y., et al. (2009). Fluorescence lifetime imaging microscopy: in vivo application to diagnosis of oral carcinoma. Opt Lett, 34(13), 2081-2083. doi:183277.;;Yankelevich et al. Design and evaluation of a device for fast multispectral time-resolved fluorescence spectroscopy and imaging. Rev Sci Instrum. Mar. 2014;85(3):034303.;;EP16860766.1 European Search Report dated Mar. 6, 2018.;;EP17186617.1 European Search Report dated Feb. 7, 2018.;;U.S. Appl. No. 15/196,354 Office Action dated Jun. 6, 2018.;;U.S. Appl. No. 15/482,442 Office Action dated Apr. 16, 2018.;;U.S. Appl. No. 15/196,354 Notice of Allowance dated Jan. 11, 2019.;;Co-pending U.S. Appl. No. 16/100,638, filed Aug. 10, 2018.;;Gallagher NB, Shaver JM, Martin EB, Morris J, Wise BM, Windig W: Curve resolution formultivariate images with applications to TOF-SIMS and Raman. Chemometrics and IntelligentLaboratory Systems 2004, 73(1): 105-117.;;Haaland, DM., et al., Hyperspectral Confocal Fluorescence Imaging: Exploring Alternative Multivariate Curve Resolution Approaches. Appl Spectrosc 2009, 63(3):271-279.;;Haaland, et al., “New augmented classical least squares methods for improved quantitative spectral analyses.” Vibrational Spectroscopy 29.1 (2002): 171-175.;;Haaland, et al., “New prediction-augmented classical least-squares (PACLS) methods: application to unmodeled interferents.” Applied Spectroscopy 54.9 (2000): 1303-1312.;;Thomas, et al., Comparison of multivariate calibration methods for quantitative spectral analysis. Analytical Chemistry 1990 62 (10), 1091-1099.;;Thomas, E.V., A primer on multivariate calibration. Analytical Chemistry 1994 66 (15), 795A-804A.",ACTIVE
296,US,A1,US 2021/0113715 A1,185-403-951-470-637,2021-04-22,2021,US 201917047638 A,2019-04-18,US 201917047638 A;;US 201862731671 P;;US 2019/0028196 W,2018-09-14,"TARGETED NANOPARTICLES FOR DIAGNOSING, DETECTING AND TREATING CANCER","The present invention provides a nanoparticle, comprising: a core, wherein the core comprises at least one iron oxide; a shell surrounding the core, wherein the shell comprises at least one polymer; and at least one targeting moiety attached to the shell, wherein the nanoparticle does not comprise boron, for use in methods for detecting and treating cancer in a subject.",CEDARS SINAI MEDICAL CENTER,PEREZ J MANUEL;;CHUNG LELAND;;ZHANG YI;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2019-04-22),https://lens.org/185-403-951-470-637,Patent Application,yes,6,1,2,2,5,A61B5/055;;A61B5/0035;;A61B5/0071;;A61B5/0042;;A61B2503/40;;A61B5/4064;;A61K31/337;;A61K38/05;;A61K31/365;;A61P35/00;;A61K31/337;;A61K31/365;;A61K31/47;;A61K31/69;;A61K45/06;;A61K49/0002;;A61K49/0032;;A61K49/0093;;A61K49/126;;A61K49/1818;;A61B5/055,A61K49/00;;A61K31/337;;A61K31/365;;A61K31/47;;A61K31/69;;A61K45/06;;A61K49/12;;A61K49/18;;A61P35/00,,0,0,,,,PENDING
297,US,A1,US 2012/0156232 A1,032-387-099-879-879,2012-06-21,2012,US 201113327125 A,2011-12-15,US 201113327125 A;;US 86417707 A;;US 82726006 P,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",YU JOHN S;;LIU GENTAO;;BLACK KEITH L;;PINILLA CLEMENCIA,YU JOHN S;;LIU GENTAO;;BLACK KEITH L;;PINILLA CLEMENCIA,TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (2009-05-07);;CEDARS-SINAI MEDICAL CENTER (2012-04-24),https://lens.org/032-387-099-879-879,Patent Application,yes,4,12,17,17,71,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/00;;A61K35/12;;C12N5/02,424/185.1;;435/377,3,3,080-647-403-540-300;;046-847-065-587-168;;019-963-559-470-014,11221866;;10.1158/0008-5472.can-03-3505;;15256471;;15076139;;10.1097/00002371-200405000-00006,"Yu et al Cancer Res. 61:842-847, 2001, Yu 2001;;Yu et al , Cancer Res. 64:4973-79, 2004, Yu 2004;;Liu et al J Immunother 27:220-226, 2004",ACTIVE
298,US,A1,US 2008/0311142 A1,003-645-042-199-060,2008-12-18,2008,US 86417707 A,2007-09-28,US 86417707 A;;US 82726006 P,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",YU JOHN S;;LIU GENTAO;;BLACK KEITH L;;PINILLA CLEMENCIA,YU JOHN S;;LIU GENTAO;;BLACK KEITH L;;PINILLA CLEMENCIA,TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (2009-05-07);;CEDARS-SINAI MEDICAL CENTER (2009-05-11),https://lens.org/003-645-042-199-060,Patent Application,yes,29,28,17,17,71,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/00;;A61K35/12;;A61P31/00,424/185.1;;424/93.7;;424/277.1,0,0,,,,ACTIVE
299,US,B2,US 8309614 B2,130-670-505-125-340,2012-11-13,2012,US 93511009 A,2009-04-10,US 93511009 A;;US 4419108 P;;US 2009/0040252 W,2008-04-11,Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery,"The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.",DING HUI;;LJUBIMOVA JULIA Y;;HOLLER EGGEHARD;;BLACK KEITH L;;CEDARS SINAI MEDICAL CENTER,DING HUI;;LJUBIMOVA JULIA Y;;HOLLER EGGEHARD;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2010-09-23),https://lens.org/130-670-505-125-340,Granted Patent,yes,2,8,9,9,2,A61K9/0019;;A61K9/0024;;A61K9/0095;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711;;A61P35/00;;A61K9/0019;;A61K9/0095;;A61K9/0024;;A61K9/4866;;A61K49/0041;;A61K49/0054;;A61K47/60;;A61K47/593;;A61K31/711,A61K47/14;;C07H21/02,514/772;;536/24.5;;977/704;;977/906,6,3,106-640-130-151-317;;009-843-764-520-632;;082-428-855-525-972,pmc3487710;;10.1021/bc0502457;;16536461;;10.1016/j.abb.2007.04.013;;pmc2025638;;17562324;;9472555;;10.1038/sj.gt.3300536,"Lee et al. (Proc. Amer. Assoc. Cancer Res. 45: Abstract 647, 2004).;;Lee et al (Bioconj. Chem. 17(2): 317-326, 2006).;;Lutsenko et al (Arch Biochem Biophys. Jul. 15, 2007; 463(2): 134-148).;;GenBank AAB52902 (1997).;;Coonrod et al (Gene Therapy (1997) 4, 1313-1321).;;International Preliminary Report on Patentability for PCT/US2009/040252 filed Apr. 10, 2009.",ACTIVE
300,EP,A1,EP 2658574 A1,152-398-034-874-553,2013-11-06,2013,EP 10861515 A,2010-12-30,US 2010/0062515 W,2010-12-30,POLYMALIC ACID-BASED NANOBIOPOLYMER COMPOSITIONS AND METHODS FOR TREATING CANCER,,CEDARS SINAI MEDICAL CENTER,INOUE SATOSHI;;DING HUI;;HOLLER EGGEHARD;;BLACK KEITH;;LJUBIMOVA JULIA,,https://lens.org/152-398-034-874-553,Patent Application,yes,0,0,4,9,9,A61K39/39558;;A61K47/593;;A61K47/60;;A61K47/6855;;A61K47/6883;;A61K2039/505;;A61P35/00;;A61P35/04;;A61P43/00;;C07K16/32;;C12N15/113;;C12N15/1138;;C12N2310/11;;C12N2310/14;;C12N2310/3233;;C12N2320/31;;C12N2320/32,A61K47/48;;A61K38/16;;A61K39/395;;A61K47/30;;A61P35/00,,0,0,,,,DISCONTINUED
301,GB,B,GB 2513974 B,030-319-727-370-014,2016-05-04,2016,GB 201404193 A,2014-03-10,US 201313832946 A,2013-03-15,Generator set adaptive droop control method,,CATERPILLAR INC,KEITH FOLKEN;;MATTHEW JOSEPH MEINHART;;EDWARD MAURER SCHROEDER;;ANDREW WILLIAM BLACK,,https://lens.org/030-319-727-370-014,Granted Patent,no,2,0,7,7,0,H02J3/46;;H02P9/42;;H02J13/0062;;H02J3/46;;H02J3/46;;H02P9/42,H02J3/46;;H02J13/00,,0,0,,,,INACTIVE
302,MX,A,MX 2012002754 A,154-192-040-395-443,2012-04-30,2012,MX 2012002754 A,2010-08-31,US 27582509 P;;US 28690909 P;;US 2010/0047260 W,2009-09-03,BED BUG CAPTURING DEVICE.,The present invention relates to a bed bug capturing device comprising: (a) a bed bug attractant element; and (b) a deadfall capturing element comprising at least one pathway comprising: (i) an upwardly sloped segment; (ii) a downwardly sloped segment having an outer portion; and (iii) a deadfall trap area: characterized in that the upwardly sloped segment and at least the outer portion of the downwardly sloped segment possesses an average surface roughness of at least about 2.5 micrometers.,FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/154-192-040-395-443,Patent Application,no,0,0,8,8,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/02;;A01M1/02;;A01M1/10;;A01M1/2011;;A01M1/2011;;A01M2200/011;;A01M2200/011;;A01N31/02;;A01N35/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01N35/02,,0,0,,,,DISCONTINUED
303,CA,A1,CA 2832484 A1,031-123-138-224-598,2012-10-11,2012,CA 2832484 A,2012-04-06,US 201161472362 P;;US 2012/0032573 W,2011-04-06,POLYMALIC ACID BASED NANOCONJUGATES FOR IMAGING,"Nanoconjugates include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold. At least one imaging moiety and at least one targeting module is conjugated to the polymalicacid based molecular scaffold. Methods of synthesizing the nanoconjugate involve providing a polymalic acid having a plurality of pendant carboxyi groups. The method reacts a compound containing sulfhydryl groups and amino acid groups through the pendant carboxyi groups to add sulfhydryl groups to the polymalic acid to form an activated polymalic acid. The method reacts at least one imaging moiety containing a sulfhydryl binding group to the activated polymalic acid to form a preconjugate. The method may involve administering to the subject a nanoconjugate that includes a polymalic acid-based molecular scaffold, at least one imaging moiety, and at least one targeting module.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;HOLLER EGGEHARD,,https://lens.org/031-123-138-224-598,Patent Application,no,0,0,11,12,0,A61K49/128;;A61K49/16;;A61K47/593;;A61P35/00;;A61K49/16;;A61K47/593;;A61K49/128,A61K49/00;;C07C211/00,,0,0,,,,DISCONTINUED
304,AU,A1,AU 2017/201353 A1,195-280-383-716-963,2017-04-27,2017,AU 2017/201353 A,2017-03-04,AU 2017/201353 A;;AU 2012/239933 A;;US 201161472362 P;;US 2012/0032573 W,2011-04-06,Polymalic acid based nanoconjugates for imaging,"A method of diagnostic imaging of a brain in a subject comprising: administering to the subject a composition comprising a polymalic acid-based molecular scaffold having a plurality of pendant carboxyl groups, at least one imaging moiety, and at least one targeting module, wherein the polymalic acid-based molecular scaffold is a homopolymer, each of the at least one imaging moiety is conjugated to the polymalic acid based molecular scaffold through one of the plurality of the pendant carboxyl groups, each of the at least one targeting module is conjugated to the polymalic-acid based molecular scaffold through one of the plurality of the pendant carboxyl group, the at least one imaging moiety comprises a contrast agent, and the at least one targeting module comprises an antibody, a peptide, an oligonucleotide, or a therapeutic chemical; and providing that the imaging moiety is visualized by an MRI imaging technique. -38- WO 2012/139030 PCT/US2012/032573 coo o o",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;HOLLER EGGEHARD,,https://lens.org/195-280-383-716-963,Patent Application,no,0,0,11,12,0,A61K49/128;;A61K49/16;;A61K47/593;;A61P35/00;;A61K49/16;;A61K47/593;;A61K49/128,C07C211/00;;A61K49/00,,0,0,,,,INACTIVE
305,GB,A,GB 2513974 A,101-345-346-742-147,2014-11-12,2014,GB 201404193 A,2014-03-10,US 201313832946 A,2013-03-15,Generator set adaptive droop control method,"A method of controlling a plurality of electric generator sets (gensets) during a failsafe condition, such as when communication is lost with one or more gensets, includes operating one or more of the gensets according to a modified isochronous control scheme 302, and operating a remainder of the gensets according an adaptive droop control scheme 304. The modified isochronous control scheme may include varying the frequency of each isochronous genset with respect to load for lower-range loads and upper-range loads, and maintaining the frequency of each isochronous genset at nominal frequencies for mid-range loads. The adaptive droop control scheme may include adjusting the frequency of each droop genset to match the frequency of the isochronous gensets, and varying the load of each droop genset with respect to frequency for lower-range loads and upper-range loads.",CATERPILLAR INC,FOLKEN KEITH;;MEINHART MATTHEW JOSEPH;;SCHROEDER EDWARD MAURER;;BLACK ANDREW WILLIAM,,https://lens.org/101-345-346-742-147,Patent Application,no,2,0,7,7,0,H02J3/46;;H02P9/42;;H02J13/0062;;H02J3/46;;H02J3/46;;H02P9/42,H02J3/46;;H02J13/00,,0,0,,,,INACTIVE
306,US,B2,US 10512699 B2,026-296-818-871-574,2019-12-24,2019,US 201715798612 A,2017-10-31,US 201715798612 A;;US 201113119596 A;;US 2009/0057569 W;;US 9820608 P,2008-09-18,Optical method for the detection of Alzheimer's disease using curcumin,"The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.",CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH;;SCHWARTZ MICHAL;;FARKAS DANIEL L,,https://lens.org/026-296-818-871-574,Granted Patent,yes,36,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61B5/00;;A61B3/00;;A61B3/10;;A61B3/14;;A61B6/00;;A61B6/03;;A61K31/404;;A61K31/437;;A61K31/496;;A61K31/4965;;A61K31/5377;;A61K49/00;;C07D401/14;;G01N33/50,,44,37,048-262-075-396-41X;;011-124-388-694-014;;057-540-982-119-962;;047-248-975-491-255;;155-116-058-123-026;;127-755-540-864-020;;006-352-234-052-186;;001-450-008-710-264;;130-962-057-320-330;;057-575-130-152-762;;051-258-321-229-657;;041-582-872-839-824;;029-266-465-122-624;;155-116-058-123-026;;168-962-786-537-184;;030-890-177-126-959;;044-996-017-028-990;;017-573-748-497-068;;130-962-057-320-330;;047-248-975-491-255;;001-071-605-851-401;;062-121-843-455-012;;023-752-202-245-804;;018-185-564-619-309;;094-757-093-302-58X;;021-351-675-495-336;;101-039-368-580-34X;;137-580-887-914-833;;019-616-143-624-925;;040-268-043-147-853;;085-892-067-132-332;;003-422-916-572-826;;011-952-969-552-421;;122-914-173-863-23X;;051-258-321-229-657;;041-582-872-839-824;;017-689-186-117-418,9267595;;10.1111/j.1442-9071.1997.tb01290.x;;17472706;;10.1111/j.1471-4159.2007.04613.x;;10.1001/archophthalmol.2009.145;;19597108;;pmc2987580;;17999464;;10.1021/mp700113r;;10.1074/jbc.m404751200;;15590663;;10.1016/j.ab.2006.04.036;;16729955;;pmc1184038;;10.1172/jci23241;;16100572;;17684098;;10.1073/pnas.0703707104;;pmc1940230;;10.1016/s0140-6736(03)12981-9;;12699953;;10.1167/iovs.08-2384;;18791173;;pmc3697019;;10.1111/j.1471-4159.2008.05606.x;;18691390;;10.1167/iovs.08-1849;;18566467;;pmc3947384;;18382494;;pmc3079576;;10.1364/josaa.25.000947;;10.1074/jbc.m404751200;;15590663;;pmc2991559;;10.1016/j.neuroimage.2010.06.020;;20550967;;10.1056/nejm198608213150804;;3736630;;10.1016/0006-8993(89)90653-7;;2819446;;10.1002/eji.200324502;;14768043;;10.1016/s0140-6736(03)12981-9;;12699953;;17999464;;10.1021/mp700113r;;10.1016/j.addr.2006.07.024;;17081648;;10.1167/iovs.03-0505;;15037592;;10.1039/b409724f;;15480453;;10.1016/j.bmc.2004.03.074;;10.1016/s0968-0896(04)00277-9;;15158792;;10.1111/j.1742-4658.2006.05525.x;;17069615;;12870844;;10.1562/0031-8655(2003)0770597psoboc2.0.co2;;10.1562/0031-8655(2003)077<0597:psoboc>2.0.co;2;;10.1111/j.1747-0285.2007.00557.x;;17718715;;10.1016/s0925-4439(00)00029-6;;10899428;;10.1073/pnas.022662599;;pmc122217;;11818542;;1690688;;17003411;;10.1167/iovs.06-0026;;10.1093/brain/123.12.2519;;11099453;;10.1111/cbdd.12552;;25776887;;17888483;;10.1016/j.visres.2007.07.025;;pmc2323206;;10.1111/j.1471-4159.2008.05606.x;;18691390;;10.1167/iovs.08-1849;;18566467;;pmc3947384;;18480561;;10.1254/fpj.131.333,"Perez et al. Invest. Ophthalmol. Vis. Sci. published online Sep. 12, 2008, 2009; 50:793-800.;;Vickers, Australian and New Zealand J. of Ophthalmol., 1997; 25:105-109.;;Garcia-Alloza et al., J. Neurochem., 2007; 102:1095-1104.;;Wang et al. ARch Ophthalmol. 2009; 127:875-881.;;Anand et al. Molecular. Pharmaceutics, 2007, 4:807-818.;;Yang et al. J. Biol. Chem., 2005; 280:5892-5901.;;LeVine Ana. Biochem. 2006; 356: 265-272.;;PCT/US09/57569 ISR and Written Opinion dated Nov. 19, 2009.;;Xie Zhao-yang, et al., Chinese Journal of New Drugs, 2007, vol. 16 No. 1, pp. 36-40.;;Koronyo et al., “Noninvasive Optical Imaging of Retinal Amyloid Plaques in Mice Model of Alzheimer's disease: Early Detection and Treatment Assessment,” alzheimer's association, Abstract, 3 pages (2010).;;Koroyno et al., “Optical imaging of amyloid plaques in the retina for Alzheimer's disease detection and treatment assessment,” Neuroscience 2009, Abstract, 2 pages (2009).;;Koroyno et al. “Noninvsive Optical Imaging of .beta.-Amyloid Plaques in Live AD Mice Retina and Identification of A.beta. Plaques in Postmortem Retinas from Human AD Patients,” Poster # P3-188, Abstract Control #2932, Cedar-Sinai Medical Center (2009).;;Koroyno et al., In Vivo Optical Imaging of Retinal Amyloid Plaques in Mice Model of Alzheimer's disease: Early Detection and Treatmet Assessment, Poster #12, Abstract, Cedar-Sinai Medical Center (2009).;;Frenkel et al., “Nasal vaccination with a proteasome-based adjuvant and glatiramer acetate clears .beta.-amyloid in a mouse model of Alzheimer disease,” The Journal of Clinical Investigation, vol. 115, No. 9, pp. 2423-2433 (2005).;;Guo et al., “Targeting amyloid-.beta. in glaucoma treatment,” Proc. National Academy of Science, vol. 104, No. 33, pp. 13444-13449 (2007).;;Goldstein et al., “Cytosolic .beta.-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease,” The Lancet, vol. 361, No. 9365, pp. 1258-1265 (2003).;;Perez et al., “.beta.-Amyloid Deposition and Functional Impairment in the Retina of the APPswe/PS1.DELTA.E9 Transgenic Mouse Model for Alzheimer's Disease,” Investigative Ophthalmology & Visual Science, vol. 50, No. 2, pp. 793-800 (2008).;;Shimazawa et al., “Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-D-asparatate receptor signaling,” Journal of Neurochemistry, vol. 107, No. 1, pp. 279-290 (2008).;;Ning et al., “Amyloid-.beta. Deposits Lead to Retinal Degeneration in a Mouse Model of Alzheimer Disease,”Investigative Ophthalmology & Visual Science, vol. 49, No. 11, pp. 5136-5143 (2008).;;Sharifzadeh et al., “Resonance Raman imaging of macular pigment distrubutions in the human retina,” Journal of the Optical Society of America, vol. 25, No. 4, pp. 947-957 (2008).;;Yang et al., “Curcumin Inhibits Formation of Amyloid .beta. Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo,” Journal of Biological Chemistry, vol. 280, No. 7, pp. 5892-5901 (2005).;;Koronyo-Hamaoui et al., “Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model,” NeuroImage, vol. 54, pp. 5204-5217 (2011).;;Hinton, D.R., et al., “Optic-nerve degeneration in Alzheimer's disease”, N Engl J Med. Aug. 21, 1986;315(8)485-7 (Abstract only).;;Blanks, J.C., et al., “Retinal ganglion cell degeneration in Alzheimer's disease”, Brain Res. Nov. 6, 1989;501(2):364-72 (Abstract only).;;M.L. Ford and B.D. Evavold, “An MHC anchor-substituted analog of myelin oligodenrocyte glycoprotein 35-55 induces IFN-.gamma. and autoantibodies in the absence of experimental autoimmune encephalomyelitis and optic neuritis”, Eur. J. Immunol., 2004, 34:388-397.;;L.E. Goldstein, et al., “Cytosolic .beta.-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease”, Lancet 2003; 361: 1258-65.;;Anand, et al., “Bioavailability of Curcumin: Problems and Promises”, Mol. Pharmaceutics, 2007, 4 (6), 807-818.;;Mannermaa, et al., “Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics”, Adv Drug Deliv Rev. Nov. 15, 2006;58(11):1136-63. Epub Sep. 16, 2006. (Abstract Only).;;Hosoya, et al., “Vitamin C transport in oxidized form across the rat blood-retinal barrier”, Invest Ophthalmol Vis Sci. Apr. 2004;45(4):1232-9.;;Zsila, et al., “Circular dichroism spectroscopic studies reveal pH dependent binding of curcumin in the minor groove of natural and synthetic nucleic acids”, Org Biomol Chem. Oct. 21, 2004;2(20):2902-10. Epub Sep. 23, 2004. (Abstract Only).;;Zsila, et al., “Induced circular dichroism spectra reveal binding of the antiinflammatory curcumin to human alpha1-acid glycoprotein”, Bioorg Med Chem. Jun. 15, 2004;12(12):3239-45. (Abstract Only).;;Gupta, et al., “Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding”, FEBS J. Dec. 2006;273(23):5302-32. Epub Oct. 26, 2006. (Abstract Only).;;Barik, et al., “Photophysical studies on binding of curcumin to bovine serum albumins”, Photochem Photobiol. Jun. 2003;77(6):597-603. (Abstract Only).;;Reinke, A. A. and Gestwicki, J. E. (2007), Structure-activity Relationships of Amyloid Beta-aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibility. Chemical Biology & Drug Design, 70: 206-215. (Abstract Only).;;L.C. Serpell, “Alzheimer's amyloid fibrils: structure and assembly”, Biochimica et Biophysica Acta, 1502:16-30 (2000).;;B. O'Nuallain and R. Wetzel, “Conformational Abs Recognizing a Generic Amyloid Fibril Epitope”, PNAS, vol. 99, No. 3, pp. 1485-1490 (2002).;;T. Cavallero, et al., “The Retinal Pigment Epithelium Is the Unique Site of Transthyretin Synthesis in the Rat Eye”, Investigative Ophthalmology & Visual Science, vol. 31, No. 3, pp. 497-501, Mar. 1990.;;P.M. Martin, et al., “Expression and Polarized Localization of the Hemochromatosis Gene Product HFE in Retinal Pigment Epithelium”, Investigative Ophthalmology & Visual Science, vol. 47, No. 10, pp. 4238-4244, Oct. 2006.;;G. Cancel, et al., “Distribution of Ataxin-7 in Normal Human Brain and Retina”, Brain, 123:2519-2530, 2000.;;P.P.N. Rao, et al., “Curcumin Binding to Beta Amyloid: A Computational Study”, Chemical Biology & Drug Design, 2015, 86:813-820.;;J.-D. Ding, et al., “Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: Anti-amyloid-.beta. antibody attenuates pathologies in an age-related macular degeneration mouse model”, Vision Research 48 (2008) 339-345.;;M. Shimazawa, et al., “Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-D-aspartate receptor signaling”, J. of Neurochemistry, 2008, 107:279-290.;;A. Ning, et al., “Amyloid-.beta. Deposits Lead to Retinal Degeneration in a Mouse Model of Alzheimer Disease”, Investigative Ophthalmology & Visual Science, Nov. 2008, vol. 49, No. 11, 5136-5143.;;N. Okamura, et al., “In Vivo Imagining of Amyloid Plaques”, Folia Pharmacol. Jpn., (2008) 131:333-337 [Japanese language reference with English language abstract].",ACTIVE
307,MX,A,MX 2012003569 A,143-819-559-920-088,2012-05-08,2012,MX 2012003569 A,2010-08-31,US 24637309 P;;US 2010/0047257 W,2009-09-28,AMPOULE FOR THE STORAGE AND DISPERSION OF VOLATILE LIQUIDS.,"In one aspect, the present invention is directed to an ampoule for the storage and dispersion of a volatile liquid comprised of (a) an outer shell composed of an impermeable material and defining at least one opening; (b) a porous diffusion member defining an internal reservoir positioned inside said outer shell; (c) a volatile liquid contained within such internal reservoir; and (d) a film member adhered to said outer shell and covering said at least one opening; wherein said film member is disposed such that an air space is present between said porous diffusion member and said film member; and wherein said porous diffusion member is configured such that molecules of the volatile liquid can only enter into said air space via diffusion through said porous diffusion member. Such ampoules are particularly suited for the storage and dispersion of organic chemicals useful as bed bug attractants, especially where such attractants are formulated in a highly volatile liquid, such as a C<sub>8</sub>-C<sub>12</sub> alkane. In another aspect, this invention is directed to a device adapted to receive one or more of such ampoules. In one preferred embodiment, such device is a bed bug capturing device.",FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/143-819-559-920-088,Patent Application,no,0,0,10,10,0,A01M1/02;;A01M1/2044;;A01M1/2044;;A01M1/2033;;A01M1/2033;;A01M13/00;;A01N29/02;;A01N31/02;;A61L9/122;;A61L9/122,A01M1/02;;A01M13/00;;A01N29/02;;A01N31/02;;A01N59/06,,0,0,,,,ACTIVE
308,CN,A,CN 104052353 A,147-580-759-137-462,2014-09-17,2014,CN 201410095132 A,2014-03-14,US 201313832946 A,2013-03-15,Generator Set Adaptive Droop Control Method,"A method of controlling a plurality of gensets during a failsafe condition is provided. The method may include operating one or more of the gensets according to a modified isochronous control scheme, and operating a remainder of the gensets according an adaptive droop control scheme. The modified isochronous control scheme may include varying the frequency of each isochronous genset with respect to load for lower-range loads and upper-range loads, and maintaining the frequency of each isochronous genset at nominal frequencies for mid-range loads. The adaptive droop control scheme may include adjusting the frequency of each droop genset to match the frequency of the isochronous gensets, and varying the load of each droop genset with respect to frequency for lower-range loads and upper-range loads.",CATERPILLAR INC,MATTHEW JOSEPH MEINHART;;ANDREW WILLIAM BLACK;;EDWARD MAURER SCHROEDER;;KEITH FOLKEN,,https://lens.org/147-580-759-137-462,Patent Application,no,3,2,7,7,0,H02J3/46;;H02P9/42;;H02J13/0062;;H02J3/46;;H02J3/46;;H02P9/42,H02P9/00,,0,0,,,,ACTIVE
309,WO,A1,WO 2016/175762 A1,078-752-533-385-225,2016-11-03,2016,US 2015/0027999 W,2015-04-28,US 2015/0027999 W,2015-04-28,STORAGE CACHE MANAGEMENT,"In one example, techniques for storage cache management include receiving a write command to write data to a logical block address (LBA) at a storage device of a storage system, storing the data to the non-volatile memory module and mark metadata associated with the data as Dirty state, sending a write command to write the data to volatile memory module at the storage system and mark the metadata associated with the data as Dirty-Flushed state, sending a cache sync command to copy the data from the volatile memory module to the LBA at the storage device at the storage system, and upon receipt, from the storage system, a message indicating completion of the cache sync command, marking the metadata associated with the data as Clean state to allow reuse of the memory space used by the data at the non-volatile memory module.",HEWLETT PACKARD ENTPR DEV LP,DENEUI NATHANIEL S;;ORSAK KEITH;;BLACK JOSEPH DAVID;;YATES JAMES KENNETH,,https://lens.org/078-752-533-385-225,Patent Application,yes,5,2,1,1,0,G06F12/0868;;G06F12/0804;;G06F2212/1016;;G06F2212/225;;G06F2212/284;;G06F2212/312;;G06F2212/313;;G06F2212/7207;;G06F2212/7209,G06F12/08;;G06F12/06,,0,0,,,,PENDING
310,WO,A3,WO 2011/028688 A3,007-771-750-771-825,2011-07-14,2011,US 2010/0047260 W,2010-08-31,US 28690909 P;;US 27582509 P,2009-09-03,BED BUG CAPTURING DEVICE,The present invention relates to a bed bug capturing device comprising: (a) a bed bug attractant element; and (b) a deadfall capturing element comprising at least one pathway comprising: (i) an upwardly sloped segment; (ii) a downwardly sloped segment having an outer portion; and (iii) a deadfall trap area: characterized in that the upwardly sloped segment and at least the outer portion of the downwardly sloped segment possesses an average surface roughness of at least about 2.5 micrometers.,FMC CORP;;BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/007-771-750-771-825,Search Report,yes,4,0,8,8,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/02;;A01M1/02;;A01M1/10;;A01M1/2011;;A01M1/2011;;A01M2200/011;;A01M2200/011;;A01N31/02;;A01N35/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01N35/02,,0,0,,,,PENDING
311,JP,A,JP 2014122245 A,002-098-911-392-481,2014-07-03,2014,JP 2014071034 A,2014-03-31,US 9820608 P,2008-09-18,OPTICAL METHOD FOR DETECTING ALZHEIMER DISEASE,"PROBLEM TO BE SOLVED: To provide an optical method for detecting Alzheimer disease.SOLUTION: The main subject of the present invention relates to a non-invasive optical imaging method for monitoring an initial pathological event (e.g., generation of amyloid plaque, the amount and position thereof) specific to Alzheimer disease (AD). The capability of monitoring such an event provides a basis for AD diagnosis, prognosis prediction and potential therapy evaluation, above all. Further, the main subject of the present invention is to introduce a new method for treating AD and a retinal disease related with AD. Aβ plaque detection is extremely limited particularly in terms of high resolution. Therefore, the present invention is based on a study focusing on an eye, as alternative means of a tissue from the brain, which can be directly, repeatedly and non-invasively imaged.",CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,YOSEF KORONYO;;MAYA KORONYO;;BLACK KEITH L;;MICHAL SCHWARTZ;;DANIEL FARKAS,,https://lens.org/002-098-911-392-481,Patent Application,no,2,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;A61K38/00;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;G01N21/64,,9,2,001-450-008-710-264;;130-962-057-320-330,17684098;;10.1073/pnas.0703707104;;pmc1940230;;10.1016/s0140-6736(03)12981-9;;12699953,"JPN6013053624; Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｉｎｖｅｓｔｉｇａｔｉｏｎ Ｖｏｌ．１１５，Ｎｏ．９, 2005, ｐ２４２３-２４３３;;JPN6013053626; Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．ＵＳＡ Ｖｏｌ．１０４，Ｎｏ．３３, 2007, ｐ１３４４４-１３４４９;;JPN6013053627; Ｌａｎｃｅｔ Ｖｏｌ．３６１，Ｎｏ．９３６５, 2003, ｐ１２５８-１２６５;;JPN6013053628; Ｉｎｖｅｓｔｉｇａｔｉｖｅ Ｏｐｈｔｈａｌｍｏｌｏｇｙ ＆ Ｖｉｓｕａｌ Ｓｃｉｅｎｃｅ ［ｏｎｌｉｎｅ］, 20080912, ｄｏｉ：１０．１１６７／ｉｏｖｓ．０８-２３８４;;JPN6013053629; Ｊｏｕｒｎａｌ ｏｆ Ｎｅｕｒｏｃｈｅｍｉｓｔｒｙ ［ｏｎｌｉｎｅ］, 20080807, ｄｏｉ：１０．１１１１／ｊ．１４７１-４１５９．２００８．０５６０６．ｘ;;JPN6013053630; Ｉｎｖｅｓｔｉｇａｔｉｖｅ Ｏｐｈｔｈａｌｍｏｌｏｇｙ ＆ Ｖｉｓｕａｌ Ｓｃｉｅｎｃｅ ［ｏｎｌｉｎｅ］, 20080619, ｄｏｉ： １０．１１６７／ｉｏｖｓ．０８-１８４９;;JPN6013053631; Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ｏｐｔｉｃａｌ Ｓｏｃｉｅｔｙ ｏｆ Ａｍｅｒｉｃａ． Ａ， Ｏｐｔｉ Ｖｏｌ．２５，Ｎｏ．４, 200804, ｐ９４７-９５７;;JPN6013053633; Ｊｏｕｒｎａｌ ｏｆ Ｂｉｏｌｏｇｉｃａｌ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２８０，Ｎｏ．７, 2005, ｐ５８９２-５９０１;;JPN6016003319; Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．３４，Ｎｏ．２, 2004, ｐ３８８-３９７",ACTIVE
312,WO,A3,WO 2023/283637 A3,079-853-826-269-788,2023-02-16,2023,US 2022/0073558 W,2022-07-08,US 202163220239 P,2021-07-09,A METHOD TO DETECT RETINAL AMYLOIDOSIS AND TAUOPATHY USING SNAP HYPERSPECTRAL IMAGING AND/OR SNAP HYPERSPECTRAL OPTICAL COHERENCE TOMOGRAPHY,"The present invention describes systems and method for the detection, diagnosis and monitoring of cognitive impairment and Alzheimer's disease. In one example, an integrated system comprising a full-field Fourier domain optical coherence tomography and an image mapping spectrometry is used for generating spectrally resolved volumetric images at wavelengths that show difference in spectral signatures of normal cells compared to spectral signatures of amyloid beta and pTau deposits, and also image inner retinal layers where amyloid beta and pTau deposits may aggregate.",CEDARS SINAI MEDICAL CENTER;;UNIV CALIFORNIA,KORONYO MAYA;;KORONYO YOSEF;;BLACK KEITH L;;MIRZAEI NAZANIN;;GAO LIANG,,https://lens.org/079-853-826-269-788,Search Report,yes,6,0,2,2,0,A61B3/12;;A61B3/102;;G16H30/20;;G16H30/40;;G16H50/20,A61B3/14;;G01J3/02;;G01J3/45;;G01N21/25,,0,0,,,,PENDING
313,WO,A2,WO 2011/037729 A2,041-487-494-966-969,2011-03-31,2011,US 2010/0047278 W,2010-08-31,US 24631509 P,2009-09-28,BED BUG CAPTURING DEVICE,"The present invention relates to a bed bug capturing device comprising: (a) a bed bug attractant element comprising (i) a heavier than air organic chemical which attracts bed bugs; and (ii) a means for producing air flow such that the air movement from the device has a face velocity of between about 5 and about 50 ml/cm2/min; and (b) a trap element. Preferably, such means of producing air flow is a fan.",FMC CORP;;BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/041-487-494-966-969,Patent Application,yes,0,4,3,3,0,A01M1/103;;A01M1/103;;A01M1/02;;A01M1/02;;A01M1/2033;;A01M1/2033;;A01M1/2055;;A01M1/2055;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01N35/02,,0,0,,,,PENDING
314,CN,A,CN 103582497 A,001-506-801-069-978,2014-02-12,2014,CN 201280026653 A,2012-04-06,US 2012/0032573 W;;US 201161472362 P,2011-04-06,Polymalic acid based nanoconjugates for imaging,"Nanoconjugates include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold. At least one imaging moiety and at least one targeting module are conjugated to the polymalicacid based molecular scaffold. Methods of synthesizing the nanoconjugate involve providing a polymalic acid having a plurality of pendant carboxyi groups. The method reacts a compound containing sulfhydryl groups and amino acid groups through the pendant carboxyi groups to add sulfhydryl groups to the polymalic acid to form an activated polymalic acid. The method reacts at least one imaging moiety containing a sulfhydryl binding group to the activated polymalic acid to form a preconjugate. The method may involve administering to the subject a nanoconjugate that includes a polymalic acid-based molecular scaffold, at least one imaging moiety, and at least one targeting module.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;HOLLER EGGEHARD,,https://lens.org/001-506-801-069-978,Patent Application,no,2,5,11,12,0,A61K49/128;;A61K49/16;;A61K47/593;;A61P35/00;;A61K49/16;;A61K47/593;;A61K49/128,A61K49/00;;C07C211/00,,2,2,106-640-130-151-317;;011-450-253-768-016,pmc3487710;;10.1021/bc0502457;;16536461;;10.1158/0008-5472.can-10-3093;;10.31234/osf.io/nyh6f;;21303974;;pmc3428373,"BONG-SEOP LEE ET AL.: ""Polycefin, a New Prototype of a Multifunctional Nanoconjugate"", 《BIOCONJUG CHEM.》;;SATOSHI INOUE ET AL.: ""Polymalic Acid–Based Nanobiopolymer Provides Efficient Systemic Breast Cancer Treatment by Inhibiting both HER2/neu Receptor Synthesis and Activity"", 《CANCER RES.》",DISCONTINUED
315,AU,A1,AU 2012/239933 A1,054-189-287-692-500,2013-10-24,2013,AU 2012/239933 A,2012-04-06,US 201161472362 P;;US 2012/0032573 W,2011-04-06,Polymalic acid based nanoconjugates for imaging,"Nanoconjugates include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold. At least one imaging moiety and at least one targeting module is conjugated to the polymalicacid based molecular scaffold. Methods of synthesizing the nanoconjugate involve providing a polymalic acid having a plurality of pendant carboxyi groups. The method reacts a compound containing sulfhydryl groups and amino acid groups through the pendant carboxyi groups to add sulfhydryl groups to the polymalic acid to form an activated polymalic acid. The method reacts at least one imaging moiety containing a sulfhydryl binding group to the activated polymalic acid to form a preconjugate. The method may involve administering to the subject a nanoconjugate that includes a polymalic acid-based molecular scaffold, at least one imaging moiety, and at least one targeting module.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;HOLLER EGGEHARD,,https://lens.org/054-189-287-692-500,Patent Application,no,0,0,11,12,0,A61K49/128;;A61K49/16;;A61K47/593;;A61P35/00;;A61K49/16;;A61K47/593;;A61K49/128,C07C211/00;;A61K49/00,,0,0,,,,INACTIVE
316,WO,A1,WO 2015/188142 A1,141-633-797-661-503,2015-12-10,2015,US 2015/0034553 W,2015-06-05,US 201462008381 P,2014-06-05,DIAGNOSIS AND MONITORING OF TRAUMATIC BRAIN INJURY BY IMAGING RETINAL ABNORMALITIES,Described herein are methods for diagnosing and monitoring traumatic brain injury by imaging a subject retinal to determine the presence and/or extent of deviations from a normal retina.,CEDARS SINAI MEDICAL CENTER,KORONYO MAYA;;LEY ERIC;;KORONYO YOSEF;;BLACK KEITH L;;KATEB BABAK,,https://lens.org/141-633-797-661-503,Patent Application,yes,2,9,1,1,0,A61K49/0032;;A61B3/0025;;A61B3/12;;A61B3/1241;;A61B5/0042;;A61B5/4064;;A61K49/0021;;A61K49/003;;A61P25/28,A61K49/00;;A61B3/00;;A61B3/14;;A61B5/00;;A61P25/28,,1,1,049-533-181-240-214,20491801;;10.1111/j.1442-9071.2010.02324.x,"VINCENT ET AL.: ""Retinal haemorrhages in inflicted traumatic brain injury: the ophthalmologist in court."", CLIN EXPERIMENT OPHTHALMOL., vol. 38, no. 5, July 2010 (2010-07-01), pages 521 - 32, XP055239343, ISSN: 1442-6404",PENDING
317,EP,A4,EP 2694117 A4,140-188-188-680-427,2014-06-11,2014,EP 12768248 A,2012-04-06,US 201161472362 P;;US 2012/0032573 W,2011-04-06,POLYMALIC ACID BASED NANOCONJUGATES FOR IMAGING,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;HOLLER EGGEHARD,,https://lens.org/140-188-188-680-427,Search Report,no,11,0,11,12,0,A61K49/128;;A61K49/16;;A61K47/593;;A61P35/00;;A61K49/16;;A61K47/593;;A61K49/128,A61K49/12;;A61K47/48;;A61K49/16;;A61P35/00,,5,2,011-450-253-768-016;;083-600-046-001-528,10.1158/0008-5472.can-10-3093;;10.31234/osf.io/nyh6f;;21303974;;pmc3428373;;10.1073/pnas.1015385107,"SATOSHI INOUE ET AL: ""Newly designed nanobioconjugate for direct targeting and systemic treatment of HER2-positive breast cancer"", CANCER RESEARCH; PROCEEDINGS: AACR 101ST ANNUAL MEETING 2010-- APR 17-21, 2010; WASHINGTON, DC. PHILADELPHIA (PA), US, vol. 70, no. 8, suppl, 1 April 2010 (2010-04-01), pages 937, XP002719407, ISSN: 0008-5472;;S. INOUE ET AL: ""Polymalic Acid-Based Nanobiopolymer Provides Efficient Systemic Breast Cancer Treatment by Inhibiting both HER2/neu Receptor Synthesis and Activity"", CANCER RESEARCH, vol. 71, no. 4, 8 February 2011 (2011-02-08), pages 1454 - 1464, XP055115086, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-3093;;""Inhibition of brain tumor growth by intravenous poly(-L-malic) acid nanobioconjugate with pH-dependent drug release"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 45, 27 October 2010 (2010-10-27), pages 19603 - 19603, XP055098887, ISSN: 0027-8424, DOI: 10.1073/pnas.1015385107;;JULIA Y LJUBIMOVA: ""Molecular Oncology"", INTERNET CITATION, 1 July 2009 (2009-07-01), XP008143608, Retrieved from the Internet <URL:http://www.cedars-sinai.edu/10141.html> [retrieved on 20110929];;See also references of WO 2012139030A1",DISCONTINUED
318,WO,A2,WO 2011/037728 A2,176-892-271-875-634,2011-03-31,2011,US 2010/0047257 W,2010-08-31,US 24637309 P,2009-09-28,AMPOULE FOR THE STORAGE AND DISPERSION OF VOLATILE LIQUIDS,"In one aspect, the present invention is directed to an ampoule for the storage and dispersion of a volatile liquid comprised of (a) an outer shell composed of an impermeable material and defining at least one opening; (b) a porous diffusion member defining an internal reservoir positioned inside said outer shell; (c) a volatile liquid contained within such internal reservoir; and (d) a film member adhered to said outer shell and covering said at least one opening; wherein said film member is disposed such that an air space is present between said porous diffusion member and said film member; and wherein said porous diffusion member is configured such that molecules of the volatile liquid can only enter into said air space via diffusion through said porous diffusion member. Such ampoules are particularly suited for the storage and dispersion of organic chemicals useful as bed bug attractants, especially where such attractants are formulated in a highly volatile liquid, such as a C 8 -C 12 alkane. In another aspect, this invention is directed to a device adapted to receive one or more of such ampoules. In one preferred embodiment, such device is a bed bug capturing device.",FMC CORP;;BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/176-892-271-875-634,Patent Application,yes,0,0,10,10,0,A01M1/02;;A01M1/2044;;A01M1/2044;;A01M1/2033;;A01M1/2033;;A01M13/00;;A01N29/02;;A01N31/02;;A61L9/122;;A61L9/122,A01M1/02;;A01M13/00;;A01N29/02;;A01N31/02;;A01N59/06,,0,0,,,,PENDING
319,US,A1,US 2014/0265354 A1,169-660-761-510-228,2014-09-18,2014,US 201313832946 A,2013-03-15,US 201313832946 A,2013-03-15,GENERATOR SET ADAPTIVE DROOP CONTROL METHOD,"A method of controlling a plurality of gensets during a failsafe condition is provided. The method may include operating one or more of the gensets according to a modified isochronous control scheme, and operating a remainder of the gensets according an adaptive droop control scheme. The modified isochronous control scheme may include varying the frequency of each isochronous genset with respect to load for lower-range loads and upper-range loads, and maintaining the frequency of each isochronous genset at nominal frequencies for mid-range loads. The adaptive droop control scheme may include adjusting the frequency of each droop genset to match the frequency of the isochronous gensets, and varying the load of each droop genset with respect to frequency for lower-range loads and upper-range loads.",CATERPILLAR INC,FOLKEN KEITH;;MEINHART MATTHEW JOSEPH;;SCHROEDER EDWARD MAURER;;BLACK ANDREW WILLIAM,CATERPILLAR INC (2013-03-12),https://lens.org/169-660-761-510-228,Patent Application,yes,40,13,7,7,0,H02J3/46;;H02P9/42;;H02J13/0062;;H02J3/46;;H02J3/46;;H02P9/42,H02P11/00,290 40 E,0,0,,,,ACTIVE
320,EP,A2,EP 2473032 A2,195-258-238-005-929,2012-07-11,2012,EP 10814348 A,2010-08-31,US 28690909 P;;US 27582509 P;;US 2010/0047260 W,2009-09-03,BED BUG CAPTURING DEVICE,,FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/195-258-238-005-929,Patent Application,yes,0,0,8,8,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/02;;A01M1/02;;A01M1/10;;A01M1/2011;;A01M1/2011;;A01M2200/011;;A01M2200/011;;A01N31/02;;A01N35/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01N35/02,,1,0,,,See references of WO 2011028688A3,DISCONTINUED
321,US,B1,US 8841787 B1,197-003-645-053-125,2014-09-23,2014,US 201313832946 A,2013-03-15,US 201313832946 A,2013-03-15,Generator set adaptive droop control method,"A method of controlling a plurality of gensets during a failsafe condition is provided. The method may include operating one or more of the gensets according to a modified isochronous control scheme, and operating a remainder of the gensets according an adaptive droop control scheme. The modified isochronous control scheme may include varying the frequency of each isochronous genset with respect to load for lower-range loads and upper-range loads, and maintaining the frequency of each isochronous genset at nominal frequencies for mid-range loads. The adaptive droop control scheme may include adjusting the frequency of each droop genset to match the frequency of the isochronous gensets, and varying the load of each droop genset with respect to frequency for lower-range loads and upper-range loads.",CATERPILLAR INC,FOLKEN KEITH;;MEINHART MATTHEW JOSEPH;;SCHROEDER EDWARD MAURER;;BLACK ANDREW WILLIAM,CATERPILLAR INC (2013-03-12),https://lens.org/197-003-645-053-125,Granted Patent,yes,43,6,7,7,0,H02J3/46;;H02P9/42;;H02J13/0062;;H02J3/46;;H02J3/46;;H02P9/42,F02D29/06;;F03B13/10;;F03B15/08;;G05D3/12;;G05D5/00;;G05D9/00;;H02M7/48;;H02P9/04;;H02P11/00,290 40E;;290/7;;700/287;;700/292;;700/295;;363/71;;307/84,0,0,,,,ACTIVE
322,WO,A3,WO 2011/037728 A3,005-384-769-716-743,2011-07-14,2011,US 2010/0047257 W,2010-08-31,US 24637309 P,2009-09-28,AMPOULE FOR THE STORAGE AND DISPERSION OF VOLATILE LIQUIDS,"In one aspect, the present invention is directed to an ampoule for the storage and dispersion of a volatile liquid comprised of (a) an outer shell composed of an impermeable material and defining at least one opening; (b) a porous diffusion member defining an internal reservoir positioned inside said outer shell; (c) a volatile liquid contained within such internal reservoir; and (d) a film member adhered to said outer shell and covering said at least one opening; wherein said film member is disposed such that an air space is present between said porous diffusion member and said film member; and wherein said porous diffusion member is configured such that molecules of the volatile liquid can only enter into said air space via diffusion through said porous diffusion member. Such ampoules are particularly suited for the storage and dispersion of organic chemicals useful as bed bug attractants, especially where such attractants are formulated in a highly volatile liquid, such as a C 8 -C 12 alkane. In another aspect, this invention is directed to a device adapted to receive one or more of such ampoules. In one preferred embodiment, such device is a bed bug capturing device.",FMC CORP;;BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/005-384-769-716-743,Search Report,yes,4,0,10,10,0,A01M1/02;;A01M1/2044;;A01M1/2044;;A01M1/2033;;A01M1/2033;;A01M13/00;;A01N29/02;;A01N31/02;;A61L9/122;;A61L9/122,A01M1/02;;A01M13/00;;A01N29/02;;A01N31/02;;A01N59/06,,0,0,,,,PENDING
323,AU,B2,AU 2017/201353 B2,024-209-196-803-284,2019-01-31,2019,AU 2017/201353 A,2017-03-04,AU 2017/201353 A;;AU 2012/239933 A;;US 201161472362 P;;US 2012/0032573 W,2011-04-06,Polymalic acid based nanoconjugates for imaging,"A method of diagnostic imaging of a brain in a subject comprising: administering to the subject a composition comprising a polymalic acid-based molecular scaffold having a plurality of pendant carboxyl groups, at least one imaging moiety, and at least one targeting module, wherein the polymalic acid-based molecular scaffold is a homopolymer, each of the at least one imaging moiety is conjugated to the polymalic acid based molecular scaffold through one of the plurality of the pendant carboxyl groups, each of the at least one targeting module is conjugated to the polymalic-acid based molecular scaffold through one of the plurality of the pendant carboxyl group, the at least one imaging moiety comprises a contrast agent, and the at least one targeting module comprises an antibody, a peptide, an oligonucleotide, or a therapeutic chemical; and providing that the imaging moiety is visualized by an MRI imaging technique. -38- WO 2012/139030 PCT/US2012/032573 coo o o",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;HOLLER EGGEHARD,,https://lens.org/024-209-196-803-284,Granted Patent,no,1,0,11,12,0,A61K49/128;;A61K49/16;;A61K47/593;;A61P35/00;;A61K49/16;;A61K47/593;;A61K49/128,C07C211/00;;A61K49/00,,1,1,026-135-913-145-143,20921419;;10.1073/pnas.1003919107;;pmc2964197,"Ding H. et al. ""Inhibition of brain tumor growth by intravenous poly (ß-L-malic acid) nanobioconjugate with pH-dependent drug release"" PNAS (2010) 107: 18143-18148",INACTIVE
324,EP,A2,EP 2482644 A2,070-662-183-170-469,2012-08-08,2012,EP 10819218 A,2010-08-31,US 24637309 P;;US 2010/0047257 W,2009-09-28,AMPOULE FOR THE STORAGE AND DISPERSION OF VOLATILE LIQUIDS,,FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/070-662-183-170-469,Patent Application,yes,0,0,10,10,0,A01M1/02;;A01M1/2044;;A01M1/2044;;A01M1/2033;;A01M1/2033;;A01M13/00;;A01N29/02;;A01N31/02;;A61L9/122;;A61L9/122,A01M1/02;;A01M13/00;;A01N29/02;;A01N31/02;;A01N59/06,,1,0,,,See references of WO 2011037728A3,DISCONTINUED
325,CA,A1,CA 2771809 A1,100-083-741-434-749,2011-03-31,2011,CA 2771809 A,2010-08-31,US 24637309 P;;US 2010/0047257 W,2009-09-28,AMPOULE FOR THE STORAGE AND DISPERSION OF VOLATILE LIQUIDS,"In one aspect, the present invention is directed to an ampoule for the storage and dispersion of a volatile liquid comprised of (a) an outer shell composed of an impermeable material and defining at least one opening; (b) a porous diffusion member defining an internal reservoir positioned inside said outer shell; (c) a volatile liquid contained within such internal reservoir; and (d) a film member adhered to said outer shell and covering said at least one opening; wherein said film member is disposed such that an air space is present between said porous diffusion member and said film member; and wherein said porous diffusion member is configured such that molecules of the volatile liquid can only enter into said air space via diffusion through said porous diffusion member. Such ampoules are particularly suited for the storage and dispersion of organic chemicals useful as bed bug attractants, especially where such attractants are formulated in a highly volatile liquid, such as a C8-C12 alkane. In another aspect, this invention is directed to a device adapted to receive one or more of such ampoules. In one preferred embodiment, such device is a bed bug capturing device.",FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/100-083-741-434-749,Patent Application,no,0,1,10,10,0,A01M1/02;;A01M1/2044;;A01M1/2044;;A01M1/2033;;A01M1/2033;;A01M13/00;;A01N29/02;;A01N31/02;;A61L9/122;;A61L9/122,A01M1/02;;A01M13/00;;A01N29/02;;A01N31/02;;A01N59/06,,0,0,,,,DISCONTINUED
326,EP,A1,EP 2694117 A1,087-543-883-937-793,2014-02-12,2014,EP 12768248 A,2012-04-06,US 201161472362 P;;US 2012/0032573 W,2011-04-06,POLYMALIC ACID BASED NANOCONJUGATES FOR IMAGING,,CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;HOLLER EGGEHARD,,https://lens.org/087-543-883-937-793,Patent Application,yes,0,0,11,12,0,A61K49/128;;A61K49/16;;A61K47/593;;A61P35/00;;A61K49/16;;A61K47/593;;A61K49/128,A61K49/12;;A61K47/48;;A61K49/16;;A61P35/00,,0,0,,,,DISCONTINUED
327,WO,A3,WO 2011/037729 A3,063-735-620-832-784,2011-07-21,2011,US 2010/0047278 W,2010-08-31,US 24631509 P,2009-09-28,BED BUG CAPTURING DEVICE,"The present invention relates to a bed bug capturing device comprising: (a) a bed bug attractant element comprising (i) a heavier than air organic chemical which attracts bed bugs; and (ii) a means for producing air flow such that the air movement from the device has a face velocity of between about 5 and about 50 ml/cm2/min; and (b) a trap element. Preferably, such means of producing air flow is a fan.",FMC CORP;;BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/063-735-620-832-784,Search Report,yes,4,0,3,3,0,A01M1/103;;A01M1/103;;A01M1/02;;A01M1/02;;A01M1/2033;;A01M1/2033;;A01M1/2055;;A01M1/2055;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01N35/02,,0,0,,,,PENDING
328,JP,A,JP 2015214588 A,033-371-423-265-669,2015-12-03,2015,JP 2015166449 A,2015-08-26,US 9820608 P,2008-09-18,OPTICAL METHOD FOR DETECTING ALZHEIMER DISEASE,"PROBLEM TO BE SOLVED: To provide an optical method for detecting Alzheimer disease.SOLUTION: The main subject of the present invention relates to a non-invasive optical imaging method for monitoring an initial pathological event (e.g., generation of amyloid plaque, the amount and position thereof) specific to Alzheimer disease (AD). The capability of monitoring such an event provides a basis for AD diagnosis, prognosis prediction and potential therapy evaluation, above all. Further, the main subject of the present invention is to introduce a new method for treating AD and a retinal disease related with AD. Aβ plaque detection is extremely limited particularly in terms of high resolution. Therefore, the present invention is based on a study focusing on an eye, as alternative means of a tissue from the brain, which can be directly, repeatedly and non-invasively imaged.",CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,YOSEF KORONYO;;MAYA KORONYO;;BLACK KEITH L;;MICHAL SCHWARTZ;;DANIEL FARKAS,,https://lens.org/033-371-423-265-669,Patent Application,no,2,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00,,10,0,,,"ＩＮＶＥＳＴＩＧＡＴＩＶＥ ＯＰＨＴＨＡＬＭＯＬＯＧＹ ＆ ＶＩＳＵＡＬ ＳＣＩＥＮＣＥ, vol. [online], JPN6013053628, 12 September 2008 (2008-09-12), pages 10 - 1167, ISSN: 0003506864;;ＬＡＮＣＥＴ, vol. 361, no. 9365, JPN6013053627, 2003, pages 1258 - 1265, ISSN: 0003506871;;ＪＯＵＲＮＡＬ ＯＦ ＴＨＥ ＯＰＴＩＣＡＬ ＳＯＣＩＥＴＹ ＯＦ ＡＭＥＲＩＣＡ． Ａ， ＯＰＴＩ, vol. 25, no. 4, JPN6013053631, April 2008 (2008-04-01), pages 947 - 957, ISSN: 0003506872;;ＪＯＵＲＮＡＬ ＯＦ ＢＩＯＬＯＧＩＣＡＬ ＣＨＥＭＩＳＴＲＹ, vol. 280, no. 7, JPN6013053633, 2005, pages 5892 - 5901, ISSN: 0003506873;;ＶＩＳＩＯＮ ＲＥＳＥＡＲＣＨ, vol. 48, no. 3, JPN6017006505, February 2008 (2008-02-01), pages 339 - 345, ISSN: 0003506865;;ＪＯＵＲＮＡＬ ＯＦ ＮＥＵＲＯＣＨＥＭＩＳＴＲＹ, vol. [online], JPN6013053629, 7 August 2008 (2008-08-07), pages 10 - 1111, ISSN: 0003506866;;ＩＮＶＥＳＴＩＧＡＴＩＶＥ ＯＰＨＴＨＡＬＭＯＬＯＧＹ ＆ ＶＩＳＵＡＬ ＳＣＩＥＮＣＥ, vol. [online], JPN6013053630, 19 June 2008 (2008-06-19), pages 10 - 1167, ISSN: 0003506867;;日本薬理学雑誌, vol. 131, no. 5, JPN6017006508, May 2008 (2008-05-01), pages 333 - 337, ISSN: 0003506868;;ＪＯＵＲＮＡＬ ＯＦ ＣＬＩＮＩＣＡＬ ＩＮＶＥＳＴＩＧＡＴＩＯＮ, vol. 115, no. 9, JPN6013053624, 2005, pages 2423 - 2433, ISSN: 0003506869;;ＰＲＯＣ．ＮＡＴＬ．ＡＣＡＤ．ＳＣＩ．ＵＳＡ, vol. 104, no. 33, JPN6013053626, 2007, pages 13444 - 13449, ISSN: 0003506870",PENDING
329,WO,A2,WO 2023/283637 A2,056-910-806-471-472,2023-01-12,2023,US 2022/0073558 W,2022-07-08,US 202163220239 P,2021-07-09,A METHOD TO DETECT RETINAL AMYLOIDOSIS AND TAUOPATHY USING SNAP HYPERSPECTRAL IMAGING AND/OR SNAP HYPERSPECTRAL OPTICAL COHERENCE TOMOGRAPHY,"The present invention describes systems and method for the detection, diagnosis and monitoring of cognitive impairment and Alzheimer's disease. In one example, an integrated system comprising a full-field Fourier domain optical coherence tomography and an image mapping spectrometry is used for generating spectrally resolved volumetric images at wavelengths that show difference in spectral signatures of normal cells compared to spectral signatures of amyloid beta and pTau deposits, and also image inner retinal layers where amyloid beta and pTau deposits may aggregate.",CEDARS SINAI MEDICAL CENTER;;UNIV CALIFORNIA,KORONYO MAYA;;KORONYO YOSEF;;BLACK KEITH L;;MIRZAEI NAZANIN;;GAO LIANG,,https://lens.org/056-910-806-471-472,Patent Application,yes,0,0,2,2,0,A61B3/12;;A61B3/102;;G16H30/20;;G16H30/40;;G16H50/20,A61B3/14;;G16H30/00,,0,0,,,,PENDING
330,US,A1,US 2019/0022255 A1,068-259-170-376-810,2019-01-24,2019,US 201715798612 A,2017-10-31,US 201715798612 A;;US 201113119596 A;;US 2009/0057569 W;;US 9820608 P,2008-09-18,Optical Method for the Detection of Alzheimer's Disease,"The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.",KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH;;SCHWARTZ MICHAL;;FARKAS DANIEL L;;CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH;;SCHWARTZ MICHAL;;FARKAS DANIEL L,,https://lens.org/068-259-170-376-810,Patent Application,yes,0,2,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00,,0,0,,,,ACTIVE
331,AU,B2,AU 2012/239933 B2,020-630-779-849-237,2017-01-05,2017,AU 2012/239933 A,2012-04-06,US 201161472362 P;;US 2012/0032573 W,2011-04-06,Polymalic acid based nanoconjugates for imaging,"Nanoconjugates include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold. At least one imaging moiety and at least one targeting module is conjugated to the polymalicacid based molecular scaffold. Methods of synthesizing the nanoconjugate involve providing a polymalic acid having a plurality of pendant carboxyi groups. The method reacts a compound containing sulfhydryl groups and amino acid groups through the pendant carboxyi groups to add sulfhydryl groups to the polymalic acid to form an activated polymalic acid. The method reacts at least one imaging moiety containing a sulfhydryl binding group to the activated polymalic acid to form a preconjugate. The method may involve administering to the subject a nanoconjugate that includes a polymalic acid-based molecular scaffold, at least one imaging moiety, and at least one targeting module.",CEDARS SINAI MEDICAL CENTER,BLACK KEITH L;;LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;HOLLER EGGEHARD,,https://lens.org/020-630-779-849-237,Granted Patent,no,6,0,11,12,0,A61K49/128;;A61K49/16;;A61K47/593;;A61P35/00;;A61K49/16;;A61K47/593;;A61K49/128,C07C211/00;;A61K49/00,,2,1,026-135-913-145-143,20921419;;10.1073/pnas.1003919107;;pmc2964197,"ancer Research, 2011, Vol. 71, No. 4, pages 1454-1464;;PNAS, Vol. 107, No. 45, pages 18143-18148",INACTIVE
332,JP,A,JP 2017052793 A,047-781-768-043-244,2017-03-16,2017,JP 2016233922 A,2016-12-01,US 9820608 P,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE,"PROBLEM TO BE SOLVED: To provide an optical method for the detection of Alzheimer's disease.SOLUTION: The present invention provides a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present invention provides a novel method for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as alternative means to a brain-derived tissue that can be imaged directly, repetitively and non-invasively.SELECTED DRAWING: Figure 1",CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,YOSEF KORONYO;;MAYA KORONYO;;BLACK KEITH L;;MICHAL SCHWARTZ;;DANIEL FARKAS,,https://lens.org/047-781-768-043-244,Patent Application,no,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;A61K38/00;;A61P9/10;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12,,0,0,,,,PENDING
333,WO,A1,WO 2012/139030 A1,082-557-453-699-364,2012-10-11,2012,US 2012/0032573 W,2012-04-06,US 201161472362 P,2011-04-06,POLYMALIC ACID BASED NANOCONJUGATES FOR IMAGING,"Nanoconjugates include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold. At least one imaging moiety and at least one targeting module is conjugated to the polymalicacid based molecular scaffold. Methods of synthesizing the nanoconjugate involve providing a polymalic acid having a plurality of pendant carboxyi groups. The method reacts a compound containing sulfhydryl groups and amino acid groups through the pendant carboxyi groups to add sulfhydryl groups to the polymalic acid to form an activated polymalic acid. The method reacts at least one imaging moiety containing a sulfhydryl binding group to the activated polymalic acid to form a preconjugate. The method may involve administering to the subject a nanoconjugate that includes a polymalic acid-based molecular scaffold, at least one imaging moiety, and at least one targeting module.",CEDARS SINAI MEDICAL CENTER;;BLACK KEITH L;;LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;HOLLER EGGEHARD,BLACK KEITH L;;LJUBIMOVA JULIA Y;;LJUBIMOV ALEXANDER V;;HOLLER EGGEHARD,,https://lens.org/082-557-453-699-364,Patent Application,yes,4,0,11,12,0,A61K49/128;;A61K49/16;;A61K47/593;;A61P35/00;;A61K49/16;;A61K47/593;;A61K49/128,A61K49/00;;C07C211/00,,2,1,106-640-130-151-317,pmc3487710;;10.1021/bc0502457;;16536461,"LEE ET AL.: ""Polycefin, a New Prototype of a Multifunctional Nanoconjugate Based on Poly(B-L-malic acid) for Drug Delivery."", BIOCONJUGATE CHEMISTRY, vol. 17, no. 2, 19 January 2006 (2006-01-19), pages 317 - 326, XP055115059, Retrieved from the Internet <URL:http://pubs.acs.org/doi/abs/10.1021/bc0502457> [retrieved on 20120711];;See also references of EP 2694117A4",PENDING
334,KR,A,KR 20120071391 A,059-094-192-986-215,2012-07-02,2012,KR 20127007395 A,2010-08-31,US 24637309 P,2009-09-28,AMPOULE FOR THE STORAGE AND DISPERSION OF VOLATILE LIQUIDS,,FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/059-094-192-986-215,Patent Application,no,0,0,10,10,0,A01M1/02;;A01M1/2044;;A01M1/2044;;A01M1/2033;;A01M1/2033;;A01M13/00;;A01N29/02;;A01N31/02;;A61L9/122;;A61L9/122,A01M1/02;;A01M13/00;;A01N29/02;;A01N31/02,,0,0,,,,DISCONTINUED
335,KR,A,KR 20120061860 A,197-534-443-167-135,2012-06-13,2012,KR 20127005541 A,2010-08-31,US 2010/0047260 W;;US 27582509 P;;US 28690909 P,2009-09-03,BED BUG CAPTURING DEVICE,,FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/197-534-443-167-135,Patent Application,no,0,0,8,8,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/02;;A01M1/02;;A01M1/10;;A01M1/2011;;A01M1/2011;;A01M2200/011;;A01M2200/011;;A01N31/02;;A01N35/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01N35/02,,0,0,,,,DISCONTINUED
336,US,A1,US 2011/0047860 A1,050-341-752-371-373,2011-03-03,2011,US 87231010 A,2010-08-31,US 87231010 A;;US 27582509 P;;US 28690909 P,2009-09-03,BED BUG CAPTURING DEVICE,The present invention relates to a bed bug capturing device comprising: (a) a bed bug attractant element; and (b) a deadfall capturing element comprising at least one pathway comprising: (i) an upwardly sloped segment; (ii) a downwardly sloped segment having an outer portion; and (iii) a deadfall trap area: characterized in that the upwardly sloped segment and at least the outer portion of the downwardly sloped segment possesses an average surface roughness of at least about 2.5 micrometers.,FMC CORP,BLACK BRUCE C;;SHAH SHREYA J;;VARANYAK LINDA A;;WOODRUFF KEITH F,FMC CORPORATION (2010-09-23),https://lens.org/050-341-752-371-373,Patent Application,yes,20,51,8,8,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/02;;A01M1/02;;A01M1/10;;A01M1/2011;;A01M1/2011;;A01M2200/011;;A01M2200/011;;A01N31/02;;A01N35/02;;Y02A50/30;;Y02A50/30,A01M1/10,43/123;;43/121;;43/107,0,0,,,,DISCONTINUED
337,KR,A,KR 20160135843 A,101-097-762-570-604,2016-11-28,2016,KR 20167031982 A,2009-09-18,US 9820608 P;;US 2009/0057569 W,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE,"본 발명의 대상은 알츠하이머병 (AD)에 대해 특이적인 초기 병리학적 이벤트, 예컨대 아밀로이드 플라크의 발달, 양 및 위치를 모니터링하기 위한 비-칩습성 광학 영상화 방법에 관한 것이다. 이같은 이벤트를 모니터링하는 능력은, 특히, AD 진단, 예후 및 가능한 치료법의 평가를 위한 기초를 제공한다. 또한, 본 발명의 대상은 AD 및 AD와 관련된 망막 질병을 치료하기 위한 신규 방법을 소개한다. 살아 있는 뇌에서의 Aβ-플라크 검출은, 특히 고해상도에서, 매우 제한된다: 따라서, 본 발명은 뇌-유래 조직에 대한 대안으로서 눈에 초점을 맞추는 연구를 기초로 하고, 이는 직접적으로, 반복적으로 및 비-침습성으로 영상화될 수 있다.",CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L,,https://lens.org/101-097-762-570-604,Patent Application,no,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;G01N33/58;;G01N33/68,,0,0,,,,DISCONTINUED
338,US,B2,US 8677679 B2,010-438-575-297-861,2014-03-25,2014,US 87227710 A,2010-08-31,US 87227710 A;;US 24637309 P,2009-09-28,Ampoule for the storage and dispersion of volatile liquids,"In one aspect, the present invention is directed to an ampoule for the storage and dispersion of a volatile liquid comprised of (a) an outer shell composed of an impermeable material and defining at least one opening; (b) a porous diffusion member defining an internal reservoir positioned inside said outer shell; (c) a volatile liquid contained within such internal reservoir; and (d) a film member adhered to the outer shell and covering the at least one opening; wherein the film member is disposed such that an air space is present between the porous diffusion member and the film member; and wherein the porous diffusion member is configured such that molecules of the volatile liquid can only enter into the air space via diffusion through the porous diffusion member. Such ampoules are particularly suited for the storage and dispersion of organic chemicals useful as bed bug attractants, such as a C 8 -C 12 alkane. In another aspect, this invention is directed to a device adapted to receive one or more of such ampoules. In one preferred embodiment, such device is a bed bug capturing device.",BLACK BRUCE C;;SHAH SHREYA J;;VARANYAK LINDA A;;WOODRUFF KEITH F;;FMC CORP,BLACK BRUCE C;;SHAH SHREYA J;;VARANYAK LINDA A;;WOODRUFF KEITH F,FMC CORPORATION (2010-09-23),https://lens.org/010-438-575-297-861,Granted Patent,yes,95,10,10,10,0,A01M1/02;;A01M1/2044;;A01M1/2044;;A01M1/2033;;A01M1/2033;;A01M13/00;;A01N29/02;;A01N31/02;;A61L9/122;;A61L9/122,A01M1/10;;A01M1/02,43/123;;43/107;;43/132.1;;43/125;;239/44;;239/51.5;;239/53;;239/55;;239/57;;261/104;;X261DIG 65;;X261DIG 88,5,2,020-977-426-330-002;;022-663-557-735-836,19736771;;10.1603/029.102.0423;;10.1007/s10886-008-9446-y;;18470566,"Storgard Insect Monitoring Systems, Advertisement Flyer, Trece, Inc. Aclair, OK, USA, Copyright 2007, [online: http://www.trece.com/stormon.html] 1 page.;;Silvandersson Sweden AB, Silvatronic Bug Dome, [online: http://www.silvandersson.se/en/hotel-restaurant/hotel-restaurant.html], 2 pages.;;McKnight S., Biosenory, Inc. Putnam, CT, USA, 'Traps and Attractants for Monitoring Bed Bug Infestations', Wang, et al., Purdue University, Dept. of Entomology, West Lafayette, IN, USA. [online: www.sternenvironmental.com/pdfs/Purdue-Presentation-12-07.ppt] 17 pages.;;Wang, C., et al., 'Bed Bug (Heteroptera: Cimicidae) Attraction to Pitfall Traps Baited with Carbon Dioxide, Heat and chemical Lure', Journal of Econ. Entomol. 102(4); pp. 1580-1585, 2009.;;Siljander, E., et al., 'Identification of the Airborne Aggregation Pheromone of the Common Bed Bug, Cimex lectularius', Journal of Chem. Ecol. 34: pp. 708-718, 2008.",INACTIVE
339,IL,A,IL 261438 A,112-640-673-376-819,2018-10-31,2018,IL 26143818 A,2018-08-28,US 201662303845 P;;US 2017/0020666 W,2016-03-04,Polymalic acid based nanoimmunoconjugates and uses thereof,,CEDARS SINAI MEDICAL CENTER;;LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD;;LJUBIMOV ALEXANDER;;DING HUI,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD;;LJUBIMOV ALEXANDER;;DING HUI,,https://lens.org/112-640-673-376-819,Patent Application,no,0,0,11,11,0,A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/6849;;A61K47/6813;;A61K47/6807;;A61K47/593;;A61K47/6851;;A61K47/6883;;A61K47/6935;;A61P35/00;;A61K31/7088;;A61K39/3955;;A61K45/06;;A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6813;;A61K47/6849;;A61K47/6807;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/10;;A61K47/183,,,0,0,,,,PENDING
340,WO,A2,WO 2011/028688 A2,126-863-333-541-933,2011-03-10,2011,US 2010/0047260 W,2010-08-31,US 28690909 P;;US 27582509 P,2009-09-03,BED BUG CAPTURING DEVICE,The present invention relates to a bed bug capturing device comprising: (a) a bed bug attractant element; and (b) a deadfall capturing element comprising at least one pathway comprising: (i) an upwardly sloped segment; (ii) a downwardly sloped segment having an outer portion; and (iii) a deadfall trap area: characterized in that the upwardly sloped segment and at least the outer portion of the downwardly sloped segment possesses an average surface roughness of at least about 2.5 micrometers.,FMC CORP;;BLACK BRUCE C;;SHAH SHREYA J;;VARANYAK LINDA A;;WOODRUFF KEITH F,BLACK BRUCE C;;SHAH SHREYA J;;VARANYAK LINDA A;;WOODRUFF KEITH F,,https://lens.org/126-863-333-541-933,Patent Application,yes,0,2,8,8,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/02;;A01M1/02;;A01M1/10;;A01M1/2011;;A01M1/2011;;A01M2200/011;;A01M2200/011;;A01N31/02;;A01N35/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01N35/02,,0,0,,,,PENDING
341,US,B2,US 9623041 B2,169-287-587-957-856,2017-04-18,2017,US 201313930533 A,2013-06-28,US 2010/0062515 W;;US 201313930533 A,2010-12-30,Polymalic acid-based nanobiopolymer compositions,"Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.",CEDARS SINAI MEDICAL CENTER,INOUE SATOSHI;;DING HUI;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2013-08-13),https://lens.org/169-287-587-957-856,Granted Patent,yes,7,2,5,9,9,C07K16/2881;;C07K16/32;;A61K2039/505;;A61K31/713;;A61K31/713;;C07K16/2881;;C07K16/32;;A61K2039/505,A61K31/713;;A61K39/00;;C07K16/28;;C07K16/32,,16,9,115-650-595-072-446;;120-680-307-644-234;;039-738-668-274-842;;026-135-913-145-143;;026-135-913-145-143;;071-446-219-522-092;;113-433-411-873-182;;016-204-634-827-524;;013-415-019-143-842,10.1093/nar/29.23.4873;;pmc96684;;11726697;;15770691;;10.1002/cncr.20970;;12855625;;20921419;;10.1073/pnas.1003919107;;pmc2964197;;20921419;;10.1073/pnas.1003919107;;pmc2964197;;pmc3487708;;17109197;;10.1007/s10456-006-9046-9;;10.1158/1538-7445.am10-3854;;17376417;;pmc2329596;;10.1016/j.cbi.2007.01.015;;pmc2734385;;18373429;;10.2217/17435889.3.2.247,"Bayse et al. (Nucleic Acids Research, 29: 4873-4880, 2001).;;Wiseman et al. (Cancer, 103(9): 1770-1777, 2005).;;Iversen et al. (Clinical Cancer Research, 9: 2510-2519, 2003).;;NCBI GenBank Accession No. NM—005228 (Dec. 26, 2010)—See the whole document.;;NCBI GenBank Accession No. X03363 (Mar. 30, 1995)—See the whole document.;;NCBI GenBank Accession No. X91171 (Oct. 7, 2008)—See the whole document.;;NCBI GenBank Accession No. NM—002291 (Nov. 21, 2010)—See the whole document.;;Ding, Hui et al. “Inhibition of brain tumor growth by intravenous poly(beta-L-malic acid) nanobioconjugate with pH-dependent drug release”, Proceedings of the National Academy of Sciences, <Correction> vol. 107, No. 45, p. 19603 (Nov. 9, 2010).;;Ding, Hui et al. “Inhibition of brain tumor growth by intravenous poly(beta-L-malic acid) nanobioconjugate with pH-dependent drug release”, Proceedings of the National Academy of Sciences, vol. 107, No. 42, pp. 18143-18148 (Oct. 19, 2010).;;Fujita, Manabu et al. “Overexpression of β1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases”, Breast Cancer Research, vol. 7, No. 4, p. R411-R421 (Apr. 6, 2005) Retrieved from the Internet: <URL:http://breast-cancer-research.com/content/7/4/R411>.;;Fujita, Manabu et al. “Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis”, Angiogenesis, vol. 9, No. 4, pp. 183-191 (2006).;;Inoue, Satoshi et al. “Newly designed nanobioconjugate for direct targeting and systemic treatment of HER2-positive breast cancer”, Proceedings of the American Association for Cancer Research Annual Meeting, 101st Annual Meeting of the American Association for Cancer Research, Washington, D.C., vol. 51, p. 937 (Apr. 17-21, 2010).;;Ljubimova, Julia Y. et al. “Nanoconjugate based on polymalic acid for tumor targeting”, Chemico-Biological Interactions, vol. 171, pp. 195-203 (2008).;;Ljubimova, Julia Y. et al. “Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery”, Nanomedicine, vol. 3(2), pp. 247-265 (Apr. 2008).;;Office Action from corresponding European Patent Application No. 10 861 515.4 dated Feb. 26, 2014, 6 pages.;;Office Action from corresponding Japanese Patent Application No. 2013-547442 dated Oct. 29, 2014, with a Brief Report in English, 6 pages.",ACTIVE
342,US,A,US 5550324 A,049-157-425-736-309,1996-08-27,1996,US 39355095 A,1995-02-23,US 39355095 A,1995-02-23,Environmental sealing system for electronic instruments,"An environmentally sealed electronic test instrument having a three-part case enclosing an electronic testing circuit of conventional design. The three parts are open-ended top and bottom parts, and an end part covering the open ends of the top and bottom parts. The top and bottom parts have adjoining sidewalls between which is positioned a first resilient seal. Respective inwardly extending flanges are formed at the open ends of the top and bottom parts. The flanges are received by a second, U-shaped seal that is, in turn, received by a U-shaped channel formed along a marginal edge of the end plate. A pair of fingers integrally formed in the second gasket project into the U-shaped channel and are positioned between the first seal and top part of the case. The side marginal edge of the bottom part of the case are recessed within the sidewall of the top part of the case to enclose the first gasket.",FLUKE CORP,BLACK MICHAEL J;;WILLOWS KEITH S;;STILES WILLIAM P;;GALLAGHER PATRICK M,FLUKE CORPORATION (1995-02-10),https://lens.org/049-157-425-736-309,Granted Patent,yes,9,23,1,1,0,H05K5/0008;;H05K5/062;;H05K5/062;;H05K5/0008,H05K5/00;;H05K5/06,174/52.3;;277/901,0,0,,,,EXPIRED
343,US,A,US 3658379 A,112-439-572-898-525,1972-04-25,1972,US 3658379D A,1970-07-22,US 5715070 A,1970-07-22,TABLE AND SUSPENDED CHAIR UNIT WITH CENTERING APPARATUS,"A support system for chairs suspended beneath a table top wherein plastic bearings are used to provide horizontal and vertical pivot surfaces and supports for chair suspension arms, a yieldable means is provided to limit rotation of each chair arm, and resilient means are provided for moving the chairs to a normally centered position.",HERMAN WENDELL BLACK;;RICHARD R WRIGHT;;DON K FULLMER;;KEITH W NAYLOR,BLACK HERMAN WENDELL;;WRIGHT RICHARD R;;FULLMER DON K;;NAYLOR KEITH W,,https://lens.org/112-439-572-898-525,Granted Patent,no,9,11,1,1,0,A47B83/02;;A47B83/02;;A47C9/022;;A47C9/022,A47B39/00;;A47B83/02,297/157;;248/417;;248/418;;297/142;;108/150,0,0,,,,EXPIRED
344,CN,A,CN 102186504 A,146-940-634-779-285,2011-09-14,2011,CN 200980136743 A,2009-09-18,US 2009/0057569 W;;US 9820608 P,2008-09-18,Optical method for the detection of alzheimer's disease,"The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Ass-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.",CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,YOSEF KORONYO;;MAYA KORONYO;;BLACK KEITH L;;MICHAL SCHWARTZ;;FARKAS DANIEL L,,https://lens.org/146-940-634-779-285,Patent Application,no,2,5,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,2,1,011-124-388-694-014,17472706;;10.1111/j.1471-4159.2007.04613.x,"谢朝阳等: ""姜黄素对β-淀粉样肽（25-35）诱导去血清培养PC12细胞周期异常与细胞凋亡的影响"", 《中国新药杂志》;;M. GARCIA-ALLOZA ET.AL.: ""Curcumin labels amyloid pathology in vivo, disrupts existing plaques,and partially restores distorted neurites in an Alzheimer mouse model"", 《JOURNAL OF NEUROCHEMISTRY》",ACTIVE
345,US,A1,US 2011/0072712 A1,175-815-714-273-769,2011-03-31,2011,US 87245610 A,2010-08-31,US 87245610 A;;US 24631509 P,2009-09-28,BED BUG CAPTURING DEVICE,"The present invention relates to a bed bug capturing device comprising: (a) a bed bug attractant element comprising (i) a heavier than air organic chemical which attracts bed bugs; and (ii) a means for producing air flow such that the air movement from the device has a face velocity of between about 5 and about 50 ml/cm 2 /min; and (b) a trap element. Preferably, such means of producing air flow is a fan.",FMC CORP,BLACK BRUCE C;;SHAH SHREYA J;;VARANYAK LINDA A;;WOODRUFF KEITH F,FMC CORPORATION (2010-09-22),https://lens.org/175-815-714-273-769,Patent Application,yes,13,32,3,3,0,A01M1/103;;A01M1/103;;A01M1/02;;A01M1/02;;A01M1/2033;;A01M1/2033;;A01M1/2055;;A01M1/2055;;Y02A50/30;;Y02A50/30,A01M1/10,43/123,0,0,,,,DISCONTINUED
346,US,A1,US 2019/0060479 A1,008-966-661-763-686,2019-02-28,2019,US 201716081584 A,2017-03-03,US 201716081584 A;;US 201662303845 P;;US 2017/0020666 W,2016-03-04,POLYMALIC ACID BASED NANOIMMUNOCONJUGATES AND USES THEREOF,"Nanoimmunoconjugates including a polymalic acid-based molecular scaffold, targeting ligands, anti-tumor immune response stimulators and anti-cancer agents are provided. Methods for treating cancer in a subject by administering the nanoimmunoconjugates that provide both systemic and local immune responses and synergistic anticancer effect are described.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD;;LJUBIMOV ALEXANDER;;DING HUI,CEDARS-SINAI MEDICAL CENTER (2018-09-24),https://lens.org/008-966-661-763-686,Patent Application,yes,3,2,11,11,8,A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/6849;;A61K47/6813;;A61K47/6807;;A61K47/593;;A61K47/6851;;A61K47/6883;;A61K47/6935;;A61P35/00;;A61K31/7088;;A61K39/3955;;A61K45/06;;A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6813;;A61K47/6849;;A61K47/6807;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/10;;A61K47/183,A61K47/68;;A61K45/06;;A61K47/10;;A61K47/18;;A61K47/59;;A61P35/00,,0,0,,,,DISCONTINUED
347,PT,T,PT 2323696 T,030-850-817-160-439,2018-11-20,2018,PT 09815306 T,2009-09-18,US 9820608 P,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE,,CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,MAYA KORONYO;;KEITH L BLACK;;MICHAL SCHWARTZ;;DANIEL L FARKAS;;YOSEF KORONYO,,https://lens.org/030-850-817-160-439,Patent Application,no,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,0,0,,,,PENDING
348,US,A1,US 2011/0286932 A1,028-554-026-031-771,2011-11-24,2011,US 200913119596 A,2009-09-18,US 200913119596 A;;US 9820608 P;;US 2009/0057569 W,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE,"The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.",KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L;;YEDA RES & DEV;;CEDARS SINAI MEDICAL CENTER,KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L,YEDA RESEARCH AND DEVELOPMENT CO. LTD (2011-05-05);;CEDARS-SINAI MEDICAL CENTER (2011-05-05),https://lens.org/028-554-026-031-771,Patent Application,yes,25,23,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;A61K39/00;;A61P25/28;;A61P27/02;;A61P27/06,424/9.6;;424/184.1,5,5,011-124-388-694-014;;048-262-075-396-41X;;047-248-975-491-255;;155-116-058-123-026;;127-755-540-864-020,17472706;;10.1111/j.1471-4159.2007.04613.x;;9267595;;10.1111/j.1442-9071.1997.tb01290.x;;17999464;;10.1021/mp700113r;;10.1074/jbc.m404751200;;15590663;;10.1016/j.ab.2006.04.036;;16729955,"Garcia-Alloza et al. J. Neurochem. 2007, 102: 1095-1104.;;Vickers, Australian and New Zealand J of Ophthalmol. 1997, 25:105-109.;;Anand et al. Molecular. Pharmaceutics, 2007, 4:807-818.;;Yang et al. J. Biol. Chem., 2005; 280:5892-5901.;;LeVine Ana. Biochem. 2006; 356: 265-272.",ACTIVE
349,MX,A,MX 2018010644 A,058-729-931-401-859,2018-11-09,2018,MX 2018010644 A,2017-03-03,US 201662303845 P;;US 2017/0020666 W,2016-03-04,POLYMALIC ACID BASED NANOIMMUNOCONJUGATES AND USES THEREOF.,"Nanoimmunoconjugates including a polymalic acid-based molecular scaffold, targeting ligands, anti-tumor immune response stimulators and anti-cancer agents are provided. Methods for treating cancer in a subject by administering the nanoimmunoconjugates that provide both systemic and local immune responses and synergistic anticancer effect are described.",CEDARS SINAI MEDICAL CENTER,JULIA Y LJUBIMOVA;;KEITH L BLACK;;EGGEHARD HOLLER;;ALEXANDER LJUBIMOV;;HUI DING,,https://lens.org/058-729-931-401-859,Patent Application,no,0,0,11,11,0,A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/6849;;A61K47/6813;;A61K47/6807;;A61K47/593;;A61K47/6851;;A61K47/6883;;A61K47/6935;;A61P35/00;;A61K31/7088;;A61K39/3955;;A61K45/06;;A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6813;;A61K47/6849;;A61K47/6807;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/10;;A61K47/183,A61K39/395;;A61K31/713;;A61K38/16;;A61K38/19;;A61K47/10;;A61P35/00;;A61P35/04,,0,0,,,,PENDING
350,EP,A1,EP 2323696 A1,094-183-021-368-643,2011-05-25,2011,EP 09815306 A,2009-09-18,US 2009/0057569 W;;US 9820608 P,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE,,CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L;;KORONYO YOSEF,,https://lens.org/094-183-021-368-643,Patent Application,yes,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,0,0,,,,ACTIVE
351,WO,A2,WO 2008/039969 A2,196-354-218-652-711,2008-04-03,2008,US 2007/0079846 W,2007-09-28,US 82726006 P,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",CEDARS SINAI MEDICAL CENTER;;YU JOHN S;;LIU GENTAO;;ZHU HUI PH D;;BLACK KEITH L,YU JOHN S;;LIU GENTAO;;ZHU HUI PH D;;BLACK KEITH L,,https://lens.org/196-354-218-652-711,Patent Application,yes,0,16,17,17,0,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/00;;A61K35/12,,0,0,,,,PENDING
352,CN,A,CN 109152836 A,048-183-200-496-618,2019-01-04,2019,CN 201780027946 A,2017-03-03,US 201662303845 P;;US 2017/0020666 W,2016-03-04,Polymalic acid based nanoimmunoconjugates and uses thereof,"Nanoimmunoconjugates including a polymalic acid-based molecular scaffold, targeting ligands, anti-tumor immune response stimulators and anti-cancer agents are provided. Methods for treating cancer ina subject by administering the nanoimmunoconjugates that provide both systemic and local immune responses and synergistic anticancer effect are described.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD;;LJUBIMOV ALEXANDER;;DING HUI,,https://lens.org/048-183-200-496-618,Patent Application,no,4,0,11,11,0,A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/6849;;A61K47/6813;;A61K47/6807;;A61K47/593;;A61K47/6851;;A61K47/6883;;A61K47/6935;;A61P35/00;;A61K31/7088;;A61K39/3955;;A61K45/06;;A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6813;;A61K47/6849;;A61K47/6807;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/10;;A61K47/183,A61K39/395;;A61K31/713;;A61K38/16;;A61K38/19;;A61K47/10;;A61P35/00;;A61P35/04,,6,5,033-140-474-456-328;;090-031-613-620-55X;;011-450-253-768-016;;020-092-879-871-25X;;028-717-412-515-25X,10.1517/14712598.2015.1035251;;26063384;;11592078;;10.1002/1521-4141(2001010)31:10<3016::aid-immu3016>3.0.co;2-j;;10.1158/0008-5472.can-10-3093;;10.31234/osf.io/nyh6f;;21303974;;pmc3428373;;23770212;;10.1016/j.jconrel.2013.06.001;;pmc3971991;;10.1371/journal.pone.0031070;;22355336;;pmc3280290,"FRANCESCO MASSARI ET AL.: ""The immunocheckpoints in modern oncology: the next 15 years"", 《EXPERT OPINION ON BIOLOGICAL THERAPY》;;CARSON WE,ET AL.: ""Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells"", 《EUR J IMMUNOL》;;SATOSHI INOUE, ET AL.: ""Polymalic Acid–Based Nanobiopolymer Provides Efficient"", 《CANCER RES》;;DING H，ER AL.: ""Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu- positive breast cancer"", 《J CONTROL RELEASE》;;SATOSHI INOUE,ET AL.: ""Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer"", 《PLOS ONE》;;克晓燕等: ""B7-1与B7-2对调节人IL-2基因的转录因子NF-κB和AP-1的相同作用 "", 《中国实验血液学杂志》",DISCONTINUED
353,KR,A,KR 20110074972 A,104-354-766-704-140,2011-07-05,2011,KR 20117006156 A,2009-09-18,US 9820608 P;;US 2009/0057569 W,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE,,CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L,,https://lens.org/104-354-766-704-140,Patent Application,no,0,1,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/14;;A61K49/00;;A61P25/28;;C12Q1/00,,0,0,,,,ACTIVE
354,WO,A2,WO 2011/119905 A2,144-382-528-230-276,2011-09-29,2011,US 2011/0029902 W,2011-03-25,US 31788210 P,2010-03-26,GENSET FUEL TRANSFER SYSTEM AND METHOD,"An electric generator set fuel control system is disclosed. The fuel control system includes an electric generator, a prime mover mechanically coupled to the generator, a first fuel tank, a fuel level sensor configured to generate a fuel level signal indicative of a fuel level in the first fuel tank, a fuel loading operator input device configured to generate a fuel loading signal, a fueling mode operator input device configured to generate a fueling mode signal, and a control module. The first fuel tank is configured to supply fuel to the prime mover, and selectively receive or supply fuel to a second fuel tank through a fuel pump. The control module is configured to generate a fuel transfer signal as a function of the fuel loading signal, the fueling mode signal, and the fuel level signal.",CATERPILLAR INC;;SCHROEDER EDWARD M;;BLACK ANDREW W;;CHAKRAVARTY JOYDIP;;FOLKEN KEITH;;SLAUGHTER NELSON,SCHROEDER EDWARD M;;BLACK ANDREW W;;CHAKRAVARTY JOYDIP;;FOLKEN KEITH;;SLAUGHTER NELSON,,https://lens.org/144-382-528-230-276,Patent Application,yes,0,1,10,10,0,F02D29/06;;F02D29/06;;F02D29/06;;F01D15/10;;F01D15/10;;F02B63/04;;F02C9/26;;F02C9/26;;F02D41/30;;F02M51/02;;F02M51/02;;F02M51/02;;Y10T137/86147;;Y10T137/86147,F02B63/04;;F02D29/06;;F02D41/30;;F02M51/02,,0,0,,,,PENDING
355,CA,C,CA 2735869 C,173-825-937-693-353,2020-08-18,2020,CA 2735869 A,2009-09-18,US 9820608 P;;US 2009/0057569 W,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE,"The present subject matter relates to a non-invasive optical imaging method for monitoring ear-ly pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events pro-vides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addi-tion, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A.beta.-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present inven-tion is based on studies focusing on the eyes as an alter-native to brain-derived tissue that can be imaged direct-ly, repetitively and non-invasively.",CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L;;KORONYO YOSEF,,https://lens.org/173-825-937-693-353,Granted Patent,no,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61B6/00;;A61B5/00;;A61B6/12;;A61F9/00;;A61K49/00;;C12Q1/00,,0,0,,,,ACTIVE
356,WO,A3,WO 2008/039969 A3,081-409-427-215-388,2008-11-20,2008,US 2007/0079846 W,2007-09-28,US 82726006 P,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",CEDARS SINAI MEDICAL CENTER;;YU JOHN S;;LIU GENTAO;;ZHU HUI PH D;;BLACK KEITH L,YU JOHN S;;LIU GENTAO;;ZHU HUI PH D;;BLACK KEITH L,,https://lens.org/081-409-427-215-388,Search Report,yes,0,0,17,17,0,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K35/00;;A61K35/12;;A61K39/00,,2,2,113-598-986-994-212;;032-084-932-733-530,18298336;;10.1089/cbr.2007.0427;;10754316;;10.4049/jimmunol.164.8.4204,"WEI ET AL.: ""Dendritic Cells Expressing a Combined PADRE/MUC 4-Derived Polyepitope DNA Vaccine Induce Multiple Cytotoxic T- Cell Responses"", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 23, no. 1, 2008, pages 121 - 128, XP055354716;;YANG ET AL.: ""Dendritic Cells Infected with a Vaccinia Vector Carrying the Human gp100 Gene Simultaneously Present Multiple Specificities and Elicit High-Affinity T Cells Reactive to Multiple Epitopes and Restricted by HLA-A2 and -A3"", J. IMMUNOL., vol. 164, no. 8, April 2000 (2000-04-01), pages 4204 - 4211, XP055354724",PENDING
357,MX,B,MX 349711 B,098-130-820-915-742,2017-08-09,2017,MX 2011002930 A,2009-09-18,US 9820608 P;;US 2009/0057569 W,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE.,"The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aß-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.",CEDARS SINAI MEDICAL CENTER,KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L,,https://lens.org/098-130-820-915-742,Granted Patent,no,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,0,0,,,,ACTIVE
358,KR,A,KR 20180115334 A,112-731-308-916-307,2018-10-22,2018,KR 20187028751 A,2017-03-03,US 201662303845 P;;US 2017/0020666 W,2016-03-04,폴리말릭산 기반 나노면역컨주게이트 및 이의 용도,"폴리말릭산 기반 분자 스캐폴드, 표적 리간드, 항종양 면역 반응 자극제, 및 항암제를 포함하는 나노면역컨주게이트가 제공된다. 전신성 및 국소 면역 반응 그리고 상승적 항암 효과 모두를 제공하는 상기 나노면역컨주게이트를 투여함으로써 대상자에서 암을 치료하는 방법이 기재된다.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD;;LJUBIMOV ALEXANDER;;DING HUI,,https://lens.org/112-731-308-916-307,Patent Application,no,0,0,11,11,16,A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/6849;;A61K47/6813;;A61K47/6807;;A61K47/593;;A61K47/6851;;A61K47/6883;;A61K47/6935;;A61P35/00;;A61K31/7088;;A61K39/3955;;A61K45/06;;A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6813;;A61K47/6849;;A61K47/6807;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/10;;A61K47/183,A61K47/59;;A61K31/7088;;A61K39/395;;A61K45/06;;A61K47/68;;A61K47/69;;A61P35/00,,0,0,,,,DISCONTINUED
359,US,A1,US 2012/0168023 A1,131-824-769-778-80X,2012-07-05,2012,US 201113071608 A,2011-03-25,US 201113071608 A;;US 31788210 P,2010-03-26,GENSET FUEL TRANSFER SYSTEM AND METHOD,"An electric generator set fuel control system is disclosed. The fuel control system includes an electric generator, a prime mover mechanically coupled to the generator, a first fuel tank, a fuel level sensor configured to generate a fuel level signal indicative of a fuel level in the first fuel tank, a fuel loading operator input device configured to generate a fuel loading signal, a fueling mode operator input device configured to generate a fueling mode signal, and a control module. The first fuel tank is configured to supply fuel to the prime mover, and selectively receive or supply fuel to a second fuel tank through a fuel pump. The control module is configured to generate a fuel transfer signal as a function of the fuel loading signal, the fueling mode signal, and the fuel level signal.",FOLKEN KEITH;;CHAKRAVARTY JOYDIP;;SCHROEDER EDWARD M;;BLACK ANDREW W;;SLAUGHTER NELSON;;CATERPILLAR INC,FOLKEN KEITH;;CHAKRAVARTY JOYDIP;;SCHROEDER EDWARD M;;BLACK ANDREW W;;SLAUGHTER NELSON,CATERPILLAR INC (2011-04-19),https://lens.org/131-824-769-778-80X,Patent Application,yes,13,6,10,10,0,F02D29/06;;F02D29/06;;F02D29/06;;F01D15/10;;F01D15/10;;F02B63/04;;F02C9/26;;F02C9/26;;F02D41/30;;F02M51/02;;F02M51/02;;F02M51/02;;Y10T137/86147;;Y10T137/86147,B65B1/04;;B65B31/00,141/1;;141/59,0,0,,,,ACTIVE
360,CA,C,CA 2700436 C,156-907-890-192-588,2017-04-18,2017,CA 2700436 A,2007-09-28,US 82726006 P;;US 2007/0079857 W,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e g , neural cancers) by dendritic cell vaccination are provided herein",TORREY PINES INST FOR MOLECULAR STUDIES;;CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;ZHU HUI;;PINILLA CLEMENCIA;;BLACK KEITH L,,https://lens.org/156-907-890-192-588,Granted Patent,no,0,0,17,17,71,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/385;;A61K35/12;;A61K39/00;;A61K47/46;;A61P35/00;;C12N5/0784,,0,0,,,,ACTIVE
361,US,A1,US 2020/0155593 A1,178-075-410-319-500,2020-05-21,2020,US 202016773769 A,2020-01-27,US 202016773769 A;;US 201715447439 A;;US 201313930533 A;;US 2010/0062515 W,2010-12-30,POLYMALIC ACID-BASED NANOBIOPOLYMER COMPOSITIONS,"Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.",CEDARS SINAI MEDICAL CENTER,INOUE SATOSHI;;DING HUI;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2013-08-13),https://lens.org/178-075-410-319-500,Patent Application,yes,0,0,5,9,9,A61K31/713;;A61K31/713;;A61K2039/505;;A61K2039/505;;C07K16/2881;;C07K16/2881;;C07K16/32;;C07K16/32,A61K31/713;;C07K16/28;;C07K16/32,,0,0,,,,DISCONTINUED
362,EP,A4,EP 3423096 A4,123-063-592-545-74X,2019-10-30,2019,EP 17760901 A,2017-03-03,US 201662303845 P;;US 2017/0020666 W,2016-03-04,POLYMALIC ACID BASED NANOIMMUNOCONJUGATES AND USES THEREOF,,CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD;;LJUBIMOV ALEXANDER;;DING HUI,,https://lens.org/123-063-592-545-74X,Search Report,no,1,0,11,11,0,A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/6849;;A61K47/6813;;A61K47/6807;;A61K47/593;;A61K47/6851;;A61K47/6883;;A61K47/6935;;A61P35/00;;A61K31/7088;;A61K39/3955;;A61K45/06;;A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6813;;A61K47/6849;;A61K47/6807;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/10;;A61K47/183,A61K47/59;;A61K9/00;;A61K31/713;;A61K38/16;;A61K38/19;;A61K39/395;;A61K45/06;;A61K47/10;;A61K47/68;;A61P35/00;;A61P35/04,,4,3,020-092-879-871-25X;;028-717-412-515-25X;;033-140-474-456-328,23770212;;10.1016/j.jconrel.2013.06.001;;pmc3971991;;10.1371/journal.pone.0031070;;22355336;;pmc3280290;;10.1517/14712598.2015.1035251;;26063384,"DING HUI ET AL: ""Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer"", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 171, no. 3, 12 June 2013 (2013-06-12), pages 322 - 329, XP028740203, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2013.06.001;;SATOSHI INOUE ET AL: ""Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer"", PLOS ONE, vol. 7, no. 2, 15 February 2012 (2012-02-15), pages e31070, XP055625201, DOI: 10.1371/journal.pone.0031070;;FRANCESCO MASSARI ET AL: ""The immunocheckpoints in modern oncology: the next 15 years"", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 15, no. 7, 10 June 2015 (2015-06-10), ASHLEY, LONDON; GB, pages 917 - 921, XP055625735, ISSN: 1471-2598, DOI: 10.1517/14712598.2015.1035251;;See also references of WO 2017152054A1",DISCONTINUED
363,MX,A,MX 148044 A,015-596-854-430-464,1983-03-08,1983,MX 17818579 A,1979-06-22,US 92202978 A,1978-07-05,MEJORAS A DISPOSITIVO DE ALIMENTACION PARA UNA CORTADORA DE COSECHAS,,DEERE & CO,LAWRENCE ALLAN KEITH;;BASS MERLYN DUANE;;BLACK ROBERT DELNO;;KRAFKA JERRY LEE,,https://lens.org/015-596-854-430-464,Granted Patent,no,0,0,21,21,0,A01F29/10;;A01F29/10,A01F29/00;;A01D43/08;;A01F29/10,32-3;;32-7,0,0,,,,EXPIRED
364,US,A1,US 2011/0072711 A1,055-028-696-018-612,2011-03-31,2011,US 87227710 A,2010-08-31,US 87227710 A;;US 24637309 P,2009-09-28,AMPOULE FOR THE STORAGE AND DISPERSION OF VOLATILE LIQUIDS,"In one aspect, the present invention is directed to an ampoule for the storage and dispersion of a volatile liquid comprised of (a) an outer shell composed of an impermeable material and defining at least one opening; (b) a porous diffusion member defining an internal reservoir positioned inside said outer shell; (c) a volatile liquid contained within such internal reservoir; and (d) a film member adhered to said outer shell and covering said at least one opening; wherein said film member is disposed such that an air space is present between said porous diffusion member and said film member; and wherein said porous diffusion member is configured such that molecules of the volatile liquid can only enter into said air space via diffusion through said porous diffusion member. Such ampoules are particularly suited for the storage and dispersion of organic chemicals useful as bed bug attractants, especially where such attractants are formulated in a highly volatile liquid, such as a C 8 -C 12 alkane. In another aspect, this invention is directed to a device adapted to receive one or more of such ampoules. In one preferred embodiment, such device is a bed bug capturing device.",FMC CORP,BLACK BRUCE C;;SHAH SHREYA J;;VARANYAK LINDA A;;WOODRUFF KEITH F,FMC CORPORATION (2010-09-23),https://lens.org/055-028-696-018-612,Patent Application,yes,93,29,10,10,0,A01M1/02;;A01M1/2044;;A01M1/2044;;A01M1/2033;;A01M1/2033;;A01M13/00;;A01N29/02;;A01N31/02;;A61L9/122;;A61L9/122,A01M1/10;;A61L9/12,43/123;;239/44;;43/107;;43/121,0,0,,,,INACTIVE
365,WO,A1,WO 2017/152054 A1,051-760-390-686-206,2017-09-08,2017,US 2017/0020666 W,2017-03-03,US 201662303845 P,2016-03-04,POLYMALIC ACID BASED NANOIMMUNOCONJUGATES AND USES THEREOF,"Nanoimmunoconjugates including a polymalic acid-based molecular scaffold, targeting ligands, anti-tumor immune response stimulators and anti-cancer agents are provided. Methods for treating cancer in a subject by administering the nanoimmunoconjugates that provide both systemic and local immune responses and synergistic anticancer effect are described.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD;;LJUBIMOV ALEXANDER;;DING HUI,,https://lens.org/051-760-390-686-206,Patent Application,yes,2,3,11,11,8,A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/6849;;A61K47/6813;;A61K47/6807;;A61K47/593;;A61K47/6851;;A61K47/6883;;A61K47/6935;;A61P35/00;;A61K31/7088;;A61K39/3955;;A61K45/06;;A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6813;;A61K47/6849;;A61K47/6807;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/10;;A61K47/183,A61K39/395;;A61K31/713;;A61K38/16;;A61K38/19;;A61K47/10;;A61P35/00;;A61P35/04,,2,1,018-516-893-647-953,10.1016/j.biomaterials.2011.03.073;;21514661;;pmc4110056,"DING ET AL.: ""The Optimization Of Polymalic Acid Peptide Copolymers For Endosomolytic Drug Delivery"", BIOMATERIALS, vol. 32, 24 July 2014 (2014-07-24), pages 1 - 24, XP028214660;;See also references of EP 3423096A4",PENDING
366,US,B2,US 10583151 B2,084-300-173-499-236,2020-03-10,2020,US 201715447439 A,2017-03-02,US 201715447439 A;;US 201313930533 A;;US 2010/0062515 W,2010-12-30,Polymalic acid-based nanobiopolymer compositions,"Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.",CEDARS SINAI MEDICAL CENTER,INOUE SATOSHI;;DING HUI;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2013-08-13),https://lens.org/084-300-173-499-236,Granted Patent,yes,29,0,5,9,9,A61K31/713;;A61K31/713;;A61K2039/505;;A61K2039/505;;C07K16/2881;;C07K16/2881;;C07K16/32;;C07K16/32,A61K31/713;;A61K39/00;;C07K16/28;;C07K16/32,,178,121,029-857-500-764-492;;010-586-072-524-473;;002-057-097-140-560;;068-659-879-554-517;;132-372-225-925-009;;120-057-020-523-828;;074-117-757-519-423;;170-853-882-083-556;;089-773-133-078-99X;;069-764-206-551-021;;024-853-541-370-254;;010-084-423-107-920;;115-650-595-072-446;;002-410-830-739-846;;053-390-613-704-481;;004-569-967-691-895;;022-962-759-811-219;;044-914-849-410-277;;030-136-053-475-941;;149-009-853-252-790;;087-365-800-456-427;;027-327-439-480-050;;160-788-201-223-007;;068-082-778-319-717;;101-523-476-724-00X;;082-428-855-525-972;;005-068-515-810-831;;019-068-052-192-616;;007-174-756-618-033;;019-524-632-030-548;;027-177-154-094-913;;078-749-765-604-979;;056-318-394-213-772;;160-717-493-067-916;;056-754-795-949-28X;;094-544-976-445-251;;071-446-219-522-092;;057-449-500-429-70X;;081-535-546-606-522;;010-713-998-880-948;;015-845-411-216-05X;;048-551-084-856-415;;043-263-823-749-982;;033-337-348-972-822;;026-135-913-145-143;;026-135-913-145-143;;011-450-253-768-016;;113-433-411-873-182;;039-738-668-274-842;;010-800-681-313-086;;012-529-188-555-935;;056-106-508-661-801;;070-217-550-786-105;;084-804-379-761-825;;000-409-501-606-70X;;016-130-071-571-991;;091-843-097-683-406;;007-736-347-486-414;;067-176-202-940-165;;080-676-605-062-549;;089-207-455-463-763;;030-564-677-109-748;;122-563-304-750-445;;101-937-544-377-16X;;121-705-764-271-79X;;064-884-073-662-848;;085-389-958-075-222;;013-753-717-969-918;;106-640-130-151-317;;145-523-027-249-174;;021-383-028-538-332;;065-084-770-968-763;;016-204-634-827-524;;001-280-492-710-987;;027-533-193-912-497;;013-415-019-143-842;;087-520-893-698-325;;076-069-720-623-007;;122-990-056-888-627;;009-843-764-520-632;;092-704-236-824-35X;;135-545-938-771-996;;041-096-604-932-631;;094-717-970-788-379;;021-138-842-966-383;;088-509-278-000-721;;039-079-455-504-396;;050-185-841-748-492;;061-454-537-963-94X;;107-990-469-227-380;;044-248-524-774-951;;143-247-059-865-683;;012-497-328-331-068;;100-392-131-292-623;;114-357-812-206-334;;116-305-745-084-880;;016-795-130-437-95X;;131-982-616-033-720;;030-769-003-988-749;;027-518-915-267-472;;088-076-682-849-849;;114-097-940-181-735;;086-499-835-921-55X;;036-550-119-702-468;;037-478-719-421-857;;065-513-307-731-185;;012-251-206-172-978;;098-337-997-673-45X;;058-546-248-134-723;;053-130-150-863-097;;031-009-176-924-174;;068-365-614-968-438;;004-329-899-218-795;;003-631-120-479-205;;040-861-043-363-027;;012-011-330-340-059;;159-835-915-641-650;;120-680-307-644-234;;017-403-655-208-27X;;016-276-524-241-605;;025-444-780-060-105,10.1038/bjc.1994.405;;pmc2033560;;7947086;;10.1016/s0928-0987(97)00069-9;;16256709;;10652480;;10.1016/s1357-4310(99)01638-x;;10.1007/s11060-009-9857-9;;19337695;;2438036;;10.1200/jco.2001.19.8.2189;;11304771;;10688605;;10.1039/b005652i;;17964023;;10.1016/j.ncl.2007.07.006;;10807948;;10.1016/s0006-2952(00)00310-5;;16985051;;10.1158/1535-7163.mct-05-0428;;10.1021/bm0300608;;14715019;;10.1093/nar/29.23.4873;;pmc96684;;11726697;;10.1002/1097-0029(20001101)51:3<280::aid-jemt7>3.0.co;2-o;;11054877;;11751392;;10.1016/s0169-409x(00)00139-3;;11259843;;10991985;;10.1021/js9800836;;9811482;;pmc2761188;;19920915;;10.2147/dddt.s3572;;10.1007/s00280-006-0407-2;;17256133;;10.1006/exnr.1996.0178;;8912898;;10.1016/j.jconrel.2003.06.001;;14636717;;10416675;;10.1016/s0141-8130(99)00042-2;;pmc1185838;;708370;;10.1042/bj1730723;;10.1002/(sici)1097-0177(200006)218:2<213::aid-dvdy1>3.0.co;2-r;;10842354;;9472555;;10.1038/sj.gt.3300536;;pmc102580;;10648777;;10.1093/nar/28.4.868;;12489851;;10.1016/j.nano.2016.07.013;;pmc5812454;;27520726;;10.1677/erc.1.01045;;16113096;;10.1038/nrd1088;;12750738;;10.1038/nrc1566;;15738981;;2765532;;10.1021/bi00438a045;;10914698;;10609647;;10.1023/a:1020614525534;;17630012;;pmc2394675;;10.1016/j.jconrel.2007.05.032;;pmc3487708;;17109197;;10.1007/s10456-006-9046-9;;10.1186/bcr1011;;15987446;;pmc1175051;;10.1074/jbc.m010155200;;11278628;;10.1002/(sici)1097-0215(19980330)76:1<63::aid-ijc11>3.0.co;2-h;;9533763;;8622906;;pmc39574;;10.1073/pnas.93.8.3161;;12454288;;pmc138567;;10.1073/pnas.252649399;;10.1016/s0006-291x(02)02642-6;;12445830;;10.1002/ijc.10233;;11920587;;20921419;;10.1073/pnas.1003919107;;pmc2964197;;20921419;;10.1073/pnas.1003919107;;pmc2964197;;10.1158/0008-5472.can-10-3093;;10.31234/osf.io/nyh6f;;21303974;;pmc3428373;;10.1158/1538-7445.am10-3854;;12855625;;9855188;;10.1016/s0142-9612(98)00095-7;;10.1016/s0140-6736(00)03207-4;;11095261;;10.1016/j.jconrel.2004.07.009;;15588910;;10845554;;10.1023/a:1006760632766;;14578463;;18952979;;pmc2718972;;10.1215/15228517-2008-090;;2937447;;10.1021/bi00350a005;;10.1002/(sici)1097-0215(19980316)75:6<864::aid-ijc8>3.0.co;2-t;;9506531;;11223987;;10.1038/sj.gt.3301327;;11156378;;10840193;;10.1016/s0939-6411(00)00075-8;;10.1139/m95-187;;pmc2913688;;10.1007/s11010-008-9831-4;;18612802;;10658911;;10.1038/modpathol.3880010;;10.1021/bc980123x;;10346884;;10.1073/pnas.97.17.9591;;pmc16909;;10944225;;11780887;;10.3171/jns.2001.95.2.0190;;10554005;;10.1007/s002530051445;;pmc3487710;;10.1021/bc0502457;;16536461;;7723285;;10.1016/s1359-6349(04)80616-5;;16146715;;10.2741/1781;;pmc3506377;;17376417;;pmc2329596;;10.1016/j.cbi.2007.01.015;;11454714;;15274074;;10.1002/cncr.20397;;pmc2734385;;18373429;;10.2217/17435889.3.2.247;;16430958;;10.1016/j.biomaterials.2005.12.022;;10.1007/s00401-007-0243-4;;17618441;;pmc1929165;;10.1017/cbo9780511546402.025;;10.1016/j.abb.2007.04.013;;pmc2025638;;17562324;;10066093;;10.1023/a:1006150506789;;12639809;;10.1016/s1567-5769(02)00271-0;;10.1083/jcb.200302126;;12741393;;pmc2172901;;10.1083/jcb.jcb.200302126;;2072663;;10.1083/jcb.137.3.685;;9151674;;pmc2139892;;6606682;;10.1016/0022-1759(83)90303-4;;19525947;;10.1038/nmat2442;;10.1016/s0076-6879(01)40429-0;;11494857;;10.1038/sj.gt.3302507;;15759014;;10.1016/j.addr.2004.10.006;;15722167;;16303268;;10.1016/j.ijpharm.2005.10.010;;12083850;;10.1016/s1044-579x(02)00023-8;;18654426;;10.1038/nnano.2007.387;;10.1177/002215540205000813;;12133914;;11733118;;10.1016/s0169-409x(01)00221-6;;10.1124/pr.54.4.561;;12429868;;10506168;;10.1074/jbc.274.41.29130;;20387095;;pmc2952070;;10.1007/s11095-010-0091-0;;12564977;;10.1016/s0169-409x(02)00179-5;;10.1017/cbo9780511546402.030;;10.1038/nm1002;;14981512;;10.1021/bc990039x;;10502354;;19699248;;10.1016/j.addr.2009.06.005;;10.1002/(sici)1098-2388(199801/02)14:1<3::aid-ssu2>3.0.co;2-f;;9407626;;pmc16586;;10840060;;10.1073/pnas.130187497;;10.1083/jcb.153.5.933;;pmc2174323;;11381080;;16648043;;10.1016/s1470-2045(06)70665-9;;10.1016/j.canrad.2005.05.001;;9212909;;10.1089/oli.1.1997.7.187;;9325016;;10.1006/cyto.1997.0212;;pmc134646;;11809810;;10.1128/mcb.22.4.1194-1202.2002;;10.1124/mol.108.045112;;18477668;;pmc3909956;;10.1023/a:1014573204062;;11964076;;10.1080/10611860400011927;;15621677;;6501412;;pmc2113570;;10.1083/jcb.99.6.2034;;10.7150/ijms.5.273;;pmc2536715;;18797509;;7508268;;10.1021/bc00024a015;;15770691;;10.1002/cncr.20970;;19296227;;pmc2664895;;10.1208/s12248-009-9096-1;;11813879;;10.14670/hh-17.301;;12095305;;10.1006/mthe.2002.0633,"Colomer et al. (Br. J. Cancer, 70:819-825, 1994).;;Notice of allowance dated Aug. 25, 2017 for U.S. Appl. No. 15/450,519.;;Notice of allowance dated Oct. 26, 2017 for U.S. Appl. No. 15/450,519.;;Abdellaoui et al. Metabolite-derived Artificial Polymers Designed for Drug Targeting, Cell Penetration and Bioresorption, European Journal of Pharmaceutical Sciences, vol. 6, No. 1 (1998), pp. 61-73.;;Agrawal et al., Anntisense Therapeutics: Is It As Simple As Complimentary Base Recognition?, Molecular Medicine Today, (Feb. 2000), pp. 72-81, 6.;;Akbar, et al. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. Journal of Neuro-Oncology 94 (2009): 203- 212.;;Albini et al. A rapid in Vitro Assay for Quantitating the Invasive Potentia of Tumor Cells, Cancer Research, (Jun. 15, 1997), pp. 3239-3245, 47(12).;;Andrews et al. Resultes of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-like Growth Factor Type I Receptor in Malignant Astrocytomas, Journal of Clinical Oncology, (Apr. 15, 2001), pp. 2189-2200, 19(8).;;Arora et al. c-Myc Antisense Limits Rat Liver Regeneration and Indicates Role for c-Myc in Regulating Cytochrome P-450 3A Activity, Kournal of Pharmacology and Experimental Therapeutics, (Mar. 2009), pp. 921-928, 292(3).;;Arrowsmith, et al. Part 39 synthesis of bis(imidazotetrazine)s with saturated spacer groups.Journal of the Chemical Society 1. 24 (2000): 4432-4438.;;Asthagiri, et al. Advances in brain tumor surgery. Neurologic Clinics 25 (2007): 975-1003.;;Astriab-Fisher et al. Antisense Inhibition of P-Glycoprotein Expression Using Peptide-Oligonucleotide Conjugates, Biochemical Pharmacology (Jul. 1, 200), pp. 83-90, 60(1).;;Auger, et al. Genetic alterations associated with acquired with temozolide resistance in SNB-19, a human glioma cell line. Molecular Cancer Therapeutics 5 (2006): 2182-2192.;;Barbosa et al. Investigation of the Degradation Mechanism of Poly(malic acid) Esters in Vitro and their Related Cytotoxicities on J774 Macrophages, Biomacromolecules 2004, vol. 5, No. 1, pp. 137-143.;;Basye, et al. Triplex formation by morpholino oligodeoxyribonucleotides in the HER-2/neu promoter requires the pyrimidine motif. Nucleic Acids Research, 29 (2001): 4873-4880.;;Belkin et al. Integrins as Receptors for Laminins, Microscopy Research and Technique, (Nov. 1, 2000), pp. 280-301, 51(3).;;Bello et al., Simultaneous Inhibition of Glioma Angiogenesis, Cell Proliferation, and Invasion by a Naturally Occurring Fragment of Human Metalloproteinase-2, Cancer Research, (Dec. 15, 2001), pp. 8730-8736, 61(24).;;Bickel et al., Delivery of Peptides and Proteins Through the Blood-Brain Barrier, Advanced Drug Delivery Reviews, (2001), pp. 247-279, 46.;;Boado et al. Antisense-Mediated Down-Regulation of the Human Huntingtin Gene, Journal of Pharmacology and Experimental Therapy, (Oct. 200), pp. 239-243, 295(1).;;Boado et al., Drug delivery of Antisense Molecules to the Brain for Treatemnet of Alzheimer's Disease and Cerebral AIDS, Journal of Pharmacological Science, (1998), pp. 1308-1315, 87.;;Braun, et al. Treatment glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Aider ligation chemistry. Drug Design, Development and Therapy, Dove Medical Press Ltd, UK, 2008.2 (2009): 289-301.;;Brem, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol. 60 (2007): 643-650.;;Broadwell et al., Transcytosis of Protein Through the Mammalian Cerebral Epithelium and Endothelium III Receptor-Mediated Transcytosis Through the Blood-Brain of Blood-Bome Transferrin and Antibpdy Against the Transferrin Receptor, Experimental Neurology, (1996), pp. 47-65, 142.;;Bulmus et al., A new pH-Responsive and Glutathione-reactive Endosomal Membrane-disruptive Polymeric Carrier for Intracellular Delivery of Biomolecular Drugs, Journal of Controlled Release, (2003), 93: 105-120.;;Cammas et al., Polymers of Malic Acid and 3-Akylmalic Acid as Synthetic PHAs in the Design of Biocompatible Hydrolyzable Devices, International Journal of Biological Macromolecules, (1999), pp. 273-282, 25.;;Carlsson, et al. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J. Sep. 1, 1978;173(3):723-737.;;CBTRUS Statistical Report 2009 : Primary Brain and Central Nervous System Tumors Diagnosed in the united States in 2004-2005. http://www.cbtrus.org/reports/2009-NPCR-04-05/CBTRUS-NPCR2004-2005-Report-.pdf (accessed (Nov. 17, 2009).;;Chen, et al. Of Escherichia coli and man: understanding glioma resistance to temozolmide therapy. In E. G. Meir (eds.), CN8 Cancer, Humana Press, Atlanta, (2009): 679-711.;;Colognato et al., Form and Function: The Laminin Family of Heterotrimers, Developmental Dynamics, (Jun. 2000), pp. 213-234, 218(2).;;Coonrod, et al. On the mechanism of DNA transfection: efficeitn gene transfer without viruses, Gene Therapy, 4 (1997): 1313-1321.;;Co-pending U.S. Appl. No. 15/450,519, filed Mar. 6, 2017.;;De Diesbach et al.,ldentification, Purification and Partial Charaterozation of an Oligonucleotide Receptor in Membranes of HepG3 Cells, Nucleic Acids Research, (Feb. 15, 2000), pp. 868-874, 28(4).;;Dias et al., Antisense Oligonucleotides: Basic Concepts and Mechanisms, Molecular Cancer Therapy, (Mar. 2002), pp. 3470355, 1(15).;;Ding et al., HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug, Nanomedicine: Nanotechnology, Biology, and Medicine, 13: 631-639 (2017).;;Duncan, et al. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocrine-Related Cancer, 12 (2005): S189-S199.;;Duncan. The dawning era of polymer therapeutics. Nat. Rev. Drug Discovery 2:347-360 (2003).;;EP10836765.7 Extended European Search Report dated Oct. 9, 2013.;;European search report dated Feb. 7, 2014 for EP10861515.;;European search report with written opinion dated Jan. 4, 2013 for EP09730249.;;Ferrari. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161-171 (2005).;;Final Office action dated Aug. 9, 2013 for U.S. Appl. No. 13/513,145.;;Final Office action dated Oct. 29, 2015 for U.S. Appl. No. 13/930,533.;;Fischer et al., An Unusual Polyanion From Physarum Polycephalum That Inhibits Homologoes DNA Polymerase A in Vitro, Biochemistry, (1989), pp. 5219-5226, 28.;;Friedman, et al. Temozolomide and treatment of malignant glioma. Clin Cancer Res. Jul. 2000;6(7):2585-97.;;Fu, et al. Calcein permeability of liposomes mediated by type A botulinum neurotoxin and its light and heavy chains. Journal of protein chemistry 18 (1999): 701-707.;;Fujita, et al. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid), Journal of Controlled Release, 122.3 (2007): 356-363.;;Fujita et al., Inhibition of Laminin-8 in Vivo Using a Novel Poly(Malic Acid)-Based Carrier Reduces Glioma Angiogenesis, Angiogenesis, (2006), pp. 183-191.;;Fujita, et al. Overexpression of beta1-chain-containing lam in ins in capillary basement membranes of human breast cancer and its metastases, Breast Cancer Research, vol. 7, No. 4, p. R411-R421 (Apr. 6, 2005) Retrieved from the Internet< URL:http://breast-cancer-research.com/contenU7/4/R411> .;;Fujiwara et al., Purification and Characterization of Human Laminin-8 Stimulates Cell Adhesion and Migration Through a3p1 and a6p Integrins, Journal of Biological Chemistry, (May 18, 2001), pp. 17550-17558, 276(20),.;;Fukushima et al. Integrin a3(31-mediated Interaction with Laminin-5 Stimulates Adhesion, Migration and Invasion of Malignant Glioma Cells, Int. Journal of Cancer (Mar. 30, 1998), 76(1), pp. 63-72.;;Gewirtz et al., Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on Its Promise, Proceedings of the National Academy of Sciences of USA, (Apr. 1996), pp. 3161-3163, 93.;;Gonzales et al., Complex Interactions Between the Laminin a4 Subunit and Integrins Regulate Endothelial Cell Behaviour In Vitro and Angiogenesis In Vivo, Proceedings of the National Academy of Sciences USA, (Dec. 10, 2002), pp. 16075-16080, 99(25).;;Hayashi et al., Identification and Recombination Production of Human Laminin a4 Subunit Splice Variants, Biochemical and Biophysical Research Communications, (Dec. 6, 2002), pp. 498-504, 299(3).;;Herold-Mende et al. Clinical Impact and Functional Aspects of Tenascin-C Expression During Glioma Progression, International Journal of Cancer, (Mar. 20, 2002), pp. 362-369, 98(3).;;Holler, Poly(malic acid) from natural sources. In N.P. Cheremisinoff (eds.), Handbook of Engineering Polymeric Materials, Marcel Dekker, New York, 1997, 93-103.;;Hui, et al. Inhibition of brain tumor growth by intravenous poly (-L-malic) acid nanobioconjugate with pH-dependent drug release; Proceedings of the National Academy of Sciences, Correction in vol. 107, No. 45, p. 19603 (Nov. 9, 2010).;;Hui, et al. Inhibition of brain tumor growth by intravenous poly (-L-malic) acid nanobioconjugate with pH-dependent drug release; Proceedings of the National Academy of Sciences, vol. 107, No. 42, pp. 18143-18148 (Oct. 19, 2010).;;Inoue et a., Polymalic Acid-Based Nanobiopolymer Provides Efficient Systemic Breast Cancer Treatment by Inhibiting both HER2/neu Receptor Synthesis and Activity, Cancer Res; 71(4):1454-1464 (2011).;;Inoue, et al. Newly designed nanobioconjugate for direct targeting and systemic treatment of HER2-positive breast cancer, Proceedings of the American Association for Cancer Research Annual Meeting, 101st Annual Meeting of the American Association for Cancer Research, Washington, D.C. vol. 51, p. 937 (Apr. 17-21, 2010).;;International search report with written opinion dated Feb. 11, 2011 for PCT/US2010/059919.;;International search report with written opinion dated Jul. 14, 2009 for PCT/US2009/040252.;;International search report with written opinion dated Oct. 25, 2011 for PCT/US2010/062515.;;Iversen, et al. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clinical Cancer Research, 9 (2003): 2510-2519.;;Iwata et al., A Novel Surgical Glue Composed of Gelatin and N-Hydroxysuccinimide Activate Poly(L-Glutamic Acid): Part 1 Synthesis of Activated Poly(L-Glutamic Acid) and Its Gelation With Gelatin, Biomaterials, (1998), pp. 1859-1876, 19.;;Jansen et al., Chemosensitisation of Malignant Melanoma by BCL2 Antisense Therapy, Lancet, (Nov. 18, 2000), pp. 1728-1733, 356(9243).;;Kabanov, et al. Polymer genomics: shifting the gene and drug delivery paradigms. Journal of Controlled Release 101 (2005): 259-271.;;Kachra et al. Expression of Matrix Metalloproteinases and Their Inhibitors in Human Brain Tumrors, Clinical and Experimental Metastasis, (1999), pp. 555-566, 17(7).;;Khazenzon et al., Antisense Inhibition of Laminin-8 Expression Reduces Invasion of Human Gliomas In Vitro, Molecular Cancer Therapeutics, (2003), pp. 985-994,2.;;KHAZENZON LAKHTER A J, ET AL: ""Novel angiogenic targets for human glioma prevention and regulation of their expression"", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS PUBLICATIONS, GR, vol. 10, no. Supplement 1, 12 October 2002 (2002-10-12), GR, pages S41, XP008091390, ISSN: 1107-3756;;Kitange, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Journal of Neuro-Oncology. 11: (2009) 281-291.;;Kleinman et al., Basement Membrane Complexes with Biological Activity, Biochemistry, (Jan. 28, 2986), pp. 312-318, 25(2).;;Knott et al., Stimulation of Extracellular Matrix Components in the Normal Brain by Invading Glioma Cells, International of Cancer, (Mar. 16, 1998), pp. 864-872, 75(6).;;Komata et al., Combination Therapy of Malignant Glioma Cells With 2-5A-Antisense Telomerase RNA and Recombinant Adenovirus p53, Gene Therapy, (Dec. 2000), pp. 20171-2079, 7(24).;;Kondraganti et al., Selective Supression of Matrix Metalloproteinase-9 in Human Glioblastoma Cells by Antisense GeneTransfer Impairs Glioblastoma Cell Invasion, Cancer Research, (Dec. 15, 2000), pp. 6851-6855, 60(24).;;Kopecek et al., HPMA Copolymer—Anticancer Drug Conjugates: Design, Activity, and Mechanism of Action, european Journal of Biopharmacology, (2000), pp. 61-81, 50.;;Korherr et al., Poly ((3-1 Malate) Hydrolase From Plasmodia of Physarum Polycephalum, Canadian Journal of Microbioligy, (1995), pp. 192-199, 41 (Suppl. 1).;;Kramerov et al., Inhibition of Protein Kinase CK2 Suppresses Angiogenesis and Hematopoietic Stem Cell Recruitment to Retinal Neovascularization Sites. Molecular and Cellular Biochemistry 316:177-186, 2008.;;Kulla et al., Tenascin Expression Patterns and Cells of Monocyte Lineage: Relationship in Human Gliomas, Moder Pathology, (Jan. 2000), pp. 58-67, 13(1).;;Kurihara et al., Epidermal Growth Factor Radiopharmaceuticals:111m Cheladon, Conjugation to a Blood-Brain Barrier Delivery Vector Via a Biotin-Polyethylene Linker, Pharmacokinetics, and In Vivo Imaging of Experimental Brain Tumors, Bioconjugate Chemistry, (1999), 505-511, 10.;;Lacera et al., Restoration of Hemaglobin A Synthesis in Erythroid Cells From Peripheral Blood of Thalassemic Patients, Proceedings of the National Academy of Sciences USA, (Aug. 15, 2000), pp. 9591-9596, 97(17).;;Lacroix, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. Journal of Neurosurgery 95 (2001): 190-198.;;Lal et al., A Public Database for Gene Expression in Human Cancers, Cancer Research, (Nov. 1, 1999), pp. 5403-5407, 59(21).;;Lee, et al. Delivery of antisense oligonucleotides and transferrin receptor antibody in vitro and in vivo using a new multifunctional drug delivery system based on polymalic acid, Proceedings of the American Association for Cancer Research, 45 (2004), Abstract #647.;;Lee et al., Effects of Culture Conditions on p-Poly(I-Malate) Production by Physarum Polycephalum, Applied Microbiology and Biotechnology, (1999), pp. 647-652, 51.;;Lee, et al. Polycefin, a New Prototype of a Multifunctional Nanoconjugate Based on Poly(B-L-malic acid for Drug Delivery, Bioconjugate Chemistry, 17.2 (2006): 317-326.;;Ljubimov et al. Human Corneal Basement Membrane Heterogeneity, Topographical Differences in the Expression of Type IV Collagen and Laminin Isoforms, Lab Invetsigation, (Apr. 1995), pp. 461-473, 72(4).;;LJUBIMOVA, J.Y. HOLLER, E. FUJITA, M. KHAZENZON, N.M. LEE, B. BLACK, K.L.: ""608 A new multifunctional drug delivery system based on polymalic acid to inhibit angiogenesis and invasion of human gliomas in vitro and in vivo"", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 2, no. 8, 1 September 2004 (2004-09-01), GB, pages 184, XP004640052, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(04)80616-5;;Ljubimova et al., Changes in Laminin Isoforms Associated with Brain Tumor Invasion and Angiogenesis, Frontiers in Bioscience, (Jan. 1, 2006), vol. 11, pp. 81-88.;;LJUBIMOVA J Y; KHAZENZON N M; LAKHTER A J; GALPERIN S N; NINGARAJ N S; VIRTANEN I; SOROKIN L M; LJUBIMOV A V; BLACK K L: ""Development of an in vitro system to block the angiogenic target, laminin-8, in human gliomas"", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 43, 10 April 2002 (2002-04-10), US, pages 177, XP001536931, ISSN: 0197-016X;;Ljubimova et al., Development of Anti-Angiogenic and Anti-Invasive Inhibitors of Human Gliomas Using a New Multifunctional Drug delivery System Based on Polymakic Acid, Preclinica (Sep./Oct. 2004), 2(5), p. 366.;;Ljubimova et al., Gene Array Analysis of Differentially Expressed Genes in Human Glial Tumors, International Journal of Oncology, (2001), pp. 287-295, 18.;;Ljubimova, et al. Nanoconjugate based on polymalic acid for tumor targeting, Chemico-Biological Interactions, 171.2 (2008): 195-203.;;Ljubimova et al., Overexpression of a4 Chain-Containing Laminins in Human Glial Tumors Identified by Gene Microarray Analysis, Cancer Research (Jul. 15, 2001), pp. 5601-5610, 61(14).;;Ljubimova, J. et al., Association between Laminin-8 and Glial Tumor Grade, Recurrence, and Patient Survival, Cancer (online Jun. 16, 2004), 101(3), pp. 604-612.;;Ljubimova, Julia Y. et al. Molecular Oncology; Internet citation, XP008143608 (Jul. 1, 2009). Retrieved from the Internet:URL:http://www.cedars-sinai.edu/10141.html (retrieved on Sep. 29, 2011 ).;;Ljubimova, Julia Y. et al. Poly( malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery, Nanomedicine, 3.2 (2008): 247-265.;;Lorenz, et al. Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials. 27 (2006): 2820-2828.;;Louis, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114 (2007): 97-109.;;Lu et al., Delivering siRNA In Vivo for Functional Genomics and Novel Therapeutics, RNA Interference Technology, (2205), pp. 303-317.;;Lutsenko, et al. Biochemical Basis of Regulation of Human Copper-Transporting ATPases, Archives of Biochemistry and Biophysics, 463.2 (2007): 134-148.;;MacDonald et al., Urokinase Induces Receptor Mediated Brain Tumor Cell Migration and Invasion, Journal of Neuro Oncology, (Dec. 1998), pp. 215-226, 40(3).;;Machine translation of CN1615855A, 2005, 4 pages.;;Maeda et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. International Immunopharmacology 3:319-328 (2003).;;McKean et al., FAK Induces Expression of Prx1 to Promote Tenascin-C-Dependent Fibroblast Migration, Journal of Cell Biology, (Apr. 28, 2003), pp. 393-402, 161(2).;;Minakawa et al., In Vitro Interaction of Astrocytes and Pericytes With Capillary-Like Structures of Brain Microvessel Endothelium, Lab Investigation, (Jul. 1991), pp. 32-40, 65(1).;;Miner et al. The Laminin Alpha Chains: Expression, Developmental Transitions, and Chromosomal Locations of A1-5, Identification of Heterotrimeric Laminins 8-11, and Cloning of a Novel a3 Isoform, Journal of Cell Biology, (May 5, 1997), pp. 685-701, 137(3).;;Mosmann. Rapid colorimetric assays for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods. 65 (1983): 55-63.;;Nagato et al., Downregulations of Laminin a-4 Chain Expression Inhibits Glioma Invasion In Vitro and In Vivo, Int. Journal of Cancer (onlune Jun. 16, 2004), pp. 604-612.;;NCBI GenBank Accession No. NM_002291 (Nov. 21, 2010)—See the whole document.;;NCBI GenBank Accession No. NM_005228 (Dec. 26, 2010)—See the whole document.;;NCBI GenBank Accession No. X03363 (Mar. 30, 1995)—See the whole document.;;NCBI GenBank Accession No. X91171 (Oct. 7, 2008)—See the whole document.;;NCBI GenBank ATP7B [Homo sapiens] AAB52902.1 (1997): 3 pages.;;Nel, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nature Materials. 8 (2009): 543-557.;;Nielsen et al., Peptide Nucleic Acid Targeting of Double-Stranded DNA. Methods in Enzymology, 2001, pp. 329-340, 340.;;Nielsen P.E. The Last Hurdle?, Gene Therapy, (2005), pp. 956-957, 12.;;Non-Final Office action dated Apr. 4, 2016 for U.S. Appl. No. 15/054,266.;;Non-Final Office action dated Aug. 27, 2015 for U.S. Appl. No. 14/179,195.;;Non-Final Office action dated Nov. 4, 2012 for U.S. Appl. No. 12/935,110.;;Non-Final Office action dated Mar. 14, 2013 for U.S. Appl. No. 13/513,145.;;Non-Final Office action dated Oct. 15, 2014 for U.S. Appl. No. 13/930,533.;;Non-Final Office action dated Jun. 18, 2015 for U.S. Appl. No. 13/930,533.;;Non-Final Office action dated Dec. 19, 2013 for U.S. Appl. No. 13/646,947.;;Nori, et al. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Advanced Drug Delivery Reviews 57 (2005): 609-636.;;Notice of allowance dated Mar. 4, 2011 for U.S. Appl. No. 10/580,999.;;Notice of allowance dated Mar. 8, 2012 for U.S. Appl. No. 12/935,110.;;Notice of allowance dated Apr. 12, 2015 for U.S. Appl. No. 14/179,195.;;Notice of allowance dated Jun. 19, 2013 for U.S. Appl. No. 13/097,364.;;Notice of allowance dated Mar. 9, 2014 for U.S. Appl. No. 14/031,561.;;Notice of allowance dated Apr. 14, 2014 for U.S. Appl. No. 13/513,145.;;Notice of allowance dated Apr. 14, 2014 for U.S. Appl. No. 13/646,947.;;Notice of allowance dated Sep. 14, 2012 for U.S. Appl. No. 12/935,110.;;Notice of allowance dated Dec. 21, 2016 for U.S. Appl. No. 15/054,266.;;Odian, G. (1991) Principles of Polymerization, Third Edition. John Wiley and Sons, Inc.;;Office action dated Jan. 14, 2009 for U.S. Appl. No. 10/580,999.;;Office action dated Feb. 5, 2014 for U.S. Appl. No. 14/031,561.;;Office action dated Mar. 5, 2010 for U.S. Appl. No. 10/580,999.;;Office action dated Apr. 24, 2012 for U.S. Appl. No. 13/097,364.;;Office action dated Aug. 4, 2009 for U.S. Appl. No. 10/580,999.;;Office action dated Sep. 20, 2012 for U.S. Appl. No. 13/097,364.;;Office action dated Dec. 7, 2010 for U.S. Appl. No. 10/580,999.;;Office Action from corresponding European Patent Application No. 10861515.4 dated Feb. 26, 2014, 6 pages.;;Office Action from corresponding Japanese Patent Application No. 2013-547442 dated Oct. 29, 2014, with a Brief Report in English, 6 pages.;;Owens, et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics 307 (2006): 93-102.;;Patarroyo et al., Laminin Isoforms in Tumor Invasion, Angiogenesis, and Metastasis Seminars, Seminars in Cancer Biology, (Jume 2002), pp. 197-207, 12(3).;;PCT/US2009/040252 International Preliminary Report on Patentability dated Oct. 21, 2010.;;Peer, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. Dec. 2007;2(12):751-60.;;Petajaniemi et al., Localization of Laminin a4-Chain in developing and Adult Human Tissues, The Journal of Hrstochemistry and Cytochemistry, (Aug. 2002), pp. 1113-1130, 50(8).;;Pichon et al., Histidine-Rich Peptides and Polymers for Nucleic Acid Delivery, Advanced Drug Delivery Reviews, (2001), pp. 75-94, 53.;;Qian et al., Targeted Drug Delivery via the Transferrin Receptor-mediated Endocytosis Pathway, Pharmacology Reviews. vol. 54, No. 4, (Dec. 2002), pp. 561-587.;;Qin et al., The Transcription Factors Sp1, Sp3, and AP-2 are required for Constitutive Matrix Metalloproteinase-2 Gene Expression in Astroglioma Cells, Journal of Biological Chemistry, (Oct. 8, 1999), pp. 29130-29137.;;Rameshwar, et al. Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Ply (1-L-malic acid). Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, 27.11 (2010): 2317-2329.;;Saito et al., drug Delivery Strategy Utilizing Conjugation via Reversible Disulide Linkages: Role and Site of Cellular Reducing Activities, Advanced Drug Delivery Reviews, (2003), pp. 192-215, 55.;;Samarsky et al., RNAi in Drug Development: Practical considerations, RNA Interference Technology, (2005), pp. 384-395.;;Satchi, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Medicine 10 (2004): 255-261.;;Schnaible et al., identification of Fluorescein-5′-Isothiocynate-Modification Sites in Proteins by Electrospray-Ionization Mass Spectrosopy, Bioconjugates Chemistry, (1999), pp. 861-866, 10.;;Segal, et al. Design and development of polymer conjugates as anti-angiogenic agents. Advanced Drug Delivery Reviews, 61 (2009): 1159-1176.;;Sehgal, A., molecular Changes During the Genesis of Human Gliomas, Seminars in Surgical Oncology, (Jan.-Feb. 1998), pp. 3-12, 14(1).;;Shi et al., Noninvasive Gene Targeting to the Brain, Proceedings of the National Academy of Sciences, (2000), pp. 7567-7572, 97.;;Sixt et al., Endothelial Cell Laminin Isoforms, Laminins 8 and 10, Play Decisive Roles in T Cell Recruitement Across the Blood-Brain Barrier in Experimental Autoimmune Encephalomyelitis, Journal of Cell Biology, (May 28, 2001), pp. 933-947, 153(5).;;Stummer, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology, 7 (2006): 392-401.;;Stupp et al., “Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma,” N. Engl. J. Med. 352:987-996 (2005).;;Summerton et al., Morpholino Antisense Oligomers: Design, Preparation and Properties, Antisense and Nucleic Acid Drug Development, (Jun. 1997), pp. 187-195, 7(3).;;Taylor et al., Comparison of Efficacy of Antisense Oligomers Directed Toward TNF-a In Helper T and Macrophage Cell Lines, Cytokine, ((Sep. 1997), pp. 672-681, 9(9).;;Thyboll et al., Deletion of the Laminin a4 Chain Leads to Impaired Microvessel Maturation, Molecular and Cellular Biology, (Feb. 2002), pp. 1194-1202, 22(4).;;Trivedi, et al. Human methyl purine DNA glycosylase and DNA polymerase b expression collectively predict sensitivity to temozolomide. Mol Pharmacal. 74 (2008): 505-516.;;Tsuji et al., Regulation of Melanoma Cell Migration and Invasion by Laminin-5 and a3(31 Integrin (VLA-3), Clinical and Experimental Metastasis, (2002), pp. 127-134, 19(2).;;Vinogradov, et al. Mixed polymer micelles of amphiphilic and cationic copolymers for delivery of antisense oligonucleotides. Journal of Drug Targeting. 12 (2004): 517-526.;;Voyta et al., Identification and Isolation of Endothelial Cells Based on Their Increased Uptake of Acetylated-Low Density Lipoprotein, Journal of Cell Biology, (Dec. 1984), pp. 2034-2040, 99(6).;;Waldeck, et al. TMZ-BioShuttle—A reformulated temozolomide. International Journal of Medical Sciences, Ivyspring International Publisher, Lake Haven, AU, 5.5 (2008): 273-284.;;West record of CN1615855A, 2005, 2 pages.;;Willner et al., (6-Maleimidocaproyl) Hydrazone of Doxorubicin—A New Derivative for the Preparation of Immunoconjugates of Doxorubicin, Boconjugate Chemistry, (193), pp. 521-527, 1993.;;Wiseman, et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer, 103.9 (2005): 1770-1777.;;Written opinion dated Jun. 5, 2006 for PCT/US2004/040660.;;Yu, et al. (2009) Targeted Delivery Systems for Oligonucleotide Therapeutics. The AAPS Journal, v.11(1):195-203.;;Zagzag et al., Angiogenesis in the Central Nervous System: A role for Vascular Endothelial Growth FactorNascular Permeability Factor and Tenascin-C. Common Molecular Effectors in Cerebral Neoplastic and Non-Neoplastic “Angiogenic Diseases,” Histol Histopathol, 17: 301-321, 2002.;;Zhang et al., Antisense Gene Therapy of Brain Cancer with Artificial Virus Gene Delivery System, Molecular Therpay, vol. 6, No. 1 (Jul. 2002), pp. 67-72.;;Zhao, et al. Synthesis and antitumour activities of 3-substituted 4-oxo-3 H-imidazo [5, 1-d][1,2,3,5] tetrazine-8-parboxylic acids and their derivatives. Chinese Journal of Medicinal Chemistry 11 (2001): 263-269.",ACTIVE
367,US,A1,US 2014/0193398 A1,148-524-484-677-40X,2014-07-10,2014,US 201313930533 A,2013-06-28,US 2010/0062515 W;;US 201313930533 A,2010-12-30,POLYMALIC ACID-BASED NANOBIOPOLYMER COMPOSITIONS,"Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.",CEDARS SINAI MEDICAL CENTER,INOUE SATOSHI;;DING HUI;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2013-08-13),https://lens.org/148-524-484-677-40X,Patent Application,yes,1,7,5,9,9,A61K31/713;;A61K31/713;;A61K2039/505;;A61K2039/505;;C07K16/2881;;C07K16/2881;;C07K16/32;;C07K16/32,A61K39/395;;A61K31/713,424/133.1;;X514 44  A;;424/174.1;;514/19.3;;514/19.4;;514/19.5,3,3,115-650-595-072-446;;120-680-307-644-234;;039-738-668-274-842,10.1093/nar/29.23.4873;;pmc96684;;11726697;;15770691;;10.1002/cncr.20970;;12855625,"Bayse et al. (Nucleic Acids Research, 29: 4873-4880, 2001);;Wiseman et al. (Cancer, 103(9): 1770-1777, 2005);;Iversen et al. (Clinical Cancer Research, 9: 2510-2519, 2003)",ACTIVE
368,US,A1,US 2005/0198797 A1,006-187-675-060-767,2005-09-15,2005,US 79915704 A,2004-03-12,US 79915704 A,2004-03-12,Engine loader and transporter apparatus and methods,"Engine loader and transporter apparatus and methods are disclosed. In one embodiment, an engine handling assembly includes a motorized drive assembly engageable with a floor surface, and an engagement unit positioned proximate the drive assembly and partially surrounding a working space. The engagement unit includes a pair of coupling assemblies positioned on opposing lateral sides of the working space that are adapted to be selectively coupleable to the aircraft engine assembly when the aircraft engine assembly is positioned at least partially within the working space. A lifting assembly is operatively coupled to the drive assembly and to the engagement unit and is operable to selectively raise and lower the engagement unit and the aircraft engine assembly with respect to the floor surface.",APPLETON JOSEPH A.;;BUSCH TIMOTHY J.;;BLACK KEITH E.;;WESCOTT KEVIN P.,APPLETON JOSEPH A;;BUSCH TIMOTHY J;;BLACK KEITH E;;WESCOTT KEVIN P,BOEING COMPANY THE (2004-03-11),https://lens.org/006-187-675-060-767,Patent Application,yes,24,11,2,2,0,B64F5/50;;B64F5/50;;F01D25/285;;F01D25/285;;F05D2230/68;;F05D2230/68;;F05D2230/72;;F05D2230/72;;Y10T29/49716;;Y10T29/49716;;Y10T29/49895;;Y10T29/49895;;Y10T29/49902;;Y10T29/49902;;Y10T29/49904;;Y10T29/49904;;Y10T29/53435;;Y10T29/53435;;Y10T29/53961;;Y10T29/53961;;Y10T29/53974;;Y10T29/53974,B21K21/16;;B23P17/04,29/401.1;;29/469;;29/799,0,0,,,,INACTIVE
369,CA,A1,CA 3015121 A1,070-146-396-221-759,2017-09-08,2017,CA 3015121 A,2017-03-03,US 201662303845 P;;US 2017/0020666 W,2016-03-04,POLYMALIC ACID BASED NANOIMMUNOCONJUGATES AND USES THEREOF,"Nanoimmunoconjugates including a polymalic acid-based molecular scaffold, targeting ligands, anti-tumor immune response stimulators and anti-cancer agents are provided. Methods for treating cancer in a subject by administering the nanoimmunoconjugates that provide both systemic and local immune responses and synergistic anticancer effect are described.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD;;LJUBIMOV ALEXANDER;;DING HUI,,https://lens.org/070-146-396-221-759,Patent Application,no,0,0,11,11,0,A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/6849;;A61K47/6813;;A61K47/6807;;A61K47/593;;A61K47/6851;;A61K47/6883;;A61K47/6935;;A61P35/00;;A61K31/7088;;A61K39/3955;;A61K45/06;;A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6813;;A61K47/6849;;A61K47/6807;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/10;;A61K47/183,A61K39/395;;A61K31/713;;A61K38/16;;A61K38/19;;A61K47/10;;A61P35/00;;A61P35/04,,0,0,,,,DISCONTINUED
370,US,B2,US 7103952 B2,103-267-779-101-363,2006-09-12,2006,US 79915704 A,2004-03-12,US 79915704 A,2004-03-12,Engine loader and transporter apparatus and methods,"Engine loader and transporter apparatus and methods are disclosed. In one embodiment, an engine handling assembly includes a motorized drive assembly engageable with a floor surface, and an engagement unit positioned proximate the drive assembly and partially surrounding a working space. The engagement unit includes a pair of coupling assemblies positioned on opposing lateral sides of the working space that are adapted to be selectively coupleable to the aircraft engine assembly when the aircraft engine assembly is positioned at least partially within the working space. A lifting assembly is operatively coupled to the drive assembly and to the engagement unit and is operable to selectively raise and lower the engagement unit and the aircraft engine assembly with respect to the floor surface.",BOEING CO,APPLETON JOSEPH A;;BUSCH TIMOTHY J;;BLACK KEITH E;;WESCOTT KEVIN P,BOEING COMPANY THE (2004-03-11),https://lens.org/103-267-779-101-363,Granted Patent,yes,24,39,2,2,0,B64F5/50;;B64F5/50;;F01D25/285;;F01D25/285;;F05D2230/68;;F05D2230/68;;F05D2230/72;;F05D2230/72;;Y10T29/49716;;Y10T29/49716;;Y10T29/49895;;Y10T29/49895;;Y10T29/49902;;Y10T29/49902;;Y10T29/49904;;Y10T29/49904;;Y10T29/53435;;Y10T29/53435;;Y10T29/53961;;Y10T29/53961;;Y10T29/53974;;Y10T29/53974,B66B9/16;;B21K21/16;;B23P17/04;;B60P1/44;;B60P1/64;;B66B9/187,29/281.4;;29/401.1;;29/464;;29/468;;29/281.1;;X254  2 R;;254/122;;244/54;;414/589,0,0,,,,INACTIVE
371,DE,T5,DE 112011101074 T5,176-659-011-363-80X,2013-02-07,2013,DE 112011101074 T,2011-03-25,US 31788210 P;;US 2011/0029902 W,2010-03-26,Brennstoffübertragungssystem und -verfahren für einen Generatorsatz,"Ein Brennstoffsteuersystem für einen elektrischen Generatorsatz wird offenbart. Das Brennstoffsteuersystem weist einen elektrischen Generator, einen Primärantrieb, der mechanisch mit dem Generator gekoppelt ist, einen ersten Brennstofftank, einen Brennstoffniveausensor, der konfiguriert ist, um ein Brennstoffniveausignal zu erzeugen, welches ein Brennstoffniveau im ersten Brennstofftank anzeigt, eine Brennstoffladebedienereingabevorrichtung, die konfiguriert ist, um ein Brennstoffladesignal zu erzeugen, eine Brennstoffversorgungsmodusbedienereingabevorrichtung, die konfiguriert ist, um ein Brennstoffversorgungsmodussignal zu erzeugen, und ein Steuermodul auf. Der erste Brennstofftank ist konfiguriert, um Brennstoff zum Primärantrieb zu liefern und selektiv Brennstoff von einem zweiten Brennstofftank durch eine Brennstoffpumpe aufzunehmen oder Brennstoff zu einem zweiten Brennstofftank zu liefern. Das Steuermodul ist konfiguriert, um ein Brennstofftransfersignal als eine Funktion des Brennstoffladesignals, des Brennstoffversorgungsmodussignals und des Brennstoffniveausignals zu erzeugen.",CATERPILLAR INC,SLAUGHTER NELSON;;SCHROEDER EDWARD M;;FOLKEN KEITH;;BLACK ANDREW W;;CHAKRAVARTY JOYDIP,,https://lens.org/176-659-011-363-80X,Patent Application,no,0,0,10,10,0,F02D29/06;;F02D29/06;;F02D29/06;;F01D15/10;;F01D15/10;;F02B63/04;;F02C9/26;;F02C9/26;;F02D41/30;;F02M51/02;;F02M51/02;;F02M51/02;;Y10T137/86147;;Y10T137/86147,F02B63/04;;F02D29/06;;F02D41/30;;F02M51/02,,0,0,,,,DISCONTINUED
372,AU,A1,AU 2017/228459 A1,059-297-792-043-261,2018-09-06,2018,AU 2017/228459 A,2017-03-03,US 201662303845 P;;US 2017/0020666 W,2016-03-04,Polymalic acid based nanoimmunoconjugates and uses thereof,"Nanoimmunoconjugates including a polymalic acid-based molecular scaffold, targeting ligands, anti-tumor immune response stimulators and anti-cancer agents are provided. Methods for treating cancer in a subject by administering the nanoimmunoconjugates that provide both systemic and local immune responses and synergistic anticancer effect are described.",CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD;;LJUBIMOV ALEXANDER;;DING HUI,,https://lens.org/059-297-792-043-261,Patent Application,no,0,0,11,11,0,A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/6849;;A61K47/6813;;A61K47/6807;;A61K47/593;;A61K47/6851;;A61K47/6883;;A61K47/6935;;A61P35/00;;A61K31/7088;;A61K39/3955;;A61K45/06;;A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6813;;A61K47/6849;;A61K47/6807;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/10;;A61K47/183,A61K39/395;;A61K31/713;;A61K38/16;;A61K38/19;;A61K47/10;;A61P35/00;;A61P35/04,,0,0,,,,DISCONTINUED
373,US,A1,US 2017/0340659 A1,166-985-889-218-150,2017-11-30,2017,US 201715447439 A,2017-03-02,US 201715447439 A;;US 201313930533 A;;US 2010/0062515 W,2010-12-30,POLYMALIC ACID-BASED NANOBIOPOLYMER COMPOSITIONS,"Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.",CEDARS SINAI MEDICAL CENTER,INOUE SATOSHI;;DING HUI;;HOLLER EGGEHARD;;BLACK KEITH L;;LJUBIMOVA JULIA Y,CEDARS-SINAI MEDICAL CENTER (2013-08-13),https://lens.org/166-985-889-218-150,Patent Application,yes,0,0,5,9,9,C07K16/2881;;C07K16/32;;A61K2039/505;;A61K31/713;;A61K31/713;;C07K16/2881;;C07K16/32;;A61K2039/505,A61K31/713;;A61K39/00;;C07K16/28;;C07K16/32,,0,0,,,,ACTIVE
374,DK,T3,DK 2323696 T3,197-797-499-294-410,2018-11-26,2018,DK 09815306 T,2009-09-18,US 9820608 P;;US 2009/0057569 W,2008-09-18,OPTISK FREMGANGSMÅDE TIL DETEKTERING AF ALZHEIMERS SYGDOM,,CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L;;KORONYO YOSEF,,https://lens.org/197-797-499-294-410,Granted Patent,no,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,0,0,,,,ACTIVE
375,US,A1,US 2019/0076555 A1,008-577-904-613-481,2019-03-14,2019,US 201816128888 A,2018-09-12,US 201816128888 A;;US 201762557380 P,2017-09-12,TUMOR TARGETING NANOAGENT FOR IMAGING AND FLUORESCENT GUIDED RESECTION OF TUMORS,"Imaging nanoagents including a polymalic acid-based molecular scaffold, a chlorotoxin peptide or a variant thereof, and at least one fluorescent moiety are provided. Methods for detecting, treating and removing a cancer in a subject by administering the imaging nanoagent are described.",CEDARS SINAI MEDICAL CENTER,PATIL RAMESHWAR;;HOLLER EGGEHARD;;LJUBIMOVA JULIA Y;;MAMELAK ADAM;;BLACK KEITH L,CEDARS-SINAI MEDICAL CENTER (2017-12-15),https://lens.org/008-577-904-613-481,Patent Application,yes,0,3,1,1,10,A61K49/0032;;A61K49/0032;;A61K49/0002;;A61K49/0054;;A61K49/0054;;A61K49/0056;;A61K49/0056;;A61K49/0093;;A61K49/0093;;A61K49/186;;B82Y5/00;;B82Y5/00;;B82Y15/00;;B82Y15/00;;B82Y30/00,A61K49/00;;A61K49/18,,0,0,,,,DISCONTINUED
376,US,B2,US 8950446 B2,043-586-106-054-033,2015-02-10,2015,US 201113071608 A,2011-03-25,US 201113071608 A;;US 31788210 P,2010-03-26,Genset fuel transfer system and method,"An electric generator set fuel control system is disclosed. The fuel control system includes an electric generator, a prime mover mechanically coupled to the generator, a first fuel tank, a fuel level sensor configured to generate a fuel level signal indicative of a fuel level in the first fuel tank, a fuel loading operator input device configured to generate a fuel loading signal, a fueling mode operator input device configured to generate a fueling mode signal, and a control module. The first fuel tank is configured to supply fuel to the prime mover, and selectively receive or supply fuel to a second fuel tank through a fuel pump. The control module is configured to generate a fuel transfer signal as a function of the fuel loading signal, the fueling mode signal, and the fuel level signal.",FOLKEN KEITH;;CHAKRAVARTY JOYDIP;;SCHROEDER EDWARD M;;BLACK ANDREW W;;SLAUGHTER NELSON;;CATERPILLAR INC,FOLKEN KEITH;;CHAKRAVARTY JOYDIP;;SCHROEDER EDWARD M;;BLACK ANDREW W;;SLAUGHTER NELSON,CATERPILLAR INC (2011-04-19),https://lens.org/043-586-106-054-033,Granted Patent,yes,18,1,10,10,0,F02D29/06;;F02D29/06;;F02D29/06;;F01D15/10;;F01D15/10;;F02B63/04;;F02C9/26;;F02C9/26;;F02D41/30;;F02M51/02;;F02M51/02;;F02M51/02;;Y10T137/86147;;Y10T137/86147,B65B1/30;;F01D15/10;;F02C9/26;;F02D29/06;;F02M51/02,141/95;;141/1;;141/94;;X290  4 D;;137/565.31;;340/613;;340/618,0,0,,,,ACTIVE
377,US,B2,US 9839699 B2,091-565-952-191-983,2017-12-12,2017,US 200913119596 A,2009-09-18,US 200913119596 A;;US 9820608 P;;US 2009/0057569 W,2008-09-18,Optical method for detecting Alzheimer's disease by systemic administration of curcumin,"The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.",KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L;;YEDA RES & DEV;;CEDARS SINAI MEDICAL CENTER,KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L,YEDA RESEARCH AND DEVELOPMENT CO. LTD (2011-05-05);;CEDARS-SINAI MEDICAL CENTER (2011-05-05),https://lens.org/091-565-952-191-983,Granted Patent,yes,33,6,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61B5/00;;A61B3/00;;A61B6/00;;A61K49/00,,44,26,011-124-388-694-014;;048-262-075-396-41X;;047-248-975-491-255;;155-116-058-123-026;;127-755-540-864-020;;051-258-321-229-657;;029-266-465-122-624;;168-962-786-537-184;;030-890-177-126-959;;044-996-017-028-990;;047-248-975-491-255;;001-071-605-851-401;;062-121-843-455-012;;023-752-202-245-804;;018-185-564-619-309;;094-757-093-302-58X;;021-351-675-495-336;;101-039-368-580-34X;;137-580-887-914-833;;019-616-143-624-925;;040-268-043-147-853;;085-892-067-132-332;;003-422-916-572-826;;011-952-969-552-421;;051-258-321-229-657;;017-689-186-117-418,17472706;;10.1111/j.1471-4159.2007.04613.x;;9267595;;10.1111/j.1442-9071.1997.tb01290.x;;17999464;;10.1021/mp700113r;;10.1074/jbc.m404751200;;15590663;;10.1016/j.ab.2006.04.036;;16729955;;10.1111/j.1471-4159.2008.05606.x;;18691390;;18382494;;pmc3079576;;10.1364/josaa.25.000947;;pmc2991559;;10.1016/j.neuroimage.2010.06.020;;20550967;;10.1056/nejm198608213150804;;3736630;;10.1016/0006-8993(89)90653-7;;2819446;;17999464;;10.1021/mp700113r;;10.1016/j.addr.2006.07.024;;17081648;;10.1167/iovs.03-0505;;15037592;;10.1039/b409724f;;15480453;;10.1016/j.bmc.2004.03.074;;10.1016/s0968-0896(04)00277-9;;15158792;;10.1111/j.1742-4658.2006.05525.x;;17069615;;12870844;;10.1562/0031-8655(2003)0770597psoboc2.0.co2;;10.1562/0031-8655(2003)077<0597:psoboc>2.0.co;2;;10.1111/j.1747-0285.2007.00557.x;;17718715;;10.1016/s0925-4439(00)00029-6;;10899428;;10.1073/pnas.022662599;;pmc122217;;11818542;;1690688;;17003411;;10.1167/iovs.06-0026;;10.1093/brain/123.12.2519;;11099453;;10.1111/cbdd.12552;;25776887;;10.1111/j.1471-4159.2008.05606.x;;18691390;;18480561;;10.1254/fpj.131.333,"Garcia-Alloza et al. J. Neurochem. 2007, 102: 1095-1104.;;Vickers, Australian and New Zealand J of Ophthalmol. 1997, 25:105-109.;;Anand et al. Molecular. Pharmaceutics, 2007, 4:807-818.;;Yang et al. J. Biol. Chem., 2005; 280:5892-5901.;;LeVine Ana. Biochem. 2006; 356: 265-272.;;PCT/US09/57569 ISR and Written Opinion dated Nov. 19, 2009.;;Xie Zhao-yang, et al., Chinese Journal of New Drugs, 2007, vol. 16 No. 1, pp. 36-40.;;U.S. Appl. No. 14/191,398, filed Feb. 26, 2014.;;U.S. Appl. No. 14/191,401, filed Feb. 26, 2014.;;Koronyo et al., “Noninvasive Optical Imaging of Retinal Amyloid Plaques in Mice Model of Alzheimer's disease: Early Detection and Treatment Assessment,” alzheimer's association, Abstract, 3 pages (2010).;;Koroyno et al., “Optical imaging of amyloid plaques in the retina for Alzheimer's disease detection and treatment assessment,” Neuroscience 2009, Abstract, 2 pages (2009).;;Koroyno et al. “Noninvsive Optical Imaging of β-Amyloid Plaques in Live AD Mice Retina and Identification of Aβ Plaques in Postmortem Retinas from Human AD Patients,” Poster # P3-188, Abstract Control #2932, Cedar-Sinai Medical Center (2009).;;Koroyno et al., In Vivo Optical Imaging of Retinal Amyloid Plaques in Mice Model of Alzheimer's disease: Early Detection and Treatmet Assessment, Poster #12, Abstract, Cedar-Sinai Medical Center (2009).;;Frenkel et al., “Nasal vaccination with a proteasome-based adjuvant and glatiramer acetate clears β-amyloid in a mouse model of Alzheimer disease,” The Journal of Clinical Investigation, vol. 115, No. 9, pp. 2423-2433 (2005).;;Guo et al., “Targeting amyloid-β in glaucoma treatment,” Proc. National Academy of Science, vol. 104, No. 33, pp. 13444-13449 (2007).;;Goldstein et al., “Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease,” The Lancet, vol. 361, No. 9365, pp. 1258-1265 (2003).;;Perez et al., “β-Amyloid Deposition and Functional Impairment in the Retina of the APPswe/PS1ΔE9 Transgenic Mouse Model for Alzheimer's Disease,” Investigative Ophthalmology & Visual Science, vol. 50, No. 2, pp. 793-800 (2008).;;Shimazawa et al., “Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-D-asparatate receptor signaling,” Journal of Neurochemistry, vol. 107, No. 1, pp. 279-290 (2008).;;Ning et al., “Amyloid-β Deposits Lead to Retinal Degeneration in a Mouse Model of Alzheimer Disease,”Investigative Ophthalmology & Visual Science, vol. 49, No. 11, pp. 5136-5143 (2008).;;Sharifzadeh et al., “Resonance Raman imaging of macular pigment distrubutions in the human retina,” Journal of the Optical Society of America, vol. 25, No. 4, pp. 947-957 (2008).;;Yang et al., “Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo,” Journal of Biological Chemistry, vol. 280, No. 7, pp. 5892-5901 (2005).;;Koronyo-Hamaoui et al., “Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model,” NeuroImage, vol. 54, pp. 5204-5217 (2011).;;Hinton, D.R., et al., “Optic-nerve degeneration in Alzheimer's disease”, N Engl J Med. Aug. 21, 1986;315(8)485-7 (Abstract only).;;Blanks, J.C., et al., “Retinal ganglion cell degeneration in Alzheimer's disease”, Brain Res. Nov. 6, 1989;501(2):364-72 (Abstract only).;;M.L. Ford and B.D. Evavold, “An MHC anchor-substituted analog of myelin oligodenrocyte glycoprotein 35-55 induces IFN-γ and autoantibodies in the absence of experimental autoimmune encephalomyelitis and optic neuritis”, Eur. J. Immunol., 2004, 34:388-397.;;L.E. Goldstein, et al., “Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease”, Lancet 2003; 361: 1258-65.;;Anand, et al., “Bioavailability of Curcumin: Problems and Promises”, Mol. Pharmaceutics, 2007, 4 (6), 807-818.;;Mannermaa, et al., “Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics”, Adv Drug Deliv Rev. Nov. 15, 2006;58(11):1136-63. Epub Sep. 16, 2006. (Abstract Only).;;Hosoya, et al., “Vitamin C transport in oxidized form across the rat blood-retinal barrier”, Invest Ophthalmol Vis Sci. Apr. 2004;45(4):1232-9.;;Zsila, et al., “Circular dichroism spectroscopic studies reveal pH dependent binding of curcumin in the minor groove of natural and synthetic nucleic acids”, Org Biomol Chem. Oct. 21, 2004;2(20):2902-10. Epub Sep. 23, 2004. (Abstract Only).;;Zsila, et al., “Induced circular dichroism spectra reveal binding of the antiinflammatory curcumin to human alpha1-acid glycoprotein”, Bioorg Med Chem. Jun. 15, 2004;12(12):3239-45. (Abstract Only).;;Gupta, et al., “Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding”, FEBS J. Dec. 2006;273(23):5302-32. Epub Oct. 26, 2006. (Abstract Only).;;Barik, et al., “Photophysical studies on binding of curcumin to bovine serum albumins”, Photochem Photobiol. Jun. 2003;77(6):597-603. (Abstract Only).;;Reinke, A. A. and Gestwicki, J. E. (2007), Structure-activity Relationships of Amyloid Beta-aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibility. Chemical Biology & Drug Design, 70: 206-215. (Abstract Only).;;L.C. Serpell, “Alzheimer's amyloid fibrils: structure and assembly”, Biochimica et Biophysica Acta, 1502:16-30 (2000).;;B. O'Nuallain and R. Wetzel, “Conformational Abs Recognizing a Generic Amyloid Fibril Epitope”, PNAS, vol. 99, No. 3, pp. 1485-1490 (2002).;;T. Cavallero, et al., “The Retinal Pigment Epithelium Is the Unique Site of Transthyretin Synthesis in the Rat Eye”, Investigative Ophthalmology & Visual Science, vol. 31, No. 3, pp. 497-501, Mar. 1990.;;P.M. Martin, et al., “Expression and Polarized Localization of the Hemochromatosis Gene Product HFE in Retinal Pigment Epithelium”, Investigative Ophthalmology & Visual Science, vol. 47, No. 10, pp. 4238-4244, Oct. 2006.;;G. Cancel, et al., “Distribution of Ataxin-7 in Normal Human Brain and Retina”, Brain, 123:2519-2530, 2000.;;P.P.N. Rao, et al., “Curcumin Binding to Beta Amyloid: A Computational Study”, Chemical Biology & Drug Design, 2015, 86:813-820.;;J.-D. Ding, et al., “Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: Anti-amyloid-β antibody attenuates pathologies in an age-related macular degeneration mouse model”, Vision Research 48 (2008) 339-345.;;M. Shimazawa, et al., “Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-D-aspartate receptor signaling”, J. of Neurochemistry, 2008, 107:279-290.;;A. Ning, et al., “Amyloid-β Deposits Lead to Retinal Degeneration in a Mouse Model of Alzheimer Disease”, Investigative Ophthalmology & Visual Science, Nov. 2008, vol. 49, No. 11, 5136-5143.;;N. Okamura, et al., “In Vivo Imagining of Amyloid Plaques”, Folia Pharmacol. Jpn., (2008) 131:333-337 [Japanese language reference with English language abstract].",ACTIVE
378,GB,A,GB 2492034 A,108-478-428-734-46X,2012-12-19,2012,GB 201219001 A,2011-03-25,US 31788210 P;;US 2011/0029902 W,2010-03-26,Genset fuel transfer system and method,"An electric generator set fuel control system is disclosed. The fuel control system includes an electric generator, a prime mover mechanically coupled to the generator, a first fuel tank, a fuel level sensor configured to generate a fuel level signal indicative of a fuel level in the first fuel tank, a fuel loading operator input device configured to generate a fuel loading signal, a fueling mode operator input device configured to generate a fueling mode signal, and a control module. The first fuel tank is configured to supply fuel to the prime mover, and selectively receive or supply fuel to a second fuel tank through a fuel pump. The control module is configured to generate a fuel transfer signal as a function of the fuel loading signal, the fueling mode signal, and the fuel level signal.",CATERPILLAR INC,SCHROEDER EDWARD M;;BLACK ANDREW W;;CHAKRAVARTY JOYDIP;;FOLKEN KEITH;;SLAUGHTER NELSON,,https://lens.org/108-478-428-734-46X,Patent Application,no,4,0,10,10,0,F02D29/06;;F02D29/06;;F02D29/06;;F01D15/10;;F01D15/10;;F02B63/04;;F02C9/26;;F02C9/26;;F02D41/30;;F02M51/02;;F02M51/02;;F02M51/02;;Y10T137/86147;;Y10T137/86147,F02D29/06;;F02B63/04;;F02D41/30;;F02M51/02,,0,0,,,,ACTIVE
379,DE,B2,DE 2926764 B2,033-422-822-916-366,1981-01-29,1981,DE 2926764 A,1979-07-03,US 92202978 A,1978-07-05,DE 2926764 B2,,"DEERE & CO., MOLINE, ILL. (V.ST.A.), NIEDERLASSUNG DEERE & CO. EUROPEAN OFFICE, 6800 MANNHEIM","LAWRENCE, ALLAN KEITH;;BASS, MERLYN DUANE;;BLACK, ROBERT DELNO;;KRAFKA, JERRY LEE","DEERE & COMPANY, MOLINE, ILL., US (1998-07-02)",https://lens.org/033-422-822-916-366,Patent Application,no,0,0,21,21,0,A01F29/10;;A01F29/10,A01D43/08;;A01F29/00;;A01F29/10,,0,0,,,,EXPIRED
380,CN,A,CN 102844546 A,114-932-039-104-338,2012-12-26,2012,CN 201180016110 A,2011-03-25,US 2011/0029902 W;;US 31788210 P,2010-03-26,Genset fuel transfer system and method,"An electric generator set fuel control system is disclosed. The fuel control system includes an electric generator, a prime mover mechanically coupled to the generator, a first fuel tank, a fuel level sensor configured to generate a fuel level signal indicative of a fuel level in the first fuel tank, a fuel loading operator input device configured to generate a fuel loading signal, a fueling mode operator input device configured to generate a fueling mode signal, and a control module. The first fuel tank is configured to supply fuel to the prime mover, and selectively receive or supply fuel to a second fuel tank through a fuel pump. The control module is configured to generate a fuel transfer signal as a function of the fuel loading signal, the fueling mode signal, and the fuel level signal.",CATERPILLAR INC,SCHROEDER EDWARD M;;BLACK ANDREW W;;CHAKRAVARTY JOYDIP;;FOLKEN KEITH;;SLAUGHTER NELSON,,https://lens.org/114-932-039-104-338,Patent Application,no,9,0,10,10,0,F02D29/06;;F02D29/06;;F02D29/06;;F01D15/10;;F01D15/10;;F02B63/04;;F02C9/26;;F02C9/26;;F02D41/30;;F02M51/02;;F02M51/02;;F02M51/02;;Y10T137/86147;;Y10T137/86147,F02B63/04;;F02D29/06;;F02D41/30;;F02M51/02,,0,0,,,,ACTIVE
381,FR,A1,FR 2430190 A1,113-580-027-148-189,1980-02-01,1980,FR 7916833 A,1979-06-29,US 92202978 A,1978-07-05,RECOLTEUSE-HACHEUSE,<P>Cette invention concerne une découpeuse-hacheuse comprenant un mécanisme de coupe et un système d'amenée constitué par des jeux de rouleaux formant des transporteurs. </P><P>Le rouleau aval du transporteur supérieur est monté sur deux bras radiaux reliés par un arbre d'équilibrage transversal formant avec eux un cadre rigide. Le rouleau supérieur amont est monté sur les deux bras de support au moyen d'un arbre transversal qui les relie ici encore rigidement. Ces bras de support sont reliés à pivotement aux bras radiaux sur l'axe du rouleau aval. Des moyens limitent le pivotement relatif des bras. </P><P>Cet agencement fournit une rigidité transversale qui évite que les rouleaux ne prennent une position oblique.</P>,DEERE & CO,LAWRENCE ALLAN KEITH;;BASS MERLYN DUANE;;BLACK ROBERT DELNO;;KRAFKA JERRY LEE,,https://lens.org/113-580-027-148-189,Patent Application,no,7,0,21,21,0,A01F29/10;;A01F29/10,A01F29/00;;A01F29/10;;A01D43/08,,0,0,,,,EXPIRED
382,WO,A3,WO 2011/119905 A3,112-994-258-505-327,2011-12-29,2011,US 2011/0029902 W,2011-03-25,US 31788210 P,2010-03-26,GENSET FUEL TRANSFER SYSTEM AND METHOD,"An electric generator set fuel control system is disclosed. The fuel control system includes an electric generator, a prime mover mechanically coupled to the generator, a first fuel tank, a fuel level sensor configured to generate a fuel level signal indicative of a fuel level in the first fuel tank, a fuel loading operator input device configured to generate a fuel loading signal, a fueling mode operator input device configured to generate a fueling mode signal, and a control module. The first fuel tank is configured to supply fuel to the prime mover, and selectively receive or supply fuel to a second fuel tank through a fuel pump. The control module is configured to generate a fuel transfer signal as a function of the fuel loading signal, the fueling mode signal, and the fuel level signal.",CATERPILLAR INC;;SCHROEDER EDWARD M;;BLACK ANDREW W;;CHAKRAVARTY JOYDIP;;FOLKEN KEITH;;SLAUGHTER NELSON,SCHROEDER EDWARD M;;BLACK ANDREW W;;CHAKRAVARTY JOYDIP;;FOLKEN KEITH;;SLAUGHTER NELSON,,https://lens.org/112-994-258-505-327,Search Report,yes,4,0,10,10,0,F02D29/06;;F02D29/06;;F02D29/06;;F01D15/10;;F01D15/10;;F02B63/04;;F02C9/26;;F02C9/26;;F02D41/30;;F02M51/02;;F02M51/02;;F02M51/02;;Y10T137/86147;;Y10T137/86147,F02B63/04;;F02D29/06;;F02D41/30;;F02M51/02,,0,0,,,,PENDING
383,DE,A1,DE 2926764 A1,173-504-466-720-935,1980-01-17,1980,DE 2926764 A,1979-07-03,US 92202978 A,1978-07-05,ZUFUEHRUNGSVORRICHTUNG ZUM MATTENFOERMIGEN ZUFUEHREN VON ERNTEGUT ZU EINEM SCHNEID- ODER ZERKLEINERUNGSKOPF,,DEERE & CO,LAWRENCE ALLAN KEITH;;BASS MERLYN DUANE;;BLACK ROBERT DELNO;;KRAFKA JERRY LEE,"DEERE & COMPANY, MOLINE, ILL., US (1998-07-02)",https://lens.org/173-504-466-720-935,Patent Application,no,3,0,21,21,0,A01F29/10;;A01F29/10,A01D43/08;;A01F29/00;;A01F29/10,,0,0,,,,EXPIRED
384,EP,B1,EP 1397246 B1,196-414-990-150-444,2006-03-08,2006,EP 01991242 A,2001-12-13,US 0148902 W;;US 25584200 P,2000-12-15,FLAME-RETARDANT IMAGED NONWOVEN FABRIC,,POLYMER GROUP INC,HARTGROVE HERBERT;;DE LEON SERGIO DIAZ;;BLACK SAMUEL KEITH;;HIJENGA FRISO JOOST,,https://lens.org/196-414-990-150-444,Granted Patent,yes,8,0,12,12,0,D06M15/248;;D06M15/263;;D06M15/564;;D06M2200/30;;Y10S428/92;;Y10S428/921;;D04H1/4266;;D04H1/43;;D04H1/4342;;D04H1/435;;D04H1/49;;D04H1/495;;D04H18/04;;D04H1/587;;D04H1/64;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D04H1/43835;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D06M15/248;;D06M15/564;;D06M2200/30;;D06M15/263;;Y10S428/921;;Y10S428/92;;D04H1/435;;D04H1/4266;;D04H18/04;;D04H1/64;;D04H1/495;;D04H1/4342;;D04H1/43;;D04H1/49;;D04H1/587;;D04H1/43835,B32B27/04;;B27N9/00;;B32B27/12;;D04H1/42;;D04H1/46;;D04H1/64;;D04H13/00;;D06M15/248;;D06M15/263;;D06M15/564,,0,0,,,,EXPIRED
385,EP,A1,EP 3423096 A1,113-356-166-799-858,2019-01-09,2019,EP 17760901 A,2017-03-03,US 201662303845 P;;US 2017/0020666 W,2016-03-04,POLYMALIC ACID BASED NANOIMMUNOCONJUGATES AND USES THEREOF,,CEDARS SINAI MEDICAL CENTER,LJUBIMOVA JULIA Y;;BLACK KEITH L;;HOLLER EGGEHARD;;LJUBIMOV ALEXANDER;;DING HUI,,https://lens.org/113-356-166-799-858,Patent Application,yes,0,0,11,11,8,A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/6849;;A61K47/6813;;A61K47/6807;;A61K47/593;;A61K47/6851;;A61K47/6883;;A61K47/6935;;A61P35/00;;A61K31/7088;;A61K39/3955;;A61K45/06;;A61K45/06;;A61K47/593;;A61K47/6883;;A61K9/0019;;A61K47/6813;;A61K47/6849;;A61K47/6807;;A61K47/6851;;A61P35/00;;A61K31/7105;;A61K47/10;;A61K47/183,A61K39/395;;A61K31/713;;A61K38/16;;A61K38/19;;A61K47/10;;A61P35/00;;A61P35/04,,0,0,,,,DISCONTINUED
386,EP,A4,EP 2323696 A4,125-386-070-080-323,2014-10-01,2014,EP 09815306 A,2009-09-18,US 2009/0057569 W;;US 9820608 P,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE,,CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L;;KORONYO YOSEF,,https://lens.org/125-386-070-080-323,Search Report,no,2,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,4,3,101-039-368-580-34X;;011-124-388-694-014;;168-962-786-537-184,10.1111/j.1747-0285.2007.00557.x;;17718715;;17472706;;10.1111/j.1471-4159.2007.04613.x;;pmc2991559;;10.1016/j.neuroimage.2010.06.020;;20550967,"ASHLEY A. REINKE ET AL: ""Structure?activity Relationships of Amyloid Beta-aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibility"", CHEMICAL BIOLOGY & DRUG DESIGN, vol. 70, no. 3, 1 September 2007 (2007-09-01), pages 206 - 215, XP055135629, ISSN: 1747-0277, DOI: 10.1111/j.1747-0285.2007.00557.x;;M. GARCIA-ALLOZA ET AL: ""Curcumin labels amyloid pathology in�vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model"", JOURNAL OF NEUROCHEMISTRY, vol. 102, no. 4, 1 August 2007 (2007-08-01), pages 1095 - 1104, XP055054058, ISSN: 0022-3042, DOI: 10.1111/j.1471-4159.2007.04613.x;;MAYA KORONYO-HAMAOUI ET AL: ""Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasiveoptical imaging of retinal plaques in a mouse model"", NEUROIMAGE, ACADEMIC PRESS, ORLANDO, FL, US, vol. 54, 7 June 2010 (2010-06-07), pages S204 - S217, XP028230298, ISSN: 1053-8119, [retrieved on 20100613], DOI: 10.1016/J.NEUROIMAGE.2010.06.020;;See also references of WO 2010033861A1",ACTIVE
387,GB,B,GB 2492034 B,141-526-889-984-648,2016-11-02,2016,GB 201219001 A,2011-03-25,US 31788210 P;;US 2011/0029902 W,2010-03-26,Genset fuel transfer system and method,,CATERPILLAR INC,EDWARD MAURER SCHROEDER;;ANDREW W BLACK;;JOYDIP CHAKRAVARTY;;KEITH FOLKEN;;NELSON SLAUGHTER,,https://lens.org/141-526-889-984-648,Granted Patent,no,4,0,10,10,0,F02D29/06;;F02D29/06;;F02D29/06;;F01D15/10;;F01D15/10;;F02B63/04;;F02C9/26;;F02C9/26;;F02D41/30;;F02M51/02;;F02M51/02;;F02M51/02;;Y10T137/86147;;Y10T137/86147,F02D29/06;;F02B63/04;;F02D41/30;;F02M51/02,,0,0,,,,ACTIVE
388,CA,A1,CA 2700579 A1,158-412-065-739-73X,2008-04-03,2008,CA 2700579 A,2007-09-28,US 82726006 P;;US 2007/0079846 W,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;ZHU HUI PH D;;BLACK KEITH L,,https://lens.org/158-412-065-739-73X,Patent Application,no,0,0,17,17,62,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/385;;A61K35/12;;A61K39/00;;A61K47/46;;A61P35/00;;C12N5/0784,,0,0,,,,DISCONTINUED
389,TR,T4,TR 201816335 T4,053-466-511-178-87X,2018-11-21,2018,TR 201816335 T,2009-09-18,US 9820608 P,2008-09-18,Alzheimer hastalığının tespitine yönelik optik yöntem.,"Mevcut konu, amiloid plaklarının gelişimi, miktarı ve lokasyonu gibi Alzheimer hastalığına (AD) özel olan erken patolojik olayların izlenmesine yönelik noninvazif bir optik görüntüleme yöntemi ile ilgilidir. Bu tür olayları izleme yeteneği, diğerlerinin yanı sıra AD teşhisi, prognozu ve potansiyel terapilerin değerlendirmesine yönelik bir temel sağlar. Ayrıca mevcut konu, AD'nin ve AD ile ilişkili retinal rahatsızlıkların tedavi edilmesine yönelik yeni yöntemler katar. Canlı beyinlerde Aß-plak tespiti, özellikle yüksek çözünürlükte oldukça sınırlıdır; bu nedenle mevcut buluş, doğrudan, tekrarlı olarak ve noninvazif bir şekilde görüntülenebilen beyin türevli dokuya bir alternatif olarak gözler üzerine odaklanan çalışmalara dayanır.",CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,MAYA KORONYO;;KEITH L BLACK;;MICHAL SCHWARTZ;;DANIEL L FARKAS;;YOSEF KORONYO,,https://lens.org/053-466-511-178-87X,Granted Patent,no,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,0,0,,,,ACTIVE
390,CA,A1,CA 2735869 A1,099-047-937-096-268,2010-03-25,2010,CA 2735869 A,2009-09-18,US 9820608 P;;US 2009/0057569 W,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE,"The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aß-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.",CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L;;KORONYO YOSEF,,https://lens.org/099-047-937-096-268,Patent Application,no,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,0,0,,,,ACTIVE
391,EP,B1,EP 2323696 B1,112-359-043-111-918,2018-09-05,2018,EP 09815306 A,2009-09-18,US 2009/0057569 W;;US 9820608 P,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE,,CEDARS SINAI MEDICAL CENTER;;YEDA RES & DEV,KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L;;KORONYO YOSEF,,https://lens.org/112-359-043-111-918,Granted Patent,yes,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,2,2,047-248-975-491-255;;062-121-843-455-012,17999464;;10.1021/mp700113r;;10.1167/iovs.03-0505;;15037592,"ANAND P ET AL: ""Bioavailability of curcumin: Problems and promises"", MOLECULAR PHARMACEU, AMERICAN CHEMICAL SOCIETY, US, vol. 4, no. 6, 1 November 2007 (2007-11-01), pages 807 - 818, XP008114486, ISSN: 1543-8384, [retrieved on 20071114], DOI: 10.1021/MP700113R;;HOSOYA ET AL.: ""Vitamin C transport in oxidized form across the rat blood-retinal barrier."", INVEST. OPTHALMOL. VIS. SCI., vol. 45, no. 4, 2004, pages 1232 - 1239",ACTIVE
392,MX,A,MX 2011002930 A,137-138-386-258-848,2011-10-11,2011,MX 2011002930 A,2009-09-18,US 9820608 P;;US 2009/0057569 W,2008-09-18,OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE.,"The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. AÎ²-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.",CEDARS SINAI MEDICAL CENTER,KORONYO YOSEF;;KORONYO MAYA;;BLACK KEITH L;;SCHWARTZ MICHAL;;FARKAS DANIEL L,,https://lens.org/137-138-386-258-848,Patent Application,no,0,0,29,29,0,A61K49/006;;A61K49/0021;;A61P25/28;;A61P27/02;;A61P27/06;;A61P27/12;;A61P9/10;;A61K49/0021;;A61K49/006;;G01N33/6896;;G01N33/582;;G01N2333/4709;;G01N2800/52;;A61K49/006;;A61K49/0004;;A61K49/0056;;A61K31/404;;A61K31/4965;;A61K49/0032;;A61K31/5377;;A61K31/496;;A61K31/437;;G01N33/5008;;A61B3/0025;;A61B3/102;;G01N2333/4709;;A61B3/14;;A61B5/4088;;G01N33/5082;;G01N2800/2821;;G01N33/5091;;G01N2800/28;;G01N2800/52;;A61B6/037;;C07D401/14;;A61B5/7264;;A61B6/506;;A61K49/0021,A61K49/00;;C12Q1/00,,0,0,,,,ACTIVE
393,US,A1,US 2002/0151238 A1,097-331-215-402-943,2002-10-17,2002,US 2145601 A,2001-12-13,US 2145601 A;;US 25584200 P,2000-12-15,Flame-retardant imaged nonwoven fabric,"
   A method of forming flame-retardant nonwoven fabrics by hydroentanglement includes providing a precursor web. The precursor web is subjected to hydroentanglement on a three-dimensional image transfer device to create a patterned and imaged fabric. Treatment with a flame-retardant binder enhances the integrity of the fabric, permitting the nonwoven to exhibit desired physical characteristics, including strength, durability, softness, and drapeability. The treated nonwoven may then be dyed by means applicable to conventional wovens. 
",HARTGROVE HERBERT PARKS;;DE LEON SERGIO DIAZ;;BLACK SAMUEL KEITH;;HIJENGA FRISO JOOST,HARTGROVE HERBERT PARKS;;DE LEON SERGIO DIAZ;;BLACK SAMUEL KEITH;;HIJENGA FRISO JOOST,AVINTIV SPECIALTY MATERIALS INC (2002-02-08),https://lens.org/097-331-215-402-943,Patent Application,yes,16,3,12,12,0,D06M15/248;;D06M15/263;;D06M15/564;;D06M2200/30;;Y10S428/92;;Y10S428/921;;D04H1/4266;;D04H1/43;;D04H1/4342;;D04H1/435;;D04H1/49;;D04H1/495;;D04H18/04;;D04H1/587;;D04H1/64;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D04H1/43835;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D06M15/248;;D06M15/564;;D06M2200/30;;D06M15/263;;Y10S428/921;;Y10S428/92;;D04H1/435;;D04H1/4266;;D04H18/04;;D04H1/64;;D04H1/495;;D04H1/4342;;D04H1/43;;D04H1/49;;D04H1/587;;D04H1/43835,D04H1/42;;D04H1/46;;D04H1/64;;D04H13/00;;D06M15/248;;D06M15/263;;D06M15/564,442/136;;442/327;;442/384;;427/389.9,0,0,,,,EXPIRED
394,AU,A,AU 2002/030982 A,151-827-877-879-818,2002-06-24,2002,AU 2002/030982 A,2001-12-13,US 25584200 P;;US 0148902 W,2000-12-15,Flame-retardant imaged nonwoven fabric,,POLYMER GROUP INC,HARTGROVE HERBERT PARKS;;LEON SERGIO DIAZ DE;;BLACK SAMUEL KEITH;;HIJENGA FRISO JOOST,,https://lens.org/151-827-877-879-818,Patent Application,no,0,0,12,12,0,D06M15/248;;D06M15/263;;D06M15/564;;D06M2200/30;;Y10S428/92;;Y10S428/921;;D04H1/4266;;D04H1/43;;D04H1/4342;;D04H1/435;;D04H1/49;;D04H1/495;;D04H18/04;;D04H1/587;;D04H1/64;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D04H1/43835;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D06M15/248;;D06M15/564;;D06M2200/30;;D06M15/263;;Y10S428/921;;Y10S428/92;;D04H1/435;;D04H1/4266;;D04H18/04;;D04H1/64;;D04H1/495;;D04H1/4342;;D04H1/43;;D04H1/49;;D04H1/587;;D04H1/43835,D04H1/42;;D04H1/46;;D04H1/64;;D04H13/00;;D06M15/248;;D06M15/263;;D06M15/564,,0,0,,,,PENDING
395,CA,A1,CA 2771398 A1,194-011-110-666-487,2011-03-10,2011,CA 2771398 A,2010-08-31,US 27582509 P;;US 28690909 P;;US 2010/0047260 W,2009-09-03,BED BUG CAPTURING DEVICE,The present invention relates to a bed bug capturing device comprising: (a) a bed bug attractant element; and (b) a deadfall capturing element comprising at least one pathway comprising: (i) an upwardly sloped segment; (ii) a downwardly sloped segment having an outer portion; and (iii) a deadfall trap area: characterized in that the upwardly sloped segment and at least the outer portion of the downwardly sloped segment possesses an average surface roughness of at least about 2.5 micrometers.,FMC CORP,BLACK BRUCE C;;SHAH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;SHETH SHREYA,,https://lens.org/194-011-110-666-487,Patent Application,no,0,0,8,8,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/02;;A01M1/02;;A01M1/10;;A01M1/2011;;A01M1/2011;;A01M2200/011;;A01M2200/011;;A01N31/02;;A01N35/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01N35/02,,0,0,,,,DISCONTINUED
396,EP,A4,EP 1397246 A4,057-719-121-371-939,2004-07-21,2004,EP 01991242 A,2001-12-13,US 0148902 W;;US 25584200 P,2000-12-15,FLAME-RETARDANT IMAGED NONWOVEN FABRIC,,POLYMER GROUP INC,HARTGROVE HERBERT PARKS;;DE LEON SERGIO DIAZ;;BLACK SAMUEL KEITH;;HIJENGA FRISO JOOST,,https://lens.org/057-719-121-371-939,Search Report,no,5,0,12,12,0,D06M15/248;;D06M15/263;;D06M15/564;;D06M2200/30;;Y10S428/92;;Y10S428/921;;D04H1/4266;;D04H1/43;;D04H1/4342;;D04H1/435;;D04H1/49;;D04H1/495;;D04H18/04;;D04H1/587;;D04H1/64;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D04H1/43835;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D06M15/248;;D06M15/564;;D06M2200/30;;D06M15/263;;Y10S428/921;;Y10S428/92;;D04H1/435;;D04H1/4266;;D04H18/04;;D04H1/64;;D04H1/495;;D04H1/4342;;D04H1/43;;D04H1/49;;D04H1/587;;D04H1/43835,D04H1/42;;D04H1/46;;D04H1/64;;D04H13/00;;D06M15/248;;D06M15/263;;D06M15/564,,1,0,,,See also references of WO 0247907A1,EXPIRED
397,US,B2,US 7188397 B2,059-997-483-763-318,2007-03-13,2007,US 13202705 A,2005-05-18,US 13202705 A;;US 2145601 A;;US 25584200 P,2000-12-15,Flame-retardant imaged nonwoven fabric,"A method of forming flame-retardant nonwoven fabrics by hydroentanglement includes providing a precursor web. The precursor web is subjected to hydroentanglement on a three-dimensional image transfer device to create a patterned and imaged fabric. Treatment with a flame-retardant binder enhances the integrity of the fabric, permitting the nonwoven to exhibit desired physical characteristics, including strength, durability, softness, and drapeability. The treated nonwoven may then be dyed by means applicable to conventional wovens.",POLYMER GROUP INC,HARTGROVE HERBERT PARKS;;DE LEON SERGIO DIAZ;;BLACK SAMUEL KEITH;;HIJENGA FRISO JOOST,AVINTIV SPECIALTY MATERIALS INC (2015-06-04),https://lens.org/059-997-483-763-318,Granted Patent,yes,22,5,12,12,0,D06M15/248;;D06M15/263;;D06M15/564;;D06M2200/30;;Y10S428/92;;Y10S428/921;;D04H1/4266;;D04H1/43;;D04H1/4342;;D04H1/435;;D04H1/49;;D04H1/495;;D04H18/04;;D04H1/587;;D04H1/64;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D04H1/43835;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D06M15/248;;D06M15/564;;D06M2200/30;;D06M15/263;;Y10S428/921;;Y10S428/92;;D04H1/435;;D04H1/4266;;D04H18/04;;D04H1/64;;D04H1/495;;D04H1/4342;;D04H1/43;;D04H1/49;;D04H1/587;;D04H1/43835,D06C23/00;;B32B5/26;;B32B7/08;;D04H1/42;;D04H1/46;;D04H1/64;;D04H13/00;;D06M15/248;;D06M15/263;;D06M15/564,28/104;;427/389.9;;442/408;;442/146;;428/172;;428/920;;428/921,1,0,,,"PCT International Search Report, PCT/US01/48902, mailed May 6, 2002.",EXPIRED
398,WO,A1,WO 2002/047907 A1,051-226-351-661-321,2002-06-20,2002,US 0148902 W,2001-12-13,US 25584200 P,2000-12-15,FLAME-RETARDANT IMAGED NONWOVEN FABRIC,"A method of forming flame-retardant nonwoven fabrics by hydroentanglement (14 and 22) includes providing a precursor web. The precursor web is subjected to hydroentanglement on a three-dimensional image transfer device (18) to create a patterned and imaged fabric. Treatment with a flame-retardant binder enhances the integrity of the fabric, permitting the nonwoven to exhibit desired physical characteristics, including strength, durability, softness, and drapeability. The treated nonwoven may then be dyed by means applicable to conventional wovens.",POLYMER GROUP INC,HARTGROVE HERBERT PARKS;;DE LEON SERGIO DIAZ;;BLACK SAMUEL KEITH;;HIJENGA FRISO JOOST,,https://lens.org/051-226-351-661-321,Patent Application,yes,3,3,12,12,0,D06M15/248;;D06M15/263;;D06M15/564;;D06M2200/30;;Y10S428/92;;Y10S428/921;;D04H1/4266;;D04H1/43;;D04H1/4342;;D04H1/435;;D04H1/49;;D04H1/495;;D04H18/04;;D04H1/587;;D04H1/64;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D04H1/43835;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D06M15/248;;D06M15/564;;D06M2200/30;;D06M15/263;;Y10S428/921;;Y10S428/92;;D04H1/435;;D04H1/4266;;D04H18/04;;D04H1/64;;D04H1/495;;D04H1/4342;;D04H1/43;;D04H1/49;;D04H1/587;;D04H1/43835,D04H1/42;;D04H1/46;;D04H1/64;;D04H13/00;;D06M15/248;;D06M15/263;;D06M15/564,,1,0,,,See also references of EP 1397246A4,PATENTED
399,CA,A1,CA 2431803 A1,131-025-763-018-163,2002-06-20,2002,CA 2431803 A,2001-12-13,US 25584200 P;;US 0148902 W,2000-12-15,FLAME-RETARDANT IMAGED NONWOVEN FABRIC,"A method of forming flame-retardant nonwoven fabrics by hydroentanglement (1 4 and 22) includes providing a precursor web. The precursor web is subjected t o hydroentanglement on a three-dimensional image transfer device (18) to creat e a patterned and imaged fabric. Treatment with a flame-retardant binder enhances the integrity of the fabric, permitting the nonwoven to exhibit desired physical characteristics, including strength, durability, softness, and drapeability. The treated nonwoven may then be dyed by means applicable to conventional wovens.",POLYMER GROUP INC,DE LEON SERGIO DIAZ;;BLACK SAMUEL KEITH;;HIJENGA FRISO JOOST;;HARTGROVE HERBERT PARKS,,https://lens.org/131-025-763-018-163,Patent Application,no,0,0,12,12,0,D06M15/248;;D06M15/263;;D06M15/564;;D06M2200/30;;Y10S428/92;;Y10S428/921;;D04H1/4266;;D04H1/43;;D04H1/4342;;D04H1/435;;D04H1/49;;D04H1/495;;D04H18/04;;D04H1/587;;D04H1/64;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D04H1/43835;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D06M15/248;;D06M15/564;;D06M2200/30;;D06M15/263;;Y10S428/921;;Y10S428/92;;D04H1/435;;D04H1/4266;;D04H18/04;;D04H1/64;;D04H1/495;;D04H1/4342;;D04H1/43;;D04H1/49;;D04H1/587;;D04H1/43835,D04H1/42;;D04H1/46;;D04H1/64;;D04H13/00;;D06M15/248;;D06M15/263;;D06M15/564,,0,0,,,,DISCONTINUED
400,EP,A1,EP 1397246 A1,150-341-832-244-011,2004-03-17,2004,EP 01991242 A,2001-12-13,US 0148902 W;;US 25584200 P,2000-12-15,FLAME-RETARDANT IMAGED NONWOVEN FABRIC,,POLYMER GROUP INC,HARTGROVE HERBERT PARKS;;DE LEON SERGIO DIAZ;;BLACK SAMUEL KEITH;;HIJENGA FRISO JOOST,,https://lens.org/150-341-832-244-011,Patent Application,yes,0,0,12,12,0,D06M15/248;;D06M15/263;;D06M15/564;;D06M2200/30;;Y10S428/92;;Y10S428/921;;D04H1/4266;;D04H1/43;;D04H1/4342;;D04H1/435;;D04H1/49;;D04H1/495;;D04H18/04;;D04H1/587;;D04H1/64;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D04H1/43835;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D06M15/248;;D06M15/564;;D06M2200/30;;D06M15/263;;Y10S428/921;;Y10S428/92;;D04H1/435;;D04H1/4266;;D04H18/04;;D04H1/64;;D04H1/495;;D04H1/4342;;D04H1/43;;D04H1/49;;D04H1/587;;D04H1/43835,D04H1/42;;D04H1/46;;D04H1/64;;D04H13/00;;D06M15/248;;D06M15/263;;D06M15/564,,0,0,,,,EXPIRED
401,US,B2,US 6930064 B2,055-678-438-864-909,2005-08-16,2005,US 2145601 A,2001-12-13,US 2145601 A;;US 25584200 P,2000-12-15,Flame-retardant imaged nonwoven fabric,"A method of forming flame-retardant nonwoven fabrics by hydroentanglement includes providing a precursor web. The precursor web is subjected to hydroentanglement on a three-dimensional image transfer device to create a patterned and imaged fabric. Treatment with a flame-retardant binder enhances the integrity of the fabric, permitting the nonwoven to exhibit desired physical characteristics, including strength, durability, softness, and drapeability. The treated nonwoven may then be dyed by means applicable to conventional wovens.",POLYMER GROUP INC,HARTGROVE HERBERT PARKS;;DE LEON SERGIO DIAZ;;BLACK SAMUEL KEITH;;HIJENGA FRISO JOOST,AVINTIV SPECIALTY MATERIALS INC (2002-02-08),https://lens.org/055-678-438-864-909,Granted Patent,yes,21,6,12,12,0,D06M15/248;;D06M15/263;;D06M15/564;;D06M2200/30;;Y10S428/92;;Y10S428/921;;D04H1/4266;;D04H1/43;;D04H1/4342;;D04H1/435;;D04H1/49;;D04H1/495;;D04H18/04;;D04H1/587;;D04H1/64;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D04H1/43835;;Y10T428/24612;;Y10T442/60;;Y10T442/2713;;Y10T442/2861;;Y10T442/663;;Y10T442/2631;;Y10T442/689;;D06M15/248;;D06M15/564;;D06M2200/30;;D06M15/263;;Y10S428/921;;Y10S428/92;;D04H1/435;;D04H1/4266;;D04H18/04;;D04H1/64;;D04H1/495;;D04H1/4342;;D04H1/43;;D04H1/49;;D04H1/587;;D04H1/43835,D04H1/42;;D04H1/46;;D04H1/64;;D04H13/00;;D06M15/248;;D06M15/263;;D06M15/564,442/146;;442/164;;442/408;;172/920;;172/921,1,0,,,"PCT International Search Report, PCT/US01/48902, mailed May 6, 2002.",EXPIRED
402,US,S,US D0791184 S,039-151-018-729-363,2017-07-04,2017,US 201529533457 F,2015-07-17,US 201529533457 F;;US 201329448539 F,2013-03-13,Portion of a display screen with an animated computer generated icon,,CATERPILLAR INC,FOLKEN KEITH R;;MEINHART MATTHEW J;;SCHROEDER EDWARD M;;OLSEN ERIK L;;BLACK ANDREW,,https://lens.org/039-151-018-729-363,Design Right,no,0,12,2,2,0,,,1404;;D14/492,0,0,,,,ACTIVE
403,DE,T5,DE 112013005803 T5,060-867-421-921-296,2015-11-12,2015,DE 112013005803 T,2013-12-03,US 201261733372 P;;US 201313843279 A;;US 2013/0072903 W,2012-12-04,Kompakte Entfeuchter und zugehörige Systeme und Verfahren,"Es werden kompakte Entfeuchter und zugehörige Systeme und Verfahren offenbart. Ein repräsentatives System beinhaltet ein Gehäuse, das einen Luftstromeinlass und einen Luftstromauslass und einen linearen Strömungsweg zwischen dem Einlass und dem Auslass beinhaltet. Das System beinhaltet des Weiteren einen Kältekreislauf, der entlang des Strömungsweges der Reihe nach einen Verdampfer, einen Kompressor, einen Kondensator und einen Luftstromtreiber aufweist. Eine Steuereinheit ist funktionsmäßig so mit dem Verdampfer, dem Kompressor, dem Kondensator und dem Luftstromtreiber verbunden, dass sie den Kältekreislauf so betreibt, dass Feuchtigkeit aus einem eintretenden Luftstrom entfernt wird.",DRI EAZ PRODUCTS INC,HOFFMANN KEITH;;BRUDERS WILLIAM;;WHITE LARRY;;BARTHOLMEY BRETT;;BLACK RICHARD A;;KIESSER MATTHEW AARON,,https://lens.org/060-867-421-921-296,Patent Application,no,0,0,9,9,0,F24F13/20;;F24F2003/144;;F24F2221/12;;F24F3/14;;Y10T29/49359;;F24F1/02;;F24F3/14;;F24F13/02;;F24F13/20;;F24F2221/12;;F24F2003/144;;Y10T29/49359;;F24F3/14;;Y10T29/49359;;F24F13/20;;F24F2003/144;;F24F2221/12,F24F1/02;;F24F13/02;;F24F13/20,,0,0,,,,DISCONTINUED
404,CA,A1,CA 2891907 A1,025-250-844-957-793,2014-06-12,2014,CA 2891907 A,2013-12-03,US 201261733372 P;;US 201313843279 A;;US 2013/0072903 W,2012-12-04,COMPACT DEHUMIDIFIERS AND ASSOCIATED SYSTEMS AND METHODS,"Compact dehumidifiers and associated systems and methods are disclosed. A representative system includes a housing having an airflow entrance, and airflow exit, and a linear flowpath between the entrance and exit. The system further includes a refrigeration cycle having, in sequence along the flowpath, an evaporator, a compressor, a condenser, and an air flow driver. A controller is operatively coupled to the evaporator, compressor, condenser, and airflow driver to operate the refrigeration cycle for removing moisture from an entering airflow.",DRI EAZ PRODUCTS INC,BLACK RICHARD A;;HOFFMAN KEITH;;BRUDERS WILLIAM;;WHITE LARRY;;BARTHOLMEY BRETT;;KIESSER AARON MATTHEW,,https://lens.org/025-250-844-957-793,Patent Application,no,0,0,9,9,0,F24F13/20;;F24F2003/144;;F24F2221/12;;F24F3/14;;Y10T29/49359;;F24F1/02;;F24F3/14;;F24F13/02;;F24F13/20;;F24F2221/12;;F24F2003/144;;Y10T29/49359;;F24F3/14;;Y10T29/49359;;F24F13/20;;F24F2003/144;;F24F2221/12,F24F1/02;;F24F13/02;;F24F13/20,,0,0,,,,DISCONTINUED
405,WO,A3,WO 2005/060596 A3,082-375-160-830-288,2007-01-25,2007,US 2004/0040927 W,2004-12-07,US 73747303 A,2003-12-16,A TRANSMITTER FOR MODULATION DISTORTION COMPENSATION,"A transmitter circuit (200, 400, 510) includes a power control error data generator (230), a feedforward predistortion data generation (240), feedforward adder logic (250) and the amplifier (210).",MOTOROLA INC;;NAGODE THOMAS D;;NANNI PETER;;NIGRA LOUIS M;;BLACK GREG R;;TILLEY KEITH ANDREW,NAGODE THOMAS D;;NANNI PETER;;NIGRA LOUIS M;;BLACK GREG R;;TILLEY KEITH ANDREW,,https://lens.org/082-375-160-830-288,Search Report,yes,2,0,9,9,0,H03C1/06;;H03C3/0975;;H03F2200/102;;H03F2200/105;;H03F2201/3221;;H03F2201/3227;;H04B1/04;;H04B2001/0416;;H04B2001/0433;;H04B2001/0441;;H03F1/34;;H03F1/3223;;H03F3/24;;H03F1/3241;;H04B2001/0416;;H04B1/04;;H03F2201/3227;;H04B2001/0441;;H03F2200/102;;H03F2201/3221;;H03C1/06;;H03C3/0975;;H03F2200/105;;H04B2001/0433,H04B1/04;;H03C1/06;;H03C3/09;;H03F1/32,,0,0,,,,PENDING
406,US,S,US D0737318 S,152-702-784-881-553,2015-08-25,2015,US 201329448539 F,2013-03-13,US 201329448539 F,2013-03-13,Portion of a display screen with an animated computer generated icon,,CATERPILLAR INC,FOLKEN KEITH R;;MEINHART MATTHEW J;;SCHROEDER EDWARD M;;OLSEN ERIK L;;BLACK ANDREW,CATERPILLAR INC (2013-03-12),https://lens.org/152-702-784-881-553,Design Right,no,0,6,2,2,0,,,1404;;D14/489,0,0,,,,ACTIVE
407,WO,A3,WO 2008/039974 A3,062-525-445-941-411,2008-07-17,2008,US 2007/0079857 W,2007-09-28,US 82726006 P,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",CEDARS SINAI MEDICAL CENTER;;TORREY PINES INST;;YU JOHN S;;LIU GENTAO;;ZHU HUI PH D;;PINILLA CLEMENCIA;;BLACK KEITH L,YU JOHN S;;LIU GENTAO;;ZHU HUI PH D;;PINILLA CLEMENCIA;;BLACK KEITH L,,https://lens.org/062-525-445-941-411,Search Report,yes,0,0,17,17,0,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K35/12;;A61K35/00;;A61K39/00;;C12N15/85;;C12N15/86,,3,3,014-782-564-302-045;;045-609-027-418-523;;128-972-796-335-47X,10.1016/j.vaccine.2006.02.025;;16530303;;pmc1850619;;10.3892/or.16.6.1317;;17089056;;10.1016/j.exphem.2006.05.011;;16982333,"WANG ET AL.: ""An effective cancer vacciene modality: lenticiral modification of dendritic cells expressing multiple cancer-specific antigens"", VACCINE, vol. 24, no. 17, 24 April 2006 (2006-04-24), pages 3477 - 3489;;YASUDA ET AL.: ""Dendritic cell-tumor ceel hybrids enhance the inducation of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells"", ONCOL. REP., vol. 16, no. 6, December 2006 (2006-12-01), pages 1317 - 1324;;WEIGEL ET AL.: ""Dendritic cells pulsed with AML cellular antigen provide comparable in vivo antitumor protective responses"", EXP HEMATOL., vol. 34, no. 10, October 2006 (2006-10-01), pages 1403 - 1412, XP025017585, DOI: doi:10.1016/j.exphem.2006.05.011",PENDING
408,EP,A1,EP 2573244 A1,081-025-971-920-432,2013-03-27,2013,EP 12006446 A,2012-09-14,EP 11007649 A;;EP 12006446 A,2011-09-20,Sound absorbing material,"Die Erfindung betrifft ein Schallabsorptionsmaterial umfassend einen Vliesstoff, der mindestens zwei Polymere enthält, wobei der Schmelzpunkt mindestens eines ersten Polymers über dem Schmelzpunkt mindestens eines zweiten Polymers liegt und wobei das erste Polymer in Form von Elementarsegmenten vorliegt, die in einer Matrix aus dem zweiten Polymer verteilt sind. Das erfindungsgemäße Schallabsorptionsmaterial weist bei geringen Dicken einen guten Luftschallabsorptionsgrad und Einzahlwert auf,",FREUDENBERG CARL KG,RUTSCH PETER DR;;GROTEN ROBERT DR;;BLACK SAMUEL KEITH;;BOLD ANKE DR;;JESTEL FRANK,,https://lens.org/081-025-971-920-432,Patent Application,yes,2,1,7,7,0,D04H3/14;;D04H3/005;;D04H3/153,D04H3/14;;D04H3/005;;D04H3/153;;E04B1/72,,0,0,,,,ACTIVE
409,AU,A1,AU 2013/355405 A1,137-813-039-867-530,2015-05-28,2015,AU 2013/355405 A,2013-12-03,US 201313843279 A;;US 201261733372 P;;US 2013/0072903 W,2012-12-04,Compact dehumidifiers and associated systems and methods,"Compact dehumidifiers and associated systems and methods are disclosed. A representative system includes a housing having an airflow entrance, and airflow exit, and a linear flowpath between the entrance and exit. The system further includes a refrigeration cycle having, in sequence along the flowpath, an evaporator, a compressor, a condenser, and an air flow driver. A controller is operatively coupled to the evaporator, compressor, condenser, and airflow driver to operate the refrigeration cycle for removing moisture from an entering airflow.",DRI EAZ PRODUCTS INC,BLACK RICHARD A;;HOFFMAN KEITH;;BRUDERS WILLIAM;;WHITE LARRY;;BARTHOLMEY BRETT;;KIESSER AARON MATTHEW,,https://lens.org/137-813-039-867-530,Patent Application,no,0,0,9,9,0,F24F13/20;;F24F2003/144;;F24F2221/12;;F24F3/14;;Y10T29/49359;;F24F1/02;;F24F3/14;;F24F13/02;;F24F13/20;;F24F2221/12;;F24F2003/144;;Y10T29/49359;;F24F3/14;;Y10T29/49359;;F24F13/20;;F24F2003/144;;F24F2221/12,F24F1/02;;F24F13/02;;F24F13/20,,0,0,,,,DISCONTINUED
410,MX,A,MX 2015007119 A,035-800-165-973-763,2016-03-07,2016,MX 2015007119 A,2013-12-03,US 201261733372 P;;US 201313843279 A;;US 2013/0072903 W,2012-12-04,COMPACT DEHUMIDIFIERS AND ASSOCIATED SYSTEMS AND METHODS.,"Compact dehumidifiers and associated systems and methods are disclosed. A representative system includes a housing having an airflow entrance, and airflow exit, and a linear flowpath between the entrance and exit. The system further includes a refrigeration cycle having, in sequence along the flowpath, an evaporator, a compressor, a condenser, and an air flow driver. A controller is operatively coupled to the evaporator, compressor, condenser, and airflow driver to operate the refrigeration cycle for removing moisture from an entering airflow.",DRI EAZ PRODUCTS INC,BLACK RICHARD A;;HOFFMAN KEITH;;BRUDERS WILLIAM;;WHITE LARRY;;BARTHOLMEY BRETT;;KIESSER AARON MATTHEW,,https://lens.org/035-800-165-973-763,Patent Application,no,0,0,9,9,0,F24F13/20;;F24F2003/144;;F24F2221/12;;F24F3/14;;Y10T29/49359;;F24F1/02;;F24F3/14;;F24F13/02;;F24F13/20;;F24F2221/12;;F24F2003/144;;Y10T29/49359;;F24F3/14;;Y10T29/49359;;F24F13/20;;F24F2003/144;;F24F2221/12,F24F1/02;;F24F13/02;;F24F13/20,,0,0,,,,PENDING
411,US,S,US D0711419 S,038-961-958-287-962,2014-08-19,2014,US 201329448531 F,2013-03-13,US 201329448531 F,2013-03-13,Display screen with animated graphical user interface,,CATERPILLAR INC,FOLKEN KEITH R;;MEINHART MATTHEW J;;SCHROEDER EDWARD M;;OLSEN ERIK L;;BLACK ANDREW,CATERPILLAR INC (2013-03-12),https://lens.org/038-961-958-287-962,Design Right,no,0,27,5,5,0,,,1404;;D14/487,0,0,,,,ACTIVE
412,US,B2,US 6977355 B2,103-315-759-487-442,2005-12-20,2005,US 17153802 A,2002-06-17,US 17153802 A;;GB 9700652 A;;US 34157599 A;;US 69488900 A;;CA 9700854 W,1997-01-14,Tailored blank,The present invention provides a tailored blank having a pair of sheet metal constituent parts each having a pair of oppositely directed major surfaces. The first constituent part has an aperture while the second constituent part has an embossment to fit the aperture. The first and second constituent parts are then secured to one another to form the tailored blank. The blank may then be subsequently formed into a component of varying material characteristics.,DULEY WALTER;;OGMEN MELIH;;HUGHES DAVID;;BLACK GARY KEITH;;MORRIS BRIAN;;STAPLES MICHAEL JAMES,DULEY WALTER;;OGMEN MELIH;;HUGHES DAVID;;BLACK GARY KEITH;;MORRIS BRIAN;;STAPLES MICHAEL JAMES,,https://lens.org/103-315-759-487-442,Granted Patent,yes,34,20,2,22,0,B21D22/00;;B23K26/244;;B23K26/26;;B23K26/242;;B23K26/282;;B23K2101/185;;Y10T428/12486;;Y10T428/12361;;Y10T428/12243;;Y10T428/12229;;Y10T428/12264;;Y10T428/12347;;Y10T428/12486;;Y10T428/12361;;Y10T428/12243;;Y10T428/12229;;Y10T428/12264;;Y10T428/12347;;B21D22/00;;B23K26/244;;B23K26/282;;B23K26/242;;B23K26/26;;B23K2101/185,B21D22/00;;B23K26/20;;B23K26/24,219/121.64;;228/173.6;;428/577;;428/579;;428/582;;428/614,2,0,,,"In Re James H. Casey, No. 7718, United States Court of Customs and Patent Appeals, 54 C.C.P.A. 938; 370 F.2d 576; 1967 CCPA Lexis 416; 152 U.S.P.Q. (BNA) 235, Oral Argument Dec. 7, 1966, Jan. 12, 1967.;;In Re Carl Louis Otto, Lanelle Burham Otto and Joan Briton, No. 6910, United States Court of Sutoms and Patent Appeals, 50C.C.P.A. 938; 312 F.2d 937; 1963 CCPA Lexis 411; 136 U.S.P.Q. (BNA) 458, Oral Argument Jan. 7, 1963, Feb. 13, 1963.",EXPIRED
413,EP,B1,EP 1694285 B1,181-037-519-823-007,2015-02-18,2015,EP 04813268 A,2004-12-07,US 2004/0040927 W;;US 73747303 A,2003-12-16,A TRANSMITTER CIRCUIT AND METHOD FOR MODULATION DISTORTION COMPENSATION,,MOTOROLA MOBILITY LLC,NAGODE THOMAS D;;NANNI PETER;;NIGRA LOUIS M;;BLACK GREG R;;TILLEY KEITH ANDREW,"MOTOROLA MOBILITY, INC. (2011-03-02);;GOOGLE TECHNOLOGY HOLDINGS LLC, US (2016-05-04);;GOOGLE TECHNOLOGY HOLDINGS LLC, MOUNTAIN VIEW, US (2016-03-02);;MOTOROLA MOBILITY LLC (2012-08-22)",https://lens.org/181-037-519-823-007,Granted Patent,yes,6,0,9,9,0,H03C1/06;;H03C3/0975;;H03F2200/102;;H03F2200/105;;H03F2201/3221;;H03F2201/3227;;H04B1/04;;H04B2001/0416;;H04B2001/0433;;H04B2001/0441;;H03F1/34;;H03F1/3223;;H03F3/24;;H03F1/3241;;H04B2001/0416;;H04B1/04;;H03F2201/3227;;H04B2001/0441;;H03F2200/102;;H03F2201/3221;;H03C1/06;;H03C3/0975;;H03F2200/105;;H04B2001/0433,H04B1/04;;H03C1/06;;H03C3/09;;H03F1/32,,0,0,,,,ACTIVE
414,US,S,US D0737284 S,179-449-396-083-510,2015-08-25,2015,US 201429492173 F,2014-05-29,US 201429492173 F;;US 201329448531 F,2013-03-13,Display screen with graphical user interface,,CATERPILLAR INC,FOLKEN KEITH R;;MEINHART MATTHEW J;;SCHROEDER EDWARD M;;OLSEN ERIK L;;BLACK ANDREW,,https://lens.org/179-449-396-083-510,Design Right,no,0,17,5,5,0,,,1404;;D14/485,0,0,,,,ACTIVE
415,US,S,US D0737287 S,180-918-820-042-887,2015-08-25,2015,US 201429492177 F,2014-05-29,US 201429492177 F;;US 201329448531 F,2013-03-13,Display screen with graphical user interface,,CATERPILLAR INC,FOLKEN KEITH R;;MEINHART MATTHEW J;;SCHROEDER EDWARD M;;OLSEN ERIK L;;BLACK ANDREW,,https://lens.org/180-918-820-042-887,Design Right,no,0,13,5,5,0,,,1404;;D14/485,0,0,,,,ACTIVE
416,US,A1,US 2005/0130609 A1,038-030-865-732-697,2005-06-16,2005,US 73747303 A,2003-12-16,US 73747303 A,2003-12-16,Transmitter circuit and method for modulation distortion compensation,"A transmitter circuit ( 200, 400, 510 ) and method reduces amplitude modulation distortion in an amplifier ( 210 ). The transmitter circuit ( 200, 400, 510 ) includes a power control error data generator ( 230 ), a feedforward predistortion data generator ( 240 ), feedforward adder logic ( 250 ) and the amplifier ( 210 ). The power control error data generator ( 230 ) receives amplitude modulation data ( 252 ) and an RF coupled output signal ( 254 ) and, in response, produces power control error data ( 256 ). The feedforward predistortion data generator ( 240 ) receives the amplitude modulation data ( 252 ) and, in response, produces feedforward predistortion data ( 258 ). The feedforward adder logic ( 250 ) receives the power control error data ( 256 ) and the feedforward predistortion data ( 258 ) and, in response, produces power control data ( 260 ). The amplifier ( 210 ) receives the power control data ( 260 ) and an RF input signal ( 261 ) and, in response, produces an RF output signal ( 262 ), such that the power control data ( 260 ) reduces amplitude modulation distortion in the RF output signal ( 262 ).",MOTOROLA INC,NAGODE THOMAS D;;NANNI PETER;;NIGRA LOUIS M;;BLACK GREG R;;TILLEY KEITH A,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2003-12-16),https://lens.org/038-030-865-732-697,Patent Application,yes,8,30,9,9,0,H03C1/06;;H03C3/0975;;H03F2200/102;;H03F2200/105;;H03F2201/3221;;H03F2201/3227;;H04B1/04;;H04B2001/0416;;H04B2001/0433;;H04B2001/0441;;H03F1/34;;H03F1/3223;;H03F3/24;;H03F1/3241;;H04B2001/0416;;H04B1/04;;H03F2201/3227;;H04B2001/0441;;H03F2200/102;;H03F2201/3221;;H03C1/06;;H03C3/0975;;H03F2200/105;;H04B2001/0433,H03C1/06;;H03C3/09;;H03F1/32;;H04B1/04,455/126,0,0,,,,EXPIRED
417,WO,A1,WO 2014/089102 A1,074-087-814-766-283,2014-06-12,2014,US 2013/0072903 W,2013-12-03,US 201261733372 P;;US 201313843279 A,2012-12-04,COMPACT DEHUMIDIFIERS AND ASSOCIATED SYSTEMS AND METHODS,"Compact dehumidifiers and associated systems and methods are disclosed. A representative system includes a housing having an airflow entrance, and airflow exit, and a linear flowpath between the entrance and exit. The system further includes a refrigeration cycle having, in sequence along the flowpath, an evaporator, a compressor, a condenser, and an air flow driver. A controller is operatively coupled to the evaporator, compressor, condenser, and airflow driver to operate the refrigeration cycle for removing moisture from an entering airflow.",DRI EAZ PRODUCTS INC,BLACK RICHARD A;;HOFFMAN KEITH;;BRUDERS WILLIAM;;WHITE LARRY;;BARTHOLMEY BRETT;;KIESSER AARON MATTHEW,,https://lens.org/074-087-814-766-283,Patent Application,yes,5,0,9,9,0,F24F13/20;;F24F2003/144;;F24F2221/12;;F24F3/14;;Y10T29/49359;;F24F1/02;;F24F3/14;;F24F13/02;;F24F13/20;;F24F2221/12;;F24F2003/144;;Y10T29/49359;;F24F3/14;;Y10T29/49359;;F24F13/20;;F24F2003/144;;F24F2221/12,F24F13/02;;F24F1/02;;F24F13/20,,0,0,,,,PENDING
418,WO,A1,WO 2000/046250 A1,177-757-693-485-85X,2000-08-10,2000,EP 0000751 W,2000-02-01,GB 9902399 A,1999-02-03,BACTERIAL SIGNAL PEPTIDASE INHIBITORS AND USES THEREOF,Substrates for bacterial signal peptidases and their use in assays to detect inhibitors of these enzymes.,SMITHKLINE BEECHAM PLC;;ASHMAN STEPHEN;;BLACK MICHAEL T;;BRUTON GORDON;;HUMPHRIES ALFRED JOHN;;MOORE KEITH JAMES MILLAN,ASHMAN STEPHEN;;BLACK MICHAEL T;;BRUTON GORDON;;HUMPHRIES ALFRED JOHN;;MOORE KEITH JAMES MILLAN,,https://lens.org/177-757-693-485-85X,Patent Application,yes,0,1,3,3,53,C07K14/8107;;C07K14/8107,C07K14/81,,4,4,033-109-514-898-943;;095-042-487-048-673;;019-570-248-354-81X;;011-726-401-336-405,6345794;;10.1016/s0022-2836(83)80341-6;;10.1006/jmbi.1997.1617;;9545377;;pmc556761;;1639057;;10.1002/j.1460-2075.1992.tb05349.x;;10.1021/bi9726032;;9530285,"PERLMAN D ET AL: ""PUTATIVE SIGNAL PEPTIDASE RECOGNITION SITE AND SEQUENCE IN EUKARYOTIC AND PROKARYOTIC SIGNAL PEPTIDES"", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 167, no. 2, 25 June 1983 (1983-06-25), pages 391 - 409, XP000572730, ISSN: 0022-2836;;KARAMYSHEV ANDREW L ET AL: ""Processing of Escherichia coli alkaline phosphatase: Role of the primary structure of the signal peptide cleavage region."", JOURNAL OF MOLECULAR BIOLOGY, vol. 277, no. 4, 10 April 1998 (1998-04-10), pages 859 - 870, XP000914377, ISSN: 0022-2836;;VAN DIJL J ET AL: ""Signal peptidase I of Bacillus subtilis: patterns of conserved amino acids in prokaryotic and eukaryotic type I signal peptidases"", EMBO JOURNAL,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 11, no. 8, 1 January 1992 (1992-01-01), pages 2819 - 2828, XP002087013, ISSN: 0261-4189;;P WREDE ET AL: ""Peptide design aided by neural networks: biological activity of rtificial signal peptidase I cleavage sites"", BIOCHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, PA, vol. 37, no. 11, 17 March 1998 (1998-03-17), pages 3588 - 3593-3593, XP002127397, ISSN: 0006-2960",PENDING
419,WO,A2,WO 2008/039974 A2,194-831-155-917-079,2008-04-03,2008,US 2007/0079857 W,2007-09-28,US 82726006 P,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",CEDARS SINAI MEDICAL CENTER;;TORREY PINES INST;;YU JOHN S;;LIU GENTAO;;ZHU HUI PH D;;PINILLA CLEMENCIA;;BLACK KEITH L,YU JOHN S;;LIU GENTAO;;ZHU HUI PH D;;PINILLA CLEMENCIA;;BLACK KEITH L,,https://lens.org/194-831-155-917-079,Patent Application,yes,0,7,17,17,0,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/00;;A61K35/12,,0,0,,,,PENDING
420,US,A1,US 2003/0087117 A1,150-189-962-035-046,2003-05-08,2003,US 17153802 A,2002-06-17,US 17153802 A;;GB 9700652 A;;US 34157599 A;;US 69488900 A;;CA 9700854 W,1997-01-14,Tailored blank,"
   The present invention provides a tailored blank having a pair of sheet metal constituent parts each having a pair of oppositely directed major surfaces. The first constituent part has an aperture while the second constituent part has an embossment to fit the aperture. The first and second constituent parts are then secured to one another to form the tailored blank. The blank may then be subsequently formed into a component of varying material characteristics. 
",DULEY WALTER;;OGMEN MELIH;;HUGHES DAVID;;BLACK GARY KEITH;;MORRIS BRIAN;;STAPLES MICHAEL JAMES,DULEY WALTER;;OGMEN MELIH;;HUGHES DAVID;;BLACK GARY KEITH;;MORRIS BRIAN;;STAPLES MICHAEL JAMES,,https://lens.org/150-189-962-035-046,Patent Application,yes,4,13,2,22,0,B21D22/00;;B23K26/244;;B23K26/26;;B23K26/242;;B23K26/282;;B23K2101/185;;Y10T428/12486;;Y10T428/12361;;Y10T428/12243;;Y10T428/12229;;Y10T428/12264;;Y10T428/12347;;Y10T428/12486;;Y10T428/12361;;Y10T428/12243;;Y10T428/12229;;Y10T428/12264;;Y10T428/12347;;B21D22/00;;B23K26/244;;B23K26/282;;B23K26/242;;B23K26/26;;B23K2101/185,B21D22/00;;B23K26/20;;B23K26/24,428/594;;428/614;;428/596;;219/121.64,0,0,,,,EXPIRED
421,US,S,US D0707705 S,161-501-266-279-058,2014-06-24,2014,US 201329448542 F,2013-03-13,US 201329448542 F,2013-03-13,Portion of a display screen with an animated computer generated icon,,CATERPILLAR INC,FOLKEN KEITH R;;MEINHART MATTHEW J;;SCHROEDER EDWARD M;;OLSEN ERIK L;;BLACK ANDREW,CATERPILLAR INC (2013-03-12),https://lens.org/161-501-266-279-058,Design Right,no,0,81,1,1,0,,,1404;;D14/490,0,0,,,,ACTIVE
422,EP,B1,EP 2573244 B1,044-115-932-764-403,2015-02-18,2015,EP 12006446 A,2012-09-14,EP 11007649 A;;EP 12006446 A,2011-09-20,Sound absorbing material,,FREUDENBERG CARL KG,RUTSCH PETER DR;;GROTEN ROBERT DR;;BLACK SAMUEL KEITH;;BOLD ANKE DR;;JESTEL FRANK,,https://lens.org/044-115-932-764-403,Granted Patent,yes,1,0,7,7,0,D04H3/14;;D04H3/005;;D04H3/153,D04H3/14;;D04H3/005;;D04H3/153;;E04B1/72,,0,0,,,,ACTIVE
423,CA,A1,CA 2700436 A1,069-215-937-913-207,2008-04-03,2008,CA 2700436 A,2007-09-28,US 82726006 P;;US 2007/0079857 W,2006-09-28,CANCER VACCINES AND VACCINATION METHODS,"Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.",TORREY PINES INST;;CEDARS SINAI MEDICAL CENTER,YU JOHN S;;LIU GENTAO;;ZHU HUI PH D;;PINILLA CLEMENCIA;;BLACK KEITH L,,https://lens.org/069-215-937-913-207,Patent Application,no,0,0,17,17,71,A61K2035/124;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61P31/00;;A61P35/00;;A61K39/4615;;A61K39/464419;;A61K39/4622;;A61K2239/31;;A61K39/464486;;A61K39/464406;;A61K39/464492;;A61K2239/47;;A61K39/464456;;A61K2035/124;;A61K2039/5154;;C12N5/0639;;C12N2501/22;;C12N2501/23;;C12N2501/25;;A61K39/001192;;A61K39/001106;;A61K39/001119;;A61K39/001156;;A61K39/001186;;A61K39/0011;;A61K2039/545;;C12N2501/2304;;C12N2501/998;;C12N2506/11,A61K39/385;;A61K35/12;;A61K39/00;;A61K47/46;;A61P35/00;;C12N5/0784,,0,0,,,,ACTIVE
424,US,B2,US 7116951 B2,061-540-326-538-143,2006-10-03,2006,US 73747303 A,2003-12-16,US 73747303 A,2003-12-16,Transmitter circuit and method for modulation distortion compensation,"A transmitter circuit ( 200, 400, 510 ) and method reduces amplitude modulation distortion in an amplifier ( 210 ). The transmitter circuit ( 200, 400, 510 ) includes a power control error data generator ( 230 ), a feedforward predistortion data generator ( 240 ), feedforward adder logic ( 250 ) and the amplifier ( 210 ). The power control error data generator ( 230 ) receives amplitude modulation data ( 252 ) and an RF coupled output signal ( 254 ) and, in response, produces power control error data ( 256 ). The feedforward predistortion data generator ( 240 ) receives the amplitude modulation data ( 252 ) and, in response, produces feedforward predistortion data ( 258 ). The feedforward adder logic ( 250 ) receives the power control error data ( 256 ) and the feedforward predistortion data ( 258 ) and, in response, produces power control data ( 260 ). The amplifier ( 210 ) receives the power control data ( 260 ) and an RF input signal ( 261 ) and, in response, produces an RF output signal ( 262 ), such that the power control data ( 260 ) reduces amplitude modulation distortion in the RF output signal ( 262 ).",MOTOROLA INC,NAGODE THOMAS D;;NANNI PETER;;NIGRA LOUIS M;;BLACK GREG R;;TILLEY KEITH ANDREW,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2003-12-16),https://lens.org/061-540-326-538-143,Granted Patent,yes,8,9,9,9,0,H03C1/06;;H03C3/0975;;H03F2200/102;;H03F2200/105;;H03F2201/3221;;H03F2201/3227;;H04B1/04;;H04B2001/0416;;H04B2001/0433;;H04B2001/0441;;H03F1/34;;H03F1/3223;;H03F3/24;;H03F1/3241;;H04B2001/0416;;H04B1/04;;H03F2201/3227;;H04B2001/0441;;H03F2200/102;;H03F2201/3221;;H03C1/06;;H03C3/0975;;H03F2200/105;;H04B2001/0433,H04B1/04;;H03C1/06;;H03C3/09;;H03F1/32,455/126;;455/114.3;;455/127.1,0,0,,,,ACTIVE
425,US,A1,US 2004/0024178 A1,077-325-221-304-964,2004-02-05,2004,US 25685002 A,2002-09-27,GB 9902399 A,1999-02-03,Bacterial signal peptidase inhibitors and uses thereof,"
   Substrates for bacterial signal peptidases and their use in assays to detect inhibitors of these enzymes. 
",ASHMAN STEPHEN;;BLACK MICHAEL T.;;BRUTON GORDON;;HUMPHRIES ALFRED JOHN;;MOORE KEITH JAMES MILLAN,ASHMAN STEPHEN;;BLACK MICHAEL T;;BRUTON GORDON;;HUMPHRIES ALFRED JOHN;;MOORE KEITH JAMES MILLAN,,https://lens.org/077-325-221-304-964,Patent Application,yes,0,8,3,3,64,C07K14/8107;;C07K14/8107,C07K14/81,530/324;;530/326;;530/327;;530/328,0,0,,,,DISCONTINUED
426,US,S,US D0737285 S,118-973-605-340-471,2015-08-25,2015,US 201429492174 F,2014-05-29,US 201429492174 F;;US 201329448531 F,2013-03-13,Display screen with graphical user interface,,CATERPILLAR INC,FOLKEN KEITH R;;MEINHART MATTHEW J;;SCHROEDER EDWARD M;;OLSEN ERIK L;;BLACK ANDREW,,https://lens.org/118-973-605-340-471,Design Right,no,0,14,5,5,0,,,1404;;D14/485,0,0,,,,ACTIVE
427,WO,A2,WO 2005/060596 A2,087-008-464-027-037,2005-07-07,2005,US 2004/0040927 W,2004-12-07,US 73747303 A,2003-12-16,A TRANSMITTER CIRCUIT AND METHOD FOR MODULATION DISTORTION COMPENSATION,"A transmitter circuit (200, 400, 510) includes a power control error data generator (230), a feedforward predistortion data generation (240), feedforward adder logic (250) and the amplifier (210).",MOTOROLA INC;;NAGODE THOMAS D;;NANNI PETER;;NIGRA LOUIS M;;BLACK GREG R;;TILLEY KEITH ANDREW,NAGODE THOMAS D;;NANNI PETER;;NIGRA LOUIS M;;BLACK GREG R;;TILLEY KEITH ANDREW,,https://lens.org/087-008-464-027-037,Patent Application,yes,0,0,9,9,0,H03C1/06;;H03C3/0975;;H03F2200/102;;H03F2200/105;;H03F2201/3221;;H03F2201/3227;;H04B1/04;;H04B2001/0416;;H04B2001/0433;;H04B2001/0441;;H03F1/34;;H03F1/3223;;H03F3/24;;H03F1/3241;;H04B2001/0416;;H04B1/04;;H03F2201/3227;;H04B2001/0441;;H03F2200/102;;H03F2201/3221;;H03C1/06;;H03C3/0975;;H03F2200/105;;H04B2001/0433,H03C1/06;;H03C3/09;;H03F1/32;;H04B1/04,,0,0,,,,PENDING
428,WO,B1,WO 2005/060596 B1,116-244-308-655-378,2007-04-05,2007,US 2004/0040927 W,2004-12-07,US 73747303 A,2003-12-16,A TRANSMITTER FOR MODULATION DISTORTION COMPENSATION,"A transmitter circuit (200, 400, 510) includes a power control error data generator (230), a feedforward predistortion data generation (240), feedforward adder logic (250) and the amplifier (210).",MOTOROLA INC;;NAGODE THOMAS D;;NANNI PETER;;NIGRA LOUIS M;;BLACK GREG R;;TILLEY KEITH ANDREW,NAGODE THOMAS D;;NANNI PETER;;NIGRA LOUIS M;;BLACK GREG R;;TILLEY KEITH ANDREW,,https://lens.org/116-244-308-655-378,Patent Application,no,0,0,9,9,0,H03C1/06;;H03C3/0975;;H03F2200/102;;H03F2200/105;;H03F2201/3221;;H03F2201/3227;;H04B1/04;;H04B2001/0416;;H04B2001/0433;;H04B2001/0441;;H03F1/34;;H03F1/3223;;H03F3/24;;H03F1/3241;;H04B2001/0416;;H04B1/04;;H03F2201/3227;;H04B2001/0441;;H03F2200/102;;H03F2201/3221;;H03C1/06;;H03C3/0975;;H03F2200/105;;H04B2001/0433,H04B1/04;;H03C1/06;;H03C3/09;;H03F1/32,,0,0,,,,PENDING
429,US,A1,US 2014/0150488 A1,124-885-625-289-631,2014-06-05,2014,US 201313843279 A,2013-03-15,US 201313843279 A;;US 201261733372 P,2012-12-04,COMPACT DEHUMIDIFIERS AND ASSOCIATED SYSTEMS AND METHODS,"Compact dehumidifiers and associated systems and methods are disclosed. A representative system includes a housing having an airflow entrance, and airflow exit, and a linear flowpath between the entrance and exit. The system further includes a refrigeration cycle having, in sequence along the flowpath, an evaporator, a compressor, a condenser, and an air flow driver. A controller is operatively coupled to the evaporator, compressor, condenser, and airflow driver to operate the refrigeration cycle for removing moisture from an entering airflow.",DRI EAZ PRODUCTS INC,BLACK RICHARD A;;HOFFMAN KEITH;;BRUDERS WILLIAM;;WHITE LARRY;;BARTHOLMEY BRETT;;KIESSER AARON MATTHEW,DRI-EAZ PRODUCTS INC (2013-03-19),https://lens.org/124-885-625-289-631,Patent Application,yes,9,26,9,9,0,F24F13/20;;F24F2003/144;;F24F2221/12;;F24F3/14;;Y10T29/49359;;F24F1/02;;F24F3/14;;F24F13/02;;F24F13/20;;F24F2221/12;;F24F2003/144;;Y10T29/49359;;F24F3/14;;Y10T29/49359;;F24F13/20;;F24F2003/144;;F24F2221/12,B23P15/26;;F24F3/14,62/404;;29/890.035,1,0,,,"Ye, Hailin (English translation provided by espacenet.com); ""Stackable Dehumidifier"" English translation; 07-2012; Chinese Publication number CN 202338972 U",DISCONTINUED
430,EP,A2,EP 1694285 A2,022-295-573-829-043,2006-08-30,2006,EP 04813268 A,2004-12-07,US 2004/0040927 W;;US 73747303 A,2003-12-16,A TRANSMITTER CIRCUIT AND METHOD FOR MODULATION DISTORTION COMPENSATION,,MOTOROLA INC,NAGODE THOMAS D;;NANNI PETER;;NIGRA LOUIS M;;BLACK GREG R;;TILLEY KEITH ANDREW,"MOTOROLA MOBILITY, INC. (2011-03-02);;GOOGLE TECHNOLOGY HOLDINGS LLC, US (2016-05-04);;GOOGLE TECHNOLOGY HOLDINGS LLC, MOUNTAIN VIEW, US (2016-03-02);;MOTOROLA MOBILITY LLC (2012-08-22)",https://lens.org/022-295-573-829-043,Patent Application,yes,0,0,9,9,0,H03C1/06;;H03C3/0975;;H03F2200/102;;H03F2200/105;;H03F2201/3221;;H03F2201/3227;;H04B1/04;;H04B2001/0416;;H04B2001/0433;;H04B2001/0441;;H03F1/34;;H03F1/3223;;H03F3/24;;H03F1/3241;;H04B2001/0416;;H04B1/04;;H03F2201/3227;;H04B2001/0441;;H03F2200/102;;H03F2201/3221;;H03C1/06;;H03C3/0975;;H03F2200/105;;H04B2001/0433,H04B1/04;;H03C1/06;;H03C3/09;;H03F1/32,,0,0,,,,ACTIVE
431,EP,A4,EP 1694285 A4,079-645-696-094-716,2007-11-14,2007,EP 04813268 A,2004-12-07,US 2004/0040927 W;;US 73747303 A,2003-12-16,A TRANSMITTER CIRCUIT AND METHOD FOR MODULATION DISTORTION COMPENSATION,,MOTOROLA INC,NAGODE THOMAS D;;NANNI PETER;;NIGRA LOUIS M;;BLACK GREG R;;TILLEY KEITH ANDREW,"MOTOROLA MOBILITY, INC. (2011-03-02);;GOOGLE TECHNOLOGY HOLDINGS LLC, US (2016-05-04);;GOOGLE TECHNOLOGY HOLDINGS LLC, MOUNTAIN VIEW, US (2016-03-02);;MOTOROLA MOBILITY LLC (2012-08-22)",https://lens.org/079-645-696-094-716,Search Report,no,4,0,9,9,0,H03C1/06;;H03C3/0975;;H03F2200/102;;H03F2200/105;;H03F2201/3221;;H03F2201/3227;;H04B1/04;;H04B2001/0416;;H04B2001/0433;;H04B2001/0441;;H03F1/34;;H03F1/3223;;H03F3/24;;H03F1/3241;;H04B2001/0416;;H04B1/04;;H03F2201/3227;;H04B2001/0441;;H03F2200/102;;H03F2201/3221;;H03C1/06;;H03C3/0975;;H03F2200/105;;H04B2001/0433,H04B1/04;;H03C1/06;;H03C3/09;;H03F1/32,,0,0,,,,ACTIVE
432,US,S,US D0737286 S,124-732-077-887-982,2015-08-25,2015,US 201429492176 F,2014-05-29,US 201429492176 F;;US 201329448531 F,2013-03-13,Display screen with graphical user interface,,CATERPILLAR INC,FOLKEN KEITH R;;MEINHART MATTHEW J;;SCHROEDER EDWARD M;;OLSEN ERIK L;;BLACK ANDREW,,https://lens.org/124-732-077-887-982,Design Right,no,0,27,5,5,0,,,1404;;D14/485,0,0,,,,ACTIVE
433,WO,A1,WO 2000/065078 A1,066-796-238-850-680,2000-11-02,2000,US 0011031 W,2000-04-24,US 29981799 A,1999-04-26,A HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)-DERIVED VECTOR FOR SELECTIVELY INHIBITING MALIGNANT CELLS AND METHODS FOR ITS USE TO TREAT CANCERS AND TO EXPRESS DESIRED TRAITS IN MALIGNANT AND NON-MALIGNANT MAMMALIAN CELLS,"Disclosed is a method of selectively inhibiting the growth of malignant cells in mammals, including humans. The method selectively inhibits the growth of malignant cells of all varieties, and is particularly useful in treating brain tumors and other malignancies of the central nervous system. The method employs HSV-1-derived vectors containing a DNA having a deletion in both copies of the LAT gene and both copies of the ICP34.5 gene of HSV-1. The vectors are delivered to malignant cells either in vivo or in vitro, in accordance with the method. The HSV-1-derived expression vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid having a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-η. A method of expressing in a mammalian cell a gene encoding a preselected protein, a method of treating a genetic defect, and a method of detecting an HSV-1 expressing cell also employ vectors of the present invention that contain at least one transcriptional unit of a constitutive LAT promoter operatively linked to and controlling the transcription of a gene encoding a preselected protein. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, useful for practicing the methods, and mammalian cells containing the HSV-derived vectors.",CEDARS SINAI MEDICAL CENTER,WESCHLER STEVEN L;;NESBURN ANTHONY B;;PERNG GUEY-CHUEN;;YU JOHN S;;BLACK KEITH L,,https://lens.org/066-796-238-850-680,Patent Application,yes,1,9,6,6,0,A61K39/00;;A61K48/00;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16622;;C12N2710/16643;;C12N2710/16661;;A61P35/00;;C12N7/00;;C07K14/005;;C12N2710/16643;;A61K39/00;;C12N2710/16622;;C12N2710/16661;;C12N15/86;;A61K48/00,A61K39/00;;A61K48/00;;A61P35/00;;C07K14/035;;C12N7/04;;C12N15/38;;C12N15/869,,4,4,105-183-770-676-499;;012-181-109-578-019;;010-749-971-686-146;;000-362-547-589-786,1662697;;10.1099/0022-1317-72-12-3057;;8627763;;10.1128/jvi.70.5.2883-2893.1996;;pmc190146;;pmc237268;;10.1128/jvi.68.12.8045-8055.1994;;7966594;;8974620;;10.1111/j.1750-3639.1995.tb00615.x,"MCGEOCH D J ET AL: ""COMPARATIVE SEQUENCE ANALYSIS OF THE LONG REPEAT REGIONS AND ADJOINING PARTS OF THE LONG UNIQUE REGIONS IN THE GENOMES OF HERPES SIMPLEX VIRUSES TYPES 1 AND 2"", JOURNAL OF GENERAL VIROLOGY 1991, vol. 72, no. 12, 1991, pages 3057 - 3076, XP000406755, ISSN: 0022-1317;;PERNG GUEY-CHUEN ET AL: ""High-dose ocular infection with a herpes simplex virus type 1 ICP34.5 deletion mutant produces no corneal disease or neurovirulence yet results in wild-type levels of spontaneous reactivation."", JOURNAL OF VIROLOGY 1996, vol. 70, no. 5, 1996, pages 2883 - 2893, XP002142268, ISSN: 0022-538X;;PERNG GUEY-CHUEN ET AL: ""The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency."", JOURNAL OF VIROLOGY 1994, vol. 68, no. 12, 1994, pages 8045 - 8055, XP000916490, ISSN: 0022-538X;;KRAMM CHRISTOF M ET AL: ""Gene therapy for brain tumors."", BRAIN PATHOLOGY 1995, vol. 5, no. 4, 1995, pages 345 - 381, XP000916435, ISSN: 1015-6305",PENDING
434,CA,A1,CA 2163290 A1,017-461-277-591-915,1996-05-24,1996,CA 2163290 A,1995-11-20,US 34436794 A,1994-11-23,PACKAGING SYSTEM FOR ELECTRONIC TEST AND MEASUREMENT INSTRUMENTS,"An electronic instrument having a keyboard, a display, and electronic circuitry coupled to the keyboard and display, all of which are housed in a case. The case is relatively narrow at one end where the keyboard is accessible, and relatively wide at the other end where the display is visible. The relatively narrow portion of the case extends into the relatively wide portion of the case below the upper surface of the relatively wide portion to atleast beyond the center of gravity of the electronic instrument. The electronic instrument may be grasped by a hand of a user with the thumb of the user extending along one sidewall of the relatively narrow portion of the case beneath the relatively wide portion of the case, the palm of the user extending across the bottom surface of the relatively narrow portion of the case, and the remaining fingers of the user extending along the other sidewall of the relatively narrow portion of the case beneath the relatively wide portion of thecase.",FLUKE CORP,KING INDLE G;;GALLAGHER PATRICK M;;BLACK MICHAEL J;;STILES WILLIAM P;;WILLOWS KEITH S,,https://lens.org/017-461-277-591-915,Patent Application,no,0,0,3,3,0,G01R1/04,G01R1/04,,0,0,,,,DISCONTINUED
435,EP,A3,EP 0715491 A3,004-616-026-571-866,1998-03-04,1998,EP 95118375 A,1995-11-22,US 34436794 A,1994-11-23,Packaging system for electronic test and measurement instruments,"An electronic instrument having a keyboard, a display, and electronic circuitry coupled to the keyboard and display, all of which are housed in a case. The case is relatively narrow at one end where the keyboard is accessible, and relatively wide at the other end where the display is visible. The relatively narrow portion of the case extends into the relatively wide portion of the case below the upper surface of the relatively wide portion to at least beyond the center of gravity of the electronic instrument. The electronic instrument may be grasped by a hand of a user with the thumb of the user extending along one sidewall of the relatively narrow portion of the case beneath the relatively wide portion of the case, the palm of the user extending across the bottom surface of the relatively narrow portion of the case, and the remaining fingers of the user extending along the other sidewall of the relatively narrow portion of the case beneath the relatively wide portion of the case.",FLUKE CORP,KING INDLE G;;GALLAGHER PATRICK M;;BLACK MICHAEL J;;STILES WILLIAM P;;WILLOWS KEITH S,,https://lens.org/004-616-026-571-866,Search Report,yes,6,0,3,3,0,G01R1/04,G01R1/04,,0,0,,,,DISCONTINUED
436,EP,A2,EP 0715491 A2,159-356-462-600-099,1996-06-05,1996,EP 95118375 A,1995-11-22,US 34436794 A,1994-11-23,Packaging system for electronic test and measurement instruments,"An electronic instrument having a keyboard, a display, and electronic circuitry coupled to the keyboard and display, all of which are housed in a case. The case is relatively narrow at one end where the keyboard is accessible, and relatively wide at the other end where the display is visible. The relatively narrow portion of the case extends into the relatively wide portion of the case below the upper surface of the relatively wide portion to at least beyond the center of gravity of the electronic instrument. The electronic instrument may be grasped by a hand of a user with the thumb of the user extending along one sidewall of the relatively narrow portion of the case beneath the relatively wide portion of the case, the palm of the user extending across the bottom surface of the relatively narrow portion of the case, and the remaining fingers of the user extending along the other sidewall of the relatively narrow portion of the case beneath the relatively wide portion of the case.",FLUKE CORP,KING INDLE G;;GALLAGHER PATRICK M;;BLACK MICHAEL J;;STILES WILLIAM P;;WILLOWS KEITH S,,https://lens.org/159-356-462-600-099,Patent Application,yes,0,4,3,3,0,G01R1/04,G01R1/04,,0,0,,,,DISCONTINUED
437,EP,A1,EP 1173598 A1,024-482-692-833-930,2002-01-23,2002,EP 00926327 A,2000-04-24,US 0011031 W;;US 29981799 A,1999-04-26,A HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)-DERIVED VECTOR FOR SELECTIVELY INHIBITING MALIGNANT CELLS AND METHODS FOR ITS USE TO TREAT CANCERS AND TO EXPRESS DESIRED TRAITS IN MALIGNANT AND NON-MALIGNANT MAMMALIAN CELLS,,CEDARS SINAI MEDICAL CENTER,WECHSLER STEVEN L;;NESBURN ANTHONY B;;PERNG GUEY-CHUEN;;YU JOHN S;;BLACK KEITH L,,https://lens.org/024-482-692-833-930,Patent Application,yes,0,0,6,6,0,A61K39/00;;A61K48/00;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16622;;C12N2710/16643;;C12N2710/16661;;A61P35/00;;C12N7/00;;C07K14/005;;C12N2710/16643;;A61K39/00;;C12N2710/16622;;C12N2710/16661;;C12N15/86;;A61K48/00,A61K39/00;;A61K48/00;;A61P35/00;;C07K14/035;;C12N7/04;;C12N15/38;;C12N15/869,,0,0,,,,DISCONTINUED
438,DE,C3,DE 2926764 C3,193-044-043-877-552,1983-12-22,1983,DE 2926764 A,1979-07-03,US 92202978 A,1978-07-05,DE 2926764 C3,,"DEERE & CO., MOLINE, ILL., US, NIEDERLASSUNG DEERE & CO. EUROPEAN OFFICE, 6800 MANNHEIM, DE","LAWRENCE, ALLAN KEITH;;BASS, MERLYN DUANE;;BLACK, ROBERT DELNO;;KRAFKA, JERRY LEE, OTTUMWA, IA., US","DEERE & COMPANY, MOLINE, ILL., US (1998-07-02)",https://lens.org/193-044-043-877-552,Granted Patent,no,0,0,21,21,0,A01F29/10;;A01F29/10,A01D43/08;;A01F29/00;;A01F29/10,,0,0,,,,EXPIRED
439,WO,A3,WO 2010/132342 A3,152-519-682-894-841,2011-03-31,2011,US 2010/0034206 W,2010-05-10,US 17815909 P,2009-05-14,PROCESS FOR RESURFACING PLASTIC LENS,"The present invention is directed to a process for resurfacing a damaged surface of plastic lenses, such as vehicle headlights and taillights to restore the plastic lens surface to its original clarity and transparency. During process, a cleaned damaged surface is preferably orbital sanded with a moistened sand paper disc mounted on a sander for removing visible scratches and yellowing of the moistened damaged surface of the plastic lens. Thereafter, the sanded surface is preferably rotary polished with the slush-resistant polishing composition of the present invention applied on a polishing pad mounted on an polisher for removing any visible score marks that may have been created during the sanding step. Then, the polished surface is preferably rotary finished with the slush-resistant finishing composition of the present invention applied on a finishing pad mounted on a finisher for removing any visible swirls marks that may have been created during the polishing step.",DU PONT;;BLACK COLON CLIVE;;HORAN PATRICK M;;LITTLE ROBERT THOMAS;;MORRISON DEBRA ANN;;SENA KEITH A,BLACK COLON CLIVE;;HORAN PATRICK M;;LITTLE ROBERT THOMAS;;MORRISON DEBRA ANN;;SENA KEITH A,,https://lens.org/152-519-682-894-841,Search Report,yes,2,0,4,4,0,B24B13/015;;B24B13/015;;B24B1/00;;B29C73/24;;B29C73/26,B60Q1/02;;B24B7/30;;B24B37/00;;B24D15/00,,0,0,,,,PENDING
440,US,A1,US 2002/0098170 A1,110-273-438-311-80X,2002-07-25,2002,US 4649101 A,2001-10-29,US 4649101 A;;US 29981799 A,1999-04-26,Herpes simplex virus type 1 ( HSV-1)-derived vector for selectively inhibiting maligant cells and methods for its use to treat cancer and to express desired traits in maligant and non-miligant mammalian cells,"
   Disclosed is a method of selectively inhibiting the growth of malignant cells in mammals, including humans. The method selectively inhibits the growth of malignant cells of all varieties, and is particularly useful in treating brain tumors and other malignancies of the central nervous system. The method employs HSV-1-derived vectors containing a DNA having a deletion in both copies of the LAT gene and both copies of the ICP34.5 gene of HSV-1. The vectors are delivered to malignant cells either in vivo or in vitro, in accordance with the method. The HSV-1-derived expression vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid having a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-. A method of expressing in a mammalian cell a gene encoding a preselected protein, a method of treating a genetic defect, and a method of detecting an HSV-1 expressing cell also employ vectors of the present invention that contain at least one transcriptional unit of a constitutive LAT promoter operatively linked to and controlling the transcription of a gene encoding a preselected protein. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, useful for practicing the methods, and mammalian cells containing the HSV-derived vectors. 
",WECHSLER STEVEN L.;;NESBURN ANTHONY B.;;PERNG GUEY-CHUEN;;YU JOHN S.;;BLACK KEITH L.,WECHSLER STEVEN L;;NESBURN ANTHONY B;;PERNG GUEY-CHUEN;;YU JOHN S;;BLACK KEITH L,,https://lens.org/110-273-438-311-80X,Patent Application,yes,12,10,6,6,0,A61K39/00;;A61K48/00;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16622;;C12N2710/16643;;C12N2710/16661;;A61P35/00;;C12N7/00;;C07K14/005;;C12N2710/16643;;A61K39/00;;C12N2710/16622;;C12N2710/16661;;C12N15/86;;A61K48/00,A61K39/00;;A61K48/00;;A61P35/00;;C07K14/035;;C12N7/04;;C12N15/38;;C12N15/869,424/93.21;;514/44;;435/456,0,0,,,,EXPIRED
441,US,B1,US 6774119 B1,151-616-262-026-528,2004-08-10,2004,US 29981799 A,1999-04-26,US 29981799 A,1999-04-26,HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)-DERIVED VECTOR FOR SELECTIVELY INHIBITING MALIGNANT CELLS AND METHODS FOR ITS USE TO TREAT CANCERS AND TO EXPRESS DESIRED TRAITS IN MALIGNANT AND NON-MALIGNANT MAMMALIAN CELLS,"
    Disclosed is a method of selectively inhibiting the growth of malignant cells in mammals, including humans. The method selectively inhibits the growth of malignant cells of all varieties, and is particularly useful in treating brain tumors and other malignancies of the central nervous system. The method employs HSV-1-derived vectors containing a DNA having a deletion in both copies of the LAT gene and both copies of the ICP34.5 gene of HSV-1. The vectors are delivered to malignant cells either in vivo or in vitro, in accordance with the method. The HSV-1-derived expression vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid having a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-. A method of expressing in a mammalian cell a gene encoding a preselected protein, a method of treating a genetic defect, and a method of detecting an HSV-1 expressing cell also employ vectors of the present invention that contain at least one transcriptional unit of a constitutive LAT promoter operatively linked to and controlling the transcription of a gene encoding a preselected protein. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, useful for practicing the methods, and mammalian cells containing the HSV-derived vectors. 
",CEDARS SINAI MEDICAL CENTER,WECHSLER STEVEN L;;NESBURN ANTHONY B;;PERNG GUEY-CHUEN;;YU JOHN S;;BLACK KEITH L,CEDAR-SINAI MEDICAL CENTER (1999-06-07),https://lens.org/151-616-262-026-528,Granted Patent,yes,9,19,6,6,0,A61K39/00;;A61K48/00;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16622;;C12N2710/16643;;C12N2710/16661;;A61P35/00;;C12N7/00;;C07K14/005;;C12N2710/16643;;A61K39/00;;C12N2710/16622;;C12N2710/16661;;C12N15/86;;A61K48/00,A61K39/00;;A61K48/00;;A61P35/00;;C07K14/035;;C12N7/04;;C12N15/38;;C12N15/869,514/44;;435/320.1;;435/455;;424/93.2;;424/130.1;;536/23.5,54,47,185-525-004-577-968;;047-976-717-627-792;;034-248-727-001-550;;014-024-615-769-970;;029-279-763-880-370;;023-792-122-594-509;;071-596-311-999-591;;081-385-081-253-219;;042-719-805-570-571;;102-650-310-937-986;;079-404-496-135-66X;;092-247-557-292-592;;176-405-370-988-609;;049-608-921-192-363;;052-512-915-173-432;;050-996-673-647-412;;001-910-111-594-083;;105-183-770-676-499;;000-362-547-589-786;;168-497-556-140-658;;013-571-395-488-216;;083-366-647-068-936;;016-171-978-858-692;;021-513-157-932-670;;014-869-048-789-696;;016-857-056-204-779;;141-664-555-732-382;;045-087-390-059-179;;061-186-977-056-712;;003-273-587-266-097;;014-605-538-511-401;;137-004-333-386-156;;096-032-891-527-198;;039-790-799-566-253;;015-716-554-029-306;;099-199-075-800-452;;079-389-376-216-649;;039-330-535-028-278;;010-749-971-686-146;;008-152-329-341-999;;012-181-109-578-019;;034-968-344-631-569;;020-325-440-936-656;;055-876-986-885-513;;171-776-383-549-411;;004-401-069-775-027;;156-665-694-535-804,10037199;;8740561;;10.1006/scbi.1996.0010;;9747461;;10.1038/sj.gt.3300643;;10932216;;10.1038/78610;;10.1089/10430340050207957;;11119418;;10.1128/jvi.75.1.480-489.2001;;11119616;;pmc113940;;10880021;;10.1038/sj.cgt.7700198;;7584113;;10845725;;10.1038/sj.gt.3301205;;9865732;;10.1089/hum.1996.7.9-1123;;8773514;;10.1006/viro.1998.9454;;9875329;;11123435;;pmc5926297;;10.1111/j.1349-7006.2000.tb00923.x;;10954902;;10.1089/10430340050111331;;10.1089/hum.1998.9.11-1571;;9694156;;10048391;;10.1089/10430349950018832;;10498254;;10.1089/10430349950017211;;1662697;;10.1099/0022-1317-72-12-3057;;8974620;;10.1111/j.1750-3639.1995.tb00615.x;;10078959;;10.1038/sj.cgt.7700003;;8186287;;10.1089/hum.1993.4.6-725;;7954393;;10.1093/clinchem/40.4.510;;8149602;;10.1227/00006123-199505000-00012;;7791989;;10.1097/00006123-199505000-00012;;8835217;;10.1089/hum.1996.7.3-291;;9414254;;10.1089/hum.1997.8.17-2057;;9766316;;10.1097/00006123-199810000-00090;;1326612;;10.3171/jns.1992.77.4.0590;;10.1097/00006123-199304000-00016;;10.1227/00006123-199304000-00016;;8386343;;1851332;;10.1126/science.1851332;;10.1146/annurev.mi.08.100154.002141;;13198114;;10.1159/000385945;;13772273;;pmc1869962;;7495307;;7568227;;pmc40896;;10.1073/pnas.92.21.9829;;pmc7056106;;10094341;;1899695;;10.3171/jns.1991.74.3.0475;;10.1097/00006123-199404000-00048;;10.1227/00006123-199404000-00048;;8008188;;10.1089/hum.1993.4.1-39;;8384892;;pmc237268;;10.1128/jvi.68.12.8045-8055.1994;;7966594;;10.1128/jvi.69.5.3033-3041.1995;;7707530;;pmc189003;;8627763;;10.1128/jvi.70.5.2883-2893.1996;;pmc190146;;9622099;;10022555;;10.1089/10430349950019093;;10026902;;10.1007/978-1-4615-5357-1_61;;3468860;;10.1111/j.1749-6632.1986.tb27155.x;;10.1097/00006123-199605000-00027;;8727825;;10.1089/hum.1995.6.12-1543;;8664379,"Dang et al. Gene Therapy and Translational Cancer Therapy, Clinical Cancer Research, vol. 5, 471-474, Feb. 1999.*;;Eck, S.L. et al., 1996, Ch. 5. Gene Based Therapy, Goodman & Gillman's The Pharmacological basis of Therapeutics, p. 77-101ck, et al.*;;Youle, Richard J., Seminars in Cancer Biology, vol. 7, 1996: pp. 65-70.*;;Herrlinger, U. et al., Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector, Gene Ther, 5(6):809-19 (Jun. 1998)(Abstract Only).;;Website reference, Inbred Rats, Fischer 344,htt://www.harlan.com/us/price/inrat/f344.htm, Jun. 4, 2002.;;Website reference, Fischer 344, http://www.simlab.com/products/fischer344.html, Jun. 4, 2002;;Website reference, Taconic Animal Models, Animal Models-Fischer 344 Inbred Rats, http://www.taconic.com/anmodels/inbdfich.htm, Jun. 4, 2002.;;Website reference, Charles River Laboratories Online Catalog, Products. Services. 2002. CRL-2002 Online Catalog, http://www.criver.com/02cat/rm/rats/fisherRats.html, Jun. 4, 2002.;;Anderson, W.F., Gene therapy scores against cancer, Nat. Med. 6(8):862-63 [Aug. 2000].;;Delman, K.A. et al., Effects of pre-existing immunity on the response to herpes simplex-based oncolytic viral therapy, Human Gene Therapy 11:2465-72 [2000].;;Ebbinghaus, C. et al., Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor 1-positive cells by using a bispecific hybrid adapter, J. Virol. 75(1):480-489 [2001].;;Haisma, H.J. et al., Targeting of adenoviral vectors through a bispecific single-chain antibody, Cancer Gene Ther. 7(6):901-04 [2000], Abstract only.;;Huard, J. et al., Herpes simplex virus type 1 vector-mediated gene transfer to muscle, Gene Ther. 2(6):385-92, Abstract only.;;Markert, J.M et al., Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial, Gene Therapy 7:867-74 [2000].;;Miller, C.R. et al., Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer, Cancer Res. 58:5738-5748 [1998].;;Mullen, C.A. et al., Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector, Human Gene Therapy 7:1123-1129 [Jun. 1996].;;Nesburn, A.B. et al., Therapeutic periocular vaccinatin with subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits, Virology 252:200-09 [1998].;;Oyama, M et al., Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207, Jpn. J. Cancer Res. 91(12):1339-44 [2000a], Abstract only.;;Oyama, M. et al., Intravesical and intravenous therapy of human bladder cance by the herpes vector G207, Hum. Gene Ther. 11(12):1683-93 [2000b], Abstract only.;;Porada et al., In utero gene therapy: transfer and long-term expression of the bacterial neor gene in sheep after direct injection of retroviral vectors into preimmune fetuses, Human Gene Therapy 9:1571-85 [Jul. 20, 1998].;;Toda, M. et al., Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity, Hum. Gene Ther. 10(3):385-93 [1999], Abstract only.;;Walker, J.R. et al., Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207, Hum. Gene Ther. 10(13):2237-43 [1999], Abstract only.;;McGeoch, Duncan J., et al., Comparative sequence analysis of the long repeat regions and adjoining parts of the long unique regions in the genomes of herpes simplex viruses type 1 and 2, Journal of General Virology, vol. 72: pp. 3057-3075 (1991).;;Kramm, Christof M., et al., Gene Therapy for Brain Tumors, Bain Pathology, vol. 5: pp. 345-381 (1995).;;Barnett, F. H., Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7, Cancer Gene ther, 6(1):14-20 (Jan.-Feb. 1999). Abstract only.;;Bi, Wan Li et al., ""In Vitro Evidence that Metabolite Cooperation is Responsible for the Bystander Effect Observed with HSV tk Retroviral Gene Therapy,"" Human Gene Therapy, 4:725-731 (1993).;;Boviatsis, E. J. et al., ""Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains as intact thymidine kinase gene,"" Cancer Res, 54(22):5745-51, (Nov. 15, 1994). Abstract Only.;;Culver, Kenneth W., ""Clinical Applications of Gene Therapy for Cancer,"" Clinical Chemistry, vol. 40, N90.4, pp. 510-512, (1994).;;Doran, S.E. et al., ""Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption,"" Neurosurgery, 36(5):965-70, (May 1995). Abstract Only.;;Kramm, C. M. et al., ""Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors,"" Hum Gene Ther, 7(3):291-300, (Feb. 10, 1996). Abstract Only.;;Kramm, C. M. et al., ""Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy,"" Hum Gene Ther, 8(17):2057-68, (Nov. 20, 1997). Abstract Only.;;Kroll, R. A. et al., Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers, Neurosurgery, 43(4):879-86; discussion 886-9, (Oct. 1998). Abstract Only.;;Markert, James M. et al., ""Expanded spectrum of viral therapy int he treatment of nervous system tumors,"" J. Neurosurg, 77:590-594 (1992).;;Markert, James M. et al., ""Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that Retain Susceptibility to Acyclovir,"" Neurosurgery, vol. 32, No. 4, pp. 597-603, (Apr. 1993).;;Martuza, Robert L., ""Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant,"" Science, vol. 252, pp. 854-856 (May 10, 1991).;;Mineta, Toshihiro et al., ""Mutant Viral Therapy for Malignant Brain Tumors Using Ribonucleotide Reductase-Deficient Herpes Simplex Virus 1,"" J. Neurosurg., vol. 80, No. 2, p. 381 (Feb. 10, 1994). Meeting Program Item #1534.;;Moore, Alice E., ""Effects of Viruses on Tumors,"" Annual Review of Microbiology, vol. 8, pp. 393-410 (1954).;;Moore, A. E., ""The Oncolytic Viruses,"" Experimental Tumor Research/Sloan-Kettering Institute for Cancer Research, 1:411-439, (1960).;;Muldoon, L. L. et al., ""Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain,"" Am J Pathol, 147(6):1840-51 (Dec. 1995). Abstract Only.;;Nilaver, G. et al., ""Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption,"" Proc Natl Acad Sci U S A, 92(21):9829-33 (Oct. 10, 1995). Abstract Only.;;Muldoon, L.L. et al., ""A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery,"" AJNR Am J Neuroradiol, 20(2):217-22 (Feb. 1999). Abstract only.;;Neuwelt, E. A. et al, ""Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier,"" J Neurosurg, 74(3):475-9 (Mar. 1991). Abstract Only.;;Neuwelt, E. A. et al., ""Delivery of virus-sized iron oxide particles to roden CNS neurons,"" Neurosurgery, 34(4):777-84 (Apr. 1994). Abstract Only.;;Oldfield, Edward H. et al., Clinical Protocols, Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with Thymidine Kinase Gene and Intravenous Ganciclovir, Human Gene Therapy, 4:39-69 (1993).;;Perng, G. C. et al., ""Evidence that the HSV-1 LAT'S Main Role May be in Reactivation from Latency Rather than in Establishment of Latency,"" Abstract presented at Association for Research in Vision and Opthalmology (ARVO) May 1997.;;Perng, Guey-Chuen et al, ""The Latency-Associated Transcript Gene of Herpes Simplex virus Type 1 (HSV-1) Is Required for Efficient In Vivo Spontaneous Reactivation of HSV-1 from Latency,"" Journal of Virology, vol. 68, No. 12, pp. 8045-8055 (Dec. 1994).;;Perng, Guey-Chuen et al., ""An Avirulent ICP34.5 Deletion Mutant of Herpes Simplex virus Type 1 Is Capable of In Vivo Spontaneous Reactivation,"" Journal of Virology, vol. 60, No. 5, pp. 3033-3041 (May 1995).;;Perng, Guey-Chuen et al., ""High-Dose Oscular Infection with a Herpes Simplex Virus Type 1 ICP34.5 Deletion Mutant Produces No Corneal Disease or Neurovirulence yet Results in Wild-Type Levels of Spontaneous Reactivation,"" Journal of Virology, vol. 70, No. 5, pp. 2883-2893 (May 1996).;;Rainov, N. G. et al. ""Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector,"" Cancer Gene Ther, 5(3):158-62 (May-Jun. 1998). Abstract Only.;;Rainov, N. G. et al. ""Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms,"" Hum Gene Ther, 10(2):311-8 (Jan. 20, 1999). Abstract Only.;;Rainov, N. G. et al., ""A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma,"" Adv Exp Med Biol, 451:393-403 (1998). Abstract Only.;;Rapoport, S. I., et al., ""Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier,"" Ann N Y Acad Sci, 481:250-67 (1986). Abstract Only.;;Yang, W. et al., ""Enhanced delivery of boronophenylkalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption,"" Neurosurgery, 38(5):985-92 (May 1996), Abstract Only.;;Rainov, N. G. et al., ""Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms,"" 6(12):1543-52 (Dec. 1995). Abstract Only.",EXPIRED
442,WO,A2,WO 2010/132342 A2,048-680-316-161-331,2010-11-18,2010,US 2010/0034206 W,2010-05-10,US 17815909 P,2009-05-14,PROCESS FOR RESURFACING PLASTIC LENS,"The present invention is directed to a process for resurfacing a damaged surface of plastic lenses, such as vehicle headlights and taillights to restore the plastic lens surface to its original clarity and transparency. During process, a cleaned damaged surface is preferably orbital sanded with a moistened sand paper disc mounted on a sander for removing visible scratches and yellowing of the moistened damaged surface of the plastic lens. Thereafter, the sanded surface is preferably rotary polished with the slush-resistant polishing composition of the present invention applied on a polishing pad mounted on an polisher for removing any visible score marks that may have been created during the sanding step. Then, the polished surface is preferably rotary finished with the slush-resistant finishing composition of the present invention applied on a finishing pad mounted on a finisher for removing any visible swirls marks that may have been created during the polishing step.",DU PONT;;BLACK COLON CLIVE;;HORAN PATRICK M;;LITTLE ROBERT THOMAS;;MORRISON DEBRA ANN;;SENA KEITH A,BLACK COLON CLIVE;;HORAN PATRICK M;;LITTLE ROBERT THOMAS;;MORRISON DEBRA ANN;;SENA KEITH A,,https://lens.org/048-680-316-161-331,Patent Application,yes,0,1,4,4,0,B24B13/015;;B24B13/015;;B24B1/00;;B29C73/24;;B29C73/26,B60Q1/02;;B24B7/30;;B24B37/00;;B24D15/00,,0,0,,,,PENDING
443,EP,A2,EP 2429859 A2,164-389-303-478-761,2012-03-21,2012,EP 10775324 A,2010-05-10,US 2010/0034206 W;;US 17815909 P,2009-05-14,PROCESS FOR RESURFACING PLASTIC LENS,,DU PONT,BLACK COLON CLIVE;;HORAN PATRICK M;;LITTLE ROBERT THOMAS;;MORRISON DEBRA ANN;;SENA KEITH A,,https://lens.org/164-389-303-478-761,Patent Application,yes,0,0,4,4,0,B24B13/015;;B24B13/015;;B24B1/00;;B29C73/24;;B29C73/26,B60Q1/02;;B24B7/30;;B24B37/00;;B24D15/00,,1,0,,,See references of WO 2010132342A3,DISCONTINUED
444,US,B2,US 6838279 B2,134-837-150-092-646,2005-01-04,2005,US 4649101 A,2001-10-29,US 4649101 A;;US 29981799 A,1999-04-26,Herpes simplex virus type 1 (HSV-1)-derived vector for selectively inhibiting malignant cells and for expressing desired traits in malignant and non-malignant mammalian cells,"Disclosed is an HSV-1-derived vector containing a DNA having a functional LAT promoter, or operative fragment thereof, a deletion in both copies of the HSV-1 LAT gene, and a deletion in both copies of the HSV-1 ICP34.5 gene. The HSV-1-derived vectors are non-neurovirulent and do not spontaneously reactivate from latency, and they optionally contain a functional HSV thymidine kinase gene, which can enhance the effectiveness against cancer of drug treatment with gancyclovir or acyclovir. Alternatively, the HSV-1-derived vectors contain at least one transcriptional unit of a LAT promoter sequence operatively linked to a nucleic acid encoding a preselected protein. In some embodiments, the preselected protein is a nucleotide sequence encoding a polypeptide toxic for cells expressing the vector, for example, human interferon-γ. Also, disclosed are kits for expressing in a mammalian cell a gene encoding a preselected protein, and mammalian cells containing the HSV-derived vectors.",CEDARS SINAI MEDICAL CENTER,WECHSLER STEVEN L;;NESBURN ANTHONY B;;PERNG GUEY-CHUEN;;YU JOHN S;;BLACK KEITH L,,https://lens.org/134-837-150-092-646,Granted Patent,yes,16,10,6,6,0,A61K39/00;;A61K48/00;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16622;;C12N2710/16643;;C12N2710/16661;;A61P35/00;;C12N7/00;;C07K14/005;;C12N2710/16643;;A61K39/00;;C12N2710/16622;;C12N2710/16661;;C12N15/86;;A61K48/00,A61K39/00;;A61K48/00;;A61P35/00;;C07K14/035;;C12N7/04;;C12N15/38;;C12N15/869,435/320.1;;435/325;;435/455;;435/456;;435/69.1;;514/44;;424/199.1,48,45,004-409-136-159-002;;081-385-081-253-219;;168-497-556-140-658;;013-571-395-488-216;;083-366-647-068-936;;016-171-978-858-692;;021-513-157-932-670;;014-869-048-789-696;;016-857-056-204-779;;141-664-555-732-382;;045-087-390-059-179;;061-186-977-056-712;;003-273-587-266-097;;014-605-538-511-401;;137-004-333-386-156;;096-032-891-527-198;;039-790-799-566-253;;015-716-554-029-306;;099-199-075-800-452;;079-389-376-216-649;;039-330-535-028-278;;010-749-971-686-146;;008-152-329-341-999;;012-181-109-578-019;;034-968-344-631-569;;020-325-440-936-656;;055-876-986-885-513;;171-776-383-549-411;;004-401-069-775-027;;156-665-694-535-804;;014-024-615-769-970;;029-279-763-880-370;;023-792-122-594-509;;071-596-311-999-591;;042-719-805-570-571;;102-650-310-937-986;;079-404-496-135-66X;;092-247-557-292-592;;176-405-370-988-609;;049-608-921-192-363;;052-512-915-173-432;;050-996-673-647-412;;001-910-111-594-083;;105-183-770-676-499;;000-362-547-589-786,8883953;;10.1016/0169-328x(96)00097-6;;7584113;;10078959;;10.1038/sj.cgt.7700003;;8186287;;10.1089/hum.1993.4.6-725;;7954393;;10.1093/clinchem/40.4.510;;8149602;;10.1227/00006123-199505000-00012;;7791989;;10.1097/00006123-199505000-00012;;8835217;;10.1089/hum.1996.7.3-291;;9414254;;10.1089/hum.1997.8.17-2057;;9766316;;10.1097/00006123-199810000-00090;;1326612;;10.3171/jns.1992.77.4.0590;;10.1097/00006123-199304000-00016;;10.1227/00006123-199304000-00016;;8386343;;1851332;;10.1126/science.1851332;;10.1146/annurev.mi.08.100154.002141;;13198114;;10.1159/000385945;;13772273;;pmc1869962;;7495307;;7568227;;pmc40896;;10.1073/pnas.92.21.9829;;pmc7056106;;10094341;;1899695;;10.3171/jns.1991.74.3.0475;;10.1097/00006123-199404000-00048;;10.1227/00006123-199404000-00048;;8008188;;10.1089/hum.1993.4.1-39;;8384892;;pmc237268;;10.1128/jvi.68.12.8045-8055.1994;;7966594;;10.1128/jvi.69.5.3033-3041.1995;;7707530;;pmc189003;;8627763;;10.1128/jvi.70.5.2883-2893.1996;;pmc190146;;9622099;;10022555;;10.1089/10430349950019093;;10026902;;10.1007/978-1-4615-5357-1_61;;3468860;;10.1111/j.1749-6632.1986.tb27155.x;;10.1097/00006123-199605000-00027;;8727825;;10.1089/hum.1995.6.12-1543;;8664379;;10932216;;10.1038/78610;;10.1089/10430340050207957;;11119418;;10.1128/jvi.75.1.480-489.2001;;11119616;;pmc113940;;10880021;;10.1038/sj.cgt.7700198;;10845725;;10.1038/sj.gt.3301205;;9865732;;10.1089/hum.1996.7.9-1123;;8773514;;10.1006/viro.1998.9454;;9875329;;11123435;;pmc5926297;;10.1111/j.1349-7006.2000.tb00923.x;;10954902;;10.1089/10430340050111331;;10.1089/hum.1998.9.11-1571;;9694156;;10048391;;10.1089/10430349950018832;;10498254;;10.1089/10430349950017211;;1662697;;10.1099/0022-1317-72-12-3057;;8974620;;10.1111/j.1750-3639.1995.tb00615.x,"Ho et al. (1996) Mol. Brain Res., vol. 41 (1-2), 200-209.*;;Huard, J. et al., Herpes simplex virus type 1 vector-mediated gene transfer to muscle, Gene Ther. 2(6):385-92 [Aug. 1995], Abstract only.;;Barnettm F. H., Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7, Cancer Gene ther, 6(1):14-20 (Jan.-Feb. 1999). Abstract Only.;;Bi, Wan Li et al., ""In Vitro Evidence that Metabolic Cooperation is Responsible for the Bystander Effect Observed with HSV tk Retroviral Gene Therapy,"" Human Gene Therapy, 4:725-731 (1993).;;Bovintsis, E. J. et al., ""Long-term survival of rats barb ring brain neoplasms treated with gancici vir and a herpes simplex virus vector that retains an intact thymidine kinase gene,"" Cancer Res, 54(22):5745-51, (N v 15, 1994). Abstract Only.;;Culver, Kenneth W., ""Clinical Applications of Gene Therapy for Cancer,"" Clinical Chemistry, vol. 40, N90. 4, pp. 510-512, (1994).;;Doran, S. E. et al., ""Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption,"" Neurosurgery, 36(5):965-70, (May 1995). Abstract Only.;;Kramm, C. M. et al., ""Herpes vector-mediated delivery of marker genes to disseminated central nervous system tum rs,"" Hum Gene Ther, 7(3):291-300, (Feb 10, 1996). Abstract Only.;;Kramm, C. M. et al., ""Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy,"" Hum Gene Ther, 8(17):2057-68, (Nov. 20, 1997). Abstract Only.;;Kroll, R. A. et al., Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers, Neurosurgery, 43(4):879-86; discussion 886-9, (Oct. 1998). Abstract Only.;;Markert, James M. et al., ""Expanded spectrum of viral therapy int he treatment of nervous system tumors,"" J. Neurosurg, 77:590-594 (1992).;;Markert, James M. et al., ""Reduction and Elimination of Encephalitis in an Experimental Glloma Therapy Model with Attenuated Herpes Simplex Mutants that Retain Susceptibility to Acyclovir,"" Neurosurgery, vol. 32, No. 4, pp. 597-603, (Apr. 1993).;;Martuza, Robert L., ""Experimental Therapy of Human Gllomo by Means of a Genetically Engineered Virus Mutant,"" Science, vol. 252, pp. 854-856 (May 10, 1991).;;Mineta, Toshihiro et al., ""Mutant Viral Therapy for Malignant Brain Tumors Using Ribonucleotide Reductase-Deficient Herpes Simplex Virus 1,"" J. Neurosurg., vol. 80, No. 2, p. 381 (Feb. 10, 1994). Meeting Program Item #1534.;;Moore, Alice E., ""Effects of Viruses on Tumors,"" Annual Review of Microbiology, vol. 8, pp. 393-410 (1954).;;Moore, A. E., ""The Oncolytic Viruses,"" Experimental Tumor Research/Sloan-Kettering Institute for Cancer Research, 1:411-439, (1960).;;Muldoon, L. L. et al., ""Comparison f intercerebral inoculation and smotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain,"" Am J Pathol, 147(6):1840-51 (Dec. 1995). Abstract Only.;;Nilaver,G. et al., ""Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption,"" Proc Natl Acad Sci U S A, 92(21):9829-33 (Oct. 10, 1995). Abstract Only.;;Muldoon, L. L. et al., ""A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery,"" AJNR Am J Neuroradiol, 20(2):217-22 (Feb. 1999). Abstract Only.;;Neuwelt, E. A. et al., ""Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier,"" J Neurosurg, 74(3):475-9 (Mar. 1991). Abstract Only.;;Neuwelt, E. A. et al., ""Delivery of virus-sized iron oxide particles to rodent CNS neurons,"" Neurosurgery, 34(4):777-84 (Apr. 1994). Abstract Only.;;Oldfield, Edward H. et al., Clinical Protocols, Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with Thymidine Kinase Gene and Intravenous Ganciclovir, Human Gene Therapy, 4:39-69 (1993).;;Perng, G. C. et al.., ""Evidence that the HSV-1 LAT's Main Role May be in Reactivation from Latency Rather than in Establishment of Latency,"" Abstract presented at Association for Research in Vision and Opthalmology (ARVO) May 1997.;;Perng, Guey-Chuen et al, ""The Latency-Associated Transcript Gene of Herpes Simplex virus Type 1 (HSV-1) is Required for Efficient In Vivo Spontaneous Reactivation of HSV-1 from Latency,"" Journal of Virology, vol. 68, No. 12, pp. 8045-8055 (Dec. 1994).;;Perng, Guey-Chuen et al., "" An Avirulent ICP34.5 Deletion Mutant of Herpes Simplex virus Type 1 is Capable of In Vivo Spontaneous Reactivation,"" Journal of Virology, vol. 60, No. 5, pp. 3033-3041 (May 1995).;;Perng, Guey-Chuen et al., ""High-Dose Oscular Infection with a Herpes Simplex Virus Type 1 ICP 34.5 Deletion Mutant Produces No Corneal Disease or Neurovirulence yet Results in Wild-Type Levels of Spontaneous Reactivation,"" Journal of Virology, vol. 70, No. 5, pp. 2883-2893 (May 1996).;;Rainov, N. G. et al. ""Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery f a therapeutic herpes simplex virus vector,"" Cancer Gene Ther, 5(3):158-62 (May-Jun. 1998). Abstract Only.;;Rainov, N. G. et al. ""Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms,"" Hum Gene Ther, 10(2):311-8 (Jan. 20, 1999). Abstract Only.;;Rainov, N. G. et al., ""A chimeric fusion protein f cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glloma,"" Adv Exp Med Biol, 451:393-403 (1998). Abstract Only.;;Rapoport, S. I., et al., ""Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier,"" Ann N Y Acad Sci, 481:250-67 (1986). Abstract Only.;;Yang, W. et al., ""Enhanced delivery of boronophenylkalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption,"" Neurosurgery, 38(5):985-92 (May 1996), Abstract Only.;;Rainov, N. G. et al., ""Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms,"" 6(12):1543-52 (Dec. 1995). Abstract Only.;;Anderson, W. F., Gene therapy scores against cancer, Nat. Med. 6(8):862-63 [Aug. 2000].;;Delman, K.A. et al., Effects of pre-existing immunity on the response to herpes simplex-based oncolytic viral therapy, Human Gene Therapy 11:2465-72 [2000].;;Ebbinghaus, C. et al., Functional and selective targeting of adenovirus to high-affinity Fcy receptor 1-positive cells by using a bispecific hybrid adapter, J. Virol. 75(1):480-489 [2001].;;Haisma, H.J. et al., Targeting of adenoviral vectors through a bispecific single-chain antibody, Cancer Gene Ther. 7(6):901-04 [2000], Abstract Only.;;Markert, J.M. et al., Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase 1 trial, Gene Therapy 7:867-74 [2000].;;Miller, C.R. et al., Differential susceptibility of primary and established human cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gen transfer, Cancer Res. 58:5738-5748 [1998].;;Mullen, C.A. et al., Molecular analysis of Tlymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes intorduced with a retroviral vector, Human Gene Therapy 7:1123-1129 [Jun. 1996].;;Nesburn, A.B. et al., Therapeutic periocular vaccination with subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits, Virology 252:200-09 [1998].;;Oyama, M et al., Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207, Jpn. J. Cancer Res. 91(12):1339-44 [2000a], Abstract only.;;Oyama, M. et al., Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207, Hum. Gene Ther. 11(12):1683-93 [2000b], Abstract only.;;Porada et al., In utero gene therapy: transfer and long-term expression of the bacterial neor gene in sheep after direct injection of retroviral vectors into preimmune fetuses, Human Gene Therapy 9:1571-85 [Jul. 20, 1998].;;Toda, M. et al., Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity, Hum. Gene Ther. 10(3):385-93 [1999], Abstract only.;;Walker, J.R. et al., Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207, Hum. Gene Ther. 10(13):2237-43 [1999], Abstract only.;;International Search Report, PCT/US 00/11031, mailed Sept. 4, 2000.;;McGeoch, Duncan J., et al., Comparative sequence analysis of the long repeat regions and adjoining parts of the long unique regions in the genomes of herpes simplex viruses types 1 and 2, Journal of General Virology, vol. 72: pp. 3057-3075 (1991).;;Kramm, Christof M., et al., Gene Therapy for Brain Tumors, Brain Pathology, vol. 5: pp. 345-381 (1995).",EXPIRED
445,AU,A,AU 2000/044873 A,164-447-963-136-014,2000-11-10,2000,AU 2000/044873 A,2000-04-24,US 29981799 A;;US 0011031 W,1999-04-26,A herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells,,CEDARS SINAI MEDICAL CENTER,WESCHLER STEVEN L;;NESBURN ANTHONY B;;PERNG GUEY-CHUEN;;YU JOHN S;;BLACK KEITH L,,https://lens.org/164-447-963-136-014,Patent Application,no,0,0,6,6,0,A61K39/00;;A61K48/00;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16622;;C12N2710/16643;;C12N2710/16661;;A61P35/00;;C12N7/00;;C07K14/005;;C12N2710/16643;;A61K39/00;;C12N2710/16622;;C12N2710/16661;;C12N15/86;;A61K48/00,A61K39/00;;A61K48/00;;A61P35/00;;C07K14/035;;C12N7/04;;C12N15/38;;C12N15/869,,0,0,,,,DISCONTINUED
446,WO,A1,WO 2017/177194 A1,069-084-352-398-097,2017-10-12,2017,US 2017/0026697 W,2017-04-07,US 201662320314 P,2016-04-08,TISSUE CLASSIFICATION METHOD USING TIME-RESOLVED FLUORESCENCE SPECTROSCOPY AND COMBINATION OF MONOPOLAR AND BIPOLAR CORTICAL AND SUBCORTICAL STIMULATOR WITH TIME-RESOLVED FLUORESCENCE SPECTROSCOPY,"Provided herein are methods for classifying or characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy and/or electrical stimulation. A biological sample may produce a responsive fluorescence signal when irradiated by a light excitation signal or pulse at a predetermined wavelength. The responsive fluorescence signal may be recorded. The intensity of the excitation wavelength may be recorded and used to normalize the recorded responsive fluorescence signal. The biological sample may produce a responsive electrical signal in response to electrical stimulation. Raw fluorescence decay data may be generated from the responsive fluorescence signal and pre-processed. The pre-processed raw fluorescence decay data may be de-convolved to remove an instrument response function therefrom and generate true fluorescence decay data. The biological sample may be characterized in response to the responsive fluorescence signal, the responsive electrical signal, the normalized responsive fluorescence signal, and/or the true fluorescence decay data.",CEDARS SINAI MEDICAL CENTER;;NIE ZHAOJUN,NIE ZHAOJUN;;BUTTE PRAMOD;;PATIL CHIRAG;;BLACK KEITH L;;VASEFI FARTASH;;KITTLE DAVID SCOTT;;BORTNIK BARTOSZ,,https://lens.org/069-084-352-398-097,Patent Application,yes,3,5,4,4,0,A61B5/7264;;G01N21/6408;;G01N21/645;;G01N21/718;;A61B2018/00577;;A61B2505/05;;A61B2562/0233;;G01N2021/6417;;G01N2021/6484;;A61B5/0071;;A61B5/4064;;G01N21/6486;;G01J3/2889;;G01J3/44;;A61B18/24;;A61B5/24;;A61B5/7264;;G01N21/6408;;G01N21/645;;G01N21/718;;A61B2562/0233;;G01J3/44;;A61B2505/05;;A61B2018/00577;;G01J3/4406;;G01J3/2889;;G01N2021/6417;;G01N2021/6484;;A61B5/24;;A61B5/0071;;A61B5/4064;;A61B5/7203;;A61B5/7271;;A61B18/24;;A61B2018/00642;;G01N21/6486,A61B5/05;;A61B6/12;;A61B18/20,,0,0,,,,PENDING
447,WO,A2,WO 2008/034069 A2,041-190-677-603-717,2008-03-20,2008,US 2007/0078513 W,2007-09-14,US 82570606 P,2006-09-14,NET MATERIAL,The present disclosure relates to a nonwoven insect barrier net. The nonwoven insect barrier may be formed into a net structure for use over and/or surrounding a sleeping surface. The nonwoven insect barrier net may inhibit insects from penetrating the area within the net structure. The insect barrier may be formed from a nonwoven material and an insect repellant composition.,FREUDENBERG NONWOVENS L P;;BLACK SAMUEL KEITH;;ERICKSON JODY ANNE;;GALLINGER SCOTT;;SIMMONS BETSY;;ZAPLETALOVA TEREZIE;;SKINNER JEAN;;STINE JEFF,BLACK SAMUEL KEITH;;ERICKSON JODY ANNE;;GALLINGER SCOTT;;SIMMONS BETSY;;ZAPLETALOVA TEREZIE;;SKINNER JEAN;;STINE JEFF,,https://lens.org/041-190-677-603-717,Patent Application,yes,0,0,4,4,0,A01M29/12;;A01M29/12;;A01M29/34;;A01M29/34;;D04H3/16;;D04H3/16;;E06B9/52;;E06B9/52;;Y10T442/2541;;Y10T442/2541,B29C59/04;;B32B5/02,,0,0,,,,PENDING
448,CL,A1,CL 2008003089 A1,069-905-690-579-996,2009-01-09,2009,CL 2008003089 A,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,"Metodo para tratar enfermedad de alzheimer que comprende un regimen de un anticuerpo que se un epitopo en el n-terminal del peptido amiloide beta, anticuerpo humanizado contra la proteina amiloide beta que tiene sustituidas las posiciones 234, 235, y 237 por alanina en la region constante de las cadenas pesadas.",Método para tratar enfermedad de Alzheimer que comprende un régimen efectivo de un anticuerpo que se une específicamente al epitopo en el n-terminal del péptido alfa beta; método para monitorear una población de pacientes a experimentar tratamiento o profilaxis para una enfermedad caracterizada por depósitos de amiloides de alfa beta en el cerebro.,WYETH LLC;;JANSSEN ALZHEIMER IMMUNOTHERAP,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JIM;;GREGG KEITH M;;JACOBSEN JACK STEVEN,,https://lens.org/069-905-690-579-996,Patent Application,no,0,1,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/395;;A61P25/28;;C07K16/18;;C12N15/13,,0,0,,,,PENDING
449,WO,A8,WO 2017/177194 A8,135-582-886-501-590,2017-12-21,2017,US 2017/0026697 W,2017-04-07,US 201662320314 P,2016-04-08,TISSUE CLASSIFICATION METHOD USING TIME-RESOLVED FLUORESCENCE SPECTROSCOPY AND COMBINATION OF MONOPOLAR AND BIPOLAR CORTICAL AND SUBCORTICAL STIMULATOR WITH TIME-RESOLVED FLUORESCENCE SPECTROSCOPY,"Provided herein are methods for classifying or characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy and/or electrical stimulation. A biological sample may produce a responsive fluorescence signal when irradiated by a light excitation signal or pulse at a predetermined wavelength. The responsive fluorescence signal may be recorded. The intensity of the excitation wavelength may be recorded and used to normalize the recorded responsive fluorescence signal. The biological sample may produce a responsive electrical signal in response to electrical stimulation. Raw fluorescence decay data may be generated from the responsive fluorescence signal and pre-processed. The pre-processed raw fluorescence decay data may be de-convolved to remove an instrument response function therefrom and generate true fluorescence decay data. The biological sample may be characterized in response to the responsive fluorescence signal, the responsive electrical signal, the normalized responsive fluorescence signal, and/or the true fluorescence decay data.",CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;PATIL CHIRAG;;BLACK KEITH L;;VASEFI FARTASH;;KITTLE DAVID SCOTT;;BORTNIK BARTOSZ;;NIE ZHAOJUN,,https://lens.org/135-582-886-501-590,Amended Application,yes,0,0,4,4,0,A61B5/7264;;G01N21/6408;;G01N21/645;;G01N21/718;;A61B2018/00577;;A61B2505/05;;A61B2562/0233;;G01N2021/6417;;G01N2021/6484;;A61B5/0071;;A61B5/4064;;G01N21/6486;;G01J3/2889;;G01J3/44;;A61B18/24;;A61B5/24;;A61B5/7264;;G01N21/6408;;G01N21/645;;G01N21/718;;A61B2562/0233;;G01J3/44;;A61B2505/05;;A61B2018/00577;;G01J3/4406;;G01J3/2889;;G01N2021/6417;;G01N2021/6484;;A61B5/24;;A61B5/0071;;A61B5/4064;;A61B5/7203;;A61B5/7271;;A61B18/24;;A61B2018/00642;;G01N21/6486,A61B5/05;;A61B6/12;;A61B18/20,,0,0,,,,PENDING
450,EP,A2,EP 2069143 A2,155-289-319-132-234,2009-06-17,2009,EP 07842520 A,2007-09-14,US 2007/0078513 W;;US 82570606 P,2006-09-14,NET MATERIAL,,FREUDENBERG NONWOVENS L P,BLACK SAMUEL KEITH;;ERICKSON JODY ANNE;;GALLINGER SCOTT;;SIMMONS BETSY;;ZAPLETALOVA TEREZIE;;SKINNER JEAN;;STINE JEFF,CARL FREUDENBERG KG (2009-08-26),https://lens.org/155-289-319-132-234,Patent Application,yes,0,0,4,4,0,A01M29/12;;A01M29/12;;A01M29/34;;A01M29/34;;D04H3/16;;D04H3/16;;E06B9/52;;E06B9/52;;Y10T442/2541;;Y10T442/2541,B32B27/04,,1,0,,,See references of WO 2008034069A3,DISCONTINUED
451,US,A1,US 2017/0290515 A1,115-323-877-874-801,2017-10-12,2017,US 201715482442 A,2017-04-07,US 201715482442 A;;US 201662320314 P,2016-04-08,TISSUE CLASSIFICATION METHOD USING TIME-RESOLVED FLUORESCENCE SPECTROSCOPY AND COMBINATION OF MONOPOLAR AND BIPOLAR CORTICAL AND SUBCORTICAL STIMULATOR WITH TIME-RESOLVED FLUORESCENCE SPECTROSCOPY,"Provided herein are methods for classifying or characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy and/or electrical stimulation. A biological sample may produce a responsive fluorescence signal when irradiated by a light excitation signal or pulse at a predetermined wavelength. The responsive fluorescence signal may be recorded. The intensity of the excitation wavelength may be recorded and used to normalize the recorded responsive fluorescence signal. The biological sample may produce a responsive electrical signal in response to electrical stimulation. Raw fluorescence decay data may be generated from the responsive fluorescence signal and pre-processed. The pre-processed raw fluorescence decay data may be de-convolved to remove an instrument response function therefrom and generate true fluorescence decay data. The biological sample may be characterized in response to the responsive fluorescence signal, the responsive electrical signal, the normalized responsive fluorescence signal, and/or the true fluorescence decay data.",CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;PATIL CHIRAG;;BLACK KEITH L;;VASEFI FARTASH;;KITTLE DAVID SCOTT;;BORTNIK BARTOSZ;;NIE ZHAOJUN,CEDARS-SINAI MEDICAL CENTER (2017-03-22),https://lens.org/115-323-877-874-801,Patent Application,yes,0,15,4,4,0,A61B5/7264;;G01N21/6408;;G01N21/645;;G01N21/718;;A61B2018/00577;;A61B2505/05;;A61B2562/0233;;G01N2021/6417;;G01N2021/6484;;A61B5/0071;;A61B5/4064;;G01N21/6486;;G01J3/2889;;G01J3/44;;A61B18/24;;A61B5/24;;A61B5/7264;;G01N21/6408;;G01N21/645;;G01N21/718;;A61B2562/0233;;G01J3/44;;A61B2505/05;;A61B2018/00577;;G01J3/4406;;G01J3/2889;;G01N2021/6417;;G01N2021/6484;;A61B5/24;;A61B5/0071;;A61B5/4064;;A61B5/7203;;A61B5/7271;;A61B18/24;;A61B2018/00642;;G01N21/6486,A61B5/00;;A61B18/24;;G01N21/64,,0,0,,,,DISCONTINUED
452,WO,A3,WO 2008/034069 A3,156-653-248-245-083,2008-07-17,2008,US 2007/0078513 W,2007-09-14,US 82570606 P,2006-09-14,NET MATERIAL,The present disclosure relates to a nonwoven insect barrier net. The nonwoven insect barrier may be formed into a net structure for use over and/or surrounding a sleeping surface. The nonwoven insect barrier net may inhibit insects from penetrating the area within the net structure. The insect barrier may be formed from a nonwoven material and an insect repellant composition.,FREUDENBERG NONWOVENS L P;;BLACK SAMUEL KEITH;;ERICKSON JODY ANNE;;GALLINGER SCOTT;;SIMMONS BETSY;;ZAPLETALOVA TEREZIE;;SKINNER JEAN;;STINE JEFF,BLACK SAMUEL KEITH;;ERICKSON JODY ANNE;;GALLINGER SCOTT;;SIMMONS BETSY;;ZAPLETALOVA TEREZIE;;SKINNER JEAN;;STINE JEFF,,https://lens.org/156-653-248-245-083,Search Report,yes,3,0,4,4,0,A01M29/12;;A01M29/12;;A01M29/34;;A01M29/34;;D04H3/16;;D04H3/16;;E06B9/52;;E06B9/52;;Y10T442/2541;;Y10T442/2541,B32B27/04,,0,0,,,,PENDING
453,GB,A,GB 2523023 A,044-647-598-326-308,2015-08-12,2015,GB 201508155 A,2013-12-03,US 201261733372 P;;US 201313843279 A;;US 2013/0072903 W,2012-12-04,Compact dehumidifiers and associated systems and methods,"Compact dehumidifiers and associated systems and methods are disclosed. A representative system includes a housing having an airflow entrance, and airflow exit, and a linear flowpath between the entrance and exit. The system further includes a refrigeration cycle having, in sequence along the flowpath, an evaporator, a compressor, a condenser, and an air flow driver. A controller is operatively coupled to the evaporator, compressor, condenser, and airflow driver to operate the refrigeration cycle for removing moisture from an entering airflow.",DRI EAZ PRODUCTS INC,BLACK RICHARD A;;HOFFMAN KEITH;;BRUDERS WILLIAM EDWARD;;BARTHOLMEY BRETT ALAN;;KIESSER AARON MATTHEW;;WHITE LARRY,,https://lens.org/044-647-598-326-308,Patent Application,no,5,0,9,9,0,F24F13/20;;F24F2003/144;;F24F2221/12;;F24F3/14;;Y10T29/49359;;F24F1/02;;F24F3/14;;F24F13/02;;F24F13/20;;F24F2221/12;;F24F2003/144;;Y10T29/49359;;F24F3/14;;Y10T29/49359;;F24F13/20;;F24F2003/144;;F24F2221/12,F24F3/14;;F24F1/02;;F24F13/02;;F24F13/20,,0,0,,,,DISCONTINUED
454,GB,A8,GB 2523023 A8,060-961-648-365-184,2015-08-19,2015,GB 201508155 A,2013-12-03,US 201261733372 P;;US 201313843279 A;;US 2013/0072903 W,2012-12-04,Compact dehumidifiers and associated systems and methods,"Compact dehumidifiers and associated systems and methods are disclosed. A representative system includes a housing having an airflow entrance, and airflow exit, and a linear flowpath between the entrance and exit. The system further includes a refrigeration cycle having, in sequence along the flowpath, an evaporator, a compressor, a condenser, and an air flow driver. A controller is operatively coupled to the evaporator, compressor, condenser, and airflow driver to operate the refrigeration cycle for removing moisture from an entering airflow.",DRI EAZ PRODUCTS INC,BLACK RICHARD A;;HOFFMAN KEITH;;BRUDERS WILLIAM EDWARD;;BARTHOLMEY BRETT ALAN;;KIESSER AARON MATTHEW;;WHITE LARRY,,https://lens.org/060-961-648-365-184,Patent Application,no,0,0,9,9,0,F24F13/20;;F24F2003/144;;F24F2221/12;;F24F3/14;;Y10T29/49359;;F24F1/02;;F24F3/14;;F24F13/02;;F24F13/20;;F24F2221/12;;F24F2003/144;;Y10T29/49359;;F24F3/14;;Y10T29/49359;;F24F13/20;;F24F2003/144;;F24F2221/12,F24F3/14;;F24F1/02;;F24F13/02;;F24F13/20,,0,0,,,,DISCONTINUED
455,TW,A,TW 201737864 A,086-931-251-561-853,2017-11-01,2017,TW 106111809 A,2017-04-07,US 201662320314 P,2016-04-08,Tissue classification method using time-resolved fluorescence spectroscopy and combination of monopolar and bipolar cortical and subcortical stimulator with time-resolved fluorescence spectroscopy,"Provided herein are methods for classifying or characterizing a biological sample in vivo or ex vivo in real-time using time-resolved spectroscopy and/or electrical stimulation. A biological sample may produce a responsive fluorescence signal when irradiated by a light excitation signal or pulse at a predetermined wavelength. The responsive fluorescence signal may be recorded. The intensity of the excitation wavelength may be recorded and used to normalize the recorded responsive fluorescence signal. The biological sample may produce a responsive electrical signal in response to electrical stimulation. Raw fluorescence decay data may be generated from the responsive fluorescence signal and pre-processed. The pre-processed raw fluorescence decay data may be de-convolved to remove an instrument response function therefrom and generate true fluorescence decay data. The biological sample may be characterized in response to the responsive fluorescence signal, the responsive electrical signal, the normalized responsive fluorescence signal, and/or the true fluorescence decay data.",CEDARS SINAI MEDICAL CENTER,BUTTE PRAMOD;;PATIL CHIRAG;;BLACK KEITH L;;VASEFI FARTASH;;KITTLE DAVID SCOTT;;BORTNIK BARTOSZ;;NIE ZHAO-JUN,,https://lens.org/086-931-251-561-853,Patent of Addition,no,0,1,4,4,0,A61B5/7264;;G01N21/6408;;G01N21/645;;G01N21/718;;A61B2018/00577;;A61B2505/05;;A61B2562/0233;;G01N2021/6417;;G01N2021/6484;;A61B5/0071;;A61B5/4064;;G01N21/6486;;G01J3/2889;;G01J3/44;;A61B18/24;;A61B5/24;;A61B5/7264;;G01N21/6408;;G01N21/645;;G01N21/718;;A61B2562/0233;;G01J3/44;;A61B2505/05;;A61B2018/00577;;G01J3/4406;;G01J3/2889;;G01N2021/6417;;G01N2021/6484;;A61B5/24;;A61B5/0071;;A61B5/4064;;A61B5/7203;;A61B5/7271;;A61B18/24;;A61B2018/00642;;G01N21/6486,A61B10/00;;G01N21/25,,0,0,,,,PENDING
456,US,A1,US 2021/0128731 A1,013-430-800-472-72X,2021-05-06,2021,US 201917047647 A,2019-04-18,US 201917047647 A;;US 201862659449 P;;US 201862731575 P;;US 2019/0028179 W,2018-04-18,"NANOPARTICLES FOR BORON NEUTRON CAPTURE THERAPY AND FOR DIAGNOSING, DETECTING, AND TREATING CANCER","The invention provides a nanovehicle, comprising: a core, wherein the core comprises at least one iron oxide: a shell surrounding the core, wherein the shell comprises at least one polymer; and at least one boron cluster. The invention provides a method of treating a disease, disorder, or disease condition in a subject, comprising administering a therapeutically effective amount of the nanovehicle to the subject; and radiating the nanovehicle with neutrons. In various embodiments, the invention provides a method for detecting a cancer in a subject, comprising administering an effective amount of at least one nanoparticle of the present invention to the subject. The invention also provides the nanovehicles (e.g., nanoparticles) described herein in the form of various pharmaceutical formulations. The invention provides a kit, the kit comprises: a quantity of the nanovehicle (e.g., nanoparticle) described herein.",CEDARS SINAI MEDICAL CENTER;;UNIV CALIFORNIA,PEREZ J MANUEL;;SPOKOYNY ALEXANDER M;;TEH JAMES;;BERNIER NICHOLAS;;BLACK KEITH L;;CHUNG LELAND;;ZHANG YI,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2020-10-07);;CEDARS-SINAI MEDICAL CENTER (2019-04-22),https://lens.org/013-430-800-472-72X,Patent Application,yes,0,1,2,2,5,A61P35/00;;A61K33/26;;A61K33/22;;A61K41/0095;;A61K49/0032;;A61K49/0054;;A61K49/0093;;A61K47/551;;A61K47/542;;A61K47/6923;;A61K47/61;;A61K47/62;;A61K47/61;;A61K47/62;;A61K47/542;;A61K47/6923;;A61K9/5115;;A61K9/5161;;A61K33/22;;A61K41/0095;;A61K49/0054;;A61K49/0093,A61K41/00;;A61K9/51;;A61K33/22;;A61K47/54;;A61K47/61;;A61K47/62;;A61K47/69;;A61K49/00,,0,0,,,,DISCONTINUED
457,WO,A1,WO 2019/204645 A1,121-134-441-120-181,2019-10-24,2019,US 2019/0028179 W,2019-04-18,US 201862659449 P;;US 201862731575 P,2018-04-18,"NANOPARTICLES FOR BORON NEUTRON CAPTURE THERAPY AND FOR DIAGNOSING, DETECTING, AND TREATING CANCER","The invention provides a nanovehicle, comprising: a core, wherein the core comprises at least one iron oxide: a shell surrounding the core, wherein the shell comprises at least one polymer; and at least one boron cluster. The invention provides a method of treating a disease, disorder, or disease condition in a subject, comprising administering a therapeutically effective amount of the nanovehicle to the subject; and radiating the nanovehicle with neutrons. In various embodiments, the invention provides a method for detecting a cancer in a subject, comprising administering an effective amount of at least one nanoparticle of the present invention to the subject. The invention also provides the nanovehicles (e.g., nanoparticles) described herein in the form of various pharmaceutical formulations. The invention provides a kit, the kit comprises: a quantity of the nanovehicle (e.g., nanoparticle) described herein..",CEDARS SINAI MEDICAL CENTER;;UNIV CALIFORNIA,PEREZ J MANUEL;;SPOKOYNY ALEXANDER M;;TEH JAMES;;BERNIER NICHOLAS;;BLACK KEITH L;;CHUNG LELAND;;ZHANG YI,,https://lens.org/121-134-441-120-181,Patent Application,yes,7,2,2,2,5,A61P35/00;;A61K33/26;;A61K33/22;;A61K41/0095;;A61K49/0032;;A61K49/0054;;A61K49/0093;;A61K47/551;;A61K47/542;;A61K47/6923;;A61K47/61;;A61K47/62;;A61K47/61;;A61K47/62;;A61K47/542;;A61K47/6923;;A61K9/5115;;A61K9/5161;;A61K33/22;;A61K41/0095;;A61K49/0054;;A61K49/0093,A61K9/14;;A61K9/51;;A61K31/704;;A61K47/36;;A61K49/00;;A61N1/40;;A61P35/00,,2,1,019-867-657-418-017,23987828;;10.1021/bc400219t,"GOPINATH P ET AL: ""Cancer Nanotheranostics"", 11 March 2015, SPRINGER, Singapore, ISBN: 978-981-2874-35-1, article GOPINATH ET AL.: ""Cancer nanotheranostics"", pages: 1 - 94, XP055645474, DOI: 10.1007/978-981-287-435-1_1;;LAI ET AL.: ""Stepwise Orthogonal Click Chemistry toward Fabrication of Paclitaxel/Galactose Functionalized Fluorescent Nanoparticles for HepG2 Cell Targeting and Delivery"", BIOCONJUGATE CHEMISTRY, vol. 24, no. 10, 16 October 2013 (2013-10-16), pages 1698 - 1709, XP055122984, ISSN: 1043-1802, DOI: 10.1021/bc400219t",PENDING
458,US,A,US 5288052 A,154-455-822-037-992,1994-02-22,1994,US 98830392 A,1992-12-08,US 98830392 A,1992-12-08,Self-draining sanitary control valve,The self-draining sanitary control valve includes a body having an inlet and an outlet and a fluid control port forming a valve seat between the inlet and the outlet. A bonnet is detachably secured to the body having a stem receiving bore aligned on a common central axis with the control port. Clamping rings are provided for securably clamping the body and bonnet together and for securing the valve body to adjacent fluid lines. The clamping rings are readily detachable for permitting the valve to be cleaned and the interior surfaces of the valve are closed to provide for self-draining of the fluid contained therein. The valve includes a stem slidably mounted in the bore with a valve plug at one end having a predetermined outer surface profile movable toward and away from the port and a flexible diaphragm is secured to a central portion of the plug for engaging the valve seat. An outer portion of the diaphragm is clamped between the body and the bonnet when the clamp ring is locked in place. A central portion of the flexible diaphragm is permanently secured to the profiled outer surface of the valve plug to provide a matching profile similar to the valve plug for cooperation with the valve seat to result in a predetermined flow characteristic that is dependent on the profile of the valve plug rather than the resilient characteristics of the diaphragm alone.,CASHCO INC,BLACK W KEITH;;HLAD JEROLD L;;ROGERS PHILLIP G;;ROHR WAYNE A;;SHARP DANIEL L;;SHIFFER BRUCE H,CASHCO INC (1992-12-04),https://lens.org/154-455-822-037-992,Granted Patent,yes,8,45,1,1,0,F16K31/1262;;F16K31/1262;;F16K37/0058;;F16K37/0058;;Y10T137/8292;;Y10T137/8292,F16K31/126;;F16K37/00,251/30.01;;137/556.3;;251/61.4;;251/291;;251/331,0,0,,,,EXPIRED
459,US,A1,US 2022/0025365 A1,167-506-024-018-251,2022-01-27,2022,US 202117382945 A,2021-07-22,US 202117382945 A;;US 202063055460 P,2020-07-23,"METHODS FOR NOMINATION OF NUCLEASE ON-/OFF-TARGET EDITING LOCATIONS, DESIGNATED ""CTL-seq"" (CRISPR Tag Linear-seq)",Described herein are methods for identifying and nominating on- and off-target CRISPR editing sites with improved accuracy and sensitivity.,INTEGRATED DNA TECH INC,MCNEILL MATTHEW;;TURK ROLF;;RETTIG GARRETT;;BLACK ELLEN;;SUN YONGMING;;SAILOR CHRIS;;WANG YU;;GUNDERSON KEITH;;KINNEY KYLE,INTEGRATED DNA TECHNOLOGIES INC (2021-08-06),https://lens.org/167-506-024-018-251,Patent Application,yes,5,0,9,9,273,C12Q1/6811;;C12Q1/6869;;C12N2310/20;;C12N9/22;;C12N15/111;;C12Q1/6853,C12N15/11;;C12N9/22;;C12Q1/6853,,3,1,101-296-414-772-981,10.1371/journal.pone.0042543;;pmc3416851;;22900027,Wang Z et al. Biotechnol. 2011 Nov 17;11:109 (Year: 2011);;Faircloth BC et al. PLoS One. 2012;7(8):e42543 (Year: 2012);;NCBI BLAST Search Results report conducted 11/8/2023 showing zero identity results (Year: 2023),PENDING
460,EP,A2,EP 4185708 A2,135-196-792-769-988,2023-05-31,2023,EP 21755231 A,2021-07-22,US 202063055460 P;;US 2021/0042733 W,2020-07-23,"METHODS FOR NOMINATION OF NUCLEASE ON-/OFF-TARGET EDITING LOCATIONS, DESIGNATED ""CTL-SEQ"" (CRISPR TAG LINEAR-SEQ)",,INTEGRATED DNA TECH INC,MCNEILL MATTHEW;;TURK ROLF;;RETTIG GARRETT;;BLACK ELLEN;;SUN YONGMING;;SAILOR CHRIS;;WANG YU;;GUNDERSON KEITH;;KINNEY KYLE,,https://lens.org/135-196-792-769-988,Patent Application,yes,0,0,9,9,0,C12Q1/6811;;C12Q1/6869;;C12N2310/20;;C12N9/22;;C12N15/111;;C12Q1/6853,C12Q1/6811;;C12N15/113;;C12Q1/6869,,0,0,,,,PENDING
461,WO,A3,WO 2022/020567 A3,006-387-982-419-879,2022-03-10,2022,US 2021/0042733 W,2021-07-22,US 202063055460 P,2020-07-23,"METHODS FOR NOMINATION OF NUCLEASE ON-/OFF-TARGET EDITING LOCATIONS, DESIGNATED ""CTL-SEQ"" (CRISPR TAG LINEAR-SEQ)","Methods for identifying and nominating on- and off-target CRISPR editing sites, particularly Cas9, with improved accuracy and sensitivity in which a tag is inserted a double-stranded breaks and the region comprising the tag and a universal adapter comprising a unique molecular index (UMI). The sequences to which the universal sequencing primer binds may be predesigned. A method for designing 52-base pair tag sequences based on (a) randomly generating 13-nucleotide sequences with 40-90% GC content, max homopolymer length A:2, C:3, G:2, T:2, weighted homopolymer rate < 20, self-folding 7m < 50 °C, and self-dimer 7m < 50 °C; (b) removing sequences that perfectly align to a particular genome or that are homopolymers or GG or CC dinucleotide motifs and obtaining a set of 13-mers; (c) selecting a subset of the 13-mer sequences that contain one or less CC or GG dinucleotide motifs; (d) concatenating four of the of 13-mer subset sequences to form random 52-mer sequences; (e) aligning the random 52-mer sequences to a genome; (f) removing the random 52-mer sequences that have similarity to the genome to produce a subset of 52-mer sequences; and (h) outputting the subset of 52-mer sequences and generating the complementary strands to produce double stranded 52-base pair tag sequences.",INTEGRATED DNA TECH INC,MCNEILL MATTHEW;;TURK ROLF;;RETTIG GARRETT;;BLACK ELLEN;;SUN YONGMING;;SAILOR CHRIS;;WANG YU;;GUNDERSON KEITH;;KINNEY KYLE,,https://lens.org/006-387-982-419-879,Search Report,yes,4,0,9,9,0,C12Q1/6811;;C12Q1/6869;;C12N2310/20;;C12N9/22;;C12N15/111;;C12Q1/6853,C12Q1/6811;;C12N15/113;;C12Q1/6869,,2,2,065-631-319-612-228;;005-011-002-599-105,32541958;;10.1038/s41587-020-0555-7;;pmc7652380;;pmc8144550;;34031394;;10.1038/s41467-021-22417-4,"LAZZAROTTO CICERA R ET AL: ""CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity"", NATURE BIOTECHNOLOGY, GALE GROUP INC, NEW YORK, vol. 38, no. 11, 15 June 2020 (2020-06-15), pages 1317 - 1327, XP037294242, ISSN: 1087-0156, [retrieved on 20200615], DOI: 10.1038/S41587-020-0555-7;;AMIT IDO ET AL: ""CRISPECTOR provides accurate estimation of genome editing translocation and off-target activity from comparative NGS data"", NATURE COMMUNICATIONS, vol. 12, no. 1, 24 May 2021 (2021-05-24), XP055852901, Retrieved from the Internet <URL:http://www.nature.com/articles/s41467-021-22417-4> DOI: 10.1038/s41467-021-22417-4",PENDING
462,WO,A2,WO 2022/020567 A2,109-163-464-238-287,2022-01-27,2022,US 2021/0042733 W,2021-07-22,US 202063055460 P,2020-07-23,"METHODS FOR NOMINATION OF NUCLEASE ON-/OFF-TARGET EDITING LOCATIONS, DESIGNATED ""CTL-SEQ"" (CRISPR TAG LINEAR-SEQ)",Described herein are methods for identifying and nominating on- and off-target CRISPR editing sites with improved accuracy and sensitivity.,INTEGRATED DNA TECH INC,MCNEILL MATTHEW;;TURK ROLF;;RETTIG GARRETT;;BLACK ELLEN;;SUN YONGMING;;SAILOR CHRIS;;WANG YU;;GUNDERSON KEITH;;KINNEY KYLE,,https://lens.org/109-163-464-238-287,Patent Application,yes,1,0,9,9,273,C12Q1/6811;;C12Q1/6869;;C12N2310/20;;C12N9/22;;C12N15/111;;C12Q1/6853,C12Q1/6811;;C12N15/113;;C12Q1/6869,,7,7,021-777-845-146-998;;029-059-817-938-044;;015-174-914-322-220;;078-629-053-158-45X;;019-579-375-012-805;;036-428-373-485-826;;019-353-110-428-846,10.1126/science.aav9023;;pmc6589096;;31000663;;10.1101/469635;;pmc6337799;;10.1186/s13059-019-1625-3;;30654827;;pmc4320685;;10.1038/nbt.3117;;25513782;;28497783;;pmc5437291;;10.1038/ncomms15058;;10.1038/nmeth.4278;;28459458;;pmc5924695;;10.1038/nmeth.3473;;pmc5292764;;26167643;;16091627;;10.1093/nar/gni120;;pmc1184225,"WIENERT ET AL.: ""Unbiased detection of CRISPR off-targets in vivo using DISCOVER-seq"", SCIENCE, vol. 364, no. 6437, 2019, pages 286 - 289, XP055787709, DOI: 10.1126/science.aav9023;;NOBLES ET AL.: ""IGUIDE: An improved pipeline for analyzing CRISPR cleavage specificity"", GENOME BIOL, vol. 20, no. 14, 2019, pages 4 - 9;;TSAI ET AL.: ""GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases"", NATURE BIOTECHNOL., vol. 33, no. 2, 2015, pages 187 - 197, XP055555627, DOI: 10.1038/nbt.3117;;YAN ET AL.: ""BLISS is a versatile and quantitative method for genome-wide profiling of DNA double-strand breaks"", NATURE COMMUN., vol. 8, 2017, pages 15058, XP055485619, DOI: 10.1038/ncomms15058;;TSAI ET AL.: ""CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets"", NATURE METHODS, vol. 14, no. 6, 2017, pages 607 - 614, XP055424040, DOI: 10.1038/nmeth.4278;;CHARMOOSBURNER: ""Unraveling CRISPR-Cas9 genome engineering parameters via a library- on-library approach"", NATURE METHODS, vol. 12, no. 9, 2015, pages 823 - 826;;RAND ET AL.: ""Headloop suppression PCR and its application to selective amplification of methylated DNA sequences"", NUCLEIC ACIDS RES., vol. 33, no. 14, 2005, pages e127, XP002515951, DOI: 10.1093/nar/gni120",PENDING
463,KR,A,KR 20230040370 A,027-552-507-846-538,2023-03-22,2023,KR 20237005951 A,2021-07-22,US 202063055460 P;;US 2021/0042733 W,2020-07-23,″CTL-seq″(CRISPR Tag Linear-seq)로 지정된 뉴클레아제 온-/오프-타겟 편집 위치의 지정 방법,본원은 향상된 정확도 및 민감도로 온- 및 오프-타겟 CRISPR 편집 부위를 식별하고 지정하는 방법을 개시한다.,INTEGRATED DNA TECH INC,MCNEILL MATTHEW;;TURK ROLF;;RETTIG GARRETT;;BLACK ELLEN;;SUN YONGMING;;SAILOR CHRIS;;WANG YU;;GUNDERSON KEITH;;KINNEY KYLE,,https://lens.org/027-552-507-846-538,Patent Application,no,0,0,9,9,0,C12Q1/6811;;C12Q1/6869;;C12N2310/20;;C12N9/22;;C12N15/111;;C12Q1/6853,C12Q1/6811;;C12N9/22;;C12N15/113;;C12Q1/6855;;C12Q1/6869,,0,0,,,,PENDING
464,CA,A1,CA 3185571 A1,193-892-183-783-162,2022-01-27,2022,CA 3185571 A,2021-07-22,US 202063055460 P;;US 2021/0042733 W,2020-07-23,"METHODS FOR NOMINATION OF NUCLEASE ON-/OFF-TARGET EDITING LOCATIONS, DESIGNATED ""CTL-SEQ"" (CRISPR TAG LINEAR-SEQ)","Methods for identifying and nominating on- and off-target CRISPR editing sites, particularly Cas9, with improved accuracy and sensitivity in which a tag is inserted a double-stranded breaks and the region comprising the tag and a universal adapter comprising a unique molecular index (UMI). The sequences to which the universal sequencing primer binds may be predesigned. A method for designing 52-base pair tag sequences based on (a) randomly generating 13-nucleotide sequences with 40-90% GC content, max homopolymer length A:2, C:3, G:2, T:2, weighted homopolymer rate < 20, self-folding 7m < 50 °C, and self-dimer 7m < 50 °C; (b) removing sequences that perfectly align to a particular genome or that are homopolymers or GG or CC dinucleotide motifs and obtaining a set of 13-mers; (c) selecting a subset of the 13-mer sequences that contain one or less CC or GG dinucleotide motifs; (d) concatenating four of the of 13-mer subset sequences to form random 52-mer sequences; (e) aligning the random 52-mer sequences to a genome; (f) removing the random 52-mer sequences that have similarity to the genome to produce a subset of 52-mer sequences; and (h) outputting the subset of 52-mer sequences and generating the complementary strands to produce double stranded 52-base pair tag sequences.",INTEGRATED DNA TECH INC,MCNEILL MATTHEW;;TURK ROLF;;RETTIG GARRETT;;BLACK ELLEN;;SUN YONGMING;;SAILOR CHRIS;;WANG YU;;GUNDERSON KEITH;;KINNEY KYLE,,https://lens.org/193-892-183-783-162,Patent Application,no,0,0,9,9,0,C12Q1/6811;;C12Q1/6869;;C12N2310/20;;C12N9/22;;C12N15/111;;C12Q1/6853,C12Q1/6811;;C12Q1/6869,,0,0,,,,PENDING
465,AU,A1,AU 2021/311713 A1,021-382-497-126-336,2023-03-09,2023,AU 2021/311713 A,2021-07-22,US 202063055460 P;;US 2021/0042733 W,2020-07-23,"Methods for nomination of nuclease on-/off-target editing locations, designated ""CTL-seq"" (CRISPR tag linear-seq)","Methods for identifying and nominating on- and off-target CRISPR editing sites, particularly Cas9, with improved accuracy and sensitivity in which a tag is inserted a double-stranded breaks and the region comprising the tag and a universal adapter comprising a unique molecular index (UMI). The sequences to which the universal sequencing primer binds may be predesigned. A method for designing 52-base pair tag sequences based on (a) randomly generating 13-nucleotide sequences with 40-90% GC content, max homopolymer length A:2, C:3, G:2, T:2, weighted homopolymer rate < 20, self-folding 7m < 50 °C, and self-dimer 7m < 50 °C; (b) removing sequences that perfectly align to a particular genome or that are homopolymers or GG or CC dinucleotide motifs and obtaining a set of 13-mers; (c) selecting a subset of the 13-mer sequences that contain one or less CC or GG dinucleotide motifs; (d) concatenating four of the of 13-mer subset sequences to form random 52-mer sequences; (e) aligning the random 52-mer sequences to a genome; (f) removing the random 52-mer sequences that have similarity to the genome to produce a subset of 52-mer sequences; and (h) outputting the subset of 52-mer sequences and generating the complementary strands to produce double stranded 52-base pair tag sequences.",INTEGRATED DNA TECHNOLOGIES INC,MCNEILL MATTHEW;;TURK ROLF;;RETTIG GARRETT;;BLACK ELLEN;;SUN YONGMING;;SAILOR CHRIS;;WANG YU;;GUNDERSON KEITH;;KINNEY KYLE,,https://lens.org/021-382-497-126-336,Patent Application,no,0,0,9,9,0,C12Q1/6811;;C12Q1/6869;;C12N2310/20;;C12N9/22;;C12N15/111;;C12Q1/6853,C12Q1/6811;;C12N15/113;;C12Q1/6869,,0,0,,,,PENDING
466,HR,T1,HR P20150790 T1,005-225-896-999-784,2015-08-28,2015,HR P20150790 T,2015-07-17,US 99942307 P;;US 8382708 P;;EP 08839961 A;;US 2008/0080382 W,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA,,https://lens.org/005-225-896-999-784,Granted Patent,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
467,CO,A2,CO 6331295 A2,117-643-174-222-36X,2011-10-20,2011,CO 10058236 A,2010-05-14,US 99942307 P;;US 8382708 P,2007-10-17,"MÉTODOS PARA TRATAR LA ENFERMEDAD DE ALZHEIMER, REDUCIR LA DISMINUCIÓN DEL VOLUMEN CEREBRAL Y MONITOREAR UNA POBLACIÓN DE PACIENTES QUE EXPERIMENTAN TRATAMIENTO O PROFILAXIS PARA UNA ENFERMEDAD, USO DE UNA MEDIDA DE NÚMERO DE COPIA APOE4, FORMA HUMAN","1.- Un método para tratar la enfermedad de Alzheimer, caracterizado por comprender administrar a un paciente que tiene alelos ApoE4 cero (""paciente no portador ApoE4"") y enfermedad de Alzheimer, un régimen efectivo de un anticuerpo que se une específicamente a un epítopo en el terminal N de Aß.2.- El método de la reivindicación 1, caracterizado porque el anticuerpo se une específicamente a un epítopo dentro de:los residuos 1-7 de Aß;los residuos 1-5 de Aß; o los residuos 3-7 de Aß.3.- El método de la reivindicación 1 ó 2, caracterizado porque la dosificación se administra cada:4 a 16 semanas; 10 a 14 semanas o 13 semanas.4.- El método de la reivindicación 1; 2 ó 3, caracterizado porque la dosificación es 0,5 mg/kg a 2 mg/kg.5.- Un método para tratar la enfermedad de Alzheimer, caracterizado por comprender administrar a un paciente no portador ApoE4 un anticuerpo que reconoce específicamente la región de terminal N de Aß en un régimen efectivo para mantener una concentración de suero media del anticuerpo en el rango de 0,1 µg/ml a 60 µg/ml.",WYETH LLC;;JANSSEN ALZHEIMER IMNUNOTHERAPY,TCHISTIAKOVA LIOUDMILA;;GILL DAVINDER;;JACOBSEN JACK STEVEN;;GREGG KEITH M;;CALLAWAY JAMES;;BLACK RONALD;;EKMAN LARS;;GRUNDMAN MICHAEL;;LIEBERBURG IVAN,,https://lens.org/117-643-174-222-36X,Patent Application,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/00,,0,0,,,,DISCONTINUED
468,US,A1,US 2008/0172200 A1,146-093-230-229-063,2008-07-17,2008,US 65442407 A,2007-01-17,US 65442407 A,2007-01-17,Custom configuration strategy for on-package genset controllers,"A method of setting up a genset system for operation includes selecting one of a plurality of different sensors to monitor an operating parameter of a genset system, and coupling the selected sensor with a data processor of the genset system. The method further includes configuring the data processor for processing inputs from the selected sensor, for example an optional replacement sensor, by entering custom sensor calibration data for the selected sensor and recording the custom sensor calibration data on at least one computer writable medium of a control system for the genset system. A genset system includes a combustion engine, a generator, a set of standard sensors, and a control system. The control system includes a data processor configured to receive and process inputs from custom sensors, and includes a computer writable medium for storing custom sensor calibration data.",FOLKEN KEITH R;;DVORSKY MICHAEL A;;MCBURNEY JAMES D;;BOLEY JULIE;;NOFSINGER STEPHEN C;;ZWETZ DAVID L;;BLACK ANDREW W,FOLKEN KEITH R;;DVORSKY MICHAEL A;;MCBURNEY JAMES D;;BOLEY JULIE;;NOFSINGER STEPHEN C;;ZWETZ DAVID L;;BLACK ANDREW W,CATERPILLAR INC (2006-12-12),https://lens.org/146-093-230-229-063,Patent Application,yes,9,0,3,3,0,F02D29/06;;G05B19/0423;;G05B2219/21065;;G05B2219/21138;;G05B2219/23332;;G05B2219/25302;;G05B2219/2623;;G05B19/0423;;G05B2219/21138;;F02D29/06;;G05B2219/23332;;G05B2219/25302;;G05B2219/21065;;G05B2219/2623,G01D18/00,702/104,0,0,,,,ACTIVE
469,US,B2,US 8779525 B2,074-608-155-900-266,2014-07-15,2014,US 201313772401 A,2013-02-21,US 201313772401 A;;US 93845710 A,2010-11-03,Method for growing strain-inducing materials in CMOS circuits in a gate first flow,"A complementary metal oxide semiconductor (CMOS) circuit incorporating a substrate and a gate wire over the substrate. The substrate comprises an n-type field effect transistor (n-FET) region, a p-type field effect transistor (p-FET) region and an isolation region disposed between the n-FET and p-FET regions. The gate wire comprises an n-FET gate, a p-FET gate, and gate material extending transversely from the n-FET gate across the isolation region to the p-FET gate. A first conformal insulator covers the gate wire and a second conformal insulator is on the first conformal insulator positioned over the p-FET gate without extending laterally over the n-FET gate. Straining regions for producing different types of strain are formed in recess etched into the n-FET and p-FET regions of the substrate.",IBM;;GLOBALFOUNDRIES INC;;GLOBALFOUNDRIES INC,BAI BO;;BLACK LINDA;;DUBE ABHISHEK;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H,ALSEPHINA INNOVATIONS INC (2018-11-26);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2013-02-25);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/074-608-155-900-266,Granted Patent,yes,12,0,4,4,0,H01L21/823807;;H01L21/823828;;H01L21/823807;;H01L21/823828,H01L21/8238,257/369;;X257E21033;;438/154;;438/222;;438/224,7,2,029-840-303-328-826;;077-224-235-941-910,10.1109/issm.2006.4493040;;10.1109/mspec.2008.4659384,"U.S. Appl. No. 12/938,457, filed Nov. 3, 2010, IBM, Office Action Communication, May 15, 2012, 6 pages.;;U.S. Appl. No. 12/938,457, filed Nov. 3, 2010, IBM, Office Action Communication, Jul. 2, 2012, 14 pages.;;U.S. Appl. No. 12/938,457, filed Nov. 3, 2010, IBM, Office Action Communication, Nov. 23, 2012, 7 pages.;;U.S. Appl. No. 12/938,457, filed Nov. 3, 2010, IBM, Notice of Allowance Communication, Dec. 19, 2012, 8 pages.;;Peters, ""Scalling to 22 nm Process"", Semiconductor International, Jan. 1, 2009, pp. 1-3.;;Monahan, ""Enabling Double Patterning at the 32nm Node"", Yield Management Solutions, Spring 2007, pp. 44-47.;;Chris A. Mack, ""Seeing Double,"" IEEE Spectrum, Nov. 2008, pp. 1-6.",INACTIVE
470,US,A1,US 2013/0161759 A1,195-861-431-405-154,2013-06-27,2013,US 201313772401 A,2013-02-21,US 201313772401 A;;US 93845710 A,2010-11-03,METHOD FOR GROWING STRAIN-INDUCING MATERIALS IN CMOS CIRCUITS IN A GATE FIRST FLOW,"A complementary metal oxide semiconductor (CMOS) circuit incorporating a substrate and a gate wire over the substrate. The substrate comprises an n-type field effect transistor (n-FET) region, a p-type field effect transistor (p-FET) region and an isolation region disposed between the n-FET and p-FET regions. The gate wire comprises an n-FET gate, a p-FET gate, and gate material extending transversely from the n-FET gate across the isolation region to the p-FET gate. A first conformal insulator covers the gate wire and a second conformal insulator is on the first conformal insulator positioned over the p-FET gate without extending laterally over the n-FET gate. Straining regions for producing different types of strain are formed in recess etched into the n-FET and p-FET regions of the substrate.",IBM;;GLOBALFOUNDRIES INC;;GLOBALFOUNDRIES INC;;IBM,BAI BO;;BLACK LINDA;;DUBE ABHISHEK;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H,ALSEPHINA INNOVATIONS INC (2018-11-26);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2013-02-25);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/195-861-431-405-154,Patent Application,yes,3,1,4,4,0,H01L21/823807;;H01L21/823828;;H01L21/823807;;H01L21/823828,H01L27/092,257/369,0,0,,,,INACTIVE
471,US,A1,US 2012/0104507 A1,061-862-988-077-552,2012-05-03,2012,US 93845710 A,2010-11-03,US 93845710 A,2010-11-03,METHOD FOR GROWING STRAIN-INDUCING MATERIALS IN CMOS CIRCUITS IN A GATE FIRST FLOW,"A method of manufacturing a complementary metal oxide semiconductor (CMOS) circuit, in which the method includes a reactive ion etch (RIE) of a CMOS circuit substrate that forms recesses, the CMOS circuit substrate including: an n-type field effect transistor (n-FET) region; a p-type field effect transistor (p-FET) region; an isolation region disposed between the n-FET and p-FET regions; and a gate wire comprising an n-FET gate, a p-FET gate, and gate material extending transversely from the n-FET gate across the isolation region to the p-FET gate, in which the recesses are formed adjacent to sidewalls of a reduced thickness; growing silicon germanium (SiGe) in the recesses; depositing a thin insulator layer on the CMOS circuit substrate; masking at least the p-FET region; removing the thin insulator layer from an unmasked n-FET region and an unmasked portion of the isolation region; etching the CMOS circuit substrate with hydrogen chloride (HCl) to remove the SiGe from the recesses in the n-FET region; and growing silicon carbon (SiC) in the exposed recesses.",BAI BO;;BLACK LINDA;;DUBE ABHISHEK;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H;;IBM,BAI BO;;BLACK LINDA;;DUBE ABHISHEK;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H,ALSEPHINA INNOVATIONS INC (2018-11-26);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-10-28);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/061-862-988-077-552,Patent Application,yes,5,2,4,4,0,H01L21/823807;;H01L21/823828;;H01L21/823807;;H01L21/823828,H01L27/092;;H01L21/8238,257/369;;438/230;;X257E27062;;X257E21639;;X257E21635,0,0,,,,INACTIVE
472,WO,A1,WO 2008/088819 A1,023-031-275-666-300,2008-07-24,2008,US 2008/0000554 W,2008-01-16,US 65442407 A,2007-01-17,CUSTOM CONFIGURATION STRATEGY FOR ON-PACKAGE GENSET CONTROLLERS,"A method of setting up a genset system (10) for operation includes selecting one of a plurality of different sensors (30) to monitor an operating parameter of a genset system (10), and coupling the selected sensor (30) with a data processor (16) of the genset system (10). The method further includes configuring the data processor (16) for processing inputs from the selected sensor (30), for example an optional replacement sensor (30), by entering custom sensor calibration data for the selected sensor (30) and recording the custom sensor calibration data on at least one computer writable medium (36) of a control system (17) for the genset system (10). A genset system (10) includes a combustion engine (14), a generator (12), a set of standard sensors (25, 26), and a control system (17). The control system (17) includes a data processor (16) configured to receive and process inputs from custom sensors (30), and includes a computer writable medium (36) for storing custom sensor calibration data.",CATERPILLAR INC;;FOLKEN KEITH R;;BLACK ANDREW W;;BOLEY JULIE L;;DVORSKY MICHAEL A;;NOFSINGER STEPHEN C;;MCBURNEY JAMES D;;ZWETZ DAVID L,FOLKEN KEITH R;;BLACK ANDREW W;;BOLEY JULIE L;;DVORSKY MICHAEL A;;NOFSINGER STEPHEN C;;MCBURNEY JAMES D;;ZWETZ DAVID L,,https://lens.org/023-031-275-666-300,Patent Application,yes,3,1,3,3,0,F02D29/06;;G05B19/0423;;G05B2219/21065;;G05B2219/21138;;G05B2219/23332;;G05B2219/25302;;G05B2219/2623;;G05B19/0423;;G05B2219/21138;;F02D29/06;;G05B2219/23332;;G05B2219/25302;;G05B2219/21065;;G05B2219/2623,G05B19/042,,0,0,,,,PENDING
473,US,A1,US 2008/0179959 A1,125-761-924-858-509,2008-07-31,2008,US 69899907 A,2007-01-29,US 69899907 A,2007-01-29,Power system with multiple generator sets,"A method of operating a power system is provided. The power system may have a plurality of generator sets and a power line. The method may include commanding a plurality of the generator sets that are disconnected from the power line to start generating electricity. The method may also include supplying to a control device acting as a coordinating control unit information about the operating state of each of the plurality of generator sets commanded to start generating electricity. Additionally, the method may include determining with the coordinating control unit which of the plurality of generator sets has become ready to supply electricity to the power line first. The method may also include initiating supply of electricity to the power line by first connecting to the power line the generator set that the coordinating control unit has determined to be the first ready to supply electricity.",FOLKEN KEITH RONALD;;DVORSKY MICHAEL ALLEN;;BOLEY JULIE LYNN;;MCBURNEY JAMES DEAN;;BLACK ANDREW WILLIAM;;ZWETZ DAVID LEE;;NOFSINGER STEPHEN CHARLES,FOLKEN KEITH RONALD;;DVORSKY MICHAEL ALLEN;;BOLEY JULIE LYNN;;MCBURNEY JAMES DEAN;;BLACK ANDREW WILLIAM;;ZWETZ DAVID LEE;;NOFSINGER STEPHEN CHARLES,CATERPILLAR INC (2007-03-16),https://lens.org/125-761-924-858-509,Patent Application,yes,11,29,5,5,0,H02J3/38;;H02J3/38,H02J3/40,307/80;;307/84;;307/87,0,0,,,,INACTIVE
474,US,B2,US 8426265 B2,153-155-795-975-754,2013-04-23,2013,US 93845710 A,2010-11-03,US 93845710 A,2010-11-03,Method for growing strain-inducing materials in CMOS circuits in a gate first flow,"A method of manufacturing a complementary metal oxide semiconductor (CMOS) circuit, in which the method includes a reactive ion etch (RIE) of a CMOS circuit substrate that forms recesses, the CMOS circuit substrate including: an n-type field effect transistor (n-FET) region; a p-type field effect transistor (p-FET) region; an isolation region disposed between the n-FET and p-FET regions; and a gate wire comprising an n-FET gate, a p-FET gate, and gate material extending transversely from the n-FET gate across the isolation region to the p-FET gate, in which the recesses are formed adjacent to sidewalls of a reduced thickness; growing silicon germanium (SiGe) in the recesses; depositing a thin insulator layer on the CMOS circuit substrate; masking at least the p-FET region; removing the thin insulator layer from an unmasked n-FET region and an unmasked portion of the isolation region; etching the CMOS circuit substrate with hydrogen chloride (HCl) to remove the SiGe from the recesses in the n-FET region; and growing silicon carbon (SiC) in the exposed recesses.",BAI BO;;BLACK LINDA;;DUBE ABHISHEK;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H;;IBM;;GLOBALFOUNDRIES INC,BAI BO;;BLACK LINDA;;DUBE ABHISHEK;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H,ALSEPHINA INNOVATIONS INC (2018-11-26);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-10-28);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/153-155-795-975-754,Granted Patent,yes,9,1,4,4,0,H01L21/823807;;H01L21/823828;;H01L21/823807;;H01L21/823828,H01L21/8238,438/224;;X257E2109;;X257E29193;;438/154;;438/222;;438/228;;438/481,3,2,029-840-303-328-826;;077-224-235-941-910,10.1109/issm.2006.4493040;;10.1109/mspec.2008.4659384,"Peters, ""Scalling to 22 nm Process"", Semiconductor International, Jan. 1, 2009, pp. 1-3.;;Monahan, ""Enabling Double Patterning at the 32nm Node"", Yield Management Solutions, Spring 2007, pp. 44-47.;;Chris A. Mack, ""Seeing Double,"" IEEE Spectrum, Nov. 2008, pp. 1-6.",INACTIVE
475,US,B2,US 7509221 B2,093-608-612-564-990,2009-03-24,2009,US 65442407 A,2007-01-17,US 65442407 A,2007-01-17,Custom configuration strategy for on-package genset controllers,"A method of setting up a genset system for operation includes selecting one of a plurality of different sensors to monitor an operating parameter of a genset system, and coupling the selected sensor with a data processor of the genset system. The method further includes configuring the data processor for processing inputs from the selected sensor, for example an optional replacement sensor, by entering custom sensor calibration data for the selected sensor and recording the custom sensor calibration data on at least one computer writable medium of a control system for the genset system. A genset system includes a combustion engine, a generator, a set of standard sensors, and a control system. The control system includes a data processor configured to receive and process inputs from custom sensors, and includes a computer writable medium for storing custom sensor calibration data.",CATERPILLAR INC,FOLKEN KEITH R;;DVORSKY MICHAEL A;;MCBURNEY JAMES D;;BOLEY JULIE;;NOFSINGER STEPHEN C;;ZWETZ II DAVID L;;BLACK ANDREW W,CATERPILLAR INC (2006-12-12),https://lens.org/093-608-612-564-990,Granted Patent,yes,9,9,3,3,0,F02D29/06;;G05B19/0423;;G05B2219/21065;;G05B2219/21138;;G05B2219/23332;;G05B2219/25302;;G05B2219/2623;;G05B19/0423;;G05B2219/21138;;F02D29/06;;G05B2219/23332;;G05B2219/25302;;G05B2219/21065;;G05B2219/2623,G01C19/00,702/104;;702/93;;702/193;;702/188;;702/108;;702/122;;700/292;;700/286;;700/287;;361/193,0,0,,,,ACTIVE
476,EA,B1,EA 022307 B1,040-713-609-578-584,2015-12-30,2015,EA 201000644 A,2008-10-17,US 99942307 P;;US 8382708 P;;US 2008/0080382 W,2007-10-17,ANTIBODIES FOR TREATING AND PROPHYLAXIS OF ALZHEIMER'S DISEASE AND USE THEREOF,"Described are the use of an antibody is that specifically binds to a N-terminal epitope of Aβ for manufacturing a preparation for treating Alzheimer's disease and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient and also a humanized form of a 3D6 antibody that specifically binds to a N-terminal epitope of Aβ, a pharmaceutical composition comprising said antibody and an isolated nucleic acid encoding said antibody.",JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JIM;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/040-713-609-578-584,Granted Patent,no,3,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/00;;C07K16/18,,3,3,046-993-473-969-443;;034-465-763-064-445;;010-111-314-030-216,10.1212/01.wnl.0000260066.98681.2e;;17452586;;10.1001/archneur.1997.00550140077016;;9041863;;17578972;;10.1213/01.ane.0000266490.64814.ff,"Kinnecom et. al. Course of cerebral amyloid angiopathy? related inflammation. Neurology. 2007 April. Vol. 68(17), p. 1411-6. Abstract; pg 1411, para 2 and 3; pg. 1415, col. 1, last para (abstract included to establish publication date);;Aylward et al. Cerebellar volume in adults with Down syndrome. Arch Neurol. 1997 Feb; 54(2):209-12. Abstract;;Kofke et al. Remifentanil-induced Cerebral Blood Flow Effects in Normal Humans: Dose and ApoE Genotype. Neurosurg Anesthes Neurosci. July 2007, Vol. 105(1). p. 167-175",ACTIVE
477,CN,A,CN 101969988 A,003-384-162-152-512,2011-02-09,2011,CN 200880120952 A,2008-10-17,US 2008/0080382 W;;US 99942307 P;;US 8382708 P,2007-10-17,Immunotherapy regimes dependent on apoe status,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,RONALD BLACK;;GREGG KEITH M;;JAMES CALLAWAY;;DAVINDER GILL;;ANGELA WIDOM;;LIOUDMILA TCHISTIAKOVA;;IVAN LIEBERBURG;;LARS EKMAN;;MICHAEL GRUNDMAN;;STEVEN JACOBSEN JACK,,https://lens.org/003-384-162-152-512,Patent Application,no,3,2,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/00;;C07K16/18,,0,0,,,,DISCONTINUED
478,CA,C,CA 2702617 C,030-250-241-084-162,2016-10-04,2016,CA 2702617 A,2008-10-17,US 99942307 P;;US 8382708 P;;US 2008/0080382 W,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JIM;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/030-250-241-084-162,Granted Patent,no,0,0,53,54,99,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/46;;A61K39/395;;C07K16/18;;C12N15/13,,0,0,,,,ACTIVE
479,AU,B2,AU 2016/208353 B2,076-643-934-961-611,2017-07-20,2017,AU 2016/208353 A,2016-07-28,AU 2016/208353 A;;AU 2013/209361 A;;AU 2008/311823 A,2008-10-17,Immunotherapy regimes dependent on ApoE status,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS Abstract The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of 5 the patient.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,WIDOM ANGELA;;GILL DAVINDER;;LIEBERBURG IVAN;;JACOBSEN JACK STEVEN;;BLACK RONALD;;GREGG KEITH M;;EKMAN LARS;;TCHISTIAKOVA LIOUDMILA;;GRUNDMAN MICHAEL;;CALLAWAY JAMES,,https://lens.org/076-643-934-961-611,Granted Patent,no,2,1,2,4,0,,C07K16/18;;A61K39/00,,0,0,,,,ACTIVE
480,CN,A,CN 107090032 A,116-924-033-959-83X,2017-08-25,2017,CN 201710032507 A,2008-10-17,US 99942307 P;;US 8382708 P;;CN 200880120952 A,2007-10-17,Immunotherapy regimes dependent on ApoE status,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;GREGG KEITH M;;CALLAWAY JAMES;;GILL DAVINDER;;WIDOM ANGELA;;TCHISTIAKOVA LIOUDMILA;;LIEBERBURG IVAN;;EKMAN LARS;;GRUNDMAN MICHAEL;;JACOBSEN JACK STEVEN,,https://lens.org/116-924-033-959-83X,Patent Application,no,5,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;C12N15/13,,2,0,,,"孙丽文 等: ""β淀粉样肽在阿尔茨海默症发病中的分子机制"", 《生物化学与生物物理进展》;;HARUHIKO AKIYAMA 等: ""Occurrence of the Diffuse Amyloid β-Protein (Aβ) Deposits With Numerous Aβ-Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer""s Disease"", 《GLIA》",DISCONTINUED
481,US,A1,US 2010/0266505 A1,198-536-615-694-165,2010-10-21,2010,US 73839608 A,2008-10-17,US 73839608 A;;US 99942307 P;;US 8382708 P;;US 2008/0080382 W,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,WYETH LLC;;JANSSEN ALZHEIMER IMMUNOTHERAP,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,ELAN PHARMA INTERNATIONAL LIMITED (2009-01-27);;CRIMAGUA LIMITED (2010-04-23);;WYETH LLC (2008-12-18);;JANSSEN SCIENCES IRELAND UC (2009-09-14);;ELAN PHARMACEUTICALS INC (2008-12-23),https://lens.org/198-536-615-694-165,Patent Application,yes,100,14,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K49/06;;A61K39/395,424/9.3;;424/133.1,5,5,037-203-592-256-491;;016-968-046-188-260;;078-951-153-033-481;;000-979-140-217-016;;102-782-883-297-511,10.1111/j.1365-2141.2006.06157.x;;16848767;;10.1016/j.neurobiolaging.2003.12.023;;15172743;;10.1089/rej.2006.9.77;;16608400;;10.1093/brain/awl280;;17018549;;16997144;;10.1016/j.drudis.2006.08.004,"Greaves P et al. Posterior reversible encephalopathy syndrome following anti-lymphocyte globulin treatment for severe aplastic anaemia. Br J Haematol. 2006 Aug; 134(3):251.;;Raber J et al. ApoE geneotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging, 2004; 25:641-50.;;Lemere et al. (2006) Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res. 9(1):77-84.;;Klafki H-W et al. (2006) Therapeutic approaches to Alzheimer's disease. Brain, 129:2840-2855.;;Wang Y-J et al. (2006) Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discovery Today, 11(19/20):931-938.",ACTIVE
482,MY,A,MY 156454 A,047-049-299-219-368,2016-02-26,2016,MY PI20101737 A,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,THE INVENTION PROVIDES METHODS OF IMMUNOTHERAPY OF ALZHEIMER?S AND SIMILAR DISEASES IN WHICH THE REGIME ADMINISTERED TO A PATIENT DEPENDS ON THE APOE GENOTYPE OF THE PATIENT.,JANSSEN SCIENCES IRELAND UC;;WYETH LLC,RONALD BLACK;;ANGELA WIDOM;;LARS EKMAN;;IVAN LIEBERBURG;;MICHAEL GRUNDMAN;;JAMES CALLAWAY;;GREGG KEITH M;;STEVEN JACOBSEN JACK;;DAVINDER GILL;;LIOUDMILA TCHISTIAKOVA,,https://lens.org/047-049-299-219-368,Granted Patent,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/395,,0,0,,,,ACTIVE
483,WO,A2,WO 2009/052439 A2,177-557-192-891-810,2009-04-23,2009,US 2008/0080382 W,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,ELAN PHARMA INT LTD;;WYETH CORP;;BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JIM;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JIM;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/177-557-192-891-810,Patent Application,yes,73,60,53,54,99,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00,,75,56,040-460-022-538-804;;058-508-659-056-830;;029-961-898-439-306;;048-784-633-528-797;;037-286-061-850-615;;091-864-623-586-036;;028-860-716-561-679;;043-587-791-478-399;;006-928-867-888-492;;040-577-067-037-463;;104-212-297-137-759;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;156-501-805-490-709;;004-529-618-392-612;;173-572-222-412-05X;;103-429-246-632-830;;058-554-802-398-866;;074-357-918-278-337;;003-248-637-497-498;;073-973-088-884-09X;;015-467-620-003-813;;079-273-865-353-930;;043-275-914-320-987;;025-882-511-311-025;;111-330-431-913-773;;078-351-288-791-088;;119-464-017-250-219;;030-323-674-660-051;;059-691-915-795-881;;156-501-805-490-709;;067-792-208-101-193;;125-983-342-134-643;;045-149-256-448-908;;138-344-087-704-67X;;013-369-899-259-645;;063-752-038-673-970;;063-752-038-673-970;;092-889-739-183-885;;001-114-569-902-888;;122-529-456-042-035;;032-146-722-129-643;;002-545-153-609-099;;059-438-714-813-60X;;062-331-261-055-487;;045-818-564-590-67X;;019-544-301-904-747;;054-802-653-967-547;;018-622-691-667-330;;048-536-112-681-339;;022-988-712-445-94X;;077-273-307-091-97X;;058-804-959-065-444;;054-717-629-774-351;;012-023-881-918-61X,10.1016/0166-2236(93)90008-a;;7504355;;8083687;;10.1097/00005072-199409000-00003;;10.1038/373476a0;;7845455;;7845465;;10.1038/373523a0;;1671712;;10.1038/349704a0;;10.1038/353844a0;;1944558;;1925564;;10.1126/science.1925564;;10.1038/ng0892-345;;1302033;;10.1016/s0166-2236(96)01030-2;;9106355;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;8069524;;10.1006/immu.1994.1004;;7561440;;10.1016/0888-7543(88)90130-9;;3243553;;10.1016/s0021-9258(18)91039-2;;6325438;;pmc397792;;10.1073/pnas.82.10.3445;;2987927;;10.1126/science.8346443;;8346443;;10.1001/jama.278.16.1349;;10.1001/jama.1997.03550160069041;;9343467;;10.1212/wnl.43.8.1467;;8350998;;10.1016/s0887-8994(98)00148-9;;10207937;;15814928;;pmc7977102;;14505162;;10.1007/s00467-003-1243-9;;15705136;;10.1111/j.1445-5994.2004.00750.x;;pmc1736949;;10811710;;10.1136/jnnp.68.6.790;;12063238;;pmc7976914;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;10.1038/nbt0796-826b;;9631001;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;1530954;;2429173;;2218494;;10.1126/science.2218494;;10.1016/s0169-409x(97)00053-7;;10837567;;8810256;;10.1126/science.274.5284.99;;9371838;;pmc24301;;10.1073/pnas.94.24.13287;;9371838;;pmc24301;;10.1073/pnas.94.24.13287;;9354339;;10.1016/s0896-6273(00)80974-5;;10.1523/jneurosci.23-26-08989.2003;;pmc6740398;;14523101;;15502844;;10.1038/nm1123;;10.1016/s0002-9440(10)64544-0;;10880403;;pmc1850215;;12895417;;10.1016/s0896-6273(03)00434-3;;10.3758/bf03205285;;10.1038/ng1197-331;;9354800;;9354801;;10.1038/ng1197-335;;pmc96482;;10024596;;10.1128/iai.67.3.1461-1470.1999;;10500855;;10.5014/ajot.53.5.471;;10.1176/ajp.141.11.1356;;6496779;;10.1212/wnl.34.7.939;;6610841;;1202204;;10.1016/0022-3956(75)90026-6;;0001202204;;10.1212/wnl.43.11.2412-a;;8232972;;10.1002/ana.410070516;;7396427;;10.4049/jimmunol.164.8.4178;;10754313;;11156399,"SELKOE, TINS, vol. 16, 1993, pages 403;;SELKOE, J. NEUROPATHOL. EXP. NEUROL., vol. 53, 1994, pages 438;;DUFF ET AL., NATURE, vol. 373, 1995, pages 476;;GAMES ET AL., NATURE, vol. 373, 1995, pages 523;;GOATE ET AL., NATURE, vol. 349, 1991, pages 704;;CHARTIER HARLAN ET AL., NATURE, vol. 353, 1991, pages 844;;MURRELL ET AL., SCIENCE, vol. 254, 1991, pages 97;;MULLAN ET AL., NATURE GENET., vol. 1, 1992, pages 345;;HARDY, TINS, vol. 20, 1997, pages 154;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;""Epitope Mapping Protocols in Methods in Molecular Biology"", vol. 66, 1996;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77;;HARDY ET AL., TINS, vol. 20, 1997, pages 155 - 158;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NATIONAL INSTITUTES OF HEALTH;;RAVETCH; KINET, ANNU. REV. IMMUNOL, vol. 9, 1991, pages 457 - 92;;CAPEL ET AL., IMMUNOMETHODS, vol. 4, 1994, pages 25 - 34;;DE HAAS ET AL., J. LAB. CLIN. MED., vol. 126, 1995, pages 330 - 41;;GENOMICS, vol. 3, 1988, pages 373 - 379;;J. BIOL. CHEM., vol. 259, 1984, pages 5495 - 5499;;PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 3445 - 3449;;CORDER, SCIENCE, vol. 261, 1993, pages 921 - 3;;FARRER, JAMA, vol. 278, 1997, pages 1349 - 56;;SAUNDERS, NEUROLOGY, vol. 43, 1993, pages 1467 - 72;;PEDIATRIC NEUROLOGY, vol. 20, no. 3, pages 241 - 243;;AJNR, vol. 26, pages 825 - 830;;NEJM, vol. 334, no. 8, pages 494 - 500;;PEDIATR NEPHROL, vol. 18, pages 1161 - 1166;;INTERNAL MEDICINE JOURNAL, vol. 35, pages 83 - 90;;JNNP, vol. 68, pages 790 - 791;;AJNR, vol. 23, pages 1038 - 1048;;PAKJ MED SCI, vol. 21, no. 2, pages 149 - 154;;AJNR, vol. 21, pages 1199 - 1209;;QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033;;NATURE, vol. 148, 1994, pages 1547 - 1553;;NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 826;;BLECK, BIOPROCESSING JOURNAL, vol. 1, September 2005 (2005-09-01);;RAVETCH; KINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457;;PARREN ET AL., J. IMMUNOL., vol. 148, 1992, pages 695;;J IMMUNOGEN, vol. 3, 1976, pages 357 - 362;;LOGHEM, MONOGR ALLERGY, vol. 19, 1986, pages 40 - 51;;CUNNINGHAM ET AL., J. BIOL. CHEM., vol. 9, 1970, pages 3161;;KABAT ET AL.: ""Sequences ofProtein of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242, US DEPARTMENT OF HEALTH AND HUMAN SERVICES;;""Remington's Pharmaceutical Science"", 1980, MACK PUBLISHING COMPANY;;LANGER, SCIENCE, vol. 249, 1990, pages 1527;;HANES, ADVANCED DRUG DELIVERY REVIEWS, vol. 28, 1997, pages 97;;HSIAO ET AL., SCIENCE, vol. 274, 1996, pages 99;;STAUFENBIEL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 13287 - 13292;;STURCHLER-PIERRAT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 13287 - 13292;;BORCHELT ET AL., NEURON, vol. 19, 1997, pages 939 - 945;;RICHARDS ET AL., J. NEUROSCI., vol. 23, 2003, pages 8989 - 9003;;CHENG, NAT MED., vol. 10, no. 11, 2004, pages 1190 - 2;;HWANG, EXP NEUROL., March 2004 (2004-03-01);;TAKEUCHI ET AL., AMERICAN JOURNAL OF PATHOLOGY, vol. 157, 2000, pages 331 - 339;;LAFERLA, NEURON, vol. 39, 2003, pages 409 - 421;;FANSELOW, ANIM. LEARN. BEHAV., vol. 18, 1990, pages 264 - 270;;WEHNER ET AL., NATURE GENET., vol. 17, 1997, pages 331 - 334;;CALDARONE ET AL., NATURE GENET., vol. 17, 1997, pages 335 - 337;;MANSOURI ET AL., INFECT. IMMUN., vol. 67, 1999, pages 1461;;GELINAS ET AL., AM J OCCUP THER, vol. 53, 1999, pages 471 - 81;;ROSEN ET AL., AM J PSYCHIATRY, vol. 141, 1984, pages 1356 - 64;;MCKHANN ET AL., NEUROLOGY, vol. 34, 1984, pages 939 - 44;;FOLSTEIN ET AL., J PSYCH RES, vol. 12, 1975, pages 189 - 198;;MORRIS, NEUROLOGY, vol. 43, 1993, pages 2412 - 2414;;ROSEN ET AL., ANN NEUROL., vol. 17, 1980, pages 486 - 488;;JOHNSON- WOOD ET AL., PROC. NATL. ACAD. SCI., 1997;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184;;PHILLIPS ET AL., CANCER RES., vol. 60, 2000, pages 6977 - 84;;APRILE ET AL., CLIN. EXP. IMMUNOL., vol. 46, 1981, pages 565 - 76;;See also references of EP 2207565A4",PENDING
484,SG,A,SG 10201607589X A,096-884-560-620-566,2016-10-28,2016,SG 10201607589X A,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/096-884-560-620-566,Unknown,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,,,0,0,,,,PENDING
485,PT,E,PT 2207565 E,167-172-096-641-758,2015-09-14,2015,PT 08839961 T,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,WYETH LLC;;JANSSEN SCIENCES IRELAND UC,WIDOM ANGELA;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;TCHISTIAKOVA LIOUDMILA;;GILL DAVINDER;;BLACK RONALD;;EKMAN LARS;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN,,https://lens.org/167-172-096-641-758,Granted Patent,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
486,HK,A1,HK 1217709 A1,052-113-101-540-987,2017-01-20,2017,HK 16105493 A,2016-05-13,US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS APOE,,JANSSEN SCIENCES IRELAND UC,RONALD BLACK;;LARS EKMAN;;IVAN LIEBERBURG;;MICHAEL GRUNDMAN;;JAMES CALLAWAY;;KEITH M GREGG;;JACK STEVEN JACOBSEN;;DAVINDER GILL;;LIOUDMILA TCHISTIAKOVA;;ANGELA WIDOM,,https://lens.org/052-113-101-540-987,Patent Application,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K/;;A61K/,,0,0,,,,PENDING
487,DE,T5,DE 112008000321 T5,054-369-630-680-602,2009-12-17,2009,DE 112008000321 T,2008-01-16,US 69899907 A;;US 2008/0000553 W,2007-01-29,Stromversorgungssystem mit mehreren Generatorsätzen,,CATERPILLAR INC,FOLKEN KEITH R;;DVORSKY MICHAEL A;;BOLEY JULIE L;;MCBURNEY JAMES D;;BLACK ANDREW W;;ZWETZ DAVID L II;;NOFSINGER STEPHEN C,,https://lens.org/054-369-630-680-602,Patent Application,no,1,0,5,5,0,H02J3/38;;H02J3/38,H02J3/38,,0,0,,,,DISCONTINUED
488,AU,A1,AU 2016/208353 A1,172-058-896-585-936,2016-08-18,2016,AU 2016/208353 A,2016-07-28,AU 2016/208353 A;;AU 2013/209361 A;;AU 2008/311823 A,2008-10-17,Immunotherapy regimes dependent on ApoE status,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS Abstract The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of 5 the patient.,WYETH LLC;;JANSSEN ALZHEIMER IMMUNOTHERAP,WIDOM ANGELA;;GILL DAVINDER;;LIEBERBURG IVAN;;JACOBSEN JACK STEVEN;;BLACK RONALD;;GREGG KEITH M;;EKMAN LARS;;TCHISTIAKOVA LIOUDMILA;;GRUNDMAN MICHAEL;;CALLAWAY JAMES,,https://lens.org/172-058-896-585-936,Patent Application,no,0,0,2,4,0,,C07K16/18;;A61K39/00,,0,0,,,,ACTIVE
489,CY,T1,CY 1116552 T1,066-181-246-238-482,2017-03-15,2017,CY 151100639 T,2015-07-21,EP 08839961 A;;US 99942307 P;;US 8382708 P,2007-10-17,ΑΝΟΣΟΘΕΡΑΠΕΥΤΙΚΑ ΣΧΗΜΑΤΑ ΕΞΑΡΤΩΜΕΝΑ ΑΠΟ ΤΗΝ ΚΑΤΑΣΤΑΣΗ ΑΡΟΕ,Η εφεύρεση παρέχει μεθόδους ανοσοθεραπείας της νόσου Alzheimer και παρόμοιων νόσων στις οποίες το θεραπευτικό σχήμα που χορηγείται σε έναν ασθενή εξαρτάται από τον γονότυπο ApoE του ασθενούς.,JANSSEN SCIENCES IRELAND UC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/066-181-246-238-482,Granted Patent,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
490,EP,A4,EP 2207565 A4,066-051-102-275-086,2012-05-02,2012,EP 08839961 A,2008-10-17,US 2008/0080382 W;;US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,JANSSEN ALZHEIMER IMMUNOTHERAPY (2014-08-13);;JANSSEN SCIENCES IRELAND UC (2015-04-22);;WYETH LLC (2015-04-22),https://lens.org/066-051-102-275-086,Search Report,no,3,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00;;C07K16/28,,2,1,064-623-910-155-101,10.1046/j.1365-2990.2003.00457.x;;12787320,"CHALMERS ET AL: ""APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein."", NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, vol. 29, no. 3, 1 June 2003 (2003-06-01), pages 231 - 238, XP055020648, ISSN: 0305-1846;;See also references of WO 2009052439A2",ACTIVE
491,SI,T1,SI 2207565 T1,095-489-231-140-602,2015-08-31,2015,SI 200831458 T,2008-10-17,US 99942307 P;;US 8382708 P;;US 2008/0080382 W;;EP 08839961 A,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/095-489-231-140-602,Granted Patent,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/00;;A61K39/00,,0,0,,,,ACTIVE
492,EP,A1,EP 2952524 A1,149-771-140-438-776,2015-12-09,2015,EP 15161872 A,2008-10-17,US 99942307 P;;US 8382708 P;;EP 08839961 A,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/149-771-140-438-776,Patent Application,yes,133,0,53,54,99,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00;;C07K16/28,,97,77,046-993-473-969-443;;006-279-007-559-077;;020-436-088-652-698;;064-623-910-155-101;;040-460-022-538-804;;058-508-659-056-830;;029-961-898-439-306;;048-784-633-528-797;;037-286-061-850-615;;091-864-623-586-036;;028-860-716-561-679;;043-587-791-478-399;;006-928-867-888-492;;040-577-067-037-463;;104-212-297-137-759;;014-277-808-472-992;;061-754-151-573-898;;113-327-994-370-771;;156-501-805-490-709;;004-529-618-392-612;;173-572-222-412-05X;;103-429-246-632-830;;058-554-802-398-866;;074-357-918-278-337;;003-248-637-497-498;;073-973-088-884-09X;;015-467-620-003-813;;079-273-865-353-930;;043-275-914-320-987;;025-882-511-311-025;;111-330-431-913-773;;078-351-288-791-088;;119-464-017-250-219;;059-691-915-795-881;;027-921-320-681-375;;156-501-805-490-709;;067-792-208-101-193;;125-983-342-134-643;;040-727-809-314-599;;018-614-032-990-767;;011-913-348-138-074;;032-092-580-398-862;;027-423-586-996-698;;055-603-661-679-187;;040-727-809-314-599;;019-962-904-527-989;;015-360-627-674-02X;;055-562-823-604-260;;110-755-777-244-623;;011-639-216-205-109;;041-650-089-669-837;;070-565-871-692-872;;046-380-159-363-732;;129-557-303-114-192;;044-939-366-190-282;;045-149-256-448-908;;138-344-087-704-67X;;013-369-899-259-645;;063-752-038-673-970;;063-752-038-673-970;;092-889-739-183-885;;001-114-569-902-888;;122-529-456-042-035;;032-146-722-129-643;;002-545-153-609-099;;059-438-714-813-60X;;062-331-261-055-487;;045-818-564-590-67X;;019-544-301-904-747;;054-802-653-967-547;;018-622-691-667-330;;048-536-112-681-339;;022-988-712-445-94X;;077-273-307-091-97X;;058-804-959-065-444;;054-717-629-774-351;;012-023-881-918-61X,10.1212/01.wnl.0000260066.98681.2e;;17452586;;pmc6725332;;15659599;;10.1523/jneurosci.4337-04.2005;;16829947;;10.1038/nm0706-780;;10.1046/j.1365-2990.2003.00457.x;;12787320;;10.1016/0166-2236(93)90008-a;;7504355;;8083687;;10.1097/00005072-199409000-00003;;10.1038/373476a0;;7845455;;7845465;;10.1038/373523a0;;1671712;;10.1038/349704a0;;10.1038/353844a0;;1944558;;1925564;;10.1126/science.1925564;;10.1038/ng0892-345;;1302033;;10.1016/s0166-2236(96)01030-2;;9106355;;2180597;;pmc1534963;;10.1111/j.1365-2249.1990.tb08089.x;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.137.11.3614;;2431039;;10.1016/0042-6822(90)90025-m;;1693247;;1697100;;10.1111/j.1365-3083.1990.tb02896.x;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;8069524;;10.1006/immu.1994.1004;;7561440;;10.1016/0888-7543(88)90130-9;;3243553;;10.1016/s0021-9258(18)91039-2;;6325438;;pmc397792;;10.1073/pnas.82.10.3445;;2987927;;10.1126/science.8346443;;8346443;;10.1001/jama.278.16.1349;;10.1001/jama.1997.03550160069041;;9343467;;10.1212/wnl.43.8.1467;;8350998;;10.1016/s0887-8994(98)00148-9;;10207937;;15814928;;pmc7977102;;14505162;;10.1007/s00467-003-1243-9;;15705136;;10.1111/j.1445-5994.2004.00750.x;;pmc1736949;;10811710;;10.1136/jnnp.68.6.790;;12063238;;pmc7976914;;10.1038/nbt0796-826b;;9631001;;16909001;;10.1159/000086429;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;1530954;;2429173;;pmc1853235;;10.1371/journal.pone.0000415;;17476337;;8957679;;10.1159/000150484;;10.1159/000067912;;12566703;;9267006;;10.1099/0022-1317-78-8-2049;;8497047;;10.1128/jvi.67.6.3191-3198.1993;;pmc237658;;3041226;;10.1038/329068a0;;pmc1853235;;10.1371/journal.pone.0000415;;17476337;;10.1073/pnas.94.14.7503;;pmc23851;;9207121;;pmc136812;;11752166;;10.1128/jvi.76.2.767-773.2002;;10.1016/s0016-5085(99)70548-2;;10381908;;10.1038/336778a0;;2462673;;8315383;;pmc2191090;;10.1084/jem.178.1.27;;10.1016/0092-8674(93)90306-b;;8334703;;10.1007/bf00188785;;8119729;;9531296;;10.4049/jimmunol.160.7.3363;;10.1056/nejm199701093360202;;8988885;;10837643;;10.1016/s0169-409x(98)00009-x;;2218494;;10.1126/science.2218494;;10.1016/s0169-409x(97)00053-7;;10837567;;8810256;;10.1126/science.274.5284.99;;9371838;;pmc24301;;10.1073/pnas.94.24.13287;;9371838;;pmc24301;;10.1073/pnas.94.24.13287;;9354339;;10.1016/s0896-6273(00)80974-5;;10.1523/jneurosci.23-26-08989.2003;;pmc6740398;;14523101;;15502844;;10.1038/nm1123;;10.1016/s0002-9440(10)64544-0;;10880403;;pmc1850215;;12895417;;10.1016/s0896-6273(03)00434-3;;10.3758/bf03205285;;10.1038/ng1197-331;;9354800;;9354801;;10.1038/ng1197-335;;pmc96482;;10024596;;10.1128/iai.67.3.1461-1470.1999;;10500855;;10.5014/ajot.53.5.471;;10.1176/ajp.141.11.1356;;6496779;;10.1212/wnl.34.7.939;;6610841;;1202204;;10.1016/0022-3956(75)90026-6;;0001202204;;10.1212/wnl.43.11.2412-a;;8232972;;10.1002/ana.410070516;;7396427;;10.4049/jimmunol.164.8.4178;;10754313;;11156399,"KINNECOM C ET AL: ""Course of cerebral amyloid angiopathy?related inflammation"", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 68, no. 17, 1 April 2007 (2007-04-01), pages 1411 - 1416, XP008132668, ISSN: 0028-3878, DOI: 10.1212/01.WNL.0000260066.98681.2E;;ARGARET M RACKE ET AL: ""Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta"", JOURNAL OF NEUROSCIENCE, THE SOCIETY, WASHINGTON, DC, US, vol. 25, no. 3, 19 January 2005 (2005-01-19), pages 629 - 636, XP002660549, ISSN: 1529-2401, DOI: 10.1523/JNEUROSCI.4337-04.2005;;MOUNT CLAIRE ET AL: ""Alzheimer disease: progress or profit?"", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 12, no. 7, 1 July 2006 (2006-07-01), pages 780 - 784, XP002620727, ISSN: 1078-8956;;CHALMERS ET AL: ""APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein."", NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, vol. 29, no. 3, 1 June 2003 (2003-06-01), pages 231 - 238, XP055020648, ISSN: 0305-1846;;SELKOE, TINS, vol. 16, 1993, pages 403;;SELKOE, J. NEUROPATHOL. EXP. NEUROL., vol. 53, 1994, pages 438;;DUFF ET AL., NATURE, vol. 373, 1995, pages 476;;GAMES ET AL., NATURE, vol. 373, 1995, pages 523;;GOATE ET AL., NATURE, vol. 349, 1991, pages 704;;CHARTIER HARLAN ET AL., NATURE, vol. 353, 1991, pages 844;;MURRELL ET AL., SCIENCE, vol. 254, 1991, pages 97;;MULLAN ET AL., NATURE GENET., vol. 1, 1992, pages 345;;HARDY, TINS, vol. 20, 1997, pages 154;;SONGSIVILAI; LACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553;;""Epitope Mapping Protocols in Methods in Molecular Biology"", vol. 66, 1996;;STAHLI ET AL., METHODS IN ENZYMOLOGY, vol. 9, 1983, pages 242;;KIRKLAND ET AL., J. IMMUNOL., vol. 137, 1986, pages 3614;;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR PRESS;;MOREL ET AL., MOL. IMMUNOL., vol. 25, no. 1, 1988, pages 7;;CHEUNG ET AL., VIROLOGY, vol. 176, 1990, pages 546;;MOLDENHAUER ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 77;;HARDY ET AL., TINS, vol. 20, 1997, pages 155 - 158;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NATIONAL INSTITUTES OF HEALTH;;RAVETCH; KINET, ANNU. REV. IMMUNOL, vol. 9, 1991, pages 457 - 92;;CAPEL ET AL., IMMUNOMETHODS, vol. 4, 1994, pages 25 - 34;;DE HAAS ET AL., J. LAB. CLIN. MED., vol. 126, 1995, pages 330 - 41;;GENOMICS, vol. 3, 1988, pages 373 - 379;;J. BIOL. CHEM., vol. 259, 1984, pages 5495 - 5499;;PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 3445 - 3449;;CORDER, SCIENCE, vol. 261, 1993, pages 921 - 3;;FARRER, JAMA, vol. 278, 1997, pages 1349 - 56;;SAUNDERS, NEUROLOGY, vol. 43, 1993, pages 1467 - 72;;PEDIATRIC NEUROLOGY, vol. 20, no. 3, pages 241 - 243;;AJNR, vol. 26, pages 825 - 830;;NEJM, vol. 334, no. 8, pages 494 - 500;;PEDIATR NEPHROL, vol. 18, pages 1161 - 1166;;INTERNAL MEDICINE JOURNAL, vol. 35, pages 83 - 90;;JNNP, vol. 68, pages 790 - 79 1;;AJNR, vol. 23, pages 1038 - 1048;;PAKJ MED SCI, vol. 21, no. 2, pages 149 - 154;;AJNR, vol. 21, pages 1199 - 1209;;QUEE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033;;NATURE, vol. 148, 1994, pages 1547 - 1553;;NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 826;;BLECK, BIOPROCESSING JOURNAL, September 2005 (2005-09-01), pages 1;;ASAMI-OD ET AL., NEURODEGENERATIVE DISEASES, vol. 2, 2005, pages 36 - 43;;RAVETCH; KINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457;;PARREN ET AL., J. IMMUNOL., vol. 148, 1992, pages 695;;J IMMUNOGEN, vol. 3, 1976, pages 357 - 362;;LOGHEM, MONOGR ALLERGY, vol. 19, 1986, pages 40 - 51;;CUNNINGHAM ET AL., J. BIOL. CHEM., vol. 9, 1970, pages 3161;;KABAT ET AL.: ""Sequences of Pro te n of Immunologcal Interest"", 1991, US DEPARTMENT OF HEALTH AND HUMAN SERVICES;;POWILLEIT ET AL., PLOS ONE, vol. 2, no. 5, 2007, pages E415;;ULRICH ET AL., INTERVIROLOGY, vol. 39, 1996, pages 126 - 132;;LECHNER ET AL., INTERVIROLOGY, vol. 45, 2002, pages 212 - 217;;KOLETZKI ET AL., J GEN VIR, vol. 78, 1997, pages 2049 - 2053;;GRIFFITHS ET AL., J VIROL., vol. 67, no. 6, 1993, pages 3191 - 3198;;ADAMS ET AL., NATURE, vol. 329, no. 3, 1987, pages 68 - 70;;POWILLEIT ET AL., PLOS ONE, vol. 2, no. 5, 2007, pages E415;;SEDLIK ET AL., PNAS, vol. 94, 1997, pages 7503 - 7508;;WATANABE ET AL., J VIROL., vol. 76, no. 2, 1996, pages 767 - 773;;BALL ET AL., GASTROENTEROLOGY, vol. 117, 1999, pages 40 - 48;;SINIGAGLIA F. ET AL., NATURE, vol. 336, 1988, pages 778 - 780;;CHICZ R.M. ET AL., J. EXP. MED., vol. 178, 1993, pages 27 - 47;;HAMMER J. ET AL., CELL, vol. 74, 1993, pages 197 - 203;;FALK K. ET AL., IMMUNOGENETICS, vol. 39, 1994, pages 230 - 242;;SOUTHWOOD S. ET AL., J. IMMUNOLOGY, vol. 160, 1998, pages 3363 - 3373;;KENSIL ET AL.: ""Vaccine Design: The Subunit and Adjuvant Approach"", 1995, PLENUM PRESS;;STOUTE ET AL., N. ENGL. J. MED., vol. 336, 1997, pages 86 - 91;;CHAN ET AL., ADVANCED DRUG DELIVERY REVIEWS, vol. 32, 1998, pages 173 - 186;;""Remington's Pharmaceutical Science"", 1980, MACK PUBLISHING COMPANY;;LANGER, SCIENCE, vol. 249, 1990, pages 1527;;HANES, ADVANCED DRUG DELIVERY REVIEWS, vol. 28, 1997, pages 97;;HSIAO ET AL., SCIENCE, vol. 274, 1996, pages 99;;STAUFENBIEL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 13287 - 13292;;STURCHLER-PIERRAT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 13287 - 13292;;BORCHELT ET AL., NEURON, vol. 19, 1997, pages 939 - 945;;RICHARDS ET AL., J. NEUROSCI., vol. 23, 2003, pages 8989 - 9003;;CHENG, NAT MED., vol. 10, no. 11, 2004, pages 1190 - 2;;HWANG, EXP NEUROL., March 2004 (2004-03-01);;TAKEUCHI ET AL., AMERICAN JOURNAL OF PATHOLOGY, vol. 157, 2000, pages 331 - 339;;LAFERLA, NEURON, vol. 39, 2003, pages 409 - 421;;FANSELOW, ANIM. LEARN. BEHAV., vol. 18, 1990, pages 264 - 270;;WEHNER ET AL., NATURE GENET., vol. 17, 1997, pages 331 - 334;;CALDARONE ET AL., NATURE GENET., vol. 17, 1997, pages 335 - 337;;MANSOURI ET AL., INFECT. IMMUN., vol. 67, 1999, pages 1461;;GELINAS ET AL., AM J OCCUP THER, vol. 53, 1999, pages 471 - 81;;ROSEN ET AL., AM J PSYCHIATRY, vol. 141, 1984, pages 1356 - 64;;MCKHANN ET AL., NEUROLOGY, vol. 34, 1984, pages 939 - 44;;FOLSTEIN ET AL., J PSYCH RES, vol. 12, 1975, pages 189 - 198;;MORRIS, NEUROLOGY, vol. 43, 1993, pages 2412 - 2414;;ROSEN ET AL., ANN NEUROL., vol. 17, 1980, pages 486 - 488;;JOHNSON-WOOD ET AL., PROC. NATL. ACAD. SCI., USA, vol. 94, 1997, pages 1550 - 55;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184;;PHILLIPS ET AL., CANCER RES., vol. 60, 2000, pages 6977 - 84;;APRILE ET AL., CLIN. EXP. IMMUNOL., vol. 46, 1981, pages 565 - 76",DISCONTINUED
493,WO,A3,WO 2009/052439 A3,166-243-515-713-461,2009-06-04,2009,US 2008/0080382 W,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,ELAN PHARMA INT LTD;;WYETH CORP;;BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JIM;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JIM;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/166-243-515-713-461,Search Report,yes,3,0,53,54,99,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00,,3,3,046-993-473-969-443;;034-465-763-064-445;;010-111-314-030-216,10.1212/01.wnl.0000260066.98681.2e;;17452586;;10.1001/archneur.1997.00550140077016;;9041863;;17578972;;10.1213/01.ane.0000266490.64814.ff,"KINNECOM ET AL.: ""Course of cerebral amyloid angiopathy?related inflammation."", NEUROLOGY., vol. 68, no. 17, April 2007 (2007-04-01), pages 1411 - 1416, XP008132668;;AYLWARD ET AL.: ""Cerebellar volume in adults with Down syndrome."", ARCH NEUROL., vol. 54, no. 2, February 1997 (1997-02-01), pages 209 - 212, XP008132674;;KOFKE ET AL.: ""Remifentanil-Induced Cerebral Blood Flow Effects in Normal Humans: Dose and ApoE Genotype."", NEUROSURG ANESTHES NEUROSCI., vol. 105, no. 1, July 2007 (2007-07-01), pages 167 - 175, XP008132669",PENDING
494,MX,A,MX 2010004250 A,037-586-522-285-239,2010-06-01,2010,MX 2010004250 A,2008-10-17,US 99942307 P;;US 8382708 P;;US 2008/0080382 W,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS.,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,JANSSEN ALZHEIMER IMMUNOTHERAP,WIDOM ANGELA;;BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA,,https://lens.org/037-586-522-285-239,Patent Application,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/00;;C07K16/18,,0,0,,,,ACTIVE
495,US,A1,US 2009/0155256 A1,093-169-177-476-969,2009-06-18,2009,US 25392908 A,2008-10-17,US 25392908 A;;US 8382708 P;;US 99942307 P,2007-10-17,Immunotherapy Regimes Dependent On APOE Status,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,WYETH CORP;;ELAN PHARMA INT LTD,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,JANSSEN ALZHEIMER IMMUNOTHERAPY (2009-09-14);;ELAN PHARMA INTERNATIONAL LIMITED (2009-01-27);;CRIMAGUA LIMITED (2009-09-14);;WYETH LLC (2008-12-18);;ELAN PHARMACEUTICALS INC (2008-12-23),https://lens.org/093-169-177-476-969,Patent Application,yes,93,81,53,54,99,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/395;;A61P25/28;;C07H21/00;;C07K16/00,424/133.1;;424/139.1;;530/387.3;;536/23.1;;530/387.1,0,0,,,,DISCONTINUED
496,ZA,B,ZA 201002544 B,101-051-971-257-557,2011-06-29,2011,ZA 201002544 A,2010-04-12,US 99942307 P;;US 8382708 P;;US 2008/0080382 W,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,WYETH LLC;;JANSSEN ALZHEIMER IMMUNOTHERAP,TCHISTIAKOVA LIODMILA;;GREGG KEITH M;;GRUNDMAN MICHAEL;;LIEBERBURG IVAN;;EKMAN LARS;;BLACK RONALD;;JACOBSEN JACK STEVEN;;WIDOM ANGELA;;GILL DAVINDER;;CALLAWAY JAMES,,https://lens.org/101-051-971-257-557,Granted Patent,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,,,0,0,,,,ACTIVE
497,ES,T3,ES 2547230 T3,108-285-519-447-561,2015-10-02,2015,ES 08839961 T,2008-10-17,US 99942307 P;;US 8382708 P;;US 2008/0080382 W,2007-10-17,Régimen dependiente de inmunoterapia en estado ApoE,"Una forma humanizada de un anticuerpo 3D6 que comprende una región constante de cadenas pesadas humanas con mutaciones L234A, L235A y G237A, donde las posiciones son enumeradas por el sistema de numeración EU, donde 3D6 es un anticuerpo producido por el acceso de ATCC número PTA- 5130.",JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/108-285-519-447-561,Granted Patent,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
498,JO,B1,JO 3076 B1,125-712-779-801-870,2017-03-15,2017,JO P20080465 A,2008-10-15,US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,IVAN LIEBERBURG;;ANGELA WIDOM;;JACK STEVEN JACOBSEN;;JIM CALLAWAY;;DAVINDER GILL;;RONALD BLACK;;KEITH M GREGG;;LARS EKMAN;;LIOUDMILA TCHISTIAKOVA;;MICHAEL GRUNDMAN,,https://lens.org/125-712-779-801-870,Granted Patent,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,,,0,0,,,,ACTIVE
499,HU,T2,HU E025684 T2,138-143-514-060-637,2016-04-28,2016,HU E08839961 A,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/138-143-514-060-637,Amended Patent,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00;;C07K16/28,,0,0,,,,PENDING
500,PL,T3,PL 2207565 T3,158-229-704-223-524,2015-10-30,2015,PL 08839961 T,2008-10-17,US 99942307 P;;US 8382708 P;;EP 08839961 A;;US 2008/0080382 W,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/158-229-704-223-524,Patent Application,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00;;C07K16/28,,0,0,,,,PENDING
501,BR,A2,BR PI0823507 A2,029-453-620-855-275,2013-10-29,2013,BR PI0823507 A,2008-10-17,US 9942307 P;;US 8382708 P,2007-10-17,USOS DE UM ANTICORPO QUE SE LIGA ESPECIFICAMENTE A UM EPÍTOPO DE TERMINAL N DE ABETA E DE UMA MEDIÇÃO DE NÚMERO DE CÓPIA DE APOE4,"USOS DE UM ANTICORPO QUE SE LIGA ESPECIFICAMENTE A UM EPÍTOPO DE TERMINAL N DE ABETA, E DE UMA MEDIÇÃO DE NÚMERO DE CÓPIA DE APOE4. A invenção fornece métodos de imunoterapia contra doenças de Alzheimer e similares em que o regime administrado a um paciente depende do genotipo de ApoE do paciente.",JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/029-453-620-855-275,Patent Application,no,0,0,1,54,0,,A61K39/00;;C07K16/18,,0,0,,,,DISCONTINUED
502,PA,A1,PA 8800801 A1,071-491-939-001-079,2010-04-21,2010,PA 8800801 A,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,REGIMENES DE INMUNOTERAPIA DEPENDIENTES DEL ESTADO APOE,LA INVENCIÓN PROPORCIONA MÉTODOS DE INMUNOTERAPIA DE ALZHEIMER Y ENFERMEDADES SIMILARES EN LAS QUE EL RÉGIMEN ADMINISTRADO A UN PACIENTE DEPENDE DEL GENOTIPO APOE DEL PACIENTE.,WYETH CORP,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JIM;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/071-491-939-001-079,Patent Application,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/00;;C07K16/18,,0,0,,,,PENDING
503,AU,B2,AU 2013/209361 B2,073-490-142-721-35X,2016-09-15,2016,AU 2013/209361 A,2013-07-26,AU 2008/311823 A;;AU 2013/209361 A,2008-10-17,Immunotherapy regimes dependent on ApoE status,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS Abstract The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of 5 the patient.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,WIDOM ANGELA;;GILL DAVINDER;;LIEBERBURG IVAN;;JACOBSEN JACK STEVEN;;BLACK RONALD;;GREGG KEITH M;;EKMAN LARS;;TCHISTIAKOVA LIOUDMILA;;GRUNDMAN MICHAEL;;CALLAWAY JAMES,,https://lens.org/073-490-142-721-35X,Granted Patent,no,3,0,2,4,0,,C07K16/18;;A61K39/00,,0,0,,,,INACTIVE
504,BR,A2,BR PI0818000 A2,158-278-312-183-181,2012-12-25,2012,BR PI0818000 A,2008-10-17,US 99942307 P;;US 8382708 P;;US 2008/0080382 W,2007-10-17,"forma humanizada de um anticorpo, anticorpo, composiÇço farmacÊutica, e, Ácido nucleico isolado","FORMA HUMANIZADA DE UM ANTICORPO, ANTICORPO, COMPOSIÇçO FARMACÊUTICA, E, ÁCIDO NUCLEICO ISOLADO. A invenção fornece métodos de imunoterapia contra doenças de Alzheimer e similares em que o regime administrado a um paciente depende do genotipo de ApoE do paciente.",JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/158-278-312-183-181,Patent Application,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00,,0,0,,,,DISCONTINUED
505,EP,B1,EP 2207565 B1,174-005-637-290-272,2015-04-22,2015,EP 08839961 A,2008-10-17,US 2008/0080382 W;;US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,JANSSEN ALZHEIMER IMMUNOTHERAPY (2014-08-13);;JANSSEN SCIENCES IRELAND UC (2015-04-22);;WYETH LLC (2015-04-22),https://lens.org/174-005-637-290-272,Granted Patent,yes,6,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/00;;C07K16/28,,4,0,,,"CHALMERS ET AL: ""APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein."", NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, vol. 29, no. 3, 1 June 2003 (2003-06-01), pages 231-238, XP55020648, ISSN: 0305-1846;;KINNECOM ET AL.: 'Course of cerebral amyloid angiopathy?related inflammation.' NEUROLOGY. vol. 68, no. 17, April 2007, pages 1411 - 1416, XP008132668;;AYLWARD ET AL.: 'Cerebellar volume in adults with Down syndrome.' ARCH NEUROL. vol. 54, no. 2, February 1997, pages 209 - 212, XP008132674;;KOFKE ET AL.: 'Remifentanil-Induced Cerebral Blood Flow Effects in Normal Humans: Dose and ApoE Genotype.' NEUROSURG ANESTHES NEUROSCI. vol. 105, no. 1, July 2007, pages 167 - 175, XP008132669",ACTIVE
506,HK,A1,HK 1146234 A1,019-407-608-893-877,2011-05-27,2011,HK 11100479 A,2011-01-18,US 2008/0080382 W;;US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,JANSSEN SCIENCES IRELAND UC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/019-407-608-893-877,Patent Application,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K/;;A61K/,,0,0,,,,DISCONTINUED
507,CA,A1,CA 2940337 A1,028-249-266-817-22X,2009-04-23,2009,CA 2940337 A,2008-10-17,US 99942307 P;;US 8382708 P;;CA 2702617 A,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/028-249-266-817-22X,Patent Application,no,0,0,53,54,99,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,C07K16/18;;A61K39/395;;A61P25/28;;C07K16/46;;C12N15/13,,0,0,,,,DISCONTINUED
508,US,A1,US 2012/0070379 A1,157-549-372-704-722,2012-03-22,2012,US 201113231903 A,2011-09-13,US 201113231903 A;;US 73839610 A;;US 2008/0080382 W;;US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,JANSSEN ALZHEIMER IMMUNOTHERAPY (2009-09-14);;ELAN PHARMA INTERNATIONAL LIMITED (2009-01-27);;CRIMAGUA LIMITED (2009-09-14);;WYETH LLC (2008-12-18);;ELAN PHARMACEUTICALS INC (2008-12-23),https://lens.org/157-549-372-704-722,Patent Application,yes,0,13,53,54,99,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/395;;A61K39/00;;A61K49/00;;A61P25/28;;G06Q90/00,424/9.2;;424/172.1;;424/133.1;;424/184.1;;705/500,1,1,079-915-796-823-557,pmc539292;;10.1186/1742-2094-1-24;;15588287,"Wilcock DM et al. (2004) Passive immunotherapy against Abeta in aged APP-trangenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation, 1:24.",DISCONTINUED
509,AU,A1,AU 2013/209361 A1,023-390-237-035-692,2013-08-15,2013,AU 2013/209361 A,2013-07-26,AU 2008/311823 A;;AU 2013/209361 A,2008-10-17,Immunotherapy regimes dependent on ApoE status,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS Abstract The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of 5 the patient.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,WIDOM ANGELA;;GILL DAVINDER;;LIEBERBURG IVAN;;JACOBSEN JACK STEVEN;;BLACK RONALD;;GREGG KEITH M;;EKMAN LARS;;TCHISTIAKOVA LIOUDMILA;;GRUNDMAN MICHAEL;;CALLAWAY JAMES,,https://lens.org/023-390-237-035-692,Patent Application,no,0,1,2,4,0,,C07K16/18;;A61K39/00,,0,0,,,,INACTIVE
510,SG,A1,SG 186649 A1,041-510-721-896-351,2013-01-30,2013,SG 2012091591 A,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUSThe invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient. FIG. 4,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/041-510-721-896-351,Patent Application,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,,,0,0,,,,PENDING
511,JP,A,JP 2015145419 A,075-727-713-458-854,2015-08-13,2015,JP 2015094806 A,2015-05-07,US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIME DEPENDENT ON ApoE STATUS,"PROBLEM TO BE SOLVED: To provide immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.SOLUTION: The invention provides a method of treating Alzheimer's disease, and the like comprising a step of administering to a patient having zero ApoE4 alleles (""ApoE4 non-carrier patient"") and Alzheimer's disease, an effective regime of an antibody that specifically binds to an N-terminal epitope of Aβ. Optionally, the antibody specifically binds to an epitope within residues 1-7 of Aβ, or an epitope within residues 1-5 of Aβ, or an epitope within residues 3-7 of Aβ.",JANSSEN SCIENCES IRELAND UC;;WYETH LLC,RONALD BLACK;;LARS EKMAN;;IVAN LIEBERBURG;;MICHAEL GRUNDMAN;;JAMES CALLAWAY;;KEITH M GREGG;;JACK STEVEN JACOBSEN;;DAVINDER GILL;;LIOUDMILA TCHISTIAKOVA;;ANGELA WIDOM,,https://lens.org/075-727-713-458-854,Patent Application,no,6,0,53,54,99,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/395;;A61K31/57;;A61K49/00;;A61P9/00;;A61P25/28;;C07K16/18;;C12N15/09;;C12P21/08,,4,0,,,"JPN6016011113; Ａｓｈｆｏｒｄ，Ｊ．Ｗ． ａｎｄ Ｍｏｒｔｉｍｅｒ，Ｊ．Ａ．: 'Ｎｏｎ-ｆａｍｉｌｉａｌ Ａｌｚｈｅｉｍｅｒ'ｓ ｄｉｓｅａｓｅ ｉｓ ｍａｉｎｌｙ ｄｕｅ ｔｏ ｇｅｎｅｔｉｃ ｆａｃｔｏｒｓ．' Ｊ． Ａｌｚｈｅｉｍｅｒｓ Ｄｉｓ． Ｖｏｌ．４， Ｎｏ．３, 200206, ｐ．１６９-７７;;JPN6016011116; Ｆａｒｒｅｒ，Ｌ．Ａ． ｅｔ ａｌ．: 'Ｅｆｆｅｃｔｓ ｏｆ ａｇｅ， ｓｅｘ， ａｎｄ ｅｔｈｎｉｃｉｔｙ ｏｎ ｔｈｅ ａｓｓｏｃｉａｔｉｏｎ ｂｅｔｗｅｅｎ ａｐｏｌｉｐｏｐｒｏｔｅｉｎ Ｅ ｇｅｎｏｔｙｐｅ ａｎｄ Ａｌｚｈｅｉｍｅ' Ｊ． Ａｍ． Ｍｅｄ． Ａｓｓｏｃ． Ｖｏｌ．２７８， Ｎｏ．１６, 199710, ｐ．１３４９-５６;;JPN6016011113; Ａｓｈｆｏｒｄ，Ｊ．Ｗ． ａｎｄ Ｍｏｒｔｉｍｅｒ，Ｊ．Ａ．: 'Ｎｏｎ-ｆａｍｉｌｉａｌ Ａｌｚｈｅｉｍｅｒ'ｓ ｄｉｓｅａｓｅ ｉｓ ｍａｉｎｌｙ ｄｕｅ ｔｏ ｇｅｎｅｔｉｃ ｆａｃｔｏｒｓ．' Ｊ． Ａｌｚｈｅｉｍｅｒｓ Ｄｉｓ． Ｖｏｌ．４， Ｎｏ．３, 200206, ｐ．１６９-７７;;JPN6016011116; Ｆａｒｒｅｒ，Ｌ．Ａ． ｅｔ ａｌ．: 'Ｅｆｆｅｃｔｓ ｏｆ ａｇｅ， ｓｅｘ， ａｎｄ ｅｔｈｎｉｃｉｔｙ ｏｎ ｔｈｅ ａｓｓｏｃｉａｔｉｏｎ ｂｅｔｗｅｅｎ ａｐｏｌｉｐｏｐｒｏｔｅｉｎ Ｅ ｇｅｎｏｔｙｐｅ ａｎｄ Ａｌｚｈｅｉｍｅ' Ｊ． Ａｍ． Ｍｅｄ． Ａｓｓｏｃ． Ｖｏｌ．２７８， Ｎｏ．１６, 199710, ｐ．１３４９-５６",ACTIVE
512,EP,A2,EP 2207565 A2,097-345-266-239-67X,2010-07-21,2010,EP 08839961 A,2008-10-17,US 2008/0080382 W;;US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,JANSSEN ALZHEIMER IMMUNOTHERAPY (2014-08-13);;JANSSEN SCIENCES IRELAND UC (2015-04-22);;WYETH LLC (2015-04-22),https://lens.org/097-345-266-239-67X,Patent Application,yes,0,0,53,54,99,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/00;;C07K16/18;;C07K16/28,,0,0,,,,ACTIVE
513,AU,A1,AU 2008/311823 A1,007-465-002-971-690,2009-04-23,2009,AU 2008/311823 A,2008-10-17,US 8382708 P;;US 99942307 P;;US 2008/0080382 W,2007-10-17,Immunotherapy regimes dependent on ApoE status,,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;GREGG KEITH M;;CALLAWAY JAMES;;GILL DAVINDER;;WIDOM ANGELA;;TCHISTIAKOVA LIOUDMILA;;LIEBERBURG IVAN;;EKMAN LARS;;GRUNDMAN MICHAEL;;JACOBSEN JACK STEVEN,,https://lens.org/007-465-002-971-690,Patent Application,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/00;;C07K16/18,,0,0,,,,DISCONTINUED
514,RS,B1,RS 54130 B1,008-663-898-815-28X,2015-12-31,2015,RS P20150479 A,2008-10-17,US 99942307 P;;US 8382708 P;;US 2008/0080382 W,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,"Humanizovani oblik 3D6 antitela koje sadrži humani konstantni region teškog lanca sa mutacijama L234A, L235A i G237A, pri čemu su pozicije numerisane prema EU sistemu numeracije, a 3D6 je antitelo proizvedeno od ATCC pristupni broj PTA-5130. Prijava sadrži još 12 patentnih zahteva.",JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/008-663-898-815-28X,Granted Patent,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/00;;C07K16/18;;C07K16/28,,0,0,,,,ACTIVE
515,NZ,A,NZ 622460 A,045-153-522-298-095,2015-10-30,2015,NZ 62246008 A,2008-10-17,US 8382708 P;;US 99942307 P;;NZ 60153408 A,2007-10-17,Immunotherapy regimes dependent on apoe status,"Disclosed is a humanized form of a mouse 3D6 (Bapineuzumab) antibody comprising three light chain and three heavy chain CDRs of the mouse 3D6 antibody and a human heavy chain in which positions 234, 235 and 237 are occupied by Ala, Ala and Ala respectively, wherein positions are numbered by the EU numbering system and 3D6 is a mouse antibody produced by hybridoma PTA-5130.",JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/045-153-522-298-095,Patent Application,no,0,0,1,1,0,,A61K39/00;;C07K16/18,,0,0,,,,DISCONTINUED
516,WO,A2,WO 2008/094403 A2,145-672-798-479-487,2008-08-07,2008,US 2008/0000553 W,2008-01-16,US 69899907 A,2007-01-29,POWER SYSTEM WITH MULTIPLE GENERATOR SETS,"A method of operating a power system (10) is provided. The power system may have a plurality of generator sets (GA) and a power line (54). The method may include commanding a plurality of the generator sets that are disconnected from the power line to start generating electricity. The method may also include supplying to a control device (40) acting as a coordinating control unit information about the operating state of each of the plurality of generator sets commanded to start generating electricity. Additionally, the method may include determining with the coordinating control unit which of the plurality of generator sets has become ready to supply electricity to the power line first. The method may also include initiating supply of electricity to the power line by first connecting to the power line the generator set that the coordinating control unit has determined to be the first ready to supply electricity.",CATERPILLAR INC;;FOLKEN KEITH R;;DVORSKY MICHAEL A;;BOLEY JULIE L;;MCBURNEY JAMES D;;BLACK ANDREW W;;ZWETZ DAVID L II;;NOFSINGER STEPHEN C,FOLKEN KEITH R;;DVORSKY MICHAEL A;;BOLEY JULIE L;;MCBURNEY JAMES D;;BLACK ANDREW W;;ZWETZ DAVID L II;;NOFSINGER STEPHEN C,,https://lens.org/145-672-798-479-487,Patent Application,yes,0,0,5,5,0,H02J3/38;;H02J3/38,H02J3/38,,0,0,,,,PENDING
517,US,B2,US 9644025 B2,170-598-563-037-59X,2017-05-09,2017,US 73839608 A,2008-10-17,US 73839608 A;;US 99942307 P;;US 8382708 P;;US 2008/0080382 W,2007-10-17,Immunotherapy regimes dependent on ApoE status,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;WYETH LLC;;JANSSEN SCIENCES IRELAND UC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,ELAN PHARMA INTERNATIONAL LIMITED (2009-01-27);;CRIMAGUA LIMITED (2010-04-23);;WYETH LLC (2008-12-18);;JANSSEN SCIENCES IRELAND UC (2009-09-14);;ELAN PHARMACEUTICALS INC (2008-12-23),https://lens.org/170-598-563-037-59X,Granted Patent,yes,582,8,53,54,99,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/395;;A61K39/00;;C07K16/18;;C07K16/28;;G06Q99/00,,1600,468,037-203-592-256-491;;016-968-046-188-260;;078-951-153-033-481;;000-979-140-217-016;;102-782-883-297-511;;062-787-149-066-843;;134-693-996-114-01X;;000-877-300-546-605;;076-917-553-108-962;;029-595-205-981-665;;080-590-749-585-843;;000-979-140-217-016;;037-347-586-563-391;;077-649-691-661-158;;103-979-796-711-169;;011-835-392-129-879;;066-884-342-101-524;;020-951-852-826-195;;030-775-995-316-080;;038-559-964-323-098;;025-517-560-624-620;;013-152-107-159-48X;;075-555-351-927-589;;119-054-312-037-486;;030-876-485-655-51X;;020-585-002-314-25X;;067-938-490-068-655;;047-276-983-956-882;;034-465-763-064-445;;019-634-111-480-014;;022-037-744-991-79X;;062-128-590-417-799;;000-286-986-959-011;;094-599-914-313-526;;007-423-670-854-742;;005-738-918-251-114;;007-939-390-479-017;;030-933-742-386-006;;116-451-971-284-333;;073-787-372-894-069;;024-434-770-196-118;;015-360-898-646-100;;092-889-739-183-885;;034-059-954-686-42X;;064-530-633-815-972;;073-212-088-312-095;;050-904-893-659-406;;038-369-944-416-855;;012-542-224-772-678;;008-233-877-486-165;;020-784-959-226-24X;;039-318-607-436-966;;018-764-108-183-317;;102-730-868-162-286;;092-442-982-141-860;;027-064-165-385-993;;067-185-161-184-264;;038-399-812-684-919;;045-942-104-775-903;;031-432-174-294-445;;035-827-274-823-879;;044-939-366-190-282;;160-214-392-839-417;;030-021-919-316-926;;026-932-424-159-079;;009-190-859-472-682;;016-549-612-137-366;;001-779-867-387-972;;005-867-866-392-660;;014-124-980-476-592;;061-518-684-585-221;;036-122-678-674-298;;039-627-035-180-959;;083-272-446-073-256;;007-274-137-236-691;;088-200-577-242-290;;029-611-134-469-353;;032-459-399-923-827;;122-726-728-582-485;;022-132-728-200-762;;080-016-574-168-258;;079-932-522-833-904;;036-240-186-933-350;;090-751-173-025-735;;000-622-311-709-073;;002-353-630-532-260;;000-577-316-851-722;;012-817-971-138-291;;031-572-620-179-426;;010-015-552-824-556;;032-248-464-621-869;;030-978-894-599-421;;038-609-450-747-46X;;099-115-126-990-495;;020-829-015-080-665;;026-020-204-822-279;;016-203-996-044-020;;052-235-650-994-848;;061-138-525-636-453;;010-580-032-489-231;;079-439-722-944-503;;029-961-898-439-306;;082-514-674-061-495;;071-739-249-532-872;;060-516-213-289-64X;;081-931-297-318-865;;040-352-080-627-647;;009-732-493-161-209;;026-705-582-083-41X;;033-261-430-402-230;;011-018-467-061-62X;;052-314-920-122-114;;072-502-991-630-873;;016-254-510-480-608;;025-153-008-303-52X;;029-754-251-794-620;;029-671-929-591-453;;153-535-023-480-748;;000-660-416-939-892;;010-426-909-189-468;;084-502-549-372-555;;038-188-049-266-093;;087-473-490-026-453;;037-585-488-418-290;;010-718-628-563-550;;020-064-881-897-637;;025-446-329-734-602;;033-917-474-538-390;;062-950-628-293-493;;037-286-061-850-615;;009-339-108-863-060;;020-654-086-791-075;;020-087-279-621-816;;000-039-020-670-537;;037-251-099-188-938;;025-259-144-662-856;;018-922-531-149-512;;083-229-815-185-306;;020-735-177-358-415;;005-443-163-550-07X;;033-359-828-790-363;;056-834-210-287-875;;107-613-998-028-412;;044-567-142-618-994;;051-832-508-795-097;;073-005-087-659-327;;042-294-149-916-499;;138-344-087-704-67X;;006-928-867-888-492;;037-159-382-365-168;;010-812-867-565-861;;013-746-336-490-529;;066-419-294-278-929;;081-007-485-098-392;;028-088-448-039-751;;082-072-693-263-53X;;046-211-567-269-035;;070-572-100-205-605;;031-100-076-670-370;;027-521-885-095-522;;173-437-109-134-471;;132-116-287-590-82X;;007-444-390-149-822;;096-581-402-100-241;;054-717-629-774-351;;048-288-450-089-717;;038-275-419-364-068;;043-555-195-168-646;;000-791-438-416-881;;090-949-702-877-890;;025-520-204-930-549;;065-032-534-741-191;;020-272-981-494-380;;044-119-173-787-636;;007-340-406-113-466;;013-020-830-774-188;;051-604-336-363-567;;014-373-893-408-150;;054-560-756-123-508;;013-289-126-795-50X;;086-473-019-813-328;;008-313-176-340-390;;033-836-147-122-932;;023-816-480-608-644;;040-140-115-628-152;;039-423-978-088-280;;129-327-796-343-271;;028-475-434-598-296;;019-823-739-993-82X;;118-080-254-805-290;;043-331-147-753-40X;;046-993-473-969-443;;010-111-314-030-216;;021-625-311-442-845;;013-171-072-503-327;;008-092-163-164-352;;010-867-373-081-486;;014-340-761-766-828;;126-503-607-558-486;;075-999-276-267-476;;061-814-751-572-049;;008-680-977-073-557;;045-149-256-448-908;;085-845-736-617-811;;157-048-066-414-879;;099-008-077-430-980;;025-451-926-268-175;;070-825-365-651-646;;005-541-339-422-581;;040-873-817-694-873;;101-242-518-241-516;;055-514-074-378-510;;020-856-089-638-67X;;001-361-726-394-580;;017-954-605-047-034;;095-334-545-560-259;;027-456-266-488-302;;039-718-493-896-421;;025-410-089-274-728;;033-127-369-026-215;;014-934-278-231-813;;081-346-616-250-347;;083-079-500-791-191;;019-576-597-534-234;;036-111-810-609-28X;;048-530-059-021-552;;027-842-692-654-639;;103-836-128-625-988;;004-919-103-971-934;;061-419-276-701-664;;026-425-754-248-895;;054-790-143-416-125;;038-493-671-632-234;;076-509-901-737-616;;017-406-169-830-577;;023-395-334-451-092;;104-261-748-580-321;;095-810-857-960-512;;173-316-381-285-26X;;018-310-131-421-743;;060-395-602-898-774;;130-338-065-581-566;;018-981-464-684-143;;020-436-088-652-698;;016-931-459-924-220;;072-947-506-321-594;;017-794-762-429-976;;052-297-073-175-765;;001-358-448-508-885;;021-997-752-050-780;;107-353-342-078-531;;041-914-433-419-519;;015-501-895-061-891;;103-932-348-507-545;;114-188-704-806-012;;048-103-697-044-146;;017-090-382-753-584;;045-872-081-200-101;;037-873-252-810-524;;062-761-744-997-508;;120-970-971-918-497;;041-373-320-451-433;;019-914-930-077-639;;014-113-432-888-031;;035-881-005-963-336;;131-712-406-843-856;;119-662-966-816-218;;025-217-190-914-764;;144-648-373-116-756;;009-094-921-501-270;;118-802-024-443-513;;149-976-668-157-584;;022-866-678-832-587;;052-263-351-062-934;;042-735-495-676-046;;021-727-523-534-140;;030-323-674-660-051;;026-976-432-199-26X;;035-481-954-812-553;;002-672-854-923-963;;042-204-626-457-327;;046-630-016-294-513;;025-119-148-366-507;;024-854-876-383-588;;027-477-313-726-928;;063-710-398-275-735;;069-014-878-848-888;;050-043-121-271-40X;;122-398-327-890-524;;038-531-877-340-717;;045-417-738-478-788;;146-107-389-930-155;;039-250-850-468-732;;015-320-459-538-208;;009-773-445-634-236;;018-279-551-255-347;;045-554-020-619-271;;058-508-659-056-830;;007-543-126-795-925;;013-818-050-095-734;;090-368-236-269-306;;033-587-909-347-413;;057-329-600-968-085;;025-624-292-135-452;;082-722-733-297-69X;;081-786-191-706-634;;008-518-555-876-864;;009-334-216-333-160;;006-564-395-473-939;;023-154-204-899-879;;006-732-374-739-136;;031-031-675-304-712;;180-253-938-858-781;;003-835-690-395-227;;079-545-054-448-932;;016-508-154-129-965;;021-725-070-166-584;;063-640-832-834-034;;055-922-767-381-715;;013-254-719-429-329;;043-573-098-833-930;;021-262-660-782-303;;024-410-221-639-40X;;044-863-698-408-681;;139-520-056-633-289;;063-452-233-596-136;;053-857-218-519-573;;043-083-554-569-335;;033-263-114-519-102;;007-461-179-248-424;;032-403-476-358-751;;118-791-488-213-571;;032-653-649-478-64X;;080-527-690-373-245;;063-830-256-321-077;;129-557-303-114-192;;061-978-293-730-521;;010-157-107-750-37X;;063-752-038-673-970;;024-833-989-356-110;;063-411-676-653-813;;110-509-109-698-351;;116-642-069-249-228;;076-790-122-173-118;;087-081-871-218-990;;006-185-434-846-68X;;104-625-348-603-541;;088-534-797-567-417;;136-816-937-886-095;;053-867-955-746-10X;;036-828-853-770-944;;030-923-297-531-500;;009-821-220-389-659;;061-409-155-521-334;;168-727-222-122-143;;051-707-000-800-833;;034-851-879-870-698;;006-063-767-579-916;;011-705-374-490-489;;067-430-079-872-54X;;018-723-091-503-108;;044-961-817-339-818;;013-983-785-316-146;;015-519-175-212-263;;009-416-320-508-847;;117-905-099-283-548;;110-722-231-150-093;;158-294-372-980-406;;042-126-278-317-369;;118-396-080-592-686;;028-383-058-454-759;;018-586-590-834-173;;040-643-947-749-269;;144-304-643-357-308;;005-191-881-126-398;;001-789-566-067-587;;067-417-618-485-594;;016-265-697-674-181;;000-704-340-950-025;;086-566-435-230-757;;116-500-317-318-138;;044-909-551-882-89X;;064-747-889-370-206;;031-729-641-207-089;;062-025-903-523-33X;;039-235-926-929-983;;001-291-693-196-367;;024-119-439-826-466;;032-904-405-298-451;;013-142-717-038-23X;;080-800-918-772-774;;080-038-523-566-560;;056-044-371-972-690;;018-588-218-354-316;;059-329-445-099-061;;013-505-543-939-870;;103-554-366-351-809;;104-750-274-393-483;;118-342-425-307-059;;064-623-910-155-101;;037-203-592-256-491;;016-968-046-188-260;;098-146-270-690-898;;020-206-908-437-886;;165-313-740-952-121;;078-149-183-531-707;;066-761-576-840-100;;109-333-179-719-910;;033-609-792-167-076;;078-951-153-033-481;;068-547-326-166-585;;037-754-987-974-624;;006-245-410-815-610;;001-531-091-705-97X;;120-431-680-784-940;;004-698-718-524-050;;081-200-540-293-137;;046-553-252-092-01X;;076-294-679-339-389;;120-171-295-499-272;;064-962-060-981-605;;081-386-365-253-32X;;021-057-999-742-869;;026-932-424-159-079;;022-590-716-806-132;;035-212-349-166-092;;028-678-809-465-642;;032-653-649-478-64X;;006-034-729-456-867;;006-803-765-992-126;;023-060-379-453-927;;039-345-013-024-44X;;112-490-789-240-840;;021-723-640-233-189;;082-753-878-298-353;;066-505-855-225-642;;092-834-378-375-137;;038-494-560-382-732;;084-214-205-349-574;;019-048-788-328-741;;002-831-094-027-36X;;072-456-642-315-483;;002-901-414-109-286;;030-713-531-955-518;;056-667-395-284-965;;033-955-564-406-161;;023-188-824-495-707;;033-303-554-980-801;;015-169-910-449-13X;;018-475-788-646-424;;067-269-085-580-318;;049-637-391-464-722;;096-165-444-000-406;;071-128-501-152-431;;036-524-526-052-248;;010-227-378-190-539;;011-578-743-707-93X;;120-925-953-960-234;;057-409-240-401-885;;033-327-932-462-929;;009-433-708-941-369;;102-782-883-297-511;;085-041-784-520-543;;079-915-796-823-557;;041-598-321-970-355;;070-453-928-748-093;;088-552-607-576-523;;131-713-215-385-658,10.1111/j.1365-2141.2006.06157.x;;16848767;;10.1016/j.neurobiolaging.2003.12.023;;15172743;;10.1089/rej.2006.9.77;;16608400;;10.1093/brain/awl280;;17018549;;16997144;;10.1016/j.drudis.2006.08.004;;10.1002/cne.903420402;;8040362;;11875473;;10.1038/nm0302-199b;;9870435;;10.1093/ndt/13.suppl_7.33;;10.1001/archpsyc.61.1.95;;14706948;;16470518;;10.1002/ana.20799;;17727329;;10.1517/14712598.7.9.1401;;10.1093/brain/awl280;;17018549;;10.1093/protein/gzn052;;18927231;;10.1007/s00213-004-2132-z;;15654502;;10.1007/bf00207506;;10.1007/s001090050030;;8862510;;1538134;;pmc2874260;;20122289;;10.1186/alzrt24;;10.4049/jimmunol.174.3.1580;;15661919;;9349807;;10.1038/39758;;10.1159/000213842;;8996836;;pmc3887148;;10.1016/s0197-4580(00)00124-x;;10858586;;10.1001/archneur.63.10.1475;;17030665;;10.1126/science.2426778;;2426778;;10.1212/wnl.45.8.1441;;7644037;;10.1016/0304-3940(91)90775-o;;10.1515/9783486783568-005;;1922940;;10.1002/gps.1260;;15660410;;2304902;;10.1073/pnas.87.4.1347;;pmc53472;;7636808;;10.1530/jrf.0.1040007;;10.1001/archneur.1997.00550140077016;;9041863;;19494285;;10.4049/jimmunol.0803366;;4198012;;10.1007/bf01249670;;1613791;;10.1016/0022-2836(92)90106-t;;10.1016/j.pharmthera.2004.08.001;;15500907;;8516492;;10.3109/08860229309054946;;10.1016/s0021-9258(19)74312-9;;8253750;;9265723;;10.1016/s0958-1669(97)80066-3;;9933117;;10.1002/(sici)1521-4141(199901)29:01<345::aid-immu345>3.0.co;2-k;;6358000;;10.3109/08820138309051966;;3607773;;10572162;;10.1056/nejm199911253412213;;2119582;;10.1016/0006-291x(90)91229-l;;10.1006/meth.1999.0835;;10525446;;9354339;;10.1016/s0896-6273(00)80974-5;;8453267;;10.1016/s0959-437x(05)80349-1;;8909140;;10.1016/0168-9525(96)60040-7;;10.1101/gr.10.4.398;;10779480;;10.1002/eji.1830170820;;2442000;;10747968;;10.1074/jbc.m000937200;;10203816;;10.1016/s0168-9525(99)01706-0;;8429314;;pmc1014781;;10.1136/jnnp.56.1.112-a;;10.1016/j.clinbiochem.2004.05.015;;15234240;;7798659;;10.1093/infdis/171.1.18;;10.1006/exnr.1993.1059;;8491281;;10.2105/ajph.88.9.1337;;pmc1509089;;9736873;;10.1007/bf02740816;;9219239;;10.1097/00002826-199201001-00216;;1498896;;10.2165/00126839-200607030-00004;;16752944;;10954269;;pmc8174901;;12850000;;10.1016/s0006-291x(03)01131-8;;7781840;;10.1128/mcb.5.12.3403-3409.1985;;pmc369169;;10.1128/mcb.5.12.3403;;3939316;;10837643;;10.1016/s0169-409x(98)00009-x;;10.1038/35050179;;11140660;;10.1038/422370a;;12660749;;11823817;;10.1038/415462a;;10.1016/s0079-6123(08)64025-x;;9932418;;10.1038/35050103;;11140684;;10.1006/jmbi.1999.3192;;10543973;;11279122;;10.1074/jbc.m100710200;;10.1128/mcb.11.6.3070;;pmc360146;;10.1128/mcb.11.6.3070-3074.1991;;2038318;;10.1016/0022-2836(85)90137-8;;4093982;;12403985;;10.1038/nn940;;10.1159/000319350;;10.1159/000425634;;9018874;;10.1007/s004010050386;;8773140;;10491577;;10.1002/(sici)1097-4547(19991001)58:1<120::aid-jnr12>3.3.co;2-5;;10.1002/(sici)1097-4547(19991001)58:1<120::aid-jnr12>3.0.co;2-e;;10.4049/jimmunol.148.4.1149;;1737932;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1023/a:1007592720793;;10801214;;12359834;;10.1101/lm.51002;;pmc187133;;10.1111/j.1532-5415.1993.tb05944.x;;8418119;;8394031;;10.1111/j.1365-3083.1993.tb01710.x;;9139482;;10.1016/s0264-410x(96)00183-1;;9054444;;10.1074/jbc.272.11.7431;;10.1093/intimm/dxg049;;pmc1483061;;12663680;;10.1016/s0024-3205(99)80009-5;;9839536;;11516777;;10.1016/s0169-409x(01)00162-4;;2450091;;10.1016/s0021-9258(18)68927-6;;7889214;;10.1515/revneuro.1994.5.3.213;;10.1006/exnr.1997.6738;;9500964;;10.1002/jmr.300040207;;1687353;;1491745;;10.1016/0197-4580(92)90104-6;;10.1042/bj3200563;;pmc1217966;;8973567;;8704175;;10.1182/blood.v88.1.202.bloodjournal881202;;10.1007/bf02698052;;17848712;;12657428;;10.1016/s1471-4914(03)00022-4;;12849209;;10.1016/s1474-4422(03)00349-1;;10.1016/s0168-9525(98)01486-3;;9635409;;9089581;;10.1016/s0047-6374(96)01810-6;;11145990;;10.1046/j.1471-4159.2001.00012.x;;1383408;;10.1099/0022-1317-73-9-2357;;10.1212/wnl.57.5.801;;11552007;;10.1038/373476a0;;7845455;;10.1046/j.1432-1327.1998.2560560.x;;9780232;;6683749;;10.1016/0022-510x(83)90019-9;;10.1016/s0165-6147(00)01599-6;;11165659;;10.1016/s0197-4580(96)00119-4;;8892356;;10.1016/0197-4580(96)00119-4;;10346900;;10.1021/bi982824n;;pmc51108;;10.1073/pnas.88.5.1779;;1900367;;pmc42951;;10.1073/pnas.91.1.380;;8278398;;1560463;;10.1016/0022-2836(92)91010-m;;9762953;;10.1093/brain/121.9.1631;;11676288;;10.1016/s0264-410x(00)00501-6;;11257400;;10.1111/j.1749-6632.1997.tb48475.x;;9329695;;9171327;;10.1016/s0022-510x(97)05399-9;;10.1016/0165-6147(92)90039-9;;1574806;;1702629;;10.1016/s0006-291x(05)80927-1;;pmc2190957;;10.1084/jem.177.4.1181;;8459212;;pmc1228260;;9347775;;pmc521991;;15297619;;10.1073/pnas.0404866101;;16338209;;10.1016/j.autrev.2005.06.007;;2062847;;10.1073/pnas.88.13.5690;;pmc51943;;pmc1130811;;1372166;;10.1042/bj2820517;;pmc2818979;;19355933;;10.2174/187152709787847298;;10.1016/s0197-4580(97)00149-8;;9461055;;10.1074/jbc.273.45.29719;;9792685;;10.1038/36014;;9495336;;10.1016/0006-291x(84)91209-9;;6236805;;6375662;;10.1016/s0006-291x(84)80190-4;;1671712;;10.1038/349704a0;;10.1146/annurev.med.46.1.57;;7598484;;7625646;;10.1111/j.1749-6632.1995.tb44445.x;;pmc15903;;10077645;;10.1073/pnas.96.6.3108;;pmc1364172;;10.1046/j.1365-2567.1998.00423.x;;9616362;;3307786;;10.1016/0006-291x(87)91008-4;;8552653;;pmc40251;;10.1073/pnas.93.1.427;;15459438;;10.1161/01.str.0000143224.36527.44;;10.1038/nm847;;12640449;;10.1126/science.275.5300.657;;9005850;;2260724;;10.1152/ajpregu.1990.259.6.r1131;;10.1016/s0264-410x(97)00034-0;;9302741;;8585280;;10.1016/0264-410x(95)00011-o;;pmc1887460;;8203468;;1383826;;10.1038/359322a0;;10.1038/nn0901-859;;11528409;;12411936;;10.1038/nm1102-1195;;10.1093/clinchem/39.9.1988;;8375089;;10.1016/s0169-409x(97)00053-7;;10837567;;10.1016/s0166-2236(96)01030-2;;9106355;;8811169;;10.3109/07853899609033127;;10.1097/00001756-199506090-00011;;7669985;;8388365;;pmc1421888;;9551944;;10.1007/bf03259509;;499332;;10.1002/eji.1830090817;;10.1128/jvi.75.24.12161-12168.2001;;11711607;;pmc116112;;12962700;;10.1016/s1357-2725(03)00169-9;;12413532;;10.1016/s0952-7915(02)00409-0;;16989900;;10.1016/j.molimm.2006.08.001;;10.1073/pnas.78.6.3824;;6167991;;pmc319665;;8034754;;10.1016/0165-5728(94)90108-2;;10.1128/cdli.2.6.726-732.1995;;8574838;;pmc170229;;7566008;;10.1056/nejm199511093331910;;18640437;;10.1016/s0140-6736(08)61047-8;;10.4049/jimmunol.164.8.4178;;10754313;;11589422;;10.1093/jnen/60.10.923;;2808689;;10.1016/0165-5728(89)90115-x;;6311964;;10.1002/jmv.1890120102;;10.1097/00002093-199505000-00009;;7605621;;10.1111/j.1600-065x.1982.tb00394.x;;7042538;;9729539;;pmc95643;;10.1128/cdli.5.5.703-710.1998;;11140685;;10.1038/35050110;;11566220;;10.1016/s0031-9384(01)00524-8;;9438067;;10.1016/s1385-299x(97)00023-8;;10.1093/ilar.37.3.119;;11528031;;1704190;;pmc1886178;;1943708;;10.1111/j.1365-2958.1991.tb01925.x;;10.1128/iai.32.2.497-502.1981;;pmc351473;;7019072;;10.1002/(sici)1097-4547(19961101)46:3<336::aid-jnr7>3.0.co;2-l;;10.1002/(sici)1097-4547(19961101)46:3<336::aid-jnr7>3.3.co;2-l;;8933373;;1280849;;10.1016/0923-2494(92)80048-p;;11134035;;10.1074/jbc.m010402200;;2446004;;pmc255980;;10.1128/jvi.61.12.3688-3693.1987;;8679109;;10.1038/354476a0;;1793460;;10191146;;10.1006/jmbi.1999.2646;;8696966;;10.1016/s0959-440x(96)80089-3;;1798701;;10.1093/protein/4.7.773;;8140051;;10.1023/a:1018977107167;;10.1016/0014-5793(94)00829-9;;8076698;;8992999;;11245211;;10.1093/jnen/60.3.274;;10.1212/01.wnl.0000260066.98681.2e;;17452586;;17578972;;10.1213/01.ane.0000266490.64814.ff;;3138286;;10.1172/jci113689;;pmc303593;;10.1016/0161-5890(92)90097-h;;1542295;;20026675;;pmc6758140;;12151510;;10.1523/jneurosci.22-15-06331.2002;;10.1006/bbrc.1994.2788;;7802646;;10.1007/s00415-002-0896-9;;12420099;;8805642;;10208861;;10.1006/bbrc.1999.0552;;3915946;;11160220;;10.4049/jimmunol.166.3.1748;;2218494;;10.1126/science.2218494;;8117426;;10.1016/0166-4328(93)90137-f;;9667848;;10.1016/s1367-5931(97)80018-x;;10.1385/jmn:24:1:105;;15314258;;10.1016/s0197-4580(02)00127-6;;12470794;;10.1016/s0079-6123(09)17506-4;;pmc2814339;;19660650;;10.1002/1531-8249(200010)48:4<553::aid-ana1>3.0.co;2-e;;10.1002/1531-8249(200010)48:4<553::aid-ana1>3.3.co;2-5;;11026438;;10.1016/s0022-2836(83)80304-0;;6193280;;10.1080/15216549700204411;;9352079;;6363521;;10.1177/32.3.6363521;;9233635;;10.1093/protein/11.6.495;;9725629;;1776393;;10.1111/j.1600-0404.1991.tb04985.x;;10.1006/jmbi.1996.0548;;8876650;;8737930;;10.1111/j.1750-3639.1996.tb00797.x;;10.1016/0006-8993(94)91725-6;;7895077;;15537049;;8781665;;10.1007/s004010050479;;pmc1861527;;8644866;;10.1016/0304-3940(95)11860-y;;7501233;;9311887;;10.1128/jvi.71.10.7960-7962.1997;;pmc192154;;15077722;;10.1080/10408360490269251;;pmc1536678;;7151332;;7652552;;10.1126/science.7652552;;10.1074/jbc.273.20.12548;;9575214;;10.1073/pnas.82.12.4245;;pmc397973;;3159021;;14512605;;10.1126/science.301.5641.1847;;9354812;;10.1152/physrev.1997.77.4.1081;;1848334;;10.1093/rheumatology/keh305;;15501998;;10.3109/02652049709015333;;9132471;;10.1002/jnr.490310305;;1640495;;10589538;;10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m;;10.1006/viro.1998.9060;;9527925;;11080787;;pmc2118953;;10.1084/jem.174.4.791;;1717632;;12935438;;17630936;;10.2174/138945007781077328;;14593170;;10.1126/science.1088469;;11140686;;10.1038/35050116;;10.1212/wnl.39.9.1159;;2771064;;16829947;;10.1038/nm0706-780;;10.1371/journal.pone.0002124;;pmc2358976;;18461171;;10.1038/sj.cgt.7700513;;12386827;;10.1538/expanim1978.43.5_711;;7498337;;10.1111/j.1600-0684.1998.tb00244.x;;9926980;;1933692;;10.1017/s0317167100032595;;7679865;;10.1016/0264-410x(93)90023-q;;10.1001/jama.283.12.1571;;10735393;;10.1093/oxfordjournals.aje.a009064;;9169904;;5855054;;10.1016/0304-4165(65)90353-3;;10.1007/978-1-4684-6831-1_14;;9556915;;10.1023/a:1017147723192;;pmc390431;;10.1073/pnas.82.14.4592;;3927286;;10.1073/pnas.86.10.3833;;2726754;;pmc287235;;pmc297746;;10.1073/pnas.86.15.5938;;2762305;;10.2210/pdb3hfm/pdb;;10.1007/s001090000163;;11434723;;pmc280147;;10.1073/pnas.85.9.3080;;3129726;;2955786;;10.1016/0006-291x(87)90726-1;;10.1602/neurorx.2.1.3;;10.1007/bf03206638;;15717053;;pmc539316;;10.2165/00003495-199753050-00003;;9129864;;12218124;;10.4049/jimmunol.169.6.3076;;10.1002/eji.1830251248;;8566048;;2499636;;10.1016/0022-1759(89)90298-6;;3131419;;pmc122814;;10.1073/pnas.042681399;;11960014;;8699826;;8913788;;10.1089/hyb.1996.15.379;;8978505;;10.1002/jnr.490460602;;10.1002/ijc.2910550126;;8344745;;1286869;;10.1111/j.1600-065x.1992.tb01525.x;;pmc44065;;10.1073/pnas.91.12.5705;;8202551;;11493021;;10.1006/nbdi.2001.0402;;7902565;;10.1073/pnas.90.22.10608;;pmc47826;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;10.1046/j.1471-4159.1998.70052099.x;;9572296;;10.1016/0952-7915(95)80033-6;;7772286;;10.1038/icb.1997.64;;9315486;;3127726;;10.1038/332323a0;;9200467;;8712790;;10.1146/annurev.med.47.1.387;;8239283;;10.1111/j.1749-6632.1993.tb23052.x;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1007/978-1-349-02718-7_1;;10.1016/s0021-9258(19)74593-1;;8227089;;10593510;;10.1016/s0161-5890(99)00087-5;;9175887;;10.1016/s0006-8993(97)00097-8;;15342006;;10.1016/j.coi.2004.07.012;;11788045;;10.1089/10445490152717532;;pmc1857916;;9212733;;2117273;;pmc54489;;10.1073/pnas.87.16.6146;;8078889;;10.1073/pnas.91.18.8368;;pmc44607;;10.1016/j.neurobiolaging.2003.12.008;;15312960;;10.1073/pnas.96.5.2262;;10051629;;pmc26771;;9194525;;10.1096/fasebj.11.6.9194525;;8083687;;10.1097/00005072-199409000-00003;;10.1016/s0962-8924(98)01363-4;;9854312;;12399581;;10.1126/science.1074069;;10932146;;10.1038/78422;;10.1126/science.275.5300.630;;9019820;;1785042;;10.1038/scientificamerican1191-68;;10.1038/354432a0;;1684220;;10.1016/0896-6273(91)90052-2;;1673054;;10.1046/j.1471-4159.2003.01818.x;;12787077;;8228231;;1321388;;10.1016/0168-0102(92)90037-d;;11102798;;10.1016/s0958-1669(00)00152-x;;10.1161/01.atv.20.6.1425;;10845854;;12470795;;10.1016/s0197-4580(02)00124-0;;12505623;;10.1016/s0304-3940(02)01192-8;;10.1016/s0002-9440(10)64151-x;;12107084;;pmc1850699;;10.1159/000213837;;8996831;;7534089;;10.1007/bf02816106;;10.1111/j.1749-6632.2000.tb06923.x;;11193151;;10.1146/annurev.bi.61.070192.004503;;1497327;;10.1146/annurev.biochem.61.1.947;;10631780;;10.1016/s0167-7799(99)01398-0;;10.1038/35086072;;11484003;;10811879;;pmc18554;;10.1073/pnas.090106797;;9566620;;10.1023/a:1022471729291;;11848876;;10.1021/cr960065d;;9359093;;10.1038/nbt1197-1222;;10.1080/01652176.1997.9694751;;9323849;;10.1016/s1380-2933(97)89100-2;;12517269;;10.1517/14712598.2.8.907;;11788047;;10.1089/10445490152717550;;9854423;;8670088;;pmc1217103;;10.1042/bj3140701;;10.1038/nm0798-822;;9662374;;15331301;;10.1016/j.cnur.2004.02.010;;9257853;;10.1038/22006;;10408433;;3349522;;10.1016/0092-8674(88)90434-5;;pmc6758007;;10.1523/jneurosci.22-17-07380.2002;;12196559;;10.1056/nejm199701093360202;;8988885;;10.1159/000126535;;8264867;;10.1093/protein/7.6.805;;7937712;;9371838;;pmc24301;;10.1073/pnas.94.24.13287;;8185615;;10.1006/bbrc.1994.1634;;12503092;;10.1002/jnr.10474;;10.1073/pnas.85.15.5409;;pmc281766;;3399498;;10.1111/j.1365-2559.1994.tb00001.x;;7868080;;9716347;;10.1016/s0014-2999(98)00344-6;;1545867;;10.1038/356152a0;;10.1038/nm0196-93;;8564851;;10.1073/pnas.92.10.4299;;7753801;;pmc41931;;10.1016/s1367-5931(00)00102-2;;10959764;;10212241;;10.1074/jbc.274.18.12619;;10.1016/s0304-3940(01)01951-6;;11427310;;2367327;;10.1023/a:1015810009701;;10.1126/science.309.5735.731;;16051787;;8832628;;10.1016/0197-4580(96)00068-1;;10.1016/s0197-4580(96)00068-1;;10.1097/00005072-199401000-00004;;8301317;;9274858;;12079396;;10.1016/s0022-2836(02)00264-4;;11849445;;10.1046/j.1523-1755.2002.00205.x;;7871387;;10.1111/j.1365-3083.1995.tb03564.x;;10727777;;10.1016/s0301-0082(99)00055-6;;10.1016/s0958-1669(98)80011-6;;9720264;;10.3109/13506120009146438;;11132093;;16763572;;10.1038/nbt0606-595;;11788049;;10.1089/10445490152717578;;pmc1887111;;7904796;;9305836;;10.1038/38410;;10.2165/00002512-200219070-00002;;12182685;;12857003;;16397165;;10.1161/01.str.0000199847.96188.12;;8021711;;10.1097/00005072-199407000-00009;;pmc9887729;;11750898;;10.1016/s0006-8993(01)03058-x;;10.1016/s0378-5173(99)00152-0;;10460913;;10.1093/nar/19.23.6475;;pmc329201;;1754385;;10.1146/annurev.iy.12.040194.004113;;10.1146/annurev.immunol.12.1.809;;8011298;;9238837;;10.1016/s0167-5699(97)01053-0;;8901511;;10.1021/bi961799n;;9384548;;10.1016/s0959-4388(97)80091-8;;10.1016/0014-5793(85)81158-3;;3972126;;10.1021/bi00489a001;;2271534;;10932157;;10.1038/78482;;2221079;;10.1152/ajpgi.1990.259.4.g687;;10.1046/j.1471-4159.2003.02064.x;;14622111;;10.1139/w98-015;;10.1139/cjm-44-4-313;;9674105;;12765602;;10.1016/s0896-6273(03)00297-6;;8397764;;10.1016/0167-5699(93)90039-n;;10.1016/0197-4580(94)90105-8;;7838284;;10.1042/bst0300574;;12196140;;pmc391510;;10.1073/pnas.82.24.8729;;2934737;;18490705;;2471978;;pmc287346;;10.1073/pnas.86.12.4726;;10556035;;10.1006/jmbi.1999.3141;;pmc508366;;9312181;;10.1172/jci119708;;7895169;;10.1016/s1074-7613(95)80001-8;;10.1046/j.1365-3083.1997.d01-108.x;;9583998;;9450547;;10.1016/s0014-5793(97)01484-1;;7865758;;10.1097/00001756-199410270-00032;;8633046;;10.1073/pnas.93.9.4229;;pmc39517;;7028111;;10.1021/bi00523a027;;6167990;;pmc319660;;10.1073/pnas.78.6.3799;;4139708;;10.1073/pnas.71.10.4032;;pmc434322;;10.1046/j.1365-2990.2003.00457.x;;12787320;;10.1111/j.1365-2141.2006.06157.x;;16848767;;10.1016/j.neurobiolaging.2003.12.023;;15172743;;10.1136/jnnp.57.suppl.72;;pmc1016733;;7964861;;7872684;;10.1371/journal.ppat.1000138;;pmc2516931;;18769719;;1334977;;10.1172/jci116141;;pmc443406;;1471412;;10.1016/0264-410x(92)90325-e;;10.1517/14712598.2010.493872;;pmc3000430;;20497044;;10.1016/s0733-8619(18)31221-0;;2417097;;10.1089/rej.2006.9.77;;16608400;;10.1016/s0531-5565(98)00028-x;;9951630;;9413094;;10.1016/s0264-410x(97)00141-2;;14872042;;10.1212/01.wnl.0000106951.94624.df;;15277614;;10.1212/01.wnl.0000129988.68657.fa;;9003240;;10.1016/s0165-5728(96)00117-8;;15975063;;10.2174/1567205043332126;;10.1358/dot.2007.43.5.1062670;;17724499;;10.1517/13543784.6.11.1715;;15989576;;pmc3693547;;21784348;;10.1016/j.jalz.2011.05.2351;;9815634;;10.1016/s0531-5565(96)00152-0;;9315445;;8796867;;10.1016/1357-4310(96)88720-x;;1549228;;10.1212/wnl.42.3.631;;11823817;;10.1038/415462a;;10.1136/jnnp.2003.033399;;15377700;;pmc1738770;;22672770;;10.1016/j.jalz.2011.09.224;;23274463;;10.1038/nrd3922;;10.1038/22006;;10408433;;23050679;;10.1111/jnc.12009;;10.1097/01.nt.0000405138.21166.8e;;10.1073/pnas.0703137104;;pmc1887581;;17517595;;10.1016/0022-510x(84)90108-4;;6699654;;10.1590/s0036-46651992000100014;;17119920;;10.1007/s00134-006-0459-0;;8949258;;10.1093/oxfordjournals.bmb.a011568;;21257628;;10.1177/0885066610393634;;10.1177/000456329002700503;;1704202;;10.1073/pnas.86.12.4761;;2734318;;pmc287353;;8981306;;10.1016/s0022-510x(96)00184-0;;pmc47235;;8102802;;10.1073/pnas.90.16.7824;;10.1111/j.1600-0404.1988.tb03680.x;;2464268;;9267856;;10.1159/000119366;;15240806;;pmc6729674;;10.1523/jneurosci.1090-04.2004;;10.1089/10445490152717596;;11788051;;10.1016/j.jalz.2013.05.564;;10.1038/nri2761;;20414204;;16973779;;10.1148/rg.265055090;;10.1016/s0958-1669(00)00202-0;;11287240;;24450890;;10.1056/nejmoa1312889;;3477820;;10.1073/pnas.84.19.6953;;pmc299203;;10.2165/00003088-199732040-00004;;9113439;;10.1056/nejmoa1304839;;pmc4159618;;24450891;;pmc2615484;;10.3233/jad-2008-15404;;19096156;;10.1007/bf00688170;;2551122;;10.1001/archneur.56.7.857;;10404988;;12764552;;10.1007/s00259-003-1202-5;;10.1111/joim.12168;;24605809;;pmc4238820;;10.1007/s00259-007-0700-2;;18188557;;10.1016/j.jalz.2009.06.003;;19751922;;pmc2756824;;10375654;;10.1016/s0006-8993(99)01479-1;;17501694;;10.1517/13543784.16.6.819;;16997144;;10.1016/j.drudis.2006.08.004;;14751766;;10.1016/j.nbd.2003.09.015;;pmc539292;;10.1186/1742-2094-1-24;;15588287;;24476230;;10.1186/alzrt237;;pmc3979042;;11021833;;pmc1850171;;10.1016/s0002-9440(10)64644-5;;17921032;;pmc2078205;;10.1016/j.nucmedbio.2007.06.015;;10.1016/s1474-4422(04)00853-1;;15324720,"Greaves P et al. Posterior reversible encephalopathy syndrome following anti-lymphocyte globulin treatment for severe aplastic anaemia. Br J Haematol. Aug. 2006; 134(3):251.;;Raber J et al. ApoE geneotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging, 2004; 25:641-50.;;Lemere et al. (2006) Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res. 9(1):77-84.;;Klafki H-W et al. (2006) Therapeutic approaches to Alzheimer's disease. Brain, 129:2840-2855.;;Wang Y-J et al. (2006) Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discovery Today, 11(19/20):931-938.;;U.S. Appl. No. 09/201,430, Office Action mailed May 10, 2000.;;U.S. Appl. No. 09/201,430, Office Action mailed Dec. 21, 1999.;;U.S. Appl. No. 09/204,838, Office Action mailed Mar. 17, 2000.;;U.S. Appl. No. 09/322,289, Office Action mailed Sep. 29, 2000.;;U.S. Appl. No. 09/497,553, Office Action mailed Oct. 3, 2003.;;U.S. Appl. No. 09/580,015, Office Action mailed Feb. 11, 2002.;;U.S. Appl. No. 09/580,018, Office Action mailed Mar. 12, 2002.;;U.S. Appl. No. 09/580,019, Office Action mailed Mar. 12, 2002.;;U.S. Appl. No. 09/723,544, Office Action mailed Sep. 23, 2002.;;U.S. Appl. No. 09/723,760, Office Action mailed Mar. 12, 2002.;;U.S. Appl. No. 09/723,765, Office Action mailed Mar. 12, 2002.;;U.S. Appl. No. 09/723,766, Office Action mailed Mar. 5, 2002.;;U.S. Appl. No. 09/723,766, Office Action mailed Jun. 11, 2002.;;U.S. Appl. No. 09/724,273, Office Action mailed Jul. 2, 2002.;;U.S. Appl. No. 09/724,273, Office Action mailed Nov. 8, 2005.;;U.S. Appl. No. 09/724,288, Office Action mailed Mar. 12, 2002.;;U.S. Appl. No. 09/724,288, Office Action mailed May 3, 2004.;;U.S. Appl. No. 09/724,319, Office Action mailed Jul. 21, 2003.;;U.S. Appl. No. 09/724,495, Office Action mailed Mar. 13, 2003.;;U.S. Appl. No. 09/724,495, Office Action mailed Sep. 24, 2002.;;U.S. Appl. No. 09/724,551, Office Action mailed Jul. 2, 2002.;;U.S. Appl. No. 09/724,552, Office Action mailed May 6, 2002.;;U.S. Appl. No. 09/724,567, Office Action mailed Mar. 27, 2002.;;U.S. Appl. No. 09/724,575, Office Action mailed Mar. 27, 2002.;;U.S. Appl. No. 09/724,921, Office Action mailed Apr. 30, 2002.;;U.S. Appl. No. 09/724,929, Office Action mailed Mar. 22, 2002.;;U.S. Appl. No. 09/724,940, Office Action mailed Mar. 13, 2003.;;U.S. Appl. No. 09/724,953, Office Action mailed Mar. 26, 2002.;;U.S. Appl. No. 09/724,961, Office Action mailed Mar. 12, 2002.;;U.S. Appl. No. 09/979,701, Office Action mailed Feb. 15, 2005.;;U.S. Appl. No. 09/979,701, Office Action mailed Sep. 15, 2005.;;U.S. Appl. No. 09/979,952, Office Action mailed Aug. 7, 2003.;;U.S. Appl. No. 09/980,568, Office Action mailed May 29, 2003.;;U.S. Appl. No. 10/010,942, Office Action mailed Sep. 24, 2003.;;U.S. Appl. No. 10/232,030, Office Action mailed Dec. 2, 2004.;;U.S. Appl. No. 10/388,214, Office Action mailed May 31, 2005.;;U.S. Appl. No. 10/388,389, Office Action mailed Nov. 22, 2005.;;U.S. Appl. No. 10/429,216, Office Action mailed Dec. 28, 2005.;;U.S. Appl. No. 10/544,093, Office Action mailed Jun. 16, 2008.;;U.S. Appl. No. 10/625,854, Office Action mailed Nov. 10, 2005.;;U.S. Appl. No. 10/703,713, Office Action mailed Nov. 5, 2004.;;U.S. Appl. No. 10/704,070, Office Action mailed Nov. 5, 2004.;;U.S. Appl. No. 10/771,174, Office Action mailed Sep. 14, 2006.;;U.S. Appl. No. 10/777,792, Office Action mailed Mar. 2, 2006.;;U.S. Appl. No. 10/788,666, Office Action mailed Jan. 12, 2005.;;U.S. Appl. No. 10/789,273, Office Action mailed Sep. 22, 2006.;;U.S. Appl. No. 10/822,968, Office Action mailed Mar. 22, 2006.;;U.S. Appl. No. 10/823,463, Office Action mailed Feb. 4, 2005.;;U.S. Appl. No. 10/828,548, Office Action mailed Feb. 4, 2005.;;U.S. Appl. No. 10/828,548, Office Action mailed Sep. 29, 2005.;;U.S. Appl. No. 10/858,855, Office Action mailed Jun. 22, 2006.;;U.S. Appl. No. 10/923,267, Office Action mailed Jul. 21, 2006.;;U.S. Appl. No. 10/923,469, Office Action mailed Mar. 29, 2007.;;U.S. Appl. No. 10/923,474, Office Action mailed Feb. 15, 2005.;;U.S. Appl. No. 10/928,926, Office Action mailed Jan. 12, 2007.;;U.S. Appl. No. 10/934,819, Office Action mailed Oct. 14, 2005.;;U.S. Appl. No. 11/058,757, Office Action mailed May 3, 2005.;;U.S. Appl. No. 11/058,757, Office Action mailed Aug. 24, 2005.;;U.S. Appl. No. 11/244,678, Office Action mailed Apr. 18, 2007.;;U.S. Appl. No. 11/245,524, Office Action mailed May 15, 2007.;;U.S. Appl. No. 11/245,916, Office Action mailed Jan. 13, 2006.;;U.S. Appl. No. 11/260,047, Office Action mailed Oct. 26, 2006.;;U.S. Appl. No. 11/303,478, Office Action mailed Apr. 1, 2008.;;U.S. Appl. No. 11/303,478, Office Action mailed Oct. 16, 2008.;;U.S. Appl. No. 11/304,072, Office Action mailed Dec. 20, 2006.;;U.S. Appl. No. 11/304,986, Office Action mailed Jan. 2, 2008.;;U.S. Appl. No. 11/305,889, Office Action mailed May 4, 2007.;;U.S. Appl. No. 11/305,889, Office Action mailed Jul. 25, 2008.;;U.S. Appl. No. 11/305,899, Office Action mailed Apr. 4, 2008.;;U.S. Appl. No. 11/342,353, Office Action mailed Mar. 26, 2008.;;U.S. Appl. No. 11/342,353, Office Action mailed Jul. 9, 2008.;;U.S. Appl. No. 11/454,772, Office Action mailed Feb. 27, 2007.;;U.S. Appl. No. 11/516,724, Office Action mailed Jan. 27, 2009.;;U.S. Appl. No. 11/520,438, Office Action mailed Apr. 2, 2009.;;U.S. Appl. No. 11/707,639, Office Action mailed Apr. 3, 2009.;;U.S. Appl. No. 11/842,085, Office Action mailed Apr. 14, 2009.;;U.S. Appl. No. 11/842,113, Office Action mailed Dec. 17, 2009.;;U.S. Appl. No. 11/842,116, Office Action mailed Mar. 31, 2010.;;U.S. Appl. No. 11/842,120, Office Action mailed Apr. 14, 2009.;;U.S. Appl. No. 12/106,206, Office Action mailed Feb. 5, 2010.;;U.S. Appl. No. 12/253,929, Office Action mailed Jan. 25, 2010.;;U.S. Appl. No. 12/297,636, Office Action mailed Jul. 20, 2011.;;U.S. Appl. No. 12/297,636, Office Action mailed Oct. 28, 2011.;;U.S. Appl. No. 12/328,740, Office Action mailed Oct. 9, 2009.;;U.S. Appl. No. 12/608,869, Office Action mailed Jul. 5, 2011.;;U.S. Appl. No. 13/123,898, Office Action mailed Nov. 15, 2011.;;U.S. Appl. No. 09/201,430, Examiner Interview Summary mailed May 30, 2001.;;U.S. Appl. No. 09/201,430, Office Action mailed Jan. 17, 2001.;;U.S. Appl. No. 09/204,838, Office Action mailed Dec. 21, 2000.;;U.S. Appl. No. 09/322,289, Examiner Interview Summary mailed Jun. 27, 2006.;;U.S. Appl. No. 09/322,289, Examiner Interview Summary mailed Jan. 15, 2009.;;U.S. Appl. No. 09/322,289, Office Action mailed Jun. 19, 2001.;;U.S. Appl. No. 09/497,553, Office Action mailed Nov. 29, 2005.;;U.S. Appl. No. 09/580,018, Office Action mailed May 20, 2003.;;U.S. Appl. No. 09/723,384, Examiner Interview Summary mailed Mar. 28, 2003.;;U.S. Appl. No. 09/723,384, Office Action mailed Oct. 9, 2002.;;U.S. Appl. No. 09/723,544, Office Action mailed Aug. 11, 2003.;;U.S. Appl. No. 09/723,713, Office Action mailed Mar. 26, 2002.;;U.S. Appl. No. 09/723,760, Office Action mailed Dec. 19, 2002.;;U.S. Appl. No. 09/723,762, Office Action mailed Oct. 2, 2001.;;U.S. Appl. No. 09/723,765, Examiner Interview Summary mailed Mar. 18, 2003.;;U.S. Appl. No. 09/723,765, Examiner Interview Summary mailed Jan. 25, 2006.;;U.S. Appl. No. 09/723,765, Examiner Interview Summary mailed Oct. 8, 2008.;;U.S. Appl. No. 09/723,765, Examiner Interview Summary mailed Jan. 16, 2009.;;U.S. Appl. No. 09/723,765, Office Action mailed Dec. 3, 2002.;;U.S. Appl. No. 09/723,766, Office Action mailed Nov. 1, 2002.;;U.S. Appl. No. 09/724,102, Office Action mailed Oct. 3, 2001.;;U.S. Appl. No. 09/724,273, Office Action mailed Apr. 21, 2003.;;U.S. Appl. No. 09/724,288, Office Action mailed Dec. 11, 2002.;;U.S. Appl. No. 09/724,319, Examiner Interview Summary mailed Jul. 19, 2004.;;U.S. Appl. No. 09/724,319, Examiner Interview Summary mailed Apr. 9, 2008.;;U.S. Appl. No. 09/724,319, Office Action mailed Apr. 26, 2004.;;U.S. Appl. No. 09/724,477, Office Action mailed Oct. 2, 2001.;;U.S. Appl. No. 09/724,489, Office Action mailed Oct. 2, 2002.;;U.S. Appl. No. 09/724,495, Office Action mailed Jan. 16, 2004.;;U.S. Appl. No. 09/724,551, Office Action mailed Jun. 3, 2003.;;U.S. Appl. No. 09/724,552, Examiner Interview Summary mailed Dec. 3, 2003.;;U.S. Appl. No. 09/724,552, Office Action mailed Jun. 3, 2003.;;U.S. Appl. No. 09/724,567, Office Action mailed Nov. 15, 2002.;;U.S. Appl. No. 09/724,575, Examiner Interview Summary mailed May 6, 2005.;;U.S. Appl. No. 09/724,575, Office Action mailed Nov. 21, 2002.;;U.S. Appl. No. 09/724,921, Office Action mailed Jan. 28, 2003.;;U.S. Appl. No. 09/724,929, Office Action mailed Jul. 22, 2003.;;U.S. Appl. No. 09/724,940, Office Action mailed Dec. 24, 2003.;;U.S. Appl. No. 09/724,953, Office Action mailed Nov. 27, 2002.;;U.S. Appl. No. 09/724,961, Examiner Interview Summary mailed Dec. 3, 2003.;;U.S. Appl. No. 09/724,961, Office Action mailed May 16, 2003.;;U.S. Appl. No. 09/979,701, Office Action mailed Jan. 10, 2006.;;U.S. Appl. No. 09/979,952, Office Action mailed Dec. 30, 2003.;;U.S. Appl. No. 09/980,568, Office Action mailed Feb. 23, 2004.;;U.S. Appl. No. 10/010,942, Examiner Interview Summary mailed May 10, 2006.;;U.S. Appl. No. 10/010,942, Examiner Interview Summary mailed May 11, 2006.;;U.S. Appl. No. 10/010,942, Examiner Interview Summary mailed Nov. 18, 2004.;;U.S. Appl. No. 10/010,942, Examiner Interview Summary mailed Feb. 22, 2006.;;U.S. Appl. No. 10/010,942, Examiner Interview Summary mailed Jan. 19, 2005.;;U.S. Appl. No. 10/010,942, Office Action mailed May 26, 2004.;;U.S. Appl. No. 10/232,030, Examiner Interview Summary mailed Feb. 17, 2006.;;U.S. Appl. No. 10/232,030, Office Action mailed Oct. 14, 2005.;;U.S. Appl. No. 10/388,214, Examiner Interview Summary mailed Oct. 2, 2006.;;U.S. Appl. No. 10/388,214, Examiner Interview Summary mailed Nov. 6, 2006.;;U.S. Appl. No. 10/388,214, Office Action mailed Jan. 31, 2006.;;U.S. Appl. No. 10/388,389, Examiner Interview Summary mailed May 31, 2006.;;U.S. Appl. No. 10/388,389, Examiner Interview Summary mailed May 22, 2006.;;U.S. Appl. No. 10/429,216, Examiner Interview Summary mailed Mar. 6, 2006.;;U.S. Appl. No. 10/429,216, Office Action mailed Apr. 11, 2006.;;U.S. Appl. No. 10/544,093, Office Action mailed Feb. 9, 2009.;;U.S. Appl. No. 10/625,854, Examiner Interview Summary mailed Jun. 26, 2007.;;U.S. Appl. No. 10/625,854, Office Action mailed Feb. 7, 2006.;;U.S. Appl. No. 10/703,713, Examiner Interview Summary mailed Feb. 21, 2006.;;U.S. Appl. No. 10/703,713, Examiner Interview Summary mailed Mar. 2, 2006.;;U.S. Appl. No. 10/703,713, Office Action mailed Sep. 27, 2005.;;U.S. Appl. No. 10/704,070, Office Action mailed Sep. 26, 2005.;;U.S. Appl. No. 10/771,174, Office Action mailed Nov. 27, 2006.;;U.S. Appl. No. 10/777,792, Office Action mailed Aug. 7, 2006.;;U.S. Appl. No. 10/788,666, Office Action mailed Dec. 15, 2005.;;U.S. Appl. No. 10/823,463, Office Action mailed Sep. 30, 2005.;;U.S. Appl. No. 10/828,548, Office Action mailed Feb. 13, 2006.;;U.S. Appl. No. 10/858,855, Office Action mailed Mar. 7, 2007.;;U.S. Appl. No. 10/889,999, Office Action mailed Jan. 5, 2005.;;U.S. Appl. No. 10/890,000, Office Action mailed Apr. 13, 2005.;;U.S. Appl. No. 10/890,024, Office Action mailed Nov. 2, 2005.;;U.S. Appl. No. 10/890,070, Office Action mailed Apr. 8, 2005.;;U.S. Appl. No. 10/890,071, Office Action mailed Dec. 18, 2006.;;U.S. Appl. No. 10/923,469, Examiner Interview Summary mailed Apr. 9, 2008.;;U.S. Appl. No. 10/923,469, Office Action mailed Jul. 3, 2007.;;U.S. Appl. No. 10/923,471, Examiner Interview Summary mailed Oct. 20, 2008.;;U.S. Appl. No. 10/923,471, Office Action mailed Jan. 5, 2005.;;U.S. Appl. No. 10/923,474, Office Action mailed Nov. 17, 2005.;;U.S. Appl. No. 10/923,605, Office Action mailed Apr. 12, 2007.;;U.S. Appl. No. 10/934,818, Office Action mailed Mar. 26, 2007.;;U.S. Appl. No. 10/934,819, Office Action mailed Jan. 24, 2006.;;U.S. Appl. No. 11/058,757, Office Action mailed Oct. 20, 2005.;;U.S. Appl. No. 11/108,102, Office Action mailed Jan. 11, 2006.;;U.S. Appl. No. 11/244,678, Office Action mailed Jul. 13, 2007.;;U.S. Appl. No. 11/245,524, Office Action mailed Sep. 27, 2007.;;U.S. Appl. No. 11/245,916, Office Action mailed May 19, 2006.;;U.S. Appl. No. 11/260,047, Examiner Interview Summary mailed May 15, 2007.;;U.S. Appl. No. 11/260,047, Office Action mailed May 15, 2007.;;U.S. Appl. No. 11/274,493, Office Action mailed Apr. 23, 2007.;;U.S. Appl. No. 11/303,478, Office Action mailed Mar. 18, 2009.;;U.S. Appl. No. 11/304,986, Office Action mailed Dec. 31, 2008.;;U.S. Appl. No. 11/305,889, Office Action mailed Aug. 14, 2007.;;U.S. Appl. No. 11/305,899, Office Action mailed Dec. 10, 2008.;;U.S. Appl. No. 11/342,353, Office Action mailed Nov. 14, 2008.;;U.S. Appl. No. 11/454,772, Examiner Interview Summary mailed Apr. 13, 2007.;;U.S. Appl. No. 11/454,772, Office Action mailed Jun. 27, 2007.;;U.S. Appl. No. 11/520,438, Office Action mailed Aug. 6, 2009.;;U.S. Appl. No. 11/842,023, Office Action mailed Nov. 13, 2008.;;U.S. Appl. No. 11/842,042, Office Action mailed Jun. 24, 2009.;;U.S. Appl. No. 11/842,056, Office Action mailed May 6, 2009.;;U.S. Appl. No. 11/842,085, Office Action mailed Sep. 30, 2009.;;U.S. Appl. No. 11/842,116, Office Action mailed Nov. 26, 2010.;;U.S. Appl. No. 12/037,045, Office Action mailed Apr. 28, 2010.;;U.S. Appl. No. 12/181,238, Examiner Interview Summary mailed Mar. 5, 2010.;;U.S. Appl. No. 12/181,238, Office Action mailed May 28, 2009.;;U.S. Appl. No. 12/253,929, Office Action mailed Apr. 28, 2010.;;U.S. Appl. No. 12/336,340, Office Action mailed Mar. 4, 2010.;;U.S. Appl. No. 12/608,869, Office Action mailed Oct. 25, 2011.;;U.S. Appl. No. 09/201,430, Office Action mailed Oct. 1, 2002.;;U.S. Appl. No. 09/204,838, Office Action mailed Apr. 18, 2003.;;U.S. Appl. No. 09/322,289, Office Action mailed Feb. 7, 2008.;;U.S. Appl. No. 09/322,289, Office Action mailed Feb. 24, 2005.;;U.S. Appl. No. 09/322,289, Office Action mailed Nov. 4, 2008.;;U.S. Appl. No. 09/322,289, Office Action mailed Nov. 17, 2006.;;U.S. Appl. No. 09/723,713, Office Action mailed Apr. 19, 2005.;;U.S. Appl. No. 09/723,713, Office Action mailed Oct. 24, 2003.;;U.S. Appl. No. 09/723,725, Office Action mailed Dec. 9, 2002.;;U.S. Appl. No. 09/723,760, Office Action mailed May 4, 2005.;;U.S. Appl. No. 09/723,765, Office Action mailed May 22, 2008.;;U.S. Appl. No. 09/723,765, Office Action mailed Aug. 10, 2004.;;U.S. Appl. No. 09/723,765, Office Action mailed Dec. 20, 2004.;;U.S. Appl. No. 09/724,273, Office Action mailed Jun. 8, 2006.;;U.S. Appl. No. 09/724,273, Office Action mailed Jun. 22, 2004.;;U.S. Appl. No. 09/724,273, Office Action mailed Dec. 22, 2006.;;U.S. Appl. No. 09/724,288, Office Action mailed Mar. 18, 2008.;;U.S. Appl. No. 09/724,288, Office Action mailed Apr. 23, 2007.;;U.S. Appl. No. 09/724,288, Office Action mailed Jun. 21, 2006.;;U.S. Appl. No. 09/724,288, Office Action mailed Oct. 3, 2007.;;U.S. Appl. No. 09/724,288, Office Action mailed Dec. 14, 2004.;;U.S. Appl. No. 09/724,319, Office Action mailed Jan. 11, 2008.;;U.S. Appl. No. 09/724,319, Office Action mailed May 16, 2007.;;U.S. Appl. No. 09/724,19, Office Action mailed Aug. 15, 2005.;;U.S. Appl. No. 09/724,575, Office Action mailed Mar. 31, 2006.;;U.S. Appl. No. 09/724,575, Office Action mailed May 6, 2005.;;U.S. Appl. No. 09/724,575, Office Action mailed Oct. 17, 2005.;;U.S. Appl. No. 09/980,568, Office Action mailed Nov. 2, 2004.;;U.S. Appl. No. 10/010,942, Office Action mailed Jan. 19, 2005.;;U.S. Appl. No. 10/010,942, Office Action mailed Mar. 10, 2005.;;U.S. Appl. No. 10/232,030, Office Action mailed Jun. 15, 2007.;;U.S. Appl. No. 10/429,216, Office Action mailed Jan. 28, 2008.;;U.S. Appl. No. 10/429,216, Office Action mailed Mar. 12, 2010.;;U.S. Appl. No. 10/429,216, Office Action mailed Sep. 15, 2010.;;U.S. Appl. No. 10/544,093, Office Action mailed Jan. 22, 2010.;;U.S. Appl. No. 10/625,854, Office Action mailed May 15, 2007.;;U.S. Appl. No. 10/703,713, Office Action mailed Jun. 2, 2006.;;U.S. Appl. No. 10/777,792, Office Action mailed Apr. 3, 2008.;;U.S. Appl. No. 10/828,548, Office Action mailed Sep. 11, 2007.;;U.S. Appl. No. 10/858,855, Office Action mailed Dec. 12, 2008.;;U.S. Appl. No. 10/858,855, Office Action mailed Dec. 15, 2009.;;U.S. Appl. No. 10/889,999, Office Action mailed Aug. 15, 2005.;;U.S. Appl. No. 10/890,000, Office Action mailed Mar. 10, 2006.;;U.S. Appl. No. 10/890,000, Office Action mailed Sep. 19, 2005.;;U.S. Appl. No. 10/890,070, Office Action mailed Sep. 29, 2005.;;U.S. Appl. No. 10/923,469, Office Action mailed Mar. 24, 2008.;;U.S. Appl. No. 10/923,471, Office Action mailed Mar. 20, 2009.;;U.S. Appl. No. 10/923,471, Office Action mailed May 15, 2006.;;U.S. Appl. No. 10/923,471, Office Action mailed Jul. 31, 2007.;;U.S. Appl. No. 10/923,471, Office Action mailed Aug. 24, 2005.;;U.S. Appl. No. 10/923,474, Office Action mailed Jun. 26, 2007.;;U.S. Appl. No. 11/244,678, Office Action mailed Sep. 23, 2008.;;U.S. Appl. No. 11/245,524, Office Action mailed Apr. 17, 2009.;;U.S. Appl. No. 11/245,524, Office Action mailed Jun. 4, 2008.;;U.S. Appl. No. 11/245,524, Office Action mailed Dec. 10, 2010.;;U.S. Appl. No. 11/245,916, Office Action mailed Jan. 28, 2008.;;U.S. Appl. No. 11/245,916, Office Action mailed May 18, 2010.;;U.S. Appl. No. 11/245,916, Office Action mailed Oct. 31, 2008.;;U.S. Appl. No. 11/245,916, Office Action mailed Dec. 14, 2011.;;U.S. Appl. No. 11/342,353, Office Action mailed Jul. 22, 2008.;;U.S. Appl. No. 11/809,552, Office Action mailed Feb. 17, 2011.;;U.S. Appl. No. 11/841,919, Office Action mailed Mar. 28, 2011.;;U.S. Appl. No. 11/842,023, Office Action mailed Aug. 14, 2009.;;U.S. Appl. No. 11/842,113, Office Action mailed Aug. 24, 2010.;;U.S. Appl. No. 11/893,123, Office Action mailed May 11, 2011.;;U.S. Appl. No. 12/106,206, Office Action mailed Jul. 9, 2010.;;U.S. Appl. No. 09/201,430, Advisory Action mailed Jun. 18, 2002.;;U.S. Appl. No. 09/201,430, Office Action mailed Nov. 26, 2001.;;U.S. Appl. No. 09/204,838, Office Action mailed Sep. 27, 2001.;;U.S. Appl. No. 09/322,289, Office Action mailed Jun. 4, 2009.;;U.S. Appl. No. 09/322,289, Office Action mailed Jul. 17, 2007.;;U.S. Appl. No. 09/322,289, Office Action mailed Oct. 16, 2005.;;U.S. Appl. No. 09/322,289, Office Action mailed Nov. 29, 2005.;;U.S. Appl. No. 09/723,713, Advisory Action mailed Dec. 20, 2004.;;U.S. Appl. No. 09/723,713, Office Action mailed Jan. 11, 2006.;;U.S. Appl. No. 09/723,713, Office Action mailed Feb. 12, 2002.;;U.S. Appl. No. 09/723,713, Office Action mailed Jun. 3, 2004.;;U.S. Appl. No. 09/723,760, Advisory Action mailed Dec. 16, 2004.;;U.S. Appl. No. 09/723,760, Office Action mailed Feb. 23, 2004.;;U.S. Appl. No. 09/723,760, Office Action mailed Dec. 29, 2005.;;U.S. Appl. No. 09/723,765, Advisory Action mailed Feb. 9, 2004.;;U.S. Appl. No. 09/723,765, Office Action mailed May 4, 2005.;;U.S. Appl. No. 09/723,765, Office Action mailed Oct. 7, 2003.;;U.S. Appl. No. 09/723,765, Office Action mailed Dec. 5, 2008.;;U.S. Appl. No. 09/724,273, Advisory Action mailed Mar. 18, 2004.;;U.S. Appl. No. 09/724,273, Advisory Action mailed Jun. 16, 2005.;;U.S. Appl. No. 09/724,273, Office Action mailed Aug. 22, 2007.;;U.S. Appl. No. 09/724,273, Office Action mailed Oct. 16, 2003.;;U.S. Appl. No. 09/724,273, Office Action mailed Dec. 28, 2004.;;U.S. Appl. No. 09/724,288, Advisory Action mailed Jan. 6, 2004.;;U.S. Appl. No. 09/724,288, Advisory Action mailed Mar. 3, 2006.;;U.S. Appl. No. 09/724,288, Office Action mailed Jul. 12, 2005.;;U.S. Appl. No. 09/724,288, Office Action mailed Sep. 9, 2003.;;U.S. Appl. No. 09/724,288, Office Action mailed Dec. 22, 2008.;;U.S. Appl. No. 09/724,319, Advisory Action mailed Oct. 28, 2009.;;U.S. Appl. No. 09/724,319, Office Action mailed Apr. 8, 2009.;;U.S. Appl. No. 09/724,319, Office Action mailed May 2, 2006.;;U.S. Appl. No. 09/724,319, Office Action mailed Dec. 21, 2010.;;U.S. Appl. No. 09/724,495, Advisory Action mailed May 16, 2006.;;U.S. Appl. No. 09/724,495, Office Action mailed Sep. 26, 2005.;;U.S. Appl. No. 09/724,567, Office Action mailed Jul. 23, 2003.;;U.S. Appl. No. 09/724,575, Advisory Action mailed Feb. 12, 2004.;;U.S. Appl. No. 09/724,575, Office Action mailed Jul. 25, 2003.;;U.S. Appl. No. 09/724,575, Office Action mailed Oct. 12, 2006.;;U.S. Appl. No. 09/724,953, Office Action mailed Jul. 25, 2003.;;U.S. Appl. No. 10/232,030, Advisory Action mailed Oct. 30, 2006.;;U.S. Appl. No. 10/232,030, Office Action mailed Apr. 1, 2008.;;U.S. Appl. No. 10/388,214, Office Action mailed Jul. 28, 2006.;;U.S. Appl. No. 10/429,216, Office Action mailed Jan. 3, 2007.;;U.S. Appl. No. 10/429,216, Office Action mailed Mar. 6, 2009.;;U.S. Appl. No. 10/429,216, Office Action mailed Oct. 16, 2008.;;U.S. Appl. No. 10/544,093, Office Action mailed Oct. 13, 2010.;;U.S. Appl. No. 10/625,854, Advisory Action mailed Jan. 8, 2008.;;U.S. Appl. No. 10/625,854, Office Action mailed Aug. 23, 2006.;;U.S. Appl. No. 10/625,854, Office Action mailed Nov. 7, 2007.;;U.S. Appl. No. 10/704,070, Office Action mailed Jun. 6, 2006.;;U.S. Appl. No. 10/771,174, Office Action mailed Aug. 23, 2007.;;U.S. Appl. No. 10/777,792, Advisory Action mailed Mar. 6, 2009.;;U.S. Appl. No. 10/777,792, Office Action mailed May 8, 2007.;;U.S. Appl. No. 10/777,792, Office Action mailed Nov. 18, 2008.;;U.S. Appl. No. 10/828,548, Advisory Action mailed Jun. 8, 2007.;;U.S. Appl. No. 10/828,548, Office Action mailed Jun. 4, 2008.;;U.S. Appl. No. 10/828,548, Office Action mailed Oct. 24, 2006.;;U.S. Appl. No. 10/858,855, Advisory Action mailed Apr. 7, 2008.;;U.S. Appl. No. 10/858,855, Office Action mailed Nov. 23, 2007.;;U.S. Appl. No. 10/889,999, Office Action mailed Mar. 14, 2006.;;U.S. Appl. No. 10/890,000, Advisory Action mailed Jan. 14, 2008.;;U.S. Appl. No. 10/890,000, Office Action mailed Nov. 24, 2006.;;U.S. Appl. No. 10/890,024, Office Action mailed Jun. 1, 2006.;;U.S. Appl. No. 10/890,070, Office Action mailed Jun. 1, 2006.;;U.S. Appl. No. 10/923,469, Advisory Action mailed Apr. 16, 2009.;;U.S. Appl. No. 10/923,469, Office Action mailed Dec. 29, 2008.;;U.S. Appl. No. 10/923,471, Office Action mailed Apr. 24, 2008.;;U.S. Appl. No. 10/923,471, Office Action mailed Dec. 24, 2009.;;U.S. Appl. No. 10/923,471, Office Action mailed Dec. 29, 2006.;;U.S. Appl. No. 10/923,474, Advisory Action mailed Feb. 22, 2007.;;U.S. Appl. No. 10/923,474, Office Action mailed Aug. 4, 2006.;;U.S. Appl. No. 11/058,757, Advisory Action mailed Mar. 5, 2007.;;U.S. Appl. No. 11/058,757, Office Action mailed Aug. 11, 2006.;;U.S. Appl. No. 11/108,102, Office Action mailed Sep. 6, 2006.;;U.S. Appl. No. 11/244,678, Office Action mailed Mar. 24, 2008.;;U.S. Appl. No. 11/245,524, Office Action mailed Nov. 20, 2009.;;U.S. Appl. No. 11/245,916, Advisory Action mailed May 15, 2007.;;U.S. Appl. No. 11/245,916, Advisory Action mailed Jun. 10, 2009.;;U.S. Appl. No. 11/245,916, Advisory Action mailed Oct. 18, 2007.;;U.S. Appl. No. 11/245,916, Office Action mailed Jan. 12, 2007.;;U.S. Appl. No. 11/274,493, Office Action mailed Nov. 2, 2007.;;U.S. Appl. No. 11/305,889, Office Action mailed May 23, 2008.;;U.S. Appl. No. 11/454,772, Office Action mailed Dec. 21, 2007.;;U.S. Appl. No. 11/664,865, Office Action mailed Feb. 11, 2011.;;U.S. Appl. No. 11/842,042, Office Action mailed Mar. 30, 2010.;;U.S. Appl. No. 12/037,045 , Office Action mailed Nov. 4, 2011.;;U.S. Appl. No. 09/723,765, BPAI Decision on Request for Re-Hearing mailed Oct. 16, 2007.;;U.S. Appl. No. 09/723,765, BPAI Order Returning Appeal to Examiner mailed Jun. 27, 2006.;;U.S. Appl. No. 09/723,765, Examiner's Answer mailed Jan. 25, 2006.;;U.S. Appl. No. 09/723,765, Reply Brief Noted mailed Jun. 16, 2006.;;U.S. Appl. No. 10/777,792, BPAI Decision mailed Aug. 30, 2010.;;U.S. Appl. No. 10/777,792, BPAI Decision on Request for Reconsideration mailed Nov. 30, 2010.;;U.S. Appl. No. 10/777,792, Examiner's Answer mailed Oct. 27, 2009.;;U.S. Appl. No. 10/777,792, Reply Brief Noted mailed Jan. 11, 2010.;;U.S. Appl. No. 10/923,469, BPAI Decision mailed Feb. 22, 2011.;;U.S. Appl. No. 10/923,469, Reply Brief Noted mailed Mar. 9, 2010.;;Abcam, “Anti-beta Amyloid antibody 6F/3D”, Nucleic Acids Res. 38:D142-D148 (2010).;;Aihara, et al., “Immunocytochemical Localization of Immunoglobulins in the Rat Brain: Relationship to the Blood-Brain Barrier”, J of Comparative Neurology 342:481-496 (1994).;;Alzheimer Research Forum, “Drugs in Clinical Trials” Oct. 18, 2010.;;Applicants' submission in EP 07012421.9 dated Jun. 16, 2009.;;Assignment executed Dec. 8, 2000 in respect of U.S. Appl. No. 60/067,740.;;Assignment executed Dec. 8, 2000 in respect of U.S. Appl. No. 60/080,970.;;Birmingham et al., “Set back to Alzheimer vaccine studies” Nature Medicine 8(3):199-200 (2002).;;Bruggermann, et al. “The Immunogenicity of Chimeric Antibodies” J. Exp Med., 170(2):153-2157 (1989).;;Communication in EP 07012421.9 pursuant to Art. 94(3) EPC dated Nov. 5, 2010.;;Decision of Opposition Division in EP 1 160 256 dated Feb. 17, 2011.;;Declaration of Shyra J. Gardai dated Mar. 2, 2009.;;Druckexemplar in EP 1 160 256 dated Jan. 25, 2010.;;Extract from EPO patent register of EP 1 160 256 retrieved on Sep. 7, 2011.;;Extract from EPO patent register of EP 1 842 859 retrieved on Sep. 7, 2011.;;Gambetti, et al., “Human brain amyloidosis,” Nephrology Dialysis Transplantation, 13(Suppl. 7):33-40, (1998).;;Hampel et al., “Measurement of Phosphorylated Tau epitopes in the Differential Diagnosis of Alzheimer Disease”, Arch Gen Psychiatry (2004) 61(1):95-102.;;Hyman, et al. “Kunitz Protease Inhibitor-Containing Amyloid β Protein Precursor Immunoreactivity in Alzheimer's Disease”, J. of Neuropathology, 51(1):76-83 (1992).;;Invitrogen Data Sheet, “Mouse anti-β-Amyloid Peptide”, Catalog No. 13-0100Z (Rev 10/08) DCC-08-1089.;;Jagust et al., “Brain Imaging Evidence of preclinical Alzheimer's disease in normal aging” Ann Neurol, (2006) 59:67-681: abstract p. 676, table 1.;;Janeway, et al., Immunobiology: The Immune System in Health and Disease 3rd Edition; cover pages and pp. 3.22-3.27 (1997).;;Jefferis, “Antibody therapeutic: isotype and glycoform selection”, Expert Opin. Biol. Ther. 7(9):1401-1413 (2007).;;Klafki et al., “Therapeutic approaches to Alzheimer's disease” Brain 129:2840-2825 (2006).;;Kuby, Immunology, 2nd Ed., Freeman pp. 126 and 168-171 (1994).;;Marx et al., “Immune recognition of the Alzheimer amyloid β protein” Poster presentation; Autoreactive T. cells P.5.18.03 Jun. 25, 1997.;;Moretto, et al., “Conformation-sensitive Antibodies against Alzheimer Amyloid-β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide”, J of Biological Chemistry, 282(14):11436-11445 (2007).;;Patentee's Grounds of Appeal in EP Patent No. 1 033 996 dated Jul. 18, 2011.;;PCT/US2011/026365 International Written Opinion and Search Report mailed Jul. 13, 2011.;;PCT/US2011/033649 International Written Opinion and Search Report mailed Aug. 26, 2011.;;Ray. “Wyeth Study Finds Alzheimer's Drug Works in ApoE4 Non-Carriers”. Poster 2008, [retrieved from the internet Jun. 16, 2011: <URL: elan2006.blogspot.com/2008/07/elan-wyeth-studfindalzheimerdrug.html>].;;Robert et al., Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers:, Protein Eng Des Sel. (2009) 22:(2):199-208.;;Stern, et al. “Monoclonal Antibodies to a Synthetic Peptide Homologous with the First 28 Amino Acids of Alzheimer's Disease β-Protein Recognize Amyloid and Diverse Glial and Neuronal Cell Types in the Central Nervous System” Am J of Pathology, 134(5):973-978 (1989).;;Takahashi, et al. “Monoclonal antibody to β peptide, recognizing amyloid deposits, neuronal cells and lipofuscin pigments in systemic organs”, Acta Neuropathol, 85:159-166 (1993).;;Van Dam et al., “Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model” Psychopharmacology 180:177-190 (2005).;;Van Noort, Multiple sclerosis: an altered immune response or an altered stress response?, J Mol Med 74:285-296 (1996).;;Wiessler, et al “The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects”, J. Neurosci. 31(25):9323-9331 (2011).;;Wikipedia entry for “Monoclonal antibody therapy” accessed on Sep. 22, 2011.;;Wu et al., “Saponin Adjuvant Enhancement of Antigen-Specific Immune Responses to an Experimental HIV-1 Vaccine” J of Immunology 149:1519-1525 (1992).;;Zhao et al., “Macrophage-Mediated Degradation of β-Amyloid via an Apolipoprotein E Isoform-Dependent Mechanism”, Neurobiology of disease (Mar. 18, 2009) 29(11):3603-3612.;;Zotova et al., “Inflammation in Azheimer's disease: relevance to pathogenesis and therapy” Alzheimer's Research & Therapy 2:1 p. 2-9 (2010).;;U.S. Appl. No. 60/999,423, filed Oct. 17, 2007, Black.;;U.S. Appl. No. 11/894,789, filed Aug. 20, 2007, Basi.;;U.S. Appl. No. 11/894,754, filed Aug. 20, 2007, Basi.;;U.S. Appl. No. 11/894,714, filed Aug. 20, 2007, Basi.;;U.S. Appl. No. 11/894,665, filed Aug. 20, 2007, Schenk.;;U.S. Appl. No. 11/893,123, filed Aug. 20, 2007, Basi et al.;;U.S. Appl. No. 11/893,110, filed Aug. 20, 2007, Basi et al.;;U.S. Appl. No. 11/893,103, filed Aug. 20, 2007, Basi et al.;;U.S. Appl. No. 11/893,094, filed Aug. 20, 2007, Basi et al.;;U.S. Appl. No. 11/842,101, filed Aug. 20, 2007, Schenk.;;U.S. Appl. No. 11/841,950, filed Aug. 20, 2007, Arumugham.;;U.S. Appl. No. 11/841,897, filed Aug. 20, 2007, Arumugham.;;U.S. Appl. No. 11/841,882, filed Aug. 20, 2007, Arumugham.;;U.S. Appl. No. 11/841,857, filed Aug. 20, 2007, Warne et al.;;U.S. Appl. No. 11/841,849, filed Aug. 20, 2007, Arumugham.;;U.S. Appl. No. 11/841,794, filed Aug. 20, 2007, Warne et al.;;U.S. Appl. No. 11/841,832, filed Aug. 20, 2007, Warne et al.;;U.S. Appl. No. 60/925,228, filed Apr. 18, 2007, Schroeter et al.;;U.S. Appl. No. 60/793,014, filed Apr. 18, 2006, not named.;;U.S. Appl. No. 11/396,417, filed Mar. 30, 2006, Schenk.;;U.S. Appl. No. 11/396,391, filed Mar. 30, 2006, Schenk.;;U.S. Appl. No. 11/358,951, filed Feb. 22, 2006, Solomon et al.;;U.S. Appl. No. 60/736,119, filed Nov. 10, 2005, Jacobson.;;U.S. Appl. No. 60/736,045, filed Nov. 10, 2005, Johnson-Wood.;;U.S. Appl. No. 60/735,687, filed Nov. 10, 2005, Jacobson.;;U.S. Appl. No. 60/691,821, filed Jun. 17, 2005, Godavarti.;;U.S. Appl. No. 09/980,568, filed Mar. 12, 2005, Hirtzer.;;U.S. Appl. No. 60/648,639, filed Jan. 28, 2005, Luisi et al.;;U.S. Appl. No. 60/648,631, filed Jan. 28, 2005, Luisi et al.;;U.S. Appl. No. 60/637,253, filed Dec. 16, 2004, Jacobson.;;U.S. Appl. No. 60/637,138, filed Dec. 16, 2004, Jacobson.;;U.S. Appl. No. 60/636,842, filed Dec. 15, 2004, Jacobson.;;U.S. Appl. No. 60/636,810, filed Dec. 15, 2004, Jacobson.;;U.S. Appl. No. 60/636,776, filed Dec. 15, 2004, Basi.;;U.S. Appl. No. 60/636,687, filed Dec. 15, 2004, Johnson-Wood.;;U.S. Appl. No. 60/636,684, filed Dec. 15, 2004, Basi.;;U.S. Appl. No. 60/622,525, filed Oct. 26, 2004, Pavliakova.;;U.S. Appl. No. 60/616,474, filed Oct. 5, 2004, Sinacore.;;U.S. Appl. No. 60/530,481, filed Dec. 17, 2003, Arumugham.;;U.S. Appl. No. 60/530,480, filed Dec. 17, 2003, Arumugham.;;U.S. Appl. No. 60/474,654, filed May 30, 2003, Basi.;;U.S. Appl. No. 60/444,150, filed Feb. 1, 2003, Yednock.;;U.S. Appl. No. 09/979,701, filed Mar. 13, 2002, Schenk.;;U.S. Appl. No. 60/363,751, filed Mar. 12, 2002, Basi.;;U.S. Appl. No. 60/254,465, filed Dec. 8, 2000, Holtzman et al.;;U.S. Appl. No. 60/254,498, filed Dec. 8, 2000, Holtzman et al.;;U.S. Appl. No. 60/251,892, filed Dec. 6, 2000, Basi et al.;;U.S. Appl. No. 09/724,842, filed Nov. 28, 2000, Chalifour et al.;;U.S. Appl. No. 09/724,929, filed Nov. 28, 2000, Weiner.;;U.S. Appl. No. 09/724,921, filed Nov. 28, 2000, Weiner.;;U.S. Appl. No. 09/724,575, filed Nov. 28, 2000, Schenk.;;U.S. Appl. No. 09/724,291, filed Nov. 28, 2000, Schenk.;;U.S. Appl. No. 09/724,273, filed Nov. 28, 2000, Schenk.;;U.S. Appl. No. 09/723,544, filed Nov. 28, 2000, Schenk.;;U.S. Appl. No. 09/724,495, filed Nov. 27, 2000, Schenk.;;U.S. Appl. No. 09/724,319, filed Nov. 27, 2000, Schenk.;;U.S. Appl. No. 09/723,766, filed Nov. 27, 2000, Hirtzer.;;U.S. Appl. No. 09/723,760, filed Nov. 27, 2000, Schenk.;;U.S. Appl. No. 09/723,725, filed Nov. 27, 2000, Hirtzer.;;U.S. Appl. No. 09/723,713, filed Nov. 27, 2000, Schenk.;;U.S. Appl. No. 09/585,656, filed Jun. 1, 2000, Hirtzer et al.;;U.S. Appl. No. 09/580,019, filed May 26, 2000, Schenk.;;U.S. Appl. No. 09/580,015, filed May 26, 2000, Schenk. et al.",ACTIVE
518,CA,A1,CA 2702617 A1,035-542-974-872-509,2009-04-23,2009,CA 2702617 A,2008-10-17,US 99942307 P;;US 8382708 P;;US 2008/0080382 W,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JIM;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/035-542-974-872-509,Patent Application,no,0,0,53,54,99,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/00;;C07K16/46;;A61K39/395;;A61P25/28;;C07K14/775;;C07K16/18;;C12N15/13;;C12Q1/68;;G01N33/53,,0,0,,,,ACTIVE
519,KR,A,KR 20100068301 A,095-602-183-557-447,2010-06-22,2010,KR 20107010304 A,2008-10-17,US 2008/0080382 W;;US 99942307 P;;US 8382708 P,2007-10-17,IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/095-602-183-557-447,Patent Application,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/395;;A61P25/00;;A61P25/28;;C07K16/18,,0,0,,,,INACTIVE
520,US,B2,US 7619324 B2,118-745-450-892-188,2009-11-17,2009,US 69899907 A,2007-01-29,US 69899907 A,2007-01-29,Power system with multiple generator sets,"A method of operating a power system is provided. The power system may have a plurality of generator sets and a power line. The method may include commanding a plurality of the generator sets that are disconnected from the power line to start generating electricity. The method may also include supplying to a control device acting as a coordinating control unit information about the operating state of each of the plurality of generator sets commanded to start generating electricity. Additionally, the method may include determining with the coordinating control unit which of the plurality of generator sets has become ready to supply electricity to the power line first. The method may also include initiating supply of electricity to the power line by first connecting to the power line the generator set that the coordinating control unit has determined to be the first ready to supply electricity.",CATERPILLAR INC,FOLKEN KEITH RONALD;;DVORSKY MICHAEL ALLEN;;BOLEY JULIE LYNN;;MCBURNEY JAMES DEAN;;BLACK ANDREW WILLIAM;;ZWETZ II DAVID LEE;;NOFSINGER STEPHEN CHARLES,CATERPILLAR INC (2007-03-16),https://lens.org/118-745-450-892-188,Granted Patent,yes,12,20,5,5,0,H02J3/38;;H02J3/38,H02J9/00,307/84;;307/85,0,0,,,,INACTIVE
521,WO,A3,WO 2008/094403 A3,124-546-129-189-168,2008-11-20,2008,US 2008/0000553 W,2008-01-16,US 69899907 A,2007-01-29,POWER SYSTEM WITH MULTIPLE GENERATOR SETS,"A method of operating a power system (10) is provided. The power system may have a plurality of generator sets (GA) and a power line (54). The method may include commanding a plurality of the generator sets that are disconnected from the power line to start generating electricity. The method may also include supplying to a control device (40) acting as a coordinating control unit information about the operating state of each of the plurality of generator sets commanded to start generating electricity. Additionally, the method may include determining with the coordinating control unit which of the plurality of generator sets has become ready to supply electricity to the power line first. The method may also include initiating supply of electricity to the power line by first connecting to the power line the generator set that the coordinating control unit has determined to be the first ready to supply electricity.",CATERPILLAR INC;;FOLKEN KEITH R;;DVORSKY MICHAEL A;;BOLEY JULIE L;;MCBURNEY JAMES D;;BLACK ANDREW W;;ZWETZ DAVID L II;;NOFSINGER STEPHEN C,FOLKEN KEITH R;;DVORSKY MICHAEL A;;BOLEY JULIE L;;MCBURNEY JAMES D;;BLACK ANDREW W;;ZWETZ DAVID L II;;NOFSINGER STEPHEN C,,https://lens.org/124-546-129-189-168,Search Report,yes,3,0,5,5,0,H02J3/38;;H02J3/38,H02J3/38;;H02P9/08,,0,0,,,,PENDING
522,DK,T3,DK 2207565 T3,182-497-635-868-96X,2015-07-13,2015,DK 08839961 T,2008-10-17,US 99942307 P;;US 8382708 P;;US 2008/0080382 W,2007-10-17,IMMUNOTERAPI-REGIMENER AFHÆNGIG AF APOE-STATUS,,JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA,,https://lens.org/182-497-635-868-96X,Granted Patent,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/00;;C07K16/18;;C07K16/28,,0,0,,,,ACTIVE
523,TW,A,TW 202233236 A,086-114-223-491-202,2022-09-01,2022,TW 110141386 A,2021-11-05,US 202063110884 P;;US 202163137972 P;;US 202163173126 P;;US 202163173919 P;;US 202163174423 P;;US 202163175440 P;;US 202163203075 P;;US 202163203077 P;;US 202163219155 P,2020-11-06,FCRN antibodies and methods of use thereof,"Methods for dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject.",JANSSEN BIOTECH INC,RAMCHANDREN SINDHU;;SUN HONG;;DENNEY WILLIAM;;ARROYO SANTIAGO;;LING LEONA;;LEU JOCELYN;;JIN JIANHUA;;JOUVIN MARIE-HELENE;;KARCHER KEITH;;BLACK SHAWN;;ZHU YAOWEI,,https://lens.org/086-114-223-491-202,Patent of Addition,no,0,0,10,20,0,A61P21/04;;C07K16/283;;A61K2039/505;;A61K9/0019;;A61K47/26;;C07K16/283;;A61K47/26;;A61K47/10;;A61K2039/545;;A61K2039/505;;A61P21/04;;A61K9/0019;;C07K16/283;;A61K47/26;;A61P21/04;;A61K2039/505;;C07K16/283;;A61P21/04;;A61K2039/505;;A61K47/10;;A61K2039/545;;A61K47/26,A61K39/395;;A61P21/04;;A61P37/00;;C07K16/28,,0,0,,,,PENDING
524,TW,A,TW 201206479 A,143-276-724-947-834,2012-02-16,2012,TW 100139936 A,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,Immunotherapy regimes dependent on ApoE status,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA M,,https://lens.org/143-276-724-947-834,Patent of Addition,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/395;;A61P25/28;;C07K16/18,,0,0,,,,PENDING
525,WO,A1,WO 2022/098955 A1,106-726-539-232-523,2022-05-12,2022,US 2021/0058188 W,2021-11-05,US 202063110884 P;;US 202163137972 P;;US 202163173126 P;;US 202163173919 P;;US 202163174423 P;;US 202163175440 P;;US 202163203075 P;;US 202163203077 P;;US 202163219155 P,2020-11-06,FCRN ANTIBODIES AND METHODS OF USE THEREOF,"Methods for dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject.",JANSSEN BIOTECH INC,RAMCHANDRAN SINDHU;;SUN HONG;;DENNEY WILLIAM;;ARROYO SANTIAGO;;LING LEONA;;JIN JIANHUA;;LEU JOCELYN;;JOUVIN MARIE-HELENE;;KARCHER KEITH;;BLACK SHAWN;;ZHU YAOWEI,,https://lens.org/106-726-539-232-523,Patent Application,yes,2,0,10,20,17,A61P21/04;;C07K16/283;;A61K2039/505;;A61K9/0019;;A61K47/26;;C07K16/283;;A61K47/26;;A61K47/10;;A61K2039/545;;A61K2039/505;;A61P21/04;;A61K9/0019;;C07K16/283;;A61K47/26;;A61P21/04;;A61K2039/505;;C07K16/283;;A61P21/04;;A61K2039/505;;A61K47/10;;A61K2039/545;;A61K47/26,A61P21/04;;A61K39/395;;A61P29/00;;A61P37/00;;C07K16/28,,0,0,,,,PENDING
526,TW,A,TW 200932264 A,115-702-547-261-287,2009-08-01,2009,TW 97139941 A,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,Immunotherapy regimes dependent on ApoE status,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.,ELAN PHARMA INT LTD;;WYETH CORP,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA M,,https://lens.org/115-702-547-261-287,Patent of Addition,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/395;;A61P25/28;;C07K16/18,,0,0,,,,INACTIVE
527,US,A1,US 2022/0144946 A1,150-629-497-303-901,2022-05-12,2022,US 202117519811 A,2021-11-05,US 202117519811 A;;US 202063110884 P;;US 202163137972 P;;US 202163173126 P;;US 202163173919 P;;US 202163174423 P;;US 202163175440 P;;US 202163203075 P;;US 202163203077 P;;US 202163219155 P,2020-11-06,FCRN ANTIBODIES AND METHODS OF USE THEREOF,"Methods for dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject.",JANSSEN BIOTECH INC,RAMCHANDRAN SINDHU;;SUN HONG;;DENNEY WILLIAM;;ARROYO SANTIAGO;;LING LEONA;;LEU JOCELYN;;JIN JIANHUA;;JOUVIN MARIE-HELENE;;KARCHER KEITH;;BLACK SHAWN;;ZHU YAOWEI,JANSSEN PHARMACEUTICALS INC (2021-12-08);;MOMENTA PHARMACEUTICALS INC (2021-12-08);;JANSSEN RESEARCH & DEVELOPMENT LLC (2021-12-21);;JANSSEN BIOTECH INC (2021-12-29),https://lens.org/150-629-497-303-901,Patent Application,yes,4,1,10,20,17,A61P21/04;;C07K16/283;;A61K2039/505;;A61K9/0019;;A61K47/26;;C07K16/283;;A61K47/26;;A61K47/10;;A61K2039/545;;A61K2039/505;;A61P21/04;;A61K9/0019;;C07K16/283;;A61K47/26;;A61P21/04;;A61K2039/505;;C07K16/283;;A61P21/04;;A61K2039/505;;A61K47/10;;A61K2039/545;;A61K47/26,C07K16/28;;A61K47/10;;A61K47/26;;A61P21/04,,4,3,073-811-428-732-497;;001-241-206-228-953;;029-633-921-319-394,pmc6587432;;30402880;;10.1002/cpt.1276;;pmc7033452;;10.3389/fimmu.2020.00212;;32117321;;pmc4623309;;10.1080/19420862.2015.1008345;;25654695,"Ling LE, et al. M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study. Clin Pharmacol Ther. 2019 Apr;105(4):1031-1039. (Year: 2019);;Lazaridis K, Tzartos SJ. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front Immunol. 2020 Feb 14;11:212. (Year: 2020);;Roopenian DC, Low BE, Christianson GJ, Proetzel G, Sproule TJ, Wiles MV. Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. MAbs. 2015;7(2):344-51. (Year: 2015);;Miniaci A, Gupta V. Loading Dose. [Updated 2022 Jun 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557418/ (Year: 2022)",PENDING
528,PE,A1,PE 20090971 A1,029-104-812-814-640,2009-07-02,2009,PE 2008001792 A,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,REGIMENES DE INMUNOTERAPIA DEPENDIENTES DEL ESTADO APOE,"SE REFIERE A UN ANTICUERPO HUMANIZADO 3D6 DE RATON TAL COMO BAPINEUZUMAB CARACTERIZADO POR QUE EN LAS POSICIONES 234, 235 Y 237 EN LA REGION CONSTANTE DE LA CADENA PESADA SON OCUPADOS POR ALA, ALA, ALA. TAMBIEN SE REFIERE A UN REGIMEN DE TRATAMIENTO DE INMUNOTERAPIA PARA PACIENTES QUE PRESENTAN EL GENOTIPO ApoE4 CERO (PACIENTE NO PORTADOR ApoE4) QUE COMPRENDE LA ADMINISTRACION DE UN SEGUNDO ANTICUERPO QUE ES UNA VARIANTE DE l234A, L235A, G237A DE BAPINEUZUMAB SIENDO UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER Y ENFERMEDADES SIMILARES",WYETH CORP;;ELAN PHARMA INT LTD,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JIM;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA M,,https://lens.org/029-104-812-814-640,Patent Application,no,0,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,A61K39/00;;C07K16/18,,0,0,,,,ACTIVE
529,TW,B,TW I581803 B,048-439-607-518-344,2017-05-11,2017,TW 97139941 A,2008-10-17,US 99942307 P;;US 8382708 P,2007-10-17,Immunotherapy regimes dependent on apoe status,,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;JACOBSEN JACK STEVEN;;GILL DAVINDER;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA M,,https://lens.org/048-439-607-518-344,Granted Patent,no,2,0,53,54,0,C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K2317/71;;C07K2317/77;;C07K2317/734;;C07K2317/732;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18;;A61P25/00;;A61P25/28;;A61P7/10;;A61P9/00;;A61K2039/505;;C07K16/2896;;C07K2317/24;;C07K2317/56;;C07K2317/71;;C07K2317/732;;C07K2317/734;;C07K2317/77;;G06Q99/00;;C07K2317/34;;C07K16/18,,,0,0,,,,INACTIVE
530,WO,A9,WO 2022/098955 A9,075-598-422-758-066,2022-06-09,2022,US 2021/0058188 W,2021-11-05,US 202063110884 P;;US 202163137972 P;;US 202163173126 P;;US 202163173919 P;;US 202163174423 P;;US 202163175440 P;;US 202163203075 P;;US 202163203077 P;;US 202163219155 P,2020-11-06,FCRN ANTIBODIES AND METHODS OF USE THEREOF,"Methods for dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject.",JANSSEN BIOTECH INC,RAMCHANDRAN SINDHU;;SUN HONG;;DENNEY WILLIAM;;ARROYO SANTIAGO;;LING LEONA;;LEU JOCELYN;;JIN JIANHUA;;JOUVIN MARIE-HELENE;;KARCHER KEITH;;BLACK SHAWN;;ZHU YAOWEI,,https://lens.org/075-598-422-758-066,Search Report,yes,0,0,10,20,17,A61P21/04;;C07K16/283;;A61K2039/505;;A61K9/0019;;A61K47/26;;C07K16/283;;A61K47/26;;A61K47/10;;A61K2039/545;;A61K2039/505;;A61P21/04;;A61K9/0019;;C07K16/283;;A61K47/26;;A61P21/04;;A61K2039/505;;C07K16/283;;A61P21/04;;A61K2039/505;;A61K47/10;;A61K2039/545;;A61K47/26,A61K39/395;;A61P21/04;;A61P29/00;;A61P37/00;;C07K16/28,,0,0,,,,PENDING
531,WO,A1,WO 2013/148688 A1,120-900-712-024-794,2013-10-03,2013,US 2013/0033883 W,2013-03-26,US 201261615624 P;;US 201261615644 P,2012-03-26,PEA PROTEIN CONTAINING NUTRITIONAL COMPOSITIONS,"This present disclosure a nutritional composition in which the protein component comprises from about 1% to about 50% by weight intact pea protein. In a particular embodiment, intact pea protein provides from about 5% to about 25% of the protein component, a milk protein concentrate provides from about 50% to about 65% of the protein component, and a soy protein isolate provides from about 5% to about 35% of the protein component.",ABBOTT LAB,DIMLER STEVEN R;;WHEELER KEITH B;;HERTZLER STEVEN R;;WALTON JOSEPH E;;WOLF DAVID R;;DUGLE JANIS E;;MCKEE JEFFREY B;;BLACK CYNTHIA J,,https://lens.org/120-900-712-024-794,Patent Application,yes,12,11,1,1,0,A23L2/66;;A23L33/185;;A23L33/19;;A23L33/40;;A61K35/20;;A61K36/48;;A61K38/011;;A61K38/018;;A61K38/168,A23L1/305;;A23L2/66;;A23L33/00;;A61K38/01;;A61K38/16;;A61K38/17,,0,0,,,,PENDING
532,AU,A1,AU 2021/376364 A1,184-256-020-054-332,2023-06-22,2023,AU 2021/376364 A,2021-11-05,US 202063110884 P;;US 202163137972 P;;US 202163173126 P;;US 202163173919 P;;US 202163174423 P;;US 202163175440 P;;US 202163203075 P;;US 202163203077 P;;US 202163219155 P;;US 2021/0058188 W,2020-11-06,FCRN ANTIBODIES AND METHODS OF USE THEREOF,"Methods for dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject.",MOMENTA PHARMACEUTICALS INC,RAMCHANDREN SINDHU;;SUN HONG;;DENNEY WILLIAM;;ARROYO SANTIAGO;;LING LEONA E;;LEU JOCELYN H;;JIN JIANHUA;;JOUVIN MARIE-HELENE;;KARCHER KEITH;;BLACK SHAWN;;ZHU YAOWEI,,https://lens.org/184-256-020-054-332,Patent Application,no,0,0,10,20,0,A61P21/04;;C07K16/283;;A61K2039/505;;A61K9/0019;;A61K47/26;;C07K16/283;;A61K47/26;;A61K47/10;;A61K2039/545;;A61K2039/505;;A61P21/04;;A61K9/0019;;C07K16/283;;A61K47/26;;A61P21/04;;A61K2039/505;;C07K16/283;;A61P21/04;;A61K2039/505;;A61K47/10;;A61K2039/545;;A61K47/26,A61K39/395;;A61P21/04;;A61P29/00;;A61P37/00;;C07K16/28,,0,0,,,,PENDING
533,EP,A1,EP 4240417 A1,027-111-362-154-00X,2023-09-13,2023,EP 21890118 A,2021-11-05,US 202063110884 P;;US 202163137972 P;;US 202163173126 P;;US 202163173919 P;;US 202163174423 P;;US 202163175440 P;;US 202163203075 P;;US 202163203077 P;;US 202163219155 P;;US 2021/0058188 W,2020-11-06,FCRN ANTIBODIES AND METHODS OF USE THEREOF,,MOMENTA PHARMACEUTICALS INC,RAMCHANDREN SINDHU;;SUN HONG;;DENNEY WILLIAM;;ARROYO SANTIAGO;;LING LEONA E;;LEU JOCELYN H;;JIN JIANHUA;;JOUVIN MARIE-HELENE;;KARCHER KEITH;;BLACK SHAWN;;ZHU YAOWEI,,https://lens.org/027-111-362-154-00X,Patent Application,yes,0,0,10,20,17,A61P21/04;;C07K16/283;;A61K2039/505;;A61K9/0019;;A61K47/26;;C07K16/283;;A61K47/26;;A61K47/10;;A61K2039/545;;A61K2039/505;;A61P21/04;;A61K9/0019;;C07K16/283;;A61K47/26;;A61P21/04;;A61K2039/505;;C07K16/283;;A61P21/04;;A61K2039/505;;A61K47/10;;A61K2039/545;;A61K47/26,A61K39/395;;A61P21/04;;A61P29/00;;A61P37/00;;C07K16/28,,0,0,,,,PENDING
534,KR,A,KR 20230117575 A,059-130-443-919-849,2023-08-08,2023,KR 20237018942 A,2021-11-05,US 202063110884 P;;US 202163137972 P;;US 202163173126 P;;US 202163173919 P;;US 202163174423 P;;US 202163175440 P;;US 202163203075 P;;US 202163203077 P;;US 202163219155 P;;US 2021/0058188 W,2020-11-06,FCRN 항체 및 이의 사용 방법,"인간 신생아 Fc 수용체(FcRn)에 대한 항체를 투여하는 방법이 기재되어 있다. 항-FcRn 항체는, 예를 들어 대상에서 자가항체의 제거를 촉진시키거나, 대상에서 항원 제시를 억제하거나, 대상에서 면역 반응, 예를 들어 면역 반응의 면역 복합체 기반 활성화를 차단하거나, 또는 대상에서 면역 질환(예를 들어, 자가면역 질환)을 치료하는 데 유용하다.",MOMENTA PHARMACEUTICALS INC,RAMCHANDREN SINDHU;;SUN HONG;;DENNEY WILLIAM;;ARROYO SANTIAGO;;LING LEONA E;;LEU JOCELYN H;;JIN JIANHUA;;JOUVIN MARIE HELENE;;KARCHER KEITH;;BLACK SHAWN;;ZHU YAOWEI,,https://lens.org/059-130-443-919-849,Patent Application,no,0,0,10,20,0,A61P21/04;;C07K16/283;;A61K2039/505;;A61K9/0019;;A61K47/26;;C07K16/283;;A61K47/26;;A61K47/10;;A61K2039/545;;A61K2039/505;;A61P21/04;;A61K9/0019;;C07K16/283;;A61K47/26;;A61P21/04;;A61K2039/505;;C07K16/283;;A61P21/04;;A61K2039/505;;A61K47/10;;A61K2039/545;;A61K47/26,C07K16/28;;A61K39/00;;A61K47/26;;A61P21/04,,0,0,,,,PENDING
535,CA,A1,CA 3200972 A1,010-039-296-334-318,2022-05-12,2022,CA 3200972 A,2021-11-05,US 202063110884 P;;US 202163137972 P;;US 202163173126 P;;US 202163173919 P;;US 202163174423 P;;US 202163175440 P;;US 202163203075 P;;US 202163203077 P;;US 202163219155 P;;US 2021/0058188 W,2020-11-06,FCRN ANTIBODIES AND METHODS OF USE THEREOF,"Methods for dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject.",MOMENTA PHARMACEUTICALS INC,RAMCHANDREN SINDHU;;SUN HONG;;DENNEY WILLIAM;;ARROYO SANTIAGO;;LING LEONA E;;LEU JOCELYN H;;JIN JIANHUA;;JOUVIN MARIE-HELENE;;KARCHER KEITH;;BLACK SHAWN;;ZHU YAOWEI,,https://lens.org/010-039-296-334-318,Patent Application,no,0,0,10,20,17,A61P21/04;;C07K16/283;;A61K2039/505;;A61K9/0019;;A61K47/26;;C07K16/283;;A61K47/26;;A61K47/10;;A61K2039/545;;A61K2039/505;;A61P21/04;;A61K9/0019;;C07K16/283;;A61K47/26;;A61P21/04;;A61K2039/505;;C07K16/283;;A61P21/04;;A61K2039/505;;A61K47/10;;A61K2039/545;;A61K47/26,A61K39/395;;A61P21/04;;A61P29/00;;A61P37/00;;C07K16/28,,0,0,,,,PENDING
536,US,B2,US 6506660 B2,058-415-951-450-357,2003-01-14,2003,US 809201 A,2001-11-13,US 809201 A;;US 71376600 A,2000-11-15,Semiconductor with nanoscale features,"
    Described is a method of increasing the capacitance of semiconductor capacitors by providing a first solid-state electrode pattern on a semiconductor medium, etching topographic features on said first electrode pattern in a manner effective in increasing the surface area of said first electrode pattern, depositing a dielectric layer upon said electrode pattern that substantially conforms to said topographic features, and depositing a second solid-state electrode pattern upon said dielectric layer and sufficiently insulated from said first solid-state electrode pattern so as to create a capacitance with said first solid-state electrode pattern. 
",IBM,HOLMES STEVEN J;;BLACK CHARLES;;FRANK DAVID J;;FURUKAWA TOSHIHARU;;HAKEY MARK C;;HORAK DAVID V;;MA WILLIAM HSIOH-LIEN;;MILKOVE KEITH R;;GUARINI KATHRYN W,,https://lens.org/058-415-951-450-357,Granted Patent,yes,3,103,3,3,0,H01L28/92;;H01L28/92,H01L21/02,438/398;;438/691;;438/700,7,7,125-090-552-563-448;;058-367-310-048-815;;171-848-627-361-424;;073-086-243-628-58X;;070-258-023-710-468;;081-345-903-680-193;;060-999-265-459-099,10.1063/1.111118;;10.1007/bf00353023;;10.1021/ja961713d;;10.1021/ja960183i;;10.1063/1.116192;;8688070;;10.1126/science.273.5277.931;;10.1126/science.276.5317.1401,"T.L. Morkved, P. Wiltzius, H.M. Jaeger, D.G. Grier, and T.A. Witten; ""Mesoscopic Self-Assembly of Gold Islands on Diblock-Copolymer Films,"" Applied Physics Letter vol. 64, No. 4, Jan. 24, 1994; pp. 422-424.;;P. Mansky, P. Chaikin, and E. L. Thomas; ""Monolayer Films of Diblock Copolymer Microdomains for Nanolithographic Applications,"" Journal of Material Science, vol. 30, No. 8, Apr. 15, 1995; pp. 1987-1992.;;Z. Ki, W. Zhao, Y. Liu, M. H. Rafailovich, and J. Sokolov; ""Self-Ordering of Diblock Copolymers from Solution,"" Journal of the American Chemical Society, vol. 118, No. 44, Nov. 6, 1996; pp. 10892-10893.;;Hiroshi Ikeda, Michiei Nakamura, Nobuyuki Ise, Naomi Oguma, Asao Nakamura, Tuskasa Ideda, Fujio Toda, and Akihiko Ueno; ""Fluorescent Cyclodextrins for Molecule Sensing: Fluorescent Properties, NMR Characterization, and Inclusion Phenoma of N-Dansylleucine-Modified Cyclodextrins,"" Journal of the American Chemical Society, vol. 118, No. 45, Nov. 13, 1996; p. 10982.;;P. Mansky, C.K. Harrison, and P.M. Chakin; ""Nanolithographic Templates from Diblock Copolymers Thin Films,"" Applied Physics Letters, vol. 68, No. 18, Apr. 29, 1996, pp. 2586-2588.;;T. L. Morkved, M. Lu, A.M. Urbas, E.E. Ehrichs, H.M. Jaeger, P. Mansky, and T.P. Russel; ""Local Control of Microdomain Orientation in Diblock Copolymer Thin Films with Electric Fields,"" Science, vol. 273, No. 5277, Aug. 16, 1996; pp. 931-933.;;Miri Park, Christopher Harrison, Paul M. Chaikin, Richard A. Register, and Douglas H. Adamson; ""Block Copolymer Lithography: Periodic Arrays of ~ 10 11 Holes in 1 Square Centimeter,"" Science, vol. 276, No. 5317, May 30, 1997; pp. 1401-1404.",EXPIRED
537,US,A1,US 2013/0175547 A1,009-494-378-272-295,2013-07-11,2013,US 201313783526 A,2013-03-04,US 201313783526 A;;US 82579110 A,2010-06-29,FIELD EFFECT TRANSISTOR DEVICE,"A method for forming a field effect transistor device includes forming a gate stack portion on a substrate, forming a spacer portion on the gates stack portion and a portion of the substrate, removing an exposed portion of the substrate, epitaxially growing a first silicon material on the exposed portion of the substrate, removing a portion of the epitaxially grown first silicon material to expose a second portion of the substrate, and epitaxially growing a second silicon material on the exposed second portion of the substrate and the first silicon material.",IBM;;GLOBALFOUNDRIES INC;;GLOBALFOUNDRIES INC;;IBM,CHAN KEVIN K;;DUBE ABHISHEK;;HARLEY ERIC C;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H;;BLACK LINDA R,TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2020-05-15);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2013-02-27);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/009-494-378-272-295,Patent Application,yes,3,0,4,4,0,H01L21/26586;;H01L21/823412;;H01L21/823425;;H01L21/823481;;H01L21/823807;;H01L21/823814;;H01L21/84;;H01L29/66628;;H01L29/66772;;H01L29/78618;;H01L29/78684;;H01L29/7848;;H01L21/823814;;H01L21/84;;H01L21/823481;;H01L21/823807;;H01L29/78684;;H01L21/823412;;H01L29/78618;;H01L21/823425;;H01L21/26586;;H01L29/66628;;H01L29/66772;;H01L29/7848,H01L29/78,257/77;;257/192,0,0,,,,ACTIVE
538,AU,A1,AU 2009/260480 A1,006-852-374-854-472,2009-12-23,2009,AU 2009/260480 A,2009-05-28,US 5653808 P;;US 14253309 P;;US 2009/0045509 W,2008-05-28,Method and apparatus for identifying dietary choices,,THRIVE 365 INTERNATIONAL INC,EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;SANOY ARLENE OLEA;;BLACK RICHARD;;YEHLING BARBARA ANN;;RUBIN KRISTIN H;;MATUSHESKI NATHAN V;;ABRAHAM TODD KEVIN;;MORREALE SANDRA JEAN,"THRIVE 365 INTERNATIONAL, INC. (2014-05-01)",https://lens.org/006-852-374-854-472,Patent Application,no,0,0,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G09B19/00;;G16H20/60,,0,0,,,,DISCONTINUED
539,ZA,B,ZA 201008490 B,027-510-724-533-305,2011-08-31,2011,ZA 201008490 A,2010-11-25,US 5653808 P;;US 14253309 P;;US 2009/0045509 W,2008-05-28,METHOD AND APPARATUS FOR IDENTIFYING DIETARY CHOICES,,KRAFT FOODS GLOBAL BRANDS LLC,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MORREALE SANDRA JEAN;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN;;RUBIN KRISTIN H;;MATUSHESKI NATHAN V,,https://lens.org/027-510-724-533-305,Granted Patent,no,0,0,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G16H20/60,,0,0,,,,ACTIVE
540,CN,A,CN 102113038 A,055-730-458-729-97X,2011-06-29,2011,CN 200980130720 A,2009-05-28,US 2009/0045509 W;;US 5653808 P;;US 14253309 P,2008-05-28,Method and apparatus for identifying dietary options,A method is provided for assigning a relative score to foods. Assignment of a relative score to foods allows consumers to select foods that will provide a desirable diet. Equations are provided which are effective to yield a predicted raw score based on measured characteristics. The predicted raw score statistically correlates to a raw score that would be determined by an actual panel. The predicted raw scores are further processed to provide a relative score number that can be easily tracked by a consumer.,KRAFT FOODS GLOBAL BRANDS LLC,RICHARD BLACK;;KEVIN ABRAHAM TODD;;RANDALL EBERHARDT KEITH;;LEE LETCHER LINDA;;JEAN MORREALE SANDRA;;OLEA SANOY ARLENE;;ANN YEHLING BARBARA;;RUBIN KRISTIN H;;MATUSHESKI NATHAN V,,https://lens.org/055-730-458-729-97X,Patent Application,no,0,1,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G09B19/00;;G16H20/60,,0,0,,,,DISCONTINUED
541,WO,A2,WO 2009/155065 A2,132-003-771-104-263,2009-12-23,2009,US 2009/0045509 W,2009-05-28,US 5653808 P;;US 14253309 P,2008-05-28,METHOD AND APPARATUS FOR IDENTIFYING DIETARY CHOICES,A method is provided for assigning a relative score number to foods. Assignment of a relative score number to foods allows consumers to select foods that will provide a desirable diet. Equations are provided which are effective to yield a predicted raw score based on measured characteristics. The predicted raw score statistically correlates to a raw score that would be determined by an actual panel. the predicted raw scores are further processed to provide a relative score number that can be easily tracked by a consumer.,KRAFT FOODS GLOBAL BRANDS LLC;;BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MORREALE SANDRA JEAN;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN;;RUBIN KRISTIN H;;MATUSHESKI NATHAN V,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MORREALE SANDRA JEAN;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN;;RUBIN KRISTIN H;;MATUSHESKI NATHAN V,,https://lens.org/132-003-771-104-263,Patent Application,yes,0,1,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G16H20/60;;G09B19/00,,0,0,,,,PENDING
542,US,B1,US 6358813 B1,015-561-028-908-366,2002-03-19,2002,US 71376600 A,2000-11-15,US 71376600 A,2000-11-15,Method for increasing the capacitance of a semiconductor capacitors,"
    Described is a method of increasing the capacitance of semiconductor capacitors by providing a first solid-state electrode pattern on a semiconductor medium, etching topographic features on said first electrode pattern in a manner effective in increasing the surface area of said first electrode pattern, depositing a dielectric layer upon said electrode pattern that substantially conforms to said topographic features, and depositing a second solid-state electrode pattern upon said dielectric layer and sufficiently insulated from said first solid-state electrode pattern so as to create a capacitance with said first solid-state electrode pattern. 
",IBM,HOLMES STEVEN J;;BLACK CHARLES;;FRANK DAVID J;;FURUKAWA TOSHIHARU;;HAKEY MARK C;;HORAK DAVID V;;MA WILLIAM HSIOH-LIEN;;MILKOVE KEITH R;;GUARINI KATHRYN W,INTERNATIONAL BUSINESS MACHINESS CORPORATION (2000-11-13);;TWITTER INC (2013-12-30),https://lens.org/015-561-028-908-366,Granted Patent,yes,1,56,3,3,0,H01L28/92;;H01L28/92,H01L21/02,438/398;;438/397;;438/396;;438/739,8,3,070-258-023-710-468;;070-258-023-710-468;;060-999-265-459-099,10.1063/1.116192;;10.1063/1.116192;;10.1126/science.276.5317.1401,"Mansky et al., ""Nanolithographic templates from diblock copolymet thi films"", 1996, Applied Physics Letters, vol. 68, pp. 2586-2588, Apr. 29, 1996.*;;Morkved et al., ""Mesoscopic self assembly of gold islands on diblock copolymet films"", Science, v. 273,pp. 931, 1998.*;;Mansky et al., Nanolithograpi Templates from Diblock copolymer Thin Films, Applied Physics Letters, vol. 68, pp. 2586-2588 (Apr., 1996).;;Park et al., Block Polymer Lithography: Periodic Arrays of 10'' Holes in 1 Square Centimeter, Science, vol. 276, May 30, p. 1401-1404 (1997).;;Morkved et al., Science, v. 273, p. 931 (1998).;;Morkved et al., Applied Physics Letters, v. 64, p. 422.;;Journal of Materials Science, v. 30, p. 1987 (1995).;;Li et al., Journal of the American Chemical Society, v. 118, p. 10982 (1996).",EXPIRED
543,US,A1,US 2015/0099246 A1,074-466-662-328-646,2015-04-09,2015,US 201414570909 A,2014-12-15,US 201414570909 A;;US 47415509 A;;US 14253309 P;;US 5653808 P,2008-05-28,Method And Apparatus For Identifying Dietary Choices,A method is provided for assigning a relative score number to foods. Assignment of a relative score number to foods allows consumers to select foods that will provide a desirable diet. Equations are provided which are effective to yield a predicted raw score based on measured characteristics. The predicted raw score statistically correlates to a raw score that would be determined by an actual panel. The predicted raw scores are further processed to provide a relative score number that can be easily tracked by a consumer.,THRIVE 365 INTERNATIONAL INC,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MATUSHESKI NATHAN V;;MORREALE SANDRA JEAN;;RUBIN KRISTIN H;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN,,https://lens.org/074-466-662-328-646,Patent Application,yes,0,3,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G09B19/00;;G16H20/60,434/127,0,0,,,,DISCONTINUED
544,US,A1,US 2011/0316046 A1,082-353-239-313-067,2011-12-29,2011,US 82579110 A,2010-06-29,US 82579110 A,2010-06-29,Field Effect Transistor Device,"A method for forming a field effect transistor device includes forming a gate stack portion on a substrate, forming a spacer portion on the gates stack portion and a portion of the substrate, removing an exposed portion of the substrate, epitaxially growing a first silicon material on the exposed portion of the substrate, removing a portion of the epitaxially grown first silicon material to expose a second portion of the substrate, and epitaxially growing a second silicon material on the exposed second portion of the substrate and the first silicon material.",CHAN KEVIN K;;DUBE ABHISHEK;;HARLEY ERIC C;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H;;BLACK LINDA R;;GLOBALFOUNDRIES INC;;IBM,CHAN KEVIN K;;DUBE ABHISHEK;;HARLEY ERIC C;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H;;BLACK LINDA R,TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2020-05-15);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-06-28);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/082-353-239-313-067,Patent Application,yes,44,15,4,4,0,H01L21/26586;;H01L21/823412;;H01L21/823425;;H01L21/823481;;H01L21/823807;;H01L21/823814;;H01L21/84;;H01L29/66628;;H01L29/66772;;H01L29/78618;;H01L29/78684;;H01L29/7848;;H01L21/823814;;H01L21/84;;H01L21/823481;;H01L21/823807;;H01L29/78684;;H01L21/823412;;H01L29/78618;;H01L21/823425;;H01L21/26586;;H01L29/66628;;H01L29/66772;;H01L29/7848,H01L21/336;;H01L29/78,257/192;;438/285;;X257E21409;;X257E29255,3,2,035-322-216-073-535;;010-732-110-549-333,10.1088/0268-1242/15/8/313;;10.1007/bf02665519,"Cheng et al., SiGe-On-Insulator SGOI: Substrate Preparation and MOSFET Fabrication for Electron Mobility Evaluation, IEEE International SOI Conference, 2001, pages 13-14;;Wieser et al., Nanoscale patterning of Si/SiGe heterostructures by electron-beam lithograpy and wet-chemical etching, Semicond. Sci. Technol., Vol. 15, No. 8, 2000, pages 862-867;;Johnson et al., Selective Chemical Etching of Polycrystalline SiGe Alloys with Respect to Si and SiO2, Journal of Electronic Materials, Vol. 21, No. 8, 1992, pages 805-810",ACTIVE
545,NZ,A,NZ 589854 A,197-644-600-165-537,2013-11-29,2013,NZ 58985409 A,2009-05-28,US 14253309 P;;US 5653808 P;;US 2009/0045509 W,2008-05-28,METHOD AND APPARATUS FOR IDENTIFYING DIETARY CHOICES,"589854 A computer-implemented method and an apparatus for facilitating selection of desirable choices are disclosed. In the method relative scores are generated in a processing device for a first group of choices in response to results from a plurality of forced choice comparisons by a plurality of informed domain representatives. The plurality of forced choice comparisons each include a selection of one choice from a pair of choices and the selections form the results for generating the relative scores. At an input device, measurements of at least two characteristics of each of a second group of choices are received and in a computing device, predicted relative scores for the individual ones of the second group of choices are calculated using the measurements of the at least two characteristics of each of the second group of choices in a model of the relative scores of the first group of choices. The predicted relative scores to communicate the predicted relative scores to facilitate selection of desirable choices are outputted via an output device. Further disclosed is a computer-implemented method for assisting a person to maintain a predetermined diet. In this method a minimum and maximum relative score number effective for maintaining a predetermined diet over a period of time are determined in a processing device. A relative score number is calculated for each of a number of possible food serving choices by fitting at least two characteristics of the possible food serving choices to a model generated from results of a plurality of forced choice comparisons of sample food choices by a plurality of informed domain representatives. The plurality of forced choice comparisons each include a selection of one food choice from a pair of food choices and the selections form the results for generating the model. Food serving choices are identified in a computing device that will provide an aggregated total relative score number between the determined minimum and maximum relative score number; and a diet plan using the identified food serving choices to thereby assist the person to maintain the predetermined diet is outputted via an output device.",INTERCONTINENTAL GREAT BRANDS LLC,MORREALE SANDRA JEAN;;RUBIN KRISTIN H;;ABRAHAM TODD KEVIN;;BLACK RICHARD;;MATUSHESKI NATHAN V;;YEHLING BARBARA ANN;;LETCHER LINDA LEE;;SANOY ARLENE OLEA;;EBERHARDT KEITH RANDALL,"THRIVE 365 INTERNATIONAL, INC., US (2014-04-17)",https://lens.org/197-644-600-165-537,Patent Application,no,0,0,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G09B19/00;;G16H20/60,,0,0,,,,DISCONTINUED
546,CR,A,CR 11844 A,008-255-945-620-504,2011-05-04,2011,CR 11844 A,2010-12-13,US 5653808 P;;US 14253309 P,2008-05-28,MÉTODO Y APARATOS PARA IDENTIFICAR ELECCIONES DIETETICAS,"El invento se refiere a métodos y aparatos para clasificar las elecciones, tales como métodos y aparatos para clasificar alimentos lo cual permite escoger alimentos que proporcionarán una dieta balanceada y saludable.",INTERCONTINENTAL GREAT BRANDS LLC,RICHARD BLACK;;TOOD KEVIN ABRAHMA;;RANDALL KEITH EBERHARDT;;LINDA LEE LETCHER;;SANDRA JEAN MORREALE;;ARLENE OLEA SANOY;;BARBARA ANN YEHLING;;KRISTIN H RUBIN;;NATHAN V MATUSHESKI,,https://lens.org/008-255-945-620-504,Patent Application,no,0,0,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G09B19/00;;G16H20/60,,0,0,,,,PENDING
547,KR,A,KR 20110021966 A,176-415-444-590-142,2011-03-04,2011,KR 20107029221 A,2009-05-28,US 5653808 P;;US 14253309 P,2008-05-28,METHOD AND APPARATUS FOR IDENTIFYING DIETARY CHOICES,,KRAFT FOODS GLOBAL BRANDS LLC,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MORREALE SANDRA JEAN;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN;;RUBIN KRISTIN H;;MATUSHESKI NATHAN V,,https://lens.org/176-415-444-590-142,Patent Application,no,0,0,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G16H20/60,,0,0,,,,DISCONTINUED
548,US,B2,US 8618617 B2,158-535-647-268-907,2013-12-31,2013,US 201313783526 A,2013-03-04,US 201313783526 A;;US 82579110 A,2010-06-29,Field effect transistor device,"A method for forming a field effect transistor device includes forming a gate stack portion on a substrate, forming a spacer portion on the gates stack portion and a portion of the substrate, removing an exposed portion of the substrate, epitaxially growing a first silicon material on the exposed portion of the substrate, removing a portion of the epitaxially grown first silicon material to expose a second portion of the substrate, and epitaxially growing a second silicon material on the exposed second portion of the substrate and the first silicon material.",IBM;;GLOBALFOUNDRIES INC,CHAN KEVIN K;;DUBE ABHISHEK;;HARLEY ERIC C;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H;;BLACK LINDA R,TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2020-05-15);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2013-02-27);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/158-535-647-268-907,Granted Patent,yes,55,3,4,4,0,H01L21/26586;;H01L21/823412;;H01L21/823425;;H01L21/823481;;H01L21/823807;;H01L21/823814;;H01L21/84;;H01L29/66628;;H01L29/66772;;H01L29/78618;;H01L29/78684;;H01L29/7848;;H01L21/823814;;H01L21/84;;H01L21/823481;;H01L21/823807;;H01L29/78684;;H01L21/823412;;H01L29/78618;;H01L21/823425;;H01L21/26586;;H01L29/66628;;H01L29/66772;;H01L29/7848,H01L27/088,257/401;;X257E21091;;438/300;;438/222,7,5,023-687-064-558-053;;089-910-758-888-974;;155-930-523-414-782;;010-732-110-549-333;;035-322-216-073-535,10.1007/s11432-009-0167-9;;10.1063/1.1819976;;10.1109/vlsit.2004.1345387;;10.1007/bf02665519;;10.1088/0268-1242/15/8/313,"Huang, Ru., et al. ""Challenges of 22 nm an beyond CMOS technology"" Science in China Series F: Information Sciences; vol. 52, No. 9, Sep. 2009. pp. 1491-1533.;;Kuppurao, Satheesh, et al., ""Integrating Selective Epitaxy in Advanced Logic & Memory Devices"", Appliaied Materials, Inc., 2008, 1 pg.;;Lee, Minjoo L. et al., ""Strained Si, SiGe, and Ge channels for high-mobility metal-oxide-semiconductor field-effect transistors"", (c) 2005 American Institute of Physics, downloaded Feb. 11, 2010, see http://jap.aip.org/jp.copyright.jsp; Journal of Applied Physics, 97, 011101 (2005), pp. 97-011101-1-011101-27.;;Mistry, K., et al., ""Delaying Forever: Uniaxial Strained Silicon Transistors in a 90nm CMOS Technology"", Sep. 2004 (c) 2004 IEEE; 2004 Symposium on VLSI Technology, Digest of Technical Papers, pp. 50-51.;;Cheng et al., ""SiGe-On-Insulator (SGOI): Substrate Preparation and MOSFET Fabrication for Electron Mobility Evaluation"", 2001 IEEE International SOI Conference, Oct. 2001, pp. 13-14.;;Johnson et al., ""Selective Chemical Etching of Polycrystalline SiGe Alloys with Respect to Si and SiO2"" Journal of Electronic Materials, vol. 21, No. 8, 1992, pp. 805-810.;;Weiser et al., ""Nanoscale patterning of Si/SiGe heterostructures by electron-beam lithography and wet-chemical etching"" Semicond. Sci. Technol., vol. 15, No. 8, 2000, pp. 862-867.",ACTIVE
549,US,A1,US 2002/0058394 A1,182-982-760-625-747,2002-05-16,2002,US 809201 A,2001-11-13,US 809201 A;;US 71376600 A,2000-11-15,Semiconductor capacitors,"
   Described is a method of increasing the capacitance of semiconductor capacitors by providing a first solid-state electrode pattern on a semiconductor medium, etching topographic features on said first electrode pattern in a manner effective in increasing the surface area of said first electrode pattern, depositing a dielectric layer upon said electrode pattern that substantially conforms to said topographic features, and depositing a second solid-state electrode pattern upon said dielectric layer and sufficiently insulated from said first solid-state electrode pattern so as to create a capacitance with said first solid-state electrode pattern. 
",IBM,HOLMES STEVEN J;;BLACK CHARLES;;FRANK DAVID J;;FURUKAWA TOSHIHARU;;HAKEY MARK C;;HORAK DAVID V;;MA WILLIAM HSIOH-LIEN;;MILKOVE KEITH R;;GUARINI KATHRYN W,,https://lens.org/182-982-760-625-747,Patent Application,yes,0,18,3,3,0,H01L28/92;;H01L28/92,H01L21/02,438/398,0,0,,,,EXPIRED
550,US,B2,US 8920175 B2,028-930-781-159-011,2014-12-30,2014,US 47415509 A,2009-05-28,US 47415509 A;;US 5653808 P;;US 14253309 P,2008-05-28,Method and apparatus for identifying dietary choices,A method is provided for assigning a relative score number to foods. Assignment of a relative score number to foods allows consumers to select foods that will provide a desirable diet. Equations are provided which are effective to yield a predicted raw score based on measured characteristics. The predicted raw score statistically correlates to a raw score that would be determined by an actual panel. The predicted raw scores are further processed to provide a relative score number that can be easily tracked by a consumer.,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MATUSHESKI NATHAN V;;MORREALE SANDRA JEAN;;RUBIN KRISTIN H;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN;;THRIVE 365 INTERNATIONAL INC,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MATUSHESKI NATHAN V;;MORREALE SANDRA JEAN;;RUBIN KRISTIN H;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN,MONDELEZ THRIVE INVESTMENT LLC (2014-02-26);;THRIVE 365 INTERNATIONAL INC (2014-03-12);;INTERCONTINENTAL GREAT BRANDS LLC (2013-05-15),https://lens.org/028-930-781-159-011,Granted Patent,yes,112,33,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G09B19/00;;G16H20/60,434/127,50,39,001-531-685-827-560;;034-426-295-052-934;;009-122-588-841-946;;097-235-134-794-519;;046-274-108-814-784;;028-155-639-939-258;;090-186-159-385-735;;039-521-894-551-804;;175-942-910-668-751;;144-061-583-490-807;;014-248-801-523-109;;024-800-120-707-032;;153-945-076-060-781;;009-805-225-809-704;;003-055-518-601-722;;042-565-280-816-997;;037-068-591-324-385;;039-521-894-551-804;;039-513-397-157-670;;007-881-359-814-703;;014-715-037-494-225;;028-155-639-939-258;;012-386-349-112-559;;005-179-380-299-408;;019-703-749-208-569;;037-068-591-324-385;;022-132-060-118-653;;082-249-696-310-400;;090-584-859-834-101;;038-054-839-115-958;;071-671-399-926-246;;060-600-735-237-611;;093-302-404-597-980;;018-269-766-656-990;;019-520-367-122-979;;121-617-541-714-530;;035-714-918-750-310;;011-562-166-317-977;;137-268-601-762-648,10.1108/00346659610108975;;10.2337/diacare.6.3.245;;6347576;;6298300;;10.1016/s0002-8223(21)00078-x;;10.2337/diacare.3.6.663;;7449597;;7389552;;10.2337/diacare.3.2.390;;10.1038/sj.ejcn.1602089;;15674301;;10.1016/s0271-5317(02)00492-x;;17197270;;10.1016/j.jada.2006.10.012;;10.1111/j.1753-4887.1997.tb01596.x;;9155219;;8623689;;10.1093/ajcn/50.6.1415;;2688396;;10.1016/j.soc.2006.05.012;;16882494;;16771073;;10.1016/j.ypmed.2003.11.007;;15020176;;10.2337/diaspect.18.4.251;;16197842;;10376780;;10.1080/07315724.1999.10718858;;17197270;;10.1016/j.jada.2006.10.012;;10.1159/000094450;;16820739;;10.1111/j.1365-2648.2006.03799.x;;16553701;;16543995;;10.1590/s0004-27302005000300012;;10.1038/sj.ejcn.1602089;;15674301;;10.1177/014572170302900221;;12728757;;10.1177/014572170202800613;;12526639;;11707563;;10.1038/oby.2001.140;;10376780;;10.1080/07315724.1999.10718858;;10.2337/diacare.22.2.191;;10333932;;12024341;;9155313;;10.1177/014572179702300205;;10.1001/archinte.157.2.169;;10.1001/archinte.1997.00440230041006;;9009974;;1728824;;10.1093/ajcn/55.1.89;;1658960;;2848414;;10.1016/0002-9343(88)90410-x;;10.2337/diacare.10.5.589;;3315515;;10.1093/ajcn/45.5.958;;3554962;;3825986;;10.1093/ajcn/45.3.625;;10.1080/00325481.1986.11699428;;3012498;;10.2337/diacare.8.4.359;;2994971;;10.1542/peds.75.5.872;;3991274,"John A. Bower; Statistics for food science III: sensory evaluation data. Part B-discrimination tests. Nutrition & Food Science, No. 2, Mar./Apr. 1996; pp. 16-22.;;Hungarian Intellectual Property Office Search Report and Written Opinion for Singapore Patent Application No. 201008447-3 dated Mar. 15, 2012, 15 pages.;;Gal Trieu, ""How many Weight Watchers Points is that?"", Jul. 18, 2007, [online], [retrieved on Feb. 14, 2012]. Retrieved from the Internet: (3 pages).;;N. K. Christensen et al., Quantitative assessment of dietary adherence in patients with insulin-dependent diabetes mellitus, Diabetes Care, United States, May-Jun. 1983, 6(3), pp. 245-250.;;C. W. Suitor et al., Planning high-carbohydrate, high-fiber diets with a microcomputer, Journal of the American Dietetic Association, United States, Mar. 1983, 82(3), pp. 279-282.;;M. L. Wheeler et al., Computer-planned menus for patients with diabetes mellitus, Diabetes Care, United States, Nov.-Dec. 1980, 3(6), pp. 663-667.;;J. M. Olefsky, Fructose, xylitol, and sorbitol, Diabetes Care, United States, Mar.-Apr. 1980, 3(2), pp. 390-393.;;R. Spencer et al., An assessment of micronutrient status, cardiovascular risk factors and weight loss in individuals following low glycaemic index diet plans, 2006, 48 pp., Research Report No. 893.;;J. Miller Jones, Nutrition, Cereal Foods World, May-Jun. 2005, 50(3), pp. 150-152.;;Z. Li et al., Long-term efficacy of soy-based meal replacements vs an individualised diet plan in obese type II DM patients: relative effects on weight loss, metabolic parameters, and C-reactive protein, European Journal of Clinical Nutrition, 2005, 59(3), pp. 411-418.;;K. Fatema et al., Serum glucose and insulin response to mango and papaya in type 2 diabetic subjects, Nutrition Research, Jan. 2003, 23(1), pp.9-14.;;L. S. Lieberman, Part IVF. 1. The nutrients-deficiencies, surfeits, and food-related disorders: diet and chronic disease: diabetes. The Cambridge World History of Food, vol. 1, 2000, pp. 1078-1086.;;J. W. Veith, The vegan-vegetarian lifestyle, Diet and Health: Scientific Perspectives, 2nd Edition, 1998, pp. 97-115.;;Anonymous, IBA helps diabetics, Confectionery Production, 1995, 61(1), p. 80.;;Susana R. Patton et al., Dietary adherence and associated glycemic control in families of young children with type 1 diabetes, Journal of the American Dietetic Association, Jan. 2007, 107, 1, 46(7).;;Unknown Author, A dietary intervention trial for nutritional management of cardiovascular risk factors, Nutrition Reviews, Feb. 1997, v55, n2, p. 54(3).;;Patrick J. Fahey et al., The athlete with type I diabetes: managing insulin, diet and exercise, American Family Physician, Apr. 1996, v53, n5, p. 1611(9).;;Inga Torsdottir et al., Gastric emptying and glycemic response after ingestion of mashed bean or potato flakes in composite meals, American Journal of Clinical Nutrition, Dec. 1989, v50, n6, p. 1415(5).;;S. Mercanligil et al., The role of dietary fiber in nutrition and medical nutrition therapy, Sendrom, Turkey, 2006, 18/7, pp. 49-55.;;A. E. Stephen et al., Neuroendocrine Tumors of the Pancreas, Excluding Gastrinoma, Surgical Oncology Clinics of North America, United States, 2006, 15/3, pp. 497-510.;;Llona A. Arteaga, The glicemic index. A current controversy, Nutricion Hospitalaria, Spain, 2006, 21/Suppl. 2, pp. 55-60.;;H. S. Englert et al., Rationale and design of the Rockford CHIP, a community-based coronary risk reduction program: Results of a pilot phase, Preventive Medicine, United States, 2004, 38/4, pp. 432-441.;;M. Powers, A popular diets project, Diabetes Spectrum, United States, 2005, 18/4, pp. 251-256.;;M. P. Vasconcelos, Assessment of an obesity clinic in a center hospital, Acta Medica Portuguesa, Portugal, 2004, 17/5, pp. 359-366.;;T. M. S. Wolever et al., Day-to-day consistency in amount and source of carbohydrate intake associated with improved blood glucose control in type 1 diabetes, Journal of the American College of Nutrition, United States, 1999, 18/3, pp. 242-247.;;I. Simon-Schnass et al., Intake and supply of alpha-tocopherol in type II diabetic patients, Diabetes und Stoffwechsel, Germany, 1997, 6/Suppl. 2, pp. 16-19.;;H. Hauner et al., Diagnosis and initial therapy in type 2 diabetes mellitus: Results obtained by a standardized questionnaire. 2. Initial therapy of type 2 diabetic patients, Diabetes und Stoffwechsel, Germany, 1995, 4/6, pp. 449-453.;;M. Toeller, Dietetic treatment in diabetes, Therapiewoche, Germany, 1985, 35/7, pp. 732-739.;;Susana R. Patton et al., Dietary adherence and associated glycemic control in families of young children with type 1 diabetes, Journal of the American Dietetic Association, United States, Jan. 2007, 107(1), pp. 46-52.;;Herwig H. Ditschuneit, Do meal replacement drinks have a role in diabetes management?, Nestle Nutrition Workshop Series, Clinical & Performance Programme, Switzerland, 2006, 11, pp. 171-179, Discussion 179-181.;;Jean Nagelkerk et al., Perceived barriers and effective strategies to diabetes self-management, Journal of Advanced Nursing, England, Apr. 2006, 54(2), pp. 151-158.;;Paula Cristina A. Da Costa et al., Introduction of sucrose in the diet plan of persons with type 1 diabetes: its influence in the glycemic control, Arquivos Brasileiros de Endocrinologia e Metabologia, Brazil, Jun. 2005, 49(3), pp. 403-409.;;Z. Li et al., Long-term efficacy of soy-based meal replacements vs an individualized diet plan in obese type II DM patients: relative effects on weight loss, metabolic parameters, and C-reactive protein, European Journal of Clinical Nutrition, England, Mar. 2005, 59(3), pp. 411-418.;;Rosemary F. Hall et al., Overcoming obstacles to behavior change in diabetes self-management, Diabetes Educator, United States, Mar.-Apr. 2003, 29(2), pp. 303-311.;;Wendy A. Jorgensen et al., Perceived adherence to prescribed or recommended standards of care among adults with diabetes, Diabetes Educator, United States, Nov.-Dec. 2002, 28(6), pp. 989-998.;;I. Yip et al., Liquid meal replacements and glycemic control in obese type 2 diabetes patients, Obesity Research, United States, Nov. 2001, 9 Suppl 4, pp. 341S-347S.;;T. M. Wolever et al., Day-to-day consistency in amount and source of carbohydrate associated with improved blood glucose control in type 1 diabetes, Journal of the American College of Nutrition, United States, Jun. 1999, 18(3), pp. 242-247.;;F. X. Pi-Sunyer et al., Multicenter randomized trial of a comprehensive prepared meal program in type 2 diabetes, Diabetes Care, United States, Feb. 1999, 22(2), pp. 191-197.;;C. L. Rudkin, Vegetarian diet planning for adolescents with diabetes, Pediatric Nursing, United States, May-Jun. 1999, 25(3), pp. 262-266.;;T. Travis, Patient perceptions of factors that affect adherence to dietary regimens for diabetes mellitus, Diabetes Educator, United States, Mar.-Apr. 1997, 23(2), pp. 152-156.;;D. A. McCARRON et al., Nutritional management of cardiovascular risk factors. A randomized clinical trial, Archives of Internal Medicine, United States, Jan. 27, 1997, 157(2), pp. 169-177.;;K. Indar-Brown et al., Glycemic and insulinemic responses after ingestion of ethnic foods by NIDDM and healthy subjects, American Journal of Clinical Nutrition, United States, Jan. 1992, 55(1), pp. 89-95.;;G. IRSY et al., New possibilities in the diabetic diet, Therapia Hungarica, English Edition, Hungary, 1991, 39(2), pp. 55-62.;;J. W. Anderson et al., New perspectives in nutrition management of diabetes mellitus, American Journal of Medicine, United States, Nov. 28, 1988, 85(5A), pp. 159-165.;;R. Stratton et al., Improved glycemic control after supervised 8-wk exercise program in insulin-dependent diabetic adolescents, Diabetes Care, United States, Sep.-Oct. 1987, 10(5), pp. 589-593.;;E. A. Chantelau et al., Intensive insulin therapy justifies simplification of the diabetes diet: a prospective study in insulin-dependent diabetic patients, American Journal of Clinical Nutrition, United States, May 1987, 45(5), pp. 958-962.;;P. A. Kendall et al., A comparison of nutrient-based and exchange-group methods of diet instruction for patients with noninsulin-dependent diabetes, American Journal of Clinical Nutrition, United States, Mar. 1987, 45(3), pp. 625-637.;;U. M. Kabadi, Nutritional therapy in diabetes. Rationale and recommendations., Postgraduate Medicine, United States, Jun. 1986, 79(8), pp. 145-156.;;J. Stevens et al., Outpatient management of diabetes mellitus with patient education to increase dietary carbohydrate and fiber, Diabetes Care, United States, Jul.-Aug. 1985, 8(4), pp. 359-366.;;R. A. Lorenz et al., Diet-related knowledge, skill, and adherence among children with insulin-dependent diabetes mellitus, Pediatrics, United States, May 1985, 75(5), pp. 872-876.",ACTIVE
551,US,B2,US 8492234 B2,149-098-852-637-071,2013-07-23,2013,US 82579110 A,2010-06-29,US 82579110 A,2010-06-29,Field effect transistor device,"A method for forming a field effect transistor device includes forming a gate stack portion on a substrate, forming a spacer portion on the gates stack portion and a portion of the substrate, removing an exposed portion of the substrate, epitaxially growing a first silicon material on the exposed portion of the substrate, removing a portion of the epitaxially grown first silicon material to expose a second portion of the substrate, and epitaxially growing a second silicon material on the exposed second portion of the substrate and the first silicon material.",CHAN KEVIN K;;DUBE ABHISHEK;;HARLEY ERIC C;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H;;BLACK LINDA R;;IBM;;GLOBALFOUNDRIES INC,CHAN KEVIN K;;DUBE ABHISHEK;;HARLEY ERIC C;;HOLT JUDSON R;;ONTALUS VIOREL C;;SCHONENBERG KATHRYN T;;STOKER MATTHEW W;;TABAKMAN KEITH H;;BLACK LINDA R,TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2020-05-15);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-06-28);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/149-098-852-637-071,Granted Patent,yes,54,16,4,4,0,H01L21/26586;;H01L21/823412;;H01L21/823425;;H01L21/823481;;H01L21/823807;;H01L21/823814;;H01L21/84;;H01L29/66628;;H01L29/66772;;H01L29/78618;;H01L29/78684;;H01L29/7848;;H01L21/823814;;H01L21/84;;H01L21/823481;;H01L21/823807;;H01L29/78684;;H01L21/823412;;H01L29/78618;;H01L21/823425;;H01L21/26586;;H01L29/66628;;H01L29/66772;;H01L29/7848,H01L21/336,438/300;;438/222;;X257E21091,7,6,035-322-216-073-535;;010-732-110-549-333;;023-687-064-558-053;;026-510-233-932-516;;089-910-758-888-974;;155-930-523-414-782,10.1088/0268-1242/15/8/313;;10.1007/bf02665519;;10.1007/s11432-009-0167-9;;10.1149/1.2986799;;10.1063/1.1819976;;10.1109/vlsit.2004.1345387,"Cheng et al., SiGe-On-Insulator SGOI: Substrate Preparation and MOSFET Fabrication for Electron Mobility Evaluation, IEEE International SOI Conference, 2001, pp. 13-14.;;Wieser et al., Nanoscale patterning of Si/SiGe heterostructures by electron-beam lithograpy and wet-chemical etching, Semicond. Sci. Technol., vol. 15, No. 8, 2000, pp. 862-867.;;Johnson et al., Selective Chemical Etching of Polycrystalline SiGe Alloys with Respect to Si and SiO2, Journal of Electronic Materials, vol. 21, No. 8, 1992, pp. 805-810.;;Huang, Ru., et al. ""Challenges of 22 nm an beyond CMOS technology"" Science in China Series F: Information Sciences; vol. 52, No. 9, Sep. 2009. pp. 1491-1533.;;Kuppurao, Satheesh, et al., ""Integrating Selective Epitaxy in Advanced Logic & Memory Devices"", Applied Materials, Inc., 2008, 1 pg.;;Lee, Minjoo L. et al., ""Strained Si, SiGe, and Ge channels for high-mobility metal-oxide-semiconductor field-effect transistors"", (c) 2005 American Institute of Physics, downloaded Feb. 11, 2010, see http://jap.aip.org/jp.copyright.jsp; Journal of Applied Physics, 97, 011101 (2005), pp. 97-011101-1-97-011101-27.;;Mistry, K., et al., ""Delaying Forever: Uniaxial Strained Silicon Transistors in a 90nm CMOS Technology"", Sep. 2004 (c) 2004 IEEE; 2004 Symposium on VLSI Technology, Digest of Technical Papers, pp. 50-51.",ACTIVE
552,BR,A2,BR PI0912053 A2,049-108-841-121-521,2016-04-26,2016,BR PI0912053 A,2009-05-28,US 2009/0045509 W;;US 5653808 P;;US 14253309 P,2008-05-28,"métodos para facilitar seleção de escolhas desejáveis, para auxiliar uma pessoa a manter uma dieta pré-determinada, para rotular itens de alimento, para prever uma pontuação bruta real e para selecionar alimentos apropriados para uma dieta pré-determinada, recipiente e aparelho.",,KRAFT FOODS GLOBAL BRANDS LLC,SANOY ARLENE OLEA;;YEHLING BARBARA ANN;;EBERHARDT KEITH RANDALL;;RUBIN KRISTIN H;;LETCHER LINDA LEE;;MATUSHESKI NATHAN V;;BLACK RICHARD;;MORREALE SANDRA JEAN;;ABRAHAM TODD KEVIN,KRAFT FOODS GLOBAL BRANDS LLC (US) (2017-05-02),https://lens.org/049-108-841-121-521,Patent Application,no,0,0,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G09B19/00;;G16H20/60,,0,0,,,,DISCONTINUED
553,CA,A1,CA 2728020 A1,066-226-932-112-931,2009-12-23,2009,CA 2728020 A,2009-05-28,US 5653808 P;;US 14253309 P;;US 2009/0045509 W,2008-05-28,METHOD AND APPARATUS FOR IDENTIFYING DIETARY CHOICES,A method is provided for assigning a relative score number to foods. Assignment of a relative score number to foods allows consumers to select foods that will provide a desirable diet. Equations are provided which are effective to yield a predicted raw score based on measured characteristics. The predicted raw score statistically correlates to a raw score that would be determined by an actual panel. the predicted raw scores are further processed to provide a relative score number that can be easily tracked by a consumer.,KRAFT FOODS GLOBAL BRANDS LLC,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MORREALE SANDRA JEAN;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN;;RUBIN KRISTIN H;;MATUSHESKI NATHAN V,,https://lens.org/066-226-932-112-931,Patent Application,no,0,0,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G09B19/00;;G16H20/60,,0,0,,,,DISCONTINUED
554,US,A1,US 2009/0298021 A1,112-877-817-871-129,2009-12-03,2009,US 47415509 A,2009-05-28,US 47415509 A;;US 5653808 P;;US 14253309 P,2008-05-28,Method And Apparatus For Identifying Dietary Choices,A method is provided for assigning a relative score number to foods. Assignment of a relative score number to foods allows consumers to select foods that will provide a desirable diet. Equations are provided which are effective to yield a predicted raw score based on measured characteristics. The predicted raw score statistically correlates to a raw score that would be determined by an actual panel. The predicted raw scores are further processed to provide a relative score number that can be easily tracked by a consumer.,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MATUSHESKI NATHAN V;;MORREALE SANDRA JEAN;;RUBIN KRISTIN H;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MATUSHESKI NATHAN V;;MORREALE SANDRA JEAN;;RUBIN KRISTIN H;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN,MONDELEZ THRIVE INVESTMENT LLC (2014-02-26);;THRIVE 365 INTERNATIONAL INC (2014-03-12);;INTERCONTINENTAL GREAT BRANDS LLC (2013-05-15),https://lens.org/112-877-817-871-129,Patent Application,yes,95,33,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G16H20/60;;G09B19/00,434/127,1,1,001-531-685-827-560,10.1108/00346659610108975,"John A. Bower; Statistics for food science III: sensory evaluation data. Part B-discrimination tests.Nutrition & Food Science, Number 2, March/April 1996; pp. 16-22",ACTIVE
555,WO,A9,WO 2009/155065 A9,132-093-227-209-901,2010-05-06,2010,US 2009/0045509 W,2009-05-28,US 5653808 P;;US 14253309 P,2008-05-28,METHOD AND APPARATUS FOR IDENTIFYING DIETARY CHOICES,,KRAFT FOODS GLOBAL BRANDS LLC;;BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MORREALE SANDRA JEAN;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN;;RUBIN KRISTIN H;;MATUSHESKI NATHAN V,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MORREALE SANDRA JEAN;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN;;RUBIN KRISTIN H;;MATUSHESKI NATHAN V,,https://lens.org/132-093-227-209-901,Search Report,yes,0,0,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G16H20/60;;G09B19/00,,0,0,,,,PENDING
556,EP,A2,EP 2304709 A2,082-060-410-110-616,2011-04-06,2011,EP 09767376 A,2009-05-28,US 2009/0045509 W;;US 5653808 P;;US 14253309 P,2008-05-28,METHOD AND APPARATUS FOR IDENTIFYING DIETARY CHOICES,,KRAFT FOODS GLOBAL BRANDS LLC,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MORREALE SANDRA JEAN;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN;;RUBIN KRISTIN H;;MATUSHESKI NATHAN V,INTERCONTINENTAL GREAT BRANDS LLC (2013-12-11),https://lens.org/082-060-410-110-616,Patent Application,yes,1,5,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G16H20/60;;G09B19/00,,0,0,,,,DISCONTINUED
557,MX,A,MX 2010012925 A,023-900-307-048-251,2011-02-24,2011,MX 2010012925 A,2009-05-28,US 5653808 P;;US 14253309 P;;US 2009/0045509 W,2008-05-28,METHOD AND APPARATUS FOR IDENTIFYING DIETARY CHOICES.,A method is provided for assigning a relative score number to foods. Assignment of a relative score number to foods allows consumers to select foods that will provide a desirable diet. Equations are provided which are effective to yield a predicted raw score based on measured characteristics. The predicted raw score statistically correlates to a raw score that would be determined by an actual panel. the predicted raw scores are further processed to provide a relative score number that can be easily tracked by a consumer.,KRAFT FOODS GLOBAL BRANDS LLC,BLACK RICHARD;;ABRAHAM TODD KEVIN;;EBERHARDT KEITH RANDALL;;LETCHER LINDA LEE;;MORREALE SANDRA JEAN;;SANOY ARLENE OLEA;;YEHLING BARBARA ANN;;RUBIN KRISTIN H;;MATUSHESKI NATAHN V,"PCW HOLDINGS, LLC (2014-02-05)",https://lens.org/023-900-307-048-251,Patent Application,no,0,0,19,19,0,G09B19/0092;;G16H20/60;;G06Q50/20;;G06Q50/22;;G09B19/00;;G16H20/60;;G09B19/0092,G16H20/60;;G09B19/00,,0,0,,,,ACTIVE
558,US,A1,US 2013/0209453 A1,013-779-379-530-368,2013-08-15,2013,US 201113642845 A,2011-04-22,US 201113642845 A;;US 73839610 A;;US 2008/0080382 W;;US 32706210 P;;US 201161450619 P;;US 99942307 P;;US 8382708 P;;US 2011/0033649 W,2007-10-17,USE OF TAU TO MONITOR IMMUNOTHERAPY,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.,BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J;;WYETH LLC;;JANSSEN ALZHEIMER IMMUNOTHERAP,BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J,,https://lens.org/013-779-379-530-368,Patent Application,yes,2,11,7,7,99,A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K39/3955,A61K39/395,424/133.1;;424/172.1;;435/7.92,3,3,044-525-626-188-120;;167-297-291-569-025;;037-685-177-961-438,10.1016/0304-3940(95)11297-a;;7777193;;10.1016/j.jns.2009.02.343;;19278690;;19523877;;10.1016/s1474-4422(09)70139-5;;10.3410/f.1166395.627365,"Jensen et al. 1995 ""increased cerebrospinal fluid tau in patients with Alzheimer's disease"" Neurosci lett 186(2-3):189-91 (abstract only);;Stefani et al. 2009 ""CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia"" J neurol sci 283(1-2):109-15 (abstract only);;Visser et al. 2009 ""prevalence and prognostic value of csf markers of alzheiemr's disease pathology in patients with subjective cognitive impairment of mild cognitive impairment in the DESCRIPA study: a prospective cohort study"" Lancet Neurol 8(7):619-27 (abstract only)",ACTIVE
559,US,B2,US 9272030 B2,184-206-513-675-940,2016-03-01,2016,US 201113642845 A,2011-04-22,US 201113642845 A;;US 73839610 A;;US 2008/0080382 W;;US 32706210 P;;US 201161450619 P;;US 99942307 P;;US 8382708 P;;US 2011/0033649 W,2007-10-17,Use of tau to monitor immunotherapy,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.,BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J;;KINNEY GENE G;;JANSSEN SCIENCES IRELAND UC;;WYETH LLC,BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J;;KINNEY GENE G,ELAN PHARMA INTERNATIONAL LIMITED (2013-04-09);;CRIMAGUA LIMITED (2013-04-09);;JANSSEN SCIENCES IRELAND UC (2013-03-05);;WYETH LLC (2013-03-25);;ELAN PHARMACEUTICALS INC (2013-03-20),https://lens.org/184-206-513-675-940,Granted Patent,yes,5,1,7,7,99,A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K39/3955,A61K39/00;;A61K39/395;;C07K16/18,,19,15,044-525-626-188-120;;167-297-291-569-025;;037-685-177-961-438;;007-100-491-028-123;;032-427-704-964-072;;061-992-603-506-631;;083-229-815-185-306;;076-917-553-108-962;;044-525-626-188-120;;037-347-586-563-391;;082-783-052-900-43X;;167-297-291-569-025;;027-001-517-398-598;;037-685-177-961-438;;080-469-494-763-753,10.1016/0304-3940(95)11297-a;;7777193;;10.1016/j.jns.2009.02.343;;19278690;;19523877;;10.1016/s1474-4422(09)70139-5;;10.3410/f.1166395.627365;;19228370;;10.1186/1741-7015-7-7;;pmc2649159;;15642910;;10.1212/01.wnl.0000148604.77591.67;;15883316;;10.1212/01.wnl.0000159740.16984.3c;;10.1038/nm847;;12640449;;10.1001/archpsyc.61.1.95;;14706948;;10.1016/0304-3940(95)11297-a;;7777193;;10.1093/protein/gzn052;;18927231;;19923550;;pmc2790221;;10.1212/wnl.0b013e3181c67808;;10.1016/j.jns.2009.02.343;;19278690;;pmc2788047;;19638957;;10.1038/mt.2009.174;;19523877;;10.1016/s1474-4422(09)70139-5;;10.3410/f.1166395.627365;;10.1523/jneurosci.5302-08.2009;;19295164;;pmc6665249,"Jensen et al. 1995 ""increased cerebrospinal fluid tau in patients with Alzheimer's disease"" Neurosci lett 186(2-3):189-91 (abstract only).;;Stefani et al. 2009 ""CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia"" J neurol sci 283(1-2):109-15 (abstract only).;;Visser et al. 2009 ""prevalence and prognostic value of csf markers of alzheiemr's disease pathology in patients with subjective cognitive impairment of mild cognitive impairment in the DESCRIPA study: a prospective cohort study"" Lancet Neurol 8(7):619-27 (abstract only).;;Rafii 2009 ""Recent developmets in Alzheimer's disease therapeutics"" BMC medicine 7:7.;;Bayer, et al., ""Evaluation of the safety and innumogenicity of synthetic Abeta42 (AN1792) in patients with AD,"" Neurology, 64:94-102, (2005).;;EP 11 77 2806 Supplementary European Search Report mailed Aug. 28, 2013.;;Gilman, et al., ""Clinical Effects of Abeta Immunization (ANI1792) in Patients with AD in an Interrupted Trial,"" Neurology, vol. 64, No. 9, pp. 1553-1562 (2005).;;Greenberg, et al., ""Alzheimer disease's double-edged vaccine,"" Nature Medicine, vol. 9, No. 4 pp. 389-390 (2003).;;Hampel, et al., ""Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease,"" Arch Gen Psychiatry, 61(1):95-102 (2004).;;Jensen et al., ""Increased cerebrospinal fluid tau in patients with Alzheimer's disease,"" Neurosci Lett, 186(2-3): 189-91 abstract only (1995).;;PCT/US2011/033649 International Preliminary Report on Patentability and Written Opinion issued Oct. 23, 2012.;;PCT/US2011/033649 International Search Report and Written Opinion mailed Aug. 26, 2011.;;Ray, ""Wyeth Study Finds Alzheimer's Drug Works in ApoE4 Non Carriers,"" Poster 2008, [Retrived from the Internet Jun. 16, 2011: >URL: http://elan2006.blogspot.com/2008/07elan-wyeth-study-finds-alzheimers-drug-html>.;;Robert, et al., ""Engineered antibody intervention strategies for Alzheimer's disease and related demenitias by targeting amyloid and toxic oligomers,"" Protein Eng Des Sel., 22(3):199-2008 (2009).;;Salloway, et al., ""A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease,"" Neurology, vol. 73, No. 24, pp. 2061-2070 (2009).;;Stefani et al., ""CSF biomarkers, Impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia,"" J Neurol Sci., 283(102):109-15 (2009).;;Sudol, et al., ""Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease,"" Molecular Therapy: The Journal of the American Society of Gene Therapy, vol. 17, No. 12, pp. 2031-2040 (2009).;;Visser et al., ""Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study,"" Lancet Neurol, (7):619-27, (2009).;;Zhao et al., ""Macrophage-Mediated Degradation of beta-Amyloid via an Apolipoprotein E Isoforrn-Dependent Mechanism,"" J Neurosci., 29(11):3603-3612 (2009).",ACTIVE
560,EP,A1,EP 2560681 A1,196-702-431-178-252,2013-02-27,2013,EP 11772806 A,2011-04-22,US 201161450619 P;;US 32706210 P;;US 2011/0033649 W,2010-04-22,USE OF TAU TO MONITOR IMMUNOTHERAPY,,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J;;KINNEY GENE G,JANSSEN ALZHEIMER IMMUNOTHERAPY (2014-08-13);;WYETH LLC (2014-08-13),https://lens.org/196-702-431-178-252,Patent Application,yes,0,0,7,7,99,A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K39/3955,A61K39/00;;C07K16/00,,0,0,,,,DISCONTINUED
561,WO,A1,WO 2011/133919 A1,157-139-088-533-338,2011-10-27,2011,US 2011/0033649 W,2011-04-22,US 201161450619 P;;US 32706210 P,2010-04-22,USE OF TAU TO MONITOR IMMUNOTHERAPY,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC;;BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J;;KINNEY GENE G,BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J;;KINNEY GENE G,,https://lens.org/157-139-088-533-338,Patent Application,yes,1,5,7,7,99,A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K39/3955,A61K39/00;;C07K16/00,,5,3,037-347-586-563-391;;076-917-553-108-962;;080-469-494-763-753,10.1093/protein/gzn052;;18927231;;10.1001/archpsyc.61.1.95;;14706948;;10.1523/jneurosci.5302-08.2009;;19295164;;pmc6665249,"RAY: ""Wyeth Study Finds Alzheimer's Drug Works in ApoE4 Non-Carriers."", POSTER, 2008, XP003031723, Retrieved from the Internet <URL:http://elan2006.blogspot.com/2008/07/elan-wyeth-study-finds-alzheimers-drug.html> [retrieved on 20110616];;ROBERT ET AL.: ""Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers."", PROTEIN ENG DES SEL., vol. 22, no. 3, 2009, pages 199 - 208, XP055070400;;HAMPEL ET AL.: ""Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease."", ARCH GEN PSYCHIATRY, vol. 61, no. 1, 2004, pages 95 - 102, XP055070403;;ZHAO ET AL.: ""Macrophage-Mediated Degradation of beta -Amyloid via an Apolipoprotein E Isoform-Dependent Mechanism."", J NEUROSCI., vol. 29, no. 11, 2009, pages 3603 - 3612, XP009144054;;See also references of EP 2560681A4",PENDING
562,WO,A4,WO 2011/133919 A4,198-796-387-505-393,2012-01-12,2012,US 2011/0033649 W,2011-04-22,US 201161450619 P;;US 32706210 P,2010-04-22,USE OF TAU TO MONITOR IMMUNOTHERAPY,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC;;BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J;;KINNEY GENE G,BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J;;KINNEY GENE G,,https://lens.org/198-796-387-505-393,Patent Application,yes,0,0,7,7,99,A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K39/3955,A61K39/00;;C07K16/00,,0,0,,,,PENDING
563,EP,A4,EP 2560681 A4,167-566-910-874-751,2013-09-25,2013,EP 11772806 A,2011-04-22,US 201161450619 P;;US 32706210 P;;US 2011/0033649 W,2010-04-22,USE OF TAU TO MONITOR IMMUNOTHERAPY,,JANSSEN ALZHEIMER IMMUNOTHERAP;;WYETH LLC,BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J;;KINNEY GENE G,JANSSEN ALZHEIMER IMMUNOTHERAPY (2014-08-13);;WYETH LLC (2014-08-13),https://lens.org/167-566-910-874-751,Search Report,no,1,0,7,7,0,A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K39/3955,A61K39/00;;C07K16/00,,4,3,082-783-052-900-43X;;027-001-517-398-598;;061-992-603-506-631,19923550;;pmc2790221;;10.1212/wnl.0b013e3181c67808;;pmc2788047;;19638957;;10.1038/mt.2009.174;;15883316;;10.1212/01.wnl.0000159740.16984.3c,"SALLOWAY S ET AL: ""A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease."", NEUROLOGY 15 DEC 2009, vol. 73, no. 24, 15 December 2009 (2009-12-15), pages 2061 - 2070, XP002711392, ISSN: 1526-632X;;SUDOL KELLY L ET AL: ""Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease."", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY DEC 2009, vol. 17, no. 12, December 2009 (2009-12-01), pages 2031 - 2040, XP002711393, ISSN: 1525-0024;;GILMAN S ET AL: ""Clinical Effects of Abeta Immunization (ANI1792) in Patients with AD in an Interrupted Trial"", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 64, no. 9, 10 May 2005 (2005-05-10), pages 1553 - 1562, XP008103962, ISSN: 0028-3878, [retrieved on 20050407], DOI: 10.1212/01.WNL.0000159740.16984.3C;;See also references of WO 2011133919A1",DISCONTINUED
564,US,A,US 5970942 A,163-804-428-277-225,1999-10-26,1999,US 3166998 A,1998-02-27,US 3166998 A;;US 88611897 A;;US 60830596 A,1996-02-28,Electronically controlled continuous lubricating oil replacement system,"An improved method and system for automatically continuously replacing an engine's used lubricating oil with fresh lubricating oil throughout operation based on engine operating conditions is disclosed. The present system includes an lube oil replacement pump system operable in a replacement mode for injecting small amounts of used lube oil into the engine's fuel system and directing controlled quantities of fresh oil into the engine's lube oil system to replace the removed oil. The process periodically determines an engine operating severity value, i.e. fuel consumption value, for an interval of engine operation and calculates a base line quantity of oil for injection based on the current fuel consumption of the engine during the current interval. The lube oil replacement pump may also be operated in a makeup mode for adding quantities of fresh oil to the engine lube oil sump to compensate for oil consumed by the engine. The system adjusts the quantity of used oil to be removed and injected based on the quantity of fresh oil supplied during the makeup mode to prevent overreplacement of the lube oil. The lube oil pump system may be in the form of a compact, unitized lube oil replacement pump assembly integrating the various components of the system. The system maintains the quality of the engine lube oil at a level necessary to provide optimal engine protection at all engine operating conditions while also maintaining the oil concentration in the engine's fuel at an acceptable level.",CUMMINS ENGINE CO INC,KOEBERLEIN DAVID E;;CANTRELL PAUL D;;KEITH ERIC S;;GRAHAM JOHN P;;WANG JERRY C;;ROETTGEN LESLIE A;;CARVER DONALD P;;BLACK COLIN I;;STEHOUWER DAVID M;;HATTON RAY C,CUMMINS ENGINE IP INC (2000-10-01);;CUMMINS ENGINE COMPANY INC (1998-04-09),https://lens.org/163-804-428-277-225,Granted Patent,yes,16,34,1,14,0,F01M11/0458;;F01M11/0458;;F01M2011/0466;;F01M2011/0466;;F01M2011/0475;;F01M2011/0475;;F01M2011/1426;;F01M2011/1426;;F01M2011/1466;;F01M2011/1466;;F02D41/3005;;F02D41/3005;;F16N2230/02;;F16N2230/02,F01M11/04;;F02D41/30,123196R;;X123 73 AD;;X123196 S,0,0,,,,EXPIRED
565,US,A9,US 2015/0118223 A9,178-085-114-073-074,2015-04-30,2015,US 201113642845 A,2011-04-22,US 201113642845 A;;US 73839610 A;;US 2008/0080382 W;;US 32706210 P;;US 201161450619 P;;US 99942307 P;;US 8382708 P;;US 2011/0033649 W,2007-10-17,USE OF TAU TO MONITOR IMMUNOTHERAPY,The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.,BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J;;KINNEY GENE G;;WYETH LLC;;JANSSEN ALZHEIMER IMMUNOTHERAP,BLACK RONALD;;JACOBSEN JACK STEVEN;;TCHISTIAKOVA LIOUDMILA;;WIDOM ANGELA;;GILL DAVINDER;;EKMAN LARS;;LIEBERBURG IVAN;;GRUNDMAN MICHAEL;;CALLAWAY JAMES;;GREGG KEITH M;;ZAGO WAGNER;;BUTTINI MANUEL J;;KINNEY GENE G,ELAN PHARMA INTERNATIONAL LIMITED (2013-04-09);;CRIMAGUA LIMITED (2013-04-09);;JANSSEN SCIENCES IRELAND UC (2013-03-05);;WYETH LLC (2013-03-25);;ELAN PHARMACEUTICALS INC (2013-03-20),https://lens.org/178-085-114-073-074,Amended Application,yes,0,1,7,7,99,A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K2039/505;;C07K16/18;;C07K2317/24;;C07K2317/34;;A61K2039/545;;A61K2039/55;;A61K39/3955,A61K39/395,424/133.1;;424/172.1;;435/7.92,0,0,,,,ACTIVE
566,CN,A,CN 103338633 A,053-531-382-539-154,2013-10-02,2013,CN 201180052163 A,2011-10-05,US 2011/0054853 W;;US 41101610 P,2010-11-08,Bed bug monitor device for vertical surfaces,"A bed bug monitor and/or capture device includes a housing defining a substantially enclosed interior space and a deadfall trap; a harborage element mounted adjacent the deadfall trap that defines at least one pathway through which bed bugs can travel; at least one bed bug attractant element positioned within the interior space of the housing; and at least one opening defined in at least one wall of the housing at a location either on or adjacent the deadfall trap and/or the harborage element, wherein fumes emanating from the bed bug attractant element can escape through the at least one opening to a location outside of the device in order to lure bed bugs toward the deadfall trap and the harborage element.",FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,,https://lens.org/053-531-382-539-154,Patent Application,no,6,1,13,13,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/026;;A01M1/026;;A01M1/10;;A01N31/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01P19/00,,0,0,,,,DISCONTINUED
567,WO,A1,WO 2012/064426 A1,183-265-984-740-36X,2012-05-18,2012,US 2011/0054853 W,2011-10-05,US 41101610 P,2010-11-08,BED BUG MONITOR DEVICE FOR VERTICAL SURFACES,"A bed bug monitor and/or capture device includes a housing defining a substantially enclosed interior space and a deadfall trap; a harborage element mounted adjacent the deadfall trap that defines at least one pathway through which bed bugs can travel; at least one bed bug attractant element positioned within the interior space of the housing; and at least one opening defined in at least one wall of the housing at a location either on or adjacent the deadfall trap and/or the harborage element, wherein fumes emanating from the bed bug attractant element can escape through the at least one opening to a location outside of the device in order to lure bed bugs toward the deadfall trap and the harborage element.",FMC CORP;;BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,,https://lens.org/183-265-984-740-36X,Patent Application,yes,4,4,13,13,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/026;;A01M1/026;;A01M1/10;;A01N31/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01P19/00,,0,0,,,,PENDING
568,EP,A1,EP 2637496 A1,172-453-544-944-122,2013-09-18,2013,EP 11840697 A,2011-10-05,US 41101610 P;;US 2011/0054853 W,2010-11-08,BED BUG MONITOR DEVICE FOR VERTICAL SURFACES,,FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,,https://lens.org/172-453-544-944-122,Patent Application,yes,0,0,13,13,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/026;;A01M1/026;;A01M1/10;;A01N31/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01P19/00,,1,0,,,See references of WO 2012064426A1,DISCONTINUED
569,SG,A1,SG 189879 A1,038-506-005-205-898,2013-06-28,2013,SG 2013027321 A,2011-10-05,US 41101610 P;;US 2011/0054853 W,2010-11-08,BED BUG MONITOR DEVICE FOR VERTICAL SURFACES,"A bed bug monitor and/or capture device includes a housing defining a substantially enclosed interior space and a deadfall trap; a harborage element mounted adjacent the deadfall trap that defines at least one pathway through which bed bugs can travel; at least one bed bug attractant element positioned within the interior space of the housing; and at least one opening defined in at least one wall of the housing at a location either on or adjacent the deadfall trap and/or the harborage element, wherein fumes emanating from the bed bug attractant element can escape through the at least one opening to a location outside of the device in order to lure bed bugs toward the deadfall trap and the harborage element.",FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,,https://lens.org/038-506-005-205-898,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/026;;A01M1/026;;A01M1/10;;A01N31/02;;Y02A50/30;;Y02A50/30,,,0,0,,,,PENDING
570,CR,A,CR 20130189 A,045-830-644-646-938,2013-09-03,2013,CR 20130189 A,2013-04-30,US 41101610 P;;US 2011/0054853 W,2010-11-08,DISPOSITIVO DE MONITOREO DE CHINCHES DE CAMA PARA SUPERFICIES VERTICALES,UN DISPOSITIVO PARA EL MONOTOREO Y / O LA CAPTURA DE CHINCHES DE CAMA QUE INCLUYE UN GABINETA QUE DEFINE UN ESPACIO INTERIOR SUSTANCIALMENTE ENCERRADO Y UNA TRAMPA.-,FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,,https://lens.org/045-830-644-646-938,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/026;;A01M1/026;;A01M1/10;;A01N31/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01P19/00,,0,0,,,,PENDING
571,KR,A,KR 20130122739 A,131-509-623-130-605,2013-11-08,2013,KR 20137011211 A,2011-10-05,US 41101610 P;;US 2011/0054853 W,2010-11-08,BED BUG MONITOR DEVICE FOR VERTICAL SURFACES,,FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,,https://lens.org/131-509-623-130-605,Patent Application,no,0,6,13,13,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/026;;A01M1/026;;A01M1/10;;A01N31/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01P19/00,,0,0,,,,DISCONTINUED
572,MX,A,MX 2013005053 A,140-141-564-842-293,2013-06-28,2013,MX 2013005053 A,2011-10-05,US 41101610 P;;US 2011/0054853 W,2010-11-08,BED BUG MONITOR DEVICE FOR VERTICAL SURFACES.,"A bed bug monitor and/or capture device includes a housing defining a substantially enclosed interior space and a deadfall trap; a harborage element mounted adjacent the deadfall trap that defines at least one pathway through which bed bugs can travel; at least one bed bug attractant element positioned within the interior space of the housing; and at least one opening defined in at least one wall of the housing at a location either on or adjacent the deadfall trap and/or the harborage element, wherein fumes emanating from the bed bug attractant element can escape through the at least one opening to a location outside of the device in order to lure bed bugs toward the deadfall trap and the harborage element.",FMC CORP,ENGRAM MICHAEL J;;BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,,https://lens.org/140-141-564-842-293,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/026;;A01M1/026;;A01M1/10;;A01N31/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01P19/00,,0,0,,,,DISCONTINUED
573,US,A1,US 2012/0110894 A1,194-220-226-624-757,2012-05-10,2012,US 201113253160 A,2011-10-05,US 201113253160 A;;US 41101610 P,2010-11-08,Bed Bug Monitor Device for Vertical Surfaces,"A bed bug monitor and/or capture device includes a housing defining a substantially enclosed interior space and a deadfall trap; a harborage element mounted adjacent the deadfall trap that defines at least one pathway through which bed bugs can travel; at least one bed bug attractant element positioned within the interior space of the housing; and at least one opening defined in at least one wall of the housing at a location either on or adjacent the deadfall trap and/or the harborage element, wherein fumes emanating from the bed bug attractant element can escape through the at least one opening to a location outside of the device in order to lure bed bugs toward the deadfall trap and the harborage element.",BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD A;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON;;FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD A;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,SEMICONDUCTOR MANUFACTURING INTERNATIONAL (SHANGHAI) CORPORATION (2011-09-14);;FMC CORPORATION (2011-10-11),https://lens.org/194-220-226-624-757,Patent Application,yes,5,28,13,13,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/026;;A01M1/026;;A01M1/10;;A01N31/02;;Y02A50/30;;Y02A50/30,A01M1/10;;A01M1/02,43/123;;43/131,0,0,,,,DISCONTINUED
574,NZ,A,NZ 609620 A,136-971-304-170-812,2013-12-20,2013,NZ 60962011 A,2011-10-05,US 2011/0054853 W;;US 41101610 P,2010-11-08,Bed bug monitor device for vertical surfaces,"609620 A bed bug monitor and/or capture device includes a housing defining a substantially enclosed interior space and a deadfall trap; a harborage element mounted adjacent the deadfall trap that defines at least one pathway through which bed bugs can travel; at least one bed bug attractant element positioned within the interior space of the housing; and at least one opening defined in at least one wall of the housing at a location either on or adjacent the deadfall trap and/or the harborage element, wherein fumes emanating from the bed bug attractant element can escape through the at least one opening to a location outside of the device in order to lure bed bugs toward the deadfall trap and the harborage element.",FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,,https://lens.org/136-971-304-170-812,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/026;;A01M1/026;;A01M1/10;;A01N31/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01P19/00,,0,0,,,,DISCONTINUED
575,AU,A1,AU 2011/326729 A1,039-405-470-273-718,2013-05-30,2013,AU 2011/326729 A,2011-10-05,US 41101610 P;;US 2011/0054853 W,2010-11-08,Bed bug monitor device for vertical surfaces,"A bed bug monitor and/or capture device includes a housing defining a substantially enclosed interior space and a deadfall trap; a harborage element mounted adjacent the deadfall trap that defines at least one pathway through which bed bugs can travel; at least one bed bug attractant element positioned within the interior space of the housing; and at least one opening defined in at least one wall of the housing at a location either on or adjacent the deadfall trap and/or the harborage element, wherein fumes emanating from the bed bug attractant element can escape through the at least one opening to a location outside of the device in order to lure bed bugs toward the deadfall trap and the harborage element.",FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,,https://lens.org/039-405-470-273-718,Patent Application,no,0,0,13,13,0,A01M1/026;;A01M1/103;;Y02A50/30;;A01M1/02;;A01M1/10;;A01N31/02;;A01M1/103;;A01M1/026;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01P19/00,,0,0,,,,DISCONTINUED
576,CA,A1,CA 2815476 A1,108-723-897-010-460,2012-05-18,2012,CA 2815476 A,2011-10-05,US 41101610 P;;US 2011/0054853 W,2010-11-08,BED BUG MONITOR DEVICE FOR VERTICAL SURFACES,"A bed bug monitor and/or capture device includes a housing defining a substantially enclosed interior space and a deadfall trap; a harborage element mounted adjacent the deadfall trap that defines at least one pathway through which bed bugs can travel; at least one bed bug attractant element positioned within the interior space of the housing; and at least one opening defined in at least one wall of the housing at a location either on or adjacent the deadfall trap and/or the harborage element, wherein fumes emanating from the bed bug attractant element can escape through the at least one opening to a location outside of the device in order to lure bed bugs toward the deadfall trap and the harborage element.",FMC CORP,BLACK BRUCE C;;SHETH SHREYA;;VARANYAK LINDA A;;WOODRUFF KEITH F;;ENGRAM MICHAEL J;;RIENDL AMELIE H;;PRUITT JOSEPH;;FOSTER JERRY V;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;JACKSON DAVID NELSON,,https://lens.org/108-723-897-010-460,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/026;;A01M1/026;;A01M1/10;;A01N31/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01P19/00,,0,0,,,,DISCONTINUED
577,BR,A2,BR 112013010914 A2,038-904-208-089-974,2016-08-02,2016,BR 112013010914 A,2011-10-05,US 2011/0054853 W;;US 41101610 P,2010-11-08,dispositivo de monitoramento de percevejo para superfícies verticais,"dispositivo de monitoramento de percevejo para superfícies verticais. trata-se de um dispositivo de captura e/ou monitoramento de percevejo inclui um alojamento que define um espaço interno substancialmente confinado e uma armadilha do tipo quixó; um elemento de refúgio montado adjacente à armadilha do tipo quixó que define pelo menos um trajeto através do qual percevejos podem passar; pelo menos um elemento atrativo de percevejo posicionado dentro do espaço interno do alojamento; e pelo menos uma fresta definida em pelo menos uma parede do alojamento em um local em ou adjacente à armadilha do tipo quixó e/ou o elemento de refúgio, sendo que fumos que emanam do elemento atrativo de percevejo podem escapar através da pelo menos uma fresta para um local fora do dispositivo a fim de atrair percevejos em direção à armadilha do tipo quixó e ao elemento de refúgio.",FMC CORP,RIENDL AMELIE H;;BLACK BRUCE C;;JACKSON DAVID NELSON;;MUNTNER DONALD;;KNIGHT ERICA;;MCNEELY JAMES NOAH;;FOSTER JERRY V;;PRUITT JOSEPH;;WOODRUFF KEITH F;;VARANYAK LINDA A;;ENGRAM MICHAEL J;;SHETH SHREYA,,https://lens.org/038-904-208-089-974,Patent Application,no,0,0,13,13,0,A01M1/02;;A01M1/103;;A01M1/103;;A01M1/026;;A01M1/026;;A01M1/10;;A01N31/02;;Y02A50/30;;Y02A50/30,A01M1/02;;A01M1/10;;A01N31/02;;A01P19/00,,0,0,,,,DISCONTINUED
578,US,B2,US 11475207 B2,027-634-206-987-387,2022-10-18,2022,US 202016901656 A,2020-06-15,US 202016901656 A;;US 201962938949 P,2019-11-21,Subject line tester,"Methods, systems, and devices supporting data processing are described. In some systems, a data processing platform may support communication message analysis using machine learning. For example, a system may receive a set of communication messages (e.g., social media messages) and perform a machine learning process on the message contents and message interaction data to train a machine learned model. The system may further receive a subject line for a communication message for analysis, input the subject line into the machine learned model, and receive, as an output of the machine learned model, an engagement score based on the subject line. The engagement score may indicate an estimated probability that a user receiving the communication message opens the communication message (e.g., based on the subject line). A user—or the system—may modify the subject line based on the analysis to improve the engagement score.",SALESFORCE COM INC;;SALESFORCE INC,XIE KEXIN;;CAGRICI GOKHAN;;WILSON DANIEL KEITH;;MALLICK SHRESTHA BASU;;BELKOWITZ JONATHAN DANIEL SHOWERS;;LESTINA JASON;;BREWER JAMES;;GASPERUT DANIEL LOUIS;;ZICKGRAF JEFFERY ALLEN;;LYMAN GREG;;BREWER MICHAEL RONALD;;BLACK EVAN;;RAUSCHUBER AUSTIN;;SCHULTZ VICTORIA;;TREPINA MATTHEW DAVID;;STADLINGER PETER,SALESFORCE.COM INC (2020-06-11),https://lens.org/027-634-206-987-387,Granted Patent,yes,6,0,2,2,0,G06F40/20;;H04L51/063;;G06N20/00;;H04L51/52;;G06F40/166;;G06N20/00;;G06F40/216;;H04L51/52,G06F40/166;;G06F40/216;;G06N20/00;;H04L51/52,,0,0,,,,ACTIVE
579,US,A1,US 2021/0157974 A1,087-508-698-212-041,2021-05-27,2021,US 202016901656 A,2020-06-15,US 202016901656 A;;US 201962938949 P,2019-11-21,SUBJECT LINE TESTER,"Methods, systems, and devices supporting data processing are described. In some systems, a data processing platform may support communication message analysis using machine learning. For example, a system may receive a set of communication messages (e.g., social media messages) and perform a machine learning process on the message contents and message interaction data to train a machine learned model. The system may further receive a subject line for a communication message for analysis, input the subject line into the machine learned model, and receive, as an output of the machine learned model, an engagement score based on the subject line. The engagement score may indicate an estimated probability that a user receiving the communication message opens the communication message (e.g., based on the subject line). A user—or the system—may modify the subject line based on the analysis to improve the engagement score.",SALESFORCE COM INC,XIE KEXIN;;CAGRICI GOKHAN;;WILSON DANIEL KEITH;;MALLICK SHRESTHA BASU;;BELKOWITZ JONATHAN DANIEL SHOWERS;;LESTINA JASON;;BREWER JAMES;;GASPERUT DANIEL LOUIS;;ZICKGRAF JEFFREY ALLEN;;LYMAN GREG;;BREWER MICHAEL RONALD;;BLACK EVAN;;RAUSCHUBER AUSTIN;;SCHULTZ VICTORIA;;TREPINA MATTHEW DAVID;;STADLINGER PETER,SALESFORCE.COM INC (2020-06-11),https://lens.org/087-508-698-212-041,Patent Application,yes,0,4,2,2,0,G06F40/20;;H04L51/063;;G06N20/00;;H04L51/52;;G06F40/166;;G06N20/00;;G06F40/216;;H04L51/52,G06F40/166;;G06F40/216;;G06N20/00;;H04L12/58,,0,0,,,,ACTIVE
580,DE,D1,DE 69926148 D1,019-322-803-126-523,2005-08-18,2005,DE 69926148 T,1999-11-09,GB 9824536 A;;GB 9916786 A;;GB 9903733 W,1998-11-09,GASTRIN UND CHOLECYSTOKININ REZEPTOR LIGANDE,,BLACK JAMES FOUNDATION,KALINDJIAN BARRET;;BUCK MARIA;;LINNEY DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAIN MAIR;;STEEL ISOBEL;;HULL ANTONY;;ROBERTS PATRICIA;;GAFFEN DAVID;;VINTER GILBERT;;WALKER KEITH;;BLACK WHYTE;;WATT FAIRFULL;;HARPER ANNE;;SHANKLEY PAUL;;TOZER JOHN;;DUNSTONE JOHN;;PETHER JOHN;;LILLEY JAMES;;SYKES ANDREW;;LOW MINLI;;GRIFFIN PETER;;WRIGHT,,https://lens.org/019-322-803-126-523,Granted Patent,no,0,0,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,EXPIRED
581,WO,A1,WO 2023/034386 A1,051-543-842-765-175,2023-03-09,2023,US 2022/0042164 W,2022-08-31,US 202163239150 P;;US 202163280074 P;;US 202263304431 P;;US 202263318993 P;;US 202263345461 P,2021-08-31,SYSTEMS AND METHODS FOR ECOSYSTEM CREDIT RECOMMENDATIONS,"Systems, methods, and computer program products for recommending ecosystem credit tokens based on modelled outcomes are provided. In various embodiments, field data comprising geospatial boundaries of one or more field are received. One or more methodology is accessed. For each of the one or more fields, one or more farming practice is accessed, wherein each farming practice comprises a location and time. For each of the one or more fields, for each crop production period, an ecosystem attribute is generated by applying one or more ecosystem attribute quantification methods to each spatially and temporally unique set of one or more farming practices. Selection of one or more program is optimized for each field based on the set of selected programs being compatible within the field and production period.",INDIGO AG INC;;CAMPBELL ELEANOR ELIZABETH;;MCDONALD JACOB S;;GOODMAN AARON J;;SALIB MICHAEL J;;BALDO ELISABETH F;;MA KEITH F;;STACK DANIEL MICHAEL;;TREISCHMAN ERICH J;;MOTEW MELISSA;;PETERS SAMUEL J;;BLACK CHRISTOPHER K;;GURUNG RAM B;;BRUMMITT CHARLES D;;SEGAL BRIAN D;;SMART DAVID P;;KUMAR ASHOK A;;ROGERS BARCLAY ROWLAND;;BELOUSOVA MARIA;;SHANKAR JYOTI;;HARBOURT CHRISTOPHER MARK;;HOVSEPIAN RONALD W;;MENIPAZ AMIT R;;WEEKS JOSEPH,CAMPBELL ELEANOR;;MCDONALD JACOB;;GOODMAN AARON;;SALIB MICHAEL;;BALDO ELISABETH;;MA KEITH;;STACK DANIEL;;TREISCHMAN ERICH;;MOTEW MELISSA;;PETERS SAMUEL;;BLACK CHRISTOPHER;;GURUNG RAM;;BRUMMITT CHARLES;;SEGAL BRIAN;;SMART DAVID;;KUMAR ASHOK;;ROGERS BARCLAY;;BELOUSOVA MARIA;;SHANKAR JYOTI;;HARBOURT CHRISTOPHER MARK;;HOVSEPIAN RONALD W;;MENIPAZ AMIT R;;WEEKS JOSEPH,,https://lens.org/051-543-842-765-175,Patent Application,yes,3,4,8,9,0,G06Q30/018;;G06Q50/02;;G06Q50/02;;G06Q2220/00;;G06F16/29;;G06Q30/018,G06Q20/36;;G06T17/05;;G06V20/10,,1,0,,,"""E-Agriculture in action: Blockchain for agriculture. Opportunities and challenges"", 31 December 2019, THE FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS (FAO) AND THE INTERNATIONAL TELECOMMUNICATION UNION, Bangkok, ISBN: 978-92-5-131227-8, article GERARD SYLVESTER: ""E-Agriculture in action: Blockchain for agriculture. Opportunities and challenges"", XP009544349",PENDING
582,PL,A1,PL 347591 A1,189-175-303-798-97X,2002-04-08,2002,PL 34759199 A,1999-11-09,GB 9903733 W;;GB 9824536 A;;GB 9916786 A,1998-11-09,GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS,,,KALINDJIAN SARKIS BARRET;;BUCK ILDIKO MARIA;;LINNEY IAN DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAIN MAIR;;STEEL KATHERINE ISOBEL MARY;;HULL ROBERT ANTONY DAVID;;ROBERTS SONIA PATRICIA;;GAFFEN JOHN DAVID;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;BLACK JAMES WHYTE;;WATT GILLIAN FAIRFULL;;HARPER ELAINE ANNE;;SHANKLEY NIGEL PAUL;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;PETHER MICHAEL JOHN;;LILLEY ELLIOT JAMES;;SYK,,https://lens.org/189-175-303-798-97X,Patent Application,no,0,0,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,DISCONTINUED
583,NO,L,NO 20012288 L,101-527-363-344-05X,2001-07-02,2001,NO 20012288 A,2001-05-09,GB 9824536 A;;GB 9916786 A;;GB 9903733 W,1998-11-09,Gastrin- og kolecystokinin-reseptorligander,"Forbindelser med formel (I) eller deres farmasøytisk akseptable salter er Ugander på gastrin- og/eller kolecystokininreseptorer. I forbindelsene er X og Y uavhengig =N-, -N(R5)-, =CH-, -S- eller -O-, n er fra l til 4; R1 er H eller Ci-ishydrokarbyl; R2 er valgt blant H, Me, Et, Pr og OH, R3 er valgt blant H, Me, Et og Pr, eller (når n er større enn 1) er hver R3 uavhengig valgt blant H, Me, Et og Pr, eller to R3-grupper på nabokarbonatomet er forbundet under dannelse av en C3^karboksyhTng, eller R2 og R3 på samme karbonatom sammen danner en =O-gruppe; R4 er Ci.|5hydrokarbyl; Z er -(NR7)a-CO-(NR8)b- (der a er O eller l, b er O eller 1), -CO-NR7-CH2-CO-NR8-, -CO-O-, -CH2-CH2-, -CH=CH-, -CH2-NR8- eller en binding; Q er -R9V, eller formel (H) (der R9 er -CHr; -CH2-CHi){ eller formel (ffl) der R9 og R8, sammen med nitrogenatomet hvor til R8 er bundet, danner en piperidin- eller pyrrolidinring som er substituert med V; V er -CO-NH-SO2-Ph, -SO2-NH-CO-Ph, -CH2OH, eller en gruppe med formel -R10U (der U er -COOH, tetrazolyl, -CONHOH- eller -SO3H; og R10 er en binding; d-ehydrokarbylen, -O-(C,.3alkylen)-; -SO2NR' '-CHR12-; -CO-NR1 '-CHR12-, eller -NH-(CO)C-CH2-, c er O eller 1).",GBGRIFFIN ERIC PETER,KALINDJIAN SARKIS BARRET;;BUCK ILDIKO MARIA;;LINNEY IAN DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAN MAIR;;STEEL KATHERINE ISOBEL MARY;;HULL ROBERT ANTHONY DAVID;;ROBERTS SONIA PATRICIA;;GAFFEN JOHN DAVID;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;BLACK JAMES WHYTE;;WATT GILLIAN FAIRFULL;;HARPER ELAINE ANNE;;SHANKLEY NIGEL PAUL;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;PETHER MICHAEL JOHN;;LILLEY ELLIOT JAMES;;SYKES DAVID ANDREW,,https://lens.org/101-527-363-344-05X,Abstract,no,0,0,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,DISCONTINUED
584,EP,A1,EP 1178969 A1,108-347-822-540-68X,2002-02-13,2002,EP 99954196 A,1999-11-09,GB 9903733 W;;GB 9824536 A;;GB 9916786 A,1998-11-09,GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS,,BLACK JAMES FOUNDATION,KALINDJIAN SARKIS BARRET;;BUCK ILDIKO MARIA;;LINNEY IAN DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAIN MAIR;;STEEL KATHERINE ISOBEL MARY;;HULL ROBERT ANTONY DAVID;;ROBERTS SONIA PATRICIA;;GAFFEN JOHN DAVID;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;BLACK JAMES WHYTE;;WATT GILLIAN FAIRFULL;;HARPER ELAINE ANNE;;SHANKLEY NIGEL PAUL;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;PETHER MICHAEL JOHN;;LILLEY ELLIOT JAMES;;SYKES DAVID ANDREW,,https://lens.org/108-347-822-540-68X,Patent Application,yes,0,0,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,EXPIRED
585,EP,B1,EP 1178969 B1,182-524-199-875-020,2005-07-13,2005,EP 99954196 A,1999-11-09,GB 9903733 W;;GB 9824536 A;;GB 9916786 A,1998-11-09,GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS,,BLACK JAMES FOUNDATION,KALINDJIAN SARKIS BARRET;;BUCK ILDIKO MARIA;;LINNEY IAN DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAIN MAIR;;STEEL KATHERINE ISOBEL MARY;;HULL ROBERT ANTONY DAVID;;ROBERTS SONIA PATRICIA;;GAFFEN JOHN DAVID;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;BLACK JAMES WHYTE;;WATT GILLIAN FAIRFULL;;HARPER ELAINE ANNE;;SHANKLEY NIGEL PAUL;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;PETHER MICHAEL JOHN;;LILLEY ELLIOT JAMES;;SYKES DAVID ANDREW,,https://lens.org/182-524-199-875-020,Granted Patent,yes,4,0,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,EXPIRED
586,NO,D0,NO 20012288 D0,186-641-491-538-329,2001-05-09,2001,NO 20012288 A,2001-05-09,GB 9824536 A;;GB 9916786 A;;GB 9903733 W,1998-11-09,Gastrin og cholecystokinin reseptor ligander,,GBGRIFFIN ERIC PETER;;GBWRIGHT LAURENCE,KALINDJIAN SARKIS BARRET;;BUCK ILDIKO MARIA;;LINNEY IAN DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAN MAIR;;STEEL KATHERINE ISOBEL MARY;;HULL ROBERT ANTHONY DAVID;;ROBERTS SONIA PATRICIA;;GAFFEN JOHN DAVID;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;BLACK JAMES WHYTE;;WATT GILLIAN FAIRFULL;;HARPER ELAINE ANNE;;SHANKLEY NIGEL PAUL;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;PETHER MICHAEL JOHN;;LILLEY ELLIOT JAMES;;SYKES DAVID ANDREW,,https://lens.org/186-641-491-538-329,Patent Application,no,0,0,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,DISCONTINUED
587,US,B2,US 11880894 B2,194-458-254-284-235,2024-01-23,2024,US 202217900428 A,2022-08-31,US 202217900428 A;;US 202163239150 P;;US 202163280074 P;;US 202263304431 P;;US 202263318993 P;;US 202263345461 P,2021-08-31,Systems and methods for ecosystem credit recommendations,"Systems, methods, and computer program products for recommending ecosystem credit tokens based on modelled outcomes are provided. In various embodiments, field data comprising geospatial boundaries of one or more field are received. One or more methodology is accessed. For each of the one or more fields, one or more farming practice is accessed, wherein each farming practice comprises a location and time. For each of the one or more fields, for each crop production period, an ecosystem attribute is generated by applying one or more ecosystem attribute quantification methods to each spatially and temporally unique set of one or more farming practices. Selection of one or more program is optimized for each field based on the set of selected programs being compatible within the field and production period.",INDIGO AG INC,CAMPBELL ELEANOR ELIZABETH;;MCDONALD JACOB S;;GOODMAN AARON J;;SALIB MICHAEL J;;BALDO ELISABETH F;;MA KEITH F;;STACK DANIEL MICHAEL;;TREISCHMAN ERICH J;;MOTEW MELISSA;;PETERS SAMUEL J;;BLACK CHRISTOPHER K;;GURUNG RAM B;;BRUMMITT CHARLES D;;SEGAL BRIAN D;;SMART DAVID P;;KUMAR ASHOK A;;ROGERS BARCLAY ROWLAND;;BELOUSOVA MARIA;;SHANKAR JYOTI;;HARBOURT CHRISTOPHER MARK;;HOVSEPIAN RONALD W;;MENIPAZ AMIT R;;WEEKS JOSEPH;;HORVATH SAMANTHA,INDIGO AG INC (2020-12-08),https://lens.org/194-458-254-284-235,Granted Patent,yes,209,0,8,9,0,G06Q30/018;;G06Q50/02;;G06Q50/02;;G06Q2220/00;;G06F16/29;;G06Q30/018,G06Q50/02;;G06F16/29;;G06Q30/018,,63,22,062-914-977-506-663;;007-297-662-001-796;;136-564-585-847-317;;062-914-977-506-663;;061-037-267-281-203;;050-012-218-543-115;;002-509-578-055-695;;132-523-730-395-93X;;053-159-081-797-354;;006-256-944-739-521;;019-168-950-276-545;;031-589-101-201-346;;179-506-785-335-708;;113-827-377-579-319;;051-996-451-395-113;;018-899-704-235-169;;007-466-994-785-237;;040-482-682-268-317;;016-886-021-956-893;;115-042-607-676-740;;094-852-219-352-124;;081-320-908-770-269,10.1016/j.ecoser.2017.12.010;;10.1016/j.ejor.2012.02.005;;10.1155/2021/8526456;;10.1016/j.ecoser.2017.12.010;;10.1029/2009gb003544;;10.1007/s10705-021-10122-z;;34467931;;10.1016/j.scitotenv.2021.149342;;10.1016/j.geoderma.2020.114529;;10.21513/0207-2564-2019-2-05-13;;10.1046/j.1365-2486.2003.00683.x;;25603267;;10.2134/jeq2014.05.0221br;;10.1016/j.agrformet.2013.01.007;;10.1016/s1002-0160(17)60321-7;;10.1094/cc-83-0529;;10.1017/s0081305200014564;;10.1038/ncomms6012;;25405548;;pmc4243251;;10.2307/1239776;;10.26716/redlands/master/2008.12;;10.1109/iccsit.2009.5234765;;10.2136/sssaj2018.03.0105;;10.1145/3209811.3212707;;10.1016/j.fcr.2004.04.004,"Kasi “A Framework and System for a Multi-Model Decision Aid for Sustainable Farming Practice”, May 2010, ProQuest. pp. 1-142 (Year: 2010).;;Denise et al “Using Information on Ecosystem Goods and Services in Corps Planning: An Examination on Authorities, Policies, Guidance, and Practices”, Sep. 2013, IWR (Institute for Water Resources), pp. 1-78. (Year: 2013).;;Marzieh et al “The impact of relative individual ecosystem demand on stacking ecosystem credit markets”, Feb. 2018, Ecosystem Services vol. 29, Part A, pp. 137-144 (Year: 2018).;;Barns “Agricultural planning of annual plants under demand, maturation, harvest, and yield risk”, Dec. 2012, European Journal of Operational Research, pp. 539-549 (Year: 2012).;;Stockdale Impacts of farming practice within organic farming systems on below-ground ecology and ecosystem function:, Dec. 2006, Aspects of Applied Biology, pp. 43-46 (Year: 2006).;;Manoj et al., “Blockchain ecosystem for credit transfer in education”, Mathematical Problems in Engineering: 1-12 (2021).;;Motallebi et al., “The impact of relative individual ecosystem demand on stacking ecosystem credit markets”, Dec. 2018, Ecosystem Services 29: 137-144 (2018).;;International Search Report and Written Opinion for International Application No. PCT/US22/42164 dated Dec. 21, 2022.;;Sylvester, “E-agriculture in action: blockchain for agriculture. Opportunities and challenges”, The Food and Agriculture Organization of the United Nations (FAO) and the International Telecommunication Union, 72 pages, (2019).;;Del Grosso et al., (2010). Estimating uncertainty in N2O emissions from U.S. cropland soils. Global Biogeochemical Cycles, 24(1), n/a-n/a. https://doi.org/10.1029/2009GB003544.;;Gurung et al (2021). Modeling ammonia volatilization from urea application to agricultural soils in the DayCent model. Nutrient Cycling in Agroecosystems, 119(2), 259-273. https://doi.org/10.1007/s10705-021-10122-z.;;Gurung et al (2021). Modeling nitrous oxide mitigation potential of enhanced efficiency nitrogen fertilizers from agricultural systems. Science of the Total Environment, 801, 149342. https://doi.org/10.1016/j.scitotenv.2021.149342.;;Gurung et al., (2020). Bayesian calibration of the DayCent ecosystem model to simulate soil organic carbon dynamics and reduce model uncertainty. Geoderma, 376, 114529.;;IPCC (2006): 2006 IPCC Guidelines for National Greenhouse Gas Inventories. vol. 1, Chapter 3 Uncertainties.;;IPCC (2019): 2019 Refinement to the 2006 IPCC Guidelines for National Greenhouse Gas Inventories. vol. 4, Chapter 5 Cropland.;;Ogle et al (2003). Uncertainty in estimating land use and management impacts on soil organic carbon storage for US agricultural lands between 1982 and 1997. Global Change Biology, 9(11), 1521-1542. https://doi.org/10.1046/j.1365-2486.2003.00683.x.;;Paustian et al (2012). COMET2.0—Decision Support System for Agricultural Greenhouse Gas Accounting. In Managing Agricultural Greenhouse Gases: Coordinated Agricultural Research through GRACEnet to Address our Changing Climate (pp. 251-270). Elsevier. https://doi.org/10.1016/B978-0-12-386897-8.00015-2.;;U.S. EPA (2022). Inventory of U.S. Greenhouse Gas Emissions and Sinks. https://www.epa.gov/ghgemissions/inventory-us-greenhouse-gas-emissions-and-sinks.;;USDA (2022), U.S. Agriculture and Forestry, Greenhouse Gas Inventory 1990-2018. Technical Bulletin No. 1957. Jan. 2022.;;Adam, B.D. et al., “Storage Hedging: What's a Merchandiser to Do ?.” Proceedings of the NCR-134 Conference on Applied Commodity Price Analysis, Forecasting, and Market Management, 1993, pp. 87-94.;;Blank. S.C., “Research on futures markets: Issues, approaches, and empirical findings,” Western Journal of Agricultural Economics, 1989, vol. 14, No. 1, pp. 126-139.;;Bolton, D.K. et al., “Forecasting crop yield using remotely sensed vegetation indices and crop phenology metrics, ” Agricultural and Forest Meteorology, vol. 173, May 2013, pp. 74-84.;;Chabala, L. M. et al., “Application of Ordinary Kringing in Mapping Soil Organic Carbon in Zambia,” Pedosphere 27(2), Apr. 2017, pp. 338-343.;;Chicago Board of Trade, Why Trade Ag Products on Project A, 1994, pp. 1-5.;;Commodity Trading Manual, published by Chicago Board of Trade, copyright 1998, 170 pages.;;Crawford, P., “The New High-Tech Investing: Computer as Fund Manager,” The International Herald Tribune, Feb. 1, 1992, 4 pages.;;Daniels Trading, “Daniels Ag Advisory Glossary,” Sep. 2004, pp. 1-2.;;Diepeveen, D. et al., “Identifying key crop performance traits using data mining,” World Conference on Agricultural Information and IT, Aug. 2008, pp. 1-6.;;Dowell, F.E. et al., “Predicting Wheat Quality Characteristics and Functionality Using Near-Infrared Spectroscopy,” Cereal Chemistry, vol. 83, Iss. 5, Sep. 2006, pp. 529-536.;;Einstein-Curtis, A., “Online grain marketplace launches grain testing service,” Feednavigator.com, Oct. 20, 2017, two pages, [Online] [Retrieved on Jun. 1, 2020] Retrieved from the Internet <URL: https://www.feednavigator.com/Article/2017/10/20/Online-grain-marketplace-launches-grain-testing-service>.;;Ethridge, D.E., “A Computerized Remote-Access Commodity Market: Telcot,” Southern Journal of Agricultural and Applied Economics, Dec. 1978, vol. 10, No. 2, pp. 177-182.;;European Patent Office, Extended European Search Report, EP Patent Application No. 20836088.3, dated Jun. 14, 2023, ten pages.;;Fields, G., “Here is How Trading Stocks by Computer Works,” Miami Herald, Oct. 25, 1987, pp. 1-2.;;Food Market Exchange, “FoodMarketExchange.com,” Jun. 20, 2000, pp. 1-7, [Online] [Retrieved from the Internet Archive] <URL: http://web.archive.org/web/*/http://www.foodmarketexchange.com>.;;Gan, Y. et al., “Improving Farming Practices Reduces the Carbon Footprint of Spring Wheat Production,” Nature Communications, vol. 5, Article No. 5012, Nov. 18, 2014, pp. 1-13.;;Hayenga, M.L. et al., “Formula pricing in five commodity marketing systems,” American Journal of Agricultural Economics, Nov. 1980, vol. 62, No. 4, pp. 753-759.;;Kastens, T.L. et al., “Post-harvest grain storing and hedging with efficient futures,” Journal of Agricultural and Resource Economics, 1999, pp. 482-505.;;Lemos, M. F., “Using GIS to Predict Corn Yields in Colombia,” University of Redlands Thesis, May 2008, pp. 1-83, [Online] [Retrieved on Apr. 6, 2020] Retrieved from the Internet <URL: https://inspire.redlands.edu/gis_gradproj/177>.;;Los Angeles Times, “Ins and Outs of Program Trading, and Why It's Being Blamed for Market Collapse,” Dec. 6, 1987, pp. 1-5.;;Meymandpour, R. et al. “The Economic Impacts of Electronic Marketplaces in Globalization Age: Examples from Agricultural Web Portals.” 2009 2nd IEEE International Conference on Computer Science and Information Technology, Aug. 8-11, 2009, pp. 109-113.;;Moschini, G. et al., “Constant or Time Varying Hedge Ratios”, Proceedings of the NCR-134 Conference on Applied Commodity Price Analysis, Forecasting and Market Risk Management, 1993, pp. 1-17.;;New York Mercantile Exchange, “A Guide to Energy Hedging,” 1999, 1-66.;;New York Times, “Gambling in Futures,” Jan. 9, 1910, 1 page.;;Norvell, J.M. et al., “Simultaneously Derived Optimal Hedge Ratios for East Central Illinois Corn and Soybean Producers”, Proceedings of the NCR-134 Conference on Applied Commodity Price Analysis Forecasting and Market Risk, Chicago, III., 1992, pp. 1-16.;;Patterson, M.D. et al., “Hedge Ratio Estimation and Soybean Storage” Proceedings of the NCR-134 Conference on Applied Commodity Price Analysis and Market Risk, Chicago, III, 1994, pp. 1-15.;;PCT International Search Report and Written Opinion, PCT Application No. PCT/US2021/064200, dated Jun. 14, 2022, 20 pages.;;Piggott, N.E., “North Carolina Soybean and Corn Prices with Basis 1980-2003,” North Carolina State University, Jul. 2003, pp. 1-26.;;Preliminary Amendment, U.S. Appl. No. 10/870,112, dated Feb. 6, 2008, 20 pages.;;Purcell, W.D. et al., “Agricultural Futures and Options: Principles and Strategies” Second Edition, 1999, pp. 1-5, 7-22, 24-29, 31-54, 362-381.;;Roper, W.R. et al., “Comparing Four Methods of Measuring Soil Organic Matter in North Carolina Soils,” Soil Science Society of America Journal, vol. 83, Mar. 28, 2019, pp. 466-474.;;Second Preliminary Amendment, U.S. Appl. No. 10/870,112, dated Mar. 21, 2008, 12 pages.;;Strobl, M. et al., “An Examination of the Spatial and Intertemporal Aspects of Basis Determination,” NCR-134 Conference on Applied Price Analysis, 1992, pp. 1-14.;;Telcot, “User's Manual for Buyers,” published by Plains Cotton Cooperative Association, 1985, pp. 1-172.;;United States Department of Agriculture, Agricultural Marketing Service, “Electronic Trading of Agricultural Products”, paper delivered Jul. 8, 1980 to Commonwealth Club, San Francisco, Jan. 1981, pp. 1-21.;;U.S. Appl. No. 60/241,543, filed Oct. 18, 2000, Inventor Reding, G. et al.;;U.S. Appl. No. 62/653,480, filed Apr. 5, 2018, Inventor Dagondon, S.D. et al.;;USA Futures, “usafutures.com,” Jan. 25, 1999, pp. 1-12, [Online] [Retrieved from the Internet Archive] <URL: http://web.archive.org/web/19990218043052/www.usafutures.com/futuresdirectory.htm>.;;Wang, A.X. et al., “Deep Transfer Learning for Crop Yield Prediction with Remote Sensing Data,” Proceedings of the 1st ACM SIGCAS Conference on Computing and Sustainable Societies, vol. 50, Jun. 2018, pp. 1-5.;;Wang, Z.J. et al., “Prediction of grain protein content in winter wheat (Triticum aestivum L.) using plant pigment ratio (PPR),” Field Crops Research, vol. 90, Dec. 2004, pp. 311-321.;;Webster's New Collegiate Dictionary, 1990, p. 265.;;Wisner, R. et al., “Grain Price Hedging Basics”, Iowa State University, Oct. 1995, pp. 1-3.;;World Book Corp, “The World Book Encyclopedia,” 1994, pp. 873-874.;;Zanini, F.C. et al., “Did Producer Hedging Opportunities in the Live Hog Market Decline,” The Proceedings of the NCR-134 Conference on Applied Commodity Price Analysis Forecasting and Market Risk, Chicago, III. 1997, 17 pages.",ACTIVE
588,US,B2,US 11830089 B2,105-719-407-458-81X,2023-11-28,2023,US 202318166639 A,2023-02-09,US 202318166639 A;;US 202217900428 A;;US 202263345461 P;;US 202263318993 P;;US 202263304431 P;;US 202163280074 P;;US 202163239150 P,2021-08-31,Systems and methods for ecosystem credit recommendations,"Systems, methods, and computer program products for maintaining a collection of ecosystem credit tokens based on modelled outcomes are provided. In various embodiments, an ecosystem attribute target profile for the collection of ecosystem credit tokens is accessed. The target profile comprises a set of ecosystem characteristics, quantities of one or more ecosystem characteristics, and permanence of one or more ecosystem characteristics. A set of ecosystem credit tokens is accessed, wherein each ecosystem credit token data record comprises one or more of: a validated and verified management event, a methodology, an ecosystem attribute, a boundary, an ecosystem impact, an ecosystem credit, and an ecosystem attribute quantification method. A current profile of the collection of ecosystem credit tokens is determined, wherein the profile comprises the set of ecosystem characteristics within the collection, quantities of ecosystem characteristics, and permanence of ecosystem characteristics. The collection is automatically updated to maintain a current profile.",INDIGO AG INC,CAMPBELL ELEANOR ELIZABETH;;MCDONALD JACOB S;;GOODMAN AARON J;;SALIB MICHAEL J;;BALDO ELISABETH F;;MA KEITH F;;STACK DANIEL MICHAEL;;TREISCHMAN ERICH J;;MOTEW MELISSA;;PETERS SAMUEL J;;BLACK CHRISTOPHER K;;GURUNG RAM B;;BRUMMITT CHARLES D;;SEGAL BRIAN D;;SMART DAVID P;;KUMAR ASHOK A;;ROGERS BARCLAY ROWLAND;;BELOUSOVA MARIA;;SHANKAR JYOTI;;HARBOURT CHRISTOPHER MARK;;HOVSEPIAN RONALD W;;MENIPAZ AMIT R;;WEEKS JOSEPH;;HORVATH SAMANTHA,INDIGO AG INC (2020-12-08),https://lens.org/105-719-407-458-81X,Granted Patent,yes,14,0,8,9,0,G06Q30/018;;G06Q50/02;;G06Q50/02;;G06Q2220/00;;G06F16/29;;G06Q30/018,G06Q50/02;;G06F16/29;;G06Q30/018,,16,9,136-564-585-847-317;;062-914-977-506-663;;061-037-267-281-203;;050-012-218-543-115;;002-509-578-055-695;;132-523-730-395-93X;;053-159-081-797-354;;006-256-944-739-521;;019-168-950-276-545,10.1155/2021/8526456;;10.1016/j.ecoser.2017.12.010;;10.1029/2009gb003544;;10.1007/s10705-021-10122-z;;34467931;;10.1016/j.scitotenv.2021.149342;;10.1016/j.geoderma.2020.114529;;10.21513/0207-2564-2019-2-05-13;;10.1046/j.1365-2486.2003.00683.x;;25603267;;10.2134/jeq2014.05.0221br,"Manoj “Blockchain Ecosystem for Credit Transfer in Education”, Dec. 2021 Hindawi Mathematical Problems in Engineering Volume, Article ID 8526456, 12 pages (Year: 2021).;;Denise et al., “Using Information on Ecosystem Goods and Services in Corps Planning: An Examination on Authorities, Policies, Guidance, and Practices”, Sep. 2013, IWR (Institute for Water Resources), pp. 1-78. (2013).;;International Search Report and Written Opinion for International Application No. PCT/US22/42164 dated Dec. 21, 2022.;;Kasi, “A Framework and System for a Multi-Model Decision Aid for Sustainable Farming Practice”, May 2010 , ProQuest. pp. 1-142 (2010).;;Marzieh et al “The impact of relative individual ecosystem demand on stacking ecosystem credit markets”, Feb. 2018, Ecosystem Services vol. 29, Part A, pp. 137-144 (2018).;;Sylvester, “E-agriculture in action: blockchain for agriculture. Opportunities and challenges”, The Food and Agriculture Organization of the United Nations (FAO) and the International Telecommunication Union, 72 pages, (2019).;;del Grosso et al., (2010). Estimating uncertainty in N2O emissions from U.S. cropland soils. Global Biogeochemical Cycles, 24(1), n/a-n/a. https://doi.org/10.1029/2009GB003544.;;Gurung et al (2021). Modeling ammonia volatilization from urea application to agricultural soils in the DayCent model. Nutrient Cycling in Agroecosystems, 119(2), 259-273. https://doi.org/10.1007/s10705-021-10122-z.;;Gurung et al.(2021). Modeling nitrous oxide mitigation potential of enhanced efficiency nitrogen fertilizers from agricultural systems. Science of The Total Environment, 801, 149342. https://doi.org/10.1016/j.scitotenv.2021.149342.;;Gurung et al., (2020). Bayesian calibration of the DayCent ecosystem model to simulate soil organic carbon dynamics and reduce model uncertainty. Geoderma, 376, 114529.;;IPCC (2006): 2006 IPCC Guidelines for National Greenhouse Gas Inventories. vol. 1, Chapter 3 Uncertainties.;;IPCC (2019): 2019 Refinement to the 2006 IPCC Guidelines for National Greenhouse Gas Inventories. vol. 4, Chapter 5 Cropland.;;Ogle et al (2003). Uncertainty in estimating land use and management impacts on soil organic carbon storage for US agricultural lands between 1982 and 1997. Global Change Biology, 9(11), 1521-1542. https://doi.org/10.1046/j.1365-2486.2003.00683.x.;;Paustian et al (2012). COMET2.0-Decision Support System for Agricultural Greenhouse Gas Accounting. In Managing Agricultural Greenhouse Gases: Coordinated Agricultural Research through GRACEnet to Address our Changing Climate (pp. 251-270). Elsevier. https://doi.org/10.1016/B978-0-12-386897-8.00015-2.;;U.S. EPA (2022). Inventory of U.S. Greenhouse Gas Emissions and Sinks. https://www.epa.gov/ghgemissions/inventory-us-greenhouse-gas-emissions-and-sinks.;;USDA (2022), U.S. Agriculture and Forestry, Greenhouse Gas Inventory 1990-2018. Technical Bulletin No. 1957. Jan. 2022.",ACTIVE
589,AR,A1,AR 126943 A1,045-045-877-925-758,2023-11-29,2023,AR P220102364 A,2022-08-31,US 202163239150 P;;US 202063280074 P;;US 202063304431 P;;US 202063318993 P;;US 202063345461 P,2020-01-28,SISTEMAS Y MÉTODOS PARA RECOMENDACIONES DE CRÉDITO DEL ECOSISTEMA,"En el presente documento se proporcionan sistemas, métodos y productos de programas informáticos para recomendar tokens de crédito del ecosistema basados en resultados modelados. En varias realizaciones, se reciben datos de campo que comprenden límites geoespaciales de uno o más campos. Se accede a una o más metodologías. Para cada uno de los uno o más campos, se accede a una o más prácticas agrícolas, en el que cada práctica agrícola comprende una ubicación y un tiempo. Para cada uno de los uno o más campos, para cada período de producción de cultivos, se genera un atributo del ecosistema aplicando uno o más métodos de cuantificación de atributos del ecosistema a cada conjunto espacial y temporalmente único de una o más prácticas agrícolas. La selección de uno o más programas se optimiza para cada campo en función de que el conjunto de programas seleccionados sea compatible dentro del campo y el período de producción.",INDIGO AG INC,CAMPBELL ELEANOR ELIZABETH;;MDONALD JACOB S;;GOODMAN AARON J;;SALIB MICHAEL J;;BALDO ELISABETH F;;MA KEITH F;;STACK DANIEL MICHAEL;;TRIESCHMAN ERICH J;;MOTEW MELISSA;;PETERS SAMUEL J;;BLACK CHRISTOPHER K;;GURUNG RAM B;;BRUMMITT CHARLES D;;SEGAL BRIAN D;;SMART DAVID P;;KUMAR ASHOK A;;ROGERS BARCLAY ROWLAND;;BELOUSOVA MARIA;;SHANKAR JYOTI;;HARBOURT CHRISTOPHER MARK;;HOVSEPIAN RONALD W;;MENIPAZ AMIT R;;HORVATH SAMANTHA,,https://lens.org/045-045-877-925-758,Patent Application,no,0,0,1,9,0,,G06Q20/36;;G06T17/05;;G06V20/10,,0,0,,,,PENDING
590,US,A1,US 2023/0306531 A1,116-170-057-474-994,2023-09-28,2023,US 202318166640 A,2023-02-09,US 202318166640 A;;US 202217900428 A;;US 202263345461 P;;US 202263318993 P;;US 202263304431 P;;US 202163280074 P;;US 202163239150 P,2021-08-31,SYSTEMS AND METHODS FOR ECOSYSTEM CREDIT RECOMMENDATIONS,"Systems, methods, and computer program products for recommending farming practices based on modelled outcomes are provided. In various embodiments, field data comprising geospatial boundaries of one or more field are received. Management event data comprising one or more management events within the one or more fields is received. For each management event, a management event boundary defining geospatial boundaries is received, and one or more management zones is determined based on the management event boundaries. The determination of one or more management zones comprises sequentially intersecting a geospatial boundary. Each sequential intersection operation creating two branches, one with the intersection of the geometries and one with the difference. This process is repeated for all management event boundaries occurring in a geospatial boundary defining a contiguous region, wherein each individual management zone contains a unique set of farming practices relative to any other management zone within the contiguous region.",INDIGO AG INC,CAMPBELL ELEANOR ELIZABETH;;MCDONALD JACOB S;;GOODMAN AARON J;;SALIB MICHAEL J;;BALDO ELISABETH R;;MA KEITH F;;STACK DANIEL MICHAEL;;TREISCHMAN ERICH J;;MOTEW MELISSA;;PETERS SAMUEL J;;BLACK CHRISTOPHER K;;GURUNG RAM B;;BRUMMITT CHARLES D;;SEGAL BRIAN D;;SMART DAVID P;;KUMAR ASHOK A;;ROGERS BARCLAY ROWLAND;;BELOUSOVA MARIA;;SHANKAR JYOTI;;HARBOURT CHRISTOPHER MARK;;HOVSEPIAN RONALD W;;MENIPAZ AMIT R;;WEEKS JOSEPH;;HORVATH SAMANTHA,INDIGO AG INC (2020-12-08),https://lens.org/116-170-057-474-994,Patent Application,yes,0,0,8,9,0,G06Q30/018;;G06Q50/02;;G06Q50/02;;G06Q2220/00;;G06F16/29;;G06Q30/018,G06Q50/02;;G06F16/29;;G06Q30/018,,0,0,,,,ACTIVE
591,US,B2,US 11810021 B2,044-470-069-955-669,2023-11-07,2023,US 202318166640 A,2023-02-09,US 202318166640 A;;US 202217900428 A;;US 202263345461 P;;US 202263318993 P;;US 202263304431 P;;US 202163280074 P;;US 202163239150 P,2021-08-31,Systems and methods for ecosystem credit recommendations,"Systems, methods, and computer program products for recommending farming practices based on modelled outcomes are provided. In various embodiments, field data comprising geospatial boundaries of one or more field are received. Management event data comprising one or more management events within the one or more fields is received. For each management event, a management event boundary defining geospatial boundaries is received, and one or more management zones is determined based on the management event boundaries. The determination of one or more management zones comprises sequentially intersecting a geospatial boundary. Each sequential intersection operation creating two branches, one with the intersection of the geometries and one with the difference. This process is repeated for all management event boundaries occurring in a geospatial boundary defining a contiguous region, wherein each individual management zone contains a unique set of farming practices relative to any other management zone within the contiguous region.",INDIGO AG INC,CAMPBELL ELEANOR ELIZABETH;;MCDONALD JACOB S;;GOODMAN AARON J;;SALIB MICHAEL J;;BALDO ELISABETH F;;MA KEITH F;;STACK DANIEL MICHAEL;;TREISCHMAN ERICH J;;MOTEW MELISSA;;PETERS SAMUEL J;;BLACK CHRISTOPHER K;;GURUNG RAM B;;BRUMMITT CHARLES D;;SEGAL BRIAN D;;SMART DAVID P;;KUMAR ASHOK A;;ROGERS BARCLAY ROWLAND;;BELOUSOVA MARIA;;SHANKAR JYOTI;;HARBOURT CHRISTOPHER MARK;;HOVSEPIAN RONALD W;;MENIPAZ AMIT R;;WEEKS JOSEPH;;HORVATH SAMANTHA,INDIGO AG INC (2020-12-08),https://lens.org/044-470-069-955-669,Granted Patent,yes,68,0,8,9,0,G06Q30/018;;G06Q50/02;;G06Q50/02;;G06Q2220/00;;G06F16/29;;G06Q30/018,G06Q50/02;;G06F16/29;;G06Q30/018,,17,10,062-914-977-506-663;;062-914-977-506-663;;007-297-662-001-796;;061-037-267-281-203;;050-012-218-543-115;;002-509-578-055-695;;132-523-730-395-93X;;053-159-081-797-354;;006-256-944-739-521;;019-168-950-276-545,10.1016/j.ecoser.2017.12.010;;10.1016/j.ecoser.2017.12.010;;10.1016/j.ejor.2012.02.005;;10.1029/2009gb003544;;10.1007/s10705-021-10122-z;;34467931;;10.1016/j.scitotenv.2021.149342;;10.1016/j.geoderma.2020.114529;;10.21513/0207-2564-2019-2-05-13;;10.1046/j.1365-2486.2003.00683.x;;25603267;;10.2134/jeq2014.05.0221br,"Marzieh et al “The impact of relative individual ecosystem demand on stacking ecosystem credit markets”, Dec. 2018, Ecosystem Services 29 (2018) 137-144 (Year: 2018).;;Denise et al., “Using Information on Ecosystem Goods and Services in Corps Planning: An Examination on Authorities, Policies, Guidance, and Practices”, Sep. 2013, IWR (Institute for Water Resources), pp. 1-78. (2013).;;International Search Report and Written Opinion for International Application No. PCT/US22/42164 dated Dec. 21, 2022.;;Kasi, “A Framework and System for a Multi-Model Decision Aid for Sustainable Farming Practice”, May 2010 , ProQuest. pp. 1-142 (2010).;;Marzieh et al “The impact of relative individual ecosystem demand on stacking ecosystem credit markets”, Feb. 2018, Ecosystem Services vol. 29, Part A, pp. 137-144 (2018).;;Sylvester, “E-agriculture in action: blockchain for agriculture. Opportunities and challenges”, The Food and Agriculture Organization of the United Nations (FAO) and the International Telecommunication Union, 72 pages, (2019).;;Barns, “Agricultural planning of annual plants under demand, maturation, harvest, and yield risk”, European Journal of Operational Research: 539-549 (2012).;;Del Grosso et al., (2010). Estimating uncertainty in N2O emissions from U.S. cropland soils. Global Biogeochemical Cycles, 24(1), n/a-n/a. https://doi.org/10.1029/2009GB003544.;;Gurung et al (2021). Modeling ammonia volatilization from urea application to agricultural soils in the DayCent model. Nutrient Cycling in Agroecosystems, 119(2), 259-273. https://doi.org/10.1007/s10705-021-10122-z.;;Gurung et al (2021). Modeling nitrous oxide mitigation potential of enhanced efficiency nitrogen fertilizers from agricultural systems. Science of The Total Environment, 801, 149342. https://doi.org/10.1016/j.scitotenv.2021.149342.;;Gurung et al., (2020). Bayesian calibration of the DayCent ecosystem model to simulate soil organic carbon dynamics and reduce model uncertainty. Geoderma, 376, 114529.;;IPCC (2006): 2006 IPCC Guidelines for National Greenhouse Gas Inventories. vol. 1, Chapter 3 Uncertainties.;;IPCC (2019): 2019 Refinement to the 2006 IPCC Guidelines for National Greenhouse Gas Inventories. vol. 4, Chapter 5 Cropland.;;Ogle et al. (2003). Uncertainty in estimating land use and management impacts on soil organic carbon storage for US agricultural lands between 1982 and 1997. Global Change Biology, 9(11), 1521-1542. https://doi.org/10.1046/j.1365-2486.2003.00683.x.;;Paustian et al (2012). COMET2.0-Decision Support System for Agricultural Greenhouse Gas Accounting. In Managing Agricultural Greenhouse Gases: Coordinated Agricultural Research through GRACEnet to Address our Changing Climate (pp. 251-270). Elsevier. https://doi.org/10.1016/B978-0-12-386897-8.00015-2.;;U.S. EPA (2022). Inventory of U.S. Greenhouse Gas Emissions and Sinks. https://www.epa.gov/ghgemissions/inventory-us-greenhouse-gas-emissions-and-sinks.;;USDA (2022), U.S. Agriculture and Forestry. Greenhouse Gas Inventory 1990-2018. Technical Bulletin No. 1957. Jan. 2022.",ACTIVE
592,US,A1,US 2023/0186408 A1,019-903-858-250-244,2023-06-15,2023,US 202318166639 A,2023-02-09,US 202318166639 A;;US 202217900428 A;;US 202263345461 P;;US 202263318993 P;;US 202263304431 P;;US 202163280074 P;;US 202163239150 P,2021-08-31,SYSTEMS AND METHODS FOR ECOSYSTEM CREDIT RECOMMENDATIONS,"Systems, methods, and computer program products for maintaining a collection of ecosystem credit tokens based on modelled outcomes are provided. In various embodiments, an ecosystem attribute target profile for the collection of ecosystem credit tokens is accessed. The target profile comprises a set of ecosystem characteristics, quantities of one or more ecosystem characteristics, and permanence of one or more ecosystem characteristics. A set of ecosystem credit tokens is accessed, wherein each ecosystem credit token data record comprises one or more of: a validated and verified management event, a methodology, an ecosystem attribute, a boundary, an ecosystem impact, an ecosystem credit, and an ecosystem attribute quantification method. A current profile of the collection of ecosystem credit tokens is determined, wherein the profile comprises the set of ecosystem characteristics within the collection, quantities of ecosystem characteristics, and permanence of ecosystem characteristics. The collection is automatically updated to maintain a current profile.",INDIGO AG INC,CAMPBELL ELEANOR ELIZABETH;;MCDONALD JACOB S;;GOODMAN AARON J;;SALIB MICHAEL J;;BALDO ELISABETH F;;MA KEITH F;;STACK DANIEL MICHAEL;;TREISCHMAN ERICH J;;MOTEW MELISSA;;PETERS SAMUEL J;;BLACK CHRISTOPHER P;;GURUNG RAM B;;BRUMMITT CHARLES D;;SEGAL BRIAN D;;SMART DAVID P;;KUMAR ASHOK A;;ROGERS BARCLAY ROWLAND;;BELOUSOVA MARIA;;SHANKAR JYOTI;;HOVSEPIAN RONALD W;;MENIPAZ AMIT R;;WEEKS JOSEPH;;HORVATH SAMANTHA;;HARBOURT CHRISTOPHER MARK,INDIGO AG INC (2020-12-08),https://lens.org/019-903-858-250-244,Patent Application,yes,2,0,8,9,0,G06Q30/018;;G06Q50/02;;G06Q50/02;;G06Q2220/00;;G06F16/29;;G06Q30/018,G06Q50/02;;G06F16/29;;G06Q30/018,,1,1,136-564-585-847-317,10.1155/2021/8526456,"Manoj ""Blockchain Ecosystem for Credit Transfer in Education"", 12/2021 Hindawi Mathematical Problems in Engineering Volume, Article ID 8526456, 12 pages (Year: 2021)",ACTIVE
593,US,A1,US 2023/0078852 A1,059-048-248-268-259,2023-03-16,2023,US 202217900428 A,2022-08-31,US 202217900428 A;;US 202163239150 P;;US 202163280074 P;;US 202263304431 P;;US 202263318993 P;;US 202263345461 P,2021-08-31,SYSTEMS AND METHODS FOR ECOSYSTEM CREDIT RECOMMENDATIONS,"Systems, methods, and computer program products for recommending ecosystem credit tokens based on modelled outcomes are provided. In various embodiments, field data comprising geospatial boundaries of one or more field are received. One or more methodology is accessed. For each of the one or more fields, one or more farming practice is accessed, wherein each farming practice comprises a location and time. For each of the one or more fields, for each crop production period, an ecosystem attribute is generated by applying one or more ecosystem attribute quantification methods to each spatially and temporally unique set of one or more farming practices. Selection of one or more program is optimized for each field based on the set of selected programs being compatible within the field and production period.",INDIGO AG INC,CAMPBELL ELEANOR ELIZABETH;;MCDONALD JACOB S;;GOODMAN AARON J;;SALIB MICHAEL J;;BALDO ELISABETH F;;MA KEITH F;;STACK DANIEL MICHAEL;;TREISCHMAN ERICH J;;MOTEW MELISSA;;PETERS SAMUEL J;;BLACK CHRISTOPHER K;;GURUNG RAM B;;BRUMMITT CHARLES D;;SEGAL BRIAN D;;SMART DAVID P;;KUMAR ASHOK A;;ROGERS BARCLAY ROWLAND;;BELOUSOVA MARIA;;SHANKAR JYOTI;;HARBOURT CHRISTOPHER MARK;;HOVSEPIAN RONALD W;;MENIPAZ AMIT R;;WEEKS JOSEPH;;HORVATH SAMANTHA,INDIGO AG INC (2020-12-08),https://lens.org/059-048-248-268-259,Patent Application,yes,6,18,8,9,0,G06Q30/018;;G06Q50/02;;G06Q50/02;;G06Q2220/00;;G06F16/29;;G06Q30/018,G06Q50/02;;G06F16/29;;G06Q30/00,,5,2,062-914-977-506-663;;007-297-662-001-796,10.1016/j.ecoser.2017.12.010;;10.1016/j.ejor.2012.02.005,"Kasi ""A FRAMEWORK AND SYSTEM FOR A MULTI-MODEL DECISION AID FOR SUSTAINABLE FARMING PRACTICE"", 5/2010, ProQuest. Pages 1-142 (Year: 2010);;Denise et al ""Using Information on Ecosystem Goods and Services in Corps Planning: An Examination on Authorities, Policies, Guidance, and Practices"", 9/2013, IWR (Institute for Water Resources), Pages 1-78. (Year: 2013);;Marzieh et al ""The impact of relative individual ecosystem demand on stacking ecosystem credit markets"", 2/2018, Ecosystem Services Volume 29, Part A, Pages 137-144 (Year: 2018);;Barns ""Agricultural planning of annual plants under demand, maturation, harvest, and yield risk"", 12/2012, European Journal of Operational Research, Pages 539-549 (Year: 2012);;Stockdale ""Impacts of farming practice within organic farming systems on below-ground ecology and ecosystem function:, 12/2006, Aspects of Applied Biology, Pages 43-46 (Year: 2006)",ACTIVE
594,US,A1,US 2024/0020775 A1,122-245-765-064-276,2024-01-18,2024,US 202318372287 A,2023-09-25,US 202318372287 A;;US 202318166640 A;;US 202217900428 A;;US 202263345461 P;;US 202263318993 P;;US 202263304431 P;;US 202163280074 P;;US 202163239150 P,2021-08-31,SYSTEMS AND METHODS FOR ECOSYSTEM CREDIT RECOMMENDATIONS,"Systems, methods, and computer program products for recommending farming practices based on modelled outcomes are provided. In various embodiments, field data comprising geospatial boundaries of one or more field are received. Management event data comprising one or more management events within the one or more fields is received. For each management event, a management event boundary defining geospatial boundaries is received, and one or more management zones is determined based on the management event boundaries. One or more ecosystem attribute quantification method is applied to each of the one or more management zones to generate one or more ecosystem attributes of the one or more management zones. One or more ecosystem attribute is selected for each management zone. An ecosystem credit token or portion thereof is generated for each selected ecosystem attribute. The ecosystem credit token is associated with a quantity of raw agricultural product.",INDIGO AG INC,CAMPBELL ELEANOR ELIZABETH;;MCDONALD JACOB S;;GOODMAN AARON J;;SALIB MICHAEL J;;BALDO ELISABETH F;;MA KEITH F;;STACK DANIEL MICHAEL;;TREISCHMAN ERICH J;;MOTEW MELISSA;;PETERS SAMUEL J;;BLACK CHRISTOPHER K;;GURUNG RAM B;;BRUMMITT CHARLES D;;SEGAL BRIAN D;;SMART DAVID P;;KUMAR ASHOK A;;ROGERS BARCLAY ROWLAND;;BELOUSOVA MARIA;;SHANKAR JYOTI;;HARBOURT CHRISTOPHER MARK;;HOVSEPIAN RONALD W;;MENIPAZ AMIT;;WEEKS JOSEPH;;HORVATH SAMANTHA,,https://lens.org/122-245-765-064-276,Patent Application,yes,0,0,8,9,0,G06Q30/018;;G06Q50/02;;G06Q50/02;;G06Q2220/00;;G06F16/29;;G06Q30/018,G06Q50/02;;G06F16/29;;G06Q30/018,,0,0,,,,PENDING
595,HU,A2,HU P0104038 A2,191-266-604-814-545,2002-05-29,2002,HU P0104038 A,1999-11-09,GB 9824536 A;;GB 9916786 A,1998-11-09,GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGAND IMIDAZOLE DERIVATIVES PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION,"A találmány szerinti vegyületek (I) általános képletében X és Yjelentése egymástól függetlenül =N-, vagy -N(R5)- általános képletűcsoport, ahol R5 jelentése H, Me, Et, Pr, Bn, -OH vagy -CH2COOR6, aholR6 jelentése H, Me, Et, Pr vagy Bn, valamint =CH-, -S- vagy -O-, nértéke 1-4, R1 jelentése H vagy 1-15 szénatomos szénhidrogéncsoport,ahol legfeljebb három szénatom helyett nitrogénatom, oxigénatomés/vagy kénatom állhat, és ahol legfeljebb három hidrogénatom helyetthalogénatom állhat, R2 jelentése n = 1 esetben H, Me, Et, Pr vagy OH,vagy n 1 esetben az egyes előfordulási helyeken egymástól függetlenülH, Me, Et, Pr vagy OH, R3 jelentése n = 1 esetben H, Me, Et vagy Pr,vagy n 1 esetben az egyes előfordulási helyeken egymástól függetlenülH, Me, Et vagy Pr vagy két szomszédos szénatomon található R3jelentése együtt 3-6 szénatomos karbociklusos gyűrű vagy kétszomszédos szénatomon található R3 jelentése együtt második kötés,vagy R2 és R3 jelentése azonos szénatomon kapcsolódva együtt =O, R4jelentése 1-15 szénatomos szénhidrogéncsoport, ahol legfeljebb kétszénatom helyett nitrogénatom, oxigénatom és/vagy kénatom állhat, éslegfeljebb két hidrogénatom helyett halogénatom állhat, Z jelentése -(NR7)a-CO-(NR8)b- általános képletű csoport, ahol a értéke 0 vagy 1, bértéke 0 vagy 1, R7 és R8 jelentése egymástól függetlenül valamely R6jelentésében megadott csoport, vagy -CO-NR7-CH2-CO-NR8-, -CO-O-, -CH2-CH2-, -CH=CH-, -CH2-NR8- vagy közvetlen kötés, Q jelentése -R9Váltalános képletű csoport vagy (a) általános képletű csoport, ahol R9jelentése -CH2-, -CH2-CH2- vagy (b) általános képletű csoport, vagy R9és R8 jelentése a kapcsolódó nitrogénatommal együtt piperidin- gyűrűvagy pirrolidingyűrű, amely V csoporttal szubsztituálva van, Vjelentése -CO-NH-SO2-Ph, -SO2-NH-CO-Ph, -CH2-OH vagy -R10U általánosképletű csoport. A találmány kiterjed a fenti vegyületek előállításáraés ezeket tartalmazó gyógyszerkészítményekre. Ó",BLACK JAMES FOUNDATION,BLACK JAMES WHYTE;;BUCK ILDIKO MARIA;;DUNSTONE DAVID JOHN;;GAFFEN JOHN DAVID;;GRIFFIN ERIC PETER;;HARPER ELAINE ANNE;;HULL ROBERT ANTONY DAVID;;KALINDJIAN SARKIS BARRET;;LILLEY ELLIOT JAMES;;LINNEY IAN DUNCAN;;LOW CAROLINE MINLI RACHEL;;MCDONALD IAIN MAIR;;PETHER MICHAEL JOHN;;ROBERTS SONIA PATRICIA;;SHANKLEY NIGEL PAUL;;STEEL KATHERINE ISOBEL MARY;;SYKES DAVID ANDREW;;TOZER MATTHEW JOHN;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;WATT GILLIAN FAIRFULL;;WRIGHT LAURENCE;;WRIGHT PAUL TREVOR,,https://lens.org/191-266-604-814-545,Patent Application,no,0,0,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,PENDING
596,US,B1,US 6479531 B1,109-550-692-818-152,2002-11-12,2002,US 83138501 A,2001-08-02,GB 9824536 A;;GB 9916786 A;;GB 9903733 W,1998-11-09,Gastrin and cholecystokinin receptor ligands,"
   

    Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently N, N(R ^{ 5 } )CH, S or O. n is from 1 to 4; R ^{ 1 } is H or C _{ 1 } to C _{ 15 } hydrocarbyl R ^{ 2 } is selected from H, Me, Et, Pr and OH, R _{ 3 } is selected from H, Me, Et and Pr; or (when n is greater than 1) each R ^{ 3 } is independently selected from H, Me, Et and Pr, or two R ^{ 3 } groups on neighbouring carbon atoms are linked to form a C _{ 3 } to C _{ 6 } carbocylic ring, or R ^{ 2 } and R ^{ 3 } on the same carbon atom together represent an O group; R ^{ 4 } is C _{ 1 } to C _{ 15 } hydrocarbyl Z is (NR ^{ 7 } ) _{ a } CO(NR ^{ 8 } ) _{ b } (wherein a is 0 or 1, b is 0 or 1, CONR ^{ 7 } CH _{ 2 } CONR ^{ 8 } , COO, CH _{ 2 } CH _{ 2 } , CHCH, CH _{ 2 } NR ^{ 8 } or a bond; Q is R ^{ 9 } V, or (II), (wherein R ^{ 9 } is CH _{ 2 } ; CH _{ 2 } CH _{ 2 } ; or (III), R ^{ 9 } and R ^{ 8 } , together with the nitrogen atom to which R ^{ 8 } is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is CONHSO _{ 2 } Ph, SO _{ 2 } NHCOPh, CH _{ 2 } OH, or a group of the formula R ^{ 10 } U, (wherein U is COOH, tetrazolyl, CONHOH or SO _{ 3 } H; and R ^{ 10 } is a bond; C _{ 1 } to C _{ 6 } hydrocarbylene, O(C _{ 1 } to C _{ 3 } alkylene); SO _{ 2 } NR ^{ 11 } CHR ^{ 12 } ; CONR ^{ 11 } CHR ^{ 12 } , or NH(CO) _{ c } CH _{ 2 } , c being 0 or 1). 
",BLACK JAMES FOUNDATION,KALINDJIAN SARKIS BARRET;;BUCK ILDIKO MARIA;;LINNEY IAN DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAIN MAIR;;STEEL KATHERINE ISOBEL MARY;;HULL ROBERT ANTONY DAVID;;ROBERTS SONIA PATRICIA;;GAFFEN JOHN DAVID;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;BLACK JAMES WHYTE;;WATT GILLIAN FAIRFULL;;HARPER ELAINE ANNE;;SHANKLEY NIGEL PAUL;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;PETHER MICHAEL JOHN;;LILLEY ELLIOT JAMES;;SYKES DAVID ANDREW;;LOW CAROLINE MINLI RACHEL;;GRIFFIN ERIC PETER;;WRIGHT LAURENCE,JAMES BLACK FOUNDATION LIMITED (2001-06-15),https://lens.org/109-550-692-818-152,Granted Patent,yes,7,14,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,514/397;;514/398;;514/399;;548/314.7;;548/326.5;;548/331.1;;548/335.1,0,0,,,,EXPIRED
597,BR,A,BR 9915194 A,114-488-861-667-540,2001-08-07,2001,BR 9915194 A,1999-11-09,GB 9824536 A;;GB 9916786 A;;GB 9903733 W,1998-11-09,"Composto, método para fabricar o mesmo, composição farmacêutica, e, método para fabricar a mesma","""COMPOSTO, MéTODO PARA FABRICAR O MESMO, COMPOSIçãO FARMACêUTICA, E, MéTODO PARA FABRICAR A MESMA"" Os compostos da fórmula (I) e seus sais farmaceuticamente aceitáveis são ligandos dos receptores de gastrina e/ou colecistocinina. X e Y são independentemente =N-, -N(R^ 5^)- =CH-, -S- ou -O-. n é de 1 a 4; R¹ é H ou hidrocarbila C~ 1~ a C~ 15~, R² é selecionado de H, Me, Et, Pr e OH, R³ é selecionado de H, Me, Et e Pr; ou (quando n é maior do que 1) cada R³ é independentemente selecionado de H, Me, Et e Pr ou dois grupos R³ próximos aos átomos de carbono são ligados para formar um anel carbocílico C~ 3~ a C~ 6~ ou R² e R³ no mesmo átomo de carbono junto representa um grupo =O; R^ 4^ é hidrocarbila C~ 1~ a C~ 15~, Z é -(NR^ 7^)~ a~-CO-(NR^ 8^)~ b~- (em que a é 0 ou 1, b é 0 ou 1, -CO-NR^ 7^-CH~ 2~-CO-NR^ 8^-, -CO-O-, -CH~ 2~-CH~ Z~-, -CH=CH-, -CH~ 2~-NR^ 8^- ou uma ligação; Q é -R^ 9^V, ou (II) (em que R9 é -CH~ 2~-; -CH~ 2~-CH~ 2~-; ou (III) R^ 9^ e R^ 8^, junto com o átomo de nitrogênio ao qual R^ 8^ está ligado, forma um anel de piperidina ou picrolidina que é substituído por V; V é -CO-NH-SO~ 2~-Ph, -SO~ 2~-NH-CO-Ph, -CH~ 2~OH, ou um grupo da fórmula -R^ 10^U, (em que U é -COOH, tetrazolila, -CONHOH- ou -SO~ 3~H e R^ 10^ é uma ligação; hidrocarbileno C~ 1~ a C~ 6~, -O-(alquileno C~ 1~ a C~ 3~)-; -SO~ 2~-NR^ 11^-CHR^ 12^ ; -CO-NR^ 11^-CHR^ 12^ ou -NH-(CO)~ c~-CH~ 2~-, c sendo 0 ou 1).",BLACK JAMES FOUNDATION,KALINDJIAN SARKIS BARRET;;BUCK ILDIKO MARIA;;LINNEY IAN DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAIN MAIR;;STEEL KATHERINE ISOBEL MARY;;HULL ROBERT ANTHONY DAVID;;ROBERTS SONIA PATRICIA;;GAFFEN JOHN DAVID;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;BLACK JAMES WHYTE;;WATT GILLIAN FAIRFULL;;HARPER ELAINE ANNE;;SHANKLEY NIGEL PAUL;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;PETHER MICHAEL JOHN;;LILLEY ELLIOT JAMES;;SYKES DAVID ANDREW;;LOW CAROLINE MINLI RACHEL;;GRIFFIN ERIC PETER;;WRIGHT LAURENCE,,https://lens.org/114-488-861-667-540,Patent Application,no,0,0,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,DISCONTINUED
598,WO,A1,WO 2000/027823 A1,033-026-624-541-108,2000-05-18,2000,GB 9903733 W,1999-11-09,GB 9824536 A;;GB 9916786 A,1998-11-09,GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS,"Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently =N-, -N(R5)- =CH-, -S- or -O-. n is from 1 to 4; R1 is H or C¿1? to C15 hydrocarbyl R?2¿ is selected from H, Me, Et, Pr and OH, R¿3? is selected from H, Me, Et and Pr; or (when n is greater than 1) each R?3¿ is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C¿3? to C6 carbocylic ring, or R?2 and R3¿ on the same carbon atom together represent an =O group; R4 is C1 to C15 hydrocarbyl Z is -(NR7)a-CO-(NR8)b- (wherein a is 0 or 1, b is 0 or 1, -CO-NR7-CH2-CO-NR8-, -CO-O-, -CH¿2?-CH2-, -CH=CH-, -CH2-NR?8¿- or a bond; Q is -R9V, or (II), (wherein R9 is -CH¿2?-; -CH2-CH2-; or (III), R?9 and R8¿, together with the nitrogen atom to which R8 is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is -CO-NH-SO¿2?-Ph, -SO2-NH-CO-Ph, -CH2OH, or a group of the formula -R?10¿U, (wherein U is -COOH, tetrazolyl, -CONHOH- or -SO¿3?H; and R?10¿ is a bond; C¿1? to C6 hydrocarbylene, -O-(C1 to C3 alkylene)-; -SO2NR?11-CHR12¿-; -CO-NR?11-CHR12¿-, or -NH-(CO)¿c?-CH2-, c being 0 or 1).",BLACK JAMES FOUNDATION;;KALINDJIAN SARKIS BARRET;;BUCK ILDIKO MARIA;;LINNEY IAN DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAIN MAIR;;STEEL KATHERINE ISOBEL MARY;;HULL ROBERT ANTONY DAVID;;ROBERTS SONIA PATRICIA;;GAFFEN JOHN DAVID;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;BLACK JAMES WHYTE;;WATT GILLIAN FAIRFULL;;HARPER ELAINE ANNE;;SHANKLEY NIGEL PAUL;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;PETHER MICHAEL JOHN;;LILLEY ELLIOT JAMES;;SYKES DAVID ANDREW;;LOW CAROLINE MINLI RACHEL;;GRIFFIN ERIC PETER;;WRIGHT LAURENCE,KALINDJIAN SARKIS BARRET;;BUCK ILDIKO MARIA;;LINNEY IAN DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAIN MAIR;;STEEL KATHERINE ISOBEL MARY;;HULL ROBERT ANTONY DAVID;;ROBERTS SONIA PATRICIA;;GAFFEN JOHN DAVID;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;BLACK JAMES WHYTE;;WATT GILLIAN FAIRFULL;;HARPER ELAINE ANNE;;SHANKLEY NIGEL PAUL;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;PETHER MICHAEL JOHN;;LILLEY ELLIOT JAMES;;SYKES DAVID ANDREW;;LOW CAROLINE MINLI RACHEL;;GRIFFIN ERIC PETER;;WRIGHT LAURENCE,,https://lens.org/033-026-624-541-108,Patent Application,yes,4,56,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,PATENTED
599,AU,A,AU 2000/010615 A,127-556-075-770-798,2000-05-29,2000,AU 2000/010615 A,1999-11-09,GB 9824536 A;;GB 9916786 A;;GB 9903733 W,1998-11-09,Gastrin and cholecystokinin receptor ligands,,BLACK JAMES FOUNDATION,KALINDJIAN SARKIS BARRET;;BUCK ILDIKO MARIA;;LINNEY IAN DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAIN MAIR;;STEEL KATHERINE ISOBEL MARY;;HULL ROBERT ANTONY DAVID;;ROBERTS SONIA PATRICIA;;GAFFEN JOHN DAVID;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;BLACK JAMES WHYTE;;WATT GILLIAN FAIRFULL;;HARPER ELAINE ANNE;;SHANKLEY NIGEL PAUL;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;PETHER MICHAEL JOHN;;LILLEY ELLIOT JAMES;;SYKES DAVID ANDREW;;LOW CAROLINE MINLI RACHEL;;GRIFFIN ERIC PETER;;WRIGHT LAURENCE,,https://lens.org/127-556-075-770-798,Patent Application,no,0,0,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,DISCONTINUED
600,CA,A1,CA 2346108 A1,010-835-321-256-786,2000-05-18,2000,CA 2346108 A,1999-11-09,GB 9824536 A;;GB 9916786 A;;GB 9903733 W,1998-11-09,GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS,"Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independent ly =N-, -N(R5)- =CH-, -S- or -O-. n is from 1 to 4; R1 is H or C1 to C15 hydrocarbyl R2 is selected from H, Me, Et, Pr and OH, R3 is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently select ed from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or R2 and R3 on the same carbon atom together represent an =O group; R4 is C1 to C15 hydrocarbyl Z is -(NR7) a- CO-(NR8)b- (wherein a is 0 or 1, b is 0 or 1, -CO-NR7-CH2-CO-NR8-, -CO-O-, - CH2-CH2-, -CH=CH-, -CH2-NR8- or a bond; Q is -R9V, or (II), (wherein R9 is - CH2-; -CH2-CH2-; or (III), R9 and R8, together with the nitrogen atom to whi ch R8 is attached, form a piperidine or pyrrolidine ring which is substituted b y V; V is -CO-NH-SO2-Ph, -SO2-NH-CO-Ph, -CH2OH, or a group of the formula -R10 U, (wherein U is -COOH, tetrazolyl, -CONHOH- or -SO3H; and R10 is a bond; C1 to C6 hydrocarbylene, -O-(C1 to C3 alkylene)-; -SO2NR11-CHR12-; -CO-NR11-CHR12- , or -NH-(CO)c-CH2-, c being 0 or 1).",BLACK JAMES FOUNDATION,GRIFFIN ERIC PETER;;HULL ROBERT ANTONY DAVID;;PETHER MICHAEL JOHN;;WRIGHT PAUL TREVOR;;LOW CAROLINE MINLI RACHEL;;WALKER MARTIN KEITH;;KALINDJIAN SARKIS BARRET;;WRIGHT LAURENCE;;BUCK ILDIKO MARIA;;SHANKLEY NIGEL PAUL;;WATT GILLIAN FAIRFULL;;BLACK JAMES WHYTE;;STEEL KATHERINE ISOBEL MARY;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;LILLEY ELLIOT JAMES;;GAFFEN JOHN DAVID;;HARPER ELAINE ANNE;;ROBERTS SONIA PATRICIA;;VINTER JEREMY GILBERT;;LINNEY IAN DUNCAN;;SYKES DAVID ANDREW;;MCDONALD IAIN MAIR,,https://lens.org/010-835-321-256-786,Patent Application,no,0,1,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,DISCONTINUED
601,AT,T1,AT E299499 T1,038-961-623-999-829,2005-07-15,2005,AT 99954196 T,1999-11-09,GB 9824536 A;;GB 9916786 A;;GB 9903733 W,1998-11-09,GASTRIN UND CHOLECYSTOKININ REZEPTOR LIGANDE,,BLACK JAMES FOUNDATION,KALINDJIAN SARKIS BARRET;;BUCK ILDIKO MARIA;;LINNEY IAN DUNCAN;;WRIGHT PAUL TREVOR;;MCDONALD IAIN MAIR;;STEEL KATHERINE ISOBEL MARY;;HULL ROBERT ANTONY DAVID;;ROBERTS SONIA PATRICIA;;GAFFEN JOHN DAVID;;VINTER JEREMY GILBERT;;WALKER MARTIN KEITH;;BLACK JAMES WHYTE;;WATT GILLIAN FAIRFULL;;HARPER ELAINE ANNE;;SHANKLEY NIGEL PAUL;;TOZER MATTHEW JOHN;;DUNSTONE DAVID JOHN;;PETHER MICHAEL JOHN;;LILLEY ELLIOT JAMES;;SYKES DAVID ANDREW;;LOW CAROLINE MINLI RACHEL;;GRIFFIN ERIC PETER;;WRIGHT LAURENCE,,https://lens.org/038-961-623-999-829,Granted Patent,no,0,0,16,18,0,C07D207/34;;C07D233/64;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D405/04;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07D233/64;;C07D401/12;;C07D277/56;;C07D403/06;;C07D401/04;;C07D405/04;;C07D233/88;;C07D403/12;;C07D263/34;;C07D403/04;;C07D233/90;;C07D207/34,A61K31/40;;A61K31/41;;A61K31/4164;;A61K31/4178;;A61K31/421;;A61K31/426;;A61K31/4427;;A61K31/443;;A61K31/4439;;A61K31/454;;A61P1/14;;A61P1/18;;A61P25/04;;A61P25/18;;A61P25/22;;A61P35/00;;C07B61/00;;C07D207/34;;C07D233/54;;C07D233/88;;C07D233/90;;C07D263/34;;C07D277/20;;C07D277/42;;C07D277/56;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/06;;C07D403/12;;C07D403/14;;C07D405/04,,0,0,,,,DISCONTINUED
